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Preface 
Hemodialysis (HD) represents the first successful long term substitutive therapy with
an artificial organ for severe failure of a vital organ. Because HD was started many 
decades ago, a book on HD may not appear up-to-date. 
Indeed, HD covers many basic and clinical aspects and this book reflects the rapid
expansion of new and controversial aspects either in the biotechnological or in the
clinical field.
The related topics are multiple because HD includes either biotechnology or multi-
organ involvement as well as different pathogenetic factors. Many efforts to reduce
dialysis complications and their treatment are made. This book revises new 
technologies and therapeutic options to improve dialysis treatment of uremic patients. 
This book consists of three parts: 
 modeling, methods and technique 
 prognosis 
 complications
The first part includes twelve chapters, five on modeling, water and electrolyte
preparation or regulation, four face membranes and biocompatibility, the remaining 
three deal with procedures or controversies. 
Besides important progress in biotechnology, a common and principal aim crossing 
most of these chapters is the attempt to reduce morbidity by the use of more 
compatible devices.
Prediction of morbidity or mortality by progress in the laboratory is a principal
general topic or aim of the second group of four chapters. These chapters underline
the relevance of the residual renal function and of the main laboratory biomarkers to
predict cardiovascular complications.
The third part includes seven chapters on clinical complications. The principal topic
crossing two chapters is the importance of metabolic disorders for the origin and the
development of the most important clinical complications (cardiovascular and bone).
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The remaining five chapters deal with lifestyle aspects (sleep or physical  activity) and 
local (vascular access) or systemic (infections) complications. 
Therefore, this book reflects either emergent biotechnological or updated clinical 
aspects concerning HD. These two topics include suggestions to improve prognosis 
and therapy of the patients on HD. 
The book will help not only general physicians, nephrologists, internists, cardiologists, 
endocrinologists but also basic researchers, including bioengineers, to approach, 
understand and manage the principal problems related to HD.  
Finally, we consider that we were medical students in the same university hospital in 
the sixties and successively we worked in the same university hospital department. 
Our original department of internal medicine specialized in nephrology, under the 
leadership of the late Prof. Gabriele Monasterio, who first proposed and validated the 
low protein diet and included teachers who were pioneers in projecting and using the 
artificial kidney. 
Thanks to them, the authors of these book chapters and the publisher, we once more 
have the pleasure to work together in this project including colleagues from multiple 
continents.  
 
Prof. Angelo Carpi, M.D.,  
Department of Reproduction and Aging, University of Pisa,  
Italy  
 
Prof. Carlo Donadio, M.D.,  
Department of Internal Medicine, University of Pisa,  
Italy 
 
Prof. Gianfranco Tramonti, M.D.,   
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Modeling, Methods and Technique
Part 1 
Modeling, Methods and Technique
 1 
Kinetic Modeling and Adequacy of Dialysis 
Malgorzata Debowska1, Bengt Lindholm2 and Jacek Waniewski1 
1Institute of Biocybernetics and Biomedical Engineering,  
Polish Academy of Sciences, Warsaw,  




The mathematical description of hemodialysis (HD) includes two parts: 1) explanation of the 
exchange between patient’s blood and dialysate fluid across a semipermeable membrane of 
the dialyzer, and 2) characterization of the solute removal from the patient. The solute 
transport across the dialyzer membrane depends on the difference in hydrostatic pressure 
and solute concentration gradients between both sides of the membrane and also on the 
permeability of the membrane to the solute. The local equations for solute and fluid 
transport through the membrane are based on a phenomenological (thermodynamic) 
description according to the Staverman-Kedem-Katchalsky-Spiegler approach (Staverman, 
1951; Kedem & Katchalsky, 1958; Katchalsky & Curran, 1965; Spiegler & Kedem, 1966). The 
two compartment model describes the functioning of the patient – dialyzer system, 
assuming that body fluid is divided into two parts: one directly (extracellular compartment) 
and one indirectly (intracellular compartment) accessible for dialysis (Schneditz & 
Daugirdas, 2001). The one compartment model of the solute distribution volume assumes 
that the solute is distributed in a single, homogenous pool. Solute kinetic modeling is based 
on a set of ordinary differential equations describing the changes of solute mass, 
concentration and distribution volume in body compartments and in the dialyzer. Using 
solute kinetic modeling one is able to evaluate dialysis efficiency. 
The question concerning dialysis dosing has been debated and remains controversial since 
the beginning of the dialysis treatment era. Between 1976 and 1981, the National 
Cooperative Dialysis Study (NCDS) was performed in the United States to establish 
objective, quantitative criteria for the adequate dose of dialysis (Gotch & Sargent, 1985; 
Sargent & Gotch, 1989; Locatelli et al., 2005). The primary analysis showed that morbidity 
was less at lower levels of time average urea concentration. The secondary ‘mechanistic’ 
analysis of the NCDS data done by Gotch and Sargent launched the issue of urea KT/V 
(Gotch & Sargent, 1985). 
Single-pool KT/V overestimates the removed amount of urea because of the postdialysis 
urea rebound, i.e., a fast postdialysis increase in urea concentration in plasma, which is a 
compartmental effect; therefore, the equilibrated KT/V (eqKT/V), estimated by the 
Daugirdas formula, was introduced to clinical practice (Daugirdas et al., 2001). Equilibrated 
KT/V values can be also calculated using an alternative equation by Daugirdas and 
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Schneditz (Daugirdas & Schneditz, 1995), or the formula derived from observations during 
the HEMO Study (Depner et al., 1999; Eknoyan et al., 2002; Daugirdas et al., 2004), or that 
introduced by Tattersall et al. (Tattersall et al., 1996). 
The usage of the KT/V index as a sole and optimal measure of dialysis dose is questioned 
by many authors. Fractional solute removal (FSR) and equivalent continuous clearance 
(ECC) are two such alternative options, which can be used instead of KT/V. FSR was 
suggested by Verrina et al. (Verrina et al., 1998) and Henderson (Henderson, 1999) for 
comparative studies of various dialysis modalities and schedules. By definition FSR is the 
removed mass over the reference solute mass in the body. The concept of FSR is closely 
related to the concept of the solute removal index (SRI) proposed by Keshaviah (Keshaviah, 
1995). Standard KT/V (stdKT/V), introduced by Gotch, is another variant of FSR (Gotch, 
1998). The time-average solute concentration (Cta) has been introduced to define ‘equivalent 
renal clearance’ (EKR), as a solute removal rate over Cta (Casino & Lopez, 1996). Using other 
reference concentrations in the definition of EKR instead of Cta, the general idea of 
equivalent continuous clearance, ECC, can be formulated (Waniewski et al., 2006; 
Waniewski et al., 2010). There are at least four different reference methods: 1) peak, p, 
2) peak average, pa, 3) time average, ta, and 4) treatment time average, trta, reference values 
of volume, mass, and concentration applied in KT/V, FSR and ECC (Waniewski et al., 2006; 
Waniewski et al., 2010). KT/V, FSR and ECC are mathematically related for the same 
reference method. However, the choice of an adequacy index and the respective reference 
method is not obvious. It is not possible to decide whether this or the other definition is 
better although some authors have declared their preferences (Keshaviah, 1995; Casino & 
Lopez, 1996; Verrina et al., 1998; Henderson, 1999). The difference between different 
hypotheses and the indices based on them may be investigated theoretically, but the choice, 
if any, may be done only on the basis of a large set of clinical data. Future research should 
hopefully provide more information about the relationship between various definitions and 
the probability of clinical outcome in dialyzed patients. 
Recent studies report some advantages of low-efficiency, frequent schedule over short, high-
efficiency HD (Depner, 1998; Charra et al., 2004). The two compartment variable volume 
urea kinetic model can be applied to examine the whole set of dialysis adequacy indices in 
different dialysis treatments, e.g. 1) conventional HD with 3 sessions per week, 2) daily HD 
with 6 sessions per week and 3) nocturnal HD with 6 long sessions using typical patient and 
treatment parameters. The peak average reference method used in FSR and ECC 
calculations seem to be a more sensitive to the frequency and time of dialysis than the 
method based on time average reference (Waniewski et al., 2006; Waniewski et al., 2010). 
The unified approach to the definition of dialysis adequacy indices proposed by Waniewski 
et al. is valid for all modalities of dialysis performed in end-stage renal disease and acute 
renal failure patients and for the assessment of residual renal function (Waniewski et al., 
2006; Debowska et al., 2010; Waniewski et al., 2010). The integrated system of dialysis 
adequacy indices takes into account all currently applied indices and allows to explain their 
relationships and specificities. 
The theory and practical application of this system of adequacy indices are here presented 
on the basis of our previous publications and a (unpublished) PhD thesis (Waniewski & 
Lindholm, 2004; Debowska & Waniewski, 2005; Debowska et al., 2005; Waniewski et al., 
2006; Debowska et al., 2007a; Debowska et al., 2007b; Debowska et al., 2010; Waniewski et 
al., 2010). 
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2. Theory of fluid and solute transport in hemodialysis 
The mathematical description of hemodialysis includes two parts: 1) one part that explains 
the fluid and solute transport across a semi-permeable membrane of the dialyzer, and 2) one 
part that characterizes the global solute transport between removal device and patient. 
2.1 Solute and fluid transport in dialyzer 
The fluid and solute transport in dialyzer consists of two processes: transport through a 
permselective membrane between blood and dialysate and transport in blood and dialysate 
channels. 
The theoretical description of transport through a permselective membrane is based on 
phenomenological (thermodynamic) descriptions according to the Staverman-Kedem-
Katchalsky-Spiegler approach (Staverman, 1951; Kedem & Katchalsky, 1958; Katchalsky & 
Curran, 1965; Spiegler & Kedem, 1966; Weryński & Nowosielcew, 1983; Werynski & 
Waniewski, 1995; Waniewski, 2006). Diffusion is the dominant factor for small solute 
transport in hemodialyzer. The transport due to convection prevails in hemofilters, plasma 
separators, etc. In hemodialyzer with highly permeable membrane used in 
hemodiafiltration, the convective transport component plays a leading role in the removal of 
middle molecules and small proteins (Werynski & Waniewski, 1995). 
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al., 2010). 
 
Kinetic Modeling and Adequacy of Dialysis 
 
5 
2. Theory of fluid and solute transport in hemodialysis 
The mathematical description of hemodialysis includes two parts: 1) one part that explains 
the fluid and solute transport across a semi-permeable membrane of the dialyzer, and 2) one 
part that characterizes the global solute transport between removal device and patient. 
2.1 Solute and fluid transport in dialyzer 
The fluid and solute transport in dialyzer consists of two processes: transport through a 
permselective membrane between blood and dialysate and transport in blood and dialysate 
channels. 
The theoretical description of transport through a permselective membrane is based on 
phenomenological (thermodynamic) descriptions according to the Staverman-Kedem-
Katchalsky-Spiegler approach (Staverman, 1951; Kedem & Katchalsky, 1958; Katchalsky & 
Curran, 1965; Spiegler & Kedem, 1966; Weryński & Nowosielcew, 1983; Werynski & 
Waniewski, 1995; Waniewski, 2006). Diffusion is the dominant factor for small solute 
transport in hemodialyzer. The transport due to convection prevails in hemofilters, plasma 
separators, etc. In hemodialyzer with highly permeable membrane used in 
hemodiafiltration, the convective transport component plays a leading role in the removal of 
middle molecules and small proteins (Werynski & Waniewski, 1995). 
Considering the dialyzer as shown in Fig. 1, the system will soon after the start of dialysis be 
at the quasi-steady state with the mass balance: 
 ( ) ( )b,i b,i d,i d,i b,i v b,o d,i v d,oQ C Q C Q Q C Q Q C+ = − + +  (1) 
where Qb,o = Qb,i – Qv and Qd,o = Qd,i + Qv are the rates of blood and dialysate flows at the 
outlet of hemodialyzer, respectively, Qv is ultrafiltration rate, Cb,i and Cd,i are the inlet blood 




Fig. 1. Schematic description of concentration and flows in dialyzer. 
After rearrangement of equation (1): 
 ( ) ( )b,i b,i b,o v b,o d,i d,o d,i v d,oQ C C Q C Q C C Q C− + = − +  (2) 
The left side of equation (2) represents the solute leaving the blood; the right side is the 
solute appearing in dialysate. The first term on each side of equation (2) is the diffusive 
component of flux and the second term represents the convective contribution. 
At any specific blood and dialysis fluid flow rates, the diffusive dialysance D is the change 
in solute amount of incoming blood over concentration driving force (Cb,i – Cd,i): 
Cd,o, Qd,o 
Cb,o, Qb,oCb,i, Qb,i 
Cd,i, Qd,i 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
6 
 ( ) ( )b,i b,i b,o d,i d,o d,i
b,i d,i b,i d,i
Q C C Q C C
D





Assuming that solute concentration in the inflowing dialysate is zero (Cd,i = 0) equation (3) 
yields the definition of diffusive clearance K: 
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Dialyzer clearance is a parameter that describes the efficiency of membrane devices, i.e. the 
solute removal rate from the blood related to blood solute concentration at the inlet to the 
hemodialyzer (Darowski et al., 2000; Waniewski, 2006). 
Ultrafiltration Qv from blood to dialysate increases diffusive solute transport from blood to 
dialysate and therefore the clearance of the hemodialyzer or hemofilter may be described as: 
 0 r vK K T Q= + ⋅  (5) 
where K0 is the diffusive clearance for Qv = 0 and Tr is the transmittance coefficient 
(Werynski & Waniewski, 1995; Darowski et al., 2000; Waniewski, 2006). Although the 
dependence of K on Qv in the one-dimensional theory is slightly nonlinear, one may assume 
the linear description used in equation (5) that was confirmed experimentally with high 
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The measurements of K0 and K for a few different values of Qv allow determining Tr using 
equation (6) and linear regression. 
2.2 One and two compartment models for the distribution of fluid and solutes in the 
body 
Compartment models consider the patient body as a single compartment (thick line in Fig. 
2) or as two compartments: intracellular and extracellular (dashed line in Fig. 2). 
The one compartment model of the solute distribution volume assumes that solute mass, 
Mb, is distributed in the body in a single, homogenous pool of volume Vb with concentration 
Cb. The two compartment model assumes that body fluid is divided into two parts: one 
directly (extracellular compartment, described by solute mass Me, concentration Ce and fluid 
volume Ve) and one indirectly (intracellular compartment, with solute mass Mi, 
concentration Ci and fluid volume Vi) accessible for dialysis (Schneditz & Daugirdas, 2001). 
It is assumed that solute generation, at the rate G, and water intake, at the rate Gw, occur 
only in the extracellular space. In the two compartment model, solute and water removal by 
the kidneys, with clearances Kr and Krw, respectively, are also related only to the 
extracellular compartment. 
Some authors use more general terminology for the two compartment model with perfused 
and non-perfused compartments, without deciding a priori about their physiological 
interpretation. This terminology may be used for the description of the distribution of small  
 
 




Fig. 2. One and two compartment models for the distribution of water and solutes in the body. 
solutes (as urea and creatinine) and proteins (as β2-microglobulin). In some papers, 
extracellular and intracellular water were called perfused and non-perfused compartments, 
respectively (Clark et al., 1999; Leypoldt et al., 2003; Leypoldt et al., 2004). 
In one compartment model the rate of the change of solute mass in the body, 
dMb/dt = d(CbVb)/dt, and in dialysate, dMd/dt = d(CdVd)/dt, during hemodialysis, are 
described by the following ordinary differential equations: 
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In the two compartment model, the removal of solute by the dialyzer with clearance K and 
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For urea and creatinine, Cd = 0 in standard hemodialysis and hemofiltration treatments, 
because fresh dialysis fluid without these solutes is continuously provided. The rate of total 
solute mass removal from the body, dMR/dt, during hemodialysis is: 
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The total solute amount removed from the body ΔMR is the mass removed by dialyzer with 
clearance K and by the kidneys with residual clearance Kr. The solute removal by dialyzer is 
proportional to the solute concentration gradient between dialysate and extracellular 
compartment (Ce – Cd) when using the two compartment model. In the one compartment 
model, the body solute concentration Cb is used in equation (9) instead of Ce. 
In the two compartment model, the changes of fluid volume in extracellular and 
intracellular compartments, Ve(t) and Vi(t), respectively, are assumed to be proportional to 
the volumes of these compartments (Canaud et al., 1995; Clark et al., 1998; Ziolko et al., 
2000): 
 ( )e b i bV (t) α V (t), V (t) 1 α V (t)= ⋅ = − ⋅  (10) 
where α is usually about 1/3, Vb for urea and creatinine is assumed to be equal to total body 
water (TBW) and Vb as well as Ve can be measured by bioimpedance (Zaluska et al., 2002). 
During HD the change of solute distribution volume is described by a linear relationship: 
 ( )b b 0V (t) V t β t= + ⋅  (11) 
where Vb(t0) is the initial volume of solute distribution and the rate of volume change: 
 w rw vβ G K Q= − −  (12) 
consists of water intake with rate Gw, residual water clearance Krw and ultrafiltration with 
rate Qv. 
3. Hemodialysis efficiency: history and definitions of dialysis adequacy 
indices 
The questions concerning how to quantify dialysis dose and how much dialysis should be 
provided, are controversial and have been debated since the beginning of the dialysis 
treatment era. Between 1976 and 1981, the National Cooperative Dialysis Study (NCDS) was 
performed in the United States to establish objective, quantitative criteria for the adequate 
dose of dialysis (Gotch & Sargent, 1985; Sargent & Gotch, 1989; Locatelli et al., 2005). It 
included 165 patients and had a 2 x 2 factorial design: the patients were randomized to two 
different midweek pre-dialysis blood urea nitrogen (BUN) levels (70 vs. 120 mg/dL) and 
two different treatment times (2.5 - 3.5 vs. 4.5 – 5.0 h). 
Concentration targeting in this study used a time average BUN concentration (Cta) of 
50 mg/dL (groups I and III) and 100 mg/dL (groups II and IV). Dialysis time was fixed for the 
protocol; hence, dialyzer clearance was the main treatment parameter that was adjusted. A one 
compartment variable volume model was used to prescribe and control the treatment. Urea 
kinetic modeling was applied to determine protein catabolic rate (pcr) and the parameters of 
dialysis necessary to achieve a specified BUN level with thrice weekly treatments. BUN 
changes in an individual patient were quantified as the product of dialyzer urea clearance (K, 
mL/min) and the treatment time (T, min), normalized to the urea distribution volume (V, mL). 
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Cpost and Cpre are postdialysis and predialysis blood urea concentration. KT/V was 
prescribed in the NCDS as a function of pcr and Cpre:  
 
pre
KT 0.49pcr 0.16)ln 1
V C
⎛ ⎞−
− = −⎜ ⎟⎜ ⎟
⎝ ⎠
 (14) 
The primary analysis showed that morbidity was less at lower levels of urea Cta and the 
number of deaths in patients assigned to groups II and IV was very high (Parker et al., 1983). 
No significant effect of treatment time was found, although there was a clear trend towards 
a benefit from longer dialysis (p = 0.06). 
The ‘mechanistic’ analysis of the NCDS data done by Gotch and Sargent launched the issue 
of urea KT/V (Gotch & Sargent, 1985). The patient groups II and IV, with high BUN, had 
low KT/V values at all levels of pcr and the groups I and III, with low pcr, had low levels of 
BUN and KT/V. For Kt/V > 0.8 the data base was comprised almost entirely of patient 
groups I and III with pcr > 0.8. KT/V < 0.8 provided inadequate dialysis with high 
probability of failure irrespective of pcr. 
The factor KT/V was described as the “fractional clearance of urea” (Gotch & Sargent, 1985). 
If K is the urea clearance and T is time, the term KT is a volume. The ratio of KT to V 
expresses the fraction of the urea distribution volume that is totally cleared from urea. 
3.1 Fast hemodialysis: two compartment effects, single-pool and equilibrated KT/V 
The human body has a large number of physical compartments. The mathematical 
description of body is usually simplified by considering it as single pool (one compartment) 
or as a few interconnected pools. In a multicompartment model, the solute and fluid 
transport between body spaces should be described. 
The one compartment model assumes that the body acts as a single, well mixed space and is 
characterized by: 1) high permeability of cells to the solute being modeled, 2) rapidly flowing 
blood that transports the solute throughout a totally perfused body. The assumptions of one 
compartment model for urea or creatinine during dialysis are valid as long as the flux of solute 
into and out of cells is faster than the flux of solute from the extracellular space accessible to 
dialysis. When the intercompartment flow between body compartments is too slow and 
constrained in comparison with the solute removal rate from the perfused compartment, then 
the solute behavior increasingly deviates from that of one compartment kinetics. 
With the available high efficiency dialyzers and the tendency to short-time, rapid dialysis at 
least the two compartment modeling appears to be necessary. The two compartment model 
assumes solute generation to and removal from the perfused space, which is for urea and 
creatinine typically the extracellular compartment. This assumption is considered 
reasonable because urea is produced in the liver and enters body water from the systemic 
circulation (Sargent & Gotch, 1989). Regarding creatinine, in most studies the previously 
determined urea distribution volumes for each patient were successfully used as an 
approximation for creatinine distribution space (Canaud et al., 1995; Clark et al., 1998; 
Waikar & Bonventre, 2009). 
The perfused (extracellular) compartment communicates with the non-perfused 
compartment (intracellular) according to the concentration gradient with an 
intercompartmental mass transport coefficient (Kc, mL/min). For a low value of Kc, the 
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discrepancy between one and two compartment modeling is larger because the immediate 
intercompartmental flow is precluded (Debowska et al., 2007b). 
Assuming one compartment model, a fixed distribution volume (no ultrafiltration) and no 
generation during the dialysis, as during a short HD session, the concentration of any solute 
can be described by the equation (Sargent & Gotch, 1989; Daugirdas et al., 2001): 
 K t /Vt preC C e
− ⋅= ⋅  (15) 
where Ct is the blood concentration of the solute at any time t during dialysis, Cpre is the 
blood concentration at the beginning of HD, K is the clearance of applied dialyzer, and V is 
the solute distribution volume. 
The single pool KT/V (spKT/V) for urea is determined from equation (15) as the natural 
logarithm (ln) of the ratio of postdialysis (Cpost) to predialysis (Cpre) plasma urea 







= − ⎜ ⎟⎜ ⎟
⎝ ⎠
 (16) 
The expression 1 – Cpost/Cpre, is called urea reduction ratio (URR): 







=  (18) 
A solute like urea or creatinine is however removed during hemodialysis more efficiently 
from the extracellular than from the intracellular compartment and its concentration in 
plasma falls faster than expected when assessed by one compartment modeling; this effect is 
called urea inbound (Daugirdas et al., 2001), Fig. 3. When dialysis is completed, the flow 
from intracellular to extracellular compartment causes a fast increase of postdialysis urea 
concentration in plasma, i.e., urea rebound (Daugirdas et al., 2001; Daugirdas et al., 2004), 
Fig. 3. Even if solute removal from a compartment directly accessible to dialyzer is relatively 
efficient during an intermittent therapy, the overall solute removal may be limited by slow 
intercompartmental mass transfer. Urea concentration measured in plasma represents the 
extracellular urea concentration. 
The effects of urea generation and urea removal due to solute convective transport that are 
not included in the basic relation between spKT/V and URR can be corrected by Daugirdas 
formula (Daugirdas, 1993): 
 spKT /V ln(R 0.008 T) (4 3.5 R) UF/W= − − ⋅ + − ⋅ ⋅  (19) 
where T is treatment time in hour, UF is ultrafiltration volume and W is the postdialysis 
weight (in kilograms). Single-pool kinetics overestimates however the removed amount of 
urea because of the postdialysis urea rebound, which is an compartmental effect, and 
therefore the equilibrated KT/V (eqKT/V) was introduced to clinical practice to be 
estimated by the following formula (Daugirdas et al., 2001): 
 e q e qeqKT /V ln(R 0.008 T) (4 3.5 R ) UF/W= − − ⋅ + − ⋅ ⋅  (20) 
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Fig. 3. The phenomena of the intradialytic drop in urea concentration in plasma (inbound), 







=  (21) 
C(Teq) is the urea concentration 30 to 60 minutes after the dialysis session. The eqKT/V is 
typically about 0.2 KT/V unit lower than the spKt/V, but this difference depends on the 
efficiency, or rate of dialysis (Daugirdas et al., 2001). Equilibrated KT/V values can be also 
calculated using an alternative equation, as described by Daugirdas and Schneditz 
(Daugirdas & Schneditz, 1995): 
 spKT /VeqKT /V spKT /V 0.6 0.03
T
= − ⋅ +  (22) 
or the formula derived from observations during the HEMO Study (Depner et al., 1999; 
Eknoyan et al., 2002; Daugirdas et al., 2004): 
 spKT /VeqKT /V spKT /V 0.39
T
= − ⋅  (23) 
or  that introduced by Tattersall et al. (Tattersall et al., 1996): 





where T indicates treatment time in minutes. Equations (22) and (23), were derived from 
regression using the rebounded BUN measured 30 or 60 minutes after dialysis. The 
Tattersall equation was derived from theoretical considerations of disequilibrium and 
rebound, but the coefficient was derived from fitting to clinical data. 
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3.2 Urea KT/V and creatinine clearance for the kidneys 
To assess the residual renal function (RRF) urine is usually collected for 24 hours and 
analyzed for urea as well as creatinine (Daugirdas et al., 2001). Residual renal clearance for a 
particular substance can be calculated as follows: 
 urine urine rr
e urine e urine e
excretion rate C V 1 ΔM 1K
C T C T C
= = =  (25) 
where Vurine is urine volume, Curine is solute concentration in urine, Turine is time of urine 
collection, Ce is plasma solute concentration and ΔMr is solute mass removed by the 
kidneys. Weekly KT/V for the kidney for 1 week time is expressed as follows: 
 ( ) urine urine rRRF
e b b
7 C V 7 ΔMweekly KT /V
C V M
⋅ ⋅
= =  (26) 
where Mb is solute mass in the body, Vb is TBW and other symbols have the same meaning 
as in equation (25). 
In clinical practice, the most popular methods used for evaluation RRF is creatinine 
clearance (ClCr), calculated as follows: 
 R ,CrCr , RRF
e,Cr






where ΔMR,Cr is creatinine total mass removed during one day due to therapy and by 
residual renal function, Ce,Cr is serum creatinine concentration, BSA is body surface area and 
1.73 is the average BSA for a typical human. Weekly creatinine clearance is the most often 
expressed in L for 1 week. 
3.3 Equivalent renal clearance (EKR) 
In a steady state, during continuous dialytic treatment or/and with renal function, the 
solute generation rate G is balanced by the solute removal rate Kss determining in this way 
the constant concentration Css  within the patient body (Gotch, 2001): 
 ss ssC G/K=  (28) 
The Kss is defined by rearrangement of equation (28): 
 ss ssK G/C=  (29) 
Calculation of a continuous clearance Kss, equivalent to the amount of dialysis provided by 
any intermittent dialysis schedule, Keq, requires calculation of G and the concentration 
profile, and selection of a point on this profile, which may be considered to be equivalent to, 
e.g. weekly, the oscillating concentration (Ceq) according to: Keq = G/Ceq. This approach to 
the clearance calculation has been reported using different definitions of Ceq. The peak 
concentration hypothesis defined Ceq as the maximum solute concentration, within e.g. one 
week duration. The mean predialysis (peak average) solute concentration was used to define 
standard K (stdK) (Gotch, 1998). The time-average solute concentration (Cta) has been 
introduced to define ‘equivalent renal clearance’ (EKR) (Casino & Lopez, 1996): 
 







=  (30) 
The equation (30) may be used in metabolically stable patients, whereas in acute renal failure 





=  (31) 
where ΔMR is total solute amount removed by replacement therapy and the kidneys, and T 
is arbitrary assumed time. EKR, in the form of equation (31), is determined as solute 
removal rate over time average solute concentration.  
3.4 Standardized KT/V 
Taking into account the average predialysis urea concentration, Gotch introduced the 
standard KT/V (stdKT/V) concept to measure the relative efficiency of the whole spectrum 
of dialytic therapies whether intermittent, continuous or mixed (Gotch, 1998). The stdKT/V 
was defined with a relation between urea generation, expressed by its equivalent 
normalized protein catabolic rate (nPCR) and the peak average urea concentration (Cpa) of 
all the weekly values (Gotch, 1998; Diaz-Buxo & Loredo, 2006): 
 
pa
0.184(nPCR 0.17) V 0.001 7 1440stdKT /V
C V
− ⋅ ⋅ ⋅
= ⋅  (32) 
where 0.184(nPCR – 0.17) V·0.001 is equal to urea generation rate G (mg/min), V is body 
water in mL and 7·1440 is number of minutes in one week´s time. Predialysis urea 
concentration (Cpa) - for any combination of frequency of intermittent HD (IHD), automated 
peritoneal dialysis (APD) and continuous dialysis between IHD or APD sessions - was 
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where K, Kp and Kr are dialyzer, peritoneal and renal urea clearances, respectively, T is 
duration of treatment sessions, N is the frequency of IHD or APD per week and eqKT/V is 
the equilibrated KT/V calculated according to equation (22). 
Assuming a symmetric weekly schedule of dialysis sessions, no residual renal function, and 
a fixed solute distribution volume V, Leypoldt et al. obtained an analytical relationship 
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where N is number of treatments per week and eqKT/V is derived from spKT/V by using 
one of the equations (20), (22), (23) or (24). stdKT/V calculated using equation (34) differs 
slightly from stdKT/V using the exact method, equation (32), that takes into account among 
other things asymmetry of weekly schedule and Kr (Leypoldt et al., 2004). The stdKT/V is a 
method to measure the efficiency of HD of variable frequency, continuous peritoneal 
dialysis (PD), intermittent PD, continuous renal replacement therapies and residual renal 
function (Diaz-Buxo & Loredo, 2006). 
3.5 Solute removal index (SRI) and fractional solute removal (FSR) 
An alternative for KT/V is fractional solute removal (FSR), which was suggested by Verrina 
et al. (Verrina et al., 1998) and Henderson (Henderson, 1999) for comparative studies of 
different dialysis modalities and schedules. The concept of FSR is closely related to the 
concept of the solute removal index (SRI) proposed by Keshaviah (Keshaviah, 1995). 
SRI was defined for HD as the ratio of net solute removed during a dialysis session (i.e., the 
solute amount removed minus the solute amount generated in the same time period) over 
the initial solute amount in the body. This parameter is however useless for comparative 
analysis of different dialysis modalities and schedules. Its numerical value for the kidneys 
and continuous therapies, such as continuous ambulatory peritoneal dialysis (CAPD), is by 
definition equal to zero (Waniewski & Lindholm, 2004). Therefore, Keshaviah (Keshaviah, 
1995) used for CAPD and automated peritoneal dialysis the definition of SRI as the ratio of 
solute removed during a dialysis session over its initial amount in the body, i.e., the 
definition of FSR. 
3.6 International guidelines on HD dose 
According to the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines the 
minimally adequate dose of thrice-weekly HD in patients with residual renal clearance (Kr) 
less than 2 mL/min/1.73 m2 should be urea single pool KT/V (excluding residual renal 
function) of 1.2 per dialysis (i.e., an average urea reduction ratio of 65%), (Work Group, 
2001). KDOQI Work Group emphasizes that the literature clearly supports the delivery of a 
minimum hemodialysis dose of at least urea spKt/V = 1.2, but does not suggest an optimal 
dose. Identification of an optimal dose of hemodialysis would require evaluation of patient 
status and clinical outcomes including survival analyses and assessment of quality of life as 
well as the cost-effectiveness of different hemodialysis regimens. Until such data are 
available, the Work Group states that the hemodialysis dose recommended is to be regarded 
as a minimum value only (Work Group, 2001; Work Group, 2006). 
The European Best Practice Guidelines recommend higher values: the minimum prescribed 
HD dose per session for thrice-weekly schedule as equilibrated KT/V for urea is set at 1.2; 
this corresponds to a value of  spKT/V equal to 1.4 (Work Group, 2002). 
4. Integrated system of dialysis adequacy indices 
The integrated system of dialysis adequacy indices aims to include currently applied 
indices, systemize their definitions and explain relationships between them. The unified 
approach to the dialysis adequacy proposed by Waniewski et al. is valid for all modalities of 
dialysis performed in end-stage renal disease and acute renal failure patients, and for the 
assessment of residual renal function (Waniewski et al., 2006; Debowska et al., 2010; 
Waniewski et al., 2010).  
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4.1 Different definition variants of KT/V, equivalent continuous clearance (ECC) and 
fractional solute removal (FSR) 
For the assessment of dialysis efficacy, a few different adequacy indices can be used: 
a) KT/V (K – dialyzer clearance, T – treatment time, V – solute distribution volume), 
b) equivalent continuous clearance, ECC and c) fractional solute removal, FSR.  
There are at least four different reference methods: 1) peak, p, 2) peak average, pa, 3) time 
average, ta, and 4) treatment time average, trta, reference values of concentration, mass and 
volume, applied in ECC, FSR and KT/V definitions, respectively (ref = p, ref = pa, ref = ta 
and ref = trta), (Waniewski et al., 2006). For certain applications also minimal average or 
minimal reference methods are used, e.g. in equation (19) post-dialysis minimal weight is 
included in calculation of spKT/V. The peak value is the maximal value of solute 
concentration or mass, the peak average value is calculated as the average of pretreatment 
values (before each HD session), the time average value is the average calculated over the 
whole cycle of dialysis, Tc, and the treatment time average value is calculated as the average 
for the time T when dialysis was performed, Fig. 4. 
 
.  
Fig. 4. Examples showing urea concentration in extracellular compartment (left side) and 
urea mass in patient body (right side) during a cycle of three hemodialysis sessions. 
The reference solute distribution volume is calculated as the reference mass over the 
reference concentration: 
 ref b,ref refV M /C=  (35) 
Note, that Vref defined in this way may be different from the volume calculated in analogy to 
Cref or Mb,ref; for example, Vta is in general different from the average volume over the 
treatment time. 
For HD, dialyzer clearance K is equal to the average effective dialyzer clearance KT defined 
as solute mass removed from the body during dialysis MRd, per the treatment time, T, and 
per the average solute concentration in extracellular compartment during treatment time, 
Ctrta (K = KT = ΔMRd/T/Ctrta), (Waniewski & Lindholm, 2004; Waniewski et al., 2006). 
Another concept of clearance, equivalent renal clearance, EKR (mL/min), was proposed by 
Casino & Lopez for metabolically stable patients, equation (30), but for metabolically 
unstable patients equation (31) should be used (Casino & Lopez, 1996; Casino & Marshall, 
2004), c.f. section 3.3. Using a different concentration in EKR instead of Cta, a general 
definition of equivalent continuous clearance, ECC, may be formulated (Waniewski et al., 
2006; Waniewski et al., 2010), Table 1: 
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where N is number of treatments per week and eqKT/V is derived from spKT/V by using 
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where index "ref" denotes a reference concentration, e.g. ref = ta or ref = p, etc. If the patient 
is in a steady metabolic state, i.e. after a cycle time (Tc) the solute concentration and solute 
mass in the body return to their initial values, then the total amount of solute removed 
during Tc is equal to the solute amount generated during Tc. Thus, for the metabolic steady 
state and t = Tc: 
 R cΔM G T= ⋅  (37) 
If one scales the total removed solute mass to some reference mass (Mb,ref) then a 
nondimensional parameter – fractional solute removal, FSR – may be defined as follows 






FSR is often called the solute removal index (SRI), although originally SRI was defined as 
the solute amount removed minus the solute amount generated in the same time over the 
initial solute amount in the body, Table 1, (Keshaviah, 1995; Waniewski & Lindholm, 2004, 
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defined by Gotch and used in some clinical and theoretical studies, Table 1 (Gotch, 1998; Gotch 
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et al., 2000; Leypoldt et al., 2003; Leypoldt et al., 2004; Waniewski et al., 2006). Both these 
clearances were defined initially for the metabolic steady state using formula (30), (Casino & 
Lopez, 1996; Gotch, 1998; Gotch et al., 2000), and were later generalized to the general case 
using formula (36), (Casino & Marshall, 2004; Debowska et al., 2010). 
ECC and FSR are not independent indices but they are correlated (Debowska et al., 2005; 
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where ECCref and FSRref may be calculated for the same time interval t; a practically 
important case is t = Tc. The coefficient of proportionality, Vref/t, depends on the choice of 
reference method, because Vref is defined as Vref = Mb,ref/Cref, equation (35). Furthermore, if 
t = Tc and the residual renal clearance is Kr, then FSR is related to KT/V (Waniewski et al., 
2006): 
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where ΔMRd and ΔMr are the removed solute mass by replacement therapy and the kidneys, 
respectively. Another correlation can be found between ECC and K for t = Tc (Waniewski et 
al., 2006): 
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The relationships between ECC and FSR, FSR and KT/V and between ECC and K, equations 
(39), (40) and (42), respectively, follow directly from their definitions and are valid for all 
reference methods and any patient and treatment modality (Waniewski et al., 2006). They 
do not depend on the assumption of the metabolic steady state. However, the coefficients in 
these relationships, which involve the ratios of different reference concentrations, must be 
calculated for each patient and treatment schedule separately. 
4.2 Typical modalities and schedules for hemodialysis 
Different dialysis modalities and schedules are applied in clinics to treat patients with end-
stage renal diseases. Although solute removal indices are normalized by the solute amount 
in the body (with the body size included), many other parameters and conditions may differ 
as the patients are treated by different forms of dialysis (continuous or automated PD, HD, 
or combination of PD and HD), different number of sessions per week, different duration of 
each session, and therefore the values of dialysis adequacy indices depend on the details of 
dialysis. Numerical simulations of different HD regimes were performed using solute 
kinetic modeling and the obtained solute mass, concentration and distribution volume 
profiles in body compartments and solute concentration, mass and volume of dialysate were 
used to calculate dialysis adequacy indices. The two compartment variable volume model, 
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equation (8), was implemented in the computer program Matlab and solved by numerical 
integration (Runge-Kutta method) to describe the solute and fluid transport between patient 
and removal device during dialysis. 
4.3 Comparison of adequacy indices for different HD regimes based on computer 
simulations 
The objective of the analysis presented here was to compare different adequacy parameters 
and their different definitions for different schedules of HD, Table 2: 
1. Conventional, daily hemodialysis with three 219-minute sessions (HD3x) 
2. Daily hemodialysis with six 147-minute sessions (HD6xd) 
3. Nocturnal hemodialysis with six 401-minute sessions (HD6xn) 
Values of HD duration and dialyzer clearance were taken to be the average for patients 
groups enrolled in the Frequent Hemodialysis Network Daily and Nocturnal clinical trails 
(Daugirdas et al., 2010). Computer simulations were carried out for several weeks of the 
treatment to achieve the metabolic steady state of the patient.  
 
Label Time schedule K, mL/min 
HD3x 3 x 219 min 272 
HD6xd 6 x 147 min 277 
HD6xn 6 x 401 min 170 
Table 2. Time schedule and dialyzer clearance K for: conventional hemodialysis provided 
three times a week (HD3x), daily hemodialysis carried out six times a week (HD6xd) and 
long, nocturnal hemodialysis (HD6xn). 
Other parameters were: urea generation rate, G = 7 mg/min, residual urea clearance 
Kr = 0.6 mL/min. The convective transport of the solute was characterized by transmittance 
coefficient, Tr = 0.3, equation (5), for hemodialyzer. For the two compartment model, it was 
assumed that the intercompartmental clearance Kc = 600 mL/min and volumes of 
extracellular and intracellular compartments were changed according to equation (10) with 
α = 1/3. The postdialysis water distribution volume was Vb = 40 L; water was generated 
with constant rate (Gw = 1.04 mL/min); weekly 10.5 L of water was removed by means of 
residual water clearance (Krw = 0.1 mL/min) and as a result of ultrafiltration Qv. 
The changes of urea concentration in the extracellular compartment of the body and the 
values of FSR, as obtained by computer simulations using parameters from Table 2, were 
shown in Fig. 5 and Fig. 6. The time average concentration, Cta, was 0.5 mg/mL in 
conventional HD performed three times per week and 0.36 mg/mL and 0.22 mg/mL for 
daily and nocturnal HD carried out six times per week, respectively, Fig. 5 and Table 3. The 
amplitude of urea concentration changes had the highest values for HD3x and the lowest for 
HD6xn, Fig. 5 and Table 3. 
The weekly values of ECC and FSR, according to all methods for the definition of reference 
values, equations (36) and (38), and the respective values of urea concentrations in blood, 
Cref, are shown in Table 3. The adequacy indices were different, with the indices ECC and 
FSR for HD3x being lower than for HD6xd and HD6xn, Table 3.  
The adequacy indices, ECC and FSR, had the highest values for the definitions based on 
treatment time (trta) reference method and the lowest values for the definitions based on the 
peak reference method (Table 3), and were between weekly ECCta = 14.03 mL/min and 
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Fig. 5. Urea concentration, Ce, in the extracellular compartment during conventional 
hemodialysis provided three times a week (HD3x), daily hemodialysis carried out six times 
a week (HD6xd) and long, nocturnal hemodialysis (HD6xn). Average urea concentration 
was plotted with dashed line. 
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Fig. 5. Urea concentration, Ce, in the extracellular compartment during conventional 
hemodialysis provided three times a week (HD3x), daily hemodialysis carried out six times 
a week (HD6xd) and long, nocturnal hemodialysis (HD6xn). Average urea concentration 
was plotted with dashed line. 
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Fig. 6. FSR, normalized by peak, p, peak average, pa, time average, ta, and treatment time 
average, trta, urea mass in the body during conventional hemodialysis provided three times 
a week (HD3x), daily hemodialysis carried out six times a week (HD6xd) and long, 
nocturnal hemodialysis (HD6xn). 
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FSRpa = 2.26 for HD3x and weekly ECCta = 32.3 mL/min and FSRpa = 5.44 for HD6xn, 
indicating more efficient solute removal with HD6xn. The difference between the values of 
the indices calculated according to different definitions (treatment time average, time 
average, peak average, peak) was high (up to 192%). 
The ratio of ECC and FSR differed slightly between the modalities and definitions (range, 
4.04 - 4.96 mL/min) and correlated with the fluctuations of water volume and urea 
concentration in the body, as shown by Vref, Table 3. Nevertheless, equation (39) is valid for 
all investigated applications. Because the cycle time was the same for all simulated dialysis 
modalities, Tc = 1 week, thus the correlation between the ratio of ECC to FSR and water 
volume confirmed the relationship described by equation (39). 
 
  ECC FSR 
ECC
FSR
 Vref Cref 
HD3x p 8.42 1.94 4.34 43.76 0.83 
 pa 9.62 2.26 4.25 42.85 0.73 
 ta 14.03 3.38 4.16 41.90 0.50 
 trta 18.83 3.80 4.96 50.01 0.37 
HD6xd p 11.28 (34%) 2.69 (39%) 4.20 42.32 0.62 
 pa 14.84 (54%) 3.64 (61%) 4.08 41.11 0.47 
 ta 19.71 (40%) 4.85 (43%) 4.07 40.99 0.36 
 trta 25.31 (34%) 5.26 (38%) 4.81 48.46 0.28 
HD6xn p 14.25 (69%) 3.42 (76%) 4.17 41.99 0.49 
 pa 21.94 (128%) 5.44 (141%) 4.04 40.69 0.32 
 ta 32.3 (130%) 7.95 (135%) 4.06 40.93 0.22 
 trta 41.66 (121%) 9.35 (146%) 4.45 44.90 0.17 
Table 3. Weekly ECC, FSR, the ratio of ECC to FSR, the solute distribution volume, Vref,  and 
urea concentration in extracellular compartment, Cref, calculated according to four different 
definitions: peak (p), peak average (pa), time average (ta) and treatment time average (trta) 
for conventional hemodialysis provided three times a week (HD3x), daily hemodialysis 
carried out six times a week (HD6xd) and long, nocturnal hemodialysis (HD6xn). Values in 
brackets present the difference in relation to conventional HD (in percent). 
The formula for the relationship between FSR and KT/V, equation (40), shows that FSR may 
be represented as a weighted sum of KT/V and KrTc/V, with the first term representing the 
urea removal by dialysis and the second one, the urea removal by residual clearance. The 
weighing coefficients are the ratios of the average urea concentration in blood during 
dialysis treatment over the reference urea concentration and the average urea concentration 
in blood during the whole treatment cycle over the reference concentration, respectively, 
Table 4. These coefficients depend on the reference method as well as the treatment 
modality and schedule. 
ECC may be related to K and Kr using equation (42). For that purpose K must be 
recalculated by the factor T/Tc, and then the recalculated value of K and the value of Kr are 
summed up with the same weighing coefficients that appear in formula (40) for the 
relationship of FSR and KT/V. The weighing coefficients show how much the average 
concentrations, during effective treatment time T, and during the whole cycle time Tc, 
respectively, differ from the reference concentration, Table 4. 
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Fig. 6. FSR, normalized by peak, p, peak average, pa, time average, ta, and treatment time 
average, trta, urea mass in the body during conventional hemodialysis provided three times 
a week (HD3x), daily hemodialysis carried out six times a week (HD6xd) and long, 
nocturnal hemodialysis (HD6xn). 
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be represented as a weighted sum of KT/V and KrTc/V, with the first term representing the 
urea removal by dialysis and the second one, the urea removal by residual clearance. The 
weighing coefficients are the ratios of the average urea concentration in blood during 
dialysis treatment over the reference urea concentration and the average urea concentration 
in blood during the whole treatment cycle over the reference concentration, respectively, 
Table 4. These coefficients depend on the reference method as well as the treatment 
modality and schedule. 
ECC may be related to K and Kr using equation (42). For that purpose K must be 
recalculated by the factor T/Tc, and then the recalculated value of K and the value of Kr are 
summed up with the same weighing coefficients that appear in formula (40) for the 
relationship of FSR and KT/V. The weighing coefficients show how much the average 
concentrations, during effective treatment time T, and during the whole cycle time Tc, 
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HD3x p 4.15 0.14 0.45 0.60 1.94 
 pa 4.24 0.14 0.51 0.69 2.26 
 ta 4.34 0.14 0.75 1.00 3.38 
 trta 3.63 0.12 1.00 1.34 3.80 
HD6xd p 5.85 0.14 0.45 0.57 2.69 
 pa 6.02 0.15 0.59 0.75 3.64 
 ta 6.04 0.15 0.78 1.00 4.85 
 trta 5.10 0.12 1.00 1.28 5.26 
HD6xn p 9.82 0.14 0.34 0.44 3.42 
 pa 10.13 0.15 0.53 0.68 5.44 
 ta 10.07 0.15 0.78 1.00 7.95 
 trta 9.18 0.13 1.00 1.29 9.35 
Table 4. Nondimensional parameters KT/Vref, residual KrTc/Vref, the ratio of treatment time 
average to reference urea concentration Ctrta/Cref, the ratio of time average to reference urea 
concentration Cta/Cref and fractional solute removal, FSR, equation (40), for conventional 
hemodialysis provided three times a week (HD3x), daily hemodialysis carried out six times 
a week (HD6xd) and long, nocturnal hemodialysis (HD6xn). 
ECC and FSR were found to be equivalent descriptions of dialysis, if the same reference 
method (peak, peak average, time average, treatment time average) was used, as suggested 
by equation (39). The ratio of ECC and FSR was similar for all definitions, in contrast to 
much different values of the indices themselves. 
5. Adequacy indices for steady and non-steady metabolic state 
The change of solute mass in the body during dialysis is due to the generation minus 
removal, but, in general, one can not assume that the solute removal is equal to the 
generation during the cycle time (i.e. intra- plus inter-dialysis time), especially in acute renal 
failure, ARF, patients; thus, even the measurement of removed solute in spent dialysate or 
filtrate does not necessarily accurately reflect the generated mass. In such cases, the real 
solute generation rate needs to be estimated using computer simulations for specific patients 
and dialysis parameters by fitting the theoretical predictions to the solute concentration 
profile using equation (8) for simulation. The calculation of FSR and ECC should then be 
based on equations (38) and (36) as it was shown by Debowska et al. (Debowska et al., 2010). 
6. Conclusions 
A unified scheme was proposed for the definitions of the adequacy indices on the basis of 
the reference values for: 1) normalization of removed solute mass to body solute mass (FSR), 
2) cleared water volume to urea distribution volume (KT/V), and 3) solute generation rate 
to solute concentration in blood (ECC). The selection of the reference method can be done 
using respectively: peak (p), peak average (pa), time average (over the whole treatment 
cycle, ta) and treatment time average (over time of all dialysis sessions during the treatment 
cycle, trta) values of solute mass or concentration. It is not clear a priori which reference 
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method should be used (ref = p, ref = pa, ref = ta or ref = trta) for the assessment of the 
treatment adequacy. To get a consistent scheme of definitions and relationships, the 
reference solute distribution volume was defined as Vref = Mb,ref / Cref. For each reference 
method, three adequacy indices, FSR, KT/V and ECC, can be defined. The computer 
simulations demonstrated that these indices are related, and that the relationships follow 
their definitions. 
In general, ECC is equivalent to FSR, equation (39), if the same type of reference method is 
applied for both parameters (Debowska et al., 2005; Waniewski et al., 2006). The coefficient 
of proportionality, Vref/Tc, depends only slightly on the details of the procedure, especially 
on the schedule of water removal and the degree of total body water variation during the 
treatment cycle as well as the difference between urea concentrations in intracellular and 
extracellular compartments that may develop during dialysis sessions. Nevertheless, the 
variations of Vref between different definitions and procedures for the same patient are 
small. If a reference method (p, pa, ta, trta) of FSR and ECC definitions is fixed, then the 
changes in FSR are reflected by the changes in ECC and vice versa for the same patient. 
However, this relationship is different for patients with different total body water, which 
may also differ between patient populations. 
One advantage of using equivalent continuous clearance, ECC, or fractional solute removal, 
FSR, is that these indices permit comparison of hemodialysis and peritoneal dialysis doses, 
and allow the addition of the contributions from HD, PD and residual renal function into 
the whole index for solute removal efficiency, and thus these indices could provide a basis 
for setting one standard target dose for all patients regardless of dialysis modality, 
frequency and duration (Depner, 2005; Debowska et al., 2007a). Note that ECC and FSR may 
also be successfully applied in continuous and semi-continuous therapies (e.g. continuous 
veno-venous hemofiltration, CVVH, slow low-efficiency daily dialysis, SLEDD) in patients 
with acute renal failure (Clark et al., 1999; Leypoldt et al., 2003; Debowska et al., 2010). 
From the beginning of the era of dialysis treatment, there has been a quest for the optimal 
dialysis index. The history reflects the complexity of this matter, and attempts to simplify 
the meander way of this process that has not yet been finished because different versions of 
existing dialysis modalities are applied, new therapies are being introduced into clinical 
practices as new techniques become available. Compartmental models and solute kinetic 
analysis, presented here, used for the mathematical and computer-based description of 
delivered dose of dialysis are important tools for the evaluation of dialysis adequacy. 
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average to reference urea concentration Ctrta/Cref, the ratio of time average to reference urea 
concentration Cta/Cref and fractional solute removal, FSR, equation (40), for conventional 
hemodialysis provided three times a week (HD3x), daily hemodialysis carried out six times 
a week (HD6xd) and long, nocturnal hemodialysis (HD6xn). 
ECC and FSR were found to be equivalent descriptions of dialysis, if the same reference 
method (peak, peak average, time average, treatment time average) was used, as suggested 
by equation (39). The ratio of ECC and FSR was similar for all definitions, in contrast to 
much different values of the indices themselves. 
5. Adequacy indices for steady and non-steady metabolic state 
The change of solute mass in the body during dialysis is due to the generation minus 
removal, but, in general, one can not assume that the solute removal is equal to the 
generation during the cycle time (i.e. intra- plus inter-dialysis time), especially in acute renal 
failure, ARF, patients; thus, even the measurement of removed solute in spent dialysate or 
filtrate does not necessarily accurately reflect the generated mass. In such cases, the real 
solute generation rate needs to be estimated using computer simulations for specific patients 
and dialysis parameters by fitting the theoretical predictions to the solute concentration 
profile using equation (8) for simulation. The calculation of FSR and ECC should then be 
based on equations (38) and (36) as it was shown by Debowska et al. (Debowska et al., 2010). 
6. Conclusions 
A unified scheme was proposed for the definitions of the adequacy indices on the basis of 
the reference values for: 1) normalization of removed solute mass to body solute mass (FSR), 
2) cleared water volume to urea distribution volume (KT/V), and 3) solute generation rate 
to solute concentration in blood (ECC). The selection of the reference method can be done 
using respectively: peak (p), peak average (pa), time average (over the whole treatment 
cycle, ta) and treatment time average (over time of all dialysis sessions during the treatment 
cycle, trta) values of solute mass or concentration. It is not clear a priori which reference 
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method should be used (ref = p, ref = pa, ref = ta or ref = trta) for the assessment of the 
treatment adequacy. To get a consistent scheme of definitions and relationships, the 
reference solute distribution volume was defined as Vref = Mb,ref / Cref. For each reference 
method, three adequacy indices, FSR, KT/V and ECC, can be defined. The computer 
simulations demonstrated that these indices are related, and that the relationships follow 
their definitions. 
In general, ECC is equivalent to FSR, equation (39), if the same type of reference method is 
applied for both parameters (Debowska et al., 2005; Waniewski et al., 2006). The coefficient 
of proportionality, Vref/Tc, depends only slightly on the details of the procedure, especially 
on the schedule of water removal and the degree of total body water variation during the 
treatment cycle as well as the difference between urea concentrations in intracellular and 
extracellular compartments that may develop during dialysis sessions. Nevertheless, the 
variations of Vref between different definitions and procedures for the same patient are 
small. If a reference method (p, pa, ta, trta) of FSR and ECC definitions is fixed, then the 
changes in FSR are reflected by the changes in ECC and vice versa for the same patient. 
However, this relationship is different for patients with different total body water, which 
may also differ between patient populations. 
One advantage of using equivalent continuous clearance, ECC, or fractional solute removal, 
FSR, is that these indices permit comparison of hemodialysis and peritoneal dialysis doses, 
and allow the addition of the contributions from HD, PD and residual renal function into 
the whole index for solute removal efficiency, and thus these indices could provide a basis 
for setting one standard target dose for all patients regardless of dialysis modality, 
frequency and duration (Depner, 2005; Debowska et al., 2007a). Note that ECC and FSR may 
also be successfully applied in continuous and semi-continuous therapies (e.g. continuous 
veno-venous hemofiltration, CVVH, slow low-efficiency daily dialysis, SLEDD) in patients 
with acute renal failure (Clark et al., 1999; Leypoldt et al., 2003; Debowska et al., 2010). 
From the beginning of the era of dialysis treatment, there has been a quest for the optimal 
dialysis index. The history reflects the complexity of this matter, and attempts to simplify 
the meander way of this process that has not yet been finished because different versions of 
existing dialysis modalities are applied, new therapies are being introduced into clinical 
practices as new techniques become available. Compartmental models and solute kinetic 
analysis, presented here, used for the mathematical and computer-based description of 
delivered dose of dialysis are important tools for the evaluation of dialysis adequacy. 
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1. Introduction 
Intradialytic hypotension (IDH) is the most common complication of hemodialysis (HD), 
occurring in up to 20 to 33% of sessions (Daugirdas, 2001). IDH is responsible for various 
minor symptoms (nausea, vomiting, muscle cramps, dizziness, and fatigue) during dialysis, 
but is also associated with more severe adverse events such as myocardial infarction (Burton 
et al., 2009) and cerebral ischemia (Mizumasa et al., 2004). Moreover, as a result of frequent 
interruption of sessions and repetitive administration of intravenous fluids, underdialysis 
and inability to reach dry weight, with subsequent chronic overhydration, can follow.  
Traditionally, HD prescriptions are based on clinical evaluation and laboratory 
measurements, and are re-evaluated periodically or when an adverse event, such as 
hypotension, commands it. The drawback of this prescription is that it relies on previous 
observations, with the assumption that the same will hold true for the next sessions. Hence, 
it implies discomfort for the patients, as the actions to remediate to IDH, for example, by 
stopping ultrafiltration (UF) or adjusting dry weight, are taken on an a posteriori basis 
(Locatelli et al., 2005). 
In an attempt to prevent IDH, technological advances have made possible the detection of 
subclinical predictors of hemodynamic instability, for example relative blood volume 
variations. With repetitive measurement of such specific parameters during HD (Mercadal 
& Petitclerc, 2009), actions can be implemented to correct the monitored parameter toward a 
desired target, with the aim of preventing overt IDH. When this action is automatic and 
regulated by a closed feedback loop, it is called biofeedback.  
In this chapter, we will review some of the physiological basis of IDH and blood volume 
reduction during HD, and we will examine the technical aspects of the various devices used 
to adjust blood volume during dialysis, with special emphasis on biofeedback systems. 
Finally, we will study the literature published on the effects of automated blood volume 
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1. Introduction 
Intradialytic hypotension (IDH) is the most common complication of hemodialysis (HD), 
occurring in up to 20 to 33% of sessions (Daugirdas, 2001). IDH is responsible for various 
minor symptoms (nausea, vomiting, muscle cramps, dizziness, and fatigue) during dialysis, 
but is also associated with more severe adverse events such as myocardial infarction (Burton 
et al., 2009) and cerebral ischemia (Mizumasa et al., 2004). Moreover, as a result of frequent 
interruption of sessions and repetitive administration of intravenous fluids, underdialysis 
and inability to reach dry weight, with subsequent chronic overhydration, can follow.  
Traditionally, HD prescriptions are based on clinical evaluation and laboratory 
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hypotension, commands it. The drawback of this prescription is that it relies on previous 
observations, with the assumption that the same will hold true for the next sessions. Hence, 
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stopping ultrafiltration (UF) or adjusting dry weight, are taken on an a posteriori basis 
(Locatelli et al., 2005). 
In an attempt to prevent IDH, technological advances have made possible the detection of 
subclinical predictors of hemodynamic instability, for example relative blood volume 
variations. With repetitive measurement of such specific parameters during HD (Mercadal 
& Petitclerc, 2009), actions can be implemented to correct the monitored parameter toward a 
desired target, with the aim of preventing overt IDH. When this action is automatic and 
regulated by a closed feedback loop, it is called biofeedback.  
In this chapter, we will review some of the physiological basis of IDH and blood volume 
reduction during HD, and we will examine the technical aspects of the various devices used 
to adjust blood volume during dialysis, with special emphasis on biofeedback systems. 
Finally, we will study the literature published on the effects of automated blood volume 
regulation devices on the occurrence of hypotensive episodes, volume overload control, 
hypertension management and quality of life in chronic HD patients.   
2. Intradialytic hypotension 
The causes of IDH are multifactorial. On one side, a number of patient-related conditions 
can promote blood pressure (BP) fall during HD: age, comorbidities such as diabetes and 
cardiomyopathy, anemia, large interdialytic weight gain (IDWG), use of anti-hypertensive 
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medication, etc. On the other hand, factors associated with the dialysis prescription itself can 
also contribute to hemodynamic instability: short HD sessions, high ultrafiltration rate, high 
dialysate temperature, low dialysate sodium concentration, inflammation caused by 
membrane activation, etc. As a consequence, various interventions aimed at modulating 
these parameters have been proposed to ameliorate the vascular tolerance to ultrafiltration 
(UF), but with variable efficacy and limited benefits. 
On a physiological basis, IDH can be viewed as the inability of the cardio-vascular system to 
respond adequately to the reduction of blood volume. Cardio-vascular reactivity involves 
reflex activation of the sympathetic system, with appropriate tachycardia and arterial and 
venous vasoconstriction in response to cardiac underfilling and hypovolemia. These 
compensatory mechanisms are altered in some patients, which put them at risk of 
developing IDH. However, these are difficult to assess and to modify. Comprehensive study 
of blood volume regulation during HD can help understand IDH susceptibility of 
individual patients. 
3. Blood volume regulation 
3.1 Concept of plasma refilling  
Blood volume is dependent on two main factors: plasma refilling capacity and UF rate. 
During HD, fluid is removed directly from the intravascular compartment. Total body water 
(TBW), which is about 60% of body weight (BW), is distributed in part in the intracellular 
(40% BW) and in part in the extracellular (20% BW) compartments. The latter is further 
subdivided in the interstitial (15% BW) and the intravascular (5% BW) spaces. Thus, only 8% 
of the TBW is readily available for UF. Therefore, in order to remove a substantial amount of 
fluid during a short period of time, the vascular compartment needs to be continuously 
refilled from the interstitial space. 
Plasma refill is mostly driven by hydrostatic and oncotic forces. During the first part of a 
HD session, the vascular oncotic pressure raises and the hydrostatic pressure lessens as a 
result of progressive UF.  Pressure gradients thus created drive the water back into the 
vascular space until a new equilibrium is reached. As UF and water withdrawal from the 
intravascular space continue, the new disequilibrium thereby generated has to be once again 
balanced, and so on until the end of the session (Santoro et al., 1996). Several factors can 
influence rate of plasma refilling by acting on these forces: hydration status, plasma 
osmolality, and plasma protein concentration. Patient’s proper refilling capacity, which is 
not measurable as a parameter, also has an effect on the rate at which water moves back in 
the blood vessels. Overall, IDH is generated when the imbalance between UF rate and 
plasma refilling capacity cannot be surpassed by cardio-vascular compensatory reflexes.  
3.2 Relative blood volume measurement 
Cardio-vascular reactivity and plasma refilling capacity of each patient, albeit central in the 
pathogenesis of IDH development, are difficult to assess and therefore are not convenient as 
monitoring tools. Direct measurement of blood volume is feasible, classically using dilution 
of radioactively labelled blood elements (such as 131I albumin or 51Cr red blood cells), but it 
implies serial blood tests and radiation, and so is clearly impractical for the repetitive 
assessment of blood volume. One way to circumvent this problem is to measure blood 
volume change during HD which, as a surrogate marker of vascular refilling, can be 
estimated using bedside devices.  
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Relative blood volume (RBV) is the term used to describe « the blood volume at any time as 
a percentage of the blood volume at the commencement of treatment » (Nesrallah et al., 
2008). Most of the non-invasive devices extrapolate the RBV change from the variation of the 
hemoconcentration of a blood element. The basic premise of this calculation is that if the 
blood component remains constant throughout the HD session (i.e., the numerator), the 
variation of its concentration is necessarily due to the change in the blood volume (i.e., the 
denominator). The various devices available vary in the blood element they measure (i.e., 
red blood cells, hematocrit, total protein concentration) and in the method used to measure 
it (i.e., optical absorbance, ultrasound, etc.). 
One caveat of these techniques is that they are based on the assumption that uniform mixing 
of the measured blood element and plasma occurs throughout the whole circulation 
(Dasselaar et al., 2007a). Venous (or systemic) hematocrit (Hctsys) is usually higher than 
whole-body hematocrit (Hctw), due to the dynamic reduction of hematocrit in the 
microcirculation during blood flow through capillaries and venules. This is expressed as the 
F-cell ratio, Hctw/Hctsys. However, during UF, it was shown that the F-cell ratio rises as a 
result of the compliance of the microcirculation and fluid transfer to the macrocirculation. 
Therefore, the equations on which the inference of the blood volume change during HD is 
based may not be always valid (Mitra et al., 2004).  
In a study from Dasselaar et al. (2007a), the blood volume reduction estimated by three 
commonly used devices (Crit-line®, Hemoscan® and BVM®, see below) was compared to a 
standard laboratory-derived Hb relative blood volume measurement during two HD 
sessions. It was shown that all three devices systematically overestimate the RBV reduction 
at modest RBV change, and underestimate the real fall in blood volume at higher RBV 
decline.  
In addition, RBV monitoring also assumes that red blood cell mass or plasma protein 
density remains constant throughout the length of the session, which may not be true if 
hemolysis or blood leak happens, or when a blood transfusion is given.  
3.3 Relation between relative blood volume and intradialytic hypotension 
While hypovolemia is clearly a major determinant in the pathogenesis of IDH, the link 
between blood volume reduction and appearance of arterial hypotension is still a matter of 
debate. Recent studies have been unable to find a linear relationship between RBV and 
blood pressure, and a specific threshold to which hypotension will certainly occur does not 
seem to exist, even in an individual patient. This is probably because of variations, for each 
treatment, in the patient’s ability to activate cardio-vascular compensatory mechanisms, in 
order to offset BP reductions induced by a wide range of hypovolemic states.  
In fact, in many trials where blood volume (BV) biofeedback was effective in reducing the 
occurrence of IDH, there was no difference in the final RBV reached by either the standard 
treatment or the BV-controlled treatment. According to some authors, it is possible that RBV 
reduction per se is not the main risk factor for development of IDH. Rather, the excessive 
fluctuations of BV and the form of the RBV slope during HD may contribute more to 
hemodynamic instability (Andrulli et al., 2002). Indeed, the slope of the RBV curve with BV 
regulation device is different from that produced by standard HD (Franssen et al, 2006). The 
initial phase is usually steeper (meaning higher UF rate), which is rendered possible and 
tolerable because of higher initial interstitial pressures and better plasma refilling rate. The 
second phase is characterized by a reduced UF rate, which in turn make the RBV more 
stable and the patient less prone to IDH in this vulnerable period.   
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4. Biofeedback system 
While monitoring may help to understand how BV is regulated during UF in an individual 
patient, the HD prescription often remains empirical. The hemodynamic stability during the 
previous HD sessions dictates the delivered parameters of the next HD treatments. Dialytic 
parameters such as UF rate and dialysate sodium concentration are usually set at the start of 
the HD session, and remain fixed throughout the treatment, with the assumption that they 
continue to be adequate for the whole treatment duration. However, this is not taking into 
account that patients may undergo physiologic variations during HD, and that fixed 
parameters, creating labile gradients, may not always be appropriate and may promote 
IDH. In fact, the standard HD prescription lacks a rapid retroactive response in case of 
variation of the monitored parameter, as the action to bring it back towards the desired 
value are taken manually (by the operator, a nurse or physician) or semi-automatically 
(authorized by the operator) (Locatelli et al., 2005), thus implying a certain lag of time that 
may be deleterious if IDH is to be prevented. 
The method used to traditionally prescribe HD parameters is far from how the kidneys 
really behave to maintain internal homeostasis, keeping biologic variables in very tight 
ranges through instantaneous adjustments in response to precise negative or positive 
feedback loops. To try to get closer to what would be called « physiological dialysis », 
technological advances of the last decades have conducted to the development of 
sophisticated softwares that allow automated biofeedback. The concept of biofeedback is 
based on repetitive on-line measurements of the patient’s biochemical parameters with 
biosensors, which are then constantly analysed by an automatic controller as being within 
the target values pre-set by the operator, or not. If the measured parameter is within the 
desired values considered safe, the treatment continues unchanged. If not, an action to bring 
it back towards the aimed values is immediately and automatically undertaken through the 
effectors, in a closed-loop that insures the stability of the monitored parameter.  
The theoretical advantage of such devices is that they not only rapidly detect physiological 
abnormalities which may predict hemodynamic instability (blood volume reduction for 
example), but they automatically adjust one or more dialytic parameters to correct the 
situation.  This obviates the need to perform manual changes by the operator and, at the same 
time, avoids the time lag before the action is undertaken. By modulating on-line some of the 
delivered dialysis parameter, these devices also address the physiological variations occurring 
during HD (and the variability of the patient’s parameters from session to session), and thus 
provide more physiological dialysis, which may be more suited to prevent IDH. 
At the present time, biofeedback systems are available for different parameters: relative 
blood volume, thermal energy balance, plasmatic conductivity, to which arterial pressure 
feedback using fuzzy logic control can be added. These devices are described here, with 
emphasis on blood volume biofeedback. 
5. Blood volume biofeedback 
Currently, only two commercially blood volume biofeedback devices are available: the 
Hemocontrol® (Gambro) and the BVM® (Fresenius) systems. Although both monitor 
change in relative blood volume during HD, they use different technologies and different 
integration systems. They are reviewed here.  
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5.1 Hemocontrol® system 
The Hemocontrol® blood volume management system was first designed by Santoro and 
colleagues (Santoro et al., 1994) and afterwards modified in collaboration with the Hospal-
Gambro research group. It is available on the Integra® and Artis® machines (with a few 
updates on the latter).  
This biofeedback system is based on an automatic multi-input multi-output controller 
(MIMO) capable of integrating a multitude of signals and to modulate controlled variables 
to force the blood volume reduction along a pre-defined trajectory towards a pre-defined 
target of blood volume reduction (Locatelli et al., 2005). This results in a smoother and more 
gradual decline of relative blood volume, limiting the irregularity of BV variation that was 
shown to be predictive of IDH (Andrulli et al., 2002). 
Basically, the monitored parameters are the actual UF (or weight loss), the actual dialysate 
sodium (or conductivity) and the actual blood volume change. The differences between the 
target values of the same three parameters (that is: desired UF, desired dialysate sodium (or 
equivalent conductivity) and desired final blood volume change) and the actual parameters 
serve as inputs to the MIMO controller. At any moment, the actual BV curve is plotted 
against the pre-determined BV trajectory and, should it deviate the least, automatic 
modulation of the UF rate and dialysate sodium (or conductivity) allows smooth redirection 
to the « ideal » curve (figures 1 and 2).  
The blood volume change during dialysis is monitored using an optical sensor located in the 
arterial line that measures on-line hemoglobin (Hb) concentration by optical absorbance, 
according to Lambert-Beer law. The law states that Hb is a function of monochromatic light 
absorbance. Provided that the amount of Hb does not change, the blood volume variation 







Fig. 1. Hemocontrol® biofeedback system (from Gambro). 
The three targets prescribed by the physician (total UF, final dialysate sodium, and final BV 
reduction) are computed in the Hemocontrol® software and are compared to the actual 
same parameters (UF, dialysate sodium, and RBV) on a continuous basis during HD. The 
controller can modulate the UF rate and dialysate sodium in order to bring the actual 
parameters back on the pre-determined trajectory of the RBV curve.   
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Fig. 2. Optimal trajectory of Relative blood volume (RBV) reduction during HD with 
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actual curve parallel to the optimal trajectory.  
In practical terms, several parameters need to be set. Before the first use, data on the 
patient’s sex, age, height and weight are needed to calculate total body water with any of the 
proposed formula. Treatment duration is also determined before the beginning of the 
treatment. Then, the three main targets need to be specified: 
1. Total body weight loss or total UF (for water balance), based on clinical evaluation of 
dry weight;  
2. Final sodium or equivalent dialysate conductivity. Conductivity refers to the electrical 
conducting property of the dialysis solution given by the dissociation of inorganic salts into 
charged ions. Since sodium is the principal ion in solution, conductivity is used as a 
surrogate for sodium concentration. For simplification purpose, conductivity was replaced 
by sodium concentration in the recent devices. Equivalent conductivity represents the 
dialysate conductivity that produces the same sodium balance at the end of a BV regulated 
session as a HD session with constant dialysate conductivity (Franssen et al., 2005); 
3. Relative BV change to be reached at the end of HD which is individually determined for 
each patient on the basis of anterior sessions. A short observation period 
(approximately two weeks) is usually required to analyse each patient’s BV curve 
morphology and to determine their respective BV/UF ratio. This ratio represents the 
%BV per each kilogram of UF fluid, and indirectly reflects the individual patient 
refilling plasma capacity. Depending on this ratio, and on the total UF prescribed for 
each dialysis, the final %BV can be adjusted. 
Of note, these three targets may sometimes be in conflict with each other, for example when 
large UF is prescribed for a patient with low plasma refilling rate (i.e. a high BV/UF ratio). 
The closed feedback loop system has then to reach the best compromise between the various 
targets and produce the most appropriate BV curve for this patient during that specific 
session.  
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Because of safety concerns, limits (or tolerance range) concerning maximum UF rate and 
sodium/conductivity range are also pre-specified (figure 2). Of note, there is no specific 
probe for plasmatic sodium with Hemocontrol®, as it is the case for Diacontrol® (see 
below). The dialysate conductivity is modulated toward a mean final value, but not in an 
automatic feedback response to patient’s plasmatic sodium. 
Overall, the goal of the Hemocontrol® system is to reach the same sodium and water 
balance as would a traditional approach, while the hemodynamic tolerability is enhanced by 
the profiling of the UF rate and the dialysate conductivity. Indeed, when the blood volume 
approaches the lower acceptable value for a given patient, UF is diminished or ceased while 
the dialysate conductivity is raised. Conversely, UF rate can be increased and/or dialysate 
conductivity decreased when blood volume is higher than expected on the pre-defined BV 
trajectory. 
5.2 BVM® Fresenius 
The Blood Volume Management (BVM®) module designed by Fresenius is available on the 
4008 and 5008 HD machines. This system also has relative blood volume as the core feature 
of the feedback loop, but rather deals with the « critical relative blood volume (cRBV) » 
concept instead of tracking an optimal curve to reach a final BV.   
The BV monitor is based on the measurement of total protein concentration (which includes 
plasma protein and Hb) by on-line ultrasound technology. Initially described by Schneditz 
(Schneditz et al., 1990), this method uses a probe in the arterial line that continuously 
measures the speed at which the ultrasounds travel through a specially designed cuvette. 
Since the sound speed is positively correlated to blood density, and, once again, assuming 
that the total content of blood does not change during UF, blood volume variations can be 
calculated from the changes in sound transmission velocity.  
The critical relative blood volume (cRBV) is individually determined for each patient. It is 
the threshold at which a particular patient would be at risk of IDH, based on the anterior 
sessions. The monitored parameter is the blood volume reduction, and a defined algorithm 
modulates the UF rate according to the relation of the actual BV to the cRBV. The algorithm 
is designed to allow the maximal UF rate at the beginning of the session, where the plasma 
refilling capacity is generally at its best, with a gradual decrease afterwards to avoid 
reaching the cRBV: 
 Actual UF rate = initial UF rate x factor        (1) 
 Initial UF rate = 2 x (remaining UF/remaining time)               (2) 
The actual UF rate is the delivered UF rate and the initial UF rate is two times the ratio 
between the remaining UF and the remaining time (remaining UF/remaining time). The 
factor is a coefficient between 0 and 1 determined according to the current RBV. When the 
cRBV is reached, the factor is 0 and so the UF is transitorily suspended until the RBV rises 
again. When the relative blood volume is more than halfway the distance between the cRBV 
and 100%, the factor is 1 and maximal UF is allowed.  Finally, when the RBV is more than 
halfway towards the cRBV, the factor is between 0 and 1 and decreases in a linear fashion 
(figure 3). This automatic feedback loop thus constantly adjust the UF rate to ensure, on one 
hand, that RBV stays over the predefined threshold and, on the other hand, that the UF rate 
is maximal at the beginning of the session and minimal at the end, where hypovolemia is  
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Fig. 3. BVM® algorithm (from Fresenius). 
This figure illustrates an example where the cRBV is set at 85%. When the actual RBV is 85% or 
less (white area), factor is 0 and UF stops. When RBV is greater than halfway between cRBV 
and 100% (here, halfway between 85% and 100% is 92,5%), the factor is 1,0 and UF is maximal 
(shaded area). In between (gray area), factor is between 0 and 1, and UF is not maximal. 
 
Fig. 4. UF rate in relation to RBV with the use of BVM® algorithm (from Fresenius). 
This figure illustrates the changes in UF rate (UFR) and RBV during HD given a cRBV 
set at 85% (same as Figure 3). The UFR is initially higher and progressively declines 
following reduction of RBV. 
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more likely to happen (figure 4). Of note, the dialysate conductivity is not an effector in this 
system and, unless a specific sodium profile is prescribed, remains unchanged. 
5.3 Impact of blood volume biofeedback systems 
The two biofeedback systems described above are designed differently but share the same 
goal: stabilizing blood volume reduction to avoid IDH and, ideally, its related 
complications. Many studies have been published on the ability of these devices to reduce 
vascular instability, mostly with the Hemocontrol® system, but few studies assessed other 
outcomes. Table 1 summarizes published trials that evaluated the impact of blood volume 
biofeedback systems. 
5.3.1 Reduction of intradialytic hypotension and nursing interventions 
Definition of IDH in the literature is not standardized and so differs between studies. Some 
authors use a strict definition based on an absolute or relative reduction of arterial pressure, 
while others report IDH as a drop in BP accompanied by symptoms and/or requiring 
nursing intervention (such as stopping or slowing UF, saline infusion or Trendelenburg’s 
position). Regardless of the definition used, the great majority of published trials, conclude 
that blood volume biofeedback systems are valuable in reducing IDH compared to standard 
hemodialysis (cf. table 1). Reduction of the proportion of HD sessions with at least one IDH 
episode ranges from 10 to 60%. However, it must be emphasized that most of these studies 
recruited patients who were already prone to hemodynamic instability, at varying degrees. 
As a general rule, the more severe and/or frequent the hemodynamic instability, the greater 
the benefits are from the automatic volume regulation. 
The largest randomized controlled trial assessing the impact of biofeedback regulation on IDH 
occurrence was published by Santoro in 2002. Thirty-two hypotension-prone patients recruited 
in ten Italian nephrology centers were analysed in a cross-over, parallel group study of 4 
months duration, comparing conventional HD to automatic BV-controlled HD. Although UF 
rate, pre and post-dialysis BP, and end-dialysis BV were the same with both treatments, a 30% 
reduction in dialysis sessions complicated by acute hypotension (systolic blood pressure ≤ 90 
mm Hg or a ≥ 25 mm Hg decrease with symptoms) was observed with the use of automatic 
biofeedback. An additional aim of this trial was to identify which patient’s parameters 
influence individual response to biofeedback. Clinical characteristics, dialysis prescriptions 
and plasma sodium values did not differ between the two treatment arms. However, two 
parameters appeared to be linked to responsiveness to BV-regulated feedback. First, good 
responders had higher final BV reduction and higher BV/UF ratio, suggesting a certain 
plasma refilling impairment. Second, poor responders had lower mean arterial pressure at the 
start of the HD sessions, and smaller increase in heart rate when standing from the lying 
position. Overall, these results indicate that IDH secondary to decreased plasma refilling 
capacity responds better to BV regulation than IDH due to impaired cardio-vascular reactivity. 
Of note, most studies that reported beneficial effects of biofeedback systems found similar 
results with regard to RBV changes during HD suggesting that reduction of IDH might not be 
exclusively explained by RBV preservation. As postulated by several authors, it is possible that 
treatment with BV automatic feedback exerts its favourable hemodynamic effect by preventing 
rapid RBV fluctuations (Santoro et al., 1994). 
To evaluate whether BP stabilisation obtained per-dialysis with Hemocontrol® in IDH-
prone patients was also sustained in the post-HD period, Franssen et al. (2005) used 24h BP 
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monitoring in a small prospective study. Following Hemocontrol®-driven HD, systolic 
blood pressure was significantly higher in the first 16 hours following HD, but this 
difference disappeared on the next morning. There was no difference in diastolic blood 
pressure. The authors concluded that the higher post HD systolic BP may explain the 
improvement of inter-HD symptoms observed in other studies (see below), although their 
study did not specifically evaluate interdialytic symptoms.  
Only one randomized controlled trial did not restrict patient selection on the basis of 
previous hemodynamic instability or fluid overload (Déziel et al. 2007). This study included 
57 patients (55% of them hypotension-prone) who were randomized to either standard HD 
or Hemocontrol®-driven HD. At 6 months, there was a 43% reduction in the number of 
sessions that required nursing interventions for IDH in the Hemocontrol® group (35% to 
19%), compared with a 36%  increase in nursing interventions  in the control group (23% to 
32%, p=0,04 for changes between groups). These results are in accordance with those 
reported by Ronco et al. (2000), who also demonstrated a significant decrease in the number 
of nursing interventions in a population prone to IDH when treated with BV biofeedback. 
Finally, two non-randomized, short-term prospective studies specifically assessed the value 
of BV-regulated HD among non hypotensive-prone patients (Wolkotte et al., 2002 and 
McIntyre et al., 2003). Both found a statistically significant improvement in dialysis tolerance 
in terms of reduction of IDH. 
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Table 1. Trials on the use of blood volume biofeedback control system in chronic 
hemodialysis 
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5.3.2 Reduction of intra- and inter- dialytic symptoms and improvement in quality of 
life 
Regarding improvement of patient’s symptoms during HD, some data are available in the 
literature but they are mostly based on secondary outcome analysis and show only limited 
evidence of benefit. Basile et al. (2001) prospectively followed patients for up to 36 months 
with BV-regulated HD during which period nurses and patients had to fill a symptoms 
questionnaire for each HD session. A reduction of muscle cramps during HD and an 
improvement in the post-HD asthenia score were found to be significantly associated with 
biofeedback system. However, self-evaluation of other intra- and inter- HD symptoms 
(notably, thirst) was not significantly different between the two treatment arms. 
Ronco et al. (2000) found a significant reduction of the proportion of sessions with self-
reported intradialytic symptoms following treatment with BV-controlled UF (21% vs. 76%, 
p<0,001). In addition, Santoro et al. (2002) also showed a 10% decrease of interdialytic 
symptoms following treatment with BV-controlled HD.  
In a study by Déziel et al. (2007), the Kidney Disease and Quality of Life questionnaire 
(KDQOL) was used to evaluate quality of life at baseline and after 6 months of treatment 
with either Hemocontrol® or standard HD. Among the 20 items related to physical and 
mental health, only one parameter, burden of kidney disease, was significantly improved in 
the Hemocontrol® group versus the control group. Finally, in a randomized controlled trial 
of 60 patients, Nesrallah et al. (2008) did not find any significant difference with regard to 
dialysis-related symptoms and quality of life between the two treatment groups 
(Hemocontrol® versus standard HD) despite the fact that a reduction of IDH could be 
observed.   
5.3.3 Hypertension and volume control 
Three RCT specifically assessed the utility of BV regulation devices in improving fluid 
status and/or BP control in chronic hemodialysis patients. First, Dasselaar et al. (2007b) 
studied 12 hypertensive and mild volume-overloaded patients managed with either 
standard HD or BV tracking, where dry weight reduction was gradually undertaken by 
nephrologists according to clinical judgement. At 12 weeks, patients treated with BV 
regulation had a significantly lower pre- and post- HD systolic and diastolic blood pressure. 
Patients achieved larger UF volume without any change in RBV and showed reduction in 
extracellular water (determined by bioimpedance analysis). Despite these improvements in 
surrogate markers of volume status, no difference in mean weight from baseline could be 
observed. Authors concluded that this observation could result from increase in lean body 
mass; however, other specific nutritional parameters were not measured. 
Second, in a trial published by Nesrallah et al. in 2008, volume-overloaded patients were 
included if bioimpedance displayed an extracellular fluid volume (ECFV) of at least 45%.  In 
the treatment group, dry weight was adjusted by an algorithm guided by the Hemocontrol® 
biofeedback software based on plasma-refilling characteristics. At 6 months, there was no 
statistically significant difference between the two groups in the primary endpoint (change 
in ECFV) nor were there any significant differences in systolic blood pressure, total UF and 
interdialytic weight gain. 
Finally, in a trial by Déziel et al. (2007), change in home blood pressure was evaluated 
following treatment with BV device versus standard HD. Patients were not selected on the 
basis of prior hypertension or volume overload history. While the use of Hemocontrol® 
effectively reduced home systolic BP, the clinical-based decision algorithm to manage BP in 
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5.3.2 Reduction of intra- and inter- dialytic symptoms and improvement in quality of 
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Regarding improvement of patient’s symptoms during HD, some data are available in the 
literature but they are mostly based on secondary outcome analysis and show only limited 
evidence of benefit. Basile et al. (2001) prospectively followed patients for up to 36 months 
with BV-regulated HD during which period nurses and patients had to fill a symptoms 
questionnaire for each HD session. A reduction of muscle cramps during HD and an 
improvement in the post-HD asthenia score were found to be significantly associated with 
biofeedback system. However, self-evaluation of other intra- and inter- HD symptoms 
(notably, thirst) was not significantly different between the two treatment arms. 
Ronco et al. (2000) found a significant reduction of the proportion of sessions with self-
reported intradialytic symptoms following treatment with BV-controlled UF (21% vs. 76%, 
p<0,001). In addition, Santoro et al. (2002) also showed a 10% decrease of interdialytic 
symptoms following treatment with BV-controlled HD.  
In a study by Déziel et al. (2007), the Kidney Disease and Quality of Life questionnaire 
(KDQOL) was used to evaluate quality of life at baseline and after 6 months of treatment 
with either Hemocontrol® or standard HD. Among the 20 items related to physical and 
mental health, only one parameter, burden of kidney disease, was significantly improved in 
the Hemocontrol® group versus the control group. Finally, in a randomized controlled trial 
of 60 patients, Nesrallah et al. (2008) did not find any significant difference with regard to 
dialysis-related symptoms and quality of life between the two treatment groups 
(Hemocontrol® versus standard HD) despite the fact that a reduction of IDH could be 
observed.   
5.3.3 Hypertension and volume control 
Three RCT specifically assessed the utility of BV regulation devices in improving fluid 
status and/or BP control in chronic hemodialysis patients. First, Dasselaar et al. (2007b) 
studied 12 hypertensive and mild volume-overloaded patients managed with either 
standard HD or BV tracking, where dry weight reduction was gradually undertaken by 
nephrologists according to clinical judgement. At 12 weeks, patients treated with BV 
regulation had a significantly lower pre- and post- HD systolic and diastolic blood pressure. 
Patients achieved larger UF volume without any change in RBV and showed reduction in 
extracellular water (determined by bioimpedance analysis). Despite these improvements in 
surrogate markers of volume status, no difference in mean weight from baseline could be 
observed. Authors concluded that this observation could result from increase in lean body 
mass; however, other specific nutritional parameters were not measured. 
Second, in a trial published by Nesrallah et al. in 2008, volume-overloaded patients were 
included if bioimpedance displayed an extracellular fluid volume (ECFV) of at least 45%.  In 
the treatment group, dry weight was adjusted by an algorithm guided by the Hemocontrol® 
biofeedback software based on plasma-refilling characteristics. At 6 months, there was no 
statistically significant difference between the two groups in the primary endpoint (change 
in ECFV) nor were there any significant differences in systolic blood pressure, total UF and 
interdialytic weight gain. 
Finally, in a trial by Déziel et al. (2007), change in home blood pressure was evaluated 
following treatment with BV device versus standard HD. Patients were not selected on the 
basis of prior hypertension or volume overload history. While the use of Hemocontrol® 
effectively reduced home systolic BP, the clinical-based decision algorithm to manage BP in 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
40 
the standard group was as effective, and the overall difference between the groups was not 
significant.   
In summary, no randomized trial has clearly demonstrated that the use of biofeedback 
devices is superior to standard HD and clinical judgement in reducing dry weight in 
volume expanded patients. Biofeedback devices may be of value in reducing blood pressure 
in hypertensive patients, although a systematic and clinical treatment algorithm may be as 
useful.  
5.3.4 Reduction of left ventricular dysfunction 
Cardiovascular morbidity and mortality are extremely high among chronic HD patients. 
Aside from the conventional risk factors for atherosclerosis, it was proposed that recurrent 
subclinical myocardial ischemia occurring during HD, as a result of silent decrease in 
myocardial perfusion, may contribute to the excessive cardio-vascular burden. In support of 
this hypothesis, Selby et al. (2006) demonstrated that reversible regional wall motion 
abnormalities which develop in a majority of hypotension-prone patients during HD, were 
substantially reduced with biofeedback dialysis. However, the observation period in this 
study was only 4 weeks, and it is unknown at the present time whether biofeedback HD 
provides any benefit on long-term cardiac dysfunction.  
5.3.5 Improvement of dialysis delivery 
Hemodialysis and UF may cause vasoconstriction of peripheral vascular beds, thus 
reducing peripheral tissue perfusion.  This phenomenon may cause sequestration of urea, as 
only a central vascular loop of blood remains to be dialyzed. When hypotension occurs, this 
phenomenon may be aggravated leading to enhanced urea compartmentalization and 
reduced HD efficiency. Hence, it was proposed that improved hemodynamic stability 
during dialysis may improve urea removal and increase Kt/V. 
Ronco et al. (2000) conducted a multi-center, cross-over randomized trial of 12 IDH-prone 
patients treated for two weeks with acetate-free biofiltration (AFB, schedule A) and for two 
weeks with AFB plus Hemocontrol® (schedule B). Parameters of urea kinetics were 
significantly improved when patients were on schedule B, with higher equilibrated Kt/V (1,12 
vs. 1,03, p<0,001), and lower urea rebound at 30 minutes post-HD (6,4 vs. 14,2 g, p<0,001), 
despite similar predialysis urea concentration, HD prescriptions and treatment time. 
However, a larger randomized trial of 26 patients followed for 12 weeks and treated with 
standard HD or BVM-controlled HD in a cross-over fashion did not find any significant 
improvement of equilibrated Kt/V in the treatment group (1,17 vs. 1,12, p=0,156) in spite of 
a slightly but significant higher treatment time and a 20% reduction of intradialytic morbid 
events (Gabrielli et al., 2009). 
5.3.6 Morbidity and mortality 
With improved hemodynamic tolerance, reduction of left ventricular wall dysfunction, and 
superior dialysis delivery, it would be reasonable to assume that the use of biofeedback 
systems would improve morbidity and mortality in chronic dialysis patients. Unfortunately, 
no trial to date has examined this issue and the question remains open. 
Nevertheless, one large trial published in 2005 assessed the effect on morbidity of a BV-
monitor based algorithm of UF control versus conventional management of volemia. The 
CLIMB (Crit-Line® Intradialytic Monitoring Benefit) study (Reddan et al., 2005) was a 
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multi-centered, randomized, controlled trial of 443 chronic HD patients followed for 6 
months during which ultrafiltration was either managed according to Crit-Line® values of 
RBV reduction, or by usual clinical strategies. Patients were not selected on a basis of prior 
IDH history, and the algorithm of the treatment group was only proposed and not 
mandatory. During the follow-up period, there were no statistically significant differences 
between the two groups regarding the number of IDH, the occurrence of intradialytic 
symptoms and the control of BP. Surprisingly, the risk ratios for both non-access and access-
related hospitalizations were higher in the Crit-Line® group (adjusted RR 1,61 and 1,52; p-
value 0,01 and 0.04, respectively). Mortality was 8.7% in the treatment group and 3.3% in the 
control group (p=0.021). The authors concluded that the availability of Crit-Line® may alter 
clinicians’ behaviour and may cause a risk for patients, although these results have to be 
interpreted cautiously since the control group had an atypically low hospitalization and 
mortality rate.     
5.4 Blood volume biofeedback and sodium overload  
One of the potential risks of automated BV regulation using sodium (Na) or conductivity 
modulation is alteration in sodium removal, with consequent Na overload and increased 
thirst, which can theoretically lead to increased interdialytic weight gain and worsening 
hypertension. Most of the studies described above did not find a significant change in pre 
and post HD sodium concentration (Santoro et al., 2002; Wolkotte et al., 2002; Dasselaar et 
al., 2007b, etc.), although plasma Na is a poor surrogate of real sodium balance.  
Moret et al. (2006) assessed the effect of such devices on sodium transfer during 
hemodialysis. In a cross-over randomized trial of 10 patients with frequent hypotension, 
plasma conductivity (PC) and ionic mass balance (IMB) were compared in four different HD 
modalities: standard HD with fixed Na concentration (140 mmol/L), linear Na profiling (150 
to 140 mmol/L), BV-controlled feedback with Hemocontrol® (mean dialysate conductivity 
(DC) 14,0 mS/cm) and plasma-conductivity (PC)-controlled feedback with Diacontrol® (see 
below) (post-dialytic PC target of 14,0 mS/cm). Mean pre- and post-dialytic PC were 
statistically higher during Na-profiled HD, and post-dialytic PC was lower in PC-controlled 
feedback, compared to the other three modalities. The effects of BV-regulated HD on PC and 
IMB did not differ from those of standard HD, and thus it seems that BV-regulated HD can 
be prescribed without any safety concern regarding sodium loading.   
6. Other biofeedback systems 
Three other biofeedback systems were designed to reduce the occurrence of hypotensive 
episodes during HD. Rather than focusing on BV changes during HD, these devices use 
other targets (e.g. arterial BP) or other means of action  (e.g. thermal balance, plasma 
conductivity). They are reviewed here briefly. 
6.1 Arterial pressure biofeedback 
Arterial pressure biofeedback aimed at stabilizing BP during HD uses repetitive 
measurement of arterial blood pressure as the monitored parameter and a fuzzy-logic 
system as the controller of fluid removal. Created by B. Braun and implemented on the 
Dialog Advanced machines, the APBS® (Automatic Blood Pressure Stabilization system) 
puts blood pressure itself as the main input to the automatic fuzzy controller rather than a 
surrogate marker (e.g. blood volume). Fuzzy logic is a problem-solving system, rather than 
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a mathematical model, and is reported to be better suited to analyse and compute non-linear 
data systems. It mimics how a person would make a decision, based on judgments such as: « 
if X, then Y», according to the rules pre-set by the operator. In a practical manner, the 
operator has to set two parameters for each patient: the BP set point and the maximal UF 
rate. The set-point is the critical BP level at which the patient experiences symptomatic 
hypotension, or simply the BP threshold at which the nurse or the physician would consider 
stopping the UF in that particular patient. The maximal UF rate is defined as the maximal 
rate of fluid removal that can be applied at any time, since this system is designed to 
maximise UF rate at the start of the HD session and to minimize it towards the end. With a 
specialized arm cuff that takes BP measurements every five minutes, three variables are 
calculated (Mancini et al., 2007): 1) Relative difference between actual systolic BP and the 
pre-adjusted set point; 2) Short-term pressure trend (15 min); 3) Long-term pressure trend 
(25 min). These input data are then computed by the fuzzy controller through several steps 
that involve probabilistic reasoning according to specific rule bases, and ultimately result in 
modulation of the UF rate, in a closed feedback loop (figure 5). This system allows gradual 




Fig. 5. Fuzzy control of the UF rate. 
Technical scheme of the closed-loop system for the fuzzy control of the UF rate. (Adapted 
from Mancini et al., 2007) 
Literature on the use of fuzzy logic control in preventing IDH is still scarce, but a 
prospective multi-center study published in 2007 (Mancini et al., 2007) showed a significant 
decrease of 25% in IDH incidence in 55 hypotension-prone patients. The authors 
emphasized the need to introduce correct critical BP for each patient for the fuzzy controller 
to perform adequately (Mancini et al., 2007).    
6.2 Thermal balance system 
During HD, body temperature usually rises due in part to an increased production of heat 
secondary to inflammatory reactions induced by imperfect dialysate water and bio-
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compatibility of membranes, and in part by decreased blood flow to the skin, with 
subsequent heat retention. This phenomenon can contribute to hemodynamic instability. 
Cooler dialysate, by inducing vasoconstriction, is known to enhance vascular stability, but 
poor tolerance due to chills and discomfort is a major drawback to its use. 
Blood temperature control (BTC®, Fresenius) is a biofeedback system aimed at keeping 
body temperature stable throughout the session, with progressive decline of dialysate 
temperature in response to progressive increased in heat production, resulting in « 
isothermic dialysis » (Mercadal & Petitclerc, 2009). Designed by Fresenius, the blood 
temperature monitor (BTM) is composed of sensors in the arterial and venous lines and 
monitors blood temperature change by a thermodilution technique. Thermal balance can be 
maintained through the automatic modulation of the dialysate temperature (the output) by 
the BTC® software (the controller) in response to BTM measurements compared to the set 
target temperature (the input). 
A systematic review, published in 2006, reviewed the most pertinent publications on the 
clinical effects of cool dialysate (Selby & McIntyre, 2006). Six of them, which were all cross-
over studies of relatively short duration, evaluated the use of BTM compared to various 
control groups. Overall, there was a significant decrease in IDH frequency with reduction in 
dialysate temperature using BTM, with a rate of IDH 2.0 (95% CI, 1.9-2.1) times less than 
control group.  
6.3 Plasma conductivity biofeedback system  
This biofeedback system was designed to allow variation in the dialysate sodium (Na)  
concentration to better suit the patient’s initial plasmatic value and parallel the changes in 
plasma Na concentration occurring during dialysis. Instead of a fixed dialysate Na 
concentration, a target final plasma conductivity (as a surrogate for Na) is rather prescribed, 
and thus the patient’s post-dialysis sodium concentration is independent of the initial status. 
The goal of this system is to maximise sodium removal individually for each session, but 
avoiding large gap between plasmatic and dialysate sodium, which can produce patient’s 
discomfort, hypotension and cramps (if dialysate Na is lower) or sodium loading, thirst and 
worsening hypertension (if dialysate Na is higher).  
The Diascan® (Gambro) module monitors the patient’s plasma conductivity every 15 
minutes through conductivity probes located at the dialysate inlet and outlet. The software 
Diacontrol® (Gambro) computes this information and softly and gradually modulates the 
dialysate conductivity in order to reach the prespecified target plasmatic conductivity at the 
end of the session. The curve of the conductivity trajectory is pre-defined and minimizes 
large variations to avoid rapid shift of plasmatic osmolality and disequilibrium syndrome.  
Again, large randomized trials are lacking to evaluate the utility of this feedback system, 
and results of two small prospective studies published recently are conflicting. Both 
compared Diacontrol® to standard dialysis in stable patients to assess whether gradual 
decrease in target conductivity, and consequent increased ionic mass balance (meaning 
increased sodium removal) could be achieved. Manlucu and colleagues (2010) found a 
significant reduction in end plasmatic conductivity and in ionic mass balance, with 
consequent reduction in IDWG and BP. On the contrary, Selby and al. (2007) found a lower 
final conductivity with fixed dialysate conductivity, and no difference in BP, IDH frequency 
or dialysis tolerability. Hence, demonstration of a Diacontrol® beneficial effect remains to be 
proven. 
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IDH is the most frequent complication of dialysis, and is associated with significant patient 
morbidity. Although pathogenesis is multifactorial, blood volume reduction appears to be 
central in the development of such events, especially when cardio-vascular compensatory 
mechanisms are impaired. In an attempt to reduce hypotensive episodes, blood volume 
biofeedback devices have been developed. The underlying premise of such devices is to 
automatically adjust dialysis parameters such as UF rate and dialysate conductivity, in 
response to variations of monitored patient’s characteristics, in order to make dialysis 
sessions more physiological and to prevent IDH by acting on subclinical signs of 
hemodynamic instability. Evidence supports BV biofeedback in hypotensive prone patients 
to reduce occurrence of IDH, nursing interventions, and probably intra- and inter- dialytic 
symptoms, although no large scale randomized trial has been published to date. BV 
biofeedback may also be helpful to enhance vascular tolerance in stable patients, but 
literature is limited. Data concerning improvement of hypertension and volume overload, as 
well as improvement of dialysis delivery, is conflicting. Finally, there is no large 
randomized trial that assessed the impact of automatic BV control on morbidity and 
mortality. Data suggesting that Crit-line® based algorithm of hypertension management is 
associated with higher hospitalisation and mortality rates are of concern. Larger and long-
term randomized trials comparing BV biofeedback devices to standard HD are needed to 
better define the impact of these novel technologies on patient outcomes. 
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1. Introduction 
The original dialysate sodium prescription was 126.5 mEq/L (Kolff, 1947). Before volumetric 
controlled ultrafiltration, sodium was removed primarily, slowly and most predictably by 
diffusion. With the development of high flux dialysis membranes, dialysate osmolality 
asserted a faster and more dramatic effect on serum osmolality. Hypotonic dialysate rapidly 
drops serum osmolality that leads to net fluid shift out of the vascular space, causing 
significant intradialytic symptoms (Stewart et al., 1972). Further, the duration of dialysis 
sessions was shortened as clearance of urea was improved, requiring an accelerated rate of 
ultrafiltration. 
To counter symptoms of hypo-osmolarity and rapid ultrafiltration, dialysate sodium 
concentration was increased. In the early 1970s, Stewart demonstrated less cramping with 
sodium of 145 mEq/L than with 132 mEq/L (Stewart et al., 1972). In the early 1980s, 
Locatelli showed improved cardiovascular stability when sodium concentration was raised 
to 148 mEq/L from 142 mEq/L (Locatelli et al., 1982). As the sodium prescription increased, 
concerns about sodium overloading arose. In 1985, Cybulsky demonstrated worsening of 
hypertension in already hypertensive patients (Cybulsky et al., 1985); and Daugirdas 
showed increasing thirst and interdialytic weight gain (IDWG), in both level and modelled 
high sodium techniques (Daugirdas et al., 1985). Nevertheless, intradialytic hemodynamic 
stability remained a valid concern and the data were not always clear. For example, Barré 
showed no worsening of hypertension and pulmonary edema at  [Na+] 145, 150 and 155 
mEq/L (Barré, 1988). The technique of sodium modelling offered a theoretical means to 
attenuate the risk of sodium loading. By the early 1990s, Acchiardo advocated, “[s]odium 
modelling [149mEq/L dropping to 140 mEq/L] should always be used in patients being 
maintained on high flux dialysis” (Acchiardo & Hayden, 1991). This approach was widely 
practiced throughout the 1990s. After more than a decade of high sodium and sodium 
profiling dialysis, trends toward exacerbation of hypertension and interdialytic weight gain 
were becoming evident (Song, 2002). 
Despite a growing body of literature on the effects of dialysis sodium, the sodium 
prescription is frequently overlooked or ineffectually utilized. Further, despite the 
increasing sophistication of dialysis delivery systems, the sodium prescription is often not 
adjusted to suit individual patient needs. First, we will erect a conceptual framework for 
understanding the dialysate sodium prescription. Second, we will review the primary 
literature regarding dialysate sodium and outcomes. Third, we will formulate 
recommendations on prescribing dialysate sodium. Finally, we will explore the technical 
and systems challenges to adjusting the actual sodium delivered to an individual patient.  
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2. Theoretical framework for consideration of dialysate sodium 
2.1 The relationship of sodium to volume 
Traditionally, sodium content of the body and extracellular volume are equivalent concepts. 
Sodium concentration is a function of osmotic regulation while total sodium content is a 
function volume regulation. In renal, hepatic, or cardiac impairment, excess sodium cannot be 
adequately offloaded, leading to extracellular fluid accumulation in the form of peripheral and 
pulmonary edema, and ascites. Dialysis offers a means of volume regulation in the form of 
ultrafiltration. Hydrostatic gradients generated across the dialysis membrane are used to 
remove (relatively) isotonic fluid from the vascular space. Intradialytic weight gain (IDWG) is 
a function of the salt and water intake between dialysis sessions. Increased IDWG is attributed 
to dietary non-compliance; conversely, decreased IDWG reflects excellent dietary compliance 
or can be a harbinger of poor nutritional status as low salt intake can parallel inadequate 
protein-calorie intake (Sarkar et al., 2006). These mutually confounding factors must always be 
recognized when designing or evaluating outcomes research evaluating IDWG. An occult 
source of sodium can offset even the most compliant diet: hypertonic dialysate. While the 
programmed hydrostatic gradient moves sodium (volume) out of the patient in the form of 
ultrafiltrate, osmotic gradients can move sodium in or out of the patient by diffusion.  
2.2 Defining the sodium space 
When dialyzing against hypertonic sodium, patient’s sodium rises – but not so much that 
causes adverse osmotic sequelae. Problems arise by utilizing the osmotic utility of elevated 
interdialytic serum sodium without weighing the volume implications. When using 
profiling techniques, serum sodium concentration only increased from a predialysis average 
of 138.6 +/- 0.2 to 141.0 +/- 0.1 when dialyzing against an average dialysate sodium of 
147mEq/L (Song et al., 2002). This change is an increase in of 2.4mEq/L; multiplying by the 
volume of distribution of sodium in a 70kg male patient results in 33meq of sodium 
transferred by diffusion. Once the set-point serum osmolality is restored by oral fluid intake, 
this represents just a little more than 200cc of normal saline (NS). As an osmotic agent, 
however, sodium’s effects are distributed beyond the extracellular fluid. A change in serum 
sodium reflects a change in total body osmolality, or “total body cation” (Charra & Chazot, 
2003; Gotch et al., 1980). When the extracellular sodium concentration rises, intracellular 
water will diffuse into the extracellular space reaching a new equilibrium: the predominant 
intracellular cation, potassium, would rise similarly to the extracellular sodium. Using the 
data presented by Song et al. (2002), an increase in serum sodium of 2.4mEq/L could be 
multiplied across the total body water; in a 70kg person this would result in a net diffusion 
of 100mEq of sodium, equivalent to 650cc of NS. Based on these calculations, the increase in 
IDWG should be between 0.20kg (ΔNa+ ≈ Δextracellular volume) and 0.65kg (Δsodium ≈ 
Δtotal body cation). The measured increase in IDWG, however, was greater than either 
calculated value. IDWG increased by 1.20kg. It is clear that the “osmolar space” is greater 
than the total body water. The body must be able to store sodium/osmoles outside the 
osmolar pool. 
2.3 Non-Osmotic sodium 
Increasing serum osmolality causes increased thirst leading to rapid re-accumulation of 
volume. As demonstrated above, this cannot account for all the sodium/volume transfer of 
hypertonic dialysate. Hypertonic dialysate causes sodium to accumulate in the extracellular 
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matrix in a concentration dependent, non-osmotic fashion. In a now classic experiment, Saul 
Farber, Maxwell Schubert, and Nancy Schuster demonstrated how sodium behaves in 
connective tissue (Farber et al., 1957). Completely ionized chondroitin sulfate can complex 
with “countercations” at a ratio of 1:100. Every mol of chondroitin can associate with 100 
mols of sodium- thereby reducing soluble (osmotically active) sodium. The proportion of 
sodium complexed with chondroitin is positively correlated to the concentration of sodium 
in the surrounding solution. In addition to chondroitin sulfate, hyaluronic acid and other 
mucopolysaccharides can interact with multiple sodium ions (Dunstone, 1959; Schubert, 
1964). Given relative equal binding capacity of chondroitin sulfate for most cations (Na+, K+, 
Mg2+, Ca2+, Sr2+, Ba2+), the relative concentration will determine the quantity of ion bound to 
the polyanion (Woodbury, 1956). Therefore, when the serum sodium concentration is 
increased (such as when dialyzing against a high sodium dialysate), it follows that the 
sodium content of the mucopolysaccharides will also increase. As each ion of sodium 
complexes with a polyanion, it leaves the osmotic pool, leaving a lower serum sodium 
concentration - restoring the dialysate:serum sodium gradient. Sodium will continue to 
diffuse into the patient until the polyanions are saturated while the patient osmolality will 
not rise appreciably. Thus, the net transfer of sodium into the patient will be much more 
than simply the difference between the predialysis and postdialysis serum sodium as 
demonstrated by the calculations in paragraph 2.2. When dialysis is complete, water intake 
will eventually restore serum sodium to the set-point determined by the hypothalamic 
osmostat. The mucopolysaccharide sodium reservoir will release sodium into the osmotic 
pool, stimulating thirst and driving extracellular volume expansion.  
Polyanions are ubiquitously distributed: bone (Woodbury, 1956), cartilage (Dunstone, 1959), 
blood vessels (Tobain et al., 1961), liver, intestine, brain, kidney (Law, 1984), lung and skin 
(Titze et al., 2003). Given this distribution, it should not be surprising that extracellular, 
soluble sodium makes up approximately 75% of total body sodium (Bergstrom, 1955). 
Therefore, 25% of total body sodium is sequestered out of the extracellular osmotic pool. 
The amplitude of the effect of non-osmotic sodium reservoirs should be significant.   
The typical acid/base cycle in hemodialysis patients amplify pathologic sodium binding & 
release of polyanions, especially those of bone. Approximately 25% of total body sodium is 
sequestered in the bone and cartilage (Harrison, 1936). Thirty to forty percent of skeletal 
sodium is exchangeable with circulating sodium every 24hrs (Kaltreider, 1941; Forbes & 
Perley, 1951; Forbes & Lewis, 1956). During acidosis, sodium is freed from the bone, the 
hydrogen ion displacing the sodium ion (Levitt, 1955; Bergstrom, 1955). This model 
approximates the interdialytic period. The inverse process occurs during dialysis; as pH 
rapidly corrects, H+ ions disassociate from bone easily leaving room for sodium – a process 
amplified by high dialysate sodium. After dialysis, pH begins to fall; hydrogen ions 
reaccumulate, displacing bound sodium back into the osmotically active sodium pool, 
driving volume expansion.  
Polyanions are not a static quantity. A high sodium environment leads to increased 
glycosaminoglycans synthesis: the expression mRNA of various enzymes for the synthesis 
of glycosaminoglycans increases 120% to 210% during high sodium intake (Heer, 2009).  
Increased polyanion synthesis leads to an expansion of the non-osmotic sodium pool. 
Further, there is increasing evidence that hypertonic stress and sodium overload stimulate 
mononuclear phagocyte system cells to release vascular endothelial growth factor C (VEGF-
C) promoting lymphangiogenesis (Titze & Machnik, 2010). Thus, hypertonic dialysate may 
stimulate the creation of reservoirs for further sodium storage. 
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3. Review of the primary literature: dialysate sodium and outcomes 
At least fourteen studies can be identified that examine the relationship between variation in 
the dialysate sodium prescription and various clinical measures. Four retrospective, case-
control studies and ten prospective, cohort studies were identified. Three additional studies 
examine variation of dialysate conductivity in a similar manner. 
3.1 Retrospective studies 
As seen in Table 1, we identified four retrospective studies evaluating the relationship 
between dialysate sodium and interdialytic weight gain and blood pressure control. In these 
chart-review approaches, patients were compared in a case-control manner. In two studies, 
58 patients dialyzed against the same sodium bath of 143mEq/L (Keen & Gotch, 2007; Levin 
et al., 2001). Patient’s pre-dialysis serum sodium ‘set point’ was compared to the dialysate 
sodium resulting in a positive or negative “sodium gradient.” Patients with a negative 
gradient had a serum sodium concentration greater than the dialysate sodium 
concentration; these patients had better interdialytic weight gain and improved blood 
pressure control than those with a positive gradient, without any change in intradialytic 
hypotension. Therefore, the lower the dialysate (compared to the patient’s sodium) the 
better the IDWG and BP control.  
In the two audits, patients dialyzing against a relatively lower sodium concentration had 
less IDWG (Davenport 2006, 2008). In the initial study, lower dialysate sodium was 
correlated with an improvement in BP control (defined as decrease in pre-dialysis blood 
pressure or number of antihypertensives prescribed). However, in the larger follow-up 
study, this relationship did not hold. It must be remembered that this retrospective design 
cannot account for the prescribing physicians reasons for the choice of dialysate sodium. It is 










Effect of Lower Dialysate [Na+] on 
IDWG BP Control Intradialytic hypotension 
Keen, Gotch 
(2007) 58 143 c/w patient’s set point
a improved improved no change 
Levin, Keen 
(2001) 58 143 c/w patient’s set point
a improved improved N/A 
Davenport 
(2006) 469 136-139, 140, >140 improved improved no change 
Davenport 
(2008) 2187 136-139, 140, >140 improved no change improved 
Table 1. Four retrospective studies examining the relationship of dialysate sodium 
prescription on interdialytic weight gain (IDWG), Blood Pressure (BP) Control, and 
Intradialytic hypotension. BP control is defined as improved pre-dialysis blood pressure 
measures and/or reduction in number of antihypertensives prescribed. n = number of 
patients in the study. c/w = ‘compared with’. N/A = data not available. a“Set Point” was 
defined as mean monthly predialysis plasma sodium concentration.  
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3.2 Prospective studies 
As seen in Table 2, we identified ten (10) prospective involving 165 patients evaluating the 
relationship between the dialysate sodium prescription and IDWG, BP control, intradialytic 
hypotension and thirst.  
3.2.1 IDWG 
Of the nine (9) prospective studies reporting data on IDWG, eight (8) showed statistically 
significant improvement in IDWG during dialysis on the lower sodium dialysate. The one 
study that did not show any change in IDWG compared the narrowest sodium difference 
(141mEq/L vs. 138 mEq/L), making it the most susceptible to beta error (Thein et al., 2007). 
This 8 month study did show a blunting of the expected seasonal increase in IDWG and BP 
(Argiles, 2004), perhaps due to the lower sodium dialysate used during the four months of 
winter typically associated with higher IDWG.  
3.2.2 Blood pressure control  
Six prospective studies demonstrate improvement in blood pressure control after switching 
patients to lower dialysate sodium. Blood pressure control is defined as reduction in 
predialysis blood pressure measures or reduction in number of prescribed 
antihypertensives. Three studies showed no change in blood pressure control. No study, 
however, showed worsening blood pressure on lower dialysate sodium. It seems certain 
that a modest reduction in dialysate sodium can have beneficial influence on blood pressure 
management.  
3.2.3 Interdialytic hypotension  
Of the five studies reporting interdialytic hypotensive events, two demonstrated more 
frequent hypotension on the lower sodium dialysate. The first found, 9% fewer dialysis 
sessions complicated by hypotension using higher dialysate sodium (Cybulsky et al., 
1985). Of note, the dialysate sodium used in the “low sodium” cohort was 133mEq/L, the 
second lowest in all of the studies reviewed. However, given the yearlong duration of this 
study, the results cannot be dismissed lightly. The other study showing worsening BP 
stability during dialysis had an increased incident rate of approxamately 10% as well 
(Song, 2002). These studies highlight the limitations of reducing sodium indefinitely. 
There is a lower limit on decreasing serum osmolality before fluid shifts into the 
interstitium enough to cause hypotension. Two studies showed no change in intradialytic 
hypotension. One had the narrowest range of dialysate sodium (Thein et al., 2007) while 
the other had nearly the largest (see table 2 and Daugirdas et al., 1985). One study actually 
demonstrated better hemodyanamic stability on lower sodium dialysate highlighting the 
sometimes paradoxical effects of high sodium (de Paula et al., 2004): As hypertonic 
dialysate drives higher IDWG, ultrafiltration must increase in order to maintain steady 
dry weight. If IDWG becomes great enough, removing this excess fluid will put the 
patient at risk for intradialytic hypotension.  
3.2.4 Thirst   
Effect of dialysate sodium on thirst was quite variable. Thirst is probably most dependent 
on subjective patient factors than any other factor.  
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3.2 Prospective studies 
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winter typically associated with higher IDWG.  
3.2.2 Blood pressure control  
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antihypertensives. Three studies showed no change in blood pressure control. No study, 
however, showed worsening blood pressure on lower dialysate sodium. It seems certain 
that a modest reduction in dialysate sodium can have beneficial influence on blood pressure 
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dialysate drives higher IDWG, ultrafiltration must increase in order to maintain steady 
dry weight. If IDWG becomes great enough, removing this excess fluid will put the 
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Effect of Lower Dialysate [Na+] on 
IDWG BP Control Intradialytic Hypotension Thirst 
Cybulsky 
(1985) 16 52 133, 144 improved
c improvedf worsened no change 
Daugirdas 
(1985) 7 12 135, 143, 160/133 model improved no change no change improved 
Barré 
(1988) 5 24 145, 150, 155 improved no change N/A variable 
Krautzig 
(1998) 8 24-30 135, 140 improved
d improved N/A N/A 
Kooman 
(2000) 6 6 136, 140 N/A no change N/A
h N/A 
Song 
(2002) 11 24 138, 140, 147
a improved improvedg worsened N/A 
de Paula 
(2004) 27 6 138, serum [Na+] x 0.95 improved improved
f improved improved 
Oliver 
(2004) 15 8 132, 137 improved
e N/A N/A worsened 
Thein 
(2007) 52 32 138, 141 no change improved no change N/A 
Sayarlioglu 
(2007) 18 8 ‘higher'  to 137 or 135
b improved improved N/A N/A 
Table 2. Ten prospective studies examining the relationship of dialysate sodium prescription 
on interdialytic weight gain (IDWG), Blood Pressure (BP) Control, Intradialytic 
Hypotension, and Thirst. BP control is defined as improved pre-dialysis blood pressure 
measures and/or reduction in number of antihypertensives prescribed. Estimated dry 
weight was not changed during these studies. n = number of patients in study. N/A = data 
not available. aPatients on Sodium Profiling with [Na+] expressed as Time Averaged 
Concentration (TAC). bPatients placed on 135 if serum was below 137, and on 137 if serum 
was above 137 (not explained what they did if it WAS 137). No record of baseline Na+ Rx 
prior to the change. cImprovement was seen in the normotensive subset.  dHalf of the 
participants had an unquantified improvement. eImprovement seen in patients with 
baseline IDWG greater than 1kg/day. fImprovement was seen in the ‘previously 
hypertensive' subset. g138 & 140 groups were improved when compared to 147 group. 
hThere was a ‘tendency’ toward worsened intradialytic hypotension, data not reported. 
3.3 Conductivity studies 
Electrical conductivity of solutions reflects the concentration of solute in solution. 
Substituting conductivity measurements for concentration measurements allows real-time 
estimations of solute concentrations. Modeling solute clearance,  sodium mass transfer, and 
access recirculation by differences in pre/post dialyzer conductivity represent powerful 
applications of this technology (Polaschegg, 1993; Locatelli et al., 1995; Petitclerc, 1999). In its 
most straightforward application, dialysate conductivity can be used as a surrogate for 
dialysate sodium concentration with one mS/cm conductivity equivalent to 10meq/L 
sodium. Three short, prospective studies involving 36 patients were identified which 
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examined the effect of lowering dialysate conductivity on blood pressure. One study 
showed improved control in blood pressure as conductivity was decreased (Farmer et al. 
2000). Another study found improvement in blood pressure control and IDWG but 
worsening intradialytic hypotension with decreasing dialysate conductivity (Lambie et al., 
2005). The study with the narrowest range of comparison did not show changes in any 








Effect of Lower Dialysate Conductivity on 
IDWG BP Control Intradialytic Hypotension Thirst 
Farmer 
(2000) 10 4 132.7, 137.7 no change improved N/A N/A 
Lambie 
(2005) 16 8
a 130,132,134,136 improved improved worsened N/A 
Selby 
(2007) 10 6 132, 134, 136 no change no change no change no change 
Table 3. Three prospective studies showing the effect of lowering dialysate conductivity on 
interdialytic weight gain (IDWG), Blood Pressure (BP) Control, Intradialytic Hypotension, 
and Thirst. Estimated dry weight was not changed during these studies. n = number of 
patients in study. N/A = data not available. aExact duration not reported, but estimated 
from number of stepwise changes in conductivity and duration of dialysis for each step. 
bCalculated from dialysate conductivity. 
4. Recommendations for the dialysate sodium prescription 
4.1 Facility-wide approach 
As demonstrated above, higher dialysate sodium provides questionable and inconsistent 
benefit for intradialytic hemodynamic stability at the cost of proven exacerbation of 
hypertension and interdialytic weight gain. “Lower” dialysate sodium should therefore be 
preferred, however, the exact definition of “lower” concentration is variable between 
studies. In the prospective studies, “lower” was defined from below 132 mEq/L to 
145mEq/L while “higher” was defined from 137 to 155 or higher. Of the 165 patients in 
these studies, we could identify 131 patients where the exact high and low settings could be 
identified. The weighted average for the lower sodium was 137mEq/L and 143mEq/L for 
the higher sodium settings.  
Given the number of potential barriers to crafting an individualized approach the sodium 
prescription for each patient, implementing a facility-wide change to 137mEq/L may be 
safely recommended. Typically, each dialysis unit sets a ‘usual’ dialysate sodium 
concentration based on the decision of the medical director. The ‘standard’ sodium can serve 
as the default with each provider making individualized changes based on individual 
patient’s needs. Therefore, the initial step is encouraging dialysis directors to choose a 
default dialysate sodium concentration at, or close to, 137mEq/L.  
4.2 Individualized approach  
Several questions must be answered when formulating an individualized dialysate sodium. 
Will changing dialysate sodium cause long-term changes in serum osmolality? Are serum 
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Sayarlioglu 
(2007) 18 8 ‘higher'  to 137 or 135
b improved improved N/A N/A 
Table 2. Ten prospective studies examining the relationship of dialysate sodium prescription 
on interdialytic weight gain (IDWG), Blood Pressure (BP) Control, Intradialytic 
Hypotension, and Thirst. BP control is defined as improved pre-dialysis blood pressure 
measures and/or reduction in number of antihypertensives prescribed. Estimated dry 
weight was not changed during these studies. n = number of patients in study. N/A = data 
not available. aPatients on Sodium Profiling with [Na+] expressed as Time Averaged 
Concentration (TAC). bPatients placed on 135 if serum was below 137, and on 137 if serum 
was above 137 (not explained what they did if it WAS 137). No record of baseline Na+ Rx 
prior to the change. cImprovement was seen in the normotensive subset.  dHalf of the 
participants had an unquantified improvement. eImprovement seen in patients with 
baseline IDWG greater than 1kg/day. fImprovement was seen in the ‘previously 
hypertensive' subset. g138 & 140 groups were improved when compared to 147 group. 
hThere was a ‘tendency’ toward worsened intradialytic hypotension, data not reported. 
3.3 Conductivity studies 
Electrical conductivity of solutions reflects the concentration of solute in solution. 
Substituting conductivity measurements for concentration measurements allows real-time 
estimations of solute concentrations. Modeling solute clearance,  sodium mass transfer, and 
access recirculation by differences in pre/post dialyzer conductivity represent powerful 
applications of this technology (Polaschegg, 1993; Locatelli et al., 1995; Petitclerc, 1999). In its 
most straightforward application, dialysate conductivity can be used as a surrogate for 
dialysate sodium concentration with one mS/cm conductivity equivalent to 10meq/L 
sodium. Three short, prospective studies involving 36 patients were identified which 
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examined the effect of lowering dialysate conductivity on blood pressure. One study 
showed improved control in blood pressure as conductivity was decreased (Farmer et al. 
2000). Another study found improvement in blood pressure control and IDWG but 
worsening intradialytic hypotension with decreasing dialysate conductivity (Lambie et al., 
2005). The study with the narrowest range of comparison did not show changes in any 








Effect of Lower Dialysate Conductivity on 
IDWG BP Control Intradialytic Hypotension Thirst 
Farmer 
(2000) 10 4 132.7, 137.7 no change improved N/A N/A 
Lambie 
(2005) 16 8
a 130,132,134,136 improved improved worsened N/A 
Selby 
(2007) 10 6 132, 134, 136 no change no change no change no change 
Table 3. Three prospective studies showing the effect of lowering dialysate conductivity on 
interdialytic weight gain (IDWG), Blood Pressure (BP) Control, Intradialytic Hypotension, 
and Thirst. Estimated dry weight was not changed during these studies. n = number of 
patients in study. N/A = data not available. aExact duration not reported, but estimated 
from number of stepwise changes in conductivity and duration of dialysis for each step. 
bCalculated from dialysate conductivity. 
4. Recommendations for the dialysate sodium prescription 
4.1 Facility-wide approach 
As demonstrated above, higher dialysate sodium provides questionable and inconsistent 
benefit for intradialytic hemodynamic stability at the cost of proven exacerbation of 
hypertension and interdialytic weight gain. “Lower” dialysate sodium should therefore be 
preferred, however, the exact definition of “lower” concentration is variable between 
studies. In the prospective studies, “lower” was defined from below 132 mEq/L to 
145mEq/L while “higher” was defined from 137 to 155 or higher. Of the 165 patients in 
these studies, we could identify 131 patients where the exact high and low settings could be 
identified. The weighted average for the lower sodium was 137mEq/L and 143mEq/L for 
the higher sodium settings.  
Given the number of potential barriers to crafting an individualized approach the sodium 
prescription for each patient, implementing a facility-wide change to 137mEq/L may be 
safely recommended. Typically, each dialysis unit sets a ‘usual’ dialysate sodium 
concentration based on the decision of the medical director. The ‘standard’ sodium can serve 
as the default with each provider making individualized changes based on individual 
patient’s needs. Therefore, the initial step is encouraging dialysis directors to choose a 
default dialysate sodium concentration at, or close to, 137mEq/L.  
4.2 Individualized approach  
Several questions must be answered when formulating an individualized dialysate sodium. 
Will changing dialysate sodium cause long-term changes in serum osmolality? Are serum 
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and dialysate sodium estimations equivalent concepts? As will be demonstrated below, 
predialysis serum sodium tends to be relatively constant over time, eliminating the need to 
measure the sodium every treatment. Further, conventions in laboratory reporting and the 
Gibbs-Donnan effect influence the direction of diffusive mass transfer between serum and 
dialysate. 
4.2.1 Sodium setpoint 
Pre-dialysis serum sodium remains rather constant over time. The sodium setpoint in dialysis 
patients is the mean monthly pre-dialysis sodium concentration. In 58 patients over 9 to 16 
months, dialyzing against constant dialysate sodium of 143mEq/L, within-subject variability 
of serum sodium was only 0.62 +/- 0.42 mEq/L (Mean +/- 2 Standard Deviations). Further, 
the average serum sodium among the 58 patients was 137.3 +/- 2.5 mEq/L (mean +/- SD). 
Therefore, 98% of this population was dialyzing against relatively hypertonic dialysate even at 
the rather ‘physiological’ sodium of 143meq/L (Keen & Gotch, 2007). 
Over the short term, the sodium set point remains constant even when dialysate sodium is 
manipulated. During a brief evaluation, 27 patients maintained constant pre-dialysis serum 
sodium despite reduction of dialysate sodium to 95% of serum sodium. The average serum 
sodium was 134.0 +/- 1.4 during the first 3 weeks dialyzing against 138 mEq/L and 
remained 134.0 +/- 1.5 (mean +/- SD) after the decrease (de Paula et al., 2004).  
During longer studies it appears that the sodium set point can be influenced slightly by 
changes of dialysate sodium. Over an 18-week period, 11 patients had a small but 
statistically significant increase in pre-dialysis sodium when the time-averaged 
concentration (TAC) of Na+ was raised from 140 to 147 mEq/L (138.1+/-0.1 to 138.6+/-0.2) 
(Song et al., 2002). Similar findings were seen in subgroup analysis of 52 patients over 8 
months. Patients in the upper tertile of pre-dialysis serum sodium at study entry had a small 
but statically significant decrease in pre-dialysis serum sodium from 141 to 140 mEq/L 
(p=0.003) after the dialysate sodium was dropped from 141 to 138 mEq/L (Thein et al, 2007). 
Several other studies show that the sodium set point may be somewhat more mutable; 
however, each significant change seems to be related to sub- or super-physiologic dialysate 
sodium concentrations (Wilkinson et al., 1977; Fischbach et al., 1988; Acchiardo & Hayden, 
1991). When dialyzing across a physiologic range of dialysate sodium, however, the concept 
of a set point remains valid, as variation of predialysis serum sodium is less than 1% (Song 
et al., 2002; de Paula et al., 2004; Keen & Gotch, 2007; Thein et al, 2007).  
4.2.2 Sodium measurements and Gibbs-Donnan considerations 
By convention, ionometric serum sodium measurements are corrected to reflect sodium 
concentration in the total serum volume thereby giving results to historicalresults equivalent 
to historical flame photometry (Burnett et al., 2000). Given that sodium is distributed only in 
the water phase, laboratory measures will underestimate the sodium available for dialytic 
exchange. Actual values should be raised by 7% given usual levels of proteins and lipids. 
The Gibbs-Donnan effect demonstrates, however, that not all this sodium is available for 
dialytic exchange. Negatively charged plasma proteins interact with a portion of ionized 
sodium essentially removing it from the ionic pool. This effect lowers the “plasma diffusible 
sodium by 4-5%” (Santos, 2008), essentially cancelling out the overestimation of the lab 
value (Lindley, 2009). More correctly, the accounting for plasma proteins is unnecessary as 
lab convention and Gibbs-Donnan cancel each other out; however, lipids are uncharged and 
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therefore do not participate in Gibbs-Donnan. Thus diffusible serum sodium is higher than 
expected in proportion to the lipid content of serum. In patients with relatively normal 
lipids, however, this difference is small enough to be ignored. In summary, dialysate 
sodium set to serum sodium can be considered functionally isonatric.  
4.2.3 Final individualized guidelines 
The default sodium prescription should be equal the serum sodium. Dialysate with identical 
sodium concentration to serum keeps sodium diffusion neutral; this approach relies 
exclusively on ultrafiltration for mass transfer of sodium/volume. If attempting to minimize 
variables, an isotonic dialysate is preferred; in this way ultrafiltration is responsible for the 
net sodium transfer while not being silently counteracted by dialysate sodium diffusing into 
the patient. 
Dialysate with higher sodium concentration than the patient’s serum sodium will provide a 
net sodium transfer into the patient. Hypertonic dialysate is only indicated chronically for 
non-hypertensive patients with significant, recurrent intradialytic hypotension or acutely for 
prevention of disequilibrium syndrome.  
Dialysate with lower sodium concentration than the patient’s serum sodium will accept a 
net sodium transfer out of the patient. If attempting to maximize methods for BP control and 
IDWG management, the utilization of hypotonic dialysate is preferred, insofar as is 
tolerated by interdialytic symptoms. 
5. Technical & systems requirements for adjustment of dialysate sodium  
As with any prescription, benefits are never greater than the level of compliance. In the case 
of dialysate sodium, several technical and systems issues must be understood in order to 
modify a dialysate sodium level. Given the many daily problems that dialysis unit staff 
must face, awareness of the prescribed sodium can easily be overlooked. Further, both 
doctors and staff may not be aware of the mechanisms required to change dialysate sodium. 
Depending on each unit’s equipment and dialysate formulation, changing dialysate sodium 
may cause changes in the other electrolytes; this can cause consternation or confusion.  
Staff awareness of the importance and compliance and Medical director interventions: In 
our experience, despite excellent and capable dialysis staff, modifications to the sodium 
prescription can easily be overlooked. In our unit, dialysate is delivered from a central 
system. The sodium concentration “out of the wall” is determined by the concentrate 
formula ordered by the unit – or even determined by a corporate purchasing office. There 
are several points of intervention. First, medical directors, need to be aware of the level of 
sodium in their concentrates. There are several manufactures of dialysate concentrate each 
with its unique formulation. Further, some manufacturers offer a variety of sodium levels 
within their own product lines. One intervention could be for the medical director to select 
the formulation that delivers the desired default sodium – based on our recommendation 
this would be 137mEq/L (see Paragraph 4.1). Changing the base solution is not the only 
method to vary the sodium in a unit and may not be economical or practical. Even if the 
central supply of dialysate does not match the “Facility-Wide” prescription, the staff can 
change to sodium concentration at each individual dialysis machine. Dialysis unit staff 
should be educated regarding the importance and technique of making changes to match 
the prescription. This education should be done even if the central supply of dialysate has 
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and dialysate sodium estimations equivalent concepts? As will be demonstrated below, 
predialysis serum sodium tends to be relatively constant over time, eliminating the need to 
measure the sodium every treatment. Further, conventions in laboratory reporting and the 
Gibbs-Donnan effect influence the direction of diffusive mass transfer between serum and 
dialysate. 
4.2.1 Sodium setpoint 
Pre-dialysis serum sodium remains rather constant over time. The sodium setpoint in dialysis 
patients is the mean monthly pre-dialysis sodium concentration. In 58 patients over 9 to 16 
months, dialyzing against constant dialysate sodium of 143mEq/L, within-subject variability 
of serum sodium was only 0.62 +/- 0.42 mEq/L (Mean +/- 2 Standard Deviations). Further, 
the average serum sodium among the 58 patients was 137.3 +/- 2.5 mEq/L (mean +/- SD). 
Therefore, 98% of this population was dialyzing against relatively hypertonic dialysate even at 
the rather ‘physiological’ sodium of 143meq/L (Keen & Gotch, 2007). 
Over the short term, the sodium set point remains constant even when dialysate sodium is 
manipulated. During a brief evaluation, 27 patients maintained constant pre-dialysis serum 
sodium despite reduction of dialysate sodium to 95% of serum sodium. The average serum 
sodium was 134.0 +/- 1.4 during the first 3 weeks dialyzing against 138 mEq/L and 
remained 134.0 +/- 1.5 (mean +/- SD) after the decrease (de Paula et al., 2004).  
During longer studies it appears that the sodium set point can be influenced slightly by 
changes of dialysate sodium. Over an 18-week period, 11 patients had a small but 
statistically significant increase in pre-dialysis sodium when the time-averaged 
concentration (TAC) of Na+ was raised from 140 to 147 mEq/L (138.1+/-0.1 to 138.6+/-0.2) 
(Song et al., 2002). Similar findings were seen in subgroup analysis of 52 patients over 8 
months. Patients in the upper tertile of pre-dialysis serum sodium at study entry had a small 
but statically significant decrease in pre-dialysis serum sodium from 141 to 140 mEq/L 
(p=0.003) after the dialysate sodium was dropped from 141 to 138 mEq/L (Thein et al, 2007). 
Several other studies show that the sodium set point may be somewhat more mutable; 
however, each significant change seems to be related to sub- or super-physiologic dialysate 
sodium concentrations (Wilkinson et al., 1977; Fischbach et al., 1988; Acchiardo & Hayden, 
1991). When dialyzing across a physiologic range of dialysate sodium, however, the concept 
of a set point remains valid, as variation of predialysis serum sodium is less than 1% (Song 
et al., 2002; de Paula et al., 2004; Keen & Gotch, 2007; Thein et al, 2007).  
4.2.2 Sodium measurements and Gibbs-Donnan considerations 
By convention, ionometric serum sodium measurements are corrected to reflect sodium 
concentration in the total serum volume thereby giving results to historicalresults equivalent 
to historical flame photometry (Burnett et al., 2000). Given that sodium is distributed only in 
the water phase, laboratory measures will underestimate the sodium available for dialytic 
exchange. Actual values should be raised by 7% given usual levels of proteins and lipids. 
The Gibbs-Donnan effect demonstrates, however, that not all this sodium is available for 
dialytic exchange. Negatively charged plasma proteins interact with a portion of ionized 
sodium essentially removing it from the ionic pool. This effect lowers the “plasma diffusible 
sodium by 4-5%” (Santos, 2008), essentially cancelling out the overestimation of the lab 
value (Lindley, 2009). More correctly, the accounting for plasma proteins is unnecessary as 
lab convention and Gibbs-Donnan cancel each other out; however, lipids are uncharged and 
 
Sodium and Hemodialysis 
 
55 
therefore do not participate in Gibbs-Donnan. Thus diffusible serum sodium is higher than 
expected in proportion to the lipid content of serum. In patients with relatively normal 
lipids, however, this difference is small enough to be ignored. In summary, dialysate 
sodium set to serum sodium can be considered functionally isonatric.  
4.2.3 Final individualized guidelines 
The default sodium prescription should be equal the serum sodium. Dialysate with identical 
sodium concentration to serum keeps sodium diffusion neutral; this approach relies 
exclusively on ultrafiltration for mass transfer of sodium/volume. If attempting to minimize 
variables, an isotonic dialysate is preferred; in this way ultrafiltration is responsible for the 
net sodium transfer while not being silently counteracted by dialysate sodium diffusing into 
the patient. 
Dialysate with higher sodium concentration than the patient’s serum sodium will provide a 
net sodium transfer into the patient. Hypertonic dialysate is only indicated chronically for 
non-hypertensive patients with significant, recurrent intradialytic hypotension or acutely for 
prevention of disequilibrium syndrome.  
Dialysate with lower sodium concentration than the patient’s serum sodium will accept a 
net sodium transfer out of the patient. If attempting to maximize methods for BP control and 
IDWG management, the utilization of hypotonic dialysate is preferred, insofar as is 
tolerated by interdialytic symptoms. 
5. Technical & systems requirements for adjustment of dialysate sodium  
As with any prescription, benefits are never greater than the level of compliance. In the case 
of dialysate sodium, several technical and systems issues must be understood in order to 
modify a dialysate sodium level. Given the many daily problems that dialysis unit staff 
must face, awareness of the prescribed sodium can easily be overlooked. Further, both 
doctors and staff may not be aware of the mechanisms required to change dialysate sodium. 
Depending on each unit’s equipment and dialysate formulation, changing dialysate sodium 
may cause changes in the other electrolytes; this can cause consternation or confusion.  
Staff awareness of the importance and compliance and Medical director interventions: In 
our experience, despite excellent and capable dialysis staff, modifications to the sodium 
prescription can easily be overlooked. In our unit, dialysate is delivered from a central 
system. The sodium concentration “out of the wall” is determined by the concentrate 
formula ordered by the unit – or even determined by a corporate purchasing office. There 
are several points of intervention. First, medical directors, need to be aware of the level of 
sodium in their concentrates. There are several manufactures of dialysate concentrate each 
with its unique formulation. Further, some manufacturers offer a variety of sodium levels 
within their own product lines. One intervention could be for the medical director to select 
the formulation that delivers the desired default sodium – based on our recommendation 
this would be 137mEq/L (see Paragraph 4.1). Changing the base solution is not the only 
method to vary the sodium in a unit and may not be economical or practical. Even if the 
central supply of dialysate does not match the “Facility-Wide” prescription, the staff can 
change to sodium concentration at each individual dialysis machine. Dialysis unit staff 
should be educated regarding the importance and technique of making changes to match 
the prescription. This education should be done even if the central supply of dialysate has 
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the ‘ideal’ sodium level as eventually an “Individualized” approach should be introduced. 
Staff awareness, training and ‘buy in’ are the only way to deliver individualized sodium. 
5.1 Review of dialysate generation 
Modern dialysate contains bicarbonate; it also contains variable amounts of calcium and 
magnesium. If such a solution were stored for any length of time, calcium and magnesium 
would combine with bicarbonate and precipitate out of solution. Dialysate must also be at 
physiologic pH which is, unfortunately, ideal for bacterial growth. In order to avoid these 
untoward consequences, bicarbonate is kept separate from calcium and magnesium in 
separate solutions or powders. The nomenclatures for these concentrates are “Acid” and 
“Bicarbonate”. The Acid typically consists of sodium, chloride, potassium, magnesium, 
calcium, dextrose, acetate, and sometimes citrate. The Bicarbonate concentrate consists of 
sodium bicarbonate with some brands containing some additional sodium chloride. 
Creation of dialysate is requires mixing the Acid and Bicarbonate solutions in exact 
proportions. This is performed in ‘real time’ in the dialysis machine based on the pre-mixed 
concentrates of Acid and Bicarbonate and the software programmed for each concentrate.  
5.2 Concentrate formulations 
All the liquid and dry concentrates in the Fresenius NaturaLyte® - 4000 Series of Acid and 
Bicarbonate will result in a final sodium concentration of 137mEq/L once mixed. Fresenius 
Citrasate® Series results in a base sodium of 137.3 mEq/L once mixed with the NaturaLyte® 
Bicarbonate (Fresenius, 2010). Rockwell Medical produces three series of formulations 
available in dry and liquid. The Rockwell Medical R-Series results in final sodium 
concentrations of 138, 139, 140, 143 mEq/L. The C-Series results in 137mEq/L. The F-Series 
results in 135 or 138 mEq/L (Rockwell Medical, 2009). Minntech’s Centrisol® results in a 
final sodium concentration of 137 mEq/L and their Renasol® results in 139,140,142,or 143 
mEq/L (Minntech, 2010).   
 
Company/ Product Final Na+ (mEq/L) Na+ from Acid (mEq/L) 
Fresenius   
          NaturaLyte® 137 100 
          Citrasate®  137.3 100.3 
Minntech   
          Centrisol®  137 unlisted 
          Renasol®  139,140,142,143 unlisted 
Rockwell Medical   
          R-Series*  138, 139, 140, 143 79, 80, 81, 84 
          C-Series* 137 100 
          F-Series* 135, 138 100, 103 
Table 4. The default sodium concentration of several available dialysate concentrates and 
the sodium contribution from the acid portion (Fresenius, 2010; Minntech, 2010; Rockwell 
Medical 2009). *RenalPure® Liquid Acid with SteriLyte® Liquid Bicarbonate or Dri-Sate® 
Dry Acid with RenalPure® Powder Bicarbonate.  
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5.3 Dialysate proportioning systems 
Given that both the Acid and Bicarbonate concentrates contain significant sodium (sodium 
chloride in Acid and sodium bicarbonate in the Bicarbonate). The sodium can therefore 
varied by adjusting the dilution of the Acid, Bicarbonate or both. The mechanism of this 
variation is determined by the design and software of the dialysis machine. Each 
manufacturer may have slightly different approach. All models of the Fresenius 2008® series 
(2008H, 2008K, 2008K2, 2008T) have an explicit mechanism behind sodium variation:  the 
amount of Acid concentrate is varied to change the sodium concentration to the target value. 
The other electrolytes in the Acid component will vary in proportion to the sodium change, 
while the electrolytes in the Bicarbonate solution will remain unchanged (Fresenius Medical 
Care, 2001, 2009a, 2009b, 2010).  Other manufactures advertise the ability to vary sodium 
across a wide range. The Gambro Artis® System can vary sodium concentration from 130-
160mEq/L - much wider than the Bicarbonate variability (24-38mEq/L). Therefore the 
majority, if not all, of the variation in sodium is produced from variation in the Acid 
concentrate (Gambro, 2008). Similar ranges apply to the Gambro AK96 Advance® and Bio® 
models:  Sodium varies 130-160mEq/L and Bicarbonate 20-40mEq/L (Gambro, 2009). 
B.Braun’s Dialog+® has a conductivity range from 12-17mS/cm, indicating a wide range of 
sodium variation, however, the relative contribution of Acid and Bicarbonate portions are 
not readily accessible (B.Braun Medical Inc., 2009). The capability and mechanism of sodium 
variation for the Baxter TINA® and ARENA® systems are not easily obtainable in an “open 
access” format. However, given the wide use if sodium modeling over the past two decades, 
any modern dialysis machine probably has the capability to generate individualized sodium 
concentrations. 
Systems like the Fresenius 2008® Series, which hold the Bicarbonate constant and vary the 
Acid in order to alter the sodium, will show the greatest variation in the other electrolytes in 
the acid component. As will be demonstrated below, however, these changes are minute 
and clinically irrelevant. If any of the other systems utilize a combination of Acid and 
Bicarbonate variations to alter sodium concentration, the changes in Acid electrolytes will be 
even less effected (the bicarbonate concentration would vary somewhat, however, the 
change would also be minimal). 
5.4 Electrolyte variability during sodium individualization 
The question arises, will there be a change in other electrolyte components during the 
sodium variation?  Clinically these variations are insignificant and should not hinder the use 
of tailored sodium. Dialysis staff needs to be reassured of this, as many of the newer 
generation dialysis machines will display the changes to all electrolytes when one is 
changed. Some staff may see a small change in the potassium and undo the change because 
the potassium level does not match the prescription. Dialysis unit policy and dialysis orders 
should be written to accept small variation in other electrolytes during adjustment of 
sodium. Of note, during sodium profiling, all the acid electrolytes in the same way, resulting 
in wider, yet still clinically insignificant, fluctuations in the other components.  
Here is an example of the nature of electrolyte variation with individualized sodium. A 
clinician determines that a particular patient’s individualized dialysate sodium should be 
133mEq/L. Some adjustment of the dialysis machine is required as none of the available 
base solutions result in this a sodium of 133mEq/L. A Fresenius 2008T®, for example, 
manipulates the final dialysate sodium by varying concentration of the Acid component 
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the ‘ideal’ sodium level as eventually an “Individualized” approach should be introduced. 
Staff awareness, training and ‘buy in’ are the only way to deliver individualized sodium. 
5.1 Review of dialysate generation 
Modern dialysate contains bicarbonate; it also contains variable amounts of calcium and 
magnesium. If such a solution were stored for any length of time, calcium and magnesium 
would combine with bicarbonate and precipitate out of solution. Dialysate must also be at 
physiologic pH which is, unfortunately, ideal for bacterial growth. In order to avoid these 
untoward consequences, bicarbonate is kept separate from calcium and magnesium in 
separate solutions or powders. The nomenclatures for these concentrates are “Acid” and 
“Bicarbonate”. The Acid typically consists of sodium, chloride, potassium, magnesium, 
calcium, dextrose, acetate, and sometimes citrate. The Bicarbonate concentrate consists of 
sodium bicarbonate with some brands containing some additional sodium chloride. 
Creation of dialysate is requires mixing the Acid and Bicarbonate solutions in exact 
proportions. This is performed in ‘real time’ in the dialysis machine based on the pre-mixed 
concentrates of Acid and Bicarbonate and the software programmed for each concentrate.  
5.2 Concentrate formulations 
All the liquid and dry concentrates in the Fresenius NaturaLyte® - 4000 Series of Acid and 
Bicarbonate will result in a final sodium concentration of 137mEq/L once mixed. Fresenius 
Citrasate® Series results in a base sodium of 137.3 mEq/L once mixed with the NaturaLyte® 
Bicarbonate (Fresenius, 2010). Rockwell Medical produces three series of formulations 
available in dry and liquid. The Rockwell Medical R-Series results in final sodium 
concentrations of 138, 139, 140, 143 mEq/L. The C-Series results in 137mEq/L. The F-Series 
results in 135 or 138 mEq/L (Rockwell Medical, 2009). Minntech’s Centrisol® results in a 
final sodium concentration of 137 mEq/L and their Renasol® results in 139,140,142,or 143 
mEq/L (Minntech, 2010).   
 
Company/ Product Final Na+ (mEq/L) Na+ from Acid (mEq/L) 
Fresenius   
          NaturaLyte® 137 100 
          Citrasate®  137.3 100.3 
Minntech   
          Centrisol®  137 unlisted 
          Renasol®  139,140,142,143 unlisted 
Rockwell Medical   
          R-Series*  138, 139, 140, 143 79, 80, 81, 84 
          C-Series* 137 100 
          F-Series* 135, 138 100, 103 
Table 4. The default sodium concentration of several available dialysate concentrates and 
the sodium contribution from the acid portion (Fresenius, 2010; Minntech, 2010; Rockwell 
Medical 2009). *RenalPure® Liquid Acid with SteriLyte® Liquid Bicarbonate or Dri-Sate® 
Dry Acid with RenalPure® Powder Bicarbonate.  
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5.3 Dialysate proportioning systems 
Given that both the Acid and Bicarbonate concentrates contain significant sodium (sodium 
chloride in Acid and sodium bicarbonate in the Bicarbonate). The sodium can therefore 
varied by adjusting the dilution of the Acid, Bicarbonate or both. The mechanism of this 
variation is determined by the design and software of the dialysis machine. Each 
manufacturer may have slightly different approach. All models of the Fresenius 2008® series 
(2008H, 2008K, 2008K2, 2008T) have an explicit mechanism behind sodium variation:  the 
amount of Acid concentrate is varied to change the sodium concentration to the target value. 
The other electrolytes in the Acid component will vary in proportion to the sodium change, 
while the electrolytes in the Bicarbonate solution will remain unchanged (Fresenius Medical 
Care, 2001, 2009a, 2009b, 2010).  Other manufactures advertise the ability to vary sodium 
across a wide range. The Gambro Artis® System can vary sodium concentration from 130-
160mEq/L - much wider than the Bicarbonate variability (24-38mEq/L). Therefore the 
majority, if not all, of the variation in sodium is produced from variation in the Acid 
concentrate (Gambro, 2008). Similar ranges apply to the Gambro AK96 Advance® and Bio® 
models:  Sodium varies 130-160mEq/L and Bicarbonate 20-40mEq/L (Gambro, 2009). 
B.Braun’s Dialog+® has a conductivity range from 12-17mS/cm, indicating a wide range of 
sodium variation, however, the relative contribution of Acid and Bicarbonate portions are 
not readily accessible (B.Braun Medical Inc., 2009). The capability and mechanism of sodium 
variation for the Baxter TINA® and ARENA® systems are not easily obtainable in an “open 
access” format. However, given the wide use if sodium modeling over the past two decades, 
any modern dialysis machine probably has the capability to generate individualized sodium 
concentrations. 
Systems like the Fresenius 2008® Series, which hold the Bicarbonate constant and vary the 
Acid in order to alter the sodium, will show the greatest variation in the other electrolytes in 
the acid component. As will be demonstrated below, however, these changes are minute 
and clinically irrelevant. If any of the other systems utilize a combination of Acid and 
Bicarbonate variations to alter sodium concentration, the changes in Acid electrolytes will be 
even less effected (the bicarbonate concentration would vary somewhat, however, the 
change would also be minimal). 
5.4 Electrolyte variability during sodium individualization 
The question arises, will there be a change in other electrolyte components during the 
sodium variation?  Clinically these variations are insignificant and should not hinder the use 
of tailored sodium. Dialysis staff needs to be reassured of this, as many of the newer 
generation dialysis machines will display the changes to all electrolytes when one is 
changed. Some staff may see a small change in the potassium and undo the change because 
the potassium level does not match the prescription. Dialysis unit policy and dialysis orders 
should be written to accept small variation in other electrolytes during adjustment of 
sodium. Of note, during sodium profiling, all the acid electrolytes in the same way, resulting 
in wider, yet still clinically insignificant, fluctuations in the other components.  
Here is an example of the nature of electrolyte variation with individualized sodium. A 
clinician determines that a particular patient’s individualized dialysate sodium should be 
133mEq/L. Some adjustment of the dialysis machine is required as none of the available 
base solutions result in this a sodium of 133mEq/L. A Fresenius 2008T®, for example, 
manipulates the final dialysate sodium by varying concentration of the Acid component 
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(Fresenius Medical Care, 2010a). If the available dialysate has a base sodium of 137mEq/L 
and the Acid concentrate contributes 100mEq/L (such as Fresenius NaturaLyte®, Citrasate® 
or Rockwell Medical C-Series), it is possible to predict the changes on the other electrolytes. 
Reducing the final sodium from 137 to 133 mEq/L requires reducing the Acid component 
from 100meq/L to 96mEq/L (a change of 4%). Reducing each Acid component by 4% will 
give the final concentration of that component. Using a standard Acid solution, such as 
Fresenius NaturaLyte® Product Number 08-2201-5, contributes 100mEq/L of sodium,  
 
Electrolyte Product Number / Acid Concentration 
New Concentration After 
5meq/L Sodium Decrease 
   
 Fresenius, 08-2201-5 
Na+ (mEq/L) 100 95 (5% reduction) 
K+ (mEq/L) 2.0 1.9 
Ca++ (mEq/L) 2.00 1.90 
Mg++ (mEq/L) 1.00 0.95 
Cl-- (mEq/L) 105.0 99.8 
Acetate (mEq/L) 4.0 3.5 
Dextrose (mg/dL) 100 95 
   
 Rockwell Medical, R-205 
Na+ (mEq/L) 79 74 (6.33% reduction) 
K+ (mEq/L) 3 2.8 
Ca++ (mEq/L) 3.5 3.2 
Mg++ (mEq/L) 1.5 1.4 
Cl-- (mEq/L) 86 80.6 
Acetate (mEq/L) 4 3.7 
Dextrose (mg/dL) 200 187 
   
 Rockwell Medical, F-215 
Na+ (mEq/L) 103 98 (4.85% reduction) 
K+ (mEq/L) 1 0.95 
Ca++ (mEq/L) 2.5 2.37 
Mg++ (mEq/L) 1 0.95 
Cl-- (mEq/L) 107.5 102.3 
Acetate (mEq/L) 3 2.85 
Dextrose (mg/dL) 200 190 
Table 5. Change in electrolyte concentrations resulting from an individualized sodium 
prescription. This example shows what happens to the other electrolytes after a 5mEq/L 
reduction in dialysate sodium. The breakdown of the Acid portion of several common 
concentrates is shown in the center column (Rockwell Medical, 2009; Fresenius Medical 
Care, 2010b).  Based on the percent change of Acid sodium, the resulting values for 
potassium, calcium, magnesium, chloride, acetate and dextrose are listed in the left column.  
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2.00mEq/L of potassium and 100mg/dL of dextrose (Fresenius Medical Care, 2010b). 
Diluting this Acid by 4% results in Na+ 96mEq/L, K+ 1.92mEq/L, and dextrose 96mg/dL. 
None of these changes carry a significant clinical effect. The smaller the sodium contribution 
of the Acid, the other electrolytes will show a larger variation. Table 5 shows the final 
electrolyte changes of several standard dialysate solutions when using the proportioning 
system to decrease the base sodium by 5mEq/L.  
6. Conclusions 
Dialysate sodium concentration must be prescribed for each dialysis session. Dialysate 
sodium standards vary from 126.5mEq/L to greater than 155mEq/L through out the history 
of dialysis. While higher concentrations can be used to promote greater hemodynamic 
stability during dialysis, their cost is worsening hypertension and greater interdialytic 
weight gain. Glycosaminoglycans and other polyanions sequester sodium out of the osmotic 
pool and amplify the sodium gain during hypertonic dialysis causing greater effects than 
the traditional ‘sodium space’ model would predict. We reviewed 17 prospective and 
retrospective studies that quantify the effects of dialysate sodium on hypertension, 
interdialytic weight gain and intradialytic hypotension. In order to minimize undesired 
effects of high or low sodium for the most patients, “facility-wide” dialysate sodium setting 
of 137mEq/L should be implemented. An individualized sodium prescription can be 
calculated by setting dialysate sodium equal the patient’s serum sodium. This calculation 
can be done without adjustments since laboratory conventions and the Gibbs-Donnan effect 
essentially negate each other. In order to deliver a facility-wide or individualized sodium 
prescription, changing dialysate concentrates could be undertaken but not necessary: 
modern proportioning systems can adjust the dilution of dialysate Acid or Bicarbonate 
components. Usually the dilution of the Acid is adjusted while Bicarbonate remains 
constant. The other Acid electrolytes will vary by the same percentage as the sodium 
variation: a clinically inconsequential change.  
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1. Introduction 
Polyethersulfone (PES) is one of the most important polymeric materials and is widely used 
in separation fields. PES and PES-based membranes show outstanding oxidative, thermal 
and hydrolytic stability as well as good mechanical and film-forming properties. PES 
membranes could endure many kinds of sterilized methods, including epoxy ethane gas, 
steam, and γ-ray. Furthermore, PES-based membranes show high permeability for low 
molecular weight proteins when used as hemodialysis membranes. Thus, PES membranes 
are also widely employed in biomedical fields such as artificial organs and medical devices 
used for blood purification, e.g., hemodialysis, hemodiafiltration, hemofiltration, 
plasmapheresis and plasma collection (Zhao et al., 2001; Tullis, et al., 2002; Samtleben et al., 
2003; Werner et al., 1995), especially in recent years.  
However, when contacting with blood, proteins will be rapidly adsorbed onto the surface of 
PES membrane and the adsorbed protein layer may lead to further undesirable results, such 
as platelet adhesion, aggregation and coagulation. As a consequence, the blood 
compatibility of PES membrane is not adequate, and injections of anti-coagulants are needed 
during its clinical application (Liu et al., 2009).  
The main disadvantage is related to the relatively hydrophobic character of PES membrane. 
And many studies have concluded that membrane fouling (as caused by protein adsorption) is 
directly related to hydrophobicity as reviewed by Van der Bruggen (Van der Bruggen, 2009) 
and Khulbe et al. (Khulbe et al., 2010), although the opposite has also been reported (Yu et al., 
2008). Membrane fouling is mainly caused by adsorption of nonpolar solutes, hydrophobic 
particles or bacteria (Van der Bruggen, 2009; Koh et al., 2005). It is a serious problem in 
membrane filtration, resulting in a higher energy demand, shorter membrane lifetime, and 
unpredictable separation performance (Agenson & Urase, 2007). Thus, PES hollow fiber 
membranes used in hemodialysis are usually modified by hydrophilic polymers. 
For the modification of PES membranes, there are three approaches: (1) bulk modification of 
PES material, and then to prepare modified membrane; (2) surface modification of prepared 
PES membrane; and (3) blending, which can also be regarded as a surface modification. The 
modification procedures allow finding a compromise between the hydrophobicity and 
hydrophilicity, and localize the hydrophilic material specifically in the membrane pores, 
where they have a positive effect on flux and fouling reduction, and on the membrane 
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surface to improve blood compatibility. However, not all the methods are suitable for the 
modification of PES hemodialysis membranes. 
For hemodialysis membranes, safety and efficiency should be evaluated firstly in vitro 
before clinical application, and simulation solutions are used. Through the experiments in 
vitro, many results, which are useful for clinical applications, could be obtained, including 
protein adsorption, platelet adhesion, ultrafiltration (UF) coefficient, and solute clearances 
(such as for urea, creatinine, and phosphate, and so on). For high-flux hemodialysis 
membranes, the clearance of 2-microglobin should be investigated. When the membranes 
are applied for patients, the safety and efficiency are also very important. 
In the present chapter, preparation and characterization of PES hemodialysis hollow fiber 
membranes are discussed firstly, and then the safety and efficiency in vitro and in vivo are 
discussed. 
2. Preparation and modification of polyethersulfone hollow fiber membranes 
 
 
Fig. 1. PES hollow fiber spinning line 
PES hollow fiber membranes for hemodialysis are usually spun by dry-wet spinning 
technique based on liquid-liquid phase separation method, see Figure 1. The cross-section 
view of the PES hollow fiber membrane is shown in Figure 2. After post-treatment, PES 
hollow fiber hemodialyzer is prepared by using polyurethane resin as the potting material. 
However, the blood compatibility of the PES membrane is not adequate, and injections of 
anticoagulants are needed during hemodialysis. Thus, all the PES membranes used for 
hemodialysis are not the pristine PES membranes. As a hydrophilic additive and a 
membrane forming agent, poly (vinyl pyrrolidone) (PVP) is most widely used for the 
modification of PES membranes by blending. Many other methods can also be used for 
modifying PES membranes. The aim of the modification is to improve the biocompatibility 
and protein antifouling property of the membranes, thus different sections are separated 

















Fig. 2. SEM images of PES hollow fiber membrane (From reference, Su et al., 2008) 
2.1 Blending 
Blending is the simplest and most widely used method to modify PES membranes both for 
flat-sheet and hollow fiber membranes, though sometimes the results might be not very 
well. By directly blending with hydrophilic polymers, such as polyvinylpyrrolidone (PVP) 
(Barzin et al., 2004; Mosqueda-Jimenez et al., 2006; Su BH, et al., 2008; Wang et al., 2009) and 
polyethyleneglycol (PEG) (Wang et al., 2006), PES membranes are easy to be modified; here 
PVP and PEG also are also used as pore-forming agents. The hydrophilicity of the 
membranes increased, the antifouling property and blood compatibility are also increased 
(Su BH, et al., 2008; Wang et al., 2006). However, the elution of the blended hydrophilic 
polymer is unavoidable. Thus, amphiphilic copolymers are synthesized recently and used 
for blending with PES to prepare membranes (Zhu et al.; 2008a, 2008b; Zhao et al., 2008; 
Peng et al., 2009). For hemodialysis membranes, the objective of blending is to improve the 
membrane hydrophilicity, biocompatibility, and other properties, such as protein 
antifouling property. 
2.1.1 Improve biocompatibility 
In our recent study (Su BH, et al., 2008), larger molecular weight PVP was used to blend 
with PES to prepare hollow fiber hemodialysis membrane, and the performance was 
evaluated in vitro and in vivo. The biocompatibility profiles of the membranes showed 
slight neutropenia and platelet adhesion at the initial stage of the hemodialysis. The 
clearance and the reduction ratio after the hemodialysis of small molecules (urea, creatinine, 
phosphate) for the PES membrane were higher in vitro than that in vivo.  
Barzin et al. (Barzin et al., 2004) prepared two kinds of PES hollow fiber membranes for 
hemodialysis by blending two ratios of PES to PVP (PES/PVP = 18/3 and 18/6 by weight). 
It was observed that the water flux of the hollow fiber increased significantly when heat-
treated in water, while decreased when heat-treated in air. On the other hand, the molecular 
weight cutoff of the hollow fiber increased slightly when heat-treated in water, while 
decreased drastically when heat-treated in air. SEM images also showed that the surface 
morphology of the membranes was different before and after heat-treatment. The 
performance data of the hollow fiber heated in air at 150 C was found to be the most 
appropriate for hemodialysis application. It was also found that the hollow fiber membrane 
prepared from the blend ratio of PES/PVP = 18/3 showed slightly higher flux than that 
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prepared from a solution with PES/PVP ratio of 18/6. Of course, PVP could also be used to 
modify PES hollow fiber membranes for hemofiltration (Yang et al., 2009). Gholami et al. 
(Gholami et al.; 2003) found that the hollow fiber membranes shrank by heat treatment, as 
evidenced by a decrease in flux and an increase in solute separation, although there was no 
visible change in the hollow-fiber dimension. However, for flat-sheet PES membranes, the 
membrane surface altered, and surface parameters (such as surface roughness) have been 
changed after non-contact heating (microwave irradiation) (Mansourpanah et al., 2009).  
Erlenkotter and coworkers (Erlenkotter et al, 2008) evaluated the dialysis membrane 
hemocompatibility. In order to compare different polymers used in the manufacturing of 
dialysis membranes, a set of the following hemocompatibility parameters was assessed and 
assembled to an overall score: generation of complement factor 5a, thrombin-antithrombin 
III-complex, release of platelet factor 4, generation and release of elastase from 
polymorphonuclear granulocytes, and platelet count. By blending polyarylate with PES, the 
membrane hemocompatibility improved. They also provided a score model to facilitate the 
selection of membrane polymers with an appropriate hemocompatibility pattern for dialysis 
therapy. 
2.1.2 Improve antifouling property 
Membrane fouling is still a crucial problem for hollow fiber membrane. When fouling takes 
place on membrane surfaces, it causes flux decline, leading to an increase in production cost 
due to increased energy demand. Qin et al. (Qin et al., 2004) selected solvent-resistant 
hollow-fiber UF membranes by measurement of fiber swelling and treatability studies on 
spent solvent cleaning rinse. The results indicated that the membranes made of both 
cellulose acetate (CA) and polyacrylonitrile (PAN) materials could tolerate the solvent 
present and were suitable or treating the spent solvent rinses, whereas PES and PSF 
membranes were not suitable. The CA membrane had the lowest fouling tendency when 
treating the spent solvent rinse. Nakatsuka et al. (Nakatsuka et al., 1996) also found that the 
permeate flux for the hydrophilic CA membranes was much higher than that of the 
hydrophobic PES membrane, a phenomenon which was explained by membrane fouling 
due to the adsorption of substances in raw water on and in the pores of the membranes. Xu 
et al. (Xu et al., 2009) observed that the fouling layer grew faster on the inside surface of the 
PES hollow fiber at a lower flow rate than that at a higher flow rate due to the lower shear 
stress. These results suggested that PES hollow fiber membrane should be modified to 
improve antifouling property by increasing hydrophilicity. 
Arahman et al. (Arahman et al., 2009) modified PES hollow-fiber membrane by blending 
with hydrophilic surfactant Tetronic 1307. The fouling of the PES membrane with blending 
Tetronic 1307 was lower than that of the original PES membrane in the case of BSA filtration. 
A functional terpolymer of poly (methyl methacrylate–acrylic acid–vinyl pyrrolidone) 
(PMMA-AA-VP) was synthesized via free radical solution polymerization using DMAC as 
the solvent in our recent study (Zou et al., 2010). The terpolymer can be directly blended 
with PES using the solvent to prepare modified PES hollow fiber membrane. The 
hydrophilicity of the blended membranes increased, and the membranes showed good 
protein antifouling property. The antifouling property is always expressed as the time-
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Fig. 3. Time-dependent flux of PMMA-AA-VP modified PES membranes during the 
ultrafiltration process.  
For the membranes: HFM-20-1.2 (The amounts of PES and the terpolymer are 20 and 1.2 
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2.2 Other methods 
Many other methods can also be used for the modification of PES hollow fiber, the following 
reviewed the methods. Though not all of them are discussed for hemodialysis membranes, 
some of the methods can be used for the modification of PES hemodialysis membranes. 
2.2.1 Surface-coating 
Torto and coworkers (Torto et al., 2004) provided a method for the in situ modification of 
hollow fiber membranes used as sampling units for microdialysis probes. The method 
consisted of adsorption-coating of high-molecular-weight PEI onto membranes, already 
fitted on microdialysis probes. Modification of membranes was designed to specifically 
explore the so-called Andrade effects and thus enhance the interaction of membranes with 
enzyme. Such a procedure can be modified and employed to either promote or reduce 
membrane-protein interaction for hollow fibers used as microdialysis sampling units or 
other similar membrane applications. 
2.2.2 Photo-induced surface grafting 
To modify PES membranes, photochemical surface technique is attractive, and has several 
advantages. Mild reaction conditions and low temperature may be applied; and high 
selectivity is possible by choosing the reactive groups or monomers and respective 
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manufacturing process (Zhao et al., 2003). However, the method is always applied to modify 
flat-sheet membrane; it is difficult to modify hollow fiber membranes, especially to modify 
the internal surface of hollow fiber membrane. 
Few studies focused on the modification of PES hollow fiber membranes by photo-induced 
grafting method, since it is difficult to apply irradiation on internal surface of hollow fiber 
membrane. Bequet and coworkers (Bequet et al., 2002) developed a way to prepare 
nanofiltration hollow fiber from ultrafiltration membranes, consisting of in-line external 
modification of the skin of a polysulfone (PSF) ultrafiltration hollow fiber by grafting AA 
under UV irradiation. The continuous photo-grafting set-up is shown in Figure 4. As shown 
in the figure, the modification is applied on the outer surface of the hollow fiber membrane. 
As mentioned above, AA and MA could be grafted on the surfaces of PES membranes by 
the photochemical method. It should be noticed that due to the present of carboxyl groups, 
these modified membranes showed pH-sensitivity. 
 
 
Fig. 4. Schema for the experimental continuous photo-grafting set-up. 
(From reference, Bequet et al., 2002) 
Shen et al. (Shen et al., 2005) modified the inner-surface of PSF hollow fiber UF membranes 
by using gas-initiation under UV and liquid-polymerization, which aimed to adjust the 
diameter of the pores in the membranes. Benzophenone (BP) was in a gaseous condition as 
photo-initiator, AM as graft monomer, the polyacrylamide (PAM) chain was grafted on the 
surface of the membranes. After the membrane surface being modified, the water flux and 
retention altered, and thus it could be seen that the diameter of the pores in the membrane 
was altered. Of course, the method could also be used to produce the PES hollow fiber 
membrane with small pore size. 
Goma-Bilongo and co-workers (Goma-Bilongo et al., 2006) developed a numerical model to 
represent the process by which hollow-fiber membranes could undergo continuous surface 
modification by UV photo-grafting, which was the same as reported by Bequet (Bequet et 
al., 2002). The model took into account the coupled effects of radiation, mass transfer with 
polymerization reaction and heat transfer with evaporation. Then, they modified PSF 
hollow fiber membranes using sodium p-styrene sulfonate (NaSS) as a vinyl monomer, for 
treatment of anionic dye solutions (Akbari et al., 2007). However, till now, no report for the 
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Hollow fiber scaffolds that compartmentalize axonal processes from their cell bodies can 
enable neuronal cultures with directed neurite outgrowth within a three-dimensional (3-D) 
space for controlling neuronal cell networking in vitro. Controllable 3-D neuronal networks 
in vitro could provide tools for studying neurobiological events. In order to create such a 
scaffold, PES micro-porous hollow fibers were ablated with a KrF excimer laser to generate 
specifically designed channels for directing neurite outgrowth into the luminal 
compartments of the fibers. These hollow fiber scaffolds can potentially be used in 
combination with perfusion and oxygenation hollow fiber membrane sets to construct a 
hollow fiber-based 3-D bioreactor for controlling and studying in vitro neuronal networking 
in three dimensions between compartmentalized cultures (Brayfield et al., 2008). 
2.2.3 Plasma treatment and plasma-induced grafting polymerization 
The same as other methods mentioned above, few study was reported on the modification 
of PES hollow fiber membranes by plasma treatment or plasma-induced grafting method. 
Only one study on the modification of PES hollow fibres by O2 plasma treatment (Batsch et 
al., 2005) was reported. After about one month of stable operation, the membrane samples 
were taken and also cleaned with chemical solutions, and the fouling could be prevented by 
the modification. 
2.2.4 Thermal-induced grafting and immobilization 
Thermal induced graft polymerization is a facile way to modify PES membranes. The 
method always uses chemical initiator or cleavage agent. Furthermore, many kinds of 
biomolecules, such as enzyme, protein and amino acid, could be covalently immobilized 
onto PES membranes by a simple chemical reaction. 
Kroll et al. (Kroll et al., 2007) chemically modified commercially available PES and PSF 
hollow fiber membranes by reacting terminal hydroxyl groups with ethylene glycol 
diglycidyl ether (EGDGE) to produce terminal epoxy groups. For increasing loading 
capacity hydroxyethyl cellulose polymers were bound to the epoxy groups. Second 
epoxidation produced final polymers containing reactive epoxy groups on the hollow fiber 
surface. From this modified PES and PSF, respectively, a wide variety of N-containing 
reagents (e.g. iminodiacetic acid (IDA)) can be bound to the epoxy groups. The different 
reactions were proved by acid orange II assay and phenol sulfuric assay. The chelating IDA-
membranes were complexed with different divalent metal ions (Cu2+, Ni2+, Co2+, and Zn2+). 
Immobilized metal ion affinity PES hollow fiber membranes were used for purification of a 
recombinant protein (GFP-His) from Escherichia coli, which carried a polyhistidine 
sequence. 
3. Biocompatibility and separation performance of the membrane in vitro 
The biocompatibility and separation performance of PES-based hemodialysis membranes in 
vitro are discussed. Protein adsorption on material surface is a common phenomenon 
during thrombogenic formation. Thus, the amount of protein adsorbed on the PES 
membrane is considered to be one of the important factors in evaluating the blood 
compatibility of the membrane. The adhesion of platelets to blood-contacting medical 
devices is a key event in thrombus formation on material surface. Thus, protein adsorption 
and platelet adhesion on PES membrane surface are studied. In addition, the clearance and 
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the reduction ratio of small molecules (urea, creatinine, phosphate) during hemodialysis for 
the PES membrane in vitro are investigated.  
3.1 Protein adsorption and platelet adhesion 
3.1.1 Experimental 
3.1.1.1 Protein adsorption 
The protein adsorption experiments were made with BSA and FNG solutions. The 
concentrations of BSA and FNG were 4.0 g/dl and 0.3 g/dl in phosphate buffered saline 
(PBS, pH=7.4), respectively. The membrane with an area (for hollow fiber, it's the total 
surface areas of inside surface and outer surface) of 1 cm2 was incubated in distilled water 
for 24 h, washed 3 times with PBS solution, and then immersed in the protein solution for 2 
h. After protein adsorption, the membranes were carefully rinsed 3 times with PBS solution 
and then rinsed with distilled water. The adsorbed proteins were quantitatively eluted with 
1.0 ml 2% SDS solution for 6 h. The amount of protein in the SDS solution was quantified by 
protein analysis (Micro BCA protein assay reagent kit). 
3.1.1.2 Platelet adhesion 
The platelet adhesion experiments were carried out using platelet-rich plasma (PRP). 
Healthy human fresh blood was collected using vacuum tubes (7 ml, Venoject II, Terumo, 
Co.), containing citrate/phosphate/dextrose/adenine-1 mixture solution (CPDA-1) as an 
anticoagulant (anticoagulant to blood ratio, 1:7). The blood was centrifuged at 1000 rpm for 
10 min to obtain platelet-rich plasma (PRP) or at 2800 rpm for 15 min to obtain platelet-poor 
plasma (PPP). The fresh PRP sample was used for the platelet adsorption experiments. 
The PES membranes (11 cm2 each piece, always flat-sheet membranes) were immersed in 
PBS solution and equilibrated at 37 C for 1 h. The PBS solution was removed and then 1ml 
of fresh PRP was introduced. The membranes were incubated with PRP at 37 C for 2 h. PRP 
was decanted off and the membranes were rinsed 3 times with PBS solution. Finally, the 
membranes were treated with 2.5 wt% glutaraldehyde in saline for 2 days at 4 C. The 
samples were washed with PBS solution, subjected to a drying process by passing them 
through a series of graded alcohol-saline solutions (0%, 25%, 50%, 75% and 100%) and then 
dried at room temperature. The dried membranes after gold coating were examined using a 
S-2500C scanning electron microscope (SEM, Hitachi, Japan). The number of adhering 
platelets on the membranes was calculated from four SEM pictures at a 500 magnification 
from different places on the same membranes. These procedures were performed on each 
membrane using four independent membranes (totally n=16), and the number was finally 
averaged to obtain reliable data. 
3.1.2 Results and discussion 
3.1.2.1 Protein adsorption 
Non-specific protein adsorption is a dominant factor for membrane fouling. When 
membrane is used for blood purification, protein adsorption is the first stage of the 
interactions of membrane and blood, which may lead to further undesirable results. Protein 
adsorption has some relationship with the blood compatibility. There are many factors 
which affect the interaction between membrane surface and protein, such as surface charged 
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character, surface free energy and topological structure, solution environment (e.g. pH, ionic 
strength), and protein characters (Leng et al., 2003; Okpalugo et al., 2004). The 
hydrophilic/hydrophobic character of membrane material plays a relatively important role 
in the interaction between protein and membrane. Since hydrophilic surface preferentially 
adsorbs water rather than solutes, many researchers have followed the idea of increasing the 
hydrophilicity of a membrane material with the goal of reducing protein fouling and/or 
protein adsorption (Mockel et al., 1999). Herein, the surfaces of the PES and some typical 
modified PES membranes (Copolymer of poly (acrylonitrile-co-acrylic acid), PAN-AA, 
modified PES membranes with the ratios of the copolymer to PES of 0/16, 0.4/16 and 
0.6/16, respectively; and BSA grafted membranes following the copolymer/PES blended 
membranes) were studied in relation to the adsorption of BSA and FNG in vitro, data are 
shown in Fig. 5.  
3.1.2.2 Platelet adhesion 
The adhesion of platelets to blood-contacting medical devices is a key event in thrombus 
formation on material surface. After the platelet adhesion and activation, a series of actions 
could produce the thrombins which led further coagulant. Therefore, in vitro platelet 
adhesion assay could reflect the blood compatibility of material surface. To study the 
platelet adhesion, the morphology of the adhering platelet and the amounts of platelet 
adhesion on the membrane surfaces are always investigated through scanning electron 
microscopy (SEM). 
Figure 6 shows the typical morphology of the platelets adhering to the PES and modified 
PES membranes. Herein, the membranes were modified by blending sulfonated PES and a 
terpolymer of poly (acrylonitrile-acrylic acid-N-vinyl pyrrolidinone) (P(AN-AA-VP)). To 
prepare the membranes, PES, SPES and P(AN-AA-VP) were dissolved in solvent NMP. The 
solution was vigorously stirred until clear homogeneous solution was obtained. The 
concentration of all the solute was 16 wt. %. In the experiment, different kinds of 
membranes were prepared by changing the ratios of PES, SPES and P(AN-AA-VP) in the 
casting solutions, and the ratios of PES, SPES and P(AN-AA-VP) were 16:0:0, 15:0:1, 14:0:2, 
10:6:0,10:5:1, 10:4:2, respectively. After vacuum degassing, the casting solutions were 
prepared into membranes by spin-coating coupled with a liquid-liquid phase separation 
technique at room temperature. The obtained membranes were washed with distilled water 
thoroughly to remove the residual solvent, which were confirmed by UV scanning. All  
the prepared membranes were in a uniform thickness of about 60~70 μm, and the 
membranes were termed M-16-0-0, M-15-0-1, M-14-0-2, M-10-6-0, M-10-5-1, and M-10-4-2, 
respectively. 
As shown in Figure 6, when compared the pictures in the same amplification multiple, it 
was observed that a large amount of platelets were adhered and aggregated on the PES 
membrane surface and the platelets formed circular or “pan-cake” shape, which suggested 
that the platelets were activated and already retracted the pseudopods. However, for the 
modified membranes, very sparse platelets were found; and the platelet expressed a 
rounded morphology with nearly no pseudopodium and deformation. 
Figure 7 shows the amounts of the adhering platelets on the membranes from platelet-rich 
plasma. It could be observed that much lower number of the adhering platelets on the 
modified membranes compared with the PES membrane. Furthermore, the platelet 
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Fig. 5. (a). BSA adsorption on the membrane surfaces with the blending ratios of PES to 
PANAA as 16/0.2, 16/0.4, 16/0.6. (■) For the blended membranes; (□) for the BSA grafted 
membranes (each point represents the means±S.D. of three independent measurements.). (b) 
BFG adsorption on the membrane surfaces with the blending ratios of PES to PANAA as 
16/0.2, 16/0.4, 16/0.6. (■) For the blended membranes; (□) for the BSA grafted membranes 
(each point represents the means±S.D. of three independent measurements.). 
(From reference, Fang et al., 2009) 
 




Fig. 6. Scanning electron micrographs of the platelets adhering to the membranes. 
adhesion on the terpolymer modified membranes decreased with the increase of the content 
of the terpolymer P(AN-AA-VP). These results were consistent with those obtained from the 
protein adsorption, which demonstrated that the platelet adhesion had some relation with 
the carboxylic groups which were supplied by P(AN-AA-VP). It could also be observed that 
the platelet adhesion of the SPES modified membrane was significantly depressed, which 
was attributed to the sulfonic acid group provided by SPES.  
Han et al. (Han et al., 1996) suggested that the sulfonic acid groups exhibited high 
adsorption of albumin and low adsorption of FBG, which might improve the blood 
compatibility. Thus, the platelet adhesion demonstrated the enhanced blood compatibility of 
SPES modified membrane. Furthermore, as the ratios of P(AN-AA-VP) to SPES changing, 
the different amounts of the platelet adhesion could be obtained, and no adhering platelet 
was found on the surface of the modified membrane M-10-4-2. The reduction of the platelet 
adhesion on the modified membranes was considered to be the introduction of the sulfonic 
acid and carboxylic groups which were supplied by SPES and P(AN-AA-VP), respectively. 
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The platelet adhesion results were consistent with FBG adsorption. It is well known that 
FBG adsorption from plasma onto a material surface might promote the adhesion of the 
platelets because it had the ability to bind specifically to the platelet membrane 
glycoprotein, GP IIb-IIIa (Phillips et al., 1988). Thus, the observed decreasing amounts of 
platelet adhesion might be attributed to the increased hydrophilicity, and decreased FBG 
adsorption. These results indicated that the surface heparin-like PES membranes modified 




Fig. 7. The number of the adhering platelets on the membranes 
3.2 Ultrafiltration and solute clearances 
3.2.1 Experimental 
3.2.1.1 Hemodialysis using a simulation solution 
The test solutions were prepared according to the international standard ISO 8637. The 
molar concentrations of urea, creatinine and phosphate in the simulation solution were 
15mmol/l, 500mol/l and 1mmol/l, respectively. The test procedure was accordant to the 
procedure in ISO 8637. The ultrafiltration coefficient was calculated as the unit ml/mmHg.h. 
The clearance (K) of small molecules (urea, creatinine, phosphate) were established by 
sampling from the inlet and outlet segments of the extracorporeal circuit 1 h after the 










where CBI is the solute concentration in the blood (here is the simulation solution); I and O 
refer to the inlet and the outlet to the device, respectively; QBI is the blood flow rate at the 
dialyser inlet; QF is the filtration rate. 
Urea was determined by a reagent Kit for Urea Determination (Diethyl-Monoxime, Beijing 
chemical regent factory, China); creatinine was quantified by the absorption at 235nm using 
an UV-VIS spectraphotometer U-200A (Hitachi Co., Ltd., Tokyo, Japan) through a standard 
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curve. Phosphate was determined using the molybdate blue method: phosphate reacts with 
ammonium molybdate and is then reduced by stannous chloride to form a blue complex, 
and then measured at 670nm with the UV-VIS spectraphotometer U-200A. 
3.2.1.2 Hemodialysis using swine blood in vitro 
Fresh swine blood was collected using a glass tank, containing citrate/phosphate/dextrose/ 
adenine-1 mixture solution (CPDA-1) as an anticoagulant (anticoagulant to blood ratio, 1:7). 
The dialysis procedure was the same as the section 3.2.1.1, and the solute clearance was 
calculated using the same formula as described in the section 2.2. The concentrations of 
urea, creatinine and phosphate were determined using an Auto Biochemistry Analyzer 
7170A (Hitachi Co., Ltd., Tokyo, Japan) 
3.2.2 Results and discussion 
Table 1 summarizes the clearance data and the reduction ratio after the dialysis for small 
molecules in vitro. It was clearly that the clearances and the reduction ratios for all the 
solutes were larger using the simulated solution than that for blood. The removal of small 
molecules during dialysis is governed by hydrodynamic conditions within the dialyser 
rather than membrane structure since the major resistance to transport from the blood into 
the dialysis fluid lies not in the membrane but boundary layers adjacent to the membrane. 
Thus, the data of clearance and the reduction ratio (Table 1) for the simulated solution were 
higher than that for the blood due to the proteins in the blood, which may induce 
concentration polarization. 
Hemolysis ratio was determined for the swine blood in vitro and for the goat blood in vivo. 
Data showed that there was only a slightly hemodialysis phenomena (about 1.7%) in vitro. 
 
 Clearance (ml/min) Reduction ratio (%)    Urea              creatinine         phosphate     Urea          creatinine 
Simulated 
solution 174.06.0 169.05.0 170.06.0 94.33.8 92.44.1 
Blood in vitro 157.57.4 143.66.8 144.57.2 71.23.9 69.94.0 
Blood in vivo 153.69.4 141.68.2 142.57.3 69.24.5 68.95.2 
Data are expressed as the meansSD, n =3 
Table 1. Small molecular clearance at a blood (or simulated solution) flow rate of 180 
ml/min and dialysate flow rate of 500 ml/min 
4. Performance evaluation in vivo 
The biocompatibility and separation performance of PES-based hemodialysis membranes in 
vivo are also discussed. Animal experiments are carried out to evaluate the PES hollow fiber 
membranes firstly, and goat was selected as the experimental animal. Experiments were 
performed to evaluate the solute clearance and the blood compatibility. The blood 
compatibility and performance of the PES-based high-flux hemodialysis membrane in 
hemodialyzation were also clinically evaluated, and compared with those of two 
conventional high-flux membranes, polysulfone (PSF) and polyamide (PA) membranes. The 
PES and PSF membranes showed similar blood compatibility and solute clearance, and the 
blood compatibility for PES and PSF might be better than that of the PA membrane. 
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4.1 Evaluation by animal experiments 
4.1.1 Experimental 
4.1.1.1 Hemodialysis procedure 
Adult hybrid goats (about 20 kg) were used in the experiment. All the animals underwent 
local anesthesia with 1.0% procaine hydrochloride by injection into the neck muscle. The 
hair on the neck was cleared away carefully. The animal was laid on its back and fixed on 
the experimental table. 
Extracorporeal circuits were primed with 500ml normal saline solution to remove the 
bubbles in the circuits and in the dialyzer, then primed with 500ml saline solution 
containing 10000 IU heparin. 150mg urea and 50mg creatinine were injected to the animal 
blood before the treatment. At the initiation of the treatment goats received a loading dose 
(3000 IU) of heparin, and followed by continuous infusion (3000 IU/h). The infusion was 
terminated at 30 min prior to the end of the dialysis. 
4.1.1.2 Solute transport 
Extracorporeal circuits with left–right neck intravenous cannulation were created on the 
animal using B. Braun blood tubing lines for hemodialysis. The clearance (K) of small 
molecules (urea, creatinine, phosphate) were established by sampling from the inlet and 
outlet segments of the extracorporeal circuit 1 h after the initiation of the treatment, and was 
calculated using the formula described in section 3.2. The fluid removal ratio during these 
measurements was maintained at (3 ml/min). 
Removal of 2-microglobulin was established from the changes in plasma 2-microglobulin 
levels during the treatment at different time intervals (30, 60, 120, 180 and 240mins). Plasma 
2-microglobulin levels were determined using a commercially produced ELISA assay 
(Cambridge Life Sciences, Cambridge, UK).  
Electrolyte levels were determined before and after hemodialysis. K+,Na+ and Cl- were 
determined using electrolyte analyzer (NOVA CRT-4, US), and Ca2+ was determined using 
an Auto Biochemistry Analyzer 7170A (Hitachi Co., Ltd., Tokyo, Japan). 
4.1.1.3 Biocompatibility 
The levels of urea, creatinine, phosphate, total proteins, albumin (ALB), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) 
were determined using an Auto Biochemistry Analyzer 7170A (Hitachi Co., Ltd., Tokyo, 
Japan).  
Blood cells including red blood cell (RBC) and white blood cell (WBC), and blood 
components including hemoglobin (HGB) and platelet were determined using a blood cell 
analyzer (BC-3000peus, Shenzhen Mairui Biomedical Device Co. Ltd., China). Blood gas was 
determined using a blood gas analyzer (CORNing 238, US). 
For complement and WBC activation investigation, various membranes were used from 
different companies, Cuprophane (Nephross, Netherlands), Cellulose acetate (Nissho, 
Japan), Hemophane (Ningbo-Yatai, China), Polysulfone (PSF, Fresenius, Germany). 
Polycarbonate (PC) was obtained from BASF Co. Ltd., and the PC membrane was prepared 
in our Lab. Complement C3 activation was determined in vitro by enzymelinked 
immunosorbent assays (ELISA) (Zwirner et al., 1995). For comparing the results, activation 
for Cuprophane membrane was used as control. 
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4.1.2 Results and discussion 
4.1.2.1 Solute transport 
Table 1 also summarizes the clearance data and the reduction ratio after the dialysis for 
small molecules in vivo. Changes in 2-microglobulin during the dialysis for the goats are 
plotted in Figure 8. The reduction ratio was about 50% after the treatment for 4hrs.  
The ultrafiltration coefficient was obtained by the hemodialysis process using the simulated 
solution with a value of 81ml/h.mmHg, from which we could conclude that the PES 
membrane was a high-flux hemodialysis membrane.  
The PES membrane was able to reduce the plasma burden of 2-microglobulin during the 
treatment, as shown in Figure 8. The data were analyzed by consideration of actual values 
and the percentage reductions achieved. The reduction ratio was about 50% after the 
treatment for 4 hrs; this value is comparable to that for PSF membrane and polyflux 
(Hoenich & Katopodis, 2002).  
As shown in table 1, the reduction ratio for the 2-microglobulin was smaller than that for 
the urea and creatinine due to the higher molecular weight (p<0.05). The alteration of 2-
microglobulin in plasma levels may not simply be a result of trans-membrane transport; the 
adsorption to the membrane may also play a role in the observed plasma changes (Hoenich 
& Katopodis, 2002). For the removal of 2-microglobulin, cellulose derived membrane is 
impermeable to 2- microglobulin due to its dense symmetrical structure which does not 
permit the easy diffusion or convection of proteins through the membrane, while 
polyacrylonitrile (PAN), polysulfone and polymethylmethacrylate (PMMA) membrane 
could be used (Moachona et al., 2002). The PMMA membrane could also adsorb 2-
microglobulin. To remove 2-microglobulin more efficiently from plasma, hemodialysis 
membranes must therefore not simply be considered as filters of low-molecular-weight 
metabolites but should be equally assessed for their capacity to eliminate potentially 
deleterious low-molecular-weight plasma proteins. For the PES membrane, 2-
microglobulin adsorption is not an important mechanism of removal. The large solute 
removal by the membrane is mainly caused by the asymmetric structure and the higher 
ultra-filtration coefficient, which was presumably caused by the larger pore size and the 




















Fig. 8. Changes in 2-microglobulin during the dialysis. Data are expressed as the 
meansSD, n =3 (From reference, Su et al., 2008) 
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Table 2 shows the electrolyte values in the goat blood before and after the dialysis process. 
Among the these ions, only the K+ exhibited statistically significant decreases after the 
dialysis, whereas Na+, Cl- and Ca2+ did not change. As shown in the table, only the K+ 
exhibited statistically significant decreases during the dialysis (p<0.05), whereas Na+, Cl- 
and Ca2+ did not change (p>0.05). The electrolyte balance could be adjusted by the dialysis 
fluid, and the accurate K+ values are critically important for the management of patients 
with little or no residual kidney function (Barry 2003; Morgera et al., 2005). 
 
 pre-dialysis post-dialysis 
K+(mmol/L) 3.710.37 2.980.17 
Na+(mmol/L) 144.03.8 142.81.8 
Cl—(mmol/L) 105.14.1 101.01.2 
Ca2+(mmol/L) 2.120.16 2.020.11 
* Data are expressed as the meansSD, n =3 
Table 2. Electrolyte values pre- and post-dialysis 
4.1.2.2 Biocompatibility 
Figure 9 summarizes the changes in the goat blood observed during the dialysis in respect 
of white cells (WBC) and platelets. Both white blood cell and platelet counts have been 
normalized to pretreatment levels and expressed as a percentage of these values. A small 
decline in both was noted at the first 30 minutes, which returned to the initial levels after 
about 2 h. These phenomena have been reported frequently in hemodialysis, hemofiltration, 
and plasma separation. 
 
 
Fig. 9. Changes in WBC and platelet during the dialysis in vivo ♦ Platelet; ■ WBC; Data are 
expressed as the meansSD, n =3 (From reference, Su et al., 2008) 
The complement and WBC activation for various membranes were investigated after 
contacting to blood for 1h. The data showed the correlation between the complement and 
WBC activation. We also found that the concentration of C3a increased rapidly at the 
beginning of the contact between the blood and the PES membrane and remained constant 
after 90 min, which was consistent with the decrease of white blood cells (Zhao et al., 2001). 
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system results in release of anaphylatoxins into the circulation which have potent 
physiological effects, thus complement activation has been the most widely used parameter 
to evaluate hemocompatibility. 
Hemolysis ratio was determined for the swine blood in vitro and for the goat blood in vivo. 
Data showed that there was only a slightly hemolysis phenomena (about 1.7%) in vitro, 
while the hemolysis ratio was zero in vivo (The absorption value for (+) is 0.832, but for the 
sample is 0).  
The red blood cell (RBC) and hemoglobin (RGB) levels were also determined during the 
dialysis. The RBC level was (2.040.12)1012/L and (1.960.10)1012/L respectively before 
and after the hemodialysis. And the HGB level was 115.08.0g/L and 110.58.0g/L before 
and after the hemodialysis, respectively.  
Biochemistry for the blood was analyzed before and after the hemodialysis, and the data 
were summarized in Table 3. Only the alkaline phosphatase (ALP) level increased. And the 
others, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total 
protein (TP) and plasma albumin (ALB) were slightly decreased. The blood gas was also 
analyzed as shown in Table 4. The data showed no statistically change during the dialysis. 
The urine solution was also analyzed before and after the hemodialysis; the pH value, urine 
protein and urine glucose had no change before and after the hemodialysis. The 
concentrations of urobilinogen were 3.5mmol/L and 3.7mmol/L before and after the 
hemodialysis, respectively. 
Red blood cells (RBC) and hemoglobins (HGB) levels decreased slightly after the treatment, 
and both of the reduction ratios were about 5%. Slightly decreases in alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), total protein (TP) and plasma 
albumin (ALB) were also observed. The reduction ratios for all of them ranged 3-10%, which 
were presumably caused by the dilution of the blood by normal saline solution infused after 
the hemodialysis process. ALP is produced primarily in the liver and in bone, and the result 
for ALP indicts that the PES membrane has no effect on the liver. 
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Table 2 shows the electrolyte values in the goat blood before and after the dialysis process. 
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Table 2. Electrolyte values pre- and post-dialysis 
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system results in release of anaphylatoxins into the circulation which have potent 
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The PES hollow fiber hemodialysis membrane could effectively remove water and waste 
products, not only small molecular weight solute such as urea and creatinine, but also 
“middle” molecular solute as 2-microglobulin. Slight neutropenia and platelet adhesion were 
observed at the initial stage of the hemodialysis and no significant differences were found in 
electrolyte, blood gas and blood biochemistry before and after the treatment. The results also 
suggested that the PES membrane hemodialyzer could be used for clinical application. 
4.2 Clinical evaluation 
4.2.1 Experimental 
4.2.1.1 Hemodialysis procedure 
Three groups of hemodialysis patients with mature functioning arteriovenous fistula 
participated in this study. Their mean age was 48 ± 12 yr, and they had been receiving 
dialysis treatments for 35 ± 14 months with an average frequency of 3 times per wk. For each 
patient, Hct was determined at the beginning of the hemodialysis session.  
Standard midweek hemodialysis sessions were analyzed, and bicarbonate dialysate was 
used. The dialysate contained 140 mmol/L sodium, 2 mmol/L potassium, 108 mmol/L 
chloride, 1.50 mmol/L calcium, 0.5 mmol/L magnesium and 32 mmol/L bicarbonate. The 
blood flow was 200 ml/min and the dialysate flow was 500 ml/min. Three kinds of 
dialyzers (PES, polysulfone (PSF), and polyamide (PA)) were used for the three groups of 
patients, respectively. 
4.2.1.2 Calculation of solute clearance 
The levels of urea, creatinine, phosphate, total proteins, albumin (ALB), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) 
were determined using an Auto Biochemistry Analyzer 7170A (Hitachi Co., Ltd., Tokyo, 
Japan).  
The removal of 2-microglobulin was established by the changes in plasma level during the 
treatment at different time intervals (30, 60, 120, 180 and 240mins). Plasma 2-microglobulin 
levels were determined using a commercially produced ELISA assay (Cambridge Life 
Sciences, Cambridge, UK).  
Electrolyte levels were determined before and after hemodialysis. The levels of K+, Na+ and 
Cl- were determined using electrolyte analyzer (NOVA CRT-4, US), and Ca2+ was 
determined using an Auto Biochemistry Analyzer 7170A (Hitachi Co., Ltd., Tokyo, Japan). 
4.2.1.3 Evaluation of blood compatibility 
In order to investigate the complement and immunoglobin activation, complement C3, C4 
and immunoglobin G, A, M and E were determined by enzyme-linked immunosorbent 
assays (ELISA)   
Blood cells including red blood cell (RBC) and white blood cell (WBC), and blood 
components including hemoglobin (HGB) and platelet were determined using a blood cell 
analyzer (BC-3000peus, Shenzhen Mairui Biomedical Device Co. Ltd., China). Blood gas was 
determined by a blood gas analyzer (CORNing 238, US). 
4.2.1.4 Statistical analysis 
The software of SPSS 13.0 was used for statistical analysis. The deviation between the three 
groups was calculated by analysis of one-factor variance (ANOVA), and the deviation 
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between samples in one group was calculated by Student-Newman-Keuls (q-test). All the 
data are shown by mean values and standard deviations (ms), p<0.05 is considered to have 
statistical difference. 
4.2.2 Results and discussion 
All the patients participated in the whole study period. The vital signs were stable with no 
adverse events during the dialysis, and there were no abnormal findings in laboratory 
security parameters. During the dialysis by PA membrane dialyzer, some clots were found 
after 175 minutes in the extracorporeal blood circuit of a male patient who was on a 
repeated bolus fraxiparine anticoagulation regimen (6000 IU in total), but the patient still 
finished the treatment. This was the only adverse event during the whole study. All of 
patients who were treated by PES, PA or PSF membrane dialyzers were performed without 
provoking any adverse symptoms, such as headache or hypotension. 
4.2.2.1 Solute clearance 
The clearance of small molecular and middle molecular toxins was expressed as the solute 
reduction ratio (RR) after 4 hours hemodialysis, and could be calculated by: RR (%) = (1-
(post-solute concentration/pre-solute concentration))100%. The blood flow was controlled 
at 200 ml/min and the dialysate flow was 500 ml/min. Figure 10 shows the RRs of urea, 
creatinine and 2-microglobulin for the three kinds of hollow fiber dialyzers. As shown in 
the figure, large amount of the toxins were removed after the hemodialysis. The RRs of urea 
for PES, PA and PSF membranes were 61.2%, 63% and 62.3%, respectively. The RRs of 
creatinine were 51.3%, 54.5% and 54.7%, respectively. Meanwhile, the RRs of 2-
microglobulin were 60.8%, 51.3% and 57.7%, respectively. The RRs of urea and creatinine for 
the PES membrane were slightly smaller than that for the PA and PSF membranes, but no 
statistical difference. However, the RRs of 2-microglobulin for the PES membrane were 
slightly larger than that for the PA and PSF membranes. It proved that the PES, PA and PSF 
hollow fiber hemodialysis membranes could effectively remove waste products including 
not only small molecular weight solutes such as urea and creatinine but also “middle” 
molecular solutes as 2-microglobulin. 
To increase the removal of large molecular solutes, the rates of diffusion and convection 
should be increased, and the membrane pore size and porosity should be increased. Pore 
size limitations arise from the concern over potential loss of blood proteins such as albumin. 
Given that dialysis patients are generally malnourished, and the relative risk of death of 
dialysis patients increases as the serum albumin concentration decreases, it is desirable to 
minimize the albumin loss to the dialysate. Furthermore, small albumin losses may be 
clinically insignificant to the patient, but may lead to practical problems in the dialysis 
clinic, such as the foam formation in the dialysate drains. An ideal dialysis membrane 
should have a uniform pore size large enough to allow the passage of 2-microglobulin but 
small enough to retain albumin (66,000 daltons). Unfortunately, methods currently used to 
produce dialysis membranes resulted in a non-uniform pore size distribution. In the phase 
inversion membrane production process, polymer is dissolved in a solvent and then 
exposed to a non-solvent as it is extruded through an annular die. The breadth of the 
distribution produced by the phase inversion process resulted from the finite rate of 
molecular diffusion through the viscous polymer solution during the membrane coagulation 
phase (Qian et al., 2009). While previous membrane improvements have resulted from 
reducing the viscosity of the polymer solution, it is unlikely that the breadth of the pore size 
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distribution can be significantly reduced by further modification of the phase inversion 
process. Given a fixed breadth of the pore size distribution, the requirement for albumin 
retention limited not only the maximum pore size but also the mean pore size. As a result, 
the sieving coefficient of 2-microglobulin is generally 0.6 or less in order to maintain the 
albumin sieving coefficient at 0.01 or less. The PES membrane may be adequate to this 
requirement (Kim & Kim, 2005). 
 
 
Fig. 10. Reduction ratios of small molecules urea and creatinine, as well as middle molecules 
2-microglobulin after four hours hemodialysis at a blood flow rate of 200 ml/min and 
dialysate flow rate of 500 ml/min. Data are expressed as the meansSD, n =3 
4.2.2.2 Biocompatibility 
Figure 11 shows the white cell (WBC) changes in the patient bloods during the dialysis for 
the three kinds of membranes. The blood cell counts have been normalized to pre-treatment 
levels and expressed as a percentage of these values. A small decline was noted at the first 
30 minutes for all the membranes, and returned to the initial levels after about 1 h, and no 
significant difference was observed among the three membranes. The changes in platelet, 
complement factor C3, and complement C4 during the hemodialysis process for the three 
membranes were also investigated, and similar results were obtained as the change in WBC 
(Data not shown). 
Retrospective analyses have shown that hemodialysis with synthetic dialysis membranes is 
associated with improved patient survival in ESRD (Kim & Kim, 2005). This observation 
was mainly attributed to membrane biocompatibility. Synthetic membranes are generally 
regarded as to be highly biocompatible, since they lead to low complement activation and 
leucopenia, which are the two classical parameters to characterizing biocompatibility in 
dialysis (Hakim et al., 1996). However, several other systems become altered during blood–
membrane interaction. Among them are the coagulation system and imbalances of the 
oxidative and anti–oxidative system (Krieter et al., 2007; Klingel et al., 2004). 
A slightly decrease in outlet leukocyte counts was observed for the three dialyzers, and 




















   For urea;    For creatinine; 
   For 2-microglobulin 
 
Polyethersulfone Hollow Fiber Membranes for Hemodialysis 
 
85 
white blood cells was caused by complement activation, thus similar results were obtained 
in the changes of complement factor C3 and complement C4 during the hemodialysis 
process. When comparing PES, PA and PSF membranes, these change showed no significant 
difference, which indicated that the blood compatibility might be the same, though different 
membrane materials were used.  
 
 
Fig. 11. Changes in WBC during the dialysis in vivo. Data are expressed as the meansSD, n =3 
The concentration of albumin (ALB) and immunoglobin (GLB) slightly increased after 4 h 
hemodialysis, and no significant difference among the three membranes. Total protein 
adsorption of the membranes was also determined, and the amounts for PES, PA and PSF 
membranes were 12.2, 10.2, and 11.9 g/cm2, respectively. 
Total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), and aspartate 
aminotransferase (AST) levels were measured after 4 h hemodialysis, and compared with 
the initial levels for the three kinds of membranes, as shown in Figure 12. There are no 
significant differences in the changes of TBIL, DBIL, ALT, and AST for the PES and PSF 
membranes, and both the TBIL and DBIL levels increased compared to the initial levels. 
However, for the PA membrane, the TBIL, and AST levels decreased obviously.  
In Figure 12, slightly changes in total bilirubin (TBIL), direct bilirubin (DBIL), alanine 
aminotransferase (ALT), and aspartate aminotransferase (AST) were also observed. The 
change ratios for all of them ranged 3-10%. There are no significant differences in the 
changes of TBIL, DBIL, ALT, and AST for the PES and PSF membranes, and both the TBIL 
and DBIL levels increased compared to the initial levels, which were presumably caused by 
the dilution of the blood by normal saline solution infused or pachemia after the 
hemodialysis process. However, for the PA membrane, the TBIL, and AST levels decreased 
obviously. TBIL, DBIL, ALT and AST are produced primarily in the liver; all of them are 
lipophilic and hydrophobic. The dialyzer permits diffusive clearance of non-protein-bound, 
water soluble uraemic solutes, such as urea and creatinine. The corollary is that the 
substances are tightly protein-bound and present in small quantities in the aqueous phase, 
or are lipophilic and removed by HD in negligible amounts, if at all. The results indicted 
that the PES and PSF membrane had no effect on the liver, and might have possibly higher 
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Fig. 12. Total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), and 
aspartate aminotransferase (AST) level changes after 4 h hemodialysis. Data are expressed 
as the meansSD, n =3 
We speculated that the high-flux dialysis membrane might possibly let some 
biocompatibility markers enter dialysis solution so that the plasma levels of these markers 
could provide biased information. The plasma levels of biocompatibility markers may have 
also been influenced by adsorption to the membrane surface (Benz et al., 2007; Gotz et al., 
2008). The adsorption to the membrane was not determined in our study. However, the 
protein adsorption capacity was investigated, and no difference was observed. On the basis 
of our results, we concluded that the designed modifications of the new high-flux PES 
dialyzer resultED in its higher middle molecule clearance efficacy, and had an effect on 
thrombogenicity as assessed by platelet behavior and fibrinolysis. Although coagulation 
system judged by one of the evaluated parameters was slightly higher compared with the 
other dialyzers, it was still within the biocompatible dialyzer range. In terms of complement 
activation and changes in leukocyte count, the new dialyzer is also comparable with the 
other biocompatible dialyzers. Besides the thrombogenicity, complement activation, and 
WBC count changes, other issues must be considered when evaluating bio(in)compatibility 
(Krieter et al., 2007; Klingel et al., 2004) 
One further aspect merits consideration is that the PES membrane dialyzer series exhibits a 
higher permeability and thus, cytokine-inducing substances, possibly present in the dialysis 
fluid, might gain access to the blood stream through internal filtration (backfiltration). 
Therefore, investigations on the pyrogen permeability of PES membranes have been 
performed to the studies on the inflammatory response of the membrane. In the study, the 
dialysate compartment was deliberately contaminated with purified lipopolysaccharides 
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maltophilia. No significant generation of interleukin 1 (IL-1), IL-6 or tumor necrosis factor 
(TNF) was found in the blood compartment for the PES dialyzer and Fresenius PSF series of 
dialyzers as compared with sterile controls. However, significant induction of IL-1, IL-6, and 
TNF was observed for the highly permeable polysulfone membrane DIAPES, suggesting 
that not all of the polysulfone membranes were alike with regard to their pyrogen 
permeability due to the different modification methods. The PES, PA, and PSF dialyzers 
offered important safety features with regard to a possible contamination of the dialysis 
fluid (Wang et al., 1996; Schiffl & Lang, 2010). 
4.2.3 Summary 
The PES hollow fiber membrane hemodialyzer was effective and safe in the therapy for 
uremic patients. The PES hollow fiber hemodialysis membrane could effectively remove 
water and waste products including not only small molecular weight solutes such as urea 
and creatinine but also “middle” molecular solute as 2-microglobulin. Slight neutropenia 
and platelet adhesion were observed at the initial stage of the hemodialysis and no 
significant difference was found in electrolyte or blood biochemistry before or after the 
treatment. The data indicated that the performances of PES, PSF and PA hemodialyzers in 
the clinical setting were comparable and the PES hemodialyzer might be better than the 
others. The results indicated that PES hollow fiber membrane had a potentially wide 
application for hemodialysis. 
5. Conclusions 
Polyethersulfone (PES) is one of the most important polymeric materials and is widely used 
in separation fields. PES and PES-based membranes show outstanding oxidative, thermal 
and hydrolytic stability as well as good mechanical and film-forming properties. 
Furthermore, PES-based membranes show high permeability for low molecular weight 
proteins when used as hemodialysis membranes. However, the blood compatibility of the 
PES membrane is not adequate, and injections of anti-coagulants are needed during its 
clinical application. 
Thus, all the PES membranes used for hemodialysis are not the pristine PES membranes, 
and most widely used modification method for hemodialysis PES membranes is blending. 
Poly (vinyl pyrrolidone) (PVP) is the most widely used for the modification of PES 
membranes by blending, and PVP also acts used as a hydrophilic additive and a membrane 
forming agent. Surface-coating and grafting methods can also be used for the modification 
of PES hollow fiber membranes. All the modifications are based on the premise that the 
materials used in the modification give inherently more hydrophilicity and adsorb less 
protein than the underlying substrate. 
Protein adsorption on material surface is a common phenomenon during thrombogenic 
formation. Thus, the amount of protein adsorbed on the PES membrane is considered to be 
one of the important factors in evaluating the blood compatibility. The adhesion of platelets 
to blood-contacting medical devices is a key event in thrombus formation on material 
surface. The clearances and the reduction ratios of small molecules (urea, creatinine, 
phosphate) for the PES membrane after the hemodialysis in vitro were larger than those in 
vivo. Animal experiments and clinical experiments indicated that the PES-based high-flux 
hemodialysis membrane had good blood compatibility, and could effectively remove 
“middle” molecular solute as 2-microglobulin. 
 





Fig. 12. Total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), and 
aspartate aminotransferase (AST) level changes after 4 h hemodialysis. Data are expressed 
as the meansSD, n =3 
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dialyzers as compared with sterile controls. However, significant induction of IL-1, IL-6, and 
TNF was observed for the highly permeable polysulfone membrane DIAPES, suggesting 
that not all of the polysulfone membranes were alike with regard to their pyrogen 
permeability due to the different modification methods. The PES, PA, and PSF dialyzers 
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clinical application. 
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Poly (vinyl pyrrolidone) (PVP) is the most widely used for the modification of PES 
membranes by blending, and PVP also acts used as a hydrophilic additive and a membrane 
forming agent. Surface-coating and grafting methods can also be used for the modification 
of PES hollow fiber membranes. All the modifications are based on the premise that the 
materials used in the modification give inherently more hydrophilicity and adsorb less 
protein than the underlying substrate. 
Protein adsorption on material surface is a common phenomenon during thrombogenic 
formation. Thus, the amount of protein adsorbed on the PES membrane is considered to be 
one of the important factors in evaluating the blood compatibility. The adhesion of platelets 
to blood-contacting medical devices is a key event in thrombus formation on material 
surface. The clearances and the reduction ratios of small molecules (urea, creatinine, 
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hemodialysis membrane had good blood compatibility, and could effectively remove 
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The blood compatibility and performance in hemodialyzation were compared with two 
conventional high-flux membranes, polysulfone (PSF) and polyamide (PA) membranes. The 
PES and PSF membranes showed similar blood compatibility and solute clearance, and the 
blood compatibility for PES and PSF might be better than the PA membrane. 
In conclusion, PES-based hollow fiber membranes have good blood compatibility and solute 
clearance, and the PES hollow fiber membrane hemodialyzer might be a good commercial 
product in the future. 
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1. Introduction 
Haemodialysis (HD) is a life-saving treatment for patients with chronic kidney disease 
(CKD) stage 5. CKD persists as a chronic worldwide epidemic and HD is the more 
frequently (70%) adopted treatment modality. Exponential growth trend continues on a 
global scale. The HD population becomes every year increasingly older (average age: 75 yrs) 
and sicker due to the associated co-morbidities such as cardiovascular disease (heart failure, 
coronary heart disease, and peripheral vascular disease), diabetes, hypertension, and 
peripheral vascular disease. Most of the complications associated with HD involve the 
cardiovascular system (Go et al., 2004; Culleton et al., 1999, Goodkin et al., 2003, Foley 2004; 
Barret, 2002). The evolution in the history of HD technology has greatly helped to make the 
HD procedure a safe and more biocompatible extracorporeal therapy. However, it must be 
admitted that despite significant improvements in HD technology and in the management 
of patients due to a better understanding of uremia toxicity, improvements in dialysis 
technology, better correction of anaemia and metabolic abnormalities, implementation of 
best practice guidelines, no significant improvement has been achieved in patient survival 
over the last decade (Rayner et al., 2004). The extracorporeal circuit offers a large surface of 
contact of the blood with foreign materials, namely the dialysis membrane, the tubings and 
the large volumes of the dialysate. The concept of biocompatibility has greatly evolved in 
the last two decades. Initially, numerous studies focused on the blood-dialyzer membrane 
interaction, leading to the activation of plasma systems (complement, coagulation, 
fibrinolysis). These studies helped in the understanding of some unknown effects occurring 
in the early stages of the HD session leading to pulmonary sequestration of leukocytes 
(mainly neutrophils) that explained the profound neutropenia associated with the 
cuproammonium membranes. The availability of reliable testing of complement-activated 
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products (C3a and C5a and their desarginated products) guided the development of less 
neutropenia-inducing membranes and ultimately to the final development of fully synthetic 
membranes which have very low if at all capacity to induce complement activation. At that 
time, coagulation was an important reason for frequent interruptions and delays in the HD 
sessions. Due to the complex interplay known to occur between the activation of the 
complement and coagulation systems, it became of great interest to try to reduce the 
propensity for intravascular coagulation. The development of high-flux membranes and 
growing awareness of the benefits of convective and convective/diffusive under several 
contexts (intradialytic cardiovascular stability, better control or the uremic status and fluid 
control) gave impetus to a large number of enlightening studies on another mechanism of 
HD bioINcompatibility. The contamination by bacterial products, particularly with the 
widespread use of bicarbonate-based dialysates opened a new era in the field of 
biocompatibility. The formulation of the “interleukin hypothesis” was a posteriori not only 
the basis for further studies on the monocyte stimulation during HD, but also provided a 
link between biocompatibility and chronic inflammation. Basically, the evolution of 
biocompatibility has led us to consider two sides of the same coin: on one side, the biological 
responses at the blood-membrane interface; on the other hand, the consequences derived 
from the contact on the membrane performances (e.g. hydraulic permeability and sieving 
coefficients). 
In this review, we will summarize the most important steps in the evolution from the 
concept of the blood-dialyzer membrane interaction to that of the whole HD system 
compatibility. In face of very recent developments of cell-to-cell communication and signal 
transduction, we will also discuss the new hypothesis for a role of microvesicles (MVs) in 
cell activation, as well as in tissue and vascular repair. We will not deal with other important 
aspects of biocompatibility such as the oxidant stress, the relevant role of additives in 
dialyzer manufacturing, and of leachables and the effects of different sterilization modes.  
2. Blood-membrane interaction: the role of complement, coagulation, kinin-
kallikrein systems and soluble mediators 
2.1 Activation of the complement alternative  pathway  
Early studies on biocompatibility focused on acute hypersensitivity-like reactions which 
in some cases were fatal. Various mechanisms were elucidated. Activation of complement 
was shown by Craddock et al in 1977 (Craddock et al, 1977). Hydroxyl radicals, present on 
the surface of cellulosic membranes, bind with the C3b in the blood and activate the 
alternative pathway leading to the release of potent anaphylatoxins, C3a and C5a. Both 
C3a and C5a and their relative desarginated products induce prompt activation and 
aggregation of polymorphonuclear neutrophils (PMNs) and leukopenia. This is a very 
rapid process reaching a nadir from 15 to 30 min after initiation of dialysis. Aggregates of 
PMNs are sequestered particularly in the lung capillaries. Although the extent of the 
anaphylatoxin generation and of the neutropenia is also patient-dependent, these studies 
failed to find a relationship with chronic clinical trade-offs despite the hypothesis that 
recurrent pulmonary sequestration could induce pulmonary fibrosis. Reduction of the 
hydroxyl groups on the membrane surface or new synthetic polymers reduced the 
activation of the alternative pathway of the complement cascade. Temperature could also 
reduce complement activation (Maggiore Q, personal communication, 1988). Testing 
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complement activation (C3a or C5a plasma levels) by highly sensitive ELISA tests has 
become a standard requirement for the evaluation of biocompatibility ever since along 
with the precise characterization of the polymer structure (Krieter et al, 2008). It also 
became clear that synthetic polymers had a very low neutropenia-inducing effect. In some 
cases such as the polyacrylonitrile membrane, this was also due to the capacity of the 
membrane to adsorb C3b and the anaphylytoxins thus masking in fact complement 
activation (Pascual et al 1993) (Figure 1).  
 
 
Fig. 1. Pathways involved in blood-membrane interactions. LTB4 denotes leukotriene B4, 
PAF, platelet-activating factor, IL-1, interleukin-1, TNF-, tumor necrosis factor. 
2.2 Activation of the coagulation system 
Numerous acquired hemostatic abnormalities have been identified in chronic renal failure. 
HD adds to these disturbances as it repetitively implies turbulent blood flow, high shear 
stress, and contact of blood to artificial surfaces. Anticoagulation in HD is targeted to 
prevent activation of coagulation during the procedure. Most anticoagulant agents inhibit 
the plasmatic coagulation cascade. Still commonly used is unfractionated heparin, followed 
by low-molecular-weight heparin preparations with distinct advantages. Immune-mediated 
heparin-induced thrombocytopenia constitutes a potentially life-threatening complication of 
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heparin therapy requiring immediate switch to nonheparin alternative anticoagulants. 
Danaparoid, lepirudin, and argatroban are currently being used for alternative 
anticoagulation, all of which possess both advantages and limitations. Recently citrate has 
been proposed as anticoagulant in maintenance HD (Wright et al, 2010). In the past, 
empirical strategies reducing or avoiding heparin were applied for patients at bleeding risk, 
whereas nowadays regional citrate anticoagulation is increasingly used to prevent bleeding 
by allowing procedures without any systemic anticoagulation. Avoidance of clotting within 
the whole hemodialyzer circuit is not granted. Specific knowledge of the mechanisms of 
coagulation, the targets of the anticoagulants in use, and their respective characteristics 
constitutes the basis for individualized anticoagulation aimed at achieving full patency of 
the circuit throughout the procedure. Patency of the circuit is an important prerequisite for 
optimal HD quality. Intrinsic coagulation Hageman factor XII as well as other coagulation 
factors are also activated (Fischer, 2007). However, the activation of the coagulation is a very 
complex phenomenon that may be enhanced by different independent factors other than the 
membrane surface per se such as: the dynamics at the dialyzer heads, defects in the hollow 
fibre cutting of the polyurethane, any condition that predisposes for blood to be stagnant. 
The activation of coagulation by a membrane in a dialyzer is difficult to assess given the 
above-mentioned factors and the host's response to the anticoagulation regime put in place 
(Figure 1). 
2.3 Activation of the kinin-kallikrein system 
Surface activation of Factor XII induces the kinin-kallikrein that ensues in the generation of 
bradykinin (Figure 2). 
Bradykinin is physiologically under the tight control of very potent kinases that are able to 
promptly lyse the molecule and inactivate its potent vasodilator activity. In certain 
conditions, however, the lytic effect of this kinase is deficient. This occurs in patients under 
therapy with angiotensin converting enzyme enzyme (ACE) inhibitors. However, there are 
patients who experience hypersensitivity-like phenomena, that can be reconducted to 
bradykinin generation, even in the absence of concomitant therapy with ACE inhibitors. The 
explanation of this phenomenon came from pioneering studies on angio-edema, a rare but 
potentially fatal condition (Adam et al., 2002). These reactions are mainly associated to 
defects in the enzymatic activity of the aminopeptidase P (Figure 2). Bradykinin acts 
through two types of tissue receptors: R1 are mostly located in the skin and respiratory 
tissues (lungs and bronchi), while R2 are mostly found in the gastrointestinal tract. The 
overproduction of bradykinin may lead to two different clinical presentations: the first is 
mainly characterized by a rapid developing skin flushing, hypotension, and dyspnoea. 
These reactions may be mild but very severe, fatal episodes of shock have been described. In 
the second instance, these reactions, which were for some time unexplained, occur after 1 h-
2 hr of HD treatment, may but may be not associated with the use of ACE inhibitors. The 
patient has severe diarrhoea which requires immediate interruption of the extracorporeal 
treatment. This manifestation may unpredictably recur and disappears upon disconnection. 
Bradykinin-induced reaction, may in principle occur following the contact with any foreign 
surface. Their potential, unpredictable severity should call for immediate action even in 
patients with mild forms. The commonest causes have been the use of strongly negative 
surfaces such as AN-69 membranes (Tielemans et al., 1990), or adsorbents used in LDL 
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apheresis (Owen et al., 1994) or in Hemodiafiltration (HDF) with regeneration of the 
ultrafiltrate (Tetta C, Wratten ML, unpublished observation, 2001). The appearance of signs 
and symptoms of a hypersensitivity-related event can be dramatic in the practice of HD. The 
complexity of the causal factors and the underlying mechanisms are often difficult to unveil 
(Arenas et al., 2006). The majority of reported cases have been due to ethylene oxide (ETO) 
(Poothullil et al., 1975), triggered by both immunoglobulin E (IgE) and non-IgE factors 
(Johansson et al., 2001). However, a considerable number of publications have focused on 
other HD substances and materials such as heparins, different dialyser membranes, iron, 
erythropoietin, polyacrylonitrile AN69® high flux membranes, latex, antiseptic or 
formaldehyde (Ebo et al, 2006). Many different underlying mechanisms have been 
postulated. Hypersensitivity reactions have been estimated to occur in ~4/100000 dialysis 
treatments. A postal survey of all HD centres in the UK suggested that 1/20 to 1/50 patients 
may be susceptible to anaphylactoid reaction to a new hemodialyser at some time in 
between, while the risk of reaction occurring with any single HD session is~1/1000 to 
1/5000. Although it is likely that many reactions are unrecognized or unreported, the scale 
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heparin therapy requiring immediate switch to nonheparin alternative anticoagulants. 
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2.3.1 Soluble mediators   
Many soluble mediators are produced and released following the blood-membrane 
interaction. Products of the phospholipase A2 such as platelet-activating factor (PAF) and 
leukotrienes are released by the direct interaction of PMNs and platelets with complement-
activating membranes. Although in the presence of blood, the mechanisms of production of 
PAF and leukotrienes can not be readily differentiated from the activation, as they follow 
the same kinetics, we could show that for PAF for example, its production and release could 
be observed in complement-independent conditions such as in the absence of plasma by 
purified cells incubated with flat HD membranes (Tetta et al., 1996). A large number of 
studies have also suggested the occurrence in the plasma of lytic enzymes normally present 
in the vacuoles of inflammatory cells such as elastases, and metalloenzymes. The release of 
these lytic enzymes is caused by a phenomenon named by cell physiologists as "frustrated 
phagocytosis".  
3. The effect of blood on dialyzer performances 
When blood enters the HD system via the arterial line, a complex interplay of factors alters 
membrane performances e.g. clearances, ultrafiltration rates and sieving coefficients. These 
factors are patient- and system- dependent.  
3.1 Patient-dependent factors 
3.1.1 Albumin: Relevant amount of albumin fragments are detectable in the serum of 
patients undergoing HD. Uremia appears to facilitate the fragmentation of albumin 
and/or the retention of albumin fragments in blood (Donadio et al., 2009). Depending 
on their molecular weight, albumin fragments may be either lost in the dialysate or 
remain trapped in the wall of the hollow fibre. More in general, plasma proteins may 
cause a phenomenon names as “protein fouling”. 
3.1.2 Plasma viscosity which is related (but not exclusively) to albumin, fibrinogen and lipids.  
3.1.3 Free hemoglobin: In vitro data have shown that blood circulation produces an increase 
of up to 280% in free hemoglobin levels and an increase of 320% in electronegative LDL 
(LDL(-) subfraction, a highly atherogenic form of oxidized LDL. The significant 
correlation between LDL(-) and free hemoglobin levels shows the oxidative activity of 
free hemoglobin (Ziouzenkova et al., 1999) (Figure 3).  
3.1.4 System-dependent factors 
3.1.4.1 Several factors are here involved such as the vascular access flow rate, and the pump 
rate and the response of the dialyzer depending on the membrane resistance and 
geometry. As seen from a kinetic perspective, the blood flow, and pressures are on-off 
events which are reflected in a “push-pull” effect on the dialyzer hollow fibre. Although 
these effects are still not completely known, they seem to be relevant on the shear rates, the 
erythrocyte orientation, leading in the worst conditions to predispose to their agglutination 
and clogging of the hollow fibre. Calculating clearances, ultrafiltration rates and sieving 
coefficient using aqueous solution can lead to an overestimate of 30%and is therefore 
hardly informative of the dialyzer behaviour in vivo. Finally, it was shown that sieving 
coefficients may change over the time of treatment rendering the calculation of clearances 
on the basis of the quantization of urea on the ultrafiltrate may also lead to an 
overestimation of the dialyzer performances (Claure-Del Granado et al., 2010).  
 




Fig. 3. Microhemolysis is the release of small quantities of hemoglobin (micro- or 
nanomolar) from erythrocytes. The tyrosine of a hemoglobin molecule can undergo a 
transition to a reactive free radical. This can react with other protein tyrosine residues to 
form a dityrosine molecule. Microhemolysis occurs during the HD procedure in which the 
erythrocytes are slightly damaged and tend to „leak“ very small quantities of hemoglobin. 
This is a very common phenomena in HD and should not be confused with gross hemolysis. 
4. The evolution of treatment biocompatibility 
4.1 From system biocompatibility to systemic chronic inflammation 
The concept that inflammation underlines many diseases once considered to be linked to 
degenerative processes has revolutionized the approach to the research into the 
pathogenesis and new therapeutics alike. In the field of cardiovascular disease, the process 
of endothelial dysfunction, vascular damage and atherosclerosis is now seen as a continuum 
(Libby et al., 2002). Cardiovascular disease is among the leading cause of morbidity and 
mortality in CKD patients on maintenance HD (US Renal Data System, 1997; Parfey & Foley, 
1999). Even before reaching the state of chronic kidney disease Stage 5, patients with chronic 
renal failure present signs of chronic inflammation. Once patients are on HD, the risk of 
cardiovascular death is approximately 30 times higher than in the general population, and 
still remains 10 to 20 times higher after stratification for age, gender, and presence of 
diabetes. Traditional risk factors seem inadequate to explain the remarkable prevalence of 
cardiovascular disease observed in the uremic population (Foley et al 1998).  
4.1.1.1 Systemic Chronic Inflammation  
Inflammatory mechanisms play a relevant role in the development and progression of 
atherosclerosis (Ross, 1999) and heart failure (Vasan et al., 2003). Epidemiological studies in 
the general population have shown that even minor elevations of C-reactive protein (CRP), 
an acute phase reactant that markedly increases during an inflammatory response (Ridker 
PM, et al., 1997) predict the development of coronary heart disease and cardiac failure 
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(Liuzzo et al 1994, Lagrand et al., 1999, Badht et al, 2002). C-reactive protein may directly 
promote the development of atherosclerosis, through complement activation, tissue damage 
and activation of endothelial cells. Recent studies performed in CKD patients have shown 
that CRP is a strong predictor of cardiovascular death (Stenvinkel, 2001, Kaysen, 2005). The 
link between CRP and cardiovascular risk was initially thought to be indirect, reflecting 
circulating CRP only to the extent of the acute phase reaction in response to nonspecific 
stimuli such as confounding risk factors, atherosclerosis, vascular injury, ischemia and 
necrosis. (Figure 4). 
 
 
Fig. 4. Acute phase response is a defence response which occurs as a consequence of an 
inflammatory stimulus occurring in the blood or at tissue level. The enhanced production of 
interleukin-6 (IL-6), the most potent inducer of this reaction at the level of the liver, triggers 
the synthesis of newly synthesized proteins, e.g., C-reactive protein (which plasma levels 
may increase up to 50-to 100-fold the normal levels) as well as to the shut-down of the 
translation of genes coding for proteins, e.g., albumin. 
Stenvinkel et al (1999) first convincingly showed that the malnutrition-inflammation 
complex syndrome described as MIA syndrome is associated with the highest mortality 
rates in ESRD. Their results were confirmed and extended (Panichi et al. 2008). As reviewed 
by Stenvinkel & Barany (2002), there is consensus on a link between CKD and inflammation. 
A number of studies have highlighted the association between increased inflammatory 
indexes and a reduced response to Erythropoietin-stimulating agents (ESAs), in particular, 
high CRP levels were found in HD patients requiring higher ESAs doses (Singh et al., 2007; 
Bradbury et al. 2009). However, the association between ESAs resistance and increased CRP 
levels (Barany et al. 1997; Gunnell et al. 1999) is unclear. Plasma IL-6 rather than CRP seem 
to better predict outcomes in CKD patients (Panichi et al., 2004). Various possible 
explanations may underline the advantage of IL-6 over CRP as a predictor of ESAs 
resistance. One possibility is that IL-6, being located upstream in the cascade of events 
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which lead to the synthesis of many acute-phase reactants, is a better marker for the 
inflammatory burden affecting the development of CVD (Panichi et al., 2011). A frequently 
asked question is what is the contribution of HD bioincompatibility to the chronic 
inflammatory state. In this context, the evolution of HD technology has moved the focus 
from membrane bioincompatibility only to a more complex and integrated view of the HD 
system. The possibility that HD may be shift to a “cardioprotective’’ therapy is inherent to 
new technologies in machines, water treatment, dialysis fluids and blood tubings. 
4.1.1.2 The Interleukin Hypothesis  
Originally introduced as an elegant concept in 1986 (Bingel et al., 1986), the “interleukin 
hypothesis” was first coined to indicate the production of interleukin-1, the endogenous 
pyrogen as produced by the result of complement-activated mononuclear cells. Indeed, 
the interleukin hypothesis explained much more than was initially predictable. Several 
studies have ever since reported an increased cytokine production secondary to blood 
interaction with contaminated dialysate. Interleukin-1 (IL-1), tumor necrosis factor-a 
(TNF-a) and mainly IL-6 are the 3 proinflammatory cytokines that are involved in the 
pathogenetic aspects of HD-related disease (as reviewed by Lonnemann, 2004, Panichi et 
al., 2000 (Figure 5).  
 
 
Fig. 5. Here are schematically depicted the mechanisms related to the 
backdiffusion/backfiltration of bacteria-derived contaminants from the dialysate into the 
blood. Their interaction with circulating monocytes/macrophages leads to the activation of 
innate immunity and to the attendant triggering of proinflammatory cytokines (interleukin-
1 (IL-1), tumor necrosis factor-. Abbreviations: CIS, cytokine-inducing substances; LAL, 
Limulus amoebocyte lysate, UF, ultrafiltrate. 
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The proposed mechanisms include blood interaction with endotoxins from the 
contaminated dialysate through HD membranes. A large number of studies have greatly 
contributed to increasing our knowledge in the mechanisms of endotoxin transfer across the 
membrane In fact, when using high permeability membranes, backfiltration and 
backdiffusion occur and have ebeen extensively described (Fiore & Ronco, 2007, Ronco, 
2007). Thus, the transmembrane passage of endotoxins or other cytokine stimulating 
substances (CIS) occurs during HD (Schindler et al., 2004, Tetta et al., 2006). The reduction of 
backfiltration of standard dialysate may reduce the plasma concentration of IL-1ra, a 
sensitive indicator of inflammation in HD patients (Dinarello personal communication, 2004), 
and IL-1 (Panichi et al., 1998). Studies on large groups of patients have shown that high-
volume exchange HDF, a treatment in which dialysate backfiltration is minimal, if any, is 
associated with significantly lower CRP plasma values (Panichi et. 1998). Comparing in a 
double cross-over study patients treated with high-flux and on line HDF using ultrapure 
dialysate and infusate, it was shown that a significant reduction of pro-inflammatory 
CD14+/CD16+ mononuclear subset (Carracedo et al., 2006) occurs in on line HDF. These 
studies emphasize that the convective component has an additional anti-inflammatory 
effects (Ramirez et al., 2007). 
The new technology of pyrogen-adsorbing, non-complement activating, high-permeability 
synthetic membrane and dedicated machines (Tetta et al., 2011), as well as the awareness of 
the deleterious effects derived from contamination of dialysis fluids has reduced the clinical 
impact to a periodic microinflammatory stimulus. Undoubtedly, the availability of monitors 
for on-line HDF and its increased popularity have spurred more restrictive measures on 
safety issues and monitoring. Water quality is a mandatory issue. The safety of online HDF 
has been shown repeatedly in several monocenter  (Canaud et al., 1998, Pizzarelli et al., 1998 
and multicenter studies (Canaud et al., 2001,Vaslaki  et al., 2000). 
Nowadays, the philosophy of ‘‘ultrapure dialysate’’is in common practice (Kessler et  
al., 2002). The clinical, consolidated experience on line HDF warrants well-defined 
procedures and leaves no space for ‘‘experiments’’ in what is now routine (Canaud et al, 
2011). The ‘‘hemocompatibility network’’ should eventually prevent the periodic 
microinflammation induction through the implementation of rigid protocols of disinfection 
and maintenance of water-treatment systems and HD monitors (Cappelli et al., 2006; Kessler 
et al. 2002).  
5. Microvesicles: their nature, release and pathophysiological relevance  
A chronic inflammatory state has been widely documented since the early stages of CKD 
and becomes more pronounced in those with CKD stage V undergoing HD. Oxidant stress 
(Wratten et al., 2000, Morena et al. 2011), endothelial dysfunction (Recio-Mayoral et al., 
2011), high circulating cytokine-producing monocyte subpopulation (Ramirez et al., 2006), 
reduced number and/or impaired function of endothelial progenitor cells (Krenning et al., 
2009), are today considered as hallmarks of vascular damage and defective repair. Uremia 
also causes telomere shortening and premature cellular senescence of immunocompetent 
cells (Jimenez et al, 2005). In recent years, increasing attention has been drawn by the 
awareness of the pathophysiologic role of small, circular membrane fragments named as 
Microvesiscles (MVs) (Ratajczak  et al., 2006) (Figure 6). 
 





For long time MVs were considered to be inert cellular debris. The frequently observed 
vesicles by electron microscopy in the interstitial space of tissues or in blood were 
considered as the consequence of cell damage or the result of dynamic plasma membrane 
turnover (Siekevitz et al., 1972). As the vesicle population detectable both in vitro and in vivo 
is a mixed population of exosomes and shedding vesicles, we will refer to  them collectively 
as MVs. Released MVs may remain in the extracellular space in proximity of the place of 
origin or may enter into the biological fluids reaching distant sites. This may explain the 
presence of MVs in plasma, urine, milk and cerebrospinal fluid. The bulk of MVs present in 
the circulation is derived from platelets (George, 1982), and in less extent from other blood 
cells and endothelial cells (Martinez et al., 2005). The MVs derived from platelets are also 
designed as microparticles while those derived from polymorphonuclear leukocytes are also 
named ectosomes (Hess et al., 1999). Finally, MVs released during morphogenesis of 
multicellular organisms are indicated as argosomes (Greco et al., 2001). Besides normal cells, 
also tumor cells may release MVs and in patients suffering for neoplastic diseases tumor-
derived MVs may be detected within the biological fluids (Kim et al, 2003, Iero et al., 2008). 
Therefore, MVs are an assorted population, differing in cellular origin, number, size and 
antigenic composition (Diamant et al., 2004) shed by various cell types in physiological and 
pathological conditions. The release of MVs may be constitutive or consequent to cell 
activation by soluble agonists, by physical or chemical stress such as the oxidative stress and 
hypoxia, and by shear stress (Ratajczak et al., 2006). Exosomes have an endosome origin and 
are a rather homogenous population with a size ranging from 30 to 120nm (7). They are 
stored as intraluminal vesicles within multivesicular bodies of the late-endosome and are 
released when these multivesicular bodies fuse with the cell membrane. Our knowledge on 
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the mechanism of assembly and sorting of the exosomes is only partial, due to the fact that a 
common sorting signal for all cell types has not so far been identified (Johnstone et al., 2006).  
Shedding vesicles are usually larger than exosomes with size ranging from 100nm to 1m. 
Formation of shedding vesicles takes place from the budding of small cytoplasmic 
protrusions followed by their detachment from the cell surface. This process is dependent 
on calcium influx, calpain and cytoskeleton reorganization. 
5.1 MV biological activities 
It is now recognized that MVs are an integral part of the intercellular microenvironment and 
may act as regulators of cell-to-cell communication. This concept is based on the observation 
that MVs released from a given cell type may interact through specific receptor-ligands with 
other cells leading to target cell stimulation directly or by transferring surface receptors 
(Janowska-Wieczorek et al., 2001,  Morel et al., 2004). This interaction may either be limited 
to a receptor-mediated binding to the surface of target cells forming a platform for assembly 
of multimolecular complexes or leading to cell signaling, either be followed by 
internalization as result of direct fusion or endocytic uptake by target cells (Cocucci et al., 
2008). Once internalized, MVs can fuse their membranes with those of endosomes, thus 
leading to a horizontal transfer of their content in the cytosol of target cells. Alternatively, 
they may remain segregated within endosomes and be transferred to lysosomes or 
dismissed by the cells following the fusion with the plasmamembrane, thus leading to a 
process of transcytosis. It was proposed that MV-mediated cell-to-cell communication 
emerged very early during evolution as a template for the development of further more 
refined mechanisms of cell communication (Ratajczak et al., 2006). MVs may influence the 
behavior of target cells in multiple ways.  
5.1.1 MVs may act as signaling complexes by direct stimulation of target cells (Ratajczak 
et al., 2006, Cocucci et al., 2008). MVs derived from platelets, for instance, play an 
important role in coagulation as their phosphatidylserine-enriched membranes provide 
a surface for assembly of clotting factors (Zwaal et al., 2004). After activation, platelets 
shed MVs coated with tissue factor which may interact with macrophages, neutrophils 
and other platelets by ligation with molecules expressed on the surface of these cells 
such as P-selectin (Polgar et al., 2005). On the other hand, MVs released from 
neutrophils express activated Mac-1 able to induce platelet activation (Andrews & 
Berndt, 2004). Moreover, platelet-derived MVs, besides coagulation, trigger various cell 
responses as they activate endothelial cells (Barry et al., 1997), polymorphonuclear 
neutrophils (Miyhamoto et al., 1988) and monocytes (Barry et al., 1999). . 
5.1.2 MVs may act by transferring receptors between cells. The transferring of receptors 
between cells is supported by the observation that bystander B cells rapidly acquire 
antigen receptors from activated B cells by a membrane transfer (Quah et al., 2008). 
5.1.3 MVs may deliver proteins within the target cells. An example of this mechanism is 
the recently reported MV-mediated transfer of a cell death message via encapsulated 
caspase-1 (Sarkar et al., 2009). It has been found that endotoxin stimulated monocytes 
induce the cell death of vascular smooth muscle cells by releasing MVs containing 
caspase-1. This trans-cellular apoptosis induction pathway depends on the function of 
the delivered caspase-1 within the target cells. It has been also suggested that MVs may 
contribute to dissemination of certain infective agents, such as HIV or prions (Facler & 
Peterlin, 2000, Fevrier et al., 2004).  
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5.1.4 MVs may mediate a horizontal transfer of genetic information. The occurrence of 
epigenetic changes has been frequently reported in co-culture conditions. An 
explanation of this phenomenon is the transfer of genetic information between cells. We 
demonstrated that MVs derived from human endothelial progenitors (EPC) can also act 
as a vehicle for mRNA transport among cells (Deregibus et al., 2007). MVs generated 
from EPC were incorporated in normal endothelial cells by interaction with 4- and 1-
integrins expressed on their surface and activated an angiogenic program. Besides 
mRNA, MVs may transfer microRNAs (miRNA) to target cells (Yuan et al., 2009). Since 
miRNAs are naturally occurring regulators of protein translation, this observation 
opens the possibility that stem cells can alter the expression of genes in neighbouring 
cells by transferring microRNAs contained in MVs. We recently characterized miRNA 
shuttled by MVs released by human adult mesenchymal stem cells (MSCs) (Collino et 
al., 2010). Hierarchical clustering and similarity analysis of microRNAs showed that 
microRNA compartmentalization and secretion by MVs are both highly regulated 
processes. 
5.2 Microvesicles in CKD 
The biologic role of MVs and their implication in pathophysiology depends on the several 
factors namely the cell of origin, their phenotype, the genetic material (mRNA and 
microRNA) and the target cells. In CKD, several studies have accrued evidence that MVs or 
MPs could participate to the vascular damage and the evolution of the atherosclerotic lesion.  
5.2.1 Circulating platelet-derived microparticles (PMPs) with procoagulant activity are 
considered a potential cause of thrombosis in uremic patients undergoing HD (Ando et 
al., 2002). Elevated counts of circulating PMPs have been reported in association with 
thrombotic disorders, such as cerebrovascular accidents (Katopodis et al., 1997), 
unstable angina (Katopodis et al., 1997), and acute myocardial infarction (Gawaz et al., 
1996). In addition, PMPs that adhered to vascular endothelium and leukocytes activate 
such cells and transport their chemical mediators to those cells, potentially leading to 
the development of thrombosis and atherosclerosis (Mallat et al., 1999, Barry et al., 
1997).  
5.2.2 Endothelial MVs (EMVs) - Treatment modalities that reduce the inflammatory 
potential of the cells originating MVs have interestingly been correlated with a 
decreased number of endothelial microparticles (Carracedo et al., 2005, Ramirez et al., 
2005). Circulating EMPs have recently been reported to correlate with impaired 
vascular function in HD patients (Faure et al., 2006). A recent study showed an increase 
in the percentage of CD14+CD16+ monocytes in CKD-NonD and HD patients. In PD 
patients, regardless of RRF, the percentage of CD14+CD16+ was similar to controls 
(Merino et al., 2010). It is interesting to note that HD patients displayed significantly 
higher apoptotic EMPs and VEGF levels than the two PD and CKD-non dialyszed 
groups. In contrast, there were no differences between CKD-NonD and PD groups. In 
CKD-non dialyszed and HD patients, the percentage of CD14+CD16+ was correlated 
with endothelial damage. It appears that PD, compared with HD, reduces but does not 
fully prevent the endothelial damage induced by uremia, in spite of presenting a 
microinflammatory status similar to that of the controls. The role of EMVs is still to be 
elucidated in the complex unbalance observed in CKD patients between circulating 
endothelial cells and endothelial progenitor cells.  
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5.2.3 MVs in treatment modalities  
Preliminary studies in our laboratory have shown an interesting trend in the reduction of 
total MVs in a cross-over clinical study when patients shifted from high-flux HD to on-line 
HDF (Figure 7).  
 
 
Fig. 7. Total MVs count in patients on maintenance HD. In a cross-over design, 8 patients 
were started on bicarbonate HD (black columns) and 8 patients on on-line HDF (grey 
columns). MVs were counted by cytofluorimetry. MVs were also characterized (data not 
shown) by the following specific markers: CD62P, CD41, CD42, CD31, for platelets; CD45, 
for leukocytes; CD31, CD146, CD144 for the endothelium: CD235 and CD242 (ICAM 4), for 
erythrocytes. 
More studies are needed to better assess the relevance of these observations and to better 
characterize the type and biological effects of the MVs. It is still to be fully elucidated 
whether MVs are a consequence or a cause of disease. Increasing evidence for their 
pathophysiologic role in other human diseases such as sepsis and tumors (Camussi et al., 
2011) is rapidly accruing. Many points require further investigation. i. The stimuli and the 
molecular pathways that regulate the assembly within MVs of the biological active 
molecules that they shuttle. ii. The stimuli that trigger their release. iii. The surface receptors 
that may confer selective specificity. iv. The full diagnostic potential of MVs in different 
pathological conditions. v. The strategy to inhibit formation or to remove from circulation 
potentially harmful MVs. The recognition of MVs has opened a new era and new 
perspectives of investigation also in biocompatibility of extracorporeal treatments. 
6. Conclusions 
The outlook of more biocompatible and physiological dialysis is today confronted with a 
older and sicker population in need of maintenance HD. The knowledge of biological 
mechanisms operating at the system level will be approached with the help of improved 
technologies hopefully able to reduce the deleterious effect of the repetitive contact with a 
foreign surface and to insure optimal performances for the elimination of small and middle 
molecule solutes. Advances in dialyzer membranes and geometries, as well as blood tubings 
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together with new concepts in machine technology have already shown their great potential  
to improve survival and cardiovascular stability.  
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1. Introduction 
The incidence of kidney disease is rapidly increasing worldwide, fueled by the increasing 
incidences of diabetes and obesity (Centers for Disease Control and Prevention, 2010), and 
thus, more patients with hypertension and diabetes develop end-stage renal disease (ESRD). 
Maintenance hemodialysis has become an established protocol for treating ESRD patients. 
This process is facilitated by two physical phenomena that facilitate mass transfer in 
purifying blood during maintenance hemodialysis. Diffusion caused by a concentration 
gradient between blood and dialysate contributes to the removal of uremic solutes, 
particularly small-size molecules. The removal of excess body water and mid-size molecules 
depends primarily on convective mass transfer, which results from hydraulic and osmotic 
pressure gradients (Daugirdas & Van Stone, 2000). 
Remarkable improvements have been made in the technologies used for renal supportive 
dialysis treatment in ESRD patients. Polymeric membranes better prevent the transfer of 
pyrogenic substances into the blood stream and membrane biocompatibilities are much 
improved (Weber et al., 2004). The sharp molecular cut-offs of these membranes also prevent 
further loss of albumin during high-dose convective treatment (Ahrenholz et al., 2004). 
Narrow pore size distributions and improved hydraulic properties in the membrane field are 
matched by the evolution of various modalities for renal supportive treatment. Furthermore, 
better outcomes achieved by convective treatment have encouraged the use of synthetic 
membranes with high water permeability and sieving characteristics in clinical setups (Woods 
& Nandakumar, 2000), to the extent that hemodiafiltration (HDF) and volume-controlled high-
flux hemodialysis (HD) are now regarded as preferred forms of convective therapy, because 
the retention of middle to large-sized molecules by chronic renal failure patients is closely 
related to renal-failure associated mortality (Leypoldt et al., 1999).  
Volume-controlled high-flux HD adequately clears mid-size solutes without sterile fluid 
infusion. Forward filtration exceeding desired volume removal is compensated for by 
backfiltration (Ofsthun & Leypoldt, 1995), and thus, this modality can provide a simpler 
form of dialysis treatment than other treatment methods. The convective dose delivered 
during high-flux HD has been shown to reduce mortality in patients at risk, as defined by a 
serum albumin level of <4 g/dl (Locatelli et al., 2009). However, overall patient survival 
remains comparable to that of low-flux HD (Eknoyan et al., 2002), which presumably is 
caused by the limited amount of internal filtration involved due to limitations imposed by 
fluid dynamics and the geometric nature of the hemodialyzer. 
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Therefore, HDF is considered the gold standard for high-dose convective therapy, and has 
even been reported to reduce mortality risk as compared with high-flux HD (Canaud et 
al., 2006). HDF, which describes an intermittent renal supportive therapy of combined 
simultaneous diffusive and convective solute transport, is characterized by a large 
filtration volume that far exceeds the desired volume removal, and hence, external 
substitution is essential. In early HDF trials, a large number of sterile bags were used to 
supply substitution fluid, which was costly and complicated (Ledebo, 2007). However, 
technical advances made in the production of pyrogen-free ultrapure water allow sterile 
dialysate to be readily produced, which enables on-line based HDF to be used on a 
clinical basis. Several types of on-line HDF are clinically available that differ in terms of 
the ways in which external replacement fluid is administered, such as, by pre- or post-
dilution. Due to their unique benefits, mixed forms of pre- and post-infusion have also 
been devised, such as, mixed-dilution or mid-dilution HDF (Krieter & Canaud, 2008, 
Pedrini & De Cristofaro, 2003). However, the inevitable complexities associated with HDF 
machines and patient monitoring, and the requirement for the exogenous infusion of 
replacement fluid is still problematic. Therefore, various modifications of HDF strategies 
have been proposed to integrate HDF and HD modes, that is, to increase convective dose 
without the requirement for external infusion. These modifications can be classified into 
three developmental categories; (1) to increase the internal filtration rate by increasing 
pressure gradients along the hemodialyzer, (2) to use independent domains for forward 
filtration and backfiltration, or ultrafiltration and diffusion, and (3) to alternate forward 
and backward filtration procedures. 
In this chapter, the trials on HDF strategies undertaken without exogenous substitution 
infusion will be discussed in terms of their technical aspects, in vivo and in vitro efficacies 
and applicabilities for clinical use. This is followed by an in-depth review on pulse 
push/pull hemodialysis (PPPHD), a recently introduced pulsatile technique that provides 
infusion-free HDF. 
2. HDF strategies that do not require exogenous substitution infusion 
Hemodiafiltration is an intermittent renal supportive therapy that involves the process of 
convection and diffusion. Total filtration volumes invariably exceed desired amounts and 
this dehydration must be corrected in real time. Despite various modifications of the HDF 
techniques based on infusion modes, the need for external replacement fluid infusion has 
not been eliminated. Accordingly, efforts continue to be made to eliminate exogenous sterile 
fluid infusion during HDF sessions. This is achieved by spontaneous fluid reinfusion at a 
rate that matches convection. Backfiltration and regenerated ultrafiltrate can be the methods 
of spontaneous fluid restoration. 
2.1 Internal Filtration Enhanced HDF (internal HDF or iHDF) 
Internal filtration (IF) is defined as the total water flux across membranes within the closed 
blood and dialysate compartments of a dialyzer (Dellanna et al., 1996). Volume controlled 
high-flux HD is a representative modality to use the internal filtration phenomenon, and 
provides a straightforward means of achieving enhanced convection by augmenting internal 
filtration rates. The amount of internal filtration is directly regulated by pressure gradients 
through the hemodialyzer. A pressure drop is inevitable, as fluid flows through a cylindrical 
tube, and it is expressed by Poiseuille’s equation: 
 




Fig. 1. Blood and Dialysate Pressure Gradient along Dialyzer Length. The sum of hydraulic 
and osmotic pressures is termed TMP, as TMP = ∆Pb- ∆Pd-∆π. Here, ΔPb represents the 
average value of arterial and venous blood pressure, ΔPd for average hydraulic dialysate 





   (1) 
Where, ΔP is the pressure drop, µ is the fluid viscosity, L and d are the length and diameter 
of the flow path, and Q the flow rates. Thus, blood and dialysate pressures drop along the 
dialyzers. However, because blood and dialysate flow in opposite directions, these pressure 
drops occur with opposing gradients, and in some region, hydraulic blood and dialysate 
pressures overlap (Fig. 1). In a normal countercurrent dialysis setup, the sum of hydraulic 
and osmotic pressures, termed transmembrane pressure (TMP), is positive in the proximal 
region of a hollow fiber dialyzer, and plasma moves to the dialysate compartment across the 
membranes (forward filtration). However, fluid movement occurs in the opposite direction 
in the distal region, because hydraulic blood pressures are below the sum of dialysate 
compartment pressure and osmotic pressure, and thus, backward filtration occurs and 
compensates for fluid loss in the proximal region.  
2.1.1 Factors influencing internal HDF 
Even though forward and backward filtration rates are highly dependent on membrane 
permeabilities and the degree of membrane fouling, they remain directly proportional to the 
positive and negative TMPs, respectively. As shown in Fig. 1, resulting TMP gradients can 
be readily increased by increasing blood and/or dialysate pressure drops (Fiore & Ronco, 
2004, 2007). For blood, the pressure drop is proportional to blood viscosity and tube length 
in accord with Poiseuille’s equation (Eq. 1), which shows that tube length increases pressure 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
114 
Therefore, HDF is considered the gold standard for high-dose convective therapy, and has 
even been reported to reduce mortality risk as compared with high-flux HD (Canaud et 
al., 2006). HDF, which describes an intermittent renal supportive therapy of combined 
simultaneous diffusive and convective solute transport, is characterized by a large 
filtration volume that far exceeds the desired volume removal, and hence, external 
substitution is essential. In early HDF trials, a large number of sterile bags were used to 
supply substitution fluid, which was costly and complicated (Ledebo, 2007). However, 
technical advances made in the production of pyrogen-free ultrapure water allow sterile 
dialysate to be readily produced, which enables on-line based HDF to be used on a 
clinical basis. Several types of on-line HDF are clinically available that differ in terms of 
the ways in which external replacement fluid is administered, such as, by pre- or post-
dilution. Due to their unique benefits, mixed forms of pre- and post-infusion have also 
been devised, such as, mixed-dilution or mid-dilution HDF (Krieter & Canaud, 2008, 
Pedrini & De Cristofaro, 2003). However, the inevitable complexities associated with HDF 
machines and patient monitoring, and the requirement for the exogenous infusion of 
replacement fluid is still problematic. Therefore, various modifications of HDF strategies 
have been proposed to integrate HDF and HD modes, that is, to increase convective dose 
without the requirement for external infusion. These modifications can be classified into 
three developmental categories; (1) to increase the internal filtration rate by increasing 
pressure gradients along the hemodialyzer, (2) to use independent domains for forward 
filtration and backfiltration, or ultrafiltration and diffusion, and (3) to alternate forward 
and backward filtration procedures. 
In this chapter, the trials on HDF strategies undertaken without exogenous substitution 
infusion will be discussed in terms of their technical aspects, in vivo and in vitro efficacies 
and applicabilities for clinical use. This is followed by an in-depth review on pulse 
push/pull hemodialysis (PPPHD), a recently introduced pulsatile technique that provides 
infusion-free HDF. 
2. HDF strategies that do not require exogenous substitution infusion 
Hemodiafiltration is an intermittent renal supportive therapy that involves the process of 
convection and diffusion. Total filtration volumes invariably exceed desired amounts and 
this dehydration must be corrected in real time. Despite various modifications of the HDF 
techniques based on infusion modes, the need for external replacement fluid infusion has 
not been eliminated. Accordingly, efforts continue to be made to eliminate exogenous sterile 
fluid infusion during HDF sessions. This is achieved by spontaneous fluid reinfusion at a 
rate that matches convection. Backfiltration and regenerated ultrafiltrate can be the methods 
of spontaneous fluid restoration. 
2.1 Internal Filtration Enhanced HDF (internal HDF or iHDF) 
Internal filtration (IF) is defined as the total water flux across membranes within the closed 
blood and dialysate compartments of a dialyzer (Dellanna et al., 1996). Volume controlled 
high-flux HD is a representative modality to use the internal filtration phenomenon, and 
provides a straightforward means of achieving enhanced convection by augmenting internal 
filtration rates. The amount of internal filtration is directly regulated by pressure gradients 
through the hemodialyzer. A pressure drop is inevitable, as fluid flows through a cylindrical 
tube, and it is expressed by Poiseuille’s equation: 
 




Fig. 1. Blood and Dialysate Pressure Gradient along Dialyzer Length. The sum of hydraulic 
and osmotic pressures is termed TMP, as TMP = ∆Pb- ∆Pd-∆π. Here, ΔPb represents the 
average value of arterial and venous blood pressure, ΔPd for average hydraulic dialysate 





   (1) 
Where, ΔP is the pressure drop, µ is the fluid viscosity, L and d are the length and diameter 
of the flow path, and Q the flow rates. Thus, blood and dialysate pressures drop along the 
dialyzers. However, because blood and dialysate flow in opposite directions, these pressure 
drops occur with opposing gradients, and in some region, hydraulic blood and dialysate 
pressures overlap (Fig. 1). In a normal countercurrent dialysis setup, the sum of hydraulic 
and osmotic pressures, termed transmembrane pressure (TMP), is positive in the proximal 
region of a hollow fiber dialyzer, and plasma moves to the dialysate compartment across the 
membranes (forward filtration). However, fluid movement occurs in the opposite direction 
in the distal region, because hydraulic blood pressures are below the sum of dialysate 
compartment pressure and osmotic pressure, and thus, backward filtration occurs and 
compensates for fluid loss in the proximal region.  
2.1.1 Factors influencing internal HDF 
Even though forward and backward filtration rates are highly dependent on membrane 
permeabilities and the degree of membrane fouling, they remain directly proportional to the 
positive and negative TMPs, respectively. As shown in Fig. 1, resulting TMP gradients can 
be readily increased by increasing blood and/or dialysate pressure drops (Fiore & Ronco, 
2004, 2007). For blood, the pressure drop is proportional to blood viscosity and tube length 
in accord with Poiseuille’s equation (Eq. 1), which shows that tube length increases pressure 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
116 
differential. Likewise, blood hematocrit and total protein levels also affect the pressure drop 
through viscosity.  
The diameter of the flow path is another important factor. Poiseuille’s equation shows that 
the pressure drop is inversely proportional to the 4th power of tube diameter, which means 
that membrane (a bundle of hollow fibers) lumen diameter is the predominant factor for 
governing blood pressure drops, and therefore, many investigations of internal HDF have 
focused on dialytic efficiencies using hemodialyzers with smaller membrane diameters. In 
early clinical studies, beta-2 microglobulin (β2M) removal was found to be significantly 
increased when membrane diameter was reduced. A 175 µm diameter dialyzer was found to 
enhance β2M clearances by factors of two and four, respectively, over 200 and 250 µm 
diameter hemodialyzers (Dellanna et al., 1996). Clearances of inulin and vitamin b12 were 
also significantly greater with 175 µm dialyzer than a 200 µm dialyzer, without changing the 
clearances of low molecular weight solutes (Ronco et al., 2000). In addition, a mathematical 
model showed that internal filtration rates increase rapidly with membrane diameter, and 
this theoretical result was also confirmed experimentally (Mineshima, 2004, Mineshima et 
al., 2000). Myoglobin clearance was increased by 34% when a membrane of diameter 150 
µm, rather than 200 µm, with the same surface area was used at the same blood flow rates. 
These benefits in dialytic efficiency afforded by reducing membrane lumen diameter allow 
internal filtration enhanced hemodialyzers to be used clinically (Lucchi et al., 2004, Righetti 
et al., 2010).  
However, the underlying risk of hemoconcentration due to high levels of forward filtration 
may not be negligible. Pressure-driven filtration causes large volume losses from blood and 
promptly increases blood viscosity, which deteriorates membrane sieving and hydraulic 
capabilities. Membrane-binding by blood components is a major cause of permeability 
reductions, and inevitably diminish membranes efficiencies, particularly in the forward 
filtration region. Nevertheless, membrane fouling, which tends to be more of an issue 
during the early stage of iHDF treatment, tends to have little effect on overall membrane 
transfer capacity during iHDF (Yamamoto et al., 2005). 
Dialysate pressure is also regulated by increasing the flow resistance on the dialysate 
stream. Several techniques can be used to increase dialysate flow resistances, such as 
increasing membrane packing density, lengthening the hemodialyzer, or placing obstacles 
in the dialysate flow path. Obviously, dialyzer length effectively regulates dialysate 
pressure drops. In one study conducted to clarify the effect of dialyzer length on solute 
clearance, middle-to-large uremic molecules, such as β2M and alpha-1 microglobulin (α1M), 
were shown to be better cleared by a 250 mm dialyzer than a 195 mm dialyzer (Sato et al., 
2003). Dialysate pressure drop can also be manipulated by modulating membrane packing 
density. The higher the packing density of membrane fibers, the greater the resistance to 
dialysate flow, because the effective cross-sectional area available for dialysate flow 
decreases. Analytical and experimental studies revealed myoglobin clearances using a 
hemodialyzer with 71.3% packing density were slightly higher than hemodialyzers with 
packing densities of 52% or 60.1% (Mineshima, 2004). However, high hemodialyzer packing 
densities cause substantial degrees of dialysate channeling and flow mismatch between 
blood and dialysate. This unmatched flow distribution leads to a loss of effective surface 
area and impairs the diffusion process (Gastaldon et al., 2003). Flow visualization studies in 
a dialyzer with a high packing density (75%) reconfirmed this disproportionate flow pattern 
of dialysate, as compared with standard packing density dialyzers (68%), and consequent 
reductions in urea clearance (Fujimura et al., 2004, Yamamoto et al., 2005). Nevertheless, a 
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unique design of housing wall, involving addition of a short taper to the inner housing 
surface effectively prevented the dialysate from being channeled (Fujimura et al., 2004). 
2.1.2 Internal filtration quantification 
The beneficial effects of internal HDF, such as increased middle-size solute clearances, may 
be quantified by evaluating internal filtration rates, because the internal filtration level is 
directly related to delivered convective dose. The flux across a membrane (Q) at a local 
region of the hemodialyzer (x) can be expressed by membrane hydraulic permeability (Kuf 
measured in ml/h/mmHg) and TMP (mmHg), as follows: 
       * ) * (  Q x Kuf x TMP x Kuf x Pb Pd        (2) 
Where, Pb, Pd and π represent the blood, dialysate and osmotic pressures. However, the 
flow dynamics inside the hemodialyzer are so complex that precise determinations of 
internal filtration rates are not available clinically. This is principally because Kuf across 
membranes is neither linearly related to the pressure gradient, nor constant at any position 
in the hemodialyzer (Ficheux et al., 2010). Kuf values are also substantially lowered by 
membrane fouling, which is remarkably affected by blood viscosity, coagulation, the 
abilities of membrane materials to bind plasma proteins, and treatment modalities. Hence, 
fluxes and permeabilities across membranes become parameters beyond the operator’s 
control. Alternatively, a semi-empirical model based on clinical data has been developed to 
determine internal filtration rates. Using this model, internal filtration volumes and 
reinfusion rates were determined during internal HDF and post-dilution HDF modes, and 
revealed that differences between total convections (4.1 and 5.4 L/h for iHDF and HDF) 
well reflected differences between β2M clearance rates (123±11 and 149±26 ml/min for 
iHDF and HDF, respectively) (Lucchi et al., 2004). In a study conducted using in vitro 
scintigraphy method to verify this semi-empirical model, the model was found to show 
excellent accuracies of around 97% and a prediction error of only 3% (Fiore et al., 2006). 
In addition to the mathematical model, methods for performing indirect measurements of 
the internal filtration have also been proposed. Changes in non-permeable molecular 
concentrations occur in response to the water content of blood, and thus, the kinetics of 
water transport across membrane can be evaluated by measuring the cumulative 
concentration changes of non-permeable molecules (Ronco et al., 1992). Radiolabeled 
albumin (a non-permeable molecule) has been employed to determine the amounts of 
convection for hemodialyzers with reduced fiber diameters or an obstacle in dialysate 
stream (Ronco et al., 2000, 1998). A series of in vitro experiments proved that this 
scintigraphic method was accurate for measuring internal filtration rates, but despite its 
precision, its clinical application is not plausible due to the safety issue raised by the use of 
radio-labeled molecules and the complexities of the procedures and equipment. 
Another approach to determine internal filtration is offered by Doppler ultrasonography, 
which measures changes in blood velocity within dialyzers. In the absence of net-filtration, 
blood volume depletion in the proximal portion of a hemodialyzer leads to a reduction in 
blood flow velocity, and after the lowest point has been reached, the blood velocity 
gradually increases due to backfiltration. Thus, changes in blood velocity along a dialyzer 
provide information on blood volume changes and on amounts of forward and backward 
filtration. In one study, the internal filtration rate of a 250 mm dialyzer was found to be 37.7 
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differential. Likewise, blood hematocrit and total protein levels also affect the pressure drop 
through viscosity.  
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densities cause substantial degrees of dialysate channeling and flow mismatch between 
blood and dialysate. This unmatched flow distribution leads to a loss of effective surface 
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unique design of housing wall, involving addition of a short taper to the inner housing 
surface effectively prevented the dialysate from being channeled (Fujimura et al., 2004). 
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revealed that differences between total convections (4.1 and 5.4 L/h for iHDF and HDF) 
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ml/min by Doppler ultrasonography, but only 11.1 ml/min for a standard 195 mm dialyzer 
(Sato et al., 2003). Doppler ultrasonography is straightforward, non-invasive, and easily 
used at bedside (Mineshima, 2011). However, the method is still incapable of measuring 
blood flow velocity precisely, particularly blood velocity deep within the membrane fiber 
bundle. In other words, this method is based on velocities measured in peripheral 
membranes, which are quite different from velocities within centrally located fibers, and as 
a result, deviations from true values are unavoidable. 
Other techniques have also been explored in an effort to quantify the filtration phenomena, 
or to visualize flow distributions inside hemodialyzers, these techniques include magnetic 
resonance imaging (Hardy et al., 2002), computed tomography (Frank et al., 2000, J. C. Kim 
et al., 2008) and a computerized scanning technique (Ronco et al., 2000, 2002). However, the 
quantification of internal filtration using these techniques is not available clinically, due to 
concerns of patient safety and technical requirements. 
Summarizing, internal HDF can provide a means of convective treatment by increasing 
internal filtration rates using specifically designed hemodialyzers, and at the same time 
spontaneous backfiltration compensates for fluid loss, and hence, this technique is simpler 
than other modalities. The hemodialyzer design for internal HDF must be optimized based 
on specified structural factors and on the filtration characteristics of membrane fibers. The 
literature suggests superior dialysis outcomes for iHDF, but the precise quantification of 
internal filtration remains to be determined. 
2.2 Double high-flux HDF 
Solute removal during extracorporeal hemodialysis, particularly for low-flux HD, is mainly 
facilitated by diffusion which is driven by the concentration gradient across membrane. 
Thus, solute clearances are highly dependent on their molecular weights. On the other hand, 
hemofiltration (HF) is purely convective. Thus, it could be speculated that HF delivers 
higher middle- to large-size solutes clearances than HD, but poorer small-size mass transfer. 
The additional advantages of this convective treatment include better maintenance of 
cardiovascular instability in ESRD patients or in ICUs. These benefits of hemofiltration 
encouraged investigations aimed at compensating for the inferior diffusive clearances of HF, 
and a hybrid configuration based on multiple membranes was introduced (Cheung et al., 
1982). 
Double high-flux HDF was first introduced in the early 1980’s as a means of combining HD 
and HF. This technique was particularly aimed at significantly increasing small (diffusion) 
and middle-size molecular removal (convection) in order to shorten overall treatment time, 
and therefore, much larger surface areas were used by arranging two high-flux 
hemodialyzers in series, in conjunction with a extremely high blood (400-500 ml/min) and 
dialysate flow rate (800-1000 ml/min) and a bicarbonate dialysate (Miller et al., 1984, von 
Albertini et al., 1984). 
This arrangement of two hemodialyzers enabled flow resistances through the two 
hemodialyzers to be manipulated, which permitted TMP gradients (both positive and 
negative) to be adjusted. A flow restrictor, placed on the intermediate blood line of two 
hemodialyzers, serves as a means of increasing blood pressures in the arterial-side 
hemodialyzer, which cause positive TMPs through this dialyzer and ultrafiltration (Fig. 2). 
On the other hand, blood pressure drops below dialysate pressures at the venous-side 
dialyzer and TMPs become negative, which leads to backfiltration (Shinzato et al., 1982). 
 
 




Fig. 2. Schematic Pressure Profiles during Double HDF, when a flow restrictor is placed on 
blood tube (upper) and on dialysate tube (below) of the two hemodialyzers. 
TMP regulation is also achieved by regulating dialysate pressure. Flow resistance applied to 
the dialysate tubing between the two dialyzers promptly increases dialysate pressures at the 
venous dialyzer because blood and dialysate flow in opposing directions. Hydraulic 
dialysate pressures exceed blood pressures, which leads to backfiltration in the venous 
dialyzer. However, dialysate pressures rapidly fall in the arterial dialyzer due to flow 
restriction, which causes ultrafiltration in the arterial dialyzer. In addition, the high blood 
and dialysate flow rates used are also associated with larger pressure gradients. Hence, 
ultrafiltration at the arterial dialyzer at levels of exceeding those required can be promptly 
compensated for by backfiltration at the venous dialyzer, and thus, exogenous replacement 
infusion is not required for this method. 
The flow resistance placed on the dialysate stream was originally made from a gauge needle 
assembled with a bypass line in parallel. A clamp on the bypass line forced the dialysate 
into the gauge needle, and created flow resistance in dialysate stream. The flow resistance in 
this configuration is fixed, and the amounts of ultrafiltration and backfiltration cannot be 
adjustable externally. Hence, the means of creating resistance to dialysate flow was 
improved in the advanced version, termed convection-controlled double high-flux HDF, in 
which variable and controllable flow resistances were integrated (Pisitkun et al., 2004).  
Therefore, together with these features, this modality achieved unmatched depurative 
outcomes, as demonstrated by far higher uremic molecular clearances regardless of 
molecular size (Cheung et al., 1982, Shinzato et al., 1982, von Albertini et al., 1985). 
Furthermore, increased clearances allowed treatment times to be shortened (Miller et al., 
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ml/min by Doppler ultrasonography, but only 11.1 ml/min for a standard 195 mm dialyzer 
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bundle. In other words, this method is based on velocities measured in peripheral 
membranes, which are quite different from velocities within centrally located fibers, and as 
a result, deviations from true values are unavoidable. 
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or to visualize flow distributions inside hemodialyzers, these techniques include magnetic 
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et al., 2008) and a computerized scanning technique (Ronco et al., 2000, 2002). However, the 
quantification of internal filtration using these techniques is not available clinically, due to 
concerns of patient safety and technical requirements. 
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internal filtration rates using specifically designed hemodialyzers, and at the same time 
spontaneous backfiltration compensates for fluid loss, and hence, this technique is simpler 
than other modalities. The hemodialyzer design for internal HDF must be optimized based 
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literature suggests superior dialysis outcomes for iHDF, but the precise quantification of 
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adjustable externally. Hence, the means of creating resistance to dialysate flow was 
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which variable and controllable flow resistances were integrated (Pisitkun et al., 2004).  
Therefore, together with these features, this modality achieved unmatched depurative 
outcomes, as demonstrated by far higher uremic molecular clearances regardless of 
molecular size (Cheung et al., 1982, Shinzato et al., 1982, von Albertini et al., 1985). 
Furthermore, increased clearances allowed treatment times to be shortened (Miller et al., 
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1984, von Albertini et al., 1984). Solute removal in a relatively short time (e.g., 2 hours) may 
cause greater rebound of uremic solute levels after post-dialysis equilibrium, thus solute 
removal rates in trials of double HDF far surpassed the removal rates desired during 
hemodialysis, achieving two and half times higher clearances over 2 hours as was achieved 
over 4 hours in conventional HD mode. These results were also confirmed by comparing 
treatment modalities. Double high-flux HDF attained significantly greater β2M reduction 
and Kt/VUREA values than high-flux HD, and showed comparable β2M clearance to that of 
on-line HDF (Susantitaphong et al., 2010, Tiranathanagul et al., 2007). Furthermore, the 
beneficial effect of this technique on patient survival was also suggested in a long-term 
assessment. In this study, double high-flux HDF was compared with high-efficiency or high-
flux HD modes in terms of treatment time, Kt/V and standardized mortality ratio over 6 
years. Kaplan-Meier Survival analysis revealed a significantly lower mortality ratio for 
double HDF versus USRDS (0.41 and 1, respectively) despite the shortened treatment time 
(Bosch et al., 2006). 
However, concerns have been raised regarding the use of two hemodialyzers in this double 
HDF technique, such as, possible increases in treatment cost and system complexity. One 
possible way of overcoming these issues involves the reuse of dialyzers, although regulatory 
guidelines on renal replacement practices in some countries do not permit reuse. Another 
concern arises from the large amount of cross-membrane flux. In particular, a large quantity 
of backfiltration should be assured by the strict and regular verification of water quality 
(Bosch & Mishkin, 1998. One positive aspect is that the venous dialyzer acts as a final barrier 
to pyrogen transfer. 
Double high-flux HDF emerged as a result of an effort to increase treatment efficiencies and 
shorten treatment times by maximizing both diffusive and convective mass transfer. Many 
observations have confirmed the high solutes clearances across a wide spectrum of 
molecular weights, which are the results of the unique features of this method. In particular, 
the unique control of hydraulic pressures possibly gives this unit the ability to regulate 
convective dose. However, the widespread implementation of this technique may require 
the identification of patients capable of tolerating treatment and the overcoming of the 
above-mentioned underlying concerns. 
2.3 Paired filtration dialysis with endogenous reinfusion (HFR) 
Another two-chamber technique for obtaining short and efficient HDF treatment is the so-
called paired filtration dialysis (PFD). Like double HDF, PFD is also a strategy of 
simultaneous HD and HF treatment aimed at increasing both diffusive and convective 
clearances, but its design principles separate convection from diffusion (Ghezzi et al., 1989, 
1987, Ronco et al., 1990). A hemofilter with a relatively small surface area is combined with a 
hemodialyzer in this sequence (Fig. 3). Ultrafiltration purely occurs at the hemofilter and 
then blood is dialyzed continually through the hemodialyzer. 
The convection, which is not connected with diffusion, can minimize interactions between 
diffusion and convection (Ghezzi et al., 1987). Total resulting clearances during HDF are 
always lower than the sum of convective and diffusive clearances, which is attributed to the 
reciprocal interactions of these two processes (Gupta & Jaffrin, 1984, Sprenger et al., 1985). 
As diffusion and convection occur within the same membranes, the contribution made by 
convection to total clearances is diminished by the presence of diffusion, particularly for 
highly diffusive molecules. This is because the concentrations of these molecules   
 
 




Fig. 3. PFD (left) and HFR (right) 
promptly decreases along the dialyzer length due to diffusion, and in this situation, solute 
concentrations in ultrafiltrate are reduced. Likewise, diffusive mass transfer is also 
disrupted by the presence of convection. High filtration rates throughout the entire 
membrane causes the formation of protein gel layer, which acts as secondary resistance; that 
is, the membrane fouling decreases membrane permeability and filtration rates, and 
consequently, convective clearances are substantially diminished. Furthermore, molecular 
sieving coefficients are also reduced because of protein binding, which eventually reduces 
membrane diffusivity (Morti & Zydney, 1998). In the PFD technique, however, convection 
occurs in a separate region from diffusion and theoretically, no interference between 
diffusion and convection occurs. 
In addition, independent convection allows ultrafiltrate volume to be regulated. The total 
amount of ultrafiltration surpasses desired volume removal, and sterile replacement fluid is 
administered at the mid-point between the hemofilter and hemodialyzer shown in the Fig. 
3. In addition, desired net-volume removal by PFD can be achieved either by balancing 
ultrafiltration and reinfusion through the hemofilter, or by balancing internal filtration in 
the hemodialyzer.  
Likewise, as for other convective treatments, simultaneous but separate convection of PFD 
permitted higher depurative outcomes than standard HD mode, and even allowed 
treatment times to be reduced (Vanholder et al., 1991). Dialysis times could be reduced to as 
little as 150 minutes per session in patients with a body weight of < 61 kg without 
compromising dialytic tolerance and efficiency (Botella et al., 1991). PFD also achieves 
dialytic efficiencies comparable with HDF despite significantly lower filtration rates (40 
versus 75 ml/min, respectively) (Bufano et al., 1991), which is primarily due to minimal 
interference between diffusion and convection. However, β2M removal is smaller than in 
HF mode (Marangoni et al., 1992). Other benefits of PFD may include the minimal use of 
backfiltration in the hemodialyzer and superior biocompatibility (Panichi et al., 1998). Since 
convection is achieved at the hemofilter, dialysis can be accomplished with minimal internal 
filtration and pressure gradients.  
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2.3 Paired filtration dialysis with endogenous reinfusion (HFR) 
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then blood is dialyzed continually through the hemodialyzer. 
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As diffusion and convection occur within the same membranes, the contribution made by 
convection to total clearances is diminished by the presence of diffusion, particularly for 
highly diffusive molecules. This is because the concentrations of these molecules   
 
 




Fig. 3. PFD (left) and HFR (right) 
promptly decreases along the dialyzer length due to diffusion, and in this situation, solute 
concentrations in ultrafiltrate are reduced. Likewise, diffusive mass transfer is also 
disrupted by the presence of convection. High filtration rates throughout the entire 
membrane causes the formation of protein gel layer, which acts as secondary resistance; that 
is, the membrane fouling decreases membrane permeability and filtration rates, and 
consequently, convective clearances are substantially diminished. Furthermore, molecular 
sieving coefficients are also reduced because of protein binding, which eventually reduces 
membrane diffusivity (Morti & Zydney, 1998). In the PFD technique, however, convection 
occurs in a separate region from diffusion and theoretically, no interference between 
diffusion and convection occurs. 
In addition, independent convection allows ultrafiltrate volume to be regulated. The total 
amount of ultrafiltration surpasses desired volume removal, and sterile replacement fluid is 
administered at the mid-point between the hemofilter and hemodialyzer shown in the Fig. 
3. In addition, desired net-volume removal by PFD can be achieved either by balancing 
ultrafiltration and reinfusion through the hemofilter, or by balancing internal filtration in 
the hemodialyzer.  
Likewise, as for other convective treatments, simultaneous but separate convection of PFD 
permitted higher depurative outcomes than standard HD mode, and even allowed 
treatment times to be reduced (Vanholder et al., 1991). Dialysis times could be reduced to as 
little as 150 minutes per session in patients with a body weight of < 61 kg without 
compromising dialytic tolerance and efficiency (Botella et al., 1991). PFD also achieves 
dialytic efficiencies comparable with HDF despite significantly lower filtration rates (40 
versus 75 ml/min, respectively) (Bufano et al., 1991), which is primarily due to minimal 
interference between diffusion and convection. However, β2M removal is smaller than in 
HF mode (Marangoni et al., 1992). Other benefits of PFD may include the minimal use of 
backfiltration in the hemodialyzer and superior biocompatibility (Panichi et al., 1998). Since 
convection is achieved at the hemofilter, dialysis can be accomplished with minimal internal 
filtration and pressure gradients.  
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However, PFD obviously requires the exogenous substitution infusion because of larger 
amounts of ultrafiltrate than required volume removal. One unique feature of PDF is that 
the ultrafiltrate is not mixed with the dialysate. In addition, the ultrafiltrate has a similar 
composition of plasma. On the other hand, the replacement fluid must possess a physiologic 
balance of electrolytes after taking into account preexisting deficits or excesses, and also 
should be sterile and free of pyrogenic substances. These features of ultrafiltrate and 
infusate enables the regeneration of ultrafiltrate to replace exogenous infusate, and 
ultrafiltrate for replacement purposes was successfully regenerated using an uncoated 
charcoal column (Ghezzi et al., 1991, 1992) (Fig. 3). As ultrafiltrate passes through the 
adsorbent column, solutes with a wide spectrum of molecular weights are adsorbed with 
the exception of some small molecules (e.g., urea and phosphate), but electrolytes and 
bicarbonate freely pass through the column. In addition, since small molecules that are not 
captured by the adsorbent can be removed by diffusion at the hemodialyzer, the 
regenerated ultrafiltrate is successfully applied as replacement fluid (Sanz-Moreno & 
Botella, 1995). Trace elements, such as manganese, selenium, arsenic, cadmium, mercury, 
lead, chromium, and zinc, also remain unaltered after passing through the adsorbent 
column, whereas copper is completely retained by the charcoal (de Francisco et al., 1997). 
Adsorption capacities were further increased by combining hydrophobic styrenic resin 
along with uncoated charcoal, because the resin has a high binding affinity for several mid 
molecular weight species, such as, β2M (Marinez de Francisco et al., 2000) and homocysteine 
(Splendiani et al., 2004), or free immunoglobulin light chains (Testa et al., 2010). 
The other benefits of this regenerated ultrafiltrate include a better acid-base balance due to 
the reinfusion of endogenous bicarbonate (de Francisco et al., 1997), and also the not 
inconsiderable advantage of combining high convection without compromising physiologic 
molecule loss. Ultrafiltrate has a composition similar to that of plasma and contains huge 
numbers of polypeptides and other beneficial substances, such as, hormones, amino acids, 
and vitamins (Weissinger et al., 2004), and ultrafiltrate regeneration allows these beneficial 
nutrients to be reinfused (La Greca et al., 1998). In terms of plasma amino acid levels, no 
significant changes in their intradialytic levels occur during HFR, whereas a ~25% reduction 
occur during acetate-free biofiltration (Borrelli et al., 2010). 
A number of clinical studies on ESRD patients have revealed that HFR remarkably improve 
dialytic efficiencies and solute removal over a wide molecular weight ranges, such as, the 
removal of uremic marker molecules (β2M, leptin and free immunoglobulin light chains) 
(Bolasco et al., 2006, S. Kim et al., 2009, Testa et al., 2006), cardiovascular risk factors 
(homocysteine) (Splendiani et al., 2004), inflammatory cytokines (CRP, IL-1, IL-6), and 
biomarkers of oxidative stress (ox-LDL, IL-1β) (Calo et al., 2011, Testa et al., 2006). In a 
comparison between HFR and on-line HDF, both were found to be highly biocompatible 
and to considerably reduce inflammatory markers, such as, CRP and IL-6 (Panichi et al., 
2006). One technical variance of HFR is the repositioning of convection and diffusion. The 
change of sequence during HFR significantly enhanced reductions in urea and β2M, 
possibly due to the less saturated use of adsorbents, and also reduced cytokine levels, e.g., 
IL6 and TNFα, more than conventional HFR (Meloni et al., 2004, 2005).  
In addition, HFR appears to be more beneficial at reducing oxidative stress and the risk of 
atherosclerotic cardiovascular disease than standard HD mode. A comparative study of 
HFR and low-flux bicarbonate HD revealed that HFR reduced not only the plasma level of 
oxidized low-density lipoprotein (LDL), but also the mRNA production of p22phox and 
PAI-1 (palsminogen activator inhibitor 1), whose protein expressions are known to be 
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closely related to inflammation and oxidative stress (Calo et al., 2007). Furthermore, plasma 
total antioxidant capacity (TAC) and antioxidant enzymes activities were found to be lower 
for HFR than high-flux HD (Gonzalez-Diez et al., 2008).  
However, contrary results have also been presented. For ESRD patients who undertook 
bicarbonate HD and then were switched to HFR, nutritional and inflammatory parameters 
remained unchanged over a year. Neither serum β2M nor PTH levels varied over the course 
of time, which led to the conclusion that although the change to HFR from bicarbonate HD 
is safe and tolerated, it is not associated with an improvement in nutritional or 
inflammatory parameters, or a reduction in β2M levels (Bossola et al., 2005). Prolonged, 
larger-scale clinical studies for HFR are warranted. 
More recently, a significant decrease was observed in cardiac troponin (cTnT) levels, a 
marker of myocardial damage and cardiac hypertrophy, throughout HFR sessions when 
using acetate-free dialysate, but cTnT increased after HFR using dialysate containing 
acetate. These results show that further explanation is required for the correlation between 
cTnT and acetate (Bolasco et al., 2011). However, both hemoglobin (Hb) levels and 
erythropoietic-stimulating agent (ESA) doses were not related to the presence of acetate. Hb 
levels increased, but ESA requirements tended to reduce continually during the 9-month 
study period (Bolasco et al., 2011).  
In summary, PFD is a HDF technique whereby ultrafiltrate is isolated from dialysate. Renal 
replacement therapies, facilitated by convection and diffusion, are still unsatisfactory for 
removing uremic toxins, and thus, adsorption as a third mechanism has been employed in 
HFR units. Adsorption during HFR allows convective treatments to be performed by the 
endogenous reinfusion of ultrafiltrate. Even if the loss of beneficial substances during HDF 
is inevitable, ultrafiltrate reinfusion reduces these losses to a minimum, like low-flux HD. 
Another feature of ultrafiltrate regeneration is the guaranteed purity of substitution fluid. 
Substitution is continuously obtained from ultrafiltrate, but the ultrafiltration, adsorption, 
and reinfusion system is totally closed during HFR, and therefore, excludes any possibility 
of contamination and ensures superior biocompatibility. However, despite these 
outstanding features, this unit has complications and associated costs. Furthermore, 
technical improvements in the preparation of ultrapure dialysate are expected to further cut 
the cost of preparing sterile, ultrapure replacement fluid, and this could increase the cost 
gap between HFR and on-line HDF. 
2.4 Push/Pull Hemodiafiltration 
A similar but simpler HDF strategy has been also introduced. This system relies on alternate 
repetitions of forward and backward filtration during dialysis treatment, and thus, it was 
named push/pull HDF. When the infusion-free HDF technique using a serial arrangement 
of two hemodiafilters was described in the early 1980’s, the push/pull concept was devised 
to eliminate the need for two hemodiafilters. It is obvious that repetitive ultrafiltration can 
increase total filtration volume, but such a system also requires a means of repeating 
backfiltration (Usuda et al., 1982). Thus, a redundant dialysate bag is integrated 
downstream of the hemodialyzer, which is connected to the dialysate stream by a 
bidirectional peristaltic pump. The push/pull action that is accomplished by this bi-
direction pump is responsible for alternating the evacuation and replenishment of the bag. 
During normal operation, inlet and outlet dialysate flow rates are equally maintained and 
the desired volume removal is achieved by a separate ultrafiltration pump. In this situation, 
when the bidirectional pump pulls a portion of dialysate into the bag (70 ml/min for 3 
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However, PFD obviously requires the exogenous substitution infusion because of larger 
amounts of ultrafiltrate than required volume removal. One unique feature of PDF is that 
the ultrafiltrate is not mixed with the dialysate. In addition, the ultrafiltrate has a similar 
composition of plasma. On the other hand, the replacement fluid must possess a physiologic 
balance of electrolytes after taking into account preexisting deficits or excesses, and also 
should be sterile and free of pyrogenic substances. These features of ultrafiltrate and 
infusate enables the regeneration of ultrafiltrate to replace exogenous infusate, and 
ultrafiltrate for replacement purposes was successfully regenerated using an uncoated 
charcoal column (Ghezzi et al., 1991, 1992) (Fig. 3). As ultrafiltrate passes through the 
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lead, chromium, and zinc, also remain unaltered after passing through the adsorbent 
column, whereas copper is completely retained by the charcoal (de Francisco et al., 1997). 
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along with uncoated charcoal, because the resin has a high binding affinity for several mid 
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(Splendiani et al., 2004), or free immunoglobulin light chains (Testa et al., 2010). 
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nutrients to be reinfused (La Greca et al., 1998). In terms of plasma amino acid levels, no 
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(Bolasco et al., 2006, S. Kim et al., 2009, Testa et al., 2006), cardiovascular risk factors 
(homocysteine) (Splendiani et al., 2004), inflammatory cytokines (CRP, IL-1, IL-6), and 
biomarkers of oxidative stress (ox-LDL, IL-1β) (Calo et al., 2011, Testa et al., 2006). In a 
comparison between HFR and on-line HDF, both were found to be highly biocompatible 
and to considerably reduce inflammatory markers, such as, CRP and IL-6 (Panichi et al., 
2006). One technical variance of HFR is the repositioning of convection and diffusion. The 
change of sequence during HFR significantly enhanced reductions in urea and β2M, 
possibly due to the less saturated use of adsorbents, and also reduced cytokine levels, e.g., 
IL6 and TNFα, more than conventional HFR (Meloni et al., 2004, 2005).  
In addition, HFR appears to be more beneficial at reducing oxidative stress and the risk of 
atherosclerotic cardiovascular disease than standard HD mode. A comparative study of 
HFR and low-flux bicarbonate HD revealed that HFR reduced not only the plasma level of 
oxidized low-density lipoprotein (LDL), but also the mRNA production of p22phox and 
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closely related to inflammation and oxidative stress (Calo et al., 2007). Furthermore, plasma 
total antioxidant capacity (TAC) and antioxidant enzymes activities were found to be lower 
for HFR than high-flux HD (Gonzalez-Diez et al., 2008).  
However, contrary results have also been presented. For ESRD patients who undertook 
bicarbonate HD and then were switched to HFR, nutritional and inflammatory parameters 
remained unchanged over a year. Neither serum β2M nor PTH levels varied over the course 
of time, which led to the conclusion that although the change to HFR from bicarbonate HD 
is safe and tolerated, it is not associated with an improvement in nutritional or 
inflammatory parameters, or a reduction in β2M levels (Bossola et al., 2005). Prolonged, 
larger-scale clinical studies for HFR are warranted. 
More recently, a significant decrease was observed in cardiac troponin (cTnT) levels, a 
marker of myocardial damage and cardiac hypertrophy, throughout HFR sessions when 
using acetate-free dialysate, but cTnT increased after HFR using dialysate containing 
acetate. These results show that further explanation is required for the correlation between 
cTnT and acetate (Bolasco et al., 2011). However, both hemoglobin (Hb) levels and 
erythropoietic-stimulating agent (ESA) doses were not related to the presence of acetate. Hb 
levels increased, but ESA requirements tended to reduce continually during the 9-month 
study period (Bolasco et al., 2011).  
In summary, PFD is a HDF technique whereby ultrafiltrate is isolated from dialysate. Renal 
replacement therapies, facilitated by convection and diffusion, are still unsatisfactory for 
removing uremic toxins, and thus, adsorption as a third mechanism has been employed in 
HFR units. Adsorption during HFR allows convective treatments to be performed by the 
endogenous reinfusion of ultrafiltrate. Even if the loss of beneficial substances during HDF 
is inevitable, ultrafiltrate reinfusion reduces these losses to a minimum, like low-flux HD. 
Another feature of ultrafiltrate regeneration is the guaranteed purity of substitution fluid. 
Substitution is continuously obtained from ultrafiltrate, but the ultrafiltration, adsorption, 
and reinfusion system is totally closed during HFR, and therefore, excludes any possibility 
of contamination and ensures superior biocompatibility. However, despite these 
outstanding features, this unit has complications and associated costs. Furthermore, 
technical improvements in the preparation of ultrapure dialysate are expected to further cut 
the cost of preparing sterile, ultrapure replacement fluid, and this could increase the cost 
gap between HFR and on-line HDF. 
2.4 Push/Pull Hemodiafiltration 
A similar but simpler HDF strategy has been also introduced. This system relies on alternate 
repetitions of forward and backward filtration during dialysis treatment, and thus, it was 
named push/pull HDF. When the infusion-free HDF technique using a serial arrangement 
of two hemodiafilters was described in the early 1980’s, the push/pull concept was devised 
to eliminate the need for two hemodiafilters. It is obvious that repetitive ultrafiltration can 
increase total filtration volume, but such a system also requires a means of repeating 
backfiltration (Usuda et al., 1982). Thus, a redundant dialysate bag is integrated 
downstream of the hemodialyzer, which is connected to the dialysate stream by a 
bidirectional peristaltic pump. The push/pull action that is accomplished by this bi-
direction pump is responsible for alternating the evacuation and replenishment of the bag. 
During normal operation, inlet and outlet dialysate flow rates are equally maintained and 
the desired volume removal is achieved by a separate ultrafiltration pump. In this situation, 
when the bidirectional pump pulls a portion of dialysate into the bag (70 ml/min for 3 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
124 
minutes), hydrostatic pressures through the dialysate compartment decrease, because the 
dialysate compartment is closed and has a fixed volume, and water flux occurs from blood 
to the dialysate compartment (ultrafiltration) at the same level as dialysate removal from the 
dialysate compartment. Soon after the ultrafiltration completes, the pump operates in 
reverse and pushes the dialysate in the bag into the dialysate stream, which causes a volume 
overload in the dialysate compartment. The surplus dialysate in the closed dialysate 
compartment is then moved to the blood compartment (backfiltration). In the same manner, 
another bag and an additional bidirectional peristaltic pump is also integrated into the 
venous chamber, and conducts the pulling and pushing of blood, although in this case, the 
actions of the blood-side pump are 180O out of phase with those of the dialysate side pump 
to keep blood flow returning to the patient constant. 
When pure dialysate is pushed into the blood stream, solute concentrations in blood are 
immediately equilibrated and decreased by dilution. Soon after, the blood-to-dialysate 
pressure gradient reverses from negative to positive, and plasma fluid in blood is forced to 
move into the dialysate compartment, which removes various molecules from plasma. This 
repetitive ultrafiltration obviously contributes to convective mass transfer and increases the 
reductions of small-sized (urea) or mid-sized (β2M) molecules as compared with HF or HD, 
respectively (Shinzato et al., 1989). On the other hand, repetitive backfiltration during 
push/pull HDF prevents volume depletion. In addition, the repetitive backflushing of 
dialysate also helps prevent membrane binding (Usuda et al., 1982). 
However, disposable bags and separate bidirectional peristaltic pumps make this unit 
complicated and increase treatment costs. Instead, a double-chamber cylinder pump was 
devised with two independent chambers and a reciprocal piston; that is, each chamber is 
connected to either dialysate or the blood stream (Tsuruta et al., 1994), as seen in Fig. 4. 
 
 
Fig. 4. Push/Pull HDF and Double-Chamber Cylinder Pump 
When the piston squeezes the chamber on the dialysate side, the dialysate compartment, 
which has a fixed volume, is pressurized and backfiltration begins. At this time, the chamber 
on the blood side expands and blood in the venous chamber starts flowing in the direction 
of the double-chambered pump. Since the blood volume that returns to the blood-side 
chamber of the pump is equal to the backfiltration volume, blood flow returning to patients 
remains constant. The piston then moves in the opposite direction and squeezes the blood-
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side chamber, the dialysate compartment begins to expand, and the dialysate compartment 
becomes depressurized, which leads ultrafiltration. However, despite the large amount of 
ultrafiltration, blood flow in the venous line is maintained, because the ultrafiltrate removed 
in the hemodialyzer is replenished in the venous chamber. 
Furthermore, the reciprocating movement of the piston is regulated by pressure differences 
between the two chambers of the cylinder pump (i.e., Pb-Pd). The rotation torque of the 
driving motor attached to the piston can be expressed in accord with TMP (i.e., torque = 
TMPxSxLxsinθ). Voltage applied to the motor is adjusted so that the TMP is set at 400 
mmHg during forward filtration, but at -400 mmHg during the backward filtration phase, 
that is, pressure-controlled push/pull HDF can maintain transmembrane pressures at the 
maximum permissible level throughout treatment (Shinzato et al., 1994). In addition, 
contrary to the original push/pull HDF, in which one cycle of filtration and backfiltration 
takes approximate 4~5 minutes, the pressure controlled push/pull HDF unit can repeat one 
cycle in 1.5~1.7 seconds.  
This optimized use of transmembrane pressure and more frequent alternations of forward 
and backward filtration in the revised push/pull HDF unit are obviously accompanied 
with a markedly larger total filtration volumes and higher solutes clearances (Shinzato et 
al., 1994). Push/pull HDF tends to relieve symptoms like arthralgia (joint pain), 
irritability, pruritus, and insomnia more rapidly than conventional HD (Maeda et al., 
1990, Maeda & Shinzato, 1995, Shinzato et al., 1995). Furthermore, the optimal 
maintenance of membrane permeabilities by prompt backfiltration has the added benefit 
of considerably inhibiting albumin loss in addition to increasing convection and diffusion 
(Shinzato et al., 1996). Albumin loss is inevitable when using membranes with high water 
permeabilities and sieving characteristics (Combarnous et al., 2002). Since convective 
therapy is based on larger amounts of fluid exchange and solvent drag during fluid 
exchange occurs randomly, albumin permeation becomes more worrisome during 
convective treatments (Ahrenholz et al., 2004). In addition, filtration-induced elevated 
albumin concentration at the inner membrane wall also aggravates the albumin loss 
(Miwa & Shinzato, 1999). Protein concentration polarization develops quickly after 
sudden TMP development and the hydraulic permeabilities of the membrane decrease 
rapidly in about 2 seconds. However, during push/pull HDF, backward flushing of 
dialysate takes place within the time frame required for the protein layer to fully develop 
(i.e., 1.5~1.7 seconds), and thus, it can effectively wash out the inner lumen and inhibit 
excessive albumin leakage (Shinzato et al., 1996). 
However, this modality still requires the use of a separate device so that dialysate pressures 
are regulated instantaneously. In addition, no clinical observation has been conducted to 
examine the long-term clinical effect of pressure-controlled push/pull HDF versus on-line 
HDF. Push/pull HDF is based on repetitive dilution at a rate of approximate 15 ml per 1.7s 
cycle, which exceeds blood flow rates (3.3~5 ml/s). Hence, push/pull HDF is assumed to be 
close to pre-dilution mode HDF (Shinzato & Maeda, 2007). Even though post-dilution HDF 
is more efficient in terms of solute removal, the substantial amount of total filtration and the 
optimal use of membrane offered by the push/pull HDF technique probably translate to 
outstanding hemodialytic outcomes. 
Push/pull HDF was developed in an effort to perform infusion-free, simultaneous HD and 
HF by using a single hemodialyzer. Thus, it alternates between forward filtration and 
backfiltration instead of dividing ultrafiltration and backfiltration regions. Pressure-
controlled push/pull HDF using a double-chambered cylinder pump can maintain TMPs at 
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minutes), hydrostatic pressures through the dialysate compartment decrease, because the 
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side chamber, the dialysate compartment begins to expand, and the dialysate compartment 
becomes depressurized, which leads ultrafiltration. However, despite the large amount of 
ultrafiltration, blood flow in the venous line is maintained, because the ultrafiltrate removed 
in the hemodialyzer is replenished in the venous chamber. 
Furthermore, the reciprocating movement of the piston is regulated by pressure differences 
between the two chambers of the cylinder pump (i.e., Pb-Pd). The rotation torque of the 
driving motor attached to the piston can be expressed in accord with TMP (i.e., torque = 
TMPxSxLxsinθ). Voltage applied to the motor is adjusted so that the TMP is set at 400 
mmHg during forward filtration, but at -400 mmHg during the backward filtration phase, 
that is, pressure-controlled push/pull HDF can maintain transmembrane pressures at the 
maximum permissible level throughout treatment (Shinzato et al., 1994). In addition, 
contrary to the original push/pull HDF, in which one cycle of filtration and backfiltration 
takes approximate 4~5 minutes, the pressure controlled push/pull HDF unit can repeat one 
cycle in 1.5~1.7 seconds.  
This optimized use of transmembrane pressure and more frequent alternations of forward 
and backward filtration in the revised push/pull HDF unit are obviously accompanied 
with a markedly larger total filtration volumes and higher solutes clearances (Shinzato et 
al., 1994). Push/pull HDF tends to relieve symptoms like arthralgia (joint pain), 
irritability, pruritus, and insomnia more rapidly than conventional HD (Maeda et al., 
1990, Maeda & Shinzato, 1995, Shinzato et al., 1995). Furthermore, the optimal 
maintenance of membrane permeabilities by prompt backfiltration has the added benefit 
of considerably inhibiting albumin loss in addition to increasing convection and diffusion 
(Shinzato et al., 1996). Albumin loss is inevitable when using membranes with high water 
permeabilities and sieving characteristics (Combarnous et al., 2002). Since convective 
therapy is based on larger amounts of fluid exchange and solvent drag during fluid 
exchange occurs randomly, albumin permeation becomes more worrisome during 
convective treatments (Ahrenholz et al., 2004). In addition, filtration-induced elevated 
albumin concentration at the inner membrane wall also aggravates the albumin loss 
(Miwa & Shinzato, 1999). Protein concentration polarization develops quickly after 
sudden TMP development and the hydraulic permeabilities of the membrane decrease 
rapidly in about 2 seconds. However, during push/pull HDF, backward flushing of 
dialysate takes place within the time frame required for the protein layer to fully develop 
(i.e., 1.5~1.7 seconds), and thus, it can effectively wash out the inner lumen and inhibit 
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HDF. Push/pull HDF is based on repetitive dilution at a rate of approximate 15 ml per 1.7s 
cycle, which exceeds blood flow rates (3.3~5 ml/s). Hence, push/pull HDF is assumed to be 
close to pre-dilution mode HDF (Shinzato & Maeda, 2007). Even though post-dilution HDF 
is more efficient in terms of solute removal, the substantial amount of total filtration and the 
optimal use of membrane offered by the push/pull HDF technique probably translate to 
outstanding hemodialytic outcomes. 
Push/pull HDF was developed in an effort to perform infusion-free, simultaneous HD and 
HF by using a single hemodialyzer. Thus, it alternates between forward filtration and 
backfiltration instead of dividing ultrafiltration and backfiltration regions. Pressure-
controlled push/pull HDF using a double-chambered cylinder pump can maintain TMPs at 
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maximal levels and the total filtration volumes achieved are far greater than that of any 
other treatment modality. In addition to the filtration quantity, repetitive cycles in a shorter 
time than the time required for a protein layer to be established ensure superior membrane 
use throughout treatment, which further inhibits albumin loss. However, given the 
advances represented by membranes with high β2M sieving coefficients (>0.8), but very 
small albumin sieving coefficients (<0.01) (Ronco et al., 2002), the differences between 
push/pull HDF and high-flux HD with respect to β2M removal may be reduced, and 
albumin leakage less problematic. To an extent in modern dialysis practice, albumin 
permeable membranes are even considered to remove non-soluble and/or much larger 
molecules (De Smet et al., 2007, Samtleben et al., 2003). Therefore, a prolonged prospective 
study on push/pull HDF may be worthwhile to determine the benefits of this modality 
versus other forms of convective renal replacement. 
3. Pulse Push/Pull Hemodialysis (PPPHD) 
Flow patterns, that is, pulsatile versus non-pulsatile, remain topics of research for treatments 
requiring extracorporeal blood circulation. Despite controversy, blood pulsation has been 
accepted to have a benefit during cardiopulmonary bypass, because it achieves greater 
perfusion to peripheral vessels and end-organs (Dapper et al., 1992, Orime et al., 1999). 
Furthermore, blood pulsation in a pediatric CRRT1 animal model was found to deliver 
adequate performance over a 2-hour period in terms of ultrafiltration rates and cross-filter 
blood pressure drops (Lopez-Herce et al., 2006, Ruperez et al., 2003). In addition, it was also 
found that the pulsatile flow tends to enhance ultrafiltration rates versus non-pulsatile flow 
(Lim et al., 2009, Runge et al., 1993), which attributed to an increased rheological power of 
pulsatile flow. However, little clinical or experimental evidence is available that explains the 
efficacy of pulsatile flow during dialysis. Pulse push/pull HD is a convection enhanced 
dialysis treatment, based on the use of pulsatile flows to achieve a cyclic repetition of 
forward and backward filtration. As explained in the previous section, the repetitive manner 
of ultrafiltration and backfiltration contributes substantially to total volume exchange and 
convective mass transfer. 
3.1 Pulse push/pull HD 
Repetitive procedures of ultrafiltration and backfiltration during PPPHD are achieved by 
replacing conventional roller pumps with pulsatile pumps for both blood and dialysate. 
During an early trial, a T-PLS pump (Twin Pulse Life Supporter, AnC Bio Inc., Seoul, Korea) 
was used as pulsatile pumps for blood and dialysate (K. Lee et al., 2008). The T-PLS consists 
of blood and dialysate sacs, a reciprocating actuator, and a motor-cam assembly (J. J. Lee et 
al., 2005). The actuator is located between blood and dialysate sacs (Fig. 5). When the 
actuator squeezes the blood sac, blood in the sac can move only in the forward direction due 
to the presence of one-way check valves. At the same time, the dialysate sac expands and is 
filled with fresh dialysate. In the same manner, dialysate also moves forward when the sac 
is squeezed, and these reciprocating movements create pulsatile flow. By setting their phase 
difference at 180O degrees, the respective pushing phases of blood and dialysate pumps 
alternate, and TMPs cycle between positive and negative, which drive consecutive periods 
of ultrafiltration and backfiltration. 
                                                                          
1 Continuous Renal Replacement Therapy   
 




Fig. 5. T-PLS pump for the original PPPHD 
The hemodialytic efficiencies of PPPHD have been demonstrated in vitro and also in vivo, 
and these studies have shown that PPPHD substantially improves the clearances of uremic 
marker molecules, particularly for mid-sized molecules (Table 1) (K. Lee et al., 2008), which 
is believed to be due to a higher level of total filtration. Pressure profiles also showed 
obvious oscillations of TMPs throughout treatment, and their magnitudes were significantly 
larger than those observed in conventional hemodialysis (CHD) mode.  
 
Group BPM QB QD 
Clearance (ml/min) 
BUN Creatinine Vitamin b12 Inulin 
CHD - 236±3.6 420±3 161.1±4.3 127.2±3.9 37.5±6.3 25.3±5.1 
PPPHD 40 234±3.1 419±3 166.2±3.8 136.9±4.2 55.7±5.0 37.8±3.9 
% Increase  - - 3.2 7.6 48 49 
P-value  NS NS 0.053 <0.05 <0.001 <0.001 
Table 1. Solutes Clearances. (CHD, conventional high-flux HD; PPPHD, pulse push/pull 
HD; BPM, beats per minute; QB, blood flowrate; QD, dialysate flowrate; BUN, blood urea 
nitrogen; NS, not significant) 
Increased filtration volumes in the PPPHD unit may also be due to reduced membrane 
fouling. In an in vivo setup on PPPHD, one cycle of ultrafiltration and backfiltration took 3 
seconds at a pulse frequency of 20 bpm (K. Lee et al., 2008). When ultrafiltration and 
backfiltration times were defined as the durations of positive and negative TMPs, 
respectively, ultrafiltration and backfiltration times for the PPPHD unit were 1.68±0.02 and 
1.31±0.03 seconds, respectively. Since protein concentration polarization on the blood-side 
membrane develops during the forward filtration phase and it is reduced by backfiltration, 
membrane convective capacity might be better maintained during PPPHD than during 
CHD, showing smaller reductions in post-dialysis hydraulic permeabilities (K. Lee et al., 
2008). Furthermore, PPPHD-treated animals were tolerably sustained and their physiologic 
parameters were stable. 
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Increased filtration volumes in the PPPHD unit may also be due to reduced membrane 
fouling. In an in vivo setup on PPPHD, one cycle of ultrafiltration and backfiltration took 3 
seconds at a pulse frequency of 20 bpm (K. Lee et al., 2008). When ultrafiltration and 
backfiltration times were defined as the durations of positive and negative TMPs, 
respectively, ultrafiltration and backfiltration times for the PPPHD unit were 1.68±0.02 and 
1.31±0.03 seconds, respectively. Since protein concentration polarization on the blood-side 
membrane develops during the forward filtration phase and it is reduced by backfiltration, 
membrane convective capacity might be better maintained during PPPHD than during 
CHD, showing smaller reductions in post-dialysis hydraulic permeabilities (K. Lee et al., 
2008). Furthermore, PPPHD-treated animals were tolerably sustained and their physiologic 
parameters were stable. 
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Pulse push/pull HD is conceptually similar to push/pull HDF. Both modalities were devised 
to increase total filtration level by alternating forward and backward filtration. However, the 
underlying design of PPPHD differs from push/pull HDF, and thus, the supplementary 
component required to switch from ultrafiltration to backfiltration phases or vice versa used in 
push/pull HDF was eliminated for PPPHD and the entire system was remarkably simplified. 
3.2 Modification of PPPHD 
Repetitive ultrafiltration and backfiltration offers a simple and efficient HDF strategy. 
However, the pulsatile circulation of blood during extracorporeal renal replacement treatment 
appears to be potentially problematic. In particular, instant suction generated by a pulse pump 
through a narrow needle or catheter may cause blood damage, vessel narrowing, or vessel 
collapse. In addition, instantaneous negative pressures generated upstream of a pulsatile 
blood pump not only introduce the risk of circuit aeration, but also lead to a failure to maintain 
predetermined blood flow rates (Depner et al., 1990, Teruel et al., 2000).  
Hence, we revised PPPHD and many aspects of the original PPPHD were retained in the 
revised version, including an alternating water flux across the membrane, but blood pulsation 
was excluded. This was achieved by employing dual pulsation in the dialysate stream, that is, 
pulsatile devices in the dialysate stream both upstream (a dialysate pump) and downstream 
(an effluent pump) of the dialyzer. Backfiltration occurs when the sum of the cross-membrane 
pressures is negative, but ultrafiltration when the sum is positive. The hydraulic pressures of 
blood and dialysate were both manipulated in the original PPPHD, but since blood pulsation 
was eliminated, the dialysate pressure is the only variable that regulates TMP in the revised 
unit. Therefore, an assumption was made; (1) dialysate compartment pressures must be far 
higher than blood-side pressures when pure dialysate is forced into the dialyzer (that is, when 
the dialysate sac is squeezed), but (2) dialysate pressures drop to lower than blood pressures 
during effluent pump expansion. For this purpose, the dialysate and effluent pumps are 
replaced with a dual pulse pump (K. Lee et al., 2008). 
The dual pulse pump (DPP) is a pulsatile device that was developed to eliminate the one-
way valves that are generally required for pulsatile devices to prevent retrograde flow; 
instead, time-delayed tube openings and closings constitutes a cycle of pulse generation (Fig. 
6). In other words, two separate silicone tubes in the DPP are periodically opened or closed. 
Pulse generation with DPP can be described in terms of four phases as determined by cam 
rotation, which translates motor rotation to actuator linear displacement. As the cam rotates, 
the four actuators periodically push on the tubing segments at the positions shown in the 
Fig. 6. Actuator 1 pushes on the tubing segments at positions 1 and 6 (p1 and p6) 
simultaneously, and actuator 3 squeezes the tubing segments at positions 3 and 4. Actuators 
2 and 4 squeeze tubing segments at p 2 and p5, respectively, and caused the dialysate in the 
tube to move in the required direction. The first phase was defined as a cam rotation angle 
(θ) between 0 and 90°. Likewise, the 2nd and 3rd phases were defined as cam rotation angles 
between 90°~180° and 180°~270°, respectively. For pulse generation by the dialysate pump, 
as the cam rotates from θ=0° to 90°, the p2 tubing segment opens and p1 closes, and these 
processes overlap such that pure dialysate fills p2 tubing. While p2 expands, p3 remains 
closed, acting as an upstream valve to prevent retrograde dialysate. These tube openings 
and closings are also depicted in the tube openness diagram in Fig. 7. Tube openness is 
defined as the ratio of compressed tube diameter to the original internal diameter, as 
described elsewhere (K. Lee et al., 2008). During the first phase, with p3 closed, p2 tube   
 





Fig. 6. Dual Pulse Pump (DPP). Its body is made of an aluminum alloy, and comprises a 
base plate, a unidirectional electric motor (not seen), a cam, and four actuators. It can also 
contain two separate silicone tubes. Pulsatile flow is generated by squeezing each dialysate 
and effluent tubing segments. (A1~A4, actuators 1 to 4; p1~p6, silicone tubing segments at 
positions 1 to 6, respectively) 
 
 
Fig. 7. Tube Openness Diagram for Dialysate (upper) and Effluent Pump (below) of DPP. 
openness increases whereas p1 tube openness decreases. During the 2nd phase 
(θ=90°~180°), with p1 closed, p2 begins to be squeezed and simultaneously p3 begins to 
open, and pure dialysate is driven into the hemodialyzer. Closure of p1 fulfills the same 
function as atrioventricular valve closure during left ventricular systole, which prevents 
retrograde flow. During the 3rd phase (θ=180°~270°), p3 is closed, while p1 and p2 remain 
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closed and in the final phase (θ=270°~360°), p1 is open, and p2 and p3 remain closed in 
preparedness for the next filling phase. These time-delayed tube openings and closures 
constitute one cycle of pulse generation. In the same manner, effluent pulsations were also 
generated through the effluent tube, although in this case, the actions of actuators 1 and 3 
were reversed, and the pulsatile flow pattern was 180O out of phase with that in the 
dialysate tube. 
Theoretically, forward and backward filtration rates during one cycle of PPPHD are 
identical to effluent and dialysate flow rates, respectively. The moment when pure dialysate 
is driven to the dialyzer (i.e., during p2 squeezing), the effluent dialysate path is closed at 
p6. At the same time, p1 is also closed, and thus, the pure dialysate pushed into dialyzer 
should move into the blood stream (backfiltration), because the whole dialysate 
compartment is fixed and closed. Immediately after the backfiltration is completed, the 
effluent tubing (p5) begins to expand (i.e., p5 expansion), and since the dialysate and 
effluent pathways are still closed at p1 and p6, respectively, dialysate pressures in the 
hemodialyzer drop steeply and ultrafiltration takes place at a rate determined by effluent 
stroke volume. 
During animal experiments using the PPPHD, in which we used an acute canine renal 
failure model (achieved by ligating renal arteries and veins), the animals remained stable 
without any procedurally related complications. Molecular removals were satisfactory, and 
total protein levels, albumin concentrations, and glucose levels were preserved uniformly 
throughout PPPHD sessions (Table 2). Furthermore, TMPs clearly cycled positive and 
negative due to huge fluctuations in hydraulic dialysate pressures (Fig. 8). In addition, 
despite the use of a peristaltic roller pump for blood, the blood pressures acquired during 
PPPHD showed an obvious fluctuation which was perfectly synchronized with dialysate 
pressure pulsation. Generally, peristaltic roller pumps create small fluctuations in flow and 
pressure, because of the way they squeeze tubing. However, the blood pressure fluctuations 
acquired during PPPHD were much larger than that observed for conventional HD, which 




Fig. 8. Pressure Profiles during PPPHD treatment (upper), and Changes in Blood Pressures 
for PPPHD and CHD (below). (MDP, mean dialysate pressure; MBP, mean blood pressure; 
CHD, conventional HD) 
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In addition, as stated before, the DPP is characterized by a lack of valves, which makes the 
pulsatile device simple and inexpensive, and thus, any medical-grade silicone tubes can be 
used as dialysate and effluent sacs. Furthermore, with the exception of small tubing sections 
at p1, p3, p4, and p5, most of the tubing is operated non-occlusively, which reduces the 
probabilities of tubing rupture and spallation (W. G. Kim & Yoon, 1998, Leong et al., 1982). 
 
PPPHD 
(h) PCV TP ALB Glu Ca2+ Na+ K+ BUN Crea 
0 28.5±4.6 5.3±0.4 3.1±0.1 119±7 12.4±0.8 136±5.7 5.7±0.6 90.3±12.7 6.5±0.9 
2 28.0±3.6 5.6±0.7 3.1±0.2 111±4 11.5±0.8 134±4.2 5.1±0.6 63.7±5.7 4.6±0.7 
4 27.3±3.5 5.3±0.4 3.1±0.2 126±44 10.8±0.5 132±3.1 4.3±0.5 47±7.2 3.8±0.4 
Table 2. Animal Experiment Results. PCV, packed cell volume (%); TP, total protein (g/dl); 
ALB, albumin (g/dl) ; Glu, glucose (mg/dl); BUN, blood urea nitrogen (mg/dl); Crea, 
creatinine (mg/dl) 
3.3 Fluid management in PPPHD 
Recently, the dual pulsatile pump integrated into the dialysate stream has been remarkably 
ameliorated to achieve a substantial increase in the accuracy of volume control. Maintaining 
pre-determined flow rates and precise volume control are pre-requisites of extracorporeal 
renal replacement treatments for ESRD patients, particularly when using membranes with 
high-water permeability. Therefore, the dual pulsation system acting on the PPPHD 
dialysate compartment was replaced with a dual piston pump, as shown in Fig. 9. This 
modification allows pulse generation and push/pull to be achieved, not only by the novel 
design of the piston pump, but also by the unique control of piston movements offered (Fig. 
10). As the dialysate piston compresses the cylinder, pure dialysate is forced into the 
dialyzer, but at this time, the effluent stream is functionally closed at the effluent piston 
pump, and thus, dialysate compartment pressures increase rapidly and backfiltration occurs 
(Phase 1).The effluent piston then begins to expand and dialysate moves into the effluent 
cylinder, while the dialysate supply line is still closed at the dialysate pump. Because of 
effluent suction, dialysate compartment pressures fall sharply and water flux from blood 
lumen to dialysate occurs (Phase 2). During the final step, pure dialysate fills the dialysate 
cylinder, and simultaneously used dialysate is drained (Phase 3). 
In an in vitro test of PPPHD with the dual piston pump, in which bovine blood was circulated 
through the blood lumen of the hemodialyzer at 200 ml/min and isotonic saline solution was 
used as dialysate at the rate of 400 ml/min, the phenomena of push (backfiltration) and pull 
(ultrafiltration) were well sustained throughout sessions, and their levels perfectly matched 
those of stroke volumes of the dialysate and effluent pumps, respectively. In addition, as was 
expected, dialysate and effluent piston pumps served as a flow equalizer, and controlled 
isovolumetic dialysate flow rates upstream and downstream of the dialyzer. Hydrostatic 
dialysate pressures were maintained at 520~700 mmHg during the backfiltration phase (Phase 
1) and at -400~-540 mmHg during the ultrafiltration phase (Phase 2). 
In addition, PPPHD is also versatile and can be easily converted to conventional high-flux 
HD. Time-controlled piston operations perform the push and pull operations, but when the 
two piston movements are synchronized alternately (that is, dialysate piston compression 
and effluent piston expansion or dialysate piston expansion and effluent piston compression 
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Fig. 8. Pressure Profiles during PPPHD treatment (upper), and Changes in Blood Pressures 
for PPPHD and CHD (below). (MDP, mean dialysate pressure; MBP, mean blood pressure; 
CHD, conventional HD) 
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In addition, as stated before, the DPP is characterized by a lack of valves, which makes the 
pulsatile device simple and inexpensive, and thus, any medical-grade silicone tubes can be 
used as dialysate and effluent sacs. Furthermore, with the exception of small tubing sections 
at p1, p3, p4, and p5, most of the tubing is operated non-occlusively, which reduces the 
probabilities of tubing rupture and spallation (W. G. Kim & Yoon, 1998, Leong et al., 1982). 
 
PPPHD 
(h) PCV TP ALB Glu Ca2+ Na+ K+ BUN Crea 
0 28.5±4.6 5.3±0.4 3.1±0.1 119±7 12.4±0.8 136±5.7 5.7±0.6 90.3±12.7 6.5±0.9 
2 28.0±3.6 5.6±0.7 3.1±0.2 111±4 11.5±0.8 134±4.2 5.1±0.6 63.7±5.7 4.6±0.7 
4 27.3±3.5 5.3±0.4 3.1±0.2 126±44 10.8±0.5 132±3.1 4.3±0.5 47±7.2 3.8±0.4 
Table 2. Animal Experiment Results. PCV, packed cell volume (%); TP, total protein (g/dl); 
ALB, albumin (g/dl) ; Glu, glucose (mg/dl); BUN, blood urea nitrogen (mg/dl); Crea, 
creatinine (mg/dl) 
3.3 Fluid management in PPPHD 
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ameliorated to achieve a substantial increase in the accuracy of volume control. Maintaining 
pre-determined flow rates and precise volume control are pre-requisites of extracorporeal 
renal replacement treatments for ESRD patients, particularly when using membranes with 
high-water permeability. Therefore, the dual pulsation system acting on the PPPHD 
dialysate compartment was replaced with a dual piston pump, as shown in Fig. 9. This 
modification allows pulse generation and push/pull to be achieved, not only by the novel 
design of the piston pump, but also by the unique control of piston movements offered (Fig. 
10). As the dialysate piston compresses the cylinder, pure dialysate is forced into the 
dialyzer, but at this time, the effluent stream is functionally closed at the effluent piston 
pump, and thus, dialysate compartment pressures increase rapidly and backfiltration occurs 
(Phase 1).The effluent piston then begins to expand and dialysate moves into the effluent 
cylinder, while the dialysate supply line is still closed at the dialysate pump. Because of 
effluent suction, dialysate compartment pressures fall sharply and water flux from blood 
lumen to dialysate occurs (Phase 2). During the final step, pure dialysate fills the dialysate 
cylinder, and simultaneously used dialysate is drained (Phase 3). 
In an in vitro test of PPPHD with the dual piston pump, in which bovine blood was circulated 
through the blood lumen of the hemodialyzer at 200 ml/min and isotonic saline solution was 
used as dialysate at the rate of 400 ml/min, the phenomena of push (backfiltration) and pull 
(ultrafiltration) were well sustained throughout sessions, and their levels perfectly matched 
those of stroke volumes of the dialysate and effluent pumps, respectively. In addition, as was 
expected, dialysate and effluent piston pumps served as a flow equalizer, and controlled 
isovolumetic dialysate flow rates upstream and downstream of the dialyzer. Hydrostatic 
dialysate pressures were maintained at 520~700 mmHg during the backfiltration phase (Phase 
1) and at -400~-540 mmHg during the ultrafiltration phase (Phase 2). 
In addition, PPPHD is also versatile and can be easily converted to conventional high-flux 
HD. Time-controlled piston operations perform the push and pull operations, but when the 
two piston movements are synchronized alternately (that is, dialysate piston compression 
and effluent piston expansion or dialysate piston expansion and effluent piston compression 
 





Fig. 9. Schematic Diagram of PPPHD with Dual Piston Pump. (D, dialysate pump; E, 
effluent pump) 
 
Fig. 10. Pulse Generation and Push/Pull during PPPHD with Dual Piston Pump. (D, 
dialysate pump; E, effluent pump) 
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occur simultaneously), dialysate passes through the hemodialyzer without significant flow 
into blood lumen. In this situation, the two piston pumps serve as a flow equalizer and 
dialysis is largely achieved by diffusive mass transfer. 
The PPPHD unit presented was developed recently, and thus, it requires further 
investigation. Convective volume attained during PPPHD was equal to the accumulated 
total dialysate volume, and consequently, this unit delivered the maximally permissible 
level of total volume exchange. This encourages us to speculate on the capability of this 
unit in terms of removing mid-sized uremic toxins. Another issue regarding the enormous 
fluid exchange is the quantification of the contribution made by convection to dialytic 
efficiency. Backfiltration and ultrafiltration repeat in a relatively short time, and despite a 
large amount of filtration, the probability that some ultrafiltrate comes directly from 
dialysate backfiltered during a previous phase cannot be excluded, because that portion of 
ultrafiltrate does not contribute to depurative efficiency. In addition, forward filtration 
and backfiltration rates exceed the blood flow rate, which implies a reduction in solute 
concentrations due to dilution. As is the case for pre-dilution HDF, this repeated dilution 
may be expressed by an efficiency drop. Finally, although convection commonly inhibits 
diffusion during HDF, this inhibition is expected to be small for PPPHD due to repetitive 
backfiltration. Although an in vitro or in vivo setup revealed that alternate backfiltration 
has a positive influence on inhibiting concentration polarization and permeability 
reduction, it is believed that optimizations, in terms of pulse frequencies and stroke 
volumes, will further benefit the optimal use of membrane convective capacities 
throughout PPPHD treatments. 
4. Conclusion 
Much evidence shows that HDF delivers better dialysis outcomes than high-flux HD; for 
example, HDF has been shown to improve middle-to-large size molecular removal, allow 
better EPO control, reduce oxidative stress and inflammation (Lornoy et al., 2000, Vaslaki et 
al., 2006, Ward et al., 2000), and even to positively influence patient mortality (Canaud et al., 
2006, Jirka et al., 2006). These benefits have been attributed to the higher convective doses 
permitted during HDF. Furthermore, ultrapure dialysate, required due to the large amount 
of substitution infusion, further inhibits the inflammation risk (Lonnemann, 2000).  
In this chapter, we review HDF techniques that do not require exogenous substitution 
infusion. These techniques must be accompanied by spontaneous fluid restoration, such as, 
backfiltration or ultrafiltrate regeneration (Table 3). A simpler way might be to increase 
forward and backward filtration rates during HD sessions, although this can only be done to 
a limited extent. Much higher efficiencies can be achieved by the two-chamber techniques, 
that is, double high-flux HDF and HFR, which were developed in an effort to increase solute 
removal and shorten treatment times, by separating ultrafiltration and backfiltration, or 
convection and diffusion domains. However, these modalities appear to unavoidably 
increase overall system complexity. Push/pull HDF, which uses a single hemodialyzer, was 
derived by considering phases, rather than physical regions, for forward and backward 
filtration. The pulse push/pull HD described here is also based on the phase-separated use 
of forward filtration and backfiltration using a single high-flux dialyzer. This strategy was 
devised as a result of efforts to modulate flow patterns for extracorporeal dialysis treatment, 
and thus, a unique design for managing dual pulsation through the dialysate compartment 
allows the whole unit to be as simple as the conventional HD unit. 
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As these novel HDF strategies evolved, remarkable improvements have been achieved in 
dialysis technologies. Modern dialysis machines offer HDF and HD as default therapies, and 
are also equipped with outstanding monitoring facilities not only for patients (BTM, BVM, 
OCM2), but also for treatments (fail-safe design and high-precision balancing) (Polaschegg, 
2010). In particular, advances in water treatment allow ultrapure replacement fluid to be 
prepared in real time. These technical advancements are certainly lowering the barriers to 
higher convective HDF therapies. 
 
Modality Filter(s) Additional components TFV
 § Filtration Reinfusion 
Internal HDF 1 - + proximal part of dialyzer BF 
Double HDF 2 flow restrictor ++ hemodialyzer (upstream) BF 
HFR 2 adsorbent column,filtrate pump + 
hemofilter 
(upstream) FR 
PP HDF 1 double-chamber pump +++ 
whole 
membrane BF 
Pulse PP HD 1 - +++ whole membrane BF 
§ Total filtration volume per session (4 hours, L); +, low (<20L); ++, moderate (20-40L); +++ high (>60L) 
Table 3. Infusion-free HDF modalities. (HFR, hemofiltrate reinfusion; TFV, total filtration 
volume; PP, push/pull; FR, filtrate regeneration; BF, backfiltration) 
Therefore, in addition to convective clearances, we believe the PPPHD system should be 
equipped by features that simplify overall treatment and enable dialysis to be performed in 
outside clinics, because this unit allows simple and efficient operation. Future development 
targets designed to accomplish these features include; greater user friendliness (that is, 
intuitive control and operation, fail-safe operations and treatment automation), readily 
available sterile dialysate, accessible maintenance, and a miniaturized unit that is both light 
and portable (without compromising depurative efficiency). A dialysis unit equipped with 
these features may also provide treatment alternatives beyond the current thrice weekly 4-h 
practice, and perhaps allow even daily dialysis for ESRD patients. 
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1. Introduction  
Uremic toxicity is described as a clinical picture resulting from impaired renal elimination 
and accumulation of uremic toxins in the body. Uremic toxins can be classified as small 
water-soluble compounds, middle molecules and protein-bound compounds. A long list of 
possible uremic toxins has been identified in recent decades. Under normal conditions these 
compounds are excreted by healthy kidneys. If kidney function fails, waste products 
accumulate in the blood and in the body. Dialysis treatment replaces some kidney functions 
through diffusion (waste removal) and ultrafiltration of fluid across a semi-permeable 
membrane, which is a thin layer of material with holes or pores of various sizes. A deeper 
understanding about the accumulation and removal mechanisms of the retained solutes 
during care of renal insufficiency is needed (Eloot, 2008; Eloot, 2007). This understanding 
would be especially informative with respect to predicting the mode of action of uremic 
toxins and their specific role in complications associated with dialysis or ureamia, but also 
with cardiovascular disease and inflammation (Vanholder, et al., 2008; Vanholder, 2003). 
The methods contributing to the identification, characterisation and evaluation of uremic 
retention solutes could be assessed in order to ensure dialysis adequacy and quality 
(Vanholder, 2005). The choice of the correct concentration of potential uremic toxins is still 
an unresolved issue (Vanholder, 2003). In everyday clinical practice, uremic components are 
not examined due to the measurement of most uremic components using the available 
laboratory methods being difficult and complex. A number of standard biochemical 
techniques are used in clinical laboratories, but there is no universal methodology. In 
addition, some chromatographic methods have been developed which explore uremic 
retention solutes.  
Dialysis efficiency and quality has been an important issue accompanied by optimisation 
and the best outcome of the treatment of chronic end stage renal disease for many years. In 
connection to this, online monitoring of the dialysis dose has been suggested as an effective 
way of improving treatment quality. The concept of online monitoring is based on the real-
time measurement of chemical signals coming from the patient. This enables the early 
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addition, some chromatographic methods have been developed which explore uremic 
retention solutes.  
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and the best outcome of the treatment of chronic end stage renal disease for many years. In 
connection to this, online monitoring of the dialysis dose has been suggested as an effective 
way of improving treatment quality. The concept of online monitoring is based on the real-
time measurement of chemical signals coming from the patient. This enables the early 
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recognition of signs of intolerance and allows for early intervention. Despite the first online 
monitors of dialysis doses being available today, it is essential to monitor the patient’s 
condition during the dialysis session and, if necessary, change some conditions of dialysis 
treatment (e.g. time) more specifically considering uremic toxins with various characteristics 
and elimination profiles.  
The aim of this chapter is to describe and assess performance of optical dialysis adequacy 
monitoring technique related to the removal of uremic retention solutes during dialysis. The 
assessment is based on the high performance liquid chromatography (HPLC) profiles of the 
serum and the spent dialysate connected to the origin of the cumulative and integrated UV 
absorbance arising from the contribution of uremic retention solutes - chromophores, among 
them probably several uremic toxins. 
2. Dialysis adequacy and online monitoring 
Dialysis adequacy means providing a sufficient amount of dialysis treatment to maintain a 
uremic patient in the best condition. The goal of qualitatively treated dialysis is to prevent 
complications due to uremic toxicity. 
Some recent studies are reviewed suggesting that uremic toxins are involved in the 
progression of renal failure and are at least partially removed by hemodialysis (Lesaffer, 
2000; Eloot, 2008; Vanholder, 2003). The efficiency of a dialysis session has been estimated 
through concentration of uremic toxins measured before and after the dialysis session. A 
classic marker of the dialysis dose and adequacy is a small molecule urea.  
Two methods are generally used to assess dialysis adequacy: URR and Kt/V. The urea 
reduction ratio (URR) is based on tests of blood urea, by measuring the levels before and 
after treatment to show how much has been removed. The Kt/V is mathematically related to 
the URR and can be derived from it (NKF-DOQI, 2006). In a simplified model of urea 
removal from a fixed volume with no urea generation, Kt/V is related to URR as follows: 
 Kt/V = -ln (1 – URR) (1) 
In general, this method of dialysis adequacy is based on pre- and post-dialysis 
measurements of urea concentration. Online methods are considered to be more accurate 
than methods based on pre- and post-dialysis urea concentrations and have been found to 
be better suited to clinical routines. Online monitoring of the dialysis dose has been 
suggested as a valuable tool in ensuring adequate dialysis prescription (Locatelli, 2005).  
3. Optical dialysis online monitoring 
Two optical techniques have made progress toward clinical use over the past ten years – 
namely the ultraviolet (UV) absorbance and near infrared (NIR) techniques. The 
experimental results indicate very good correlation between UV absorbance and several 
small solutes such as urea, creatinine and uric acid in the spent dialysate and in the blood 
for every individual treatment at a fixed wavelength of 285 nm (Fridolin, 2002). Good 
correlation between UV absorbance and a small removed waste solute such as urea enables 
the determination of Kt/V for urea (Fridolin, 2003). The NIR method can measure urea 
directly using signal processing of the raw NIR spectra (Cho, 2008; Eddy, 2001; Eddy, 2003).   
To implement NIR technology as a simple and robust sensor based on Fourier transform 
near-infrared (FT-NIR) spectrometer or acousto optical tunable filter (AOFT) based 
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spectrometer is far more complicated because of the underlying optical principle, in which 
interference or diffraction is utilised (Jensen, 2002; Cho, 2008). The UV method is more 
straightforward and is not as demanding considering the source and detector characteristics 
and other technological modules. The UV method has recently been commercialised as a 
monitoring tool for dialysis dose in terms of the urea-based parameters, Kt/V and URR. 
Validation studies of the system have shown that the results with UV technology are 
indistinguishable from blood based Kt/V (Castellarnau, 2010). 
An optical dialysis online monitoring system utilising UV absorbance has been developed 
for the continuous monitoring of the toxins eliminated by the spent dialysate. This system 
represents a spectrophotometer connected to the fluid outlet of the dialysis machine. All 
spent dialysate passes through a specially designed optical cuvette. The transmitted light 
intensity of the spent dialysate is measured. All substances – chromophores – absorbing the 
UV-radiation at a particular wavelength, give the total online UV absorbance curve. The 
schematic clinical set-up of online monitoring experiments is shown in Figure 1.  
 
 
Fig. 1. Clinical experimental set-up and sample analysis 
The obtained UV absorbance values are processed and presented on the computer screen by 
a PC incorporated in the spectrophotometer using special software. The absorbance A of a 
solution, obtained by the spectrophotometer using the pure dialysate as the reference 
solution, is determined as: 




  (2) 
where Ir is the intensity of transmitted light through the reference solution (pure dialysate) 
and Ir+s is the summated intensity of transmitted light through the reference solution 
containing the solutions under study (pure dialysate + waste products from the blood). The 
absorbance is measured in arbitrary units (a.u.). A sampling frequency at two samples per 
minute is usually sufficient, but can be much higher (e.g. if a more detailed curve is desired 
or noise reduction is necessary). 
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The examples of two online signals measured at 280 nm from two different dialysis treatments 
are shown in Figure 2. The UV absorbance is higher at the beginning of treatment because of 
the high concentration of metabolic waste products in the body fluids. When the waste 
products are removed from the blood the UV absorbance decreases during the dialysis session. 
The times at which the blood and dialysate samples were collected are also shown in this 
figure. Blood samples were drawn before the start of dialysis treatment (Bstart) and 
immediately after the treatment (Bend). Dialysate samples were taken 10 minutes after the start 
of the dialysis session (Dstart) and at the end of the treatment (Dend) (210 or 240 minutes). 
 
 
Fig. 2. Example of two different online UV absorbance measurements (at 280 nm). Time 
points when the samples were taken for later analysis are as follows: Dstart - dialysate sample 
collected 10 minutes after start of hemodialysis, Dend- dialysate sample collected at the end 
of hemodialysis, Bstart – blood sample collected before dialysis session, Bend – blood sample 
collected at the end of hemodialysis 
This figure presents a classic picture of UV absorbance signals obtained by the optical online 
dialysis dose monitor, which can be used for estimation of uremic solutes removal.  
As seen from Figure 2, the UV absorbance curves are somewhat different. The exponential 
decrease of the UV absorbance curve represents the elimination rate of the all UV-absorbing 
compounds – chromophores – which varies from patient to patient and from treatment to 
treatment. Good correlation between the UV absorbance measured in the spent dialysate and 
the concentration of several uremic retention solutes, both in the spent dialysate and in the 
blood of the dialysis patients, has been previously shown (Fridolin, 2002). For these reasons 
the origin of the cumulative and integrated UV absorbance arising from the contribution of 
uremic retention solutes, among them probably several uremic toxins, should be investigated.  
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4. HPLC as an analysis tool for biological samples 
High performance liquid chromatography (HPLC) is a technique of analytical chemistry 
which can separate and identify the components of a mixture of different chemical 
compounds in liquid solution. The reversed-phase HPLC technique is the most commonly 
used form of HPLC. This method is recommended as a sensitive, accurate and reproducible 
tool for qualitative and quantitative analysis of aqueous samples (Vanholder, 2001). 
Furthermore, the use of ambient temperature in reversed-phase columns makes it possible 
to investigate the many non-volatile or thermally unstable compounds commonly found in 
biological samples. The principle involved in HPLC testing enables the separation of 
compounds in a mixture more efficiently and faster than that of traditional column 
chromatography.  
In general, the HPLC system consists of two essential components – a stationary phase and a 
mobile phase. The stationary phase is a column packed with small solid sorbent particles 
and where the separation of different compounds takes place. The mobile phase is a flowing 
liquid (solvent) that transports the compounds from the sample through the stationary 
phase. Thus, the compounds of the mixture travel at different rates due to their relative 
affinities with the solvent and stationary phase. Separation of compounds in the stationary 
phase occurs with slight differences in chemical properties, such as chemical polarity and 
size of non-polar groups. 
Figure 3 is a simple block diagram illustrating the main components of a modern HPLC. A 
system consists of several units: pumping, sample-injection, separation (column), detection 
and data-processing.   
 
 
Fig. 3. Schematic reversed-phase HPLC method principle 
The results of chromatographic analysis are known as chromatograms, where the signal 
intensity from the detector is recorded on the time axis. For HPLC there are several different 
detection methods; the most popular are optical. An ultraviolet-visual light (UV-VIS) 
absorption detector is the main optical detection method. This detector is effective in the 
detection of components with an absorption wavelength of 400 nm or less in the ultraviolet 
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region. There are three types of UV-VIS detectors: a fixed wavelength detector; a variable 
wavelength detector; and a diode array detector (DAD). However, in modern HPLC 
systems DAD is commonly used, which in addition to the UV-VIS signal offers the ability to 
produce an absorption spectrum for every time slice during the chromatogram. A DAD 
detects the absorption in the UV to VIS region. Using the DAD, absorption on a large 
number of wavelengths can be measured simultaneously. This enables us to select the best 
wavelengths for actual analysis. Additionally, one of the advantages of DAD is that it allows 
us to detect sufficiently pure peaks. Often the peak shape itself does not reveal that it 
actually corresponds to two or even more components. In such a case, absorbance rationing 
on several wavelengths is particularly helpful in deciding whether the peak represents a 
single compound or a composite peak. However, compared with a UV-VIS detector, the 
DAD is susceptible to changes, such as lamp fluctuations, and noise is large because the 
amount of light is small.   
For those compounds which fluoresce or which exhibit an appropriate fluorescence due to 
derivatisation, a fluorescence detector is the most sensitive of the existing modern HPLC 
detectors. Its sensitivity is 10-1000 times higher than that of the UV detector for strong UV-
absorbing materials. Fluorescence detectors are very specific and selective compared to 
other optical detectors. A universal detector, but the least sensitive for non-ionic compound 
monitoring, is the refractive index detector. To estimate oxidisable and reducible 
compounds, the most suitable is the electrochemical detector. 
Reversed-phase HPLC has been found to be useful in the analysis of uremic biofluids. A 
number of authors have reported the application of the HPLC method in the analysis of 
dialysate and serum samples already in several decades ago (Schoots, 1989; Schoots, 1982). 
Different detectors have been used. Some naturally fluorescent compounds have been 
separated and identified with a fluorescence detector, in both serum and haemodialysate 
(Niwa, 1993; Barnett, 1985; Swan, 1983). A liquid chromatographic method including a UV 
detector for detection of UV-absorbing solutes in uremic serum has been developed 
(Schoots, 1985; Senftleber, 1976; Knudson 1978). A fixed wavelength at 254 nm was mainly 
used in these studies. Additionally, several types of chromatographic methods, such as gas 
chromatography mass spectrometry (GC-MS), for the detection of uremic toxins has also 
been developed (Niwa, 1997; Niwa, 2009). Mass spectrometry (MS) has been applied to the 
identification and quantification of uremic toxins and uremia-associated modified proteins 
(Niwa, 2009). However, GC-MS cannot analyse highly polar, thermally labile and high-
molecular weight compounds and usually requires sample preparation, such as extraction 
or derivation to make non-volatile compounds thermally stable and volatile.  Compared 
with GC-MS, liquid chromatography mass spectrometry (LC-MS) can separate and identify 
highly polar, thermally labile or high-molecular weight mixture compounds and does not 
require derivation; sample preparation is also simple. Newly developed LC-MS techniques 
have been successfully applied to uremic toxin research with the discovery of novel uremic 
toxins that range from low-molecular weight solutes to small-molecule proteins (Niwa, 
2011). This new analytical method is available today, opening up new horizons for uremic 
toxin identification detected earlier as unidentified HPLC peaks. 
5. HPLC study of UV absorbance profiles 
In order to explain the origin and potential of the online UV absorbance dialysis dose 
monitoring method, the HPLC method of analysing UV absorbance profiles was developed.  
Optical Dialysis Adequacy Monitoring:  
Small Uremic Toxins and Contribution to UV-Absorbance Studied by HPLC 149 
Ten uremic patients – three females and seven males (mean age 62.6 ± 18.6 years) – 
participated in the study. All of the patients were investigated over a course of 30 
hemodialysis treatments. Three different polysulphone dialysers were used (Fresenius 
Medical Care, Germany): a low flux membrane dialyser F8 HPS (N=14), a low flux 
membrane dialyser F10 HPS (N=3) and a high flux membrane dialyser FX 80 (N=11). The 
elimination of toxins by the different types of semi-permeable membranes was also 
estimated. 
Blood samples were drawn before the start of dialysis treatment (Bstart) and immediately 
after the treatment (Bend) (Figure 2) using the slow flow/stop pump sampling technique. 
Blood was sampled into BD Vacutainer® Glass Serum Tube (red cup, Beckton Dickinson) 
and was allowed to clot. After centrifugation at 3000 r.p.m. the serum was ready for clinical 
chemistry analysis. Small molecules – creatinine (MW=113.12 Da), uric acid (MW=168.11 
Da) and urea (MW=60.06 Da) – were measured at the Clinical Chemistry Laboratory of the 
North Estonia Medical Centre using standardised methods (Hitachi 912 autoanalyser, 
Roche, Switzerland). The accuracy for creatinine was 5%, for uric acid 2% and for urea 4%. 
For HPLC analysis the additional pre-treatment of the centrifugated serum was necessary to 
release the blood proteins. The serum samples were purified from proteins by centrifuging 
with two different Microcon centrifugal filters (Millipore, USA): a YM-3 with cut-off 3 kDa 
and a YM-100 with cut-off 70 kDa. The aim of using different filters was to estimate the 
presence of different-sized molecules in the serum.  
Dialysate samples were taken 10 minutes after the start of the dialysis session (Dstart) and 
immediately after the treatment (Dend) (210 or 240 minutes) (Figure 2). Also, pure dialysate, 
used as the reference solution, was collected before each dialysis session, when the dialysis 
machine was being prepared and the conductivity was stable. For HPLC analysis, the 
dialysate samples were acidified with formic acid to pH 4.0. Sample sizes of 50 μL or 100 μL 
were used for chromatographic separation. Figure 4 presents a block diagram illustrating 
the collection and handling of blood and dialysate samples.  
 
 
Fig. 4. Block diagram of blood and dialysate sample collection and handling 
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Fig. 4. Block diagram of blood and dialysate sample collection and handling 
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The HPLC instrumentation and tools were as follows: a diode array spectrophotometric 
detector (DAD, Perkin Elmer, USA); a manual injector (Rheodyne, USA); and a Zorbax C8 4.6 
x 250 mm column (Du Pont Instruments, USA) with security guard KJO-4282 (Phenomenex, 
USA). The eluent was mixed with 0.05 M formic acid (pH 4.0), HPLC grade methanol and 
HPLC-S grade acetonitrile (Rathburn, Scotland), with a six-step gradient programme. The total 
flow rate of 1 mL/min was used continuously and the column temperature was adjusted to 
30ºC. The method followed has been described previously (Lauri, 2010). The chromatographic 
peaks were detected by the UV detector at wavelengths of 254 and 280 nm. The data was 
processed by means of Turbochrom WS and Turboscan 200 software from Perkin Elmer.  
The decrease of the uremic retention solutes was estimated as the reduction ratio (RR) and 
assessed as a percentage (%). Thus, the RR of compounds was defined as a function of pre-
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5.1 Results 
The results from the studies obtained by the HPLC method in order to analyse the UV 
absorbance profiles of the serum and dialysate samples are presented below. The results are 
presented as mean ± standard deviation (SD). A student’s t-test was used to compare groups 
of values wherein p < 0.05 was considered significant. Pearson’s correlation coefficient (r) 
between the UV absorbance from HPLC and online monitoring versus concentration of the 
substances in the blood was investigated. Samples taken at times coinciding with the self-
tests or alarms of the dialysis machine were excluded (3 of 60 dialysate samples). Some 
sessions were excluded due to the technical failure of the spectrophotometer (3 of 30 
sessions) and due to laboratory errors (3 of 30 sessions). The data analyses were performed 
in Microsoft Excel 2003 (for Windows). 
The characteristic HPLC profiles of the spent dialysate at the start of the dialysis session 
(Dstart) and at the end (Dend) are presented in Figure 5. When comparing the start and end 
values, the decrease in the height of the peaks (due to solute removal from the blood and 
into dialysate during dialysis) can be clearly seen.  
As can be seen from this figure, a number of higher prevalent peaks can be observed from 
the HPLC profiles indicating the presence of chromophores, which are the main cause of 
cumulative and integrated UV absorbance. The highest peak on the HPLC profile is detected 
as uric acid causing a substantial amount of UV absorbance. 
Figure 6 shows the HPLC chromatograms of the serum (filter YM-3 with cut-off 3 kDa) 
measured on wavelengths of 254 nm and 280 nm. Identified HPLC peaks, such as creatinine, 
uric acid (the highest contribution), hypoxanthine, indoxyl sulphate and hippuric acid, are 
shown. Absorbing spectra of two unknown persistent peaks (P1 and P2) were identified at 
retention times (RT) of 15.46 and 15.82 min.  
Some chromophores, such as P2, creatinine, hypoxanthine and hippuric acid, give higher 
peaks on a wavelength of 254 nm, while P1 and indoxyl sulphate are better identified on a 
wavelength of 280 nm. This is due to the absorbing spectrum characteristics of the UV 
chromophores. This confirms the results obtained by the spectrophotometric analysis in this 
UV region.  
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Fig. 5. Characteristic HPLC profiles of spent dialysate monitored on a wavelength of 280 
nm; Dstart - dialysate sample collected 10 minutes after start of hemodialysis, Dend - dialysate 
sample collected at the end of hemodialysis  
 
Fig. 6. Characteristic HPLC profiles of serum monitored on different wavelengths. Blood 
samples were collected before the dialysis session (Bstart ) and monitored on wavelengths of 
254 nm and 280 nm. Detected HPLC peaks – uremic toxins – are presented. 
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Fig. 5. Characteristic HPLC profiles of spent dialysate monitored on a wavelength of 280 
nm; Dstart - dialysate sample collected 10 minutes after start of hemodialysis, Dend - dialysate 
sample collected at the end of hemodialysis  
 
Fig. 6. Characteristic HPLC profiles of serum monitored on different wavelengths. Blood 
samples were collected before the dialysis session (Bstart ) and monitored on wavelengths of 
254 nm and 280 nm. Detected HPLC peaks – uremic toxins – are presented. 
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As seen from Figure 6, around ten peaks on the HPLC profiles can be selected forming the 
major part of the total HPLC signal. As a result of this, the total area of the ten main peaks 
(Top 10 area %) was estimated. The comparison for Top 10 area % in the serum and 
dialysate is presented in Figure 7. The contribution of ten main peaks forms approximately 
80-90% of all HPLC peaks in both spent dialysate and serum. However, there is a difference 
in the number of peaks on different wavelengths. In comparison with the 254 nm 
wavelength, the Top 10 area % on the 280 nm wavelength is higher. According to the HPLC 
profiles obtained (Figure 5 and 6), the largest contribution to Top 10 area % on the 280 nm 
wavelength originates from the small water-soluble non-protein-bound uremic toxin uric 
acid. Additionally, there was no significant difference between the serum results filtered 
with different type of filter cut-off (3 kDa and 70 kDa) (p< 0.05). 
 
 
Fig. 7. Comparison of Top 10 area % on wavelengths of 254 nm and 280 nm in serum (filter 
YM-3 with cut-off 3 kDa) and spent dialysate 
The RR of the detected chromatographic solutes was estimated. Table 1 presents the 
comparison of the RR (%) of solutes and all HPLC UV absorbance peaks on wavelengths of 
254 nm and 280 nm in serum and for the online UV absorbance at 280 nm in the spent 
dialysate for different types of membranes: low flux (F8 HPS, F10 HPS) and high flux 
(FX80). There was no significant difference between the results for RR of low flux and high 
flux membranes (p < 0.05).  
Hippuric acid had the highest RR, while the small water-soluble compound hypoxanthine 
and protein-bound solute indoxyl sulphate had the lowest RR. The RR of all HPLC Ppeaks 
at 280 nm was similar to uric acid and urea and higher than the RR of online UV absorbance 
at 280 nm and creatinine. At the same time, the RR of all HPLC peaks at 254 nm and P2 were 
lower than uric acid and urea. Online UV absorbance at 280 nm, creatinine and P2 were all 
removed in a statistically similar way (p < 0.05) and had lower RR than uric acid, urea and 
all HPLC peaks at 280 nm. 
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RR (%) 
Low flux High flux 
Hippuric acid 75.1 ± 11.5 (N=15) 68.1 ± 9.4 (N=10) 
Uric acid 67.7 ± 8.5 (N=15) 65.6 ± 6.7 (N=15) 
Urea 67.0 ± 8.7 (N=15) 63.2 ± 5.07 (N=15) 
All HPLC peaks, 280 nm 65.2 ± 9.6 (N=15) 60.6 ± 7.9 (N=14) 
P1 62.1 ± 13.0 (N=12) 61.0 ± 5.3 (N=7) 
All HPLC peaks, 254 nm 60.2 ± 12.5 (N=14) 57.2 ± 7.7 (N=13) 
P2 59.2 ± 17.5 (N=13) 51.6 ± 5.9 (N=12) 
Online UV absorbance,  280 nm 58.1 ± 8.3 (N=15) 57.0 ± 10.4 (N=13) 
Creatinine 58.2 ± 7.7 (N=15) 56.6 ± 5.4 (N=15) 
Hypoxanthine 42.6 ± 16.0 (N=10) 46.1 ± 18.5 (N=8) 
Indoxyl sulphate 42.1 ± 18.0 (N=13) 47.8 ± 14.0 (N=12) 
Table 1. RR (%) of solutes and total area of all HPLC UV absorbance peaks on wavelengths 
of 254 nm and 280 nm in serum and RR of online UV absorbance at 280 nm in spent 
dialysate for different types of membranes 
As the low flux and high flux membranes showed similar RR for every uremic solute, the 
results can be combined. Figure 8 present an illustrative comparison between the RR of 
serum uric acid, urea and creatinine measured in the clinical laboratory using standardised 
methods, all HPLC peaks measured on two different wavelengths (254 and 280 nm) and 
dialysate online UV absorbance measurement (280 nm).  
 
 
Fig. 8. Comparison of RR of small molecular uremic retention solutes (uric acid, urea and 
creatinine) in serum, RR of all HPLC serum peaks on two different wavelengths (254 and 
280 nm) and spent dialysate online UV absorbance (280 nm) 
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The RR of urea and uric acid and the RR of all HPLC peaks at 280 nm are > 60%, while the 
RR of all HPLC peaks at 254 nm, of online UV absorbance measurement and creatinine are < 
60%. Interestingly, the removal of urea and uric acid was statistically undifferentiated (p > 
0.05). Figure 8 shows that the RR of serum creatinine is statistically different (p < 0.05) from 
the RR of serum urea and uric acid concentrations and from the RR of all HPLC peaks in the 
serum (at 280 nm), but not different from that of 254 nm. The RR of online measurement is 
comparable with the RR of creatinine and of all HPLC peaks at 254 nm and lower than the 
RR of urea, uric acid and all HPLC peaks at 280 nm (p < 0.05). At the same time, the RR of 
serum urea and uric acid are not statistically different; neither are they different from the RR 
of all HPLC peaks at 254 nm and 280 nm (p < 0.05). 
The correlation coefficients between RR UV absorbance at 254 nm and at 280 nm from the 
total area of the HPLC peaks, from online monitoring at 280 nm and RR for certain 
substances with different molecular weights in spent dialysate and serum are shown in 
Table 2.  
  
 Uric acid Urea Creatinine 
RR of all HPLC peaks, 254 nm 0.755 0.811 0.812 
RR of all HPLC peaks, 280 nm 0.933 0.881 0.926 
Online UV absorbance, 280 nm 0.890 0.873 0.888 
Table 2. Pearson correlation coefficients between RR of all HPLC peaks (254 nm and 280 
nm), online absorbance at 280 nm and RR of uric acid, urea and creatinine in serum. The 
significance level of the results is P<0.01. 
A high correlation for uric acid, urea and creatinine was obtained in both spent dialysate 
and serum. Some differences regarding 254 nm and 280 nm can be observed. However, urea 
does not represent as good a correlation as uric acid. 
6. Discussion 
From the investigations presented in this chapter we can conclude the following: (i) UV 
absorbance decreases during the dialysis session as the waste products are removed; (ii) a 
number of higher prevalent peaks can be detected in the HPLC profiles; (iii) some low-
molecular-weight uremic solutes were identified from the HPLC profiles contributing to UV 
absorbance, and the main solute responsible for the UV absorbance is uric acid; (iv) a 
difference between HPLC profiles on wavelengths of 254 and 280 nm was found; (v) a higher 
number of detected HPLC peaks in the serum comparing to spent dialysate has been detected; 
(vi) the low flux and high flux membranes showed similar RR for all studied uremic solutes; 
and (vii) the classic dialysis adequacy marker urea and the uremic solute uric acid have good 
correlation with uremic retention solute elimination forming the UV absorbance curve. 
Figures 2 and 5 show how the concentration of the uremic retention solutes – chromophores 
– decreases during a dialysis session in spent dialysate. UV absorbance as well as the height 
of the HPLC peaks are higher at the beginning of the treatment because of the high 
concentration of metabolic waste products in the body fluids and UV absorbance is lower at 
the end of the dialysis session. This demonstrates the possibility of following a single 
dialysis session continuously and to monitor deviations during treatment using a UV 
absorbance online monitor. This enables us to estimate the dialysis efficiency and adjust the 
treatment settings if needed.  
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A number of higher prevalent HPLC peaks representing chromophores can be observed 
(Figure 5 and 6). This indicates that there is a group of compounds, among them several 
uremic toxins, which are the main cause of cumulative and integrated UV absorbance. The 
10 main peaks formed app. 80-90% of the total area of all HPLC peaks; some of these are 
small molecular weight uremic toxins such as uric acid, creatinine, hippuric acid and 
indoxyl sulphate. The variations in the number of HPLC peaks depending on hemodialysis 
treatments and patients have been demonstrated in earlier studies (Schoots, 1982; 
Vanholder, 1992). The difference between two dialysis sessions may arise as shown in 
Figure 2, because of the different composition and removal of the uremic retention solutes 
contained in spent dialysate. When comparing the HPLC profiles of the spent dialysate in 
Figure 5 and those of the serum in Figure 6, more peaks are detected in the serum. Thus, not 
all solutes in serum are transported to dialysate and removed through the semi-permeable 
membrane. 
The number of detected HPLC peaks at 254 nm and 280 nm is also demonstrated in Figure 6 
and 7. The difference in the number of detected HPLC peaks on the wavelengths of 254 nm 
and 280 nm arises due to the characteristic absorbing spectra of the UV chromophores. The 
absorption of many components is higher on the wavelength of 254 nm than 280 nm. This 
confirms the results obtained via the spectrophotometric analysis in this UV region 
(Fridolin, 2003). However, the studies of relations between UV and small water soluble 
molecules such as urea and uric acid indicated that the wavelength of 280 nm may be 
preferred for online measurements when small water soluble molecules should be 
estimated. On this wavelength a relatively strong linear relationship exists between UV 
absorbance and concentrations of urea, creatinine and uric acid (Fridolin, 2002; Uhlin, 2003). 
While the contribution of uric acid forms a considerable part of the total area of HPLC 
peaks, uric acid plays an important role in online UV absorbance dialysis dose monitoring. 
Interestingly, the removal of urea and uric acid was statistically undifferentiated (p > 0.05). 
This information gives us alternative possibilities to use other components and methods to 
monitor urea reduction (URR) in a single hemodialysis session. 
Additionally, the low flux and high flux membranes showed no different removal of the 
studied small molecule uremic toxins as presented in earlier studies (Lesaffer, 2000). In this 
study it was found that the cellulose triacetate and polysulphone HF membranes removed 
similarly classical markers and protein-bound liphophilic solutes as an LF polysulphone 
membrane. Parallel results were obtained even with the concentrations corrected using a 
correction factor based on the total protein concentration at the start and at the end of 
dialysis as used by Lesaffer et al. (Lesaffer, 2000). Furthermore, there was no statistical 
difference between intradialytic start-end values, and removal efficiency for the LF and HF 
membranes estimated by the total area of HPLC peaks at 254 nm and 280 nm in the serum 
and online UV absorbance at 280 nm in the spent dialysate. This indicates that UV 
absorbance follows the behaviour of UV-absorbing compounds – uremic toxins – which are 
the origin of total UV absorbance in serum and spent dialysate. 
The RR values of different identified compounds, the total area of all HPLC UV absorbance 
peaks on the wavelengths of 254 nm and 280 nm in the serum and the RR of online UV 
absorbance at 280 nm in spent dialysate are presented in Table 1 and Figure 8. Taking into 
account the removal efficiency, a difference can be observed in the relation of UV 
absorbance to small water-soluble non-protein-bound solutes and to small protein-bound 
solutes such as indoxyl sulphate. The small non-protein-bound solutes uric acid and urea 
showed a far more substantial decrease of concentration than creatinine being statistically 
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different (p < 0.05) from the RR of serum uric acid and urea. The similar removal of urea and 
uric acid makes it possible to use other components and methods to monitor urea reduction 
during a single hemodialysis session. At the same time, the RR of creatinine is statistically 
different (p < 0.05) from the RR of all HPLC peaks in the serum at 280 nm, but not different 
from that of 254 nm. The RR for online UV absorbance is lower compared to urea. 
Considering that RR (URR) is correlated to Kt/V (NKF-DOQI, 2006), this tendency is 
reported earlier, as the dialysis dose estimated by online UV absorbance was lower than 
Kt/V urea (Uhlin, 2003). The difference between the RR of all HPLC peaks in serum and 
online UV absorbance measurement (at 280 nm) in spent dialysate could be due to different 
chromophores in the serum and spent dialysate and because the serum was collected before 
and the dialysate sample 10 minutes after the start of dialysis. Moreover, the different 
binding of individual uremic retention solutes to serum proteins may modify percentage 
concentration changes of individual solutes in the course of haemodialytic treatment 
(Vanholder, 1992), supported by observations of decreased drug/protein interactions in 
uremic serum (De Smet, 1999).  
The correlation analysis also provides additional insights into the removal characteristics of 
solutes and UV absorbance monitoring (Table 2). The RR of uric acid has the highest 
correlation for RR at 280 nm in both serum and spent dialysate, but not at 254 nm in serum. 
The explanation is the highest contribution of uric acid to UV absorbance compared to other 
chromophores at 280 nm (Figures 5 and 6). However, there are several other strong 
contributions from other compounds beside uric acid at 254 nm, and therefore the 
correlation is lower. The outcome in Table 2 is confirmed by comparing the millimolar 
extinction coefficients versus wavelengths for uric acid (Vasilevsky, 2005). A higher value of 
the extinction coefficient corresponds to the higher correlation for RR of uric acid at 280 nm.  
The RR of urea is more related to RR at 280 nm both in serum and spent dialysate, but less 
so at 254 nm in serum (Fridolin, 2003). This means that relatively good correlation between 
the RR of UV absorbance and a particular solute may be achieved when the removal rate of 
a non-absorbing solute (e.g. urea) is similar to that of UV-absorbing substances during 
haemodialysis. This is also confirmed by very good correlation between several small 
molecular weight waste products and UV absorbance (Fridolin, 2002) and similar 
concentration changes during dialysis for several azotemic markers (e.g. urea, creatinine 
and uric acid) (Vanholder, 1992). The dominance of small molecular weight waste products 
among chromophores in serum and spent dialysate can be concluded because the number of 
detected HPLC peaks is not significantly different for serum filtered with a filter in cut-off 3 
kDa and 70 kDa. Furthermore, it seems that the UV-absorbing solutes can be subject to 
similar corrections regarding distribution volume and intercompartmental equilibration 
rates, similar to urea, although not with exactly the same distribution and equilibration 
intercompartmental rates in the body as urea. This makes it possible to estimate the 
delivered dialysis dose in terms of Kt/V by monitoring UV absorbance in spent dialysate 
online (Uhlin, 2003).  
The RR of creatinine demonstrates a high correlation for RR at 280 nm in both serum and 
spent dialysate. The reason could be similar removal of creatinine and other chromophores 
at 280 nm, where creatinine does not contribute significantly to UV absorbance (Figure 5).  
As previous studies have shown, and as is confirmed by this work, the HPLC is a method 
which has its own place for the detection of uremic solutes in biological solutes. This is an 
effective method of studying accumulated metabolites in patients’ blood and removed in 
dialysis. Identification of these metabolites gives us the opportunity to understand the 
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cumulative and integrated UV absorbance curve utilised during optical dialysis dose online 
monitoring. The online methods are felt to be more accurate than methods based on pre- 
and post-dialysis urea concentrations, and to be better suited to clinical routine. Continuous 
monitoring of uremic retention solute concentrations during a dialysis session could be 
beneficial for the prevention of intradialytic morbidity and for the confirmation of dialysis 
adequacy. 
7. Conclusions 
This chapter contributes new information about the removal of uremic retention solutes 
during hemodialysis and the origin of the optical dialysis adequacy monitoring signal. The 
relationship between characteristics of the online UV absorbance curve measured during 
dialysis and the identified HPLC peaks in spent dialysate was investigated.  It was 
demonstrated that the absorbance signal reflects the contribution of several UV-absorbing 
compounds in spent dialysate, with the strongest influence coming from the low-molecular-
weight water-soluble non-protein bound compounds. Moreover, UV absorbance behaves 
more like small water-soluble non-protein-bound solutes than small protein-bound solutes.  
Monitoring the removal of compounds with different properties and elimination 
characteristics during various dialysis strategies adds knowledge of dialysis treatment and 
would be useful for future research in order to decrease complications related to dialysis 
quality and cardiovascular risk factors. Hopefully the online methods will add a new 
technique and methodology to the wide discussion about the quality and adequacy of 
dialysis, uremic toxicity and kidney functionality. 
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weight water-soluble non-protein bound compounds. Moreover, UV absorbance behaves 
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1. Introduction 
In renal replacement therapy (RRT) a wide range of uremic toxins have to be removed 
(Vanholder et al., 2003; Vanholder et al., 2008). It is well known that the combination of 
diffusive and convective dialysis strategies (online hemodiafiltration, olHDF) improves the 
removal of uremic toxins, i.e. middle molecules, hydrophobic substances and protein 
(albumin) bound materials (Krieter et al., 2005; Ahrenholz et al., 2004; Ronco et al., 1999; 
Kim, 1994; Testa et al., 2006; Meyer et al., 2005; Mandolfo et al., 2006; Kanter et al., 2008). In 
the presence of  ultrapure dialysis fluid which is ultrafiltrated by endotoxin restraint 
systems (Weber et al., 2000; Canaud et al., 2001; Minetti et al., 1985; Hakim et al., 1984) and 
biocompatible high flux dialysis membranes the convective diffusive treatment significantly 
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depends on inflammatory episodes and malnutrition (Del et al., 2005; Brimble et al., 2005). 
This retrospective, non randomized, multicentre, descriptive clinical evaluation examined 
the influence of olHDF on hemoglobin concentration (Hb), ESA dosage (ESA), Hb variability 
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2. Materials and methods 
233 chronic hemodialysis patients were included in this clinical evaluation (dialysis center 1 
(D1) n= 94, D2 n= 35, D3 n= 104 patients). 54.9% were male; the mean age was 63.8 years 
(range 22 - 89).  The patients in all three centers were comparable with regard to gender 
distribution, mean age, mean time on dialysis, and distribution of underlying kidney 
disease.  The clinical evaluation was carried out for 12 months retrospectively. 
Laborchemical parameters were estimated for hemoglobin (Hb) every 2 weeks 
(labanalyzer), CRP (turbidometry), albumin (alb; nephelometry) and ferritin 
(chemiluminescence technique) every three months.  Serum iron (photometry) and 
transferrin (turbidometry) were necessary to calculate the transferrin saturation (every 4 
weeks). Single pool kt/V was evaluated every 3 months with the Daugirdas technique 
(Daugirdas, 1993). Intraindividual variability of hemoglobin (Hbvar) was defined as the 
difference between minimal and maximal concentration (range) and by time to reach the 
target between Hb 6.8 mmol/l and 8.0 mmol/l within 9 months. Relevant changes in ESA 
dosages were defined as an elevation greater than two fold and lowering of a half of the 
ESA dosage, the end of ESA application or the start with more than 4200 U/week. 
Hemodialysis (HD) was performed by MTS 5008 (Fresenius Medical Care), low flux dialyser 
FX8, FX10 (helixone, Fresenius Medical Care), QB 300 ml/min, QD 500 ml/min, ultrapure 
dialysis fluid, online hemodiafiltration (olHDF) by MTS 5008 (Fresenius Medical Care; 
automatic procedure with factor 1.2), high flux dialyser FX 60, FX80 (helixone, Fresenius 
Medical Care), QB 300 ml/min, QD 350…..360 ml/min, QS 51….60 ml/min, ultrapure 
dialysis fluid and Nikkiso DBB 05 (Nikkiso Medical Ltd.), high flux dialyser FDY 15 G 
(PEPA, Nikkiso Medical Ltd.), QB 300 ml/min, QD 700 ml/min, QS 60 ml/min, ultrapure 
dialysis fluid (QB… blood flow; QD…dialysate flow; Qs…substitution flow). The group 
“mixed” contained patients started with HD and switched to olHDF (at least 6 months 
olHDF). We compared the mean values of collected serum parameters three times a month. 
Descriptive statistical evaluation was calculated by mean, standard deviation and 
significance by Wilcoxon test, correlation by Spearman rang correlation. The level of 
significance was defined as p< 0.05. 
3. Results 
The distribution of ESA applications in the three observed dialysis centers can be seen in 
table 1. Totally 185 of 233 patients received at least one ESA dosage. The mean value of 
ferritin was 538 mg/L. The transferrin saturation (TSAT) did not differ significantly in the 
observed dialysis units.  
 
 
Dialysis unit Total 1 2 3 
N % N % N % N % 
Application of ESA 37 39.4 4 11.4 7 6.7 48 20.6 without ESA 
At least 1 ESA dosage 57 60.6 31 88.6 97 93.3 185 79.4 
Table 1. Application of ESA per dialysis unit and overall. 
The mean weekly ESA dosage can be seen in table 2: 
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 Dialysis unit  Total 1 2 3 
All patients  N 94 35 104 233 
Mean 3550 5934 9177 6420 
SD 4443 5316 8487 7129 
Min 0 0 0 0 
Median 1577 5077 6500 4692 
Max 18667 26769 46538 46538 
Patients with at least one ESA dosage  N 57 31 97 185 
Mean 5855 6700 9840 8086 
SD 4365 5170 8409 7109 
Min 231 167 308 167 
Median 4714 5538 6769 6231 
Max 18667 26769 46538 46538 
Table 2. Mean weekly ESA dosage 
In nearly all patients (98.9%) an adjustment of ESA dosage was essential. Relevant changes 
in ESA dosages were defined as an elevation greater than two fold and lowering of a half of 
the ESA dosage, the end of ESA application or the start with more than 4200 U/week.  
The mean value of Hb (measured per patient over the whole study time) was 7.35 mmol/l 
(Table 3). In patients without ESA application during the 12 months study the mean value of 
Hb was larger (7.66 mmol/l) in comparison to patients with ESA dosage (7.27 mmol/l).  
 
 Dialysis unit Total 1 2 3 
Patients   37 4 7 48 without ESA Mean Hb N 
Mean 7.63 7.76 7.74 7.66 
SD 0.46 0.61 0.63 0.49 
Min 6.7 6.9 7.2 6.7 
Median 7.5 8.0 7.5 7.5 
Max 8.8 8.3 8.8 8.8 
At least one ESA dosage Mean Hb N 57 31 97 185 
Mean 7.38 7.09 7.25 7.27 
SD 0.41 0.52 0.53 0.50 
Min 6.2 6.0 5.1 5.1 
Median 7.5 7.2 7.4 7.4 







Mean Hb N 94 35 104 233 
Mean 7.48 7.17 7.29 7.35 
SD 0.44 0.57 0.55 0.52 
Min 6.2 6.0 5.1 5.1 
Median 7.5 7.2 7.4 7.4 
Max 8.8 8.4 8.8 8.8 
Table 3. Mean Hb concentrations 
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Table 4 shows the intra-individual variability of hemoglobin (Hbvar): 
 
 
 Dialysis unit Total 1 2 3 
ESA   37 4 7 48 without ESA Hb range (min-max) N 
Mean 1.98 1.35 1.93 1.92 
SD 0.92 0.68 1.11 0.93 
at least one ESA dosage Hb range (min-max) N 57 31 97 185 
Mean 2.20 1.74 2.41 2.23 
SD 0.73 0.85 0.88 0.86 
Total Hb range (min-max) N 94 35 104 233 
Mean 2.11 1.70 2.37 2.17 
SD 0.81 0.83 0.90 0.88 
Table 4. Means of haemoglobin variability 
The relation between the treatment mode (HD, olHDF) and ESA dosage as well as Hb is 
shown in the tables 5 and 6: 
 
 
 Dialysis unit Total 1 2 3 
HD All patients  N 40 32 74 146 
Mean 3608 6132 8833 6809 
SD 5058 5511 8313 7293 
Patients with at least one ESA dosage  N 22 28 69 119 
Mean 6560 7009 9473 8354 
SD 5217 5339 8248 7234 
HDF All patients  N 15 . 4 19 
Mean 3515 . 7750 4407 
SD 4160 . 5535 4660 
Patients with at least one ESA dosage  N 9 . 4 13 
Mean 5859 . 7750 6441 
SD 3853 . 5535 4287 
Mixed All patients  N 39 3 26 68 
Mean 3505 3821 10378 6147 
SD 3960 1500 9441 7313 
Patients with at least one ESA dosage  N 26 3 24 53 
Mean 5257 3821 11243 7887 
SD 3775 1500 9314 7410 
Table 5. Relationship between treatment mode and required weekly ESA dosage 
Hb was larger in the olHDF group and the required ESA dosage to reach the Hb 
concentration lower (Hb olHDF 7.56± 0.35 mmol/l, HD 7.25± 0.52 mmol/l, p= 0.01; 
ESA/week olHDF 4407± 4660 U/l, HD 6809±7293 U/l, p= 0.1): Table 6. 
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 Dialysis unit Total 1 2 3 
Treatment mode   
40 32 74 146 HD Mean Hb [mmol/L] N 
Mean 7.37 7.16 7.23 7.25 
SD 0.43 0.59 0.53 0.52 
HDF Mean Hb [mmol/L] N 15 . 4 19 
Mean 7.58 . 7.50 7.56 
SD 0.38 . 0.25 0.35 
Mixed Mean Hb [mmol/L] N 39 3 26 68 
Mean 7.56 7.22 7.41 7.49 
SD 0.46 0.11 0.61 0.52 
Total Mean Hb [mmol/L] N 94 35 104 233 
Mean 7.48 7.17 7.29 7.35 
SD 0.44 0.57 0.55 0.52 
Table 6. Relationship between treatment mode and Hb value 
In the olHDF group the intraindividual Hbvar was significantly lower than in HD (HD 
0.66±0.28 mmol/l vs olHDF 0.53±0.16 mmol/l, p<= 0.05): Table 7. 
 








Intra-individual standard deviation of 
the Hb-value 
N 40 32 74 146 
Mean 0.69 0.51 0.71 0.66 
SD 0.29 0.24 0.26 0.28 
All 
patients  
Intra-individual standard deviation of 
the Hb-value 
N 15 . 4 19 
Mean 0.52 . 0.57 0.53 
SD 0.11 . 0.30 0.16 
Table 7. Intra-individual standard deviation of the Hb-values as a function of the treatment 
mode 
In the subanalysis the single pool Kt/V (spkt/V) was >1.2 on average in all centers. But 
there is a significant improvement of spKt/V for olHDF compared to HD (p = 0.04): Table 8: 
 
 Dialysis unit 
Total 
1 2 3 
HD Mean treatment efficacy (spkt/V) N   
Mean 1.46 1.32 1.55 1.48 
SD 0.60 0.29 0.38 0.44 
HDF Mean treatment efficacy (spkt/V) N 15 . 4 19 
Mean 1.57 . 1.82 1.62 
SD 0.17 . 0.52 0.28 
Mixed Mean treatment efficacy (spkt/V) N 38 3 26 67 
Mean 1.48 1.16 1.45 1.45 
SD 0.24 0.04 0.31 0.27 
Table 8. Single Pool Kt/V as a function of the treatment mode 
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Further analyses regarded the relationship between CRP and albumin. The tables 9 and 10 
show the mean levels of CRP and albumin: 
 
 Dialysis units Total1 2 3 
Mean CRP [mg/l] N 87 33 98 218
Mean 15.82 14.77 13.58 14.65
SD 19.48 8.75 9.67 14.30
Min 3.6 4.5 3.1 3.1
Median 10.2 13.1 10.4 10.6
Max 160 47.6 40.5 160
Table 9. Mean CRP level per dialysis unit and overall   
 
 Dialysis unit Total1 2 3 
Mean albumin [g/l] N 93 35 104 232
Mean 40.28 39.44 38.81 39.49
SD 3.10 2.17 2.84 2.93
Min 30.4 35.8 31.0 30.4
Median 40.5 39.6 39.0 39.6
Max 47.1 43.7 45.9 47.1
Table 10. Mean albumin level per dialysis unit and overall 
For all patients the Hb level was negatively correlated to CRP (r= - 0.24, p< 0.0005) and 
positively to Albumin (r= 0.30, p< 0.0001) and TSAT (r= 0.20, p< 0.005): see table 11: 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 

























Table 11. Correlation of the total values for CRP, Albumin and TSAT with Hemoglobin 
In a subanalysis we found significantly larger albumin levels and lower CRP concentrations 
in olHDF vs HD (albumin olHDF 40.63+/-2.23 g/l, HD 39.11± 2.76 g/l, p< 0.05; CRP olHDF 
9.96± 8.28 mg/l, HD 16.07 ±  16.26 mg/l, p< 0.05): Tables 12 and 13: 
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 Dialysis unit Total1 2 3 
Mode   
40 32 74 146HD albumin 
 [g/l] 
N 
Mean 39.89 39.35 38.58 39.11
SD 3.10 2.11 2.72 2.76
HDF albumin 
 [g/l] 
N 14 . 4 18
Mean 40.74 . 40.24 40.63
SD 2.32 . 2.17 2.23
Mixed albumin 
 [g/l] 
N 39 3 26 68
Mean 40.51 40.35 39.24 40.02
SD 3.35 3.06 3.21 3.30
Table 12. Relationship between albumin levels and treatment mode 
 
 Dialysis unit Total1 2 3 
Mode   
39 30 71 140HD CRP 
 [mg/l] 
N 
Mean 18.56 15.52 14.94 16.07
SD 26.70 8.82 10.05 16.26
HDF CRP 
[mg/l] 
N 12 . 2 14
Mean 10.81 . 4.81 9.96
SD 8.68 . 0.22 8.28
Mixed CRP 
 [mg/l] 
N 36 3 25 64
Mean 14.52 7.36 10.43 12.59
SD 10.79 2.55 7.81 9.66
Table 13. Relationship between CRP levels and treatment mode  
4. Discussion 
Our retrospective analysis was performed in three different dialysis centers for 12 months. 
The D1 center had the largest percentage of patients treated with olHDF (olHDF+”mixed”) 
(57 % in D1 vs. 9 % in D2, 29 % in D3).  In D1 the lowest dosage of ESA to reach the Hb 
target was used (Table 2; D1 vs D2 p= 0.003; D1 vs D3 p< 0.0001), the smallest number of D1 
patients were treated with ESA and the time in target was longer than in D2 and D3. In 
addition, it could be demonstrated that in D1 patients the frequency of adaptation of ESA 
dosage and Hbvar were reduced in comparison to the other centers.  
Concerning the ferritin values and the transferrrin saturation (TSAT) there were no 
noticeable differences between the observed centers. But the subanalysis shows a positive 
correlation of the overall TSAT values with the Hb values (p = 0.002, see Table 11) and a 
negative one with the mean ESA consumption (p = 0.05). These results comply with the 
expectation because an improved Hb value is connected with a larger TSAT level and 
reduced ESA needs. 
The treatment efficacy (single pool and equilibrated Kt/V; spKt/V, eKt/V), which was 
measured periodically in the 3 dialysis units, did not show any significant influence on ESA 
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Further analyses regarded the relationship between CRP and albumin. The tables 9 and 10 
show the mean levels of CRP and albumin: 
 
 Dialysis units Total1 2 3 
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Mean 15.82 14.77 13.58 14.65
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Min 3.6 4.5 3.1 3.1
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Max 160 47.6 40.5 160
Table 9. Mean CRP level per dialysis unit and overall   
 
 Dialysis unit Total1 2 3 
Mean albumin [g/l] N 93 35 104 232
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Table 10. Mean albumin level per dialysis unit and overall 
For all patients the Hb level was negatively correlated to CRP (r= - 0.24, p< 0.0005) and 
positively to Albumin (r= 0.30, p< 0.0001) and TSAT (r= 0.20, p< 0.005): see table 11: 
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Table 11. Correlation of the total values for CRP, Albumin and TSAT with Hemoglobin 
In a subanalysis we found significantly larger albumin levels and lower CRP concentrations 
in olHDF vs HD (albumin olHDF 40.63+/-2.23 g/l, HD 39.11± 2.76 g/l, p< 0.05; CRP olHDF 
9.96± 8.28 mg/l, HD 16.07 ±  16.26 mg/l, p< 0.05): Tables 12 and 13: 
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 Dialysis unit Total1 2 3 
Mode   
40 32 74 146HD albumin 
 [g/l] 
N 
Mean 39.89 39.35 38.58 39.11
SD 3.10 2.11 2.72 2.76
HDF albumin 
 [g/l] 
N 14 . 4 18
Mean 40.74 . 40.24 40.63
SD 2.32 . 2.17 2.23
Mixed albumin 
 [g/l] 
N 39 3 26 68
Mean 40.51 40.35 39.24 40.02
SD 3.35 3.06 3.21 3.30
Table 12. Relationship between albumin levels and treatment mode 
 
 Dialysis unit Total1 2 3 
Mode   
39 30 71 140HD CRP 
 [mg/l] 
N 
Mean 18.56 15.52 14.94 16.07
SD 26.70 8.82 10.05 16.26
HDF CRP 
[mg/l] 
N 12 . 2 14
Mean 10.81 . 4.81 9.96
SD 8.68 . 0.22 8.28
Mixed CRP 
 [mg/l] 
N 36 3 25 64
Mean 14.52 7.36 10.43 12.59
SD 10.79 2.55 7.81 9.66
Table 13. Relationship between CRP levels and treatment mode  
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dosage and Hb levels. But the subanalysis calculating the impact of the different treatment 
modes on Kt/V resulted in a significant increased spKt/V for olHDF treatments compared 
with HD (1.62±0.28 for olHDF versus 1.48±0.44 for HD; Table 8).  
Interestingly the correlation analysis also shows a highly significant positive correlation of 
the mean albumin level with the mean Hb values (p < 0.001, Table 11) and a negative one 
with the mean ESA dosage (p = 0.0003). Simultaneously CRP is negatively correlated with 
Hb (p = 0.0004, Table 11). 
The significant difference in albumin concentration most likely played the decisive role for 
ESA dosage and Hb level (Ward, 2005). It is known that in patients who underwent 
convective-diffusive treatment the ESA dosage could be reduced (Vaslaki et al., 2006; 
Bonforte et al., 2002; Eiselt et al., 2000).  That observation was confirmed by our results, 
reaching an economically interesting level of savings in ESA costs: Fig. 1. 
 
 

























Fig. 1. Mean Hb level and ESA dosage HD vs. HDF (ESA: p=0.1, ns., Hb: p=0.01) 
Typically, convective diffusive procedures are characterized by an additional removal of 
hydrophobic middle molecules and protein (albumin) bound uremic toxins depending on 
the membrane characteristics (hydrophobic areas, pore size, adsorptive properties, 
biocompatibility) (Ahrenholz et al., 2004; Panicchi et al., 2008). The loss of protein bound 
substances leads to a membrane determined loss of albumin during olHDF sessions 
(Ahrenholz et al., 2004; Samtleben et al., 2003; Combarnous et al., 2002). In low flux dialysis 
protein removal only occurs with adsorptive membranes (PMMA, polyacrilonitrile) with 
decreasing dialysis efficacy for water soluble toxins (Parzer et al., 1993). This removal of 
albumin can be compensated after a time of about 12 weeks in the absence of relevant 
inflammation (Ding et al., 2002; Kaysen et al., 1997). In chronic ambulant peritoneal dialysis 
protein losses are in-between 6 to 10 g/d and albumin losses up to 5 g/d over the peritoneal 
membrane (Kaysen et al., 1984).  
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Fig. 2. Mean serum albumin concentration HD vs. olHDF (p=0.01)  
Albumin losses during renal replacement procedures are generally thought of being 
unwanted, as low serum albumin correlates with poor outcome in dialysis patients. 
Therefore, olHDF, that technically spoken is an albumin-loosing therapy, might carry the 
danger of exposing the treated patients to threads associated with low albumin levels. 
It is striking that in our analysis the olHDF group had the largest serum albumin concentration 
(Fig. 2, Table 12). All patients of the “mixed” group (containing patients that had switched 
from HD to olHDF) showed an increase in albumin level rather than a decrease. 
Moreover, olHDF can remove proinflammatory substances such as cytokines (Bellomo et al., 
1991; Lee et al., 2004). Again, we could confirm this phenomenon with lower CRP levels in 
the olHDF group vs. HD group (9.96+/- 8.28 mgl/l vs. HD 16.07+/- 16.26 mg/l, p=0.02), see 
Fig. 3, and Table 13: 
 














Fig. 3. Mean CRP concentration HD vs. olHDF (p=0.02) 
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Because albumin is a negative acute phase protein we can, in general, expect higher 
concentrations at lower inflammation (Panicchi et al., 2006; Kaysen et al., 1997). However, 
none-biocompatible membranes and partly low flux hemodialysis increases 
proinflammatory cytokines such as TNF-alpha. Ultrapure dialysis fluid is of relevant 
importance to prevent inflammation (Panicchi et al., 2008). On the other hand complement 
activation plays a role for inflammation during the dialysis sessions therefore biocompatible 
membranes are urgently necessary (Hakim et al., 1984). In the olHDF method as use in this 
study, both ultrapure dialysate and biocompatible membrane materials were used, enabling 
clear attenuation of procedure-associated inflammatory processes. This attenuation of 
inflammation to us seems the key factor for increased albumin production that even makes 
up for procedure-associated albumin losses. The nutritional situation (nPCR) has only a 
secondary influence (Savica et al., 2006; Stenvinkel, 2005). Hbvar also depends on 
inflammation and albumin concentration (Brimble et al., 2007). Hbvar in olHDF is lower 
than in HD because of less inflammation and higher concentration of albumin.  
5. Conclusions 
In a retrospective, descriptive, multicentre study the influence of olHDF on Hb Level, ESA 
dosage and Hbvar was evaluated. 233 patients were included in the clinical analysis in three 
dialysis departments (D1 n=94; D2 n= 35, D3 n= 104). Mean dialysis efficacy expressed as 
spkt/V by Daugirdas was comparable in all dialysis units. We found differences in the 
frequency of olHDF in the dialysis departments followed by varying parameters of 
inflammation (CRP) and nutrition (albumin). It can be demonstrated that patients who 
underwent olHDF showed the highest serum albumin levels and the lowest signs of 
inflammation (CRP). This combination leads to significantly higher Hb concentrations and 
surprisingly lower ESA dosages to reach the target Hb in ol HDF vs HD. Due to the reduced 
inflammation Hbvar was improved in olHDF vs HD. There is a correlation between serum 
albumin concentration, Hb level and ESA dosage. OlHDF could be the gold standard for 
prevention of inflammation because of removal of proinflammatory substances and 
hydrophobic and protein bound uremic toxins. OlHDF influences positively inflammation, 
nutrition, Hb level, Hb variability and required ESA dosage in chronic renal replacement 
therapy.  
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1. Introduction 
Patients with chronic kidney disease and patients on renal replacement therapy, such as 
hemodialysis and peritoneal dialysis, have an increased susceptibility to infectious diseases 
compared with healthy subjects (Sarnak & Jaber 2000; Allon et al. 2003). Infection is also the 
second most common cause of morbidity and mortality in patients with end-stage renal 
disease (Bloembergen & Port 1996; Powe et al. 1999; Graff et al. 2002).  
One contributing factor could be the chronic inflammatory activation seen in patients with 
chronic kidney disease and patients on dialysis, which causes a refractoriness of leukocytes 
when confronted with invading microorganisms. 
1.1 The innate and adaptive immune responses  
The immune system is designed to defend us from invading microorganisms, such as 
viruses and bacteria. The first response is called the innate immune response, mostly 
dependent on recruitment and activation of neutrophils (Parkin & Cohen 2001). 
Complement activation occurs on the bacterial cell surface, triggering a cascade of 
proteolytic reactions that are specific in so far as they act on microbial surfaces but not on 
host cells. Neutrophils have receptors both for common bacterial constituents and for 
complement. Neutrophils become activated through complement (C3b and C5a) but can 
also get activated directly by bacterial peptides, such as lipopolysaccharide, lipotechoic acid, 
mannans and fMLP (N-formylmethionyl leucyl phenylalanine) (Parkin & Cohen 2001).  
Activation of neutrophils occurs in several steps, comprising both priming and further 
activation, and is necessary for neutrophils to perform their specific actions at the 
inflammatory sites: phagocytosis and release of inflammatory mediators (Swain et al. 2002). 
Neutrophils are effector cells of great importance in the innate immune system. An impaired 
neutrophil function leads to several dysfunctions in the defense against invading 
microorganisms. Neutrophils have previously been regarded as wholly differentiated and 
static cells whose function is based on preformed receptors and soluble factors, and solely 
part of the innate immune system. This idea has been challenged by publications that show 
a high gene transcriptional activity following both activation and extravasation (Theilgaard-
Monch et al. 2006). The transcriptional activation occurs at the inflammatory site and 
engages genes involved in multiple neutrophil functions, such as production of reactive 
oxygen species, hydrogen peroxide, cytokines and chemokines (Theilgaard-Monch et al. 
2004; Coldren et al. 2006). Neutrophils direct both innate and adaptive immune responses, 
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by interacting with immune modulating cells (Cohen et al. 2001; Yamashiro et al. 2001; 
Cohen et al. 2003; Theilgaard-Monch et al. 2004). Neutrophil cytokine and chemokine 
production can be an important link between the innate and the adaptive immune 
responses. Cytokine-activated neutrophils produce and release multiple proinflammatory 
cytokines and chemokines, including IL-1, IL-8, monocyte chemotactic protein-1 (MCP-
1/CCL2) and macrophage inflammatory protein-1α and 1β (MIP-1α/MIP-1β). MCP-1 and 
MIP-1α act as chemotactic and activating signals for mononuclear cells, especially 
monocytes, and for mobilization of other cell surface molecules involved in the adaptive 
immune response (Yamashiro et al. 2001; Kobayashi 2008).  
Chemokines attract neutrophils and monocytes from the circulation to the 
inflammatory/infectious site by first making the endothelium more adhesive to the 
circulating cells and then through a chemokine gradient through the tissue leading the way 
to the site of inflammation (Janeway & Travers 2005). Circulating monocytes that 
extravasate and get activated rapidly develop into mature macrophages with the principal 
function of phagocyting microorganisms (Janeway & Travers 2005).  
1.2 Adhesion molecules 
The recruitment and accumulation of monocytes and neutrophils at inflammatory sites is an 
essential step in the defense against invading microorganisms. The process of extravasation, 
when leukocytes slip through the endothelial cells and basement membrane into the 
underlying interstitium and further to the inflammatory site requires the expression of 
adhesion molecules on the endothelium. This serves to initiate leukocyte adherence by 
interaction between adhesion molecules on leukocytes and vascular endothelial cells 
(Johnson-Leger et al. 2000; van Buul & Hordijk 2004). The main families of adhesion 
molecules are the intercellular adhesion molecules (ICAMs); integrins, selectins and 
cadherins (calcium-dependent adherins) (Parkin & Cohen 2001).  
The selectins, P-selectin (PADGEM, CD62P) and E-selectin (ELAM-1, CD62E), are 
membrane glycoproteins with a lectin-like domain that binds transiently to oligosaccharide 
molecules on passing leukocytes after cytokine-mediated activation of the endothelial cells. 
CD62L is present on circulating leukocytes (Janeway & Travers 2005). Selectin binding leads 
to tethering, which allows leukocytes to search the endothelium for the presence of 
activating factors. In a second step, leukocytes bind firmly to the endothelium, followed by 
the process of diapedesis (Albelda et al. 1994). The tighter adhesion is mediated by β2-
integrins CD11a/CD18 (LFA-1) and CD11b (Mac-1 or CR3) expressed on leukocytes after a 
chemokine-mediated conformational change in the integrins. β2-integrins bind to 
intercellular adhesion molecules (ICAM-2 on resting endothelium and ICAM-1 on activated 
endothelium) (Adams & Shaw 1994; Gonzalez-Amaro & Sanchez-Madrid 1999; Janeway & 
Travers 2005). The β1- integrin very late antigen-4 (VLA-4) is present principally on 
mononuclear cells, mediating monocyte transmigration by binding to vascular adhesion 
molecules (VCAM-1) on activated endothelial cells (Chuluyan & Issekutz 1993). 
1.3 Leukocyte adhesion and extravasation 
Leukocyte adhesion is made possible by the action of chemokines: small, structurally related 
molecules that interact with G-protein-coupled receptors. They perform activation of 
integrins in order to confer tight adhesion between leukocytes and endothelial cells, and 
promote the migration of adherent leukocytes across the endothelium and through the 
extracellular matrix (Adams & Shaw 1994). Chemokines are small molecules, divided into 
 
 




Fig. 1. Leukocyte adhesion to the endothelium, subsequent extravasation and 
transmigration through a chemotactic gradient in the interstitium towards a site of 
inflammation. 
 
Fig. 2. Neutrophil adhesion, extravasation and transmigration. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
176 
by interacting with immune modulating cells (Cohen et al. 2001; Yamashiro et al. 2001; 
Cohen et al. 2003; Theilgaard-Monch et al. 2004). Neutrophil cytokine and chemokine 
production can be an important link between the innate and the adaptive immune 
responses. Cytokine-activated neutrophils produce and release multiple proinflammatory 
cytokines and chemokines, including IL-1, IL-8, monocyte chemotactic protein-1 (MCP-
1/CCL2) and macrophage inflammatory protein-1α and 1β (MIP-1α/MIP-1β). MCP-1 and 
MIP-1α act as chemotactic and activating signals for mononuclear cells, especially 
monocytes, and for mobilization of other cell surface molecules involved in the adaptive 
immune response (Yamashiro et al. 2001; Kobayashi 2008).  
Chemokines attract neutrophils and monocytes from the circulation to the 
inflammatory/infectious site by first making the endothelium more adhesive to the 
circulating cells and then through a chemokine gradient through the tissue leading the way 
to the site of inflammation (Janeway & Travers 2005). Circulating monocytes that 
extravasate and get activated rapidly develop into mature macrophages with the principal 
function of phagocyting microorganisms (Janeway & Travers 2005).  
1.2 Adhesion molecules 
The recruitment and accumulation of monocytes and neutrophils at inflammatory sites is an 
essential step in the defense against invading microorganisms. The process of extravasation, 
when leukocytes slip through the endothelial cells and basement membrane into the 
underlying interstitium and further to the inflammatory site requires the expression of 
adhesion molecules on the endothelium. This serves to initiate leukocyte adherence by 
interaction between adhesion molecules on leukocytes and vascular endothelial cells 
(Johnson-Leger et al. 2000; van Buul & Hordijk 2004). The main families of adhesion 
molecules are the intercellular adhesion molecules (ICAMs); integrins, selectins and 
cadherins (calcium-dependent adherins) (Parkin & Cohen 2001).  
The selectins, P-selectin (PADGEM, CD62P) and E-selectin (ELAM-1, CD62E), are 
membrane glycoproteins with a lectin-like domain that binds transiently to oligosaccharide 
molecules on passing leukocytes after cytokine-mediated activation of the endothelial cells. 
CD62L is present on circulating leukocytes (Janeway & Travers 2005). Selectin binding leads 
to tethering, which allows leukocytes to search the endothelium for the presence of 
activating factors. In a second step, leukocytes bind firmly to the endothelium, followed by 
the process of diapedesis (Albelda et al. 1994). The tighter adhesion is mediated by β2-
integrins CD11a/CD18 (LFA-1) and CD11b (Mac-1 or CR3) expressed on leukocytes after a 
chemokine-mediated conformational change in the integrins. β2-integrins bind to 
intercellular adhesion molecules (ICAM-2 on resting endothelium and ICAM-1 on activated 
endothelium) (Adams & Shaw 1994; Gonzalez-Amaro & Sanchez-Madrid 1999; Janeway & 
Travers 2005). The β1- integrin very late antigen-4 (VLA-4) is present principally on 
mononuclear cells, mediating monocyte transmigration by binding to vascular adhesion 
molecules (VCAM-1) on activated endothelial cells (Chuluyan & Issekutz 1993). 
1.3 Leukocyte adhesion and extravasation 
Leukocyte adhesion is made possible by the action of chemokines: small, structurally related 
molecules that interact with G-protein-coupled receptors. They perform activation of 
integrins in order to confer tight adhesion between leukocytes and endothelial cells, and 
promote the migration of adherent leukocytes across the endothelium and through the 
extracellular matrix (Adams & Shaw 1994). Chemokines are small molecules, divided into 
 
 




Fig. 1. Leukocyte adhesion to the endothelium, subsequent extravasation and 
transmigration through a chemotactic gradient in the interstitium towards a site of 
inflammation. 
 
Fig. 2. Neutrophil adhesion, extravasation and transmigration. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
178 
CXC (α-chemokines) and CC (β-chemokines) depending on the positions of two cysteine 
residues (C) relative to other amino acids (X) (Charo & Ransohoff 2006). Chemokines are 
produced by inflammatory cells after stimulation with proinflammatory cytokines or 
bacterial products, and there are both soluble and membrane-bound chemokines, with 
various functions (Parkin & Cohen 2001). Some of the chemokines and cytokines analyzed 
in our study, and their respective functions, are listed in Table 1 and Table 2. 
Leukocyte binding to endothelial cells induces production of signaling molecules in the 
endothelial cells and activation of NADPH oxidase in leukocytes. NADPH oxidase 
promotes production of reactive oxygen species that break down the barrier to leukocyte 
passage between the endothelial cells and through the basement membrane (van Buul & 
Hordijk 2004). PECAM-1 plays an important role in transendothelial migration of 
leukocytes, by inducing phosphorylation of tyrosine in junctional proteins which leads to 
loss of cell-cell adhesion (van Buul & Hordijk 2004).  
When neutrophils extravasate, they produce enzymes (i.e. elastase and other proteases such 
as matrix metalloproteinase-9, MMP-9) that break down extracellular matrix proteins and in 
this way promote leukocyte migration through the interstitium (Hermant et al. 2003).  
The final step of the transmigration is the chemokine concentration gradient, which guides 
leukocytes through the interstitium and towards the inflammatory site. CXCL8 (IL-8) and 
CCL2 (MCP-1) act as chemotactic factors for neutrophils and monocytes, respectively. They 
bind to proteoglycans in the extracellular matrix and to similar molecules on the leukocytes 
(Janeway & Travers 2005).  
Neutrophils and monocytes in blood normally express a low amount of CD11b on their 
surface. Following chemokine-mediated activation of the cells, CD11b is mobilized on the 
cell surface and the molecules are activated in order to display their functions (Adams & 
Shaw 1994; Albelda et al. 1994; Adams & Lloyd 1997; Gonzalez-Amaro & Sanchez-Madrid 
1999). Mobilization of CD11b is important in the process of leukocyte transmigration, 
phagocytosis and complement activation as a response to inflammation/infection (Bainton 
et al. 1987; Borregaard et al. 1987; Miller et al. 1987). 
1.4 Respiratory burst 
The enzyme complex NADPH oxidase promotes the generation of reactive oxygen species 
(e.g. superoxide anions) in leukocytes, in a process referred to as the respiratory burst. 
Respiratory burst is a central mechanism for the leukocyte function of phagocytosis and 
elimination of invading microorganisms (Babior 1999). Superoxide anions are converted to 
hydrogen peroxide in the phagolysosome by the action of superoxide dismutase. In the 
absence of superoxide dismutase, superoxide anions can form the highly aggressive 
oxidative substance peroxynitrite (by reacting with nitric oxide) and hydroxyl radicals 
(Dahlgren & Karlsson 1999; Johnson & Giulivi 2005). 
1.5 Apoptosis 
In early apoptosis, there is a reconformation of the cell membrane, with phosphatidyl serine 
(PS) translocated from the inner surface to the outer leaflet of the cell membrane. 
Fluorescein-conjugated Annexin V binds to PS with high affinity and identifies early 
apoptotic cells. Propidium iodide enters through damaged cell membranes after loss of 
membrane integrity and stains DNA, identifying late stages of apoptosis and secondary 
necrotic cells. PS is identified by phagocytes in the extracellular milieu in order to remove 
the dying cells by phagocytosis. 
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TNF-α (tumor 
necrosis factor-α)
  Produced by macrophages 
and monocytes in acute and 
chronic inflammation. Pro-
apoptotic. Up-regulates 
adhesion molecules on 
endothelial cells. Chemotactic 
factor for monocytes and 





and causes the septic 
syndrome and failure of vital 
organs. 
(Idriss & Naismith 
2000; Janeway & 
Travers 2005) 
IL-6     Inflammatory marker, 
important role in acute 
inflammation and production 
of acute phase proteins from 
the liver. 
(Adams & Lloyd 
1997; Pupim et al. 
2004; Pecoits-Filho et 
al. 2002; Panichi et 
al. 2004) 
Table 2. Cytokines analyzed in our study and their respective functions. 
1.6 Leukocyte dysfunction in chronic kidney disease 
There is a complex state of leukocyte dysfunction in chronic kidney disease patients. The most 
important contributing factors are metabolic and functional abnormalities of leukocytes 
caused by the accumulation of uremic toxins that inhibit leukocyte function. In patients on 
dialysis, another factor influencing leukocyte function is bioincompatibility of the dialysis 
procedure resulting in a dysfunctional inflammatory activation (Lundberg et al. 1994; 
Vanholder et al. 1996; Cohen et al. 2001; Horl 2001; Cohen et al. 2003; Cheung et al. 2008).  
In chronic kidney disease, there is an altered leukocyte adherence to endothelial cells, 
decreased activation of inflammatory cells, impaired phagocytosis and chemotaxis and an 
altered generation of reactive oxygen species and hydrogen peroxide (Gibbons et al. 1990; 
Haag-Weber & Horl 1996b; Horl 2001). Chemokine and cytokine dysregulation in chronic 
kidney disease gives rise to a dysfunctional activation of the immune system (Descamps-
Latscha 1993; Malaponte et al. 2007; Carrero et al. 2008). 
The comorbidity of the patient, such as a state of malnutrition and other chronic diseases, 
also plays an important role in this non-physiological inflammatory activity (Cohen et al. 
1997; Stenvinkel et al. 2000; Pecoits-Filho et al. 2002). A study from our group has 
demonstrated that neutrophils and monocytes from patients with advanced chronic kidney 
disease have an impaired expression of CD11b in the interstitium compared with the 
corresponding cells from healthy subjects (Dadfar et al. 2004b, 2004a). The same result has 
been demonstrated for patients on peritoneal dialysis (Dadfar et al. 2004c). 
1.6.1 Uremic toxins with effects on leukocytes 
There are several uremic toxins that inhibit neutrophil functions, e.g. guanidino compounds, 
granulocyte inhibitory protein I and II, degranulation inhibitory protein I and II (identified 
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as angiogenin and complement factor D), κ- and λ-light chains and chemotaxis inhibitory 
protein (Vanholder et al. 1994b; Haag-Weber & Horl 1996a; Kaysen 2001; Horl 2002; Kaysen 
& Kumar 2003; Cohen & Horl 2009b, 2009a).  
1.6.2 Patients on hemodialysis 
Historically, dialysis has contributed to saving many lives over the years. Without dialysis, a 
uremic patient unavoidably goes towards death. However, the life quality of patients on 
dialysis still has to be improved to develop an optimal treatment. In spite of the process in 
the last years to strive towards more biocompatible materials and methods, including high-
flux dialysis treatment, patients on hemodialysis still display a high morbidity and mortality 
in infections (Bloembergen & Port 1996; Powe et al. 1999; Graff et al. 2002). Neutrophil 
dysfunction in dialysis patients is manifested by reduced chemotaxis, adherence, respiratory 
burst and glucose consumption in response to an inflammatory stimulus (Vanholder et al. 
1993b; Vanholder et al. 1993a).  
The dysfunctional state of inflammatory activation seen in dialysis patients could be caused 
by several different factors (Cheung et al. 1989; Haag-Weber et al. 1991; Descamps-Latscha 
1993; Schindler et al. 2001; Carracedo et al. 2002; Horl 2002; Raj et al. 2002; Kosch et al. 2003; 
Koller et al. 2004). Fragments of bacterial products can be present in small amounts in the 
dialysate and enter the circulation by diffusion through the dialysis membrane (Horl 2002). 
These bacterial fragments activate proinflammatory cytokines such as IL-6, TNF-α and IL-1. 
There is also direct activation of complement factors and of leukocytes by contact with the 
dialysis membrane. Another aspect is the removal of cytokines and other inflammatory 
markers (lipopolysaccharide fragments, granulocyte inhibitory proteins 1 and 2, IL-1, TNF-
α) and complement factors (C3a, C5a) by the hemodialysis procedure as well as the 
adsorption of substances to the hydrophobic high-flux membrane (e.g. factor D) (Clark et al. 
1999; Schindler et al. 2006). Dialysis can reduce leukocyte-endothelial interactions and 
impair transmigration (Thylen et al. 1997). In patients on hemodialysis with cuprophane or 
polysulfone membranes, a significantly higher serum level of MCP-1 is seen compared with 
healthy subjects both before and after the hemodialysis session, independent of the 
membrane used (Jacobson et al. 2000; Thylen et al. 2000).  
Biocompatibility of dialysis membranes probably plays an important role in determining 
leukocyte function in patients on hemodialysis (Himmelfarb et al. 1991; Himmelfarb et al. 
1993; Hernandez et al. 2004; Schindler et al. 2006). High serum levels of cytokines and 
chemokines have been observed in patients on hemodialysis with modified cellulose 
membranes (Descamps-Latscha 1993; Pawlak et al. 2004; Muniz-Junqueira et al. 2005). High-
flux hemodialysis causes lower levels of IL-6 and IL-1β than low-flux hemodialysis or 
dialysis with cuprophane membranes (Schindler et al. 2006). Our group has previously 
demonstrated that neutrophils and monocytes recruited to an induced interstitial 
inflammatory site in patients treated with low-flux bioincompatible hemodialysis have an 
impaired capacity of mobilizing CD11b in response to the induced inflammation, compared 
with the corresponding cells from healthy subjects (Thylen et al. 2000; Jacobson et al. 2002).  
Chronic kidney disease is a state that induces apoptosis, but this is normalized with 
continuous and high-flux hemodialysis modalities (D'Intini et al. 2004; Bordoni et al. 2006). 
This is in accordance with studies showing that dialysis membrane characteristics affect 
leukocyte cell apoptosis (Martin-Malo et al. 2000; Sela et al. 2005; Sardenberg et al. 2006). The 
degree of spontaneous apoptosis of leukocytes is higher when bioincompatible membranes 
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flux hemodialysis causes lower levels of IL-6 and IL-1β than low-flux hemodialysis or 
dialysis with cuprophane membranes (Schindler et al. 2006). Our group has previously 
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with the corresponding cells from healthy subjects (Thylen et al. 2000; Jacobson et al. 2002).  
Chronic kidney disease is a state that induces apoptosis, but this is normalized with 
continuous and high-flux hemodialysis modalities (D'Intini et al. 2004; Bordoni et al. 2006). 
This is in accordance with studies showing that dialysis membrane characteristics affect 
leukocyte cell apoptosis (Martin-Malo et al. 2000; Sela et al. 2005; Sardenberg et al. 2006). The 
degree of spontaneous apoptosis of leukocytes is higher when bioincompatible membranes 
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are used for hemodialysis, than when biocompatible membranes are used (Martin-Malo et 
al. 2000). This higher apoptotic activity in leukocytes is probably due to an antibody-
dependent activation of the complement system caused by the material or structure of the 
dialysis filters. It has been shown that heat-inactivation of complement components results 
in significantly lower apoptosis rates and that bioincompatible membranes cause a higher 
degree of apoptosis than biocompatible membranes (Koller et al. 2004).  
The dialysis membrane permeability and flux are also of importance in determining the 
acute and chronic effects of hemodialysis on the inflammatory system. High-flux 
polysulfone dialysis, as opposed to low-flux polysulfone and cuprophane treatment, has 
been shown to improve the transmigration of circulating neutrophils (Moshfegh et al. 2002). 
High-flux dialysis membranes decrease the levels of the two degranulation inhibitory 
proteins (angiogenin and complement factor D), which could contribute to the maintained 
respiratory burst and phagocytic capacity seen in patients on high-flux hemodialysis (Horl 
2002). There are several molecules, mainly middle-sized molecules, that are cleared to a 
greater extent by convective therapies, such as hemofiltration or hemodiafiltration (Clark et 
al. 1999). Postdilution hemofiltration was the first convective therapy used, and this method 
provides a high clearance of middle- and large-sized molecules but a lower clearance of 
small molecules. Through predilution hemofiltration, with on-line ultrafiltration, the 
clearance of small molecules increased substantially. In hemodiafiltration, convection is 
combined with diffusion, and with this mechanism the clearance of small-, middle- and 
large-sized molecules can be achieved to more or less the same extent (Ledebo 1998).  
A number of previous studies have suggested that the type of dialysis membrane (low-flux 
or high-flux) is associated with differences in long-term outcome of patients undergoing 
hemodialysis, both in terms of morbidity and mortality (Hornberger et al. 1992; Woods & 
Nandakumar 2000; Cheung et al. 2003; Locatelli 2003; Chauveau et al. 2005; Canaud et al. 
2006). However, the results have been conflictive regarding different outcomes. 
The HEMO study, which was the first large randomized clinical trial on patient outcome 
depending on membrane permeability, failed to show any difference in all-cause mortality 
between high-flux and low-flux hemodialysis, except in some subgroups of patients 
(Eknoyan et al. 2002; Cheung et al. 2003; Rocco et al. 2005). Some criticism regarding the 
generalizability of the results from the HEMO study has been raised (Locatelli 2003). 
Important results from the HEMO study indicate that middle-sized molecules, e.g. 
parathyreoid hormone, β2-microglobulin, advanced glycosylation end products, granulocyte 
inhibitory proteins, advanced lipoxidation end products, advanced oxidation protein 
products and leptin (Horl 2002) are associated with systemic toxicity and that their 
accumulation predisposes dialysis patients to severe infections. An increased clearance of 
these molecules, e.g. β2-microglobulin, by high-flux hemodialysis is associated with a lower 
mortality by infectious disease (Cheung et al. 2008). An increased removal of middle-sized 
molecules could also have positive effects of the cardiovascular system (Vanholder et al. 
2001; Vanholder et al. 2008).  
In a Cochrane database review by Rabindranath et al. in 2006, the authors were unable to 
demonstrate a significant advantage with convective therapies over low-flux hemodialysis 
with regard to clinical outcomes such as mortality, dialysis-related hypotension and 
hospitalization (Rabindranath et al. 2006). 
The DOPPS study (Dialysis Outcomes and Practice Patterns Study) revealed that patients on 
high-flux hemodiafiltration had a 35 % lower mortality rate than patients on low-flux 
hemodialysis (Canaud et al. 2006; Canaud et al. 2008).  
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The MPO-study (Membrane Permeability Outcome) was a European randomized clinical 
trial on the effect of high-flux treatment in a large hemodialysis population. It was a 
prospective study which analyzed the long-term effects of membrane permeability on 
clinical outcomes such as mortality, morbidity, vascular access survival and nutritional 
status. The authors of the MPO-study did not find any significant survival benefit overall by 
high-flux hemodialysis versus low-flux hemodialysis. However, for some dialysis 
populations with low serum albumin and for patients with diabetes mellitus, a significantly 
lower mortality rate was observed using high-flux hemodialysis as compared with low-flux 
hemodialysis (Locatelli et al. 2009). 
2. Leukocyte functional studies in patients on high-flux biocompatible 
hemodialysis 
Our research group has described functions of in vivo extravasated monocytes and 
neutrophils from patients on high-flux hemodialysis/hemodiafiltration and healthy subjects 
(Olsson et al. 2007). The objective was to study leukocyte function and specifically, to study 
the up-regulation of CD11b, production of hydrogen peroxide and apoptosis of in vivo 
extravasated monocytes and neutrophils at the site of an induced interstitial inflammation in 
patients on high-flux hemodialysis/hemodiafiltration, compared with healthy subjects. Our 
group has also described the concentrations of important inflammatory mediators for 
neutrophils (IL-8 and MMP-9/NGAL) and monocytes (MCP-1 and MIP-1α) in the 
peripheral circulation and at sites of interstitial inflammation in patients on high-flux 
hemodialysis/hemodiafiltration, compared with healthy subjects (Olsson et al. 2009).  
2.1 Methods for leukocyte functional studies 
The method used was the skin chamber technique, which is well documented and has been 
used by a number of investigators to study transmigration and recruitment of leukocytes at 
the inflammatory site (Scheja & Forsgren 1985; Follin 1999; Thylen et al. 2000; Jacobson et al. 
2002; Theilgaard-Monch et al. 2004; Dadfar et al. 2007; Paulsson et al. 2007). With the skin 
chamber technique, we measured leukocyte functions at time 0 (before the high-flux 
hemodialysis/hemodiafiltration session) and after 10 hours (within which time the high-
flux hemodialysis/hemodiafiltration treatment was performed). The terms intermediate and 
intense inflammation were used to designate the blister stimulated with buffer and with 
autologous serum, respectively. 
Leukocytes were measured with flow cytometry or FACS (fluorescence-activated cell 
sorting) a method in which cells are scanned by a laser and recognized as different cell 
populations through their light-scattering properties. Different leukocyte populations 
(lymphocytes, monocytes and neutrophils) can thus be counted and expressed as a 
percentage of the total leukocyte population. Mean fluorescence intensity (MFI) values for 
the different analyses of cell functions (CD11b expression, hydrogen peroxide formation and 
apoptosis) can also be measured and quantified.  
The CD11b expression on leukocytes, both unstimulated and after stimulation with fMLP, 
was studied through immunostaining. Analysis of leukocyte hydrogen peroxide formation, 
after stimulation with fMLP or PMA, was performed using the 2’, 7’-dichlorofluorescein 
diacetate (DCFH-DA) method. We also stained leukocytes with Annexin V and propidium 
iodide (PI) to identify cells that were in an early or late apoptotic state.  
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The MPO-study (Membrane Permeability Outcome) was a European randomized clinical 
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the up-regulation of CD11b, production of hydrogen peroxide and apoptosis of in vivo 
extravasated monocytes and neutrophils at the site of an induced interstitial inflammation in 
patients on high-flux hemodialysis/hemodiafiltration, compared with healthy subjects. Our 
group has also described the concentrations of important inflammatory mediators for 
neutrophils (IL-8 and MMP-9/NGAL) and monocytes (MCP-1 and MIP-1α) in the 
peripheral circulation and at sites of interstitial inflammation in patients on high-flux 
hemodialysis/hemodiafiltration, compared with healthy subjects (Olsson et al. 2009).  
2.1 Methods for leukocyte functional studies 
The method used was the skin chamber technique, which is well documented and has been 
used by a number of investigators to study transmigration and recruitment of leukocytes at 
the inflammatory site (Scheja & Forsgren 1985; Follin 1999; Thylen et al. 2000; Jacobson et al. 
2002; Theilgaard-Monch et al. 2004; Dadfar et al. 2007; Paulsson et al. 2007). With the skin 
chamber technique, we measured leukocyte functions at time 0 (before the high-flux 
hemodialysis/hemodiafiltration session) and after 10 hours (within which time the high-
flux hemodialysis/hemodiafiltration treatment was performed). The terms intermediate and 
intense inflammation were used to designate the blister stimulated with buffer and with 
autologous serum, respectively. 
Leukocytes were measured with flow cytometry or FACS (fluorescence-activated cell 
sorting) a method in which cells are scanned by a laser and recognized as different cell 
populations through their light-scattering properties. Different leukocyte populations 
(lymphocytes, monocytes and neutrophils) can thus be counted and expressed as a 
percentage of the total leukocyte population. Mean fluorescence intensity (MFI) values for 
the different analyses of cell functions (CD11b expression, hydrogen peroxide formation and 
apoptosis) can also be measured and quantified.  
The CD11b expression on leukocytes, both unstimulated and after stimulation with fMLP, 
was studied through immunostaining. Analysis of leukocyte hydrogen peroxide formation, 
after stimulation with fMLP or PMA, was performed using the 2’, 7’-dichlorofluorescein 
diacetate (DCFH-DA) method. We also stained leukocytes with Annexin V and propidium 
iodide (PI) to identify cells that were in an early or late apoptotic state.  
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Chemokines in skin blister fluids and serum from the peripheral circulation were analyzed 
with commercially available immunoassays (Quantikine®, R&D Systems Inc. Minneapolis, 
MN, USA). All immunoassays were used in accordance with the manufacturer’s 




There was a similar expression of CD11b on monocytes and neutrophils in patients on high-
flux hemodialysis/hemodiafiltration and healthy subjects, both in the peripheral circulation 
and at the three sites of interstitial inflammation. In vitro activation with fMLP induced a 
significant increase in the expression of CD11b on monocytes and neutrophils in the 
peripheral circulation and at the sites of interstitial inflammation, both in patients on high-
flux hemodialysis/hemodiafiltration and healthy subjects.  
The preserved capacity of both monocytes and neutrophils to express CD11b at the sites of 
interstitial inflammation in patients on high-flux hemodialysis/hemodiafiltration, as shown 
by our findings, may have important biological consequences in terms of an adequate 
performance of leukocyte functions in which the CD11b molecule plays a key role (Thylen et 
al. 1997; Moshfegh et al. 2002). Extravasated neutrophils and monocytes from patients on 
high-flux hemodialysis/hemodiafiltration showed a maintained response to fMLP as a 
second inflammatory stimulus after extravasation.  
The mechanism behind this preserved leukocyte function in patients on high-flux 
biocompatible hemodialysis/hemodiafiltration could be the removal of small and middle-
sized leukocyte inhibitory molecules by high-flux hemodialysis/hemodiafiltration 
(Vanholder et al. 1994a), but membrane compatibility could also play an important role.  
2.2.2 Hydrogen peroxide formation 
Results for hydrogen peroxide production in neutrophils and monocytes are displayed in 
Figures 3-6. The findings indicate the presence of a dose-response phenomenon in terms of 
leukocyte function at the site of interstitial inflammation in patients on high-flux 
hemodialysis/hemodiafiltration, which could be due to leukocyte refractoriness when 
encountered with an intense inflammatory stimulus. Refractoriness of leukocytes could be 
caused by previous priming, giving rise to an impaired response to a second activating 
stimulus. 
2.2.3 Apoptosis and cell counts 
There was no significant difference in the total number of leukocytes at the inflammatory 
sites between patients on high-flux hemodialysis/hemodiafiltration and healthy subjects.  
In our study of leukocytes from patients on high-flux hemodialysis/hemodiafiltration, 
leukocytes were studied at their actual site of action, namely after in vivo extravasation. This 
is advantageous, since leukocyte function in patients with chronic kidney disease or on 
dialysis has previously almost exclusively been studied on cells collected from the 
peripheral circulation. 
In both the neutrophil and monocyte populations, we observed no significant differences in 
the percentage of apoptotic cells (Annexin V+ and Annexin V+ PI+) in the peripheral 
circulation or at the sites of interstitial inflammation between patients on high-flux 
hemodialysis/hemodiafiltration and healthy subjects.  
 









































Fig. 3. Respiratory burst in neutrophils at the site of an intermediate interstitial 
inflammation expressed as mean fluorescence intensity (MFI). P is indicated where a 
significant difference is present. 
p < 0.001 
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Fig. 3. Respiratory burst in neutrophils at the site of an intermediate interstitial 
inflammation expressed as mean fluorescence intensity (MFI). P is indicated where a 
significant difference is present. 
p < 0.001 
 














































Fig. 4. Respiratory burst (MFI) in neutrophils at the site of intense interstitial inflammation.  
p < 0.05 
p < 0.01 
p < 0.001 
 









































Fig. 5. Respiratory burst (MFI) in monocytes at the site of intermediate interstitial 
inflammation. No significant difference for any comparison.  
 














































Fig. 4. Respiratory burst (MFI) in neutrophils at the site of intense interstitial inflammation.  
p < 0.05 
p < 0.01 
p < 0.001 
 









































Fig. 5. Respiratory burst (MFI) in monocytes at the site of intermediate interstitial 
inflammation. No significant difference for any comparison.  
 




















Fig. 6. Respiratory burst (MFI) in monocytes at the site of intense interstitial inflammation. 
2.2.4 Concentrations of chemokines 
Patients on high-flux hemodialysis/hemodiafiltration had significantly higher 
concentrations of MCP-1, MIP-1α, IL-6, IL-8, TNF-α and high-sensitivity CRP (hsCRP) in the 
peripheral circulation, prior to dialysis treatment, compared with healthy subjects (Olsson et 
al. 2009). MMP-9/NGAL serum concentration was similar in patients on high-flux 
hemodialysis/hemodiafiltration and healthy subjects (Olsson et al. 2009). Significantly 
higher serum levels of β2-microglobulin and serum amyloid A (SAA) were observed in 
patients on high-flux hemodialysis/hemodiafiltration, compared with healthy subjects. The 
serum concentrations of chemokines, hsCRP, SAA and oxidized LDL were not influenced by 
the high-flux hemodialysis/hemodiafiltration session, while the concentration of β2-
microglobulin was significantly reduced (unpublished data).  
The concentrations of MIP-1α, MMP-9/NGAL and IL-8 at the sites of intermediate and intense 
inflammation were similar in patients and healthy subjects, and the concentration of MCP-1 at 
the sites of intermediate and intense inflammation was significantly higher in patients on high-
flux hemodialysis/hemodiafiltration, compared with healthy subjects (Olsson et al. 2009). At 
the site of intermediate inflammation, the concentration of IL-6 and TNF-α was significantly 
higher in patients compared with healthy subjects, reflecting a high inflammatory activity 
(unpublished data). There were no significant correlations between the concentrations of 
chemokines or the gradient between the concentration in the peripheral circulation and the 
interstitium, and the recruitment of neutrophils and monocytes and their expression of CD11b 
at the site of interstitial inflammation (unpublished data). 
p < 0.05 
p < 0.05 
p < 0.05 
 




In vivo extravasated monocytes and neutrophils from patients on high-flux 
hemodialysis/hemodiafiltration have a preserved capacity to mobilize CD11b, compared 
with the corresponding cells from healthy subjects (Olsson et al. 2007). Furthermore, 
monocytes and neutrophils were able to respond to a second signal (fMLP) at the site of 
interstitial inflammation, indicating an adequate response to bacterial peptides (Olsson et al. 
2007). After the most potent stimulation, both monocytes and neutrophils that had 
extravasated in vivo and been recruited to the site of intense inflammation showed a lower 
capacity to produce hydrogen peroxide in response to activation, compared with the 
corresponding cells from healthy individuals (Olsson et al. 2007). The apoptotic rates of 
neutrophils and monocytes were similar in patients and in healthy subjects (Olsson et al. 
2007). Clearance of leukocytes from the site of infection via apoptosis is essential for the 
coordinated resolution of inflammation. The balance between pro-apoptotic and anti-
apoptotic factors is necessary for the maintenance of an effective immune response without 
the harmful side effects of an excessive neutrophil activation.  
The higher concentration of MCP-1 and equal concentration of IL-8, MMP-9/NGAL and 
MIP-1α at the sites of intermediate and intense inflammation in patients on high-flux 
hemodialysis/hemodiafiltration (Olsson et al. 2009) could be of importance for the 
maintained capacity of leukocytes to extravasate and mobilize CD11b compared with 
healthy subjects (Olsson et al. 2007). These data contrast with our previous studies on 
patients with chronic kidney disease or patients on peritoneal dialysis, in which the 
concentrations of MCP-1 and IL-8 are significantly lower, coupled with an impaired 
capacity to up-regulate CD11b on neutrophils at sites of interstitial inflammation (Dadfar et 
al. 2004c; Dadfar et al. 2004b, 2004a).  
The results of our study support a preserved neutrophil and monocyte function in terms of 
extravasation and activation at the inflammatory focus. One possible explanation for the 
preserved capacity of monocytes and neutrophils to express CD11b in response to an 
interstitial inflammation in patients on high-flux hemodialysis/hemodiafiltration may be 
that the cells extravasate into a milieu which contains equal or higher concentrations of 
factors involved in transmigration and CD11b expression (MCP-1, IL-8, MIP-1α and MMP-
9/NGAL) compared with healthy subjects. The maintained capacity to produce chemokines 
in the interstitium in patients on high-flux hemodialysis/hemodiafiltration may be due to 
an increased intradialytic removal of uremic substances that inhibit leukocyte function. 
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1. Introduction  
In the dialysis clinic, water is an essential vehicle to deliver life-saving treatment to patients 
suffering from varying degrees of kidney failure, both acute and chronic. Clean water is 
vital, as the key ingredient used to prepare hemodialysis fluid (dialysate solution), and on-
line generation of substitution fluid for hemodiafiltration. Generally all fluids used to treat 
patients suffering from kidney failure may come into contact with the blood of the patient, 
whether directly or indirectly (across a membrane), and theoretically could transport 
contaminants resulting in a negative impact on patient health. Of the microbiological 
contaminants found in water, endotoxin is given considerable attention, given its difficulty 
for removal and inactivation from water and water distribution systems (Smeets et al., 2003; 
Perez-Garcia & Rodriguez-Benitez, 2000) and its inherent pyrogenicity (G. Lonnemann, 
2000). 
Endotoxins are found in all gram-negative bacteria, although slight differences in chemical 
structure are found between varying bacterial strains. The term endotoxin is typically used 
to describe a complex of protein and lipopolysaccharide (LPS) molecules found in the outer 
cell wall of gram-negative bacteria, that either slough off during growth, or are released 
upon cell lysis. Endotoxin and lipopolysaccharide are typically used interchangeably in 
literature, although in clinical discussion the term endotoxin is most often used, as it is the 
metric used to monitor water and dialysis fluid quality. Lipopolysaccharide is a vital 
component of the outer membrane of gram-negative bacteria, providing numerous 
physiological functions and comprising nearly 75% of the bacterium outer surface area 
(Raetz, 1991). Lipopolysaccharides consist of three components: a long heteropolysaccharide 
chain (O-specific chain) which represents a surface antigen; a core oligosaccharide; and a 
lipid component termed lipid A used as an anchor in the outer cell membrane (Rietschel et 
al., 1994; Gorbet & Sefton, 2005). Molecular weights of most lipopolysaccharides are 10 – 20 
kDa; however, due to their amphiphilic nature, LPS molecules can form aggregates (100 – 
1000 kDa) which are too large to pass through dialysis membranes. It has been shown that 
components of lipopolysaccharide (lipid A) are able to pass through dialysis membranes, 
can elicit a pyrogenic response (Naveh-Many et al., 1999), and contribute to long-term 
morbidity and inflammation (H. Schiffl, 2000; Raj et al., 2009).  
Lipid A is the most conserved component of lipopolysaccharide throughout all gram-
negative bacteria, and as such is responsible for the majority of the pyrogenic activity. Lipid 
A consists of a phosphorylated N-acetylglucosamine (NAG) dimmer connected to saturated 
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fatty acid chains; variability within the composition of the fatty acids will determine the 
toxic property of lipid A, as well as play a role in resistance to host antimicrobial factors and 
avoiding recognition from specific components of the host immune system (Bland et al., 
1994; Gunn, 2001; Qureshi et al., 1999). The O-specific side chain component of LPS is 
responsible for complement activation and contributes to fever and hypotension, as well as 
binding to endotoxin recognition molecules within the body (Valvano, 1992; Bailat et al., 
1997). Once within the body, LPS tend to be found at higher concentrations within the 
spleen and liver (uptake by phagocytosis) where they are cleared from the body (Haeffner-
Cavaillon et al., 1998).            
Dialysis patients are typically exposed to 90 – 120 liters of dialysis fluid per treatment, which 
equates to an annual exposure of 20 – 30,000 liters (Weber et al., 2004; I. Ledebo, 2002). With 
constant exposure to large amounts of fluid, the opportunity for a dialysis patient to 
experience an inflammatory or pyrogenic reaction due to contamination within the dialysis 
fluid is increased. For hemodialysis, fluids that are used for treatments do not have to be 
sterile; however, the lower the microbial concentration, the lower the risk of patient reaction. 
Because of this risk, regional regulatory boards have implemented limits to the total 
microbial count that can be present in fluids that are to be used in dialysis treatments. 
However, even if water treatment systems are in place, contamination is still a possibility 
and a risk. Dialysis fluid used for clinical treatments may become contaminated from either 
the source water, the dialysate concentrate, or from the water distribution system. Due to 
the ubiquitous nature of biofilm, and its propensity to generate endotoxin, this problem 
affects not only hemodialysis, but all extracorporeal therapies (Kanagasundaram et al., 
2009).     
Regardless of the treatment processes used to create water for dialysis fluid, the final 
opportunity to remove microbial contaminants from the fluid path prior to patient exposure 
is the dialysis membrane contained within the dialyzer. Dialysis fluid comes into direct 
contact with this membrane, and due to transmembrane pressure differences and the 
permeability of the filter, especially for high-flux dialyzers, the potential for dialysis fluid to 
enter the blood compartment and return to the patient is significant (N. Hoenich, 2007). It is 
this final barrier, the dialyzer membrane, where the last opportunity resides to remove 
endotoxins from solution (Weber et al., 2009), by means of membrane manipulation. The 
aim of the following research is to achieve a more thorough understanding of how 
endotoxin interacts with various physical characteristics of the dialysis membrane, and how 
to exploit these interactions to increase endotoxin removal from dialysis fluid. 
2. Membrane manipulation for endotoxin removal 
The degree of contaminated dialysis fluid including bacteria, bacterial fragments and 
endotoxin that may enter the bloodstream of a patient during treatment depends largely 
upon the porosity and other physical characteristics of the membrane being utilized. Back-
filtration is based upon geometrical and permeability properties of the hollow fiber 
membrane, and cannot be avoided in high-flux hemodialysis (Ofsthun & Leypoldt, 1995). 
However, both physical and chemical means can be used to prohibit endotoxin from 
crossing the membrane, by removing it from solution and holding it within the dialyzer 
membrane. Numerous studies have been performed to determine the properties of 
hemodialysis membranes that best manipulate the transfer of endotoxin, by removing it 
from the dialysis circuit (Canaud et al., 2000; Lonnemann et al., 2001). Surface treatments, 
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polymer modifications, as well as chemical changes to the membrane composition, have 
been investigated to ascertain their influence on preventing or minimizing endotoxin and 
bacterial fragment flux across the membrane. Some studies have shown that even the choice 
of sterilization modality may have an impact on the membrane, and affect the ability to 
retain endotoxin (Gomila et al, 2006; Krieter et al., 2008). It is necessary to understand how a 
particular dialysis membrane interacts with endotoxin and other dialysis fluid 
contaminants, as the membrane is the last barrier to the patients’ blood. Endotoxins (and 
other types of microbial contamination) are removed from dialysis fluid mainly by one of 
two methods: filtration and adsorption. Studies have shown that both methods of endotoxin 
removal occur during dialysis treatment (Osumi et al., 1995). Understanding endotoxin 
interactions with various membrane surfaces is imperative in order to orchestrate changes 
that will have a positive impact on endotoxin removal. The end goal of all endotoxin 
research is to limit patient exposure, in hopes of reducing the chance for pyrogenic 
reactions, inflammation, and shock. 
2.1 Membrane geometry 
Prior to synthetic membranes occupying the majority of the dialysis filter market, cellulosic 
membranes were the predominant choice for manufacturers. Cellulose was a material that 
could be modified to improve its biocompatibility; however its geometrical manipulation 
was limited due to the production process. As membrane materials progressed from 
cellulose-based to synthetic, numerous adjustments could be made to the physical 
characteristics of the membrane by relatively simple manufacturing process changes. 
One of the most direct methods to inhibit endotoxin is to change the material structure of 
the membrane itself, as the physical attributes of the membrane will perhaps have the 
greatest effect on endotoxin removal. Typically a thin-wall membrane is not as robust as a 
thick-wall membrane, in terms of endotoxin adsorption, since a thicker membrane can offer 
more surface area for the endotoxin to come into contact with. A thicker membrane provides 
a longer path for the endotoxin to maneuver through, before it reaches the blood circuit. An 
important characteristic of this path from outer membrane surface to inner membrane 
lumen is tortuosity, the curving path that the endotoxin must follow in order to reach the 
blood compartment of the fiber membrane (Osumi et al., 1995). As tortuosity is increased, 
the greater the chance the membrane has at prohibiting the passage of endotoxin. 
Membrane geometry changes can lead to differences in the adsorptive capacity for 
endotoxin (Vanholder & Pedrini, 2008; Vaslaki et al., 2000) and for bacteria (Waterhouse & 
Hall, 1995). 
Changes in membrane permeability are controlled to enhance convective transfer, which 
targets middle molecular removal of species such as β2Microglobulin and vitamin B12. As 
dialysis membranes are pushed for more convective removal ability, the opportunity for 
endotoxin trans-membrane flux increases due to the higher chance of back-filtration. Future 
membranes designed to address middle molecule removal by increasing internal filtration 
(Mineshima et al., 2009) will not improve on patient inflammation (Kerr et al., 2007) unless 
membrane geometry is modified to improve endotoxin removal.  
The effect of membrane thickness and permeability on endotoxin removal was studied by 
testing various membrane configurations, and by observing their ability to restrict 
contaminant flux. Synthetic membranes for testing were manufactured with specific 
geometries to observe their performance relative to a control. Fiber geometries tested 
included low flux, high flux, thin wall, thick wall, macrovoid, and a control. Characteristics 
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of each test membrane produced for this study are listed below in Table 1. The endotoxin 
challenge solution used was comprised of a 1:1 mixture of bacterial culture filtrates of 
Stenotrophomonas maltophilia (ATCC 13637) and Pseudomonas aeruginosa (ATCC 27853), 
both common water organisms. Cultures of each microorganism were ultra-sonicated to lyse 
the cells and release the endotoxin fragments, then filtered using a sequentially-decreasing 
process resulting in a final 0.2 μm filtration step.  
 





Control 185 35 200 Polysulfone (PS), asymmetric 
Low Flux 181 39 48 PS, asymmetric 
High Flux 182 37 522 PS, asymmetric 
Thin Wall 187 24 231 PS, asymmetric 
Thick Wall 184 44 190 PS, asymmetric 
Macrovoid 212 33 130 PS, dual skin 
Table 1. Fiber membrane geometries  
Bacterial culture filtrates were used instead of purified LPS to produce challenge material 
that would closely resemble clinical experiences. Membranes were tested for their ability to 
restrict the passage of endotoxin across the membrane by either filtration or adsorption, by 
using a test setup (Figure 1) that focused on the diffusive and convective aspects of 
hemodialysis. The first setup focuses on diffusive testing, whereby the counter current flow 
mimics a typical hemodialysis treatment. The second setup in the test forces fluid to flow 
through the membrane, testing the filtration capacities of each fiber membrane. Initially, the 
test setup involved connecting the test dialyzer to a recirculating loop, where it could be 
connected to a peristaltic pump to control the flow of fluid on the blood loop. The dialysis 
fluid loop consisted of tubing that was connected to a reservoir, which allowed fluid to be 
recirculated through the dialysis fluid compartment, via another peristaltic pump. This 
reservoir held 1 liter of challenge solution, containing bacterial culture filtrate mixed into 




Fig. 1. Endotoxin challenge test setup, showing the blood loop and dialysis fluid loop 
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peristaltic pump was set at 200 mL/min to recirculate the enclosed saline, while the dialysis 
fluid loop pump was set at 500 mL/min to recirculate the endotoxin challenge solution from 
the reservoir, through the dialyzer, and back. This test setup was maintained inside an 
incubator set at 37 C. Prior to starting the test, the dialyzer (both blood loop and dialysis 
fluid loop) were primed with sterile saline, to rinse out any residual endotoxin that may be 
contained within the test setup. Once the pumps were initiated, a timer was started and 
samples were taken from both the blood loop and dialysis fluid loop at the following times: 
0, 7, 15, and 60 minutes. Following the 60 minute sample, the test setup was changed 
according to Figure 1, so that dialysis fluid was forced across the membrane into the blood 
loop, and back into the challenge reservoir. Again, samples were taken following the start of 
the second half of the experiment at 67, 75, and 120 minutes. Samples were kept refrigerated 
at 4 C until ready to be analyzed for endotoxin content.  
Endotoxin activity was measured using a kinetic turbidimetric Limulus Amoebocyte Lysate 
(LAL) assay from Charles River Labs. Each sample was measured in duplicate, along with a 
positive control to verify recovery within the sample. Results from these tests are shown in 
Figure 2, with curves to represent both blood side and dialysis fluid side endotoxin 
concentrations. The data were able to show that only the control and thick wall membranes 
were able to contain the endotoxin in the blood side below < 0.1 EU/mL; all other 
membrane types allowed measurable amounts of endotoxin to cross into the enclosed blood 
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Fig. 2. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 
b) Low and High Kuf membranes; c) Thin, Thick Wall membranes; d) Macrovoid 
membrane. 
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of each test membrane produced for this study are listed below in Table 1. The endotoxin 
challenge solution used was comprised of a 1:1 mixture of bacterial culture filtrates of 
Stenotrophomonas maltophilia (ATCC 13637) and Pseudomonas aeruginosa (ATCC 27853), 
both common water organisms. Cultures of each microorganism were ultra-sonicated to lyse 
the cells and release the endotoxin fragments, then filtered using a sequentially-decreasing 
process resulting in a final 0.2 μm filtration step.  
 





Control 185 35 200 Polysulfone (PS), asymmetric 
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Thick Wall 184 44 190 PS, asymmetric 
Macrovoid 212 33 130 PS, dual skin 
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contained within the test setup. Once the pumps were initiated, a timer was started and 
samples were taken from both the blood loop and dialysis fluid loop at the following times: 
0, 7, 15, and 60 minutes. Following the 60 minute sample, the test setup was changed 
according to Figure 1, so that dialysis fluid was forced across the membrane into the blood 
loop, and back into the challenge reservoir. Again, samples were taken following the start of 
the second half of the experiment at 67, 75, and 120 minutes. Samples were kept refrigerated 
at 4 C until ready to be analyzed for endotoxin content.  
Endotoxin activity was measured using a kinetic turbidimetric Limulus Amoebocyte Lysate 
(LAL) assay from Charles River Labs. Each sample was measured in duplicate, along with a 
positive control to verify recovery within the sample. Results from these tests are shown in 
Figure 2, with curves to represent both blood side and dialysis fluid side endotoxin 
concentrations. The data were able to show that only the control and thick wall membranes 
were able to contain the endotoxin in the blood side below < 0.1 EU/mL; all other 
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Fig. 2. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 
b) Low and High Kuf membranes; c) Thin, Thick Wall membranes; d) Macrovoid 
membrane. 
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diffusive endotoxin flux than convective endotoxin flux, and vice versa. In particular, the 
high flux and thin wall membranes allowed the highest amounts of endotoxin into the blood 
compartment, as these membranes present the shortest tortuous path (thin wall) and the 
highest potential for back-diffusion along the membrane (high flux). These findings suggest 
that asymmetric, thick membranes are better suited at removing endotoxin from solution, as 
well as allowing endotoxin and other pyrogenic substances from crossing the membrane 
and contaminating a patient blood-flow.    
Not only is a thick fiber good at preventing endotoxin contamination to the patient, but the 
outer or inner membrane surface of the fiber membrane are imperative at preventing trans-
membrane endotoxin flux. Pore size distribution, or surface morphology, is a strictly 
controlled process in how to determine the flux of the dialyzer, and in allowing molecules of 
a certain size to either pass through the membrane surface, or be retained. Dialysis 
membrane pore sizes are not manufactured with endotoxin transfer in mind; however the 
pores play a critical role in regulating trans-membrane passage. Membrane thickness, 
structure, and surface morphology influence the membranes’ ability in preventing 
endotoxin transfer through geometrical means, mostly by way of filtration. However, 
chemical changes within the membrane can also add benefits towards increased endotoxin 
performance, with respect to removal by way of adsorption.      
2.2 Membrane surface changes 
Similar to how membrane geometry directly affects the endotoxin sieving ability, the surface 
properties of membranes will govern the adsorption capacity for endotoxin by providing a 
suitable surface for endotoxin and endotoxin fragments to adsorb by utilizing their 
amphiphilic nature. The hydrophobic lipid A moiety is typically attracted to hydrophobic 
surfaces, however the hydrophilic polysaccharide component will also allow for adsorption 
to hydrophilic surfaces (Takemoto et al., 2003). Recent studies have shown this to be the 
case, particularly for ultrafilters which remove endotoxin by way of adsorption through 
ionic and hydrophobic interactions (Vaslaki et al, 2000). When adjusting the polymer ratios 
of dialysis fiber membrane, chemical changes as well as physical changes can be produced. 
The overall geometry of the fiber can be manipulated by the polymer ratio – whether the 
fiber is based upon a sponge structure, whether the membrane possesses macrovoids, or 
whether the membrane exhibits one skin or two.  
Synthetic dialysis membranes from polysulfone are typically hydrophobic in nature, thus 
adding to their ability in being a good hemocompatible membrane for blood interaction. 
When manufacturing such membranes it is necessary to utilize a hydrophilic polymer that 
allows for the membrane to “wet”; to possess hydrophilic regions or properties. By simply 
adjusting the ratio of hydrophobic polymer (polysulfone) to hydrophilic polymer 
(polyvinylpyrrolidone or PVP), the membrane hydrophobicity composition can be changed 
significantly. A membrane that incorporates varying regions of hydrophobicity may be able 
to exploit the amphiphilic nature of endotoxin, resulting in numerous opportunities to 
remove it from dialysis fluid via adsorption (Maitz et al., 2009). Enhanced endotoxin 
removal has been shown feasible by increasing the surface polarity of the membrane 
(Rimmele et al, 2008). Polysulfone membranes typically exhibit a net negative surface 
charge, termed zeta potential, which may aid in their ability to remove endotoxin through 
adsorption (Mares et al, 2009; Shao et al., 2007). Similar behaviors are witnessed when 
endotoxin solutions are kept in glass containers; the glassware adsorbs a portion of the 
endotoxin, thus necessitating the glass to be cleaned or “depyrogenated.” 
 
Dialysis Membrane Manipulation for Endotoxin Removal 
 
203 
A special consideration to not overlook is where dialysis clinics practice reuse; numerous 
studies have investigated the effect of reprocessing agents on dialysis membrane 
performance and the resulting effect on endotoxin retention (Teehan et al., 2004; Sundaram 
et al., 1996). For those using bleach as a disinfectant and sterilizing agent, its use has to be 
taken into account as repeated exposure to membranes have been shown to increase solute 
clearance, as well as increase the net negative charge, thus increasing hydrophilicity (Shao et 
al., 2007).   
Polymer mixes were varied for test membranes, to study the endotoxin removal 
performance based upon chemical surface changes. Membranes, manufactured for this 
study, included those composed of high and low PVP content, a membrane consisting of a 
polymer mixture (polysulfone, PEG) and a membrane exposed to bleach – to determine how 
fiber surface differences affect the overall ability to remove endotoxin from solution. Also, 
membranes were tested using a fluorescent-labeled endotoxin to show the distribution of 
endotoxin within the membrane, modified from prior studies (Hayama et al., 2002). The 
experimental test setup was similar to that used to test fiber geometries – the test 
environment temperature, blood loop and dialysis fluid loop flow rates, endotoxin 
challenge concentration, and sample analysis method were all kept constant as described 
previously.  
An additional test was performed for these membranes, using a labeled endotoxin to identify 
where the endotoxin molecule is removed from solution within the fiber membrane. To 
accomplish this, miniature dialyzers were constructed of small polycarbonate housings and 
T’s to create a membrane dialyzer that could filter a smaller volume of fluorescent challenge 
solution, a mixture of Alexa Fluor 568 (Invitrogen, Carlsbad, CA) in saline to produce a 
concentration of 2,000 EU/mL. Membranes were challenged using a test setup similar to the 
diffusive setup used for the endotoxin challenge simulations, utilizing a challenge fluid flow 
on the dialysis fluid side of 5 mL/min, and a countercurrent fluid flow of saline on the blood 
side of 2 mL/min. Upon completion of the diffusive test, fibers were extracted from the 
miniature dialyzer housings and fixed into freezing media. A cryostat was used to slice the 
membrane samples into 10 um sections, which were then imaged using a microscope fit with a 
resorufin filter to observe the distribution of endotoxin on the membrane.  
Membrane permeability tests (Figure 3) were able to show how the bleached membrane, the 
high PVP content membrane, as well as the polymer mixture membrane, all allowed   
significant amounts of endotoxin to cross into the blood loop compartment. Fluorescent 
imaging revealed that for all membranes the majority of the endotoxin (highest intensity) 
was bound at either the inner or outer lumen of the fiber; also, differences could be seen in 
the distribution of endotoxin inside the bulk of the membrane, with some membranes 
showing high intensity, while others hardly could be imaged due to the low intensity of the 
endotoxin (Figure 4). 
These results indicate that chemical changes to the membrane can be manipulated in order 
to direct the preferential adsorption of endotoxin in a discreet region of the fiber, such as the 
outer lumen or inner lumen. These types of changes may be beneficial depending upon the 
intended use of the membrane, such as dialysis or ultrafiltration. Researchers have 
postulated that the region within the membrane where endotoxin is removed is important, 
as it has been shown to induce cytokine activation in blood within a dialyzer when bound 
adjacent to the lumen surface (Okamoto et al., 2004). These test results also provide insight 
into the nature of where and how endotoxin is bound or adsorbs to the membrane, 
furthering our understanding in how to remove it from solutions.  
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Fig. 3. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 




           
Fig. 4. Fiber membrane sections showing the distribution of fluorescent-labeled endotoxin 
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2.3 Membrane material 
The type of membrane structure possible, which directly relates to the endotoxin removal 
mechanism (filtration, adsorption), is largely governed by the material used to produce the 
membrane. Polysulfone is currently the most common membrane material in the chronic 
dialysis market, but is only one of several choices available to patients and nephrologists. 
Dialysis membranes may also be produced from materials such as cellulose, poly methyl 
methacrylate (PMMA), polyester-polymer alloy (PEPA), polyethersulfone, polyamide, and 
cuprophane. Use of cuprophane membranes modified with vitamin E (Girndt et al., 2000), 
highlight the potential for modifications of specific membrane materials.  Significant research 
has been produced to show superior performance for endotoxin removal by synthetic 
membranes (Yamamoto & Kim, 1996; Nube & Grooteman, 2001); however, research has also 
exploited differences in the capacity for endotoxin between membranes of the same material, 
indicating that slight differences in the manufacturing and finishing processes may have a 
significant impact on the ultimate performance (Opatrny Jr. et al., 2006). On the contrary, 
studies have shown that in some instances it is difficult to show a clinical benefit when 
comparing differing membranes (Boudville et al., 2009; Urena et al., 1992).  
The effect of various fiber membrane materials on endotoxin retention was studied by 
testing polysulfone, cellulose triacetate, and polyethersulfone dialysis membranes using 
endotoxin permeability studies. An endotoxin challenge of 400 ± 50 EU/mL was created by 
spiking sterile saline with bacterial culture filtrates of a 1:1 mixture of P. aeruginosa (ATCC 
27853) and S. maltophilia (ATCC 13637). Simulation experiments were conducted to assess 
endotoxin transfer under both diffusive and convective conditions, with sterile saline used 
to model blood in the blood-side circuit. Flow rates used were similar to prior studies (QB = 
200 mL/min, QD = 500 mL/min) and the experimental temperature was kept constant at 37 
C. Samples were taken at times similar to prior studies, and were analyzed using a kinetic 
turbidimetric LAL assay with a detection limit of 0.1 EU/mL.    
The results from these studies (Figure 5) show sponge-structure polysulfone performed the 
best at prohibiting endotoxin to cross the membrane, under diffusive and convective 
hydraulic conditions. Cellulose triacetate and polyethersulfone both allowed endotoxin to 
cross into the inner lumen space of the membrane; it is unclear if these results are 
indications to limits of endotoxin removal regarding the fiber lumen (pore size) or lumen 
surface adsorption. Material choice will dictate what type of endotoxin removal will 
predominate – filtration or adsorption – as certain materials will produce specific structure 
geometries when undergoing the manufacturing process.  
Also, material choice will determine if a membrane is a good candidate for a particular 
coating or surface treatment to be applied; to aid in either creating a more biocompatible 
surface, or to enhance the endotoxin retentive properties.   
2.4 Membrane coatings 
Membrane coatings or surface treatments are not usually found on general use dialyzers; 
rather, they are used to add enhancements to dialyzers to better help a niche group of 
patients – whether the need is improved biocompatibility, better anticoagulation, or a 
reduction in circulating inflammatory cytokines. Surface treatments or coatings could be 
used to remove endotoxin; however, no coatings for dialyzer membranes (to date) have 
been produced to directly address endotoxin adsorption or removal. A coating which could 
produce a mixture of hydrophobic and hydrophilic regions would increase the adsorptive 
capacity of the membrane to retain circulating endotoxin – and at the same time may aid in 
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filtrative endotoxin removal. Coatings applied to the membrane post-production should be 
designed to not decrease/impede any solute clearance performance of the membrane, or 
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Fig. 5. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane 
(PS); b) Polysulfone, low-flux and high-flux; c) Cellulose, CTA and PEG coated; d) 
Polyethersulfone, low-flux and high-flux. 
Charcoal suspension has been tested as a potential adsorbent for diaysis, although it has 
been shown to induce platelet activation (Kramer et al., 2000). One significant area of 
research on endotoxin adsorption is for septic patients. Numerous techniques have been 
tested to remove circulating inflammatory cytokines from patient blood, as well as remove 
endotoxin. Polymyxin-B has been studied as an endotoxin binder, due to its affinity to the 
lipid A component and as it disrupts the permeability of cytoplasmic membranes of Gram 
negative bacteria (Uriu et al., 2002; Jaber & Pereira, 1997; Tani et al., 1998).  Polyethylenimine 
has been researched as a potential endotoxin adsorbent, and may be more compatible than 
other types of resins in similar applications (Mitzner et al., 1993). The most prevalent 
treatment is to use apheresis and hemoperfusion, removing specific targets by resins or 
coated fibers (Ronco et al., 2000; Szathmary et al., 2004; Yaroustovsky et al., 2009; Umgelter 
et al., 2008). Some of these endotoxin-specific adsorbents that have been proven effective 
may come with deleterious side effects (Steczko et al., 1999; Tani et al., 1998).  
Efficacy of a potential endotoxin-specific coating application was investigated by treating 
standard dialysis membranes with two specific polysaccharides (neutral and positive 
charged chitosan), a tri-block copolymer, and by using a bleach rinse. These modified 
membranes were tested for their endotoxin retention capacity by using the endotoxin 
simulation procedure described previously, with the same flow rates (QB = 200 mL/min, QD 
= 500 mL/min) and an endotoxin dialysis fluid challenge of 440 ± 55 EU/mL. However, the 
duration of the experiment was extended to 6 hours (3 hrs. diffusive, 3 hrs. convective) to 
observe if any plateau of endotoxin filtration or adsorption were to occur. Sampling from 
the blood and dialysis fluid circuits occurred at the following times (minutes): -5, 0, 7, 15, 30, 
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and every 30 minutes afterwards until 3 hours had transpired. Samples were analyzed for 
endotoxin activity using a kinetic turbidimetric LAL assay with a detection limit of 0.1 
EU/mL.  
Results obtained from the test dialyzers with membrane coatings are shown in Figure 5, 
showing the endotoxin profile curves for the full 6 hours of testing. Samples analyzed from 
the chitosan and +chitosan membranes exhibited inflated spike recovery samples, indicative 
of false positive readings. It is likely that polysaccharide leaching out of the coating and into 
the recirculating saline solution in the blood compartment compromised the integrity of the 
samples. It is likely that the actual endotoxin crossing into the blood compartment for the 
chitosan and +chitosan samples is lower, however the overall endotoxin reduction in the 
dialysis fluid compartment did not justify repeating the tests using a buffering agent to 
mask the effects of the polysaccharides. The findings suggest that while all of the 
investigative treatments did enhance the removal of endotoxin, some were more successful 





























































































Fig. 5. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane; 
b) Bleach treated membrane; c) Chitosan, +Chitosan coated membranes; d) Polymer coated 
membrane. 
Follow-up experiments were conducted to further observe the ability of each membrane 
coating at adsorption of endotoxin by exposing each test membrane to a semi-static 
adsorption environment. Fiber membranes were extracted from test dialyzers, placing 35 
cm2 of each fiber type into a series of 50 mL conical tubes. Each tube was filled with 50 mL 
of sterile saline, and then spiked with varying amounts of endotoxin resulting in a gradient 
of concentrations for each membrane type (1, 2.5, 5, 10, 20, and 50 EU/mL). These tubes 
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filtrative endotoxin removal. Coatings applied to the membrane post-production should be 
designed to not decrease/impede any solute clearance performance of the membrane, or 
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Fig. 5. Endotoxin challenge results for test simulations (all tests, n=3). a) Control membrane 
(PS); b) Polysulfone, low-flux and high-flux; c) Cellulose, CTA and PEG coated; d) 
Polyethersulfone, low-flux and high-flux. 
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and every 30 minutes afterwards until 3 hours had transpired. Samples were analyzed for 
endotoxin activity using a kinetic turbidimetric LAL assay with a detection limit of 0.1 
EU/mL.  
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of false positive readings. It is likely that polysaccharide leaching out of the coating and into 
the recirculating saline solution in the blood compartment compromised the integrity of the 
samples. It is likely that the actual endotoxin crossing into the blood compartment for the 
chitosan and +chitosan samples is lower, however the overall endotoxin reduction in the 
dialysis fluid compartment did not justify repeating the tests using a buffering agent to 
mask the effects of the polysaccharides. The findings suggest that while all of the 
investigative treatments did enhance the removal of endotoxin, some were more successful 
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b) Bleach treated membrane; c) Chitosan, +Chitosan coated membranes; d) Polymer coated 
membrane. 
Follow-up experiments were conducted to further observe the ability of each membrane 
coating at adsorption of endotoxin by exposing each test membrane to a semi-static 
adsorption environment. Fiber membranes were extracted from test dialyzers, placing 35 
cm2 of each fiber type into a series of 50 mL conical tubes. Each tube was filled with 50 mL 
of sterile saline, and then spiked with varying amounts of endotoxin resulting in a gradient 
of concentrations for each membrane type (1, 2.5, 5, 10, 20, and 50 EU/mL). These tubes 
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were then fixed to a rotor in a 37 C environment, which provided thorough mixing for the 
test duration of 72 hours. Samples were taken at set intervals, and analyzed immediately 
using the kinetic turbidimetric LAL assay with a detection limit of 0.01 EU/mL. Data 
gathered from these tests were used to generate adsorption isotherms for each membrane, 
shown in Figure 6. These plots indicate that the polymer coated membrane removed more 
endotoxin, and at a higher rate, than both the bleach treated and control membranes. For all 
three test membranes, adsorption rates for the 1 and 2.5 EU/mL concentrations reached a 
plateau at about 60 hours, although at 72 hours the 20 and 50 EU/mL concentrations were 
still showing measurable adsorption of endotoxin. The adsorption rates were calculated as 
follows: control – 0.15 ml/cm2*hr; bleach – 0.11 ml/cm2*hr; polymer – 0.30 mL/cm2*hr. The 
results from the polymer coated membrane are promising, given that the adsorption rate of 
endotoxin was twice that of the control. These findings suggest that endotoxin-specific 
coatings for dialysis or ultra filtration membranes are a theoretical possibility, and may aid 





















































































Fig. 6. Adsorption isotherm curves calculated for control, bleach treated, and polymer 
coated membranes. Curves were calculated from endotoxin challenge solutions of 1, 2.5, 5, 
10, 20, and 50 EU/mL. Correlation coefficients for the control, bleach treated, and polymer 
coated membranes were r2 = 0.991, r2 = 0.994, and r2 = 0.989, respectively. 
 




Patient health, as it relates to hemodialysis treatment, is of the utmost importance as the 
mortality and morbidity of ESRD patients is typically high. A strong push recently has been 
to move to the use of ultrapure dialysate in clinics, as studies have shown correlations 
between improvements in markers of inflammation and the use of dialysis fluid meeting the 
criteria of <0.1 CFU/mL and <0.03 EU/mL (Lonnemann & Kock, 2002; Ledebo, 2007a; 
Schindler, 2009; Schiffl et al., 2002). As some studies have shown that typical endotoxin 
concentrations are higher in dialysis fluid than RO water entering the hemodialysis machine 
(von Sengbusch et al., 1993), the ultrapure criteria of the dialysis fluid needs to be created 
just prior to the patient receiving treatment.  One method to produce and ensure the 
production of ultrapure dialysis fluid is to place an ultrafilter in the hydraulic path between 
the patient and the dialysis machine, as this filter will have the greatest impact to the final 
dialysis fluid solution prior to entrance into the dialyzer (Oliver et al., 1992; Schindler et al., 
2004).  
Studies in the literature have revealed significant removal rates for ultrafilters in vitro, 
typically >99% for endotoxin (Oliver et al., 1992; Krautzig et al., 1996), with log reduction 
values >3 desirable (Tsuchida et al., 2009). Ultrafilters are commonly used in HDF, where 
two filters are typically used in series to guarantee sterile fluid production – manufacturers 
of ultrafilters state that sterility of substitution fluid is only guaranteed if the machine feed 
water falls within certain criteria (Penne et al., 2009). However, as ultrafilters are exposed to 
disinfection agents and cleaning cycles their efficacy in removing endotoxin is reduced. A 
desirable application would be a novel surface treatment or coating that would enhance 
endotoxin removal, while able to resist efficiency loss induced by age and chemical 
exposure. Durable membranes have been studied, with some researchers looking at ceramic 
or alumina membranes. As these membranes do perform well in retaining endotoxin, their 
expense in manufacturing seems to limit their application, as well as some membranes have 
been shown to leach aluminum when cleaned with NaOH (Bender et al., 2000).    
The goal of endotoxin removal is ultimately to reduce patient inflammation, as 
contaminated dialysate has been linked to the systemic micro-inflammatory state observed 
in many hemodialysis patients (Ouseph et al., 2007). Other studies have reported links 
between inflammation and cardiovascular disease (CVD) in hemodialysis patients (Merino 
et al., 2008; Wang et al., 2011; Kerr et al., 2007), while some have shown association between 
inflammation and nutritional status (Raj et al., 2009), implicating the breadth of influence 
caused by repeated endotoxin exposure. As more ESRD patients are treated with high-flux 
dialysis membranes, the opportunity increases for bacterial contaminants in dialysis fluid to 
cross the membrane into the blood and activate numerous cell types, releasing pro-
inflammatory cytokines which heighten the inflammatory condition  (Vanholder et al., 1992; 
Almeida et al., 2006). This is also the case in the acute market, as membranes with increased 
permeabilities are being used in ARF for their higher clearances of cytokines (Haase et al., 
2007; Vanholder et al., 2000); these patients will have higher risks for endotoxin 
contamination, based upon the membrane flux.  
Aside from removal, advances in the detection of endotoxin and other pyrogenic substances 
at low concentrations would further propel endotoxin research forward by providing 
researchers tools to better distinguish bacterial contaminant changes, or by making highly 
sensitive endotoxin detection available to clinics to provide advanced microbiological 
observation of their water systems. Specific research in this field has focused on the efficacy 
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researchers tools to better distinguish bacterial contaminant changes, or by making highly 
sensitive endotoxin detection available to clinics to provide advanced microbiological 
observation of their water systems. Specific research in this field has focused on the efficacy 
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of utilizing photometry to detect and measure endotoxin in patient plasma samples 
(Nakazawa et al., 2010), which would have direct impact on research clinics and for septic 
patients. PCR techniques have also been utilized for their application to dialysis research, by 
analyzing total flora in dialysis water via the 16s rDNA. As this technique guarantees a high 
degree of detection, it does not specify whether bacteria or live or dead, or what species are 
prevalent within the sample (Nystrand, 2006).      
4. Future work 
Studies involving endotoxin in hemodialysis have been going on for quite some time – 
covering how to prevent and remove biofilm from water distribution systems, how 
endotoxin interacts with the body, and how to increase removal efficiencies. Going forward, 
future work may involve identifying new bacterial contaminants that cause adverse patient 
reactions, but may not be identified by the LAL assay (Glorieux et al., 2009). There are a 
number of smaller bacterial components released during cell lysis, with bacterial DNA 
fragments recently receiving considerable attention in research studies (Handelman et al., 
2009; Schindler et al., 2004). Some of these studies have shown a correlation between bDNA 
fragments present in patient blood, and higher levels of CRP and IL-6 (Bossola et al., 2009). 
Current limitations in endotoxin quantitative methodology, which influence how bacterial 
contaminant results and target values are interpreted (Ledebo, 2007b) will hopefully be 
improved upon and expanded to cover additional areas of focus in ESRD treatment.  
The future of any therapy used to treat patients with ESRD needs to focus on the associated 
mortality and morbidity influencing factors. Whether ESRD therapy will focus on smaller, 
wearable devices (Gura et al., 2008; Ronco & Fecondini, 2007), strive for increases in home 
treatment (Moran, 2009), or devices utilizing living cells (Humes et al., 2006), the effect of 
endotoxin must be taken into account for each application – and to address the specific 
actions necessary to remove endotoxin thus ensuring patient safety. Future progress in 
endotoxin research will hopefully alleviate inflammation-related complications, and 
improve patient outcomes for all aspects of ESRD.  
5. Conclusion 
In conclusion, endotoxin contamination of fluid for dialysis therapy is an important aspect 
of patient safety and well-being. Regardless of the microbiological quality of the water 
coming into the hemodialysis machine, the dialysis membrane is the final barrier between 
potentially contaminated dialysis fluid, and the blood of the patient. We have examined 
how manipulation of specific fiber membrane parameters (geometric properties, materials, 
coatings, chemical modifications) can be utilized to improve the endotoxin retentive 
properties to limit trans-membrane flux, whether they contribute to adsorptive 
improvements, sieving improvements, or both. Membrane structure, surface chemistry, 
material, and surface coatings all have an impact on how endotoxin is filtered and adsorbed 
from solution. In addition to better understanding endotoxin-membrane interactions, 
studies of endotoxin removal by membrane modifications will result in better approaches to 
manufacture dialysis membranes that remove endotoxin from solution quickly and with 
improved efficiency. 
As future hemodialysis membranes are designed to further improve upon convective 
removal of larger middle molecular solutes such as B2M, the opportunity for pyrogenic 
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materials to enter the blood stream via back filtration becomes greater. An improved 
comprehension of how endotoxin is removed using a fiber membrane can lead to new 
improvements and future product designs, by streamlining concepts from development to 
production.   
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1. Introduction 
In hemodialysis, the patient’s blood is flown through an extracorporeal circuit containing a 
hemodialyzer. This process stimulates coagulation for several reasons, most notably the 
blood’s contact with the artificial surfaces of the tubing and dialyzer membrane and with air in 
the venous bubble trap, turbulent and stagnant blood flow, shear stress and 
hemoconcentration during the treatment [1]. Technological advances, e.g., the development of 
air-free blood circuits and more biocompatible materials for both tubing and dialyzer 
membranes, may eventually help reduce thrombogenicity of the extracorporeal circuit but are 
unlikely to eliminate this problem anytime soon. As a result, anticoagulation is (and will be, 
for the years to come) generally required for hemodialysis in the vast majority of patients. 
In most cases in the United States, unfractionated heparin is the agent of choice to provide 
dialysis anticoagulation. While this is usually well-tolerated and relatively safe, there are 
significant drawbacks. The most obvious of these is that the anticoagulation is systemic in 
nature, which translates into an increased bleeding risk. This is certainly undesirable in end-
stage renal disease patients, who are already afflicted with uremic thrombocytopathy, and it 
is particularly dangerous for patients with additionally increased bleeding risk, e.g., patients 
after surgery or trauma, and patients with active (e.g., gastro-intestinal) bleeding. Another 
possible complication related to heparin use, albeit rare in dialysis patients, is heparin-
induced thrombocytopenia (HIT) type II [2], a potentially life-threatening condition 
associated with a mortality rate of 8 to 20 percent. Other possible side-effects of heparin use 
include osteoporosis, hair loss, and hyperlipidemia. Starting in late 2007, a series of severe 
anaphylactoid reactions had caused serious injuries and deaths. These reactions were later 
linked to heparin contaminated with oversulfated chondroitin sulfate [3, 4]. 
Several alternatives to heparin anticoagulation are potentially available, each of them 
accompanied by specific disadvantages. Intermittent saline flushes, i.e., flushing of the 
extracorporeal circuit with 25 to 50 mL of 0.9% sodium chloride solution every 15 to 30 
minutes, is often used during acute dialysis in patients with increased bleeding risk or in 
patients with HIT type II. Since the procedure, surprisingly, is not automated, it is very 
laborious. Furthermore, its capacity to prevent clotting is rather limited, with partial clotting 
occurring in approximately 20 percent, and complete clotting of the extracorporeal circuit in 
about 7 percent of treatments [1]. Clotting of the extracorporeal system, of course, is 
associated with blood loss to the patient, and even with partial clotting, solute clearances 
will be impaired. Other agents used for systemic anticoagulation in hemodialysis are 
fondaparinux, danaparoid, and direct thrombin inhibitors. These have other downsides, 
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such as long half-life, lack of an antidote, or high cost, and all of them increase the bleeding 
risk as they are administered systemically. 
The primary purpose of anticoagulation during hemodialysis is to prevent clotting of the 
blood while it is traveling through the blood tubing and dialyzer. Against this background, 
the cornerstones of optimal anticoagulation for hemodialysis are complete suppression of 
the activation of the clotting cascade, strict limitation to the extracorporeal circuit, absence of 
serious side-effects, and low cost. 
Limitation of anticoagulation to the extracorporeal circuit, also known as regional 
anticoagulation, is important because it eliminates the increased bleeding risk associated 
with systemic anticoagulation. Originally, this was accomplished by infusing heparin into 
the arterial line of the blood circuit and antagonizing its anticoagulant effect by infusing its 
antidote protamine into the venous line. Since protamine’s half-life is shorter than heparin’s, 
the anticoagulant effect may return after the dialysis procedure, increasing the bleeding risk. 
Also, this mode of anticoagulation is not suitable for HIT type II patients because of the 
heparin administration. Regional anticoagulation by infusing the arachidonic acid 
derivative prostacyclin into the arterial line is based on this molecule’s inhibitory effect on 
thrombocyte aggregation and its short half-life of only a few minutes. The downsides are its 
vasodilatatory properties, which can cause significant hypotension during the treatment, 
and its prohibitive cost. Regional citrate anticoagulation is an alternative to these two 
methods that also confines anticoagulation to the extracorporeal circuit but does not come 
with the disadvantages mentioned above. In fact, it conveys a set of additional advantages 
that go above and beyond merely providing regional anticoagulation. 
2. The principles and history of citrate anticoagulation in hemodialysis 
The anticoagulant properties of citrate have been known since the late 1800s already and are 
based on its capacity to chelate calcium ions. Ionized calcium (iCa) is an important co-factor 
at several steps in the coagulation cascade and, in that role, was formerly called coagulation 
factor IV. Addition of citrate to whole blood leads to formation of stable calcium-citrate 
complexes, thereby lowering the concentration of ionized calcium. At iCa levels below 0.5 
mmol/L, clotting becomes impaired; at levels below approximately 0.3 mmol/L, 
coagulation is virtually blocked. This principle has been applied for storage of red cells in 
transfusion medicine since the early 20th century and later on for blood cell apheresis and 
lipid apheresis. Citrate physiologically occurs in the human body. It is an intermediate 
metabolite in the mitochondrial Krebs cycle, and all human cells that possess mitochondria 
can generate and metabolize citrate, particularly those tissues that are rich in mitochondria, 
such as the liver. 
The first mention of citrate for anticoagulation in hemodialysis dates back to 1961 [5]. 
Traditionally, regional citrate anticoagulation in hemodialysis involves infusion of 
trisodium citrate into the arterial line of the extracorporeal circuit in sufficient quantities to 
lower iCa levels to around 0.25 to 0.35 mmol/L in order to substantially inhibit coagulation. 
In the venous limb of the dialysis tubing, ideally close to the point of blood reinfusion into 
the patient, calcium is substituted in the form of a calcium chloride or calcium carbonate 
infusion. This calcium substitution primarily serves to raise the iCa concentration in the 
blood to safe levels before the blood re-enters the patient’s circulation, but there is another 
aspect to it as we shall see later. Classically, a calcium-free dialysate is used in this setting so 
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as not to compromise anticoagulation due to calcium influx from the dialysate [6]. This 
setup of regional citrate anticoagulation is depicted in Figure 1. 
 
 
Fig. 1. Conventional setup of regional citrate anticoagulation in hemodialysis. 
A question of central importance is how plasma citrate concentrations relate to iCa 
concentrations. We analyzed the data from 21 regional citrate anticoagulation treatments 
performed at Renal Research Institute facilities in New York, USA, in 10 patients, during 
which 4% trisodium citrate (136 mmol/L) was infused into the arterial line and iCa 
measured before the dialyzer. Blood flow rates were 350 mL/min in 4 treatments, 400 
mL/min in 13 treatments, and 450 mL/min in 4 treatments. Hematocrit and iCa were 
measured 13 minutes into the treatment using an Abbott i-Stat point-of-care analyzer. 
Hematocrits ranged from 28% to 39% (average, 33.6%). Citrate infusion rates ranged from 
140 to 480 mL/h, and iCa ranged from 0.27 to 0.68 mmol/L (average, 0.38 mmol/L). Plasma 
citrate concentrations were calculated based on citrate infusion rates and calculated plasma 
flow rates. Figure 2 illustrates the relationship between pre-dialyzer blood iCa activity and 
plasma citrate concentration. As can be seen, a plasma citrate concentration of >3.5 mmol/L 
is typically required to bring iCa levels to below 0.3 mmol/L. The exact citrate concentration 
necessary depends mainly on the individual patient’s plasma calcium and protein 
(primarily albumin) concentrations. Total calcium in the serum comprises a protein-bound 
and a free (ionized) fraction, and the equilibrium concentrations of each can be estimated 
based on the respective dissociation constant [7-10]. Likewise, free citrate reacts with free 
calcium to form calcium-citrate complexes, again with a known dissociation constant [11]. 
Strictly, the multi-ionic milieu of the plasma should be considered, but reducing the 
relationships to calcium, protein, and citrate is a fair approximation. In clinical practice, 
these relationships are, however, not calculated. Instead, the citrate infusion rate is generally 
based on empirical knowledge and in most cases only tailored to the patient’s blood flow 
rate. As can be expected, this may occasionally lead to citrate concentrations that are either 
too low to provide sufficient anticoagulation, or unnecessarily high. To assess the individual 
situation, pre-dialyzer (some groups use post-dialyzer) iCa levels can be measured in the 
plasma to ascertain that they are within the desired target range of approximately 0.25 to 
0.35 mmol/L. If they are not, adjustments to the citrate infusion rate can be implemented 
and the iCa levels reassessed. Likewise, the post-dialyzer iCa concentrations are not known 
in clinical practice, and the rate of calcium substitution is based on empirical knowledge. 
Routinely, systemic iCa levels are measured in the patient at multiple time points during the 
treatment, and the calcium substitution rate is adjusted to counter drops or rises in systemic 
iCa concentration. Each adjustment usually necessitates a reassessment of iCa levels after 15 
to 30 minutes to monitor its effect. 
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Fig. 2. Pre-dialyzer ionized calcium (iCa) concentration plotted against plasma citrate 
concentration. 
During regional citrate anticoagulation, citrate enters the body in the form of both free 
citrate and calcium-citrate complexes. When this citrate is metabolized, each molecule yields 
three molecules of bicarbonate, which will have an impact on the acid-base status. Also, 
calcium is released from calcium-citrate complexes as they are metabolized, which impacts 
serum calcium concentration. The use of trisodium citrate or Acid Citrate Dextrose (ACD) 
solution further entails an additional sodium load to the patient that should be taken into 
account. In clinical practice, the dialysis prescriptions for regional citrate anticoagulation 
typically incorporate reduced sodium (by about 2 mmol/L) and bicarbonate (by about 5 
mmol/L) concentrations. Magnesium concentration in the dialysate may be increased since 
citrate also complexes magnesium, leading to increased magnesium losses across the 
dialyzer. 
Over the years, different algorithms for the administration of regional citrate 
anticoagulation have been suggested and studied, both for intermittent as well as 
continuous hemodialysis. These algorithms usually define blood and dialysate flow rates, 
the starting rates for citrate infusion and calcium substitution, rules on how these rates 
should be adjusted in case of iCa deviations from the specified circuit or systemic target 
ranges, time points for monitoring iCa, and downward adjustments for sodium and 
bicarbonate in the dialysate. Since citrate and calcium kinetics during dialysis depend on 
many factors, including the type of dialyzer used and the blood and dialysate flow rates, 
such algorithms generally are only applicable to the particular dialysis setting for which 
they have been validated. The purpose of all these algorithms is always to make the 
administration of regional citrate anticoagulation as safe and simple as possible, i.e. to 
minimize the risk for calcium or acid-base derangements, circuit clotting or other 
complications while requiring as little monitoring or intervention by the staff as possible. 
3. The benefits of regional citrate anticoagulation 
Regional citrate anticoagulation does not increase the patient’s bleeding risk and is, 
therefore, not only an ideal mode of anticoagulation in any patient with high bleeding risk 
or active bleeding but also for the average hemodialysis patient. Furthermore, citrate 
anticoagulation avoids all the other potential side effects of heparin use noted above, which 
also makes it a choice mode of anticoagulation in patients with HIT type II. Aside from these 
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obvious advantages, however, there are several additional benefits to using regional citrate 
anticoagulation. One of these appears to be improved biocompatibility of the dialysis 
procedure: comparing heparin anticoagulation with citrate anticoagulation, Böhler et al. 
found that citrate anticoagulation reduced complement activation, neutropenia and 
lactoferrin release with the use of cuprophane dialyzers, and significantly inhibited 
neutrophil degranulation with the use of polymethyl methacrylate membranes [12]. 
Likewise, Gritters and colleagues compared anticoagulation using unfractionated heparin, 
low molecular weight heparin and citrate in a randomized crossover trial and found that 
citrate anticoagulation suppressed the dialysis-associated degranulation of 
polymorphonuclear cells and platelets. Furthermore, pro-atherogenic oxidized low-density 
lipoprotein levels were reduced by a median of 26% after only one week on citrate 
anticoagulation [13]. In view of the heightened inflammatory state of chronic hemodialysis 
patients, the reduction of oxidative stress, complement and cell activation associated with 
citrate dialysis may be a relevant benefit with regard to reducing the high cardiovascular 
morbidity in these patients. Hofbauer et al. compared anticoagulation with unfractionated 
heparin, low molecular weight heparin and citrate during dialysis with a single-use 
polysulfone dialyzer and used scanning electron microscopy to quantify the degree of 
membrane-associated clotting [14]. The highest degree of cell adhesion and thrombus 
formation was observed with unfractionated heparin, and it was only slightly reduced with 
the use of low molecular weight heparin. With regional citrate anticoagulation, on the other 
hand, thrombus formation was found to be negligible, indicating a far superior 
anticoagulation using citrate compared to both unfractionated and fractionated heparin. 
Gabutti et al. employed a randomized controlled cross-over design to compare standard 
heparin dialysis with regional citrate anticoagulation, dosed to achieve a similar degree of 
coagulation activation, and study the effects on complement activation and interleukin-1 
beta release. In this setting, complement activation was slightly but significantly higher in 
the citrate dialysis group, but at the same time, interleukin-1 beta release was markedly 
reduced. Citrate can, and often is, dosed higher in regional citrate anticoagulation than was 
done in this study, and it stands to reason that with such higher citrate concentrations, 
complement activation would have been lower than with standard heparin dialysis, 
associated perhaps with a further decrease in interleukin-1 beta secretion. In line with 
Hofbauer’s results mentioned above, regional citrate anticoagulation appears to allow for 
markedly prolonged filter patency times in continuous dialysis [15-18]. Lastly, a recent 
study by Oudemans-van Straaten and colleagues found higher patient and kidney survival 
in critically ill patients on citrate versus low-molecular weight heparin [19]. On top of these 
benefits, citrate is a relatively inexpensive compound compared to heparin. 
4. The downsides of regional citrate anticoagulation 
The single biggest concern with regional citrate anticoagulation is the development of 
potentially life-threatening systemic calcium derangements. Acute changes in systemic iCa 
can develop quickly when calcium elimination across the dialyzer (in the form of free 
calcium and calcium-citrate complexes), calcium release from the metabolism of calcium-
citrate complexes, and calcium substitution (from the calcium infusion and/or the dialysate, 
if a calcium-containing dialysate is used) are mismatched. From this concern springs the 
need to monitor, at least initially, systemic iCa levels fairly closely during regional citrate 
anticoagulation. This, along with the more complex setup, presents a significant strain on 
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staff resources and, consequently, can make citrate dialysis more costly than standard 
heparin dialysis. The prolonged filter patency times seen with citrate anticoagulation, 
however, may also introduce cost savings compared to heparin dialysis in continuous 
dialysis therapies [20]. The administration of buffer base in the form of citrate can further 
lead to metabolic alkalosis [20-22]. Hypernatremia can occur secondary to the additional 
sodium load administered with the citrate infusion (e.g., in the form of trisodium citrate, 
which carries 3 moles of sodium for each mole of citrate) [5, 21]. With high citrate infusion 
rates and/or in patients with impaired liver function (liver failure, cirrhosis), systemic 
citrate accumulation may occur. Measurements of plasma citrate concentrations are not 
usually readily available in clinical laboratories, but citrate accumulation may be detected 
by looking for its effects on calcium levels: citrate accumulation traps calcium in the form of 
calcium-citrate complexes. The growing plasma pool of calcium-citrate complexes and the 
insufficient release of calcium from this pool via citrate metabolism lead to a drop in 
systemic iCa which is spotted in systemic iCa measurements and countered by an increase 
in the calcium substitution rate in order to restore systemic iCa to physiologic levels. Under 
such conditions, the amounts of free calcium, calcium-protein complexes and the increased 
amount of calcium-citrate complexes add up to an increased total calcium concentration. 
Therefore, citrate accumulation may be detected by an increased total calcium concentration 
or an increased ratio of total to ionized serum calcium concentration [23]. An increased 
anion gap may also point towards citrate accumulation [24]. 
5. The future of citrate anticoagulation in hemodialysis 
The fundamental roadblocks to widespread implementation of regional citrate 
anticoagulation are fear of electrolyte or metabolic disturbances and the relative 
laboriousness of this mode of anticoagulation. These two domains are interconnected. What 
current citrate dialysis algorithms have in common is that they are empiric. There is some 
degree of individualization, but only on a relatively low level. As a consequence, while these 
algorithms may work for the average patient, or even a majority of patients, there will 
always be the concern that the characteristics of a particular patient situation are not 
captured adequately, leading to unexpected and possibly dangerous changes in electrolyte 
or acid-base parameters. And for this very reason, these algorithms will never help 
eliminate the intensive laboratory monitoring that, at least initially, is currently required for 
regional citrate anticoagulation. 
Tailoring the citrate infusion rate to the blood flow rate alone is a crude oversimplification. 
Anticoagulation along the extracorporeal circuit depends on a myriad things, such as the 
hematocrit, the void volume fraction, the plasma water calcium concentration, the 
composition of the other ionic species in the multi-ionic milieu of the plasma, the 
ultrafiltration rate, the type, size and geometry of the dialyzer used and, consequently, its 
solute removal characteristics, the blood and dialysate flow rates, the concentration of the 
citrate infusion (high concentrations entail low infusion rates, which may cause mixing 
issues or discontinuous, pulsatile flow), the dialysate composition (e.g., in terms or calcium, 
magnesium and citrate concentration), the plasma protein concentration, the rates of citrate 
generation and metabolism, the systemic citrate levels, the degree of access recirculation, the 
patient’s capacity to buffer changes in extracellular calcium concentration, and so on, to 
name but a few. Some of these have greater impact than others; some are easier to model 
than others. But if the kinetics of calcium and citrate are to be predicted (not on average, but 
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for a particular patient) with any degree of reliability, then these factors must be taken into 
account. Needless to say, the interactions between all these factors cannot possibly be 
assessed (let alone integrated over an entire treatment and beyond) based on intuition or 
clinical experience. Computer-aided calcium and citrate kinetic modeling is the only way to 
simulate in detail the processes during regional citrate anticoagulation. We have recently 
published a comprehensive, yet versatile, mathematical model for citrate dialysis [25]. A 
refinement of this model (comprised of our original model combined with a statistical 
correction component), recently presented as a talk at the XLVII ERA-EDTA conference in 
Munich, Germany, showed excellent prediction quality [26]. When applied to 120 patients 
on pure dialysate-side citrate dialysis (dialysate containing 2.4 mEq/L citrate and 2.25 
mEq/L calcium), the model overestimated end-dialysis ionized calcium levels by only 0.026 
mmol/L on average. While current clinical citrate dialysis algorithms are only applicable to 
a rather narrow setting for which they have been developed, computer-aided calcium and 
citrate kinetic modeling affords much greater flexibility and could possibly even be adapted 
on-the-fly to different conditions. 
As was mentioned above, the calcium substitution in regional citrate anticoagulation is 
currently dosed empirically and adjusted so as to keep systemic iCa within the physiologic 
range. However, it must be born in mind that this approach pays no heed to the question of 
calcium mass balance. This is, of course, not done deliberately but simply from necessity, 
because clinicians have no way of assessing intradialytic calcium mass balance reliably, let 
alone under such complex conditions as occur in regional citrate anticoagulation. The 
difference between calcium substitution and calcium loss across the dialyzer membrane 
determines the intradialytic calcium mass balance, and from this perspective, the calcium 
substitution should be chosen so as to effect the desired mass balance. The challenges with 
determining what calcium mass balance is required for a given patient is a related but 
separate issue and shall not be discussed here. With higher citrate infusion rates, and 
accompanying citrate accumulation and calcium “trapped” systemically in the form of 
calcium-citrate complexes, calcium mass balances can easily become positive. In practice, 
this point is often dismissed and calcium substitution rates justified with reference to the 
need to maintain serum ionized calcium within the normal range. What becomes clear, 
however, when simulating citrate dialysis is that many roads lead to Rome, and, within 
limits, different calcium mass balances can be achieved without compromising the 
extracorporeal anticoagulation by modifying parameters such as dialysate calcium and 
citrate concentrations and blood and dialysate flow rates. Dialysis dose issues certainly have 
to be considered, and the combination of calcium and citrate kinetic modeling with urea 
kinetic modeling would be a particularly powerful tool. Conversely, the same calcium mass 
balance can be achieved in different ways, potentially allowing for individualization of the 
citrate dialysis prescription according to particular patient characteristics, such as impaired 
liver function or reduced calcium buffering capacity. In view of the ever-increasing 
awareness of the potential importance of calcium mass balance for long-term outcomes in 
hemodialysis patients, calcium and citrate kinetic modeling offers a unique opportunity for 
actively incorporating this parameter into the dialysis prescription. This may turn out to be 
crucial for translating the compelling short-term benefits associated with regional citrate 
anticoagulation into long-term improvements in cardiovascular outcomes and ultimately 
survival. Currently, this mode of anticoagulation is thoroughly ignoring this aspect and is 
lagging behind the trend towards neutral calcium mass balance seen in standard heparin 
hemodialysis. Similar to calcium mass balance considerations, dialysis-related sodium 
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staff resources and, consequently, can make citrate dialysis more costly than standard 
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for a particular patient) with any degree of reliability, then these factors must be taken into 
account. Needless to say, the interactions between all these factors cannot possibly be 
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range. However, it must be born in mind that this approach pays no heed to the question of 
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citrate dialysis prescription according to particular patient characteristics, such as impaired 
liver function or reduced calcium buffering capacity. In view of the ever-increasing 
awareness of the potential importance of calcium mass balance for long-term outcomes in 
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lagging behind the trend towards neutral calcium mass balance seen in standard heparin 
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loading is another topic that has been receiving more and more attention in recent years and 
is another domain of solute kinetic modeling that should ultimately be integrated into 
citrate dialysis modeling, particularly given the additional sodium load administered with 
the use of regional citrate anticoagulation. 
The use of dialysate-side citrate anticoagulation (i.e., the use of a citrate- and calcium-
containing dialysate without arterial citrate infusion or venous calcium substitution) has 
sparked interest recently for its alleged heparin-sparing potential and its safety and ease of 
use [27-29]. At unchanged heparin doses, using citrate-containing dialysate (instead of 
bicarbonate dialysate acidified with acetate) appears to improve solute removal [30]. 
Citrate anticoagulation holds great promises for improving the outcomes of hemodialysis 
patients. Ultimately, kinetic modeling will be essential for taking this therapy to the next 
level (i.e., a high degree of individualization and increased safety through accurate 
prediction of electrolyte and acid-base kinetics) and to facilitate its widespread use in 
routine clinical practice. 
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1. Introduction 
The incidence rates of End-stage renal disease (ESRD) have increased steadily 
internationally since 1989. The United States has the highest incident rate of ESRD, followed 
by Japan; Japan has the highest prevalence per million population, with the United States 
second (1). Of the 490,000 patients with ESRD in the United States, more than 380,000 are 
currently on hemodialysis (HD) (2). 
ESRD on HD disproportionately affects minority populations. Whites represent the majority 
of the HD population (59.8%), while African Americans (33.2%), Asians (3.6%), and Native 
Americans (1.6%) comprise the rest of the ESRD population. However, the incidence rate of 
ESRD among African Americans is 4-fold higher and Native Americans 2-fold higher than 
that for whites. ESRD is slightly more prevalent in men than in women (male-to-female 
ratio, 1.2:1) and more prevalent in older adults (3).   
2. Morbidity/mortality 
Chronic renal failure is associated with a very high morbidity and hospitalization rate, likely 
due to existing comorbid conditions, such as hypertension, coronary artery disease, and 
peripheral vascular disease. The first-year age-adjusted mortality rate of patients on dialysis 
is 9.4%, the two-year mortality rate is 32.3%, and the 5-year mortality rate is 60.8% (3). ESRD 
patients with diabetes have a first-year mortality rate of 23% (3). In patients with ESRD, 
cardiovascular disease is the primary cause of death, followed by sepsis and cerebrovascular 
disease. The dialysis population in the United States has a 10- to 20-fold higher risk of death 
due to cardiovascular complications than the general population after adjusting for age, 
race, and sex. The relative risk with respect to the general population is much higher in 
younger patients, with cardiovascular event rates in ESRD patients in their 20s equivalent to 
the event rates in the general population in their 80s (3). Increased understanding of the 
disease process, new insights into pathogenic mechanisms, and new therapeutic options are 
emerging that may improve survival rates and quality of life for patients with ESRD. 
3. The need for dialysis 
Given the poor outcomes for patients on HD, every effort should be undertaken to preserve 
residual renal function, which is associated with improved survival (4). Early nephrology 
referrals, patient education, and consideration of transplant options may be helpful in 
decreasing the progression to ESRD. Preparation for dialysis therapy is critical for the 
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smooth transition from CKD care to ESRD. Poor planning for initiation of dialysis is a major 
cause of increased morbidity and mortality. The use of temporary or tunneled dialysis 
catheters contributes to dialysis mortality by increasing the incidence of sepsis, acting as a 
stimulus for chronic inflammation, and damaging the central veins, thereby preventing or 
shortening the survival of more permanent vascular access once created. The chapter will 
discuss in detail regarding type of dialysis access. 
3.1 Indications for initiation of dialysis 
The appropriate time to initiate dialysis for a patient is not clearly defined. The decision to 
initiate dialysis in a patient with CKD involves the consideration of subjective and objective 
parameters by the physician and the patient. Over the past decade a trend of increasing 
estimated glomerular filtration rate (eGFR) at the initiation of dialysis for treatment of ESRD 
has been noted in the United States. In 1996, only 19% of patients began dialysis therapy 
with an eGFR of greater than 10 ml/min/1.73 m2 (denoted as 'early start'), but by 2005 the 
fraction of early start dialysis patients had risen to 45% (5). It is not known whether early 
start of dialysis is beneficial, harmful or neutral with respect to the outcome of dialysis 
treatment for ESRD (5). The timing of initiation of dialysis for ESRD is a matter of clinical 
judgment guided by values of residual renal function and symptoms and signs present in 
the patients, including those related to comorbidity. By the time the eGFR falls below 10 
ml/min/1.73 m2, most patients require dialysis. However, many patients appear to function 
quite well until the eGFR approaches 5 ml/min/1.73 m2. As a general rule, patients with 
diabetes require earlier intervention (eGFR<15 ml/min/1.73 m2) than do those with other 
etiologies for renal failure (6). Clearly, dialysis must be initiated before the uremic 
symptoms of peripheral neuropathy, encephalopathy, malnutrition, or serositis (including 
pericarditis) become evident (See Table 1). 
 
 Pericarditis or pleuritis (urgent indication)  
 Progressive uremic encephalopathy or neuropathy, with signs such as confusion, 
asterixis, myoclonus, wrist or foot drop, or, in severe cases, seizures (urgent 
indication) 
 A clinically significant bleeding diathesis attributable to uremia (urgent indication) 
 Fluid overload refractory to diuretics 
 Hypertension poorly responsive to antihypertensive medications 
 Persistent metabolic disturbances that are refractory to medical therapy; these 
include hyperkalemia, metabolic acidosis, hypercalcemia, hypocalcemia, and 
hyperphosphatemia 
 Persistent nausea and vomiting 
 Evidence of malnutrition 
Table 1. Clinical indications to initiate dialysis in patients with CKD. (7) 
3.2 ‘Early’ versus ‘Late’ dialysis 
There is conflicting evidence concerning the effect of the early initiation of dialysis on 
survival. Some retrospective and uncontrolled prospective studies have reported no 
survival benefits with early dialysis while others have found that early start of dialysis may 
be harmful (8). After a comprehensive review of the published literature by the National 
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Kidney Foundation (NKF) workgroup in 1997, they recommended that initiation of dialysis 
be considered when the arithmetic mean of the urea and creatinine clearances fell below 
approximately 10.5 ml/min/1.73 m2 except in well-nourished, asymptomatic patients (9). In 
1999 Obrador et al., observed that 23% of the US ESRD population, between 1995 and 1997, 
started dialysis at an eGFR less than 5 ml/min/1.73 m2. They opined that this 'late start' of 
dialysis needed further examination, including studies of the impact on outcomes and cost 
of ESRD treatment (10).  
In 2006, the NKF work group updated the guidelines for initiation of hemodialysis and 
stated that 'at CKD Stage 5, when the eGFR is < 15 ml/min/1.73 m2, that nephrologists 
should evaluate the benefits, risks and disadvantages of beginning renal replacement 
therapy'. They also suggested that initiation of dialysis therapy before CKD Stage 5 (an 
eGFR of > 15 ml/min/1.73 m2) may be appropriate in patients who have symptoms 
believed to be related to both their comorbidities and their level of residual kidney function 
(11). Only one study has reported the outcomes of patients with CKD who initiated dialysis 
only after the onset of symptoms due to uremia. In this prospective cohort study of 233 
consecutive patients with advanced uremia, 151 were elective starters on dialysis, while 82 
initially declined dialysis. Among the initial refusers, 55 percent developed a uremic 
emergency, while 48 percent were eventually established on maintenance dialysis. In this 
study, one year mortality was significantly higher among the initial refusers than the 
elective starters (18 versus 7 percent). However, these results are confounded by lack of 
randomization and by three deaths among the initial refusers resulting from treatment 
withdrawal (12). 
Additional published studies have not been able to demonstrate any clear-cut survival 
benefits for early start of dialysis. The only randomized controlled trial that examined 
mortality and time of dialysis initiation, the IDEAL study (13), found no difference in 
survival between early or late initiation of dialysis. In this study, 828 patients with 
progressive CKD and an estimated GFR between 10.0 and 15.0 mL/min/1.73 m2 (as 
determined by the Cockcroft-Gault equation) were randomly assigned to dialysis initiation 
when the estimated GFR was either 10 to 14 mL/min/1.73 m2 or 5 to 7 mL/min/1.73 m2. 
The median time to the initiation of dialysis was 1.8 and 7.4 months in the early and late 
start groups, respectively. At a median follow-up period of 3.6 years, the authors noted no 
significant difference in survival (38 and 37 percent mortality, hazard ratio of 1.05 with early 
initiation, 95% CI of 0.83 to 1.30) as well as no difference in cardiovascular events, infections, 
or dialysis complications between the late start group and early start group. 
However, these results do not imply that the initiation of dialysis can be delayed until the 
GFR is between 5 to 7 mL/min/1.73 m2 in all patients. The design of the IDEAL study 
permitted clinicians to initiate dialysis based upon the presence of symptoms due to uremia 
as well as on the estimated GFR. As a result, 76 percent of patients assigned to the late start 
arm initiated dialysis when the GFR was much greater than 5 to 7 mL/min/1.73 m2. This 
resulted in a mean GFR of 9.8 mL/min/1.73 m2 at the start of dialysis for the late start 
group, which was only 2.2 mL/min/1.73 m2 less than the mean start GFR for the early 
group (12.0 mL/min/1.73 m2). Thus, approximately 88 percent of all enrolled patients had 
initiated dialysis with an estimated GFR of approximately 10 mL/min/1.73 m2 or more, 
either because of symptoms or enrollment in the early dialysis arm (13). 
A recent study published in Canadian Medical Association Journal examined trends in 
initiation of hemodialysis within Canada and compared the risk of death between patients 
with early and late initiation of dialysis (14). Using the Canadian Organ Replacement 
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with early and late initiation of dialysis (14). Using the Canadian Organ Replacement 
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Registry from 2001 to 2007, the investigators identified a cohort of 25,910 patients 18 years or 
older who began hemodialysis. Dialysis was defined as beginning early if the eGFR exceeded 
10.5 mL/minute/1.73 m2. Mean eGFR at initiation of dialysis increased from 9.3 
mL/minute/1.73 m2 in 2001 to 10.2 mL/minute/1.73 m2 in 2007 (P < .001). During the same 
period, the proportion of early dialysis initiations increased from 28% (95% confidence interval 
[CI], 27% - 30%) to 36% (95% CI, 34% - 37%). Among those starting dialysis early, mean GFR at 
initiation was 15.5 mL/minute/1.73 m2 vs 7.1 mL/minute/1.73 m2 among those who started 
dialysis late. For early vs late initiation of dialysis, the unadjusted hazard ratio (HR) for death 
was 1.48 (95% CI, 1.43 - 1.54). This suggests that early initation is associated with higher 
mortality. After adjustment for demographic factors, serum albumin, primary cause of end-
stage renal disease, type of vascular access, comorbid conditions, late referral, and transplant 
status, the hazard ratio for death decreased to 1.18 (95% CI, 1.13 - 1.23). Difference in mortality 
per 1000 patient-years between starting dialysis early vs late decreased after 1 year of follow-
up but persisted and began increasing again after 24 months of follow-up, with significant 
differences at 6, 12, 30, and 36 months. (14) 
There may be two additional advantages to early dialysis: control of hypertension and 
increased dietary intake. Reversal of volume overload with dialysis often leads to a 
reduction in blood pressure, which is typically volume-dependent in CKD. Perhaps more 
important, patients on dialysis patients require at least 1 g/kg of protein per day to replace 
dialysis losses and maintain nitrogen balance. Thus, early institution of dialysis can allow a 
more liberal diet in terms of both food and fluid. 
The overall conclusion of these trials largely supports current practice that dialysis initiation 
should be based upon clinical factors rather than the estimated GFR alone. Patients with 
progressive CKD require close follow up, early nephrology referral, and adequate advance 
dialysis planning (including the presence of a functioning peritoneal or vascular access and 
referral for transplantation). Among patients with progressive CKD, clinicians must be 
vigilant for the presence of symptoms and/or signs of uremia and dialysis should be 
initiated in the patient with these symptoms. 
4. Dialysis modality selection 
Although the life expectancy of patients with end-stage renal disease has improved since the 
introduction of dialysis in the 1960s, it is still far below that of the general population. As an 
example, the mean life span at age 49 in the United States is 33 years in the general 
population but only approximately seven years in patients receiving maintenance dialysis 
(15), in whom the overall five-year survival rate is about 30 to 50 percent in nondiabetics 
(depending upon the co-morbid diagnoses) and 25 percent in diabetics (15). Despite 
improvements in technology and patient care, the mortality rate of patients on maintenance 
dialysis remains alarmingly high, at approximately 15 to 20 percent per year (16). 
There are two principal choices for maintenance dialysis: hemodialysis (HD) and peritoneal 
dialysis (PD). Selecting one of these modalities is influenced by a number of considerations 
such as availability and convenience, comorbid conditions, socioeconomic and dialysis 
center factors, the patient's home situation, method of physician reimbursement, and the 
ability to tolerate volume shifts (17-23). Most studies suggest a better survival rate in PD 
than in HD patients during the first few years after starting therapy (24). However, after 2 or 
3 years, outcome on PD becomes equal to HD, or worse (25-28). This section mainly focuses 
on different means of receiving hemodialysis. 
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The European Best Practice Guidelines for Hemodialysis recommends the standard 
hemodialysis dose should be delivered as three times per week for 4 hours each session (29). 
In an attempt to improve outcomes, it was postulated that a higher dialysis dose than 
commonly provided during conventional dialysis may increase survival among patients 
undergoing renal replacement therapies (30). 
However, this hypothesis was refuted in two large well-designed studies in both 
hemodialysis and peritoneal dialysis patients: 
- The HEMO study found that increasing the dialysis dose within the general restrictions 
of a thrice weekly regimen failed to decrease patient mortality (31). 
- In the ADEMEX study, no decrease in mortality was seen with peritoneal dialysis doses 
greater than a weekly Kt/V of 1.7 (32) 
In light of these negative studies, significant attention has turned to alternative dialysis 
schedules, such as, short-daily HD (SHD), nocturnal HD (NHD), and long, intermittent 
hemodialysis (LHD). It is suggested that more frequent dialysis may be associated an 
improvement in health-related quality of life (HRQoL) and with improved survival (33-34). 
The first successful use of short daily, or "quotidian" hemodialysis was first reported by 
DePalma in 1969 (35). This approach was based upon the premise that improved patient 
outcomes, compared with conventional three times per week hemodialysis, would occur 
with a dialysis schedule that consisted of the same number of hours of dialysis per week but 
delivered over twice as many sessions. More specifically, it involves five to seven treatments 
per week, each lasting 1.5 to 2.5 hours. The rationale for short daily hemodialysis is based 
upon a strategy that is proposed to enhance both dialysis efficiency and hemodynamic 
stability. With short daily dialysis, shortening the dialysis time while increasing the 
frequency of dialysis allows more time to be spent dialyzing against higher uremic solute 
concentration gradients. This enhances the efficiency of solute removal (36). More frequent 
dialysis allows for less interdialytic fluid accumulation. This is likely to improve 
hemodynamic stability during dialysis with increased potential for normalizing the 
extracellular fluid volume. This form of therapy has been associated with significant 
improvement in serum albumin, calcium phosphate, and volume control in small scale 
studies. However, no mortality data is available.  
A recent study, Frequent Hemodialysis Network (FHN) Daily Trial, was a multicenter, 
randomized trial that included 245 patients assigned to either frequent hemodialysis (six 
times weekly) or conventional hemodialysis. Two primary composite outcomes were 
determined at one year, including death or one-year change from baseline in left ventricular 
(LV) mass as assessed by cardiac resonance imaging, and death or one-year change in 
physical health as assessed by a RAND health survey. Both composite outcomes showed 
significant benefit to the frequent-dialysis group compared with the conventional-dialysis 
group (with hazard ratios of 0.61, 95% CI, 0.46-0.82 for death or change in LV mass; and 
0.70, 95% CI, 0.53-0.92, for death or change in physical health) (37). This study also 
demonstrated benefits in pre-determined secondary outcomes to the frequent dialysis group 
such as a decrease in LV mass, improved blood pressure control and phosphate balance but 
not on cognitive performance, depression, serum albumin concentration, or use of 
erythropoiesis-stimulating agents. 
Nocturnal hemodialysis (e.g, long nightly home hemodialysis) was introduced as a 
potentially more desirable alternative to conventional dialysis, since it provides superior 
dialysis based upon dose, duration, and frequency (38). This can be accomplished because it 
is performed during nightly sleep, an otherwise unproductive time (39).  The late Robert 
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Uldall started the first quotidian (daily) nocturnal hemodialysis program in 1994 at the 
Wellesley Hospital in Toronto (40). Since then, its use has been extended to more centers in 
Canada, the United States, Australia, and several European countries (41-44). This 
hemodialysis modality is performed five to seven times per week, with each treatment 
lasting 6 to 8 hours. Although the number of patients studied has been rather limited, but 
these evidence suggest signficant improvements in caloric intake and serum albumin 
results. 
Long intermittent hemodialysis is given three times a week and a dialysis time of 6 to 8 
hours. This procedure is practiced in Tassin, France, and has been associated with 
improvements in blood pressure control and better overall nutritional status. 
Although, no data on randomized controlled trials are available on home hemodialysis, 
some recent well-conceived cohort studies have indicated that outcome of home (daily) HD 
is superior to conventional in-centre dialysis, and even equal to cadaveric transplantation, 
when differences in case mix are taken into account (45). 
4.1 Hemofiltration and hemodiafiltration 
Hemodiafiltration is a form of chronic renal replacement therapy used most in Europe, 
particularly Germany and Belgium, and very rarely used currently in the United States (46). 
Based upon relatively better clearance of larger "middle" molecules through solvent drag, 
some claim that replacement therapy with hemodiafiltration may be superior to that with 
hemodialysis, including improved hemodynamics. 
For chronic renal replacement therapy, the two principal regimens used to provide 
substantial removal of larger MW uremic toxins via convection are intermittent 
hemofiltration (HF) and intermittent hemodiafiltration (HDF). Daily convective therapy has 
also been used. 
 Hemofiltration — With HF, fluid is removed by the dialysis machine through increased 
transmembrane pressure and the replacement solution is infused intravenously at equal 
volume minus the desired fluid volume removal. The clearance of the method for a 
particular solute is dictated by the ultrafiltration volume and the sieving coefficient. As 
the sieving coefficient for low MW unbound solutes equals 1, the clearance for small 
molecules equals the ultrafiltrate volume. Although hemofiltration is effective in the 
removal of the larger MW solutes, it is less effective in the removal of small molecules 
as it is restricted by the ultrafiltration volume. 
 Hemodiafiltration — HDF is a combination of hemodialysis and hemofiltration devised 
to overcome the low clearance of small solutes by hemofiltration by adding a diffusive 
component. 
For chronic renal replacement therapy, the standard regimen for both HF and HDF includes 
three sessions per week for three to five hours, as with conventional intermittent 
hemodialysis. A typical conservative (or high dose) regimen for HDF includes a post 
dilution configuration with a blood flow of 300 mL/min (500 mL/min for high dose), a 
dialysate flow of 500 mL/min, a flow of a substitution volume of 60 mL/min (120 mL/min 
for high dose) and a high flux dialyzer of 1.4 m2 (2.2 m2 for high dose) (47). 
Several small studies using daily HF/HDF have been published.  
 One study that addressed the short term effects of daily HF reported that predialysis 
beta-2-microglobulin levels decreased by 40 percent (48). 
 In one study in which 12 patients switched from HD to HF at home on a daily basis for 
one month, HF was associated with a lower blood pressure, higher caloric intake, and 
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improved quality of life, findings consistent with previous reports on short daily HD 
(49-50). A trend toward a decrease in serum beta-2-microglobulin could be ascribed to 
the HF alone. The infusion volume used was 40 percent of total body water, which 
offered a standard Kt/V of approximately 2.0. 
 In another study of eight patients undergoing in center daily hemodiafiltration for six 
months, there were lower serum levels of predialysis BUN and creatinine (which were 
expected by the change to a daily schedule), as well as lower levels of other solutes 
including beta-2-microglobulin and homocysteine (51). Additional benefits included 
improved phosphate control, discontinuation of all antihypertensive agents, and a 30 
percent regression in left ventricular mass. Although some of these results can be 
attributed to the daily treatment schedule, the decrease in the pretreatment levels of 
beta-2-microglobulin and the improvement in phosphate control are clearly attributable 
to both convection and the increased treatment frequency. 
4.2 Adequacy of hemodialysis 
For greater than 50 years hemodialysis (HD) has been performed in some form or another. 
Outcomes for dialysis patients expressed in terms of quality of life (QOL), mortality, and 
hospitalization, is reportedly similar to those seen in patients with solid organ cancer. 
Despite improvements in long-term outcomes demonstrated with all dialysis modalities, the 
adjusted annual mortality of dialysis patient remains high at 19% (52-53). There are many 
factors (dialysis and non-dialysis) that determines outcome. One such influential factor is 
“adequacy” of dialysis. Adequate dialysis was originally used to describe dialysis dosing 
measured by small solute removal, but is now deemed as the amount of dialysis required to 
keep a patient symptoms free, functional, with a life expectancy similar to that of healthy 
individuals. Since its inception, there have been numerous approaches to quantify the 
delivered dialysis dose in a reproducible manner, and to link the dialysis dose with clinical 
outcomes. 
4.3 Importance of urea and its use as a surrogate marker of uremic toxicity  
Solute removal during hemodialysis focuses on urea. Urea is produced from the anabolism, 
catabolism of proteins and is the principal way by which nitrogenous substances are 
excreted from the body. Urea is a small water soluble molecule (molecular weight 60 
daltons) that is slightly toxic. Recent studies have demonstrated that urea removal does not 
closely parallel that of other small water-soluble compounds, protein-bound solutes, or 
middle molecules. (54) Despite this information, adequacy of HD dosing is predominantly 
evaluated by removal of urea. During the development of the uremic syndrome, losses of 
kidney function are accompanied by deteriorating organ function attributable to the 
accumulation of uremic retention solutes or uremic toxins. (54) Uremic toxins are diverse 
and complex, they include inorganic compounds (phosphate water, potassium, water and 
trace elements), as well as organic compounds that comprises small water-soluble solutes 
(<500 d), middle molecules (>500 d), and protein-bound solutes. These peptides can be 
altered by glycosylation, oxidization or carbamylation, and they can provoke inflammation, 
hypertrophy, oxidative stress, coagulation, constriction, thus uremia is more than the 
retention and accumulation of urea or water-soluble compounds alone. (54)  Mortality has 
repeatedly been shown to be associated with the clearance of urea. Of commonly measured 
protein-derived substances, only the serum concentration of ß2-microglobulin correlates 
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with mortality. Recently, a higher free concentration of the protein-bound solute p-cresol has 
also been reported to be associated with mortality. (55) Current dialysis and dialysis-related 
treatments do not remove any significant quantity of substances larger than 10 to 15 kd. 
Future means of removing higher molecular weight toxins or protein-bound substances may 
include the use of sorbents in addition to traditional diffusive and convective dialysis 
strategies.  
4.4 Urea kinetic modeling, URR and KT/V  
The mathematical model known as urea kinetics can be used to calculate the rate of 
production and removal of urea. Measurement of the dialysis dose has, for the most part, 
relied on estimation of clearance of the small, water-soluble, and nitrogenous waste product 
urea, and hence the mathematical model is referred to as urea kinetic modeling (UKM). 
Formal (UKM) is the most accurate method for assessment of delivered dialysis dose. It 
assumes that urea is distributed in a single, well-mixed pool. UKM presumes that full 
equilibration occurs immediately between blood and tissue compartments. However, in 
vivo there is a delay in redistribution and it takes 30 to 60 minutes for equilibration between 
blood and tissue compartments post dialysis. UKM also assumes that urea is generated at a 
constant rate by protein metabolism and is removed at a constant rate by residual renal 
function, and intermittently by dialysis. Hence, in a person with negligible renal function, 
the extent of urea removal provides a measure of dialysis adequacy, and the rate of 
production correlates with dietary protein intake. (56) Thus, it’s inappropriate to follows 
predialysis blood urea nitrogen (BUN) or serum urea only; because low serum urea could be 
attributed to malnutrition (insufficient protein diet) rather than adequate dialysis urea 
removal. UKM has formed the basis for retrospective interpretation of the National 
Cooperative Dialysis Study and for prescription and control of the HEMO and the Frequent 
Hemodialysis Network studies. (60) Due its mathematical intricacy, UKM requires 
advanced computer support. UKM is the most rigorous available method for prescribing 
and evaluating dialysis dose and is widely used in the United States. Current methods for 
assessment of dialysis dose are based on the predialysis and postdialysis difference in BUN 
and include the urea reduction ratio (URR), the single-pool Kt/V (spKt/V), the equilibrated 
Kt/V (eKt/V), and the weekly standard Kt/V (std-Kt/V). 
Kt/V is a dimensionless ratio representing fractional urea clearance, where K is the dialyzer 
urea clearance (liters per hour), t is the length of HD session (hours), and V is the volume of 
distribution of urea (liters). It is the most widely used parameter to assess dialysis dose. 
Kt/V is derived from single-pool urea kinetics and is referred to as spKt/V. A value of 
spKt/V of 1 indicates that the total volume of blood completely cleared of urea during a 
dialysis session is equivalent to the volume of distribution of urea. Solute disequilibrium 
occurs when dialysis time is decreased in addition to increasing dialysis and blood flow 
rates. Solute disequilibrium can be corrected by adjusting the Kt/V for the rebound in urea, 
which happens mainly in the 30–60 minutes immediately post dialysis. The resultant Kt/V 
is termed equilibrated Kt/V or eKt/V. Numerous equations have been developed by 
Daugirdas and others to help derive the eKt/V from spKt/V.(57-59) With a conventional 4-
hour HD treatment, eKt/V is usually about 0.2 units lower than spKt/V. The difference is 
even larger with short, high-efficiency HD or hemodiafiltration, in which urea rebound is 
higher. Single-pool Kt/V or, even better, eKt/V should be assessed monthly, and dialysis 
prescription should be adapted accordingly. In large cross-sectional studies, mortality 
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increases when spKt/V falls below 1.2, and international guidelines (e.g., KDOQI) 
recommend a target spKt/V of 1.3 for a conventional dialysis schedule of three times per 
week. 
Online clearance is the term used when the dialysis dose is calculated by measuring 
conductivity or ionic clearance across the dialysis membrane. Multiple ions can be tracked at 
the same time to minimize error, and the delivered Kt/V can be predicted in real time before 
the treatment is over. Although sound in theory, the practical application is limited. UKM is 
also used to calculate the protein catabolic rate (PCR) and the protein catabolic rate 
normalized to body weight (nPCR), both of which are useful measures of nutrition. 
Urea reduction ratio (URR) is another way of quantifying the delivered dialysis dose.  
However, it’s over simplified since it does not take into account intradialytic urea generation 
and convective urea removal by ultrafiltration. Because the relative decrease in urea 
concentration during dialysis is the most significant determinant of Kt/V, direct 
measurement of URR is an accepted method for assessment of dialysis adequacy. The URR 
equation is as follows: URR = (BUNpre -BUNpost)/BUNpre where BUNpre is pre-dialysis 
urea concentration and BUNpost is post-dialysis urea concentration. By convention, the 
value is multiplied by 100 and expressed as a percentage. A minimum URR of 65% to 70% is 
recommended for adequate HD. Kt/V and URR are mathematically linked by the following 
equation: Kt/V= -ln(1-URR), where ln is the natural logarithm. (60) Accordingly, Kt/V 
equals 1.0 when URR equals 0.63 or 63% of whole-body urea has been removed. (60) 
4.5 Limitations of UKM 
One of the criticisms of UKM is the use of urea as the reference marker for measurement. 
We know that it’s a very small solute. Clearance of a solute is multifactorial; it is dependent 
on the molecular weight, charge, volume of distribution, and protein binding. Furthermore, 
clearance of solutes with different molecular weights from urea or bound to proteins would 
be different. Thus, clearance of urea cannot be extrapolated to other substances such as 
“uremic toxin” because they act differently. In addition UKM does not take into account 
residual renal function (RRF), which has a significant impact on patient outcome. (57) Also, 
it has been shown that V calculated by anthropometric formulas systematically 
overestimates volume by about 15%. (58) Kt/V underestimate that body water has an 
independent effect on outcomes, it is now recognized that smaller patients require higher 
Kt/v compared to larger patients. (61) Also, Kt/V does not confer that time (t) has an 
independent effect on outcome. The National Cooperative Dialysis (NCDS) was the first 
multicenter, randomized controlled trial of hemodialysis adequacy in which UKM was used 
to analyse the effect of BUN and HD time. Longer time was associated with better outcomes, 
however the statistical relationship between treatment time and patient outcome in was 
considered not to be significant (p value of 0.056). (61-62) Kt/V does not account for QOL, 
BP and volume control, clinically stability or biochemical factors. We know from the 
analysis of Hurricane Katrina that patients who missed three HD sessions were associated 
with odds ratio for hospitalization of 2.15. (61,63) Thus, Kt/V only measure the adequacy of 
one dialysis session, it does not incorporate missed HD sessions or shorten dialysis time.  
Some of these limitations are rectifiable.  One can increase HD time for intradialytic 
hypotension, inability to control volume, or if dialysis dosage is inadequate. HD dose can be 
based on body surface area (BSA), thus, smaller patients can receive more dialysis.   
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with mortality. Recently, a higher free concentration of the protein-bound solute p-cresol has 
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is termed equilibrated Kt/V or eKt/V. Numerous equations have been developed by 
Daugirdas and others to help derive the eKt/V from spKt/V.(57-59) With a conventional 4-
hour HD treatment, eKt/V is usually about 0.2 units lower than spKt/V. The difference is 
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BP and volume control, clinically stability or biochemical factors. We know from the 
analysis of Hurricane Katrina that patients who missed three HD sessions were associated 
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one dialysis session, it does not incorporate missed HD sessions or shorten dialysis time.  
Some of these limitations are rectifiable.  One can increase HD time for intradialytic 
hypotension, inability to control volume, or if dialysis dosage is inadequate. HD dose can be 
based on body surface area (BSA), thus, smaller patients can receive more dialysis.   
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4.6 Hemodialysis dose  
Quantifying removal of toxic uremic solutes is important to assess the adequacy of HD. The 
delivered dialysis dose is a function of length of the session (t), dialysate and blood flow 
rates, volume of distribution (V) of the uremic toxin studied, and the dialyzer efficiency 
(KoA). Volume of distribution is very different for urea (total body water volume), than 
other small-molecular-weight. The minimum frequency and dosage of dialysis is three times 
per week, for a minimum treatment time of 3 to 4 hours, a blood flow rate of at least 250 
ml/min, and a dialysate flow rate of 500 to 800 ml/min. Patients that are initiated on HD, V 
is unknown and has to be estimated (men, 58% of body weight; women, 55% of body 
weight). After obtaining measured Kt/V the dialysis prescription can be adjusted to meet the 
Kt/V goals. For patients with severe and long-standing uremia, it’s recommended to provide 
several sessions in achieving target dose to avoid the dialysis disequilibrium syndrome. 
4.7 Recommendations for dialysis dose adequacy  
Current recommendations in the United States are as follows (KDOQI) (64):  
- A minimum spKt/V of at least 1.2 for both adult and pediatric HD patients. When URR 
is used, the delivered dose should be equivalent to a Kt/V of 1.2, that is, an average URR 
of 65%.  
- To prevent the delivered dose of HD from falling below the recommended minimum 
dose, the prescribed dose of HD should be spKt/V of 1.3, which corresponds to an 
average URR of 70%.  
- The delivered dose of HD should be measured at least once per month in all adult and 
pediatric HD patients. 
4.8 Factors affecting delivered Kt/V  
Factors that influences delivery of Kt/V is multifactorial: hematocrit, the effective dialyzer 
urea clearance Kd depends on blood and dialysate flow rates, dialyzer KoA, effective 
dialyzer surface area, anticoagulation, and recirculation. (60) Dialysis session time (t) is 
critical for reaching the Kt/V goal. Prescribe treatment time (PTT) and effective treatment 
time (ETT) may not always correlate, EET may be significantly less secondary to patient 
demand, clotting of dialyser, or  intermittent pump stops. V does not substantially change 
during a single HD session but may change over time. Dialysis dose needs to be adjusted for 
an increase in V. However, if there is a loss in body mass (weight loss, amputation of limb), 
is associated with a decrease in V, Kt/V should not be reduced but rather adjusted to the 
higher, ideal patient V or BSA. 
If faced with an inadequate delivered Kt/V, first check if that session was representative of 
an average session and no unusual problems may have occurred (e.g., shortened time 
because of patient request, needle difficulty, leaks, alarm triggering). (60) The use of 
commercial technologies that measure ionic dialysance can be implemented to monitor each 
dialysis. A frequent cause of low Kt/V is fistula integrity that causes a vascular access 
problem leading to recirculation. Blood sampling errors should be considered because 
delayed post-HD sampling will reduce Kt/V. Standardized blood sampling procedures 
should be implemented in each center. If, despite these checks, a low Kt/V remains 
unexplained, treatment time should be increased to 4.5 or 5 hours. Prescription of a more 
efficient dialyzer and higher blood and dialysate flow rates should also be considered. 
However, increasing treatment time, rather than increasing dialysate flow, or using two 
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dialysers, would be more beneficial and practical to improve adequacy. Muscle exercise 
before or during dialysis improves Kt/V by increasing blood supply to poorly perfused urea 
rich muscle tissue and thus facilitates urea equilibration. Delivered Kt/V should be checked 
whenever the dialysis prescription has been modified substantially. Online clearance 
monitoring allows assessment of Kt/V during each single session without blood sampling. 
4.9 Should volume (V) be included in Kt/V to assess target clearance?  
In an attempt to address the question of optimal dialysis dose, several clinical trial have 
proposed that patients with small urea V, such as women, do worst compared to larger 
people. This is secondary to the notion that muscle mass closely correlate to total body water 
than to body weight. Thus, small urea V is a good indicator for low muscle mass. The 
Hemodialysis Study (HEMO) was performed in which 1846 patients were randomly 
assigned to a standard or high dose of dialysis and a low- or high-flux dialyzer (based on 
clearance of beta-2-microglobulin) which revealed a beneficial effect of higher Kt/V for 
women but not for men. (65) This suggests that individuals with low muscle mass may 
require a higher clearance in relation to V and therefore raises the question of whether V is 
the appropriate denominator for dialysis dose. (60)  Native renal clearances, in contrast, are 
commonly related to body surface area (BSA), not to total body water. (60) It has been 
suggested to relate BSA to dialysis clearances. The ratio of BSA to urea V is generally higher 
in women than in men and decreases with an increment in V. Prescribing dialysis dose in 
relation to BSA (K × t/BSA) would result in more dialysis for smaller patients of either 
gender and for women of any size. (57,60) More work need to be done to validate this novel 
idea.  
4.10 Other dialysis factors related to outcomes  
There are many other factors that play a role in the outcome of dialysis adequacy. Such 
factor includes but is not restricted to middle molecule removal, hyperphosphatemia, 
preservation of RRF, vascular access, QOL and treatment time. In general, middle molecule 
removal is determined by the dialyser permeability, the presence of convection, protein 
binding, and dialysis duration. Given that daily dialysis results in more frequent solute level 
equilibration with less rebound, this technique provides higher middle molecule removal 
than with conventional hemodialysis.  The retention of solutes of middle molecular size is 
proposed to play an important role in the pathogenesis of the uremic state and contribute 
significantly to the high mortality of dialysis patients. (60) High-flux dialyzers have the 
propensity to remove larger amounts of middle molecules than low-flux dialyzers due to 
higher membrane porosity, and this may even be further increased by the use of convective 
dialysis strategies, such as hemodiafiltration. Serum β2-microglobulin, is a surrogate for 
other uremic middle molecules, is effectively removed by high-flux than by low-flux 
dialysis, and predialysis β2-microglobulin levels were found to be related to mortality in 
patients treated randomly with high-flux or low-flux dialyzers. (70) Patient who has 
diabetes on HD, or on dialysis for longer than 3.7 years, and those with serum albumin 
levels below 40 g/l, may benefit most from high-flux dialysis. (69,71) The European Best 
Practice Guidelines have recommended maximizing the removal of middle molecules in all 
dialysis patients. (60,72) 
Hyperphosphatemia is a major problem in HD and is managed by phosphate removal via 
dialysis, use of phosphate binder medication to prevent intestinal phosphate absorption 
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dialysers, would be more beneficial and practical to improve adequacy. Muscle exercise 
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rich muscle tissue and thus facilitates urea equilibration. Delivered Kt/V should be checked 
whenever the dialysis prescription has been modified substantially. Online clearance 
monitoring allows assessment of Kt/V during each single session without blood sampling. 
4.9 Should volume (V) be included in Kt/V to assess target clearance?  
In an attempt to address the question of optimal dialysis dose, several clinical trial have 
proposed that patients with small urea V, such as women, do worst compared to larger 
people. This is secondary to the notion that muscle mass closely correlate to total body water 
than to body weight. Thus, small urea V is a good indicator for low muscle mass. The 
Hemodialysis Study (HEMO) was performed in which 1846 patients were randomly 
assigned to a standard or high dose of dialysis and a low- or high-flux dialyzer (based on 
clearance of beta-2-microglobulin) which revealed a beneficial effect of higher Kt/V for 
women but not for men. (65) This suggests that individuals with low muscle mass may 
require a higher clearance in relation to V and therefore raises the question of whether V is 
the appropriate denominator for dialysis dose. (60)  Native renal clearances, in contrast, are 
commonly related to body surface area (BSA), not to total body water. (60) It has been 
suggested to relate BSA to dialysis clearances. The ratio of BSA to urea V is generally higher 
in women than in men and decreases with an increment in V. Prescribing dialysis dose in 
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idea.  
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other uremic middle molecules, is effectively removed by high-flux than by low-flux 
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from dietary phosphate and dietary restriction. With the use of larger dialyzer surface area, 
hemodiafiltration, high-flux HD, removal of phosphate is significantly removal. Must 
monitor for hypophosphatemia with long frequent dialysis  
End stage renal patients initiated on dialysis initially posess considerable residual renal 
function (RRF). However, most of these patients lose their RRF by the end of the first year 
on dialysis. By year three only 10% to 20% of patients retain their RRF. RRF of 2 to 3 ml/min 
urea clearance contributes significantly to the elimination of uremic toxins. (73) The 
retention of RRF results in lower serum β2-microglobulin, phosphate, potassium, urea, 
creatinine, and uric acid levels; higher hemoglobin concentration; enhanced nutritional 
status; better quality of life scores; and a reduced need for dietary and fluid restrictions. (60) 
Left ventricular hypertrophy is associated with loss of RRF. Patient with an estimated TBW 
of 40 liters, a residual urea clearance of 2 to 3 ml/min is equivalent to a std-Kt/V of 0.5 to 
0.75/week. Dialysate water impurities, nephrotoxic agents such as radiocontrast, 
nonsteroidal anti-inflammatory drugs, aminoglycosides and activation of the immune 
system by bioincompatible membranes, intradialytic hypotension are risk factors for the loss 
of RRF. Patients who retain urine output may enhance survival augment with the regulation 
of fluid and electrolyte balance.  
5. Frequency of dialysis  
DePalma first reported in 1969 the successful use of short daily or "quotidian" hemodialysis. 
(35) Short daily dialysis (SDD) was based upon the premise that patient outcomes would 
improved, compared with conventional three times per week hemodialysis.  SDD would 
occur with a dialysis schedule that consisted of the same number of hours of dialysis per 
week but delivered over twice as many sessions. More specifically, this schedule consists of 
daily hemodialysis (five to seven days per week) provided for a duration of 1.5 to 3 or more 
hours per session. Initial attempts to popularize daily dialysis in the United States were 
suppressed by financial and logistical issues. This led to a decline in its use both in the home 
and in-center settings. However, over the last decade there has been resurgence in the use of 
daily dialysis, with several studies emerging from the United States and Europe showing 
improvements in various intermediate outcomes. Most recently, in the wake of the HEMO 
study, attention has turned from increasing the per-session dialytic dose, to altering 
variables such as treatment frequency or duration to improve outcomes (75-76) Daily 
dialysis has also been proposed as a rescue therapy and in the intensive care unit setting.  
The mortality rate of patients undergoing maintenance hemodialysis is unacceptably high. 
An extremely high morbidity, relatively low quality of life (due in part to a high level of 
dependence and unemployment), and high cost have also been observed. Contrast this with 
frequent dialysis which provides a more physiological renal replacement, because it allows 
more gentle volume removal, reduction of hemodynamic stress and better blood pressure 
control. More frequent dialysis and prolonged-duration HD have the greatest effect on 
middle molecule clearance. (74) In addition, phosphorus removal is increased secondarily to 
its predominant intracellular distribution. Protein bound solutes like p-cresol are not 
changed, because these solutes depend on RRF. The benefits of more frequent dialysis 
improve BP, thus decreasing anti-hypertensive medications, decreasing intradialytic 
hypotension, lowering serum phosphate, raising albumin and hemoglobin with lower 
requirements for erythropoiesis stimulating agents. HD patients switch to nocturnal dialysis 
improved sleep efficiency especially in stage 3 and 4 sleep with decreased in daytime fatigue 
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after 6 months. (75) Nocturnal dialysis is also associated with beneficial effects on vascular 
smooth muscle which restore the proliferation of the apoptosis ratio, which directly 
associated to serum phosphorus. However, there are no published randomized trials of 
nocturnal hemodialysis compared to other modalities. Thus studies comparing nocturnal 
hemodialysis to conventional hemodialysis should be performed to better understand the 
benefits with nocturnal hemodialysis. 
Due to the nightly schedule with nocturnal hemodialysis, the cost of consumables is higher 
than conventional hemodialysis and is similar to the cost of short daily hemodialysis. 
However, the personnel cost of nocturnal hemodialysis is lower than that with in-center 
hemodialysis regimens. (76) 
Depending upon the consumable/personnel cost ratio in different countries, nocturnal 
hemodialysis can be less or more expensive than in-center conventional hemodialysis. In 
addition, the cost of medications, including EPO, antihypertensive agents, and phosphate 
binders, is lower with nocturnal hemodialysis as well as cost of hospitalization.  
5.1 Vascular access 
Performing hemodialysis requires the ability to access and return a patient’s blood at a high 
rate. The optimal access would allow a high rate of blood flow, with no recirculation of 
dialyzed blood into the pre-dialysis blood, with maximal durability, minimal complications, 
and minimal gap from creation to use.  Currently, no hemodialysis access approaches this 
goal; each available access has shortcomings. 
The preferred access currently is the arteriovenous fistula (AVF). The AVF is created 
surgically by connecting an artery to a vein, with the subsequent increased flow and 
pressure causing the vein to “arterialize,” with thickened wall and increased size.  This 
arterialized vein can then be accessed for hemodialysis.  The advantages to the AVF are a 
high rate of blood flow with minimal recirculation, minimal complications because of the 
absence of foreign material, and an extended functional life.  The primary shortcoming of 
the AVF is the significant time from initial placement to maturation for use, which ranges 
from 25 to 98 days (81). Typically AVF is not used until 3 months after placement. However, 
a recent study of the practice patterns at dialysis facilities in DOPPS suggests that earlier 
cannulation of AVFs (even prior to 4 weeks) was not associated with increased risk of access 
failure (81). Other issues include a significant rate of primary failure of AVFs (82), vascular 
steal syndrome, inability to create AVFs because of lack of suitable vessels (82-84), and 
development of stenoses leading to AVF thrombosis and AVF failure (82-84). 
Given the significant time for their maturation, AVFs must be placed well before initiation 
of hemodialysis to avoid use of other accesses, such as tunneled catheters.  Currently, only 
15 percent of patients starting on hemodialysis use an AVF, and only 24 percent have a 
maturing AVF (85). One cause is late referral to nephrologists, but even with a timely 
referral to nephrologists, 46% of the patients did not have a permanent access placed prior 
to starting HD (85). Some barriers leading to this problem include patient resistance to 
creation of AVFs, poor access to surgeons, and decreased rate of primary patency of AVFs 
(85).  Possible solutions include improved patient education, often through patient support 
groups in CKD clinics and referral to nephrologist at earlier stage of chronic kidney disease 
(85). 
Where creation of an AVF is impossible, insertion of an arteriovenous graft (AVG) may be 
feasible. The advantage of an AVG is the high primary patency rate and minimal gap 
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from dietary phosphate and dietary restriction. With the use of larger dialyzer surface area, 
hemodiafiltration, high-flux HD, removal of phosphate is significantly removal. Must 
monitor for hypophosphatemia with long frequent dialysis  
End stage renal patients initiated on dialysis initially posess considerable residual renal 
function (RRF). However, most of these patients lose their RRF by the end of the first year 
on dialysis. By year three only 10% to 20% of patients retain their RRF. RRF of 2 to 3 ml/min 
urea clearance contributes significantly to the elimination of uremic toxins. (73) The 
retention of RRF results in lower serum β2-microglobulin, phosphate, potassium, urea, 
creatinine, and uric acid levels; higher hemoglobin concentration; enhanced nutritional 
status; better quality of life scores; and a reduced need for dietary and fluid restrictions. (60) 
Left ventricular hypertrophy is associated with loss of RRF. Patient with an estimated TBW 
of 40 liters, a residual urea clearance of 2 to 3 ml/min is equivalent to a std-Kt/V of 0.5 to 
0.75/week. Dialysate water impurities, nephrotoxic agents such as radiocontrast, 
nonsteroidal anti-inflammatory drugs, aminoglycosides and activation of the immune 
system by bioincompatible membranes, intradialytic hypotension are risk factors for the loss 
of RRF. Patients who retain urine output may enhance survival augment with the regulation 
of fluid and electrolyte balance.  
5. Frequency of dialysis  
DePalma first reported in 1969 the successful use of short daily or "quotidian" hemodialysis. 
(35) Short daily dialysis (SDD) was based upon the premise that patient outcomes would 
improved, compared with conventional three times per week hemodialysis.  SDD would 
occur with a dialysis schedule that consisted of the same number of hours of dialysis per 
week but delivered over twice as many sessions. More specifically, this schedule consists of 
daily hemodialysis (five to seven days per week) provided for a duration of 1.5 to 3 or more 
hours per session. Initial attempts to popularize daily dialysis in the United States were 
suppressed by financial and logistical issues. This led to a decline in its use both in the home 
and in-center settings. However, over the last decade there has been resurgence in the use of 
daily dialysis, with several studies emerging from the United States and Europe showing 
improvements in various intermediate outcomes. Most recently, in the wake of the HEMO 
study, attention has turned from increasing the per-session dialytic dose, to altering 
variables such as treatment frequency or duration to improve outcomes (75-76) Daily 
dialysis has also been proposed as a rescue therapy and in the intensive care unit setting.  
The mortality rate of patients undergoing maintenance hemodialysis is unacceptably high. 
An extremely high morbidity, relatively low quality of life (due in part to a high level of 
dependence and unemployment), and high cost have also been observed. Contrast this with 
frequent dialysis which provides a more physiological renal replacement, because it allows 
more gentle volume removal, reduction of hemodynamic stress and better blood pressure 
control. More frequent dialysis and prolonged-duration HD have the greatest effect on 
middle molecule clearance. (74) In addition, phosphorus removal is increased secondarily to 
its predominant intracellular distribution. Protein bound solutes like p-cresol are not 
changed, because these solutes depend on RRF. The benefits of more frequent dialysis 
improve BP, thus decreasing anti-hypertensive medications, decreasing intradialytic 
hypotension, lowering serum phosphate, raising albumin and hemoglobin with lower 
requirements for erythropoiesis stimulating agents. HD patients switch to nocturnal dialysis 
improved sleep efficiency especially in stage 3 and 4 sleep with decreased in daytime fatigue 
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after 6 months. (75) Nocturnal dialysis is also associated with beneficial effects on vascular 
smooth muscle which restore the proliferation of the apoptosis ratio, which directly 
associated to serum phosphorus. However, there are no published randomized trials of 
nocturnal hemodialysis compared to other modalities. Thus studies comparing nocturnal 
hemodialysis to conventional hemodialysis should be performed to better understand the 
benefits with nocturnal hemodialysis. 
Due to the nightly schedule with nocturnal hemodialysis, the cost of consumables is higher 
than conventional hemodialysis and is similar to the cost of short daily hemodialysis. 
However, the personnel cost of nocturnal hemodialysis is lower than that with in-center 
hemodialysis regimens. (76) 
Depending upon the consumable/personnel cost ratio in different countries, nocturnal 
hemodialysis can be less or more expensive than in-center conventional hemodialysis. In 
addition, the cost of medications, including EPO, antihypertensive agents, and phosphate 
binders, is lower with nocturnal hemodialysis as well as cost of hospitalization.  
5.1 Vascular access 
Performing hemodialysis requires the ability to access and return a patient’s blood at a high 
rate. The optimal access would allow a high rate of blood flow, with no recirculation of 
dialyzed blood into the pre-dialysis blood, with maximal durability, minimal complications, 
and minimal gap from creation to use.  Currently, no hemodialysis access approaches this 
goal; each available access has shortcomings. 
The preferred access currently is the arteriovenous fistula (AVF). The AVF is created 
surgically by connecting an artery to a vein, with the subsequent increased flow and 
pressure causing the vein to “arterialize,” with thickened wall and increased size.  This 
arterialized vein can then be accessed for hemodialysis.  The advantages to the AVF are a 
high rate of blood flow with minimal recirculation, minimal complications because of the 
absence of foreign material, and an extended functional life.  The primary shortcoming of 
the AVF is the significant time from initial placement to maturation for use, which ranges 
from 25 to 98 days (81). Typically AVF is not used until 3 months after placement. However, 
a recent study of the practice patterns at dialysis facilities in DOPPS suggests that earlier 
cannulation of AVFs (even prior to 4 weeks) was not associated with increased risk of access 
failure (81). Other issues include a significant rate of primary failure of AVFs (82), vascular 
steal syndrome, inability to create AVFs because of lack of suitable vessels (82-84), and 
development of stenoses leading to AVF thrombosis and AVF failure (82-84). 
Given the significant time for their maturation, AVFs must be placed well before initiation 
of hemodialysis to avoid use of other accesses, such as tunneled catheters.  Currently, only 
15 percent of patients starting on hemodialysis use an AVF, and only 24 percent have a 
maturing AVF (85). One cause is late referral to nephrologists, but even with a timely 
referral to nephrologists, 46% of the patients did not have a permanent access placed prior 
to starting HD (85). Some barriers leading to this problem include patient resistance to 
creation of AVFs, poor access to surgeons, and decreased rate of primary patency of AVFs 
(85).  Possible solutions include improved patient education, often through patient support 
groups in CKD clinics and referral to nephrologist at earlier stage of chronic kidney disease 
(85). 
Where creation of an AVF is impossible, insertion of an arteriovenous graft (AVG) may be 
feasible. The advantage of an AVG is the high primary patency rate and minimal gap 
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between creation and first use (84,86).  Because of the presence of foreign material, there is 
increased risk of access infection, although less than that with tunneled catheters, and there 
is an increased rate of stenosis, thrombosis, and graft failure compared with AVFs. One new 
technique in the creation of AVGs is the Hemodialysis Reliable Outflow (HeROTM) dialysis 
catheter, a new FDA approved device for catheter-dependent and significant vasculopathic 
patients. The HeRO device is an AVG that extends from the arm into the right ventricle.  
This may avoid problems with stenosis at the venous anastomosis leading to graft failure.   
The third means of chronic hemodialysis access is the tunneled catheter. This catheter, like 
the standard non-tunneled dialysis catheter used for acute hemodialysis access and non-
tunneled catheters used for venous access, is inserted into a central vein, usually the internal 
jugular vein, but the risk of infection is reduced by increasing the distance between the vein 
and skin entry by running the catheter through a subcutaneous tunnel. This access has the 
advantage of being usable immediately upon insertion, but it has the highest rate of 
infection, particularly catheter-related bacteremia, and is associated with higher costs, 
morbidity, and mortality, compared with other accesses (87-88). Other complications of the 
tunneled catheter include intraluminal thrombosis and fibrin sheath. 
6. Management of access complications 
6.1 Detection and treatment of stenosis and thrombosis of AVF and AVG 
Stenosis of AVF and AVG commonly develop over time, generally resulting from response 
to endothelial damage.  This can occur at the anastamosis between native vessels or between 
a graft and a native vessel, with endothelial damage caused by surgical trauma, or distal to 
the venous anastamosis, with endothelial damage from rapid turbulent flow. If these 
stenoses are not recognized and corrected, increased access pressures and decreased flow 
can result in thrombosis of the access. Once an access has thrombosed, even if it can be 
salvaged, the duration of secondary patency is relatively short, with 62% one year patency 
average (89). Therefore, monitoring and subsequent treatment of stenosis in AVFs and 
AVGs is critical to prolonging the life of these hemodialysis accesses. For an excellent review 
of the various methods of monitoring accesses, see reference 90. There are several ways to 
monitor for stenosis. Physical exam, looking for abnormalities such as change in thrill, bruit 
or pulse, presence of arm swelling, or prolonged bleeding after dialysis, can be quite helpful 
in detecting access problems (91). Another common way to detect stenosis is with dynamic 
venous pressure monitoring. With this technique, the pressure at the venous needle is 
measured with low dialysis pump rate.  If the pressure is over 80, or if there is significant 
increase from prior pressures, there is a high likelihood of outflow stenosis (92). Measuring 
static access pressures (with blood pump off) is more accurate, and can also detect arterial 
stenoses, but this technique requires additional equipment, and is therefore not common 
(93). Another monitoring method growing in use is Doppler flow measurement.  If the flow 
decreases to less than 650 mL/minute, or if there has been significant interval decrease in 
flow, there is a high likelihood of stenosis (94). Stenoses can be detected by Doppler 
ultrasound, but the gold standard for detection and treatment of access stenosis is 
fistulogram, or the injection of contrast into the access to demonstrate visually the stenosis.  
When a fistulogram demonstrates stenosis, the stenosis can be repaired with angioplasty or 
surgical revision.  While angioplasty has a shorter secondary patency than surgical revision, 
angioplasty is generally the first line treatment of stenosis and thrombosis of AVF and AVG, 
since surgical revision can be performed after angioplasty in case of recurrent stenosis or 
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thrombosis (95). Treatment with anticoagulant or anti-platelet therapy, e.g. aspirin, 
ticlopidine or warfarin, has a modest effect on reducing stenosis and increasing patency of 
fistulas; however, this treatment is associated with increased risk of hemorrhage (96). 
Antiplatelet therapy should be a part of routine care in patient with graft but not AV fistula 
(97). Other pharmacological approaches for prevention of stenosis and patency of vascular 
access including calcium channel blocker, ACE-I and fish oil have been investigated, but 
further research is required to determine the role of these agents in maintaining fistula 
patency. 
Another complication of AVF and AVG is vascular access induced ischemia and is related to 
significant amounts of blood flow via AV fistulas. This diversion of blood via the fistula 
could cause decrease of blood flow to the distal tissue and cause ischemia (known as steal 
syndrome). It could rarely cause exacerbation of heart failure in paints with underlying 
disease. Elderly patients, patients with diabetics, peripheral vascular disease or coronary 
artery disease are at increase risk of ischemia. Pain during hemodialysis is a characteristic 
symptom.  
Another vascular access complication is central venous obstruction occurring in patients 
with previously inserted venous catheter or pacemaker placement. The rate of central 
venous obstruction is higher in patients who had their brachial venous accessed prior to 
dialysis access placement compare to patient who had internal jugular vein accessed. The 
most common clinical presentation is pain and swelling of the ipsilateral arm usually 
accompanied with the superficial collateral vein around the shoulder. Other clue for 
diagnosis of central venous obstruction is finger ulceration, pain and inadequate dialysis. 
The first option for treatment is percutaneous transluminal angioplasty and stent placement 
(angioplasty alone has a high rate of restenosis). The second option is surgical revision with 
bypass grafting and placement of HERO catheter (as discussed above).  
6.2 Catheter thrombosis and fibrin sheath formation 
One of the most common complications of hemodialysis catheters is decrease of flow or 
thrombosis.  Catheter thrombosis prevention is generally achieved through instillation of 
heparin into the catheter ports after completion of dialysis; a recent study suggests that 
weekly instillation of recombinant tissue plasminogen activator (tPA) may prevent 
thrombosis more effectively (98). Catheter thrombosis can be treated effectively by 
instillation of tPA into the catheter lumens or with exchange of the catheter over a 
guidewire; however, thrombosis frequently recurs, necessitating further procedures.  One 
cause of frequent catheter malfunction is the formation of a fibrin sheath around the tip of 
the catheter.  This can be treated with a 3 hour infusion of low-dose tPA or with mechanical 
stripping, although secondary patency rates remain low (99). 
6.3 Catheter related blood stream infection (CRBSI) 
The prevalence of central venous catheters in the United States is about 20-30% despite 
recommendations from major societies to increase the use of AV fistulas known as fistula 
first initiative. There is an increased risk of mortality with the use of catheters compared 
with the use of AV fistulas (100). This increased rate of mortality is likely related to 
infection. The rate of catheter related blood stream infection is 0.5 to 6.6 episodes per 1,000 
catheter days (101). The source of this infection is bacterial seeding from biofilms that form 
on the inside and outside of the blood stream catheter. The rate of CRBSI is directly related 
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between creation and first use (84,86).  Because of the presence of foreign material, there is 
increased risk of access infection, although less than that with tunneled catheters, and there 
is an increased rate of stenosis, thrombosis, and graft failure compared with AVFs. One new 
technique in the creation of AVGs is the Hemodialysis Reliable Outflow (HeROTM) dialysis 
catheter, a new FDA approved device for catheter-dependent and significant vasculopathic 
patients. The HeRO device is an AVG that extends from the arm into the right ventricle.  
This may avoid problems with stenosis at the venous anastomosis leading to graft failure.   
The third means of chronic hemodialysis access is the tunneled catheter. This catheter, like 
the standard non-tunneled dialysis catheter used for acute hemodialysis access and non-
tunneled catheters used for venous access, is inserted into a central vein, usually the internal 
jugular vein, but the risk of infection is reduced by increasing the distance between the vein 
and skin entry by running the catheter through a subcutaneous tunnel. This access has the 
advantage of being usable immediately upon insertion, but it has the highest rate of 
infection, particularly catheter-related bacteremia, and is associated with higher costs, 
morbidity, and mortality, compared with other accesses (87-88). Other complications of the 
tunneled catheter include intraluminal thrombosis and fibrin sheath. 
6. Management of access complications 
6.1 Detection and treatment of stenosis and thrombosis of AVF and AVG 
Stenosis of AVF and AVG commonly develop over time, generally resulting from response 
to endothelial damage.  This can occur at the anastamosis between native vessels or between 
a graft and a native vessel, with endothelial damage caused by surgical trauma, or distal to 
the venous anastamosis, with endothelial damage from rapid turbulent flow. If these 
stenoses are not recognized and corrected, increased access pressures and decreased flow 
can result in thrombosis of the access. Once an access has thrombosed, even if it can be 
salvaged, the duration of secondary patency is relatively short, with 62% one year patency 
average (89). Therefore, monitoring and subsequent treatment of stenosis in AVFs and 
AVGs is critical to prolonging the life of these hemodialysis accesses. For an excellent review 
of the various methods of monitoring accesses, see reference 90. There are several ways to 
monitor for stenosis. Physical exam, looking for abnormalities such as change in thrill, bruit 
or pulse, presence of arm swelling, or prolonged bleeding after dialysis, can be quite helpful 
in detecting access problems (91). Another common way to detect stenosis is with dynamic 
venous pressure monitoring. With this technique, the pressure at the venous needle is 
measured with low dialysis pump rate.  If the pressure is over 80, or if there is significant 
increase from prior pressures, there is a high likelihood of outflow stenosis (92). Measuring 
static access pressures (with blood pump off) is more accurate, and can also detect arterial 
stenoses, but this technique requires additional equipment, and is therefore not common 
(93). Another monitoring method growing in use is Doppler flow measurement.  If the flow 
decreases to less than 650 mL/minute, or if there has been significant interval decrease in 
flow, there is a high likelihood of stenosis (94). Stenoses can be detected by Doppler 
ultrasound, but the gold standard for detection and treatment of access stenosis is 
fistulogram, or the injection of contrast into the access to demonstrate visually the stenosis.  
When a fistulogram demonstrates stenosis, the stenosis can be repaired with angioplasty or 
surgical revision.  While angioplasty has a shorter secondary patency than surgical revision, 
angioplasty is generally the first line treatment of stenosis and thrombosis of AVF and AVG, 
since surgical revision can be performed after angioplasty in case of recurrent stenosis or 
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thrombosis (95). Treatment with anticoagulant or anti-platelet therapy, e.g. aspirin, 
ticlopidine or warfarin, has a modest effect on reducing stenosis and increasing patency of 
fistulas; however, this treatment is associated with increased risk of hemorrhage (96). 
Antiplatelet therapy should be a part of routine care in patient with graft but not AV fistula 
(97). Other pharmacological approaches for prevention of stenosis and patency of vascular 
access including calcium channel blocker, ACE-I and fish oil have been investigated, but 
further research is required to determine the role of these agents in maintaining fistula 
patency. 
Another complication of AVF and AVG is vascular access induced ischemia and is related to 
significant amounts of blood flow via AV fistulas. This diversion of blood via the fistula 
could cause decrease of blood flow to the distal tissue and cause ischemia (known as steal 
syndrome). It could rarely cause exacerbation of heart failure in paints with underlying 
disease. Elderly patients, patients with diabetics, peripheral vascular disease or coronary 
artery disease are at increase risk of ischemia. Pain during hemodialysis is a characteristic 
symptom.  
Another vascular access complication is central venous obstruction occurring in patients 
with previously inserted venous catheter or pacemaker placement. The rate of central 
venous obstruction is higher in patients who had their brachial venous accessed prior to 
dialysis access placement compare to patient who had internal jugular vein accessed. The 
most common clinical presentation is pain and swelling of the ipsilateral arm usually 
accompanied with the superficial collateral vein around the shoulder. Other clue for 
diagnosis of central venous obstruction is finger ulceration, pain and inadequate dialysis. 
The first option for treatment is percutaneous transluminal angioplasty and stent placement 
(angioplasty alone has a high rate of restenosis). The second option is surgical revision with 
bypass grafting and placement of HERO catheter (as discussed above).  
6.2 Catheter thrombosis and fibrin sheath formation 
One of the most common complications of hemodialysis catheters is decrease of flow or 
thrombosis.  Catheter thrombosis prevention is generally achieved through instillation of 
heparin into the catheter ports after completion of dialysis; a recent study suggests that 
weekly instillation of recombinant tissue plasminogen activator (tPA) may prevent 
thrombosis more effectively (98). Catheter thrombosis can be treated effectively by 
instillation of tPA into the catheter lumens or with exchange of the catheter over a 
guidewire; however, thrombosis frequently recurs, necessitating further procedures.  One 
cause of frequent catheter malfunction is the formation of a fibrin sheath around the tip of 
the catheter.  This can be treated with a 3 hour infusion of low-dose tPA or with mechanical 
stripping, although secondary patency rates remain low (99). 
6.3 Catheter related blood stream infection (CRBSI) 
The prevalence of central venous catheters in the United States is about 20-30% despite 
recommendations from major societies to increase the use of AV fistulas known as fistula 
first initiative. There is an increased risk of mortality with the use of catheters compared 
with the use of AV fistulas (100). This increased rate of mortality is likely related to 
infection. The rate of catheter related blood stream infection is 0.5 to 6.6 episodes per 1,000 
catheter days (101). The source of this infection is bacterial seeding from biofilms that form 
on the inside and outside of the blood stream catheter. The rate of CRBSI is directly related 
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to the species and level of virulence of the seeding bacteria. Meticulous catheter care and 
reeducation of personnel responsible for insertion of the catheters are the key elements in 
lowering the rate of catheter related infection (101). The catheter care includes but is not 
limited to sterile technique of catheter placement, exit –site care, sterile technique during 
initiation and termination of dialysis (including the use of a sterile barrier, sterile gloves, 
and antiseptic to clean the tubes) and the replacement of malfunctioning catheters over a 
guidewire (empirical administration of antibiotics does not reduce the incidence of catheter 
associated bacteremia) (102). Using standard antiseptic precautions the incidence of catheter 
related infection could drop to one episode per 1,000 catheter days which could be used to 
assess the quality of catheter care. 
The current guidelines indicate the use of tunneled cuffed catheter for long term use (more 
than 3 weeks duration) in patients in need of hemodialysis based on pathophysiological 
considerations as well as a generally lower rate of infection of tunneled, cuffed catheters 
compared to nontunneled catheters (103). The location of catheters influences the risk of 
infection. The femoral lines carry a higher rate of infection compare with the subclavian or 
jugular lines. Subsequent studies, however, only confirm an increase risk of femoral catheter 
infection in the patients with a higher BMI (87-88,102).  
Although the prophylactic use of systemic antibiotics at the time of insertion of a catheter is 
not currently recommended, the antimicrobial lock solutions for prevention of catheter 
related infection and bactremia are recommended (101). The ideal lock solution has 
anticoagulant and antimicrobial activity, is safe, and does not induce bacterial resistance. 
The antimicrobial solutions most frequently used are antibiotics or chemicals, citrate (30% 
concentrated since the lower concentration has little antimicrobial affect) (104). 
Antimicrobial lock solutions substantially reduce the risk of catheter related infection (102). 
The potential disadvantage of usage of antibiotics for antimicrobial lock solution is bacterial 
resistance and predisposition to highly resistance bacterial infection. There is also a potential 
adverse effect of these antibiotics including aminoglycoside-related ototoxicity. The 
disadvantage of usage of citrate is hypocalcemia and adverse cardiac event if the locking 
solution is pushed to the patient blood (105).  
Application of topical antibiotics to the exit site may reduce the incidence of catheter related 
infection in patients on hemodialysis. The most recent CDC guideline recommends use of 
povidone iodine antiseptic ointment or bacitracin/gramicidin/polymyxin B at the 
hemodialysis catheter exit site after each dialysis session (101). A recent Cochrane review on 
this subject concluded that the current data support only the topical application of 
mupirocin alone (among antibacterial agents) for prevention of catheter related infection 
(106). The use of antibiotic coated catheter in hemodialysis patients has not been shown to 
reduce the incidence of catheter related infection (101,107). 
Staphylococcus species in general and S. aureus in particular are among the most common 
cause of bacterial related infection.  Mortality rate is high among the patient infected with S. 
aureus (8%). Morbidity related to S. aureus is secondary to its high propensity to colonize 
prosthetic materials, heart valves, bones and joints. Nasal carriage of S. aureus is common 
among patients on dialysis, in whom it is associated with an increased risk of S. aureus 
infection. Successful elimination of S. aureus nasal carriage can be achieved by a short (5-
day) course of mupirocin applied daily to the anterior nares (108).  
Treatment of CRBSI requires systemic antibiotics and frequently discontinuation of the 
catheter and placement of temporary catheter. There are four possible options for treatment 
of CRBSI. Intravenous antibiotics alone, prompt catheter removal with delayed placement of 
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a new long term catheter, exchange of the infected catheter with a new one over guidewire, 
or use of systemic antibiotics and an antibiotic lock in the existing catheter. Antibiotic 
therapy for catheter-related infection is often initiated empirically. The initial choice of 
antibiotics will depend on the severity of the patient’s clinical disease, the risk factors for 
infection, and the likely pathogens associated with the specific intravascular device (109). 
Antibiotic therapy should be administered to patients with persistent fungemia or 
bacteremia after catheter removal (especially if the infection is caused by S. aureus). Long-
term catheters should be removed from patients with CRBSI associated with any of the 
following conditions: severe sepsis; suppurative thrombophlebitis; endocarditis; 
bloodstream infection that continues despite antimicrobial therapy to which the infecting 
microbes are susceptible (110). In uncomplicated CRBSI involving long-term catheters due 
to pathogens other than S. aureus, P. aeruginosa, fungi, because of the limited access sites in 
many patients who require long-term intravascular access for survival in hemodialysis 
patients, treatment should be attempted without catheter removal, with use of both systemic 
and antimicrobial lock therapy for 14 days and cultures should be repeated one week after 
completion of antibiotics treatment. The rate of treatment failure, however, is higher for 
patient treated with antibiotics alone (111). If the symptoms resolve after 2–3 days of 
intravenous antibiotic therapy, guidewire exchange of the catheter is associated with cure 
rates that are comparable to those associated with immediate removal and delayed 
placement of a new catheter (110). Localized Cellulites (exit site infection) should be treated 
with systemic antibiotics and exit site care. Tunnel track infection, however, requires 
catheter removal since it involves space in an area with limited vascular supply (112). 
6.4 Acute vascular access 
A large diameter venous catheter (a dual lumen venous catheter) usually placed in the 
internal jugular or femoral vein, is needed for acute or urgent hemodialysis in the absence of 
permanent vascular access. This catheter is used in patients with acute kidney injury who 
need urgent hemodialysis, in patients who need removal of a toxic agent by means of 
dialysis, or with chronic dialysis patients with a temporary inability to use a permanent 
access, as with catheter-related bacteremia. Using this type of access, one lumen of the 
venous catheter is allocated to draw blood (arterial side) and the other lumen is allocated to 
return the blood. Separation of arterial from venous lumen minimized the recirculation of 
blood during hemodialysis. Because of high risk of infection, non-tunneled femoral catheter 
should be removed within a week, while non-tunneled internal jugular catheters can be 
used for about 2 weeks. Hemodialysis catheters placed in the subclavian veins have a 
significant risk of subclavian stenosis, which can cause the arm on that side to be unsuitable 
for AVF or AVG placement, and so catheters are generally not placed in the subclavian 
veins.   An indwelling cuffed catheter is tunneled under the skin and placed in the internal 
jugular vein by an interventional nephrologist, interventional radiologist or surgeon. It is 
used when acute renal failure is expected to require hemodialysis for more than 2 weeks 
because of the decreased rate of infection (1034).  
6.5 Extracorporeal therapies in the ICU setting - continuous renal replacement 
therapy 
Critically ill, hemodynamically unstable intensive care unit (ICU) patients are typically the 
most challenging to treat with conventional dialytic modalities as described above. The 
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to the species and level of virulence of the seeding bacteria. Meticulous catheter care and 
reeducation of personnel responsible for insertion of the catheters are the key elements in 
lowering the rate of catheter related infection (101). The catheter care includes but is not 
limited to sterile technique of catheter placement, exit –site care, sterile technique during 
initiation and termination of dialysis (including the use of a sterile barrier, sterile gloves, 
and antiseptic to clean the tubes) and the replacement of malfunctioning catheters over a 
guidewire (empirical administration of antibiotics does not reduce the incidence of catheter 
associated bacteremia) (102). Using standard antiseptic precautions the incidence of catheter 
related infection could drop to one episode per 1,000 catheter days which could be used to 
assess the quality of catheter care. 
The current guidelines indicate the use of tunneled cuffed catheter for long term use (more 
than 3 weeks duration) in patients in need of hemodialysis based on pathophysiological 
considerations as well as a generally lower rate of infection of tunneled, cuffed catheters 
compared to nontunneled catheters (103). The location of catheters influences the risk of 
infection. The femoral lines carry a higher rate of infection compare with the subclavian or 
jugular lines. Subsequent studies, however, only confirm an increase risk of femoral catheter 
infection in the patients with a higher BMI (87-88,102).  
Although the prophylactic use of systemic antibiotics at the time of insertion of a catheter is 
not currently recommended, the antimicrobial lock solutions for prevention of catheter 
related infection and bactremia are recommended (101). The ideal lock solution has 
anticoagulant and antimicrobial activity, is safe, and does not induce bacterial resistance. 
The antimicrobial solutions most frequently used are antibiotics or chemicals, citrate (30% 
concentrated since the lower concentration has little antimicrobial affect) (104). 
Antimicrobial lock solutions substantially reduce the risk of catheter related infection (102). 
The potential disadvantage of usage of antibiotics for antimicrobial lock solution is bacterial 
resistance and predisposition to highly resistance bacterial infection. There is also a potential 
adverse effect of these antibiotics including aminoglycoside-related ototoxicity. The 
disadvantage of usage of citrate is hypocalcemia and adverse cardiac event if the locking 
solution is pushed to the patient blood (105).  
Application of topical antibiotics to the exit site may reduce the incidence of catheter related 
infection in patients on hemodialysis. The most recent CDC guideline recommends use of 
povidone iodine antiseptic ointment or bacitracin/gramicidin/polymyxin B at the 
hemodialysis catheter exit site after each dialysis session (101). A recent Cochrane review on 
this subject concluded that the current data support only the topical application of 
mupirocin alone (among antibacterial agents) for prevention of catheter related infection 
(106). The use of antibiotic coated catheter in hemodialysis patients has not been shown to 
reduce the incidence of catheter related infection (101,107). 
Staphylococcus species in general and S. aureus in particular are among the most common 
cause of bacterial related infection.  Mortality rate is high among the patient infected with S. 
aureus (8%). Morbidity related to S. aureus is secondary to its high propensity to colonize 
prosthetic materials, heart valves, bones and joints. Nasal carriage of S. aureus is common 
among patients on dialysis, in whom it is associated with an increased risk of S. aureus 
infection. Successful elimination of S. aureus nasal carriage can be achieved by a short (5-
day) course of mupirocin applied daily to the anterior nares (108).  
Treatment of CRBSI requires systemic antibiotics and frequently discontinuation of the 
catheter and placement of temporary catheter. There are four possible options for treatment 
of CRBSI. Intravenous antibiotics alone, prompt catheter removal with delayed placement of 
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a new long term catheter, exchange of the infected catheter with a new one over guidewire, 
or use of systemic antibiotics and an antibiotic lock in the existing catheter. Antibiotic 
therapy for catheter-related infection is often initiated empirically. The initial choice of 
antibiotics will depend on the severity of the patient’s clinical disease, the risk factors for 
infection, and the likely pathogens associated with the specific intravascular device (109). 
Antibiotic therapy should be administered to patients with persistent fungemia or 
bacteremia after catheter removal (especially if the infection is caused by S. aureus). Long-
term catheters should be removed from patients with CRBSI associated with any of the 
following conditions: severe sepsis; suppurative thrombophlebitis; endocarditis; 
bloodstream infection that continues despite antimicrobial therapy to which the infecting 
microbes are susceptible (110). In uncomplicated CRBSI involving long-term catheters due 
to pathogens other than S. aureus, P. aeruginosa, fungi, because of the limited access sites in 
many patients who require long-term intravascular access for survival in hemodialysis 
patients, treatment should be attempted without catheter removal, with use of both systemic 
and antimicrobial lock therapy for 14 days and cultures should be repeated one week after 
completion of antibiotics treatment. The rate of treatment failure, however, is higher for 
patient treated with antibiotics alone (111). If the symptoms resolve after 2–3 days of 
intravenous antibiotic therapy, guidewire exchange of the catheter is associated with cure 
rates that are comparable to those associated with immediate removal and delayed 
placement of a new catheter (110). Localized Cellulites (exit site infection) should be treated 
with systemic antibiotics and exit site care. Tunnel track infection, however, requires 
catheter removal since it involves space in an area with limited vascular supply (112). 
6.4 Acute vascular access 
A large diameter venous catheter (a dual lumen venous catheter) usually placed in the 
internal jugular or femoral vein, is needed for acute or urgent hemodialysis in the absence of 
permanent vascular access. This catheter is used in patients with acute kidney injury who 
need urgent hemodialysis, in patients who need removal of a toxic agent by means of 
dialysis, or with chronic dialysis patients with a temporary inability to use a permanent 
access, as with catheter-related bacteremia. Using this type of access, one lumen of the 
venous catheter is allocated to draw blood (arterial side) and the other lumen is allocated to 
return the blood. Separation of arterial from venous lumen minimized the recirculation of 
blood during hemodialysis. Because of high risk of infection, non-tunneled femoral catheter 
should be removed within a week, while non-tunneled internal jugular catheters can be 
used for about 2 weeks. Hemodialysis catheters placed in the subclavian veins have a 
significant risk of subclavian stenosis, which can cause the arm on that side to be unsuitable 
for AVF or AVG placement, and so catheters are generally not placed in the subclavian 
veins.   An indwelling cuffed catheter is tunneled under the skin and placed in the internal 
jugular vein by an interventional nephrologist, interventional radiologist or surgeon. It is 
used when acute renal failure is expected to require hemodialysis for more than 2 weeks 
because of the decreased rate of infection (1034).  
6.5 Extracorporeal therapies in the ICU setting - continuous renal replacement 
therapy 
Critically ill, hemodynamically unstable intensive care unit (ICU) patients are typically the 
most challenging to treat with conventional dialytic modalities as described above. The 
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intermittent volume and solute fluxes may cause significant morbidity, which includes 
worsening of hypotension and arrhythmias. Multiple modalities of renal replacement 
therapy are currently available. These include intermittent hemodialysis (IHD), continuous 
renal replacement therapies (CRRTs), and hybrid therapies, such as sustained low-efficiency 
dialysis (SLED). 
 
INDICATIONS FOR AND TIMING OF INITIATION OF DIALYSIS — Accepted 
indications for renal replacement therapy (RRT) in patients with Acute Kidney Injury 
(AKI) generally include: 
Refractory fluid overload 
Hyperkalemia (plasma potassium concentration >6.5 meq/L) refractory to medical 
therapy 
Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline 
in mental status 
Metabolic acidosis (pH less than 7.1) refractory to medical therapy. 
Certain alcohol and drug intoxications 
 
CRRTs involve either dialysis (diffusion-based solute removal) or filtration (convection-
based solute and water removal) treatments that operate in a continuous mode (114-117). 
The major advantage of continuous therapy is the slower rate of solute or fluid removal per 
unit of time. Thus, CRRT is generally better tolerated than conventional therapy, since many 
of the complications of intermittent hemodialysis are related to the rapid rate of solute and 
fluid loss. It must be emphasized, however, that the protection afforded by CRRT is relative, 
not absolute. 
7. Outcomes in CRRT 
Outcomes of an increased dose of CRRT have been assessed in several randomized 
controlled trials and two meta-analyses (78-80,116-117). Conflicting results related to 
survival have been reported. To address the issue of optimal dose in CRRT and IHD, the 
United States VA/NIH Acute Renal Failure Trial Network study (ATN), the Randomized 
Evaluation of Normal versus Augmented Level of RRT study (RENAL) and two meta-
analyses were performed. All studies found that, compared with standard intensity dialysis, 
higher intensity dialysis did not result in improved survival or clinical benefits: 
In the United States VA/NIH Acute Renal Failure Trial Network study (ATN), all 1124 
patients were treated with IHD, CRRT, or SLED based upon hemodynamic status. Patients 
were randomly assigned to one of two dosing arms:  
- Intensive therapy: Hemodialysis and SLED were given six times per week and a target 
Kt/V of 1.2 to 1.4 per treatment, while CRRT was provided with an effluent flow rate of 
35 mL/kg per hour.  
- Less intensive therapy: Hemodialysis and SLED were given three times per week, while 
CRRT was provided with a flow rate of 20 mL/kg per hour.  
The death rate at day 60 was the same for both groups (53.6 percent with intensive therapy 
and 51.5 percent with less intensive therapy). In addition, the duration of renal replacement 
therapy and the rate of recovery of kidney function or nonrenal organ failure were similar 
for both treatment arms. The group that received intensive therapy had an increased 
number of hypotensive episodes. Thus, more intensive renal support beyond that obtained 
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with a standard thrice-weekly regimen (with a target Kt/V of 1.2 to 1.4 per treatment) or 
standard CRRT (with an effluent flow rate of 20 mL/kg per hour) does not improve clinical 
outcomes. 
In the RENAL study (a trial in Australia and New Zealand), 1508 patients with AKI were 
randomly assigned to CVVHDF at an effluent flow of either 25 or 40 mL/kg per hour (119). 
At 90 days, mortality was the same in each group (44.7 percent, odds ratio 1.00, 95% CI 0.31 
to 1.23). In addition, the incidence of patients who continued to receive renal replacement 
therapy at 90 days was similar with both dialysis doses (6.8 and 4.4 percent of higher and 
lower-intensity groups, odds ratio 1.59, 95% CI 0.86 to 2.92). 
Two meta-analyses, one consisting of 3841 patients and 8 trials and the other 3999 patients 
and 12 trials, found that more intense therapy did not improve survival compared with less 
intensive regimens (118-119). There was significant trial heterogeneity. 
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intermittent volume and solute fluxes may cause significant morbidity, which includes 
worsening of hypotension and arrhythmias. Multiple modalities of renal replacement 
therapy are currently available. These include intermittent hemodialysis (IHD), continuous 
renal replacement therapies (CRRTs), and hybrid therapies, such as sustained low-efficiency 
dialysis (SLED). 
 
INDICATIONS FOR AND TIMING OF INITIATION OF DIALYSIS — Accepted 
indications for renal replacement therapy (RRT) in patients with Acute Kidney Injury 
(AKI) generally include: 
Refractory fluid overload 
Hyperkalemia (plasma potassium concentration >6.5 meq/L) refractory to medical 
therapy 
Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline 
in mental status 
Metabolic acidosis (pH less than 7.1) refractory to medical therapy. 
Certain alcohol and drug intoxications 
 
CRRTs involve either dialysis (diffusion-based solute removal) or filtration (convection-
based solute and water removal) treatments that operate in a continuous mode (114-117). 
The major advantage of continuous therapy is the slower rate of solute or fluid removal per 
unit of time. Thus, CRRT is generally better tolerated than conventional therapy, since many 
of the complications of intermittent hemodialysis are related to the rapid rate of solute and 
fluid loss. It must be emphasized, however, that the protection afforded by CRRT is relative, 
not absolute. 
7. Outcomes in CRRT 
Outcomes of an increased dose of CRRT have been assessed in several randomized 
controlled trials and two meta-analyses (78-80,116-117). Conflicting results related to 
survival have been reported. To address the issue of optimal dose in CRRT and IHD, the 
United States VA/NIH Acute Renal Failure Trial Network study (ATN), the Randomized 
Evaluation of Normal versus Augmented Level of RRT study (RENAL) and two meta-
analyses were performed. All studies found that, compared with standard intensity dialysis, 
higher intensity dialysis did not result in improved survival or clinical benefits: 
In the United States VA/NIH Acute Renal Failure Trial Network study (ATN), all 1124 
patients were treated with IHD, CRRT, or SLED based upon hemodynamic status. Patients 
were randomly assigned to one of two dosing arms:  
- Intensive therapy: Hemodialysis and SLED were given six times per week and a target 
Kt/V of 1.2 to 1.4 per treatment, while CRRT was provided with an effluent flow rate of 
35 mL/kg per hour.  
- Less intensive therapy: Hemodialysis and SLED were given three times per week, while 
CRRT was provided with a flow rate of 20 mL/kg per hour.  
The death rate at day 60 was the same for both groups (53.6 percent with intensive therapy 
and 51.5 percent with less intensive therapy). In addition, the duration of renal replacement 
therapy and the rate of recovery of kidney function or nonrenal organ failure were similar 
for both treatment arms. The group that received intensive therapy had an increased 
number of hypotensive episodes. Thus, more intensive renal support beyond that obtained 
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with a standard thrice-weekly regimen (with a target Kt/V of 1.2 to 1.4 per treatment) or 
standard CRRT (with an effluent flow rate of 20 mL/kg per hour) does not improve clinical 
outcomes. 
In the RENAL study (a trial in Australia and New Zealand), 1508 patients with AKI were 
randomly assigned to CVVHDF at an effluent flow of either 25 or 40 mL/kg per hour (119). 
At 90 days, mortality was the same in each group (44.7 percent, odds ratio 1.00, 95% CI 0.31 
to 1.23). In addition, the incidence of patients who continued to receive renal replacement 
therapy at 90 days was similar with both dialysis doses (6.8 and 4.4 percent of higher and 
lower-intensity groups, odds ratio 1.59, 95% CI 0.86 to 2.92). 
Two meta-analyses, one consisting of 3841 patients and 8 trials and the other 3999 patients 
and 12 trials, found that more intense therapy did not improve survival compared with less 
intensive regimens (118-119). There was significant trial heterogeneity. 
8. References 
[1] Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview 
of patient numbers, treatment modalities and associated trends. Nephrol. Dial. 
Transplant. 2005, 20 (12): 2587-2593. 
[2] United States Renal Data System. USRDS 2010 Annual Data Report: Atlas of End-Stage 
Renal Disease in the United States 2010; Bethesda, MD, National Institute of Health, 
National Institutes of Diabetes and Digestive and Kidney Diseases. 
[3] Alper B, Shenava, R, Young, B, et. al. Uremia. Medscape. Batuman V. Mar 17, 2010. 
http://emedicine.medscape.com/article/245296-overview 
[4] Termorshuizen F, Dekker FW, van Manen JG et al., Relative contribution of residual 
renal function and different measures of adequacy to survival in hemodialysis 
patients: an analysis of the Netherlands Cooperative Study on the Adequacy of 
Dialysis (NECOSAD)-2, J Am Soc Nephrol 2004; 15:1061-70 
[5] Rosansky SJ, Clark WF, Eggers P, Glassock RJ. Initiation of dialysis at higher GFRs: is the 
apparent rising tide of early dialysis harmful or helpful? Kidney Int. 2009 
Aug;76(3):257-61. 
[6] Schrier R. Manual of Nephrology: Diagnosis and Therapy. Philadelphia: Lippincott 
Williams & Wilkins, 2009. 
[7] Pendse, S, Singh, A, Zawada, E. Initiation of dialysis in Handbook of Dialysis, 4th ed, 
Daugirdas, JT, Blake, PG, Ing, TS (Eds). Lippincott Williams & Wilkins, 
Philadelphia 2007. 
[8] Rosansky SJ, Eggers P, Jackson K, Glassock R, Clark WF. Early Start of Hemodialysis 
May Be Harmful. Arch Intern Med. 2011; 171(5):396-403) 
[9] NKF-KDOQI Clinical Practice Guidelines. Am J Kidney Dis 1997; 30(3 Suppl 2): S67–
S136. 
[10] Obrador RT, Auora P, Kausz AT et al. Level of renal function at the initiation of 
dialysis in the US end-stage renal disease population. Kidney Int 1999; 5: 2227–
2235. 
[11] National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice 
recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis 
adequacy and vascular access. Am J Kidney Dis 2006; 48(Suppl 1): S1–S322. 
[12] Tang, SC, Ho, YW, Tang, AW, et al. Delaying initiation of dialysis till symptomatic 
uraemia--is it too late? Nephrol Dial Transplant 2007; 22:1926. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
246 
[13] Cooper, BA, Branley, P, Bulfone, L, et al. A randomized, controlled trial of early versus 
late initiation of dialysis. N Engl J Med 2010; 363:609. 
[14] Clark, W., Na, Y., Rosansky, S., et.al. Association between estimated glomerular 
filtration rate at initiation of dialysis and mortality. CMAJ. 2011 Jan 11;183(1):47-53. 
[15] United States Renal Data System. Excerpts from the USRDS 2009 annual data report: 
Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 
1(Suppl 1):S1. 
[16] USRDS: The United States Renal Data System: Overall hospitalization and mortality. 
Am J Kidney Dis 2010; 55(Suppl 1):S1.] 
[17] Van Biesen W, Vanholder R, Lameire N. The role of peritoneal dialysis as the first-line 
renal replacement modality. Perit Dial Int. 2000;20(4):375 
[18] Goldstein A, Kliger AS, Finkelstein FO. Recovery of renal function and the 
discontinuation of dialysis in patients treated with continuous peritoneal 
dialysis.Perit Dial Int. 2003;23(2):151 
[19] Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis. 2003;42(5):1082 
[20] Wauters JP, Uehlinger D. Non-medical factors influencing peritoneal dialysis 
utilization: the Swiss experience. Nephrol Dial Transplant. 2004;19(6):1363 
[21] Mendelssohn DC, Langlois N, Blake PG. Peritoneal dialysis in Ontario: a natural 
experiment in physician reimbursement methodology. Perit Dial Int. 2004;24(6):531 
[22] Tonelli M, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, Manns B, 
Alberta Kidney Disease Network.  Mortality of Canadians treated by peritoneal 
dialysis in remote locations. Kidney Int. 2007;72(8):1023 
[23] Mehrotra R, Khawar O, Duong U, Fried L, Norris K, Nissenson A, Kalantar-Zadeh K. 
Ownership patterns of dialysis units and peritoneal dialysis in the United States: 
utilization and outcomes. Am J Kidney Dis. 2009;54(2):289. 
[24] Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis 
compared with peritoneal dialysis in patients new on dialysis treatment: a 
randomized controlled trial. Kidney Int 2003;64:2222-2228. 
[25] Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis 
modality among incident ESRD patients with and without coronary artery disease. 
J Am Soc Nephrol 2003;14:415-424 
[26] Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of 
new ESRD patients with congestive heart failure in the United States. Kidney Int 
2003;64:1071-1079 
[27] Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on 
mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004;66:2389-2401 
[28] Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal 
dialysis and hemodialysis in a national cohort of patients with chronic kidney 
disease. Ann Intern Med 2005;143:174-183. 
[29] Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner 
K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, 
Vanholder R: EBPG guideline on dialysis strategies. Nephrol Dial Transplant 
22[Suppl 2]: ii5–ii21, 2007. 
[30] Lowrie, E, Laird, NM. National Cooperative Dialysis Study. Kidney Int Suppl 1983; 
23:19. 
 
Hemodialysis Principles and Controversies 
 
247 
[31] Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey 
J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, 
Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) 
Study Group. Effect of dialysis dose and membrane flux in maintenance 
hemodialysis. N Engl J Med. 2002;347(25):2010. 
[32] Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, 
Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal 
clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, 
randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307 
[33] Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner 
K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, 
Vanholder R: EBPG guideline on dialysis strategies. Nephrol Dial Transplant 
22[Suppl 2]: ii5–ii21, 2007 
[34] Kjellstrand CM, Buoncristiani U, Ting G, Traeger J, Piccoli GB, Sibai-Galland R, Young 
BA, Blagg CR: Short daily haemodialysis: Survival in 415 patients treated for 1006 
patient-years. Nephrol Dial Transplant 23: 3283–3289, 2008. 
[35] DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 
'daily' dialysis. Proc EDTA 1969; 6:26....DePalma, JR, Pecker, EA, Maxwell, MH. A 
new automatic coil dialyser system for 'daily' dialysis. Semin Dial 1999; 12:410. 
[36] Henderson LW, Leypoldt JK, Lysaght MJ, Cheung AK. Death on dialysis and the 
time/flux trade-off. Blood Purif. 1997;15(1):1. 
[37] FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman 
JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, 
Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman 
G, Ting GO, Unruh ML, Star RA, Kliger AS. In-center hemodialysis six times per 
week versus three times per week. N Engl J Med. 2010;363(24):2287. 
[38] Kalirao P and Kaplan JM, Nocturnal Hemodialysis, Clin Exp Nephrol 2009; 13:257-62 
[39] Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, Langos V, 
Uldall R. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 
1998;9(5):859. 
[40] Udall, PR, Francoeur, R, Ouwendyk, M. Simplified nocturnal home hemodialysis 
(SNHHD). A new approach to renal replacement therapy. J Am Soc Nephrol 1994; 
5:428 
[41] Lindsay RM, Daily/Nocturnal Dialysis Study Group. The London, Ontario, 
Daily/Nocturnal Hemodialysis Study. Semin Dial. 2004;17(2):85 
[42] Lockridge RS Jr, Spencer M, Craft V, Pipkin M, Campbell D, McPhatter L, Albert J, 
Anderson H, Jennings F, Barger T. Nocturnal home hemodialysis in North 
America. Adv Ren Replace Ther. 2001;8(4):250. 
[43] Agar JW, Somerville CA, Dwyer KM, Simmonds RE, Boddington JM, Waldron CM. 
Nocturnal hemodialysis in australia. Hemodial Int. 2003;7(4):278. 
[44] Kooistra MP. Frequent prolonged home haemodialysis: three old concepts, one 
modern solution. Nephrol Dial Transplant. 2003;18(1):16. 
[45] Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: survival in 
415 patients treated for 1006 patient-years. Nephrol Dial Transplant 2008;23:3283-
3289. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
246 
[13] Cooper, BA, Branley, P, Bulfone, L, et al. A randomized, controlled trial of early versus 
late initiation of dialysis. N Engl J Med 2010; 363:609. 
[14] Clark, W., Na, Y., Rosansky, S., et.al. Association between estimated glomerular 
filtration rate at initiation of dialysis and mortality. CMAJ. 2011 Jan 11;183(1):47-53. 
[15] United States Renal Data System. Excerpts from the USRDS 2009 annual data report: 
Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 
1(Suppl 1):S1. 
[16] USRDS: The United States Renal Data System: Overall hospitalization and mortality. 
Am J Kidney Dis 2010; 55(Suppl 1):S1.] 
[17] Van Biesen W, Vanholder R, Lameire N. The role of peritoneal dialysis as the first-line 
renal replacement modality. Perit Dial Int. 2000;20(4):375 
[18] Goldstein A, Kliger AS, Finkelstein FO. Recovery of renal function and the 
discontinuation of dialysis in patients treated with continuous peritoneal 
dialysis.Perit Dial Int. 2003;23(2):151 
[19] Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis. 2003;42(5):1082 
[20] Wauters JP, Uehlinger D. Non-medical factors influencing peritoneal dialysis 
utilization: the Swiss experience. Nephrol Dial Transplant. 2004;19(6):1363 
[21] Mendelssohn DC, Langlois N, Blake PG. Peritoneal dialysis in Ontario: a natural 
experiment in physician reimbursement methodology. Perit Dial Int. 2004;24(6):531 
[22] Tonelli M, Hemmelgarn B, Culleton B, Klarenbach S, Gill JS, Wiebe N, Manns B, 
Alberta Kidney Disease Network.  Mortality of Canadians treated by peritoneal 
dialysis in remote locations. Kidney Int. 2007;72(8):1023 
[23] Mehrotra R, Khawar O, Duong U, Fried L, Norris K, Nissenson A, Kalantar-Zadeh K. 
Ownership patterns of dialysis units and peritoneal dialysis in the United States: 
utilization and outcomes. Am J Kidney Dis. 2009;54(2):289. 
[24] Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis 
compared with peritoneal dialysis in patients new on dialysis treatment: a 
randomized controlled trial. Kidney Int 2003;64:2222-2228. 
[25] Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis 
modality among incident ESRD patients with and without coronary artery disease. 
J Am Soc Nephrol 2003;14:415-424 
[26] Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of 
new ESRD patients with congestive heart failure in the United States. Kidney Int 
2003;64:1071-1079 
[27] Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on 
mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004;66:2389-2401 
[28] Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal 
dialysis and hemodialysis in a national cohort of patients with chronic kidney 
disease. Ann Intern Med 2005;143:174-183. 
[29] Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner 
K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, 
Vanholder R: EBPG guideline on dialysis strategies. Nephrol Dial Transplant 
22[Suppl 2]: ii5–ii21, 2007. 
[30] Lowrie, E, Laird, NM. National Cooperative Dialysis Study. Kidney Int Suppl 1983; 
23:19. 
 
Hemodialysis Principles and Controversies 
 
247 
[31] Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey 
J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, 
Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis (HEMO) 
Study Group. Effect of dialysis dose and membrane flux in maintenance 
hemodialysis. N Engl J Med. 2002;347(25):2010. 
[32] Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, 
Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal 
clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, 
randomized, controlled trial. J Am Soc Nephrol. 2002;13(5):1307 
[33] Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner 
K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, 
Vanholder R: EBPG guideline on dialysis strategies. Nephrol Dial Transplant 
22[Suppl 2]: ii5–ii21, 2007 
[34] Kjellstrand CM, Buoncristiani U, Ting G, Traeger J, Piccoli GB, Sibai-Galland R, Young 
BA, Blagg CR: Short daily haemodialysis: Survival in 415 patients treated for 1006 
patient-years. Nephrol Dial Transplant 23: 3283–3289, 2008. 
[35] DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 
'daily' dialysis. Proc EDTA 1969; 6:26....DePalma, JR, Pecker, EA, Maxwell, MH. A 
new automatic coil dialyser system for 'daily' dialysis. Semin Dial 1999; 12:410. 
[36] Henderson LW, Leypoldt JK, Lysaght MJ, Cheung AK. Death on dialysis and the 
time/flux trade-off. Blood Purif. 1997;15(1):1. 
[37] FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman 
JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, 
Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman 
G, Ting GO, Unruh ML, Star RA, Kliger AS. In-center hemodialysis six times per 
week versus three times per week. N Engl J Med. 2010;363(24):2287. 
[38] Kalirao P and Kaplan JM, Nocturnal Hemodialysis, Clin Exp Nephrol 2009; 13:257-62 
[39] Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, Langos V, 
Uldall R. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 
1998;9(5):859. 
[40] Udall, PR, Francoeur, R, Ouwendyk, M. Simplified nocturnal home hemodialysis 
(SNHHD). A new approach to renal replacement therapy. J Am Soc Nephrol 1994; 
5:428 
[41] Lindsay RM, Daily/Nocturnal Dialysis Study Group. The London, Ontario, 
Daily/Nocturnal Hemodialysis Study. Semin Dial. 2004;17(2):85 
[42] Lockridge RS Jr, Spencer M, Craft V, Pipkin M, Campbell D, McPhatter L, Albert J, 
Anderson H, Jennings F, Barger T. Nocturnal home hemodialysis in North 
America. Adv Ren Replace Ther. 2001;8(4):250. 
[43] Agar JW, Somerville CA, Dwyer KM, Simmonds RE, Boddington JM, Waldron CM. 
Nocturnal hemodialysis in australia. Hemodial Int. 2003;7(4):278. 
[44] Kooistra MP. Frequent prolonged home haemodialysis: three old concepts, one 
modern solution. Nephrol Dial Transplant. 2003;18(1):16. 
[45] Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: survival in 
415 patients treated for 1006 patient-years. Nephrol Dial Transplant 2008;23:3283-
3289. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
248 
[46] ERA-EDTA Registry: Annual Academic Medical Center. Amsterdam, The 
Netherlands, 2003. 
[47] Wizemann V, Külz M, Techert F, Nederlof B. Efficacy of haemodiafiltration. Nephrol 
Dial Transplant. 2001;16 Suppl 4:27. 
[48] Canaud B, Assounga A, Kerr P, Aznar R, Mion C. Failure of a daily haemofiltration 
programme using a highly permeable membrane to return beta 2-microglobulin 
concentrations to normal in haemodialysis patients. Nephrol Dial Transplant. 
1992;7(9):924. 
[49] Jaber BL, Zimmerman DL, Teehan GS, Swedko P, Burns K, Meyer KB, Leypoldt JK. 
Daily hemofiltration for end-stage renal disease: a feasibility and efficacy trial. 
Blood Purif. 2004;22(6):481. 
[50] Zimmerman, DL, Swedko, P, Posen, G, Burns, K. Daily hemofiltration with a 
simplified method of delivery. J Am Soc Nephrol 2002; 13:61A. 
[51] Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA. Change 
from three times a week on-line hemodiafiltration to short daily on-line 
hemodiafiltration. Kidney Int. 2003;64(1):305. 
[52] US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney 
Disease and End Stage Renal Disease in the United States, Bethesda, NIH, National 
Institute of Diabetes and Digestive and Kidney Disease, 2008 
[53] US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney 
Disease and End Stage Renal Disease in the United States, Bethesda, NIH, National 
Institute of Diabetes and Digestive and Kidney Disease, 2009 
[54] Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity?. Pediatr 
Nephrol 2008; 23:1211-1221. 
[55] Vanholder R, De Smet R, Glorieux G, et al: Review on uremic toxins: Classification, 
concentration, and interindividual variability. Kidney Int 2003; 63:1934-1943. 
[56] Ankit N. Mehta, MD; Andrew Z. Fenves, MD: Hemodialysis Adequacy: A Review; 
January 2010 Dialysis & Transplantation 
[57] Daugirdas JT. Simplifi ed equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. 
Adv Renal Replace Ther. 1995; 2:295-304. 
[58] Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K. The post-
hemodialysis rebound: predicting and quantifying its effect on Kt/V. Kidney Int. 
1996; 50: 2094-2102. 
[59] Leypoldt JK, Jaber BL, Zimmerman DL. Predicting treatment dose for novel therapies 
using urea standard Kt/V. Semin Dial. 2004; 17:142-145. 
[60]  Feehally, J, Floege, J, Johnson, R. The Comprehensive Clinical Nephrology. Chapter 
90; Hemodialysis: Outcomes and Adequacy. Copyright © 2010 Elsevier 
[61] Agarwal, R, Mehrotra, R, Townsend RR, Goldfarb, S. NephSap, Vol9, No. 6, November 
2010;pp 366-371 
[62] Powell JR, Oluwaseum O, Woo YM, Padmanabhan N, Narasingham E, Latta C, 
Tortolana J, Jardine AG, Geddes CC. Ten year experience of in-center thrice weekly 
long overnight hemodialysis. Clin J Am Soc Nephrol 4:1097-1101, 2009 
[63] Anderson AH, Cohen AJ, Kutner NG, Kopp JB, Kimmel PL, Mutner P; Missed dialysis 
sessions and hospitalization in hemodialysis patients after Hurricane Katrina. 
Kidney Int 75:1202-1208, 2009 
 
Hemodialysis Principles and Controversies 
 
249 
[64] National Kidney Foundation : KDOQI Clinical Practice Guidelines and Clinical 
Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal 
Dialysis Adequacy and Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1-
S322 
[65] Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey 
J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, 
Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Effect of dialysis dose and 
membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25):2010. 
Hemodialysis (HEMO) Study Group  
[66] DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 
'daily' dialysis. Proc EDTA 1969; 6:26.  
[67] DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 
'daily' dialysis. Semin Dial 1999; 12:410. 
[68] Uldall, PR, Francoeur, R, Ouwendyk, M. Simplified nocturnal home hemodialysis 
(SNHHD). A new approach to renal replacement therapy. J Am Soc Nephrol 1994; 
5:428.  
[69] Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year 
experience. J Am Soc Nephrol 1998; 9:859. 
[70] Cheung AK, Rocco MV, Yan G, et al: Serum β2-microglobulin levels predict mortality 
in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 2006; 17:546-
555. 
[71] Locatelli F, Martin-Malo A, Hannedouche T, et al: Effect of membrane permeability on 
survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645-654.  
[72] European Best Practice Guidelines Expert Group on Hemodialysis, European Renal 
Association. Nephrol Dial Transplant 2002; 17(Suppl 7):16-31.  
[73] Bargman JM, Golper TA: The importance of residual renal function for patients on 
dialysis. Nephrol Dial Transplant 2005; 20:671-673. 
[74] Kliger AS, More Intensive hemodialysis. Clin J Am Soc Nephrol 4[suppll 1] S121-S124, 
2009 
[75] Beecroft JM, Hoffstein V, Pierratos A, Chan Ct, McFarlane P, Hanly PJ, Nocturnal 
heamodialysis increases pharyngeal size in patients with sleep apnea and end stage 
renal disease. Nephrol Dialy Transplant 23: 673-679, 2008 
[76] McFarlane PA Reducing hemodialysis costs: conventional and quotidian home 
hemodialysis in Canada. Semin Dial. 2004: 17(2):118. 
[77] Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. 
Am J Kidney Dis. 1998;32(2):185. 
[78] Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. 
Effects of early high-volume continuous venovenous hemofiltration on survival 
and recovery of renal function in intensive care patients with acute renal failure: a 
prospective, randomized trial. Crit Care Med. 2002;30(10):2205. 
[79] Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of 
different doses in continuous veno-venous haemofiltration on outcomes of acute 
renal failure: a prospective randomised trial. Lancet. 2000;356(9223):26 
[80] Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T, Martin PY. 
Adding a dialysis dose to continuous hemofiltration increases survival in patients 
with acute renal failure. Kidney Int. 2006;70(7):1312. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
248 
[46] ERA-EDTA Registry: Annual Academic Medical Center. Amsterdam, The 
Netherlands, 2003. 
[47] Wizemann V, Külz M, Techert F, Nederlof B. Efficacy of haemodiafiltration. Nephrol 
Dial Transplant. 2001;16 Suppl 4:27. 
[48] Canaud B, Assounga A, Kerr P, Aznar R, Mion C. Failure of a daily haemofiltration 
programme using a highly permeable membrane to return beta 2-microglobulin 
concentrations to normal in haemodialysis patients. Nephrol Dial Transplant. 
1992;7(9):924. 
[49] Jaber BL, Zimmerman DL, Teehan GS, Swedko P, Burns K, Meyer KB, Leypoldt JK. 
Daily hemofiltration for end-stage renal disease: a feasibility and efficacy trial. 
Blood Purif. 2004;22(6):481. 
[50] Zimmerman, DL, Swedko, P, Posen, G, Burns, K. Daily hemofiltration with a 
simplified method of delivery. J Am Soc Nephrol 2002; 13:61A. 
[51] Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA. Change 
from three times a week on-line hemodiafiltration to short daily on-line 
hemodiafiltration. Kidney Int. 2003;64(1):305. 
[52] US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney 
Disease and End Stage Renal Disease in the United States, Bethesda, NIH, National 
Institute of Diabetes and Digestive and Kidney Disease, 2008 
[53] US Renal Data System: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney 
Disease and End Stage Renal Disease in the United States, Bethesda, NIH, National 
Institute of Diabetes and Digestive and Kidney Disease, 2009 
[54] Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity?. Pediatr 
Nephrol 2008; 23:1211-1221. 
[55] Vanholder R, De Smet R, Glorieux G, et al: Review on uremic toxins: Classification, 
concentration, and interindividual variability. Kidney Int 2003; 63:1934-1943. 
[56] Ankit N. Mehta, MD; Andrew Z. Fenves, MD: Hemodialysis Adequacy: A Review; 
January 2010 Dialysis & Transplantation 
[57] Daugirdas JT. Simplifi ed equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. 
Adv Renal Replace Ther. 1995; 2:295-304. 
[58] Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K. The post-
hemodialysis rebound: predicting and quantifying its effect on Kt/V. Kidney Int. 
1996; 50: 2094-2102. 
[59] Leypoldt JK, Jaber BL, Zimmerman DL. Predicting treatment dose for novel therapies 
using urea standard Kt/V. Semin Dial. 2004; 17:142-145. 
[60]  Feehally, J, Floege, J, Johnson, R. The Comprehensive Clinical Nephrology. Chapter 
90; Hemodialysis: Outcomes and Adequacy. Copyright © 2010 Elsevier 
[61] Agarwal, R, Mehrotra, R, Townsend RR, Goldfarb, S. NephSap, Vol9, No. 6, November 
2010;pp 366-371 
[62] Powell JR, Oluwaseum O, Woo YM, Padmanabhan N, Narasingham E, Latta C, 
Tortolana J, Jardine AG, Geddes CC. Ten year experience of in-center thrice weekly 
long overnight hemodialysis. Clin J Am Soc Nephrol 4:1097-1101, 2009 
[63] Anderson AH, Cohen AJ, Kutner NG, Kopp JB, Kimmel PL, Mutner P; Missed dialysis 
sessions and hospitalization in hemodialysis patients after Hurricane Katrina. 
Kidney Int 75:1202-1208, 2009 
 
Hemodialysis Principles and Controversies 
 
249 
[64] National Kidney Foundation : KDOQI Clinical Practice Guidelines and Clinical 
Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal 
Dialysis Adequacy and Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1-
S322 
[65] Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey 
J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, 
Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Effect of dialysis dose and 
membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25):2010. 
Hemodialysis (HEMO) Study Group  
[66] DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 
'daily' dialysis. Proc EDTA 1969; 6:26.  
[67] DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 
'daily' dialysis. Semin Dial 1999; 12:410. 
[68] Uldall, PR, Francoeur, R, Ouwendyk, M. Simplified nocturnal home hemodialysis 
(SNHHD). A new approach to renal replacement therapy. J Am Soc Nephrol 1994; 
5:428.  
[69] Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year 
experience. J Am Soc Nephrol 1998; 9:859. 
[70] Cheung AK, Rocco MV, Yan G, et al: Serum β2-microglobulin levels predict mortality 
in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 2006; 17:546-
555. 
[71] Locatelli F, Martin-Malo A, Hannedouche T, et al: Effect of membrane permeability on 
survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645-654.  
[72] European Best Practice Guidelines Expert Group on Hemodialysis, European Renal 
Association. Nephrol Dial Transplant 2002; 17(Suppl 7):16-31.  
[73] Bargman JM, Golper TA: The importance of residual renal function for patients on 
dialysis. Nephrol Dial Transplant 2005; 20:671-673. 
[74] Kliger AS, More Intensive hemodialysis. Clin J Am Soc Nephrol 4[suppll 1] S121-S124, 
2009 
[75] Beecroft JM, Hoffstein V, Pierratos A, Chan Ct, McFarlane P, Hanly PJ, Nocturnal 
heamodialysis increases pharyngeal size in patients with sleep apnea and end stage 
renal disease. Nephrol Dialy Transplant 23: 673-679, 2008 
[76] McFarlane PA Reducing hemodialysis costs: conventional and quotidian home 
hemodialysis in Canada. Semin Dial. 2004: 17(2):118. 
[77] Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. 
Am J Kidney Dis. 1998;32(2):185. 
[78] Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. 
Effects of early high-volume continuous venovenous hemofiltration on survival 
and recovery of renal function in intensive care patients with acute renal failure: a 
prospective, randomized trial. Crit Care Med. 2002;30(10):2205. 
[79] Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of 
different doses in continuous veno-venous haemofiltration on outcomes of acute 
renal failure: a prospective randomised trial. Lancet. 2000;356(9223):26 
[80] Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T, Martin PY. 
Adding a dialysis dose to continuous hemofiltration increases survival in patients 
with acute renal failure. Kidney Int. 2006;70(7):1312. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
250 
[81] Creation, cannulation and survival of arteriovenous fistulae: Data from the Dialysis 
Outcomes and Practice Patterns Study. Kidney International; Jan2003, Vol. 63 Issue 
1, p323-330, 8p 
[82] Schild AF: Maintaining vascular access: the management of hemodialysis 
arteriovenous grafts. Vasc Access. 2010 Apr-Jun;11(2):92-9. 
[83] Robin M et al. Hemodialysis Arteriovenous Fistula Maturity: US Evaluation Radiology 
2002, vol 221:1, 59-64 
[84]  Biuckians A, Scott EC, Meier GH, et al: The natural history of autologous fistulas as 
first-time dialysis access in the KDOQI era. J Vasc Surg  2008; 47:415-421. 
[85] Ronald L Pisoni, Eric W Young, Dawn M Dykstra, Roger N Greenwood, 
Erwin Hecking, Brenda Gillespie, Robert A Wolfe, David A Goodkin and Philip 
J HeldVascular access use in Europe and the United States: Results from the 
DOPPS, Kidney International (2002) 61, 305–316 
[86] Lazarides MK, Georgiadis GS, Papasideris CP, et al: Transposed brachial-basilic 
arteriovenous fistulas versus prosthetic upper limb grafts: A meta-analysis. Eur J 
Vasc Endovasc Surg  2008; 36:597-601. 
[87] Parienti, J. J. et al. Femoral vs jugular venous catheterization and risk of nosocomial 
events in adults requiring acute renal replacement therapy: a randomized 
controlled trial. JAMA 299, 2413-2422 (2008). 
[88] Hamilton, H. C. & Foxcroft, D. R. Central venous access sites for the prevention of 
venous thrombosis, stenosis and infection in patients requiring long-term 
intravenous therapy. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: 
CD004084. doi:10.1002/14651858.CD004084.pub2 (2007). 
[89] Kakkos SK, Haddad GK, Haddad JA et al., Secondary patency of thrombosed 
prosthethc vascular access grafts with aggressive surveillance, monitoring, and 
endovascular management, Eur J Endovasc Surg 2008; 36:356-65 
[90] Tessitore N, Bedogna V, Melilli E et al., In search of an optimal bedside screening 
program for arteriovenous fistula stenosis, Clin J Am Soc Nephrol 2011; 6:819-26 
[91] Beathard GA, An algorithm for the physical examination of early fistula failure, Semin 
Dial 2005; 18:331-335 
[92] Besarab A, Asif A, Roy-Chaudury P et al., The native arteriovenous fistula in 2007.  
Surveillance and monitoring.  J Nephrol 2007; 20:656-667 
[93] Besarab A, Sullivan KL, Ross R et al., The utility of intra-access monitoring in detecting 
and correcting venous outlet stenoses prior to thrombosis, Kidney Int 1995; 1364-
1373 
[94] Tessitore N, Bedogna V, Gammaro L et al., Diagnostic accuracy of ultrasound dilution 
access blood flow measurement in detecting stenosis and predicting thrombosis in 
native forearm arteriovenous fistulae for hemodialysis, Am J Kidney Dis 2003; 
42:331-341 
[95] Napoli M, Prudenzano R, Russo F et al., Juxta-anastomotic stenosis of native 
arteriovenous fistulas: surgical treatment versus percutaneous transluminal 
angioplasty, J Vasc Access 2010; 11:346-351 
[96] Dixon BS, Beck GJ, Vazquez MA, et al: Effect of dipyridamole plus aspirin on 
hemodialysis graft patency. N Engl J Med  2009; 360:2191-2201. 
 
Hemodialysis Principles and Controversies 
 
251 
[97] Dember LM, Besk GJ, Allon M, et al: Effect of clopidogrel on early failure of 
arteriovenous fistulas for hemodialysis: A randomized controlled 
trial. JAMA  2008; 299:2205-2207 
[98] Hemmelgarn BR, Moist LM, Lok CE et al., Prevention of dialysis catheter malfunction 
with recombinant tissue plasminogen activator, N Engl J Med 2011; 364:303-312 
[99] Kamper L, Piroth, W, and Haage P, Endovascular treatment of dysfunctional 
hemodialysis catheters, J Vasc Access 2010; 11:263-268 
[100] Allon M, Daugirdas J, Depner TA, et al: Effect of change in vascular access on patient 
mortality in hemodialysis patients. Am J Kidney Dis  2006; 47:469-477 
[101] 2011 CDC Guidelines for the Prevention of Intravascular Catheter-Related 
Infections 
[102] Rabindranath, K. S. et al. Systematic review of antimicrobials for the prevention of 
haemodialysis catheter-related infections. Nephrol. Dial. Transplant. 24, 3763-3774 
(2009). 
[103] Vanholder, R. et al. Diagnosis, prevention and treatment of haemodialysis catheter-
related bloodstream infections (CRBSI): a position statement of the European Renal 
Best Practice (ERBP). NDTPlus 3, 234-246 (2010). 
[104] Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis 
catheter-related infections using catheter-restricted filling with gentamicin and 
citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13:2133–9 
[105] Punt, C. D. & Boer, W. E. Cardiac arrest following injection of concentrated trisodium 
citrate. Clin. Nephrol. 69, 317-318 (2008) 
[106] McCann, M. & Moore, Z. E. H. Interventions for preventing infectious complications in 
haemodialysis patients with central venous catheters. Cochrane Database of 
Systematic Reviews, Issue 1. Art. No.: CD006894. 
doi:10.1002/14651858.CD006894.pub2 (2010) 
[107] Chatzinikolaou, I. et al. Antibiotic-coated hemodialysis catheters for the prevention of 
vascular catheter-related infections: a prospective, randomized study. Am. J. Med. 
115, 352-357 (2003). 
[108] von Eiff, C. et al. Nasal carriage as source of Stapylococcus aureus bacteremia. Study 
Group. N. Engl. J. Med. 344, 11-16 (2001) 
[109] Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin structure infections and 
catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 
study. Clin Infect Dis 2009; 48: 203–12. 
[110] Clinical practice guidelines for the diagnosis and management of intravascular 
catheter-related infection: 2009 Update by the Infectious Diseases Society of 
America 
[111] Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunnelled 
haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, 
infectious complications and mortality. Nephrol Dial Transplant 2006; 21:1024–31 
[112] NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J 
Kidney Dis  2001; 37:S137-S181 
[113] McCarthy JT, Moran J, Posen G, Leypoldt JK, Hull AR, Jaber BL, Correa-Rotter R. A 
time for rediscovery: chronic hemofiltration for end-stage renal disease. Semin Dial. 
2003;16(3):199. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
250 
[81] Creation, cannulation and survival of arteriovenous fistulae: Data from the Dialysis 
Outcomes and Practice Patterns Study. Kidney International; Jan2003, Vol. 63 Issue 
1, p323-330, 8p 
[82] Schild AF: Maintaining vascular access: the management of hemodialysis 
arteriovenous grafts. Vasc Access. 2010 Apr-Jun;11(2):92-9. 
[83] Robin M et al. Hemodialysis Arteriovenous Fistula Maturity: US Evaluation Radiology 
2002, vol 221:1, 59-64 
[84]  Biuckians A, Scott EC, Meier GH, et al: The natural history of autologous fistulas as 
first-time dialysis access in the KDOQI era. J Vasc Surg  2008; 47:415-421. 
[85] Ronald L Pisoni, Eric W Young, Dawn M Dykstra, Roger N Greenwood, 
Erwin Hecking, Brenda Gillespie, Robert A Wolfe, David A Goodkin and Philip 
J HeldVascular access use in Europe and the United States: Results from the 
DOPPS, Kidney International (2002) 61, 305–316 
[86] Lazarides MK, Georgiadis GS, Papasideris CP, et al: Transposed brachial-basilic 
arteriovenous fistulas versus prosthetic upper limb grafts: A meta-analysis. Eur J 
Vasc Endovasc Surg  2008; 36:597-601. 
[87] Parienti, J. J. et al. Femoral vs jugular venous catheterization and risk of nosocomial 
events in adults requiring acute renal replacement therapy: a randomized 
controlled trial. JAMA 299, 2413-2422 (2008). 
[88] Hamilton, H. C. & Foxcroft, D. R. Central venous access sites for the prevention of 
venous thrombosis, stenosis and infection in patients requiring long-term 
intravenous therapy. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: 
CD004084. doi:10.1002/14651858.CD004084.pub2 (2007). 
[89] Kakkos SK, Haddad GK, Haddad JA et al., Secondary patency of thrombosed 
prosthethc vascular access grafts with aggressive surveillance, monitoring, and 
endovascular management, Eur J Endovasc Surg 2008; 36:356-65 
[90] Tessitore N, Bedogna V, Melilli E et al., In search of an optimal bedside screening 
program for arteriovenous fistula stenosis, Clin J Am Soc Nephrol 2011; 6:819-26 
[91] Beathard GA, An algorithm for the physical examination of early fistula failure, Semin 
Dial 2005; 18:331-335 
[92] Besarab A, Asif A, Roy-Chaudury P et al., The native arteriovenous fistula in 2007.  
Surveillance and monitoring.  J Nephrol 2007; 20:656-667 
[93] Besarab A, Sullivan KL, Ross R et al., The utility of intra-access monitoring in detecting 
and correcting venous outlet stenoses prior to thrombosis, Kidney Int 1995; 1364-
1373 
[94] Tessitore N, Bedogna V, Gammaro L et al., Diagnostic accuracy of ultrasound dilution 
access blood flow measurement in detecting stenosis and predicting thrombosis in 
native forearm arteriovenous fistulae for hemodialysis, Am J Kidney Dis 2003; 
42:331-341 
[95] Napoli M, Prudenzano R, Russo F et al., Juxta-anastomotic stenosis of native 
arteriovenous fistulas: surgical treatment versus percutaneous transluminal 
angioplasty, J Vasc Access 2010; 11:346-351 
[96] Dixon BS, Beck GJ, Vazquez MA, et al: Effect of dipyridamole plus aspirin on 
hemodialysis graft patency. N Engl J Med  2009; 360:2191-2201. 
 
Hemodialysis Principles and Controversies 
 
251 
[97] Dember LM, Besk GJ, Allon M, et al: Effect of clopidogrel on early failure of 
arteriovenous fistulas for hemodialysis: A randomized controlled 
trial. JAMA  2008; 299:2205-2207 
[98] Hemmelgarn BR, Moist LM, Lok CE et al., Prevention of dialysis catheter malfunction 
with recombinant tissue plasminogen activator, N Engl J Med 2011; 364:303-312 
[99] Kamper L, Piroth, W, and Haage P, Endovascular treatment of dysfunctional 
hemodialysis catheters, J Vasc Access 2010; 11:263-268 
[100] Allon M, Daugirdas J, Depner TA, et al: Effect of change in vascular access on patient 
mortality in hemodialysis patients. Am J Kidney Dis  2006; 47:469-477 
[101] 2011 CDC Guidelines for the Prevention of Intravascular Catheter-Related 
Infections 
[102] Rabindranath, K. S. et al. Systematic review of antimicrobials for the prevention of 
haemodialysis catheter-related infections. Nephrol. Dial. Transplant. 24, 3763-3774 
(2009). 
[103] Vanholder, R. et al. Diagnosis, prevention and treatment of haemodialysis catheter-
related bloodstream infections (CRBSI): a position statement of the European Renal 
Best Practice (ERBP). NDTPlus 3, 234-246 (2010). 
[104] Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis 
catheter-related infections using catheter-restricted filling with gentamicin and 
citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13:2133–9 
[105] Punt, C. D. & Boer, W. E. Cardiac arrest following injection of concentrated trisodium 
citrate. Clin. Nephrol. 69, 317-318 (2008) 
[106] McCann, M. & Moore, Z. E. H. Interventions for preventing infectious complications in 
haemodialysis patients with central venous catheters. Cochrane Database of 
Systematic Reviews, Issue 1. Art. No.: CD006894. 
doi:10.1002/14651858.CD006894.pub2 (2010) 
[107] Chatzinikolaou, I. et al. Antibiotic-coated hemodialysis catheters for the prevention of 
vascular catheter-related infections: a prospective, randomized study. Am. J. Med. 
115, 352-357 (2003). 
[108] von Eiff, C. et al. Nasal carriage as source of Stapylococcus aureus bacteremia. Study 
Group. N. Engl. J. Med. 344, 11-16 (2001) 
[109] Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin structure infections and 
catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 
study. Clin Infect Dis 2009; 48: 203–12. 
[110] Clinical practice guidelines for the diagnosis and management of intravascular 
catheter-related infection: 2009 Update by the Infectious Diseases Society of 
America 
[111] Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunnelled 
haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, 
infectious complications and mortality. Nephrol Dial Transplant 2006; 21:1024–31 
[112] NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J 
Kidney Dis  2001; 37:S137-S181 
[113] McCarthy JT, Moran J, Posen G, Leypoldt JK, Hull AR, Jaber BL, Correa-Rotter R. A 
time for rediscovery: chronic hemofiltration for end-stage renal disease. Semin Dial. 
2003;16(3):199. 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
252 
[114] Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson 
JR. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on 
the hemodynamic course and outcome in patients with intractable circulatory 
failure resulting from septic shock. Crit Care Med. 2000;28(11):3581. 
[115] Palevsky PM. Dialysis modality and dosing strategy in acute renal failure. Semin Dial. 
2006;19(2):165. 
[116] Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM.  Standard versus 
high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 
2008;19(6):1233. 
[117] Jun M, Heerspink HJ, Ninomiya T, Gallagher M, Bellomo R, Myburgh J, Finfer S, 
Palevsky PM, Kellum JA, Perkovic V, Cass A. Intensities of renal replacement 
therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am 
Soc Nephrol. 2010;5(6):956. 
[118] Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK, University of Toronto 
Acute Kidney Injury Research Group. High-dose renal replacement therapy for 
acute kidney injury: Systematic review and meta-analysis. Crit Care Med. 
2010;38(5):1360. 
[119] RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, 
Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel 
C, Su S. Intensity of continuous renal-replacement therapy in critically ill patients. 
N Engl J Med. 2009;361(17):1627. 
[120] Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, Mariano F, 
Formica M, Marchesi M, René R, Livigni S, Ronco C, DOse REsponse Multicentre 
International collaborative Initiative (DO-RE-MI Study Group). Delivered dose of 
renal replacement therapy and mortality in critically ill patients with acute kidney 




Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
252 
[114] Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson 
JR. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on 
the hemodynamic course and outcome in patients with intractable circulatory 
failure resulting from septic shock. Crit Care Med. 2000;28(11):3581. 
[115] Palevsky PM. Dialysis modality and dosing strategy in acute renal failure. Semin Dial. 
2006;19(2):165. 
[116] Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM.  Standard versus 
high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 
2008;19(6):1233. 
[117] Jun M, Heerspink HJ, Ninomiya T, Gallagher M, Bellomo R, Myburgh J, Finfer S, 
Palevsky PM, Kellum JA, Perkovic V, Cass A. Intensities of renal replacement 
therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am 
Soc Nephrol. 2010;5(6):956. 
[118] Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK, University of Toronto 
Acute Kidney Injury Research Group. High-dose renal replacement therapy for 
acute kidney injury: Systematic review and meta-analysis. Crit Care Med. 
2010;38(5):1360. 
[119] RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, 
Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel 
C, Su S. Intensity of continuous renal-replacement therapy in critically ill patients. 
N Engl J Med. 2009;361(17):1627. 
[120] Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, Mariano F, 
Formica M, Marchesi M, René R, Livigni S, Ronco C, DOse REsponse Multicentre 
International collaborative Initiative (DO-RE-MI Study Group). Delivered dose of 
renal replacement therapy and mortality in critically ill patients with acute kidney 




Residual Renal Function in  
Hemodialysis Patients 
Zachary Z. Brener1, Stephan Thijssen2, Peter Kotanko2,  
James F. Winchester1 and Michael Bergman3 
1Beth Israel Medical Center, New York;  
2Renal Research Institute, New York 





The role of residual renal function (RRF) in the health and quality of life of both pre-dialysis 
and dialysis patients is equally important and now well established (Termorshuizen, 
Korevaar et al, 2003). 
RRF plays an important role in maintaining fluid balance, phosphorus control, and removal 
of uremic toxins in dialysis patients. The importance of RRF in hemodialysis (HD) patients 
is less well appreciated and it is believed that RRF declined rapidly in HD patients 
(Morduchowicz, Winkler et al, 1994; Wang, Woo, et al, 2005). Decline of RRF also 
contributed significantly to anemia, inflammation, and malnutrition in end-stage renal 
disease (ESRD) patients (Wang, Sea et al, 2001; Pecoits-Filho, Heimburger et al, 2003; 
Pecoits-Filho, Heimburger et al, 2002; Wang, Wang et al, 2004). More importantly, RRF has 
also been shown to be a powerful predictor of mortality, especially in patients on peritoneal 
dialysis (PD) (Bargman, Thorpe et al, 2001; Brener, Thijssen et al, 2011; Maiorca, Brunori et 
al, 19951).  
Glomerular filtration rate (GFR) measured by isotope clearance is considered to be the 
standard measure of renal function. Other tests, such as serum creatinine, creatinine 
clearance, urea clearance, an average of the creatinine and urea clearances, and urine 
volume have been used to assess RRF in chronic kidney disease (Levey, 1990). Despite its 
limitations, urine volume, the simplest measure of RRF, has been correlated to GFR in 
studies and most authors defined loss of RRF as urine volume < 200 ml/24 hours (Moist, 
Port et al, 2000). Urine collections (24 hours for PD, interdialytic for HD) to measure urea 
and/or creatinine clearance usually done at beginning of chronic dialysis and every 1-3 
months in patients with RRF. 
In this chapter, we will review available data that have shown a positive impact of RRF on 
the survival and quality of life of dialysis patients, and outline the current strategies to 
preserve RRF in PD and HD patients.    
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2. The benefits of preserved RRF (Table 1) 
 
 Improving patients survival 
 Maintaining fluid balance 
 Blood pressure control 
 Decrease left ventricular hypertrophy 
 Anemia control 
 Phosphorus control 
 Potassium control 
 Uric acid control 
 Improving nutritional status 
 Decreasing inflammatory response 
Table 1. Benefits of preserved RRF 
2.1 RRF and patient survival (Table 2) 
In 1995, Maiorca et al noted an independent relationship between the presence of RRF and 
survival in dialysis patients (Maiorca, Brunori et al, 2011). In their multivariate survival 
analysis of 102 PD and HD dialysis patients, each 1-ml/min increase in GFR was associated 
with a 40% reduced risk of death in the entire cohort and a 50% reduced risk of death in PD 
patients. Multicenter prospective cohort Canada-USA (CANUSA) Study of 680 incident PD 
patients clearly demonstrated that the predictive power for mortality in PD patients was 
attributed to RRF and not to the dose of PD (Bargman, Thorpe et al, 2001). The impact of 
RRF on outcome has not been examined in large cohorts of HD patients, likely due to the 
more rapid rate of decrease in RRF and its smaller relative contribution to total small-
molecule clearance in HD compared with PD patients. In our retrospective study of 118 
incident HD patients survival time was significantly lower in patients without RRF (48 vs 55 
months) (Brener, Thijssen et al, 2011). Crude mortality was 19.4% in anuric patients and 
7.8% in patients with RRF, and cardiovascular disease was a leading cause of death for both 
groups. The presence of RRF was also associated with a strong trend toward fewer hospital 
days per patient-year. Shemin et al (Shemin, Bostom et al, 2001) reported that in the 
prospective observational study of 114 incident and prevalent HD patients, the presence of 
RRF was independently associated with a 65% decrease in risk of death, even after 
adjustment for duration of dialysis treatment, age, presence of diabetes, cardiovascular 
disease and serum albumin level.  Netherlands Cooperative Study on the Adequacy of 
Dialysis (NECOSAD) (Termorshuizen, Dekkeret al, 2004) has prospectively evaluated the 
contribution of treatment adequacy and RRF to patients survival after 3 and 6 months of 
treatment in a large incident HD population (740 patients). It showed the important 
 
 RRF is a powerful predictor of mortality 
 Each 1-ml/min increase in GFR was associated with a 40% reduced risk of death  
 Each 1-unit increase in renal Kt/V resulted in 66% decrease in relative risk of death 
 Independent relationship between the presence of RRF and survival in dialysis patients 
 Preservation of RRF is important in the survival of dialysis patients 
Table 2. RRF and dialysis patient survival  
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contribution of RRF to the overall survival of HD patients: each 1-unit increase in renal 
Kt/V resulted in 66% decrease in relative risk of death. Moreover, in patients with 
preserved RRF, increasing dialysis dose did not result in improved patient outcomes. The 
international prospective observational DOPPS study has also recently reported the diuretic 
use and presence of RRF was associated with a better survival in prevalent HD patients 
(Bragg-Gresham, Fissell et al, 2007). Diuretic use declined after the start of dialysis (9.2% in 
Europe versus 21.3% in the United States). Patients with RRF on diuretics had almost twice 
the chances of retaining RRF after 1 year with 7% lower all-cause and mortality and 14% 
lower cardiac-specific mortality compared to patients not receiving diuretics. All these and 
other observational studies suggest that preservation of RRF has an important role in the 
survival of both HD and PD patients.      
2.2 RRF, volume control and cardiac hypertrophy 
RRF has been found to be important in maintaining fluid balance of dialysis patients, 
especially in patients on PD. Suboptimal fluid removal in PD patients is associated with 
greater rates of all-cause hospitalization and mortality (Ates, Nergizoglu et al, 2001). In the 
CANUSA Study, urine volume was a strong independent predictor of survival. Every 250 
ml/imin urine output was associated with a 36% reduction in overall mortality ((Bargman, 
Thorpe et al, 2001). RRF may reduce or avoid the need for fluid restriction. Loss of RRF is 
independently associated with suboptimal blood pressure control, likely a result of chronic 
volume expansion (Ates, Nergizoglu et al, 2001; Konings, Kooman et al, 2003). The severity 
of left ventricular hypertrophy (LVH), a strong independent predictor of mortality in 
dialysis patients, inversely correlates with the presence of RRF Pecoits-Filho, Heimburger et 
al, 2002; Wang, Wang et al, 2004). In addition, loss of RRF is associated with more severe 
anemia, hypoalbuminemia, and higher arterial pressure (Pecoits-Filho, Heimburger et al, 
2003), all of which are important risk factors for cardiac hypertrophy in dialysis patients. 
Extracellular fluid (ECF) volume has been also reported to be associated with hypertension 
and left ventricular hypertrophy in HD patients (Fagugli, Pasini et al, 2003). 
2.3 RRF and metabolic control 
Middle molecule clearance is one of the most widely recognized benefits of RRF. Patients 
with significant RRF are shown to have lower ß2-mocroglobulin (ß2M) levels (McCarthy, 
Williams et al, 1994; Montenegro, Martinez et al, 1992; Amici G, Virga et al, 1993) and thus 
are less prone to dialysis-associated amyloidosis (Copley JB, Lindberg et al, 2001). Preserved 
RRF is also associated with lower blood levels of uric acid, potassium (Morduchowicz, 
Winkler et al, 1994), and aluminium (Altmann , Butter et al, 1987), and higher levels of 
hemoglobin (Pecoits-Filho, Heimburger et al, 2002), presumably due to increased levels of 
endogenous erythropoietin.  
Hyperphosphatemia is prevalent in dialysis patients (Yavuz, Ersoy et al, 2008; Wang, Woo 
et al, 2004) and has been linked to vascular calcification and increased cardiovascular 
mortality in both HD and PD patients (Block, Hulbert-Shearon et al, 1998; Wang AY, Lai et 
al, 2006).  RRF plays a major role in improving phosphate balance in both PD and HD 
patients ((Morduchowicz, Winkler et al, 1994). 
2.4 RRF and inflammation 
Inflammation is highly prevalent in dialysis patients (Arici M, Walls et al, 2001) and 
established to be a strong predictor of mortality in dialysis patients. Loss of RRF was 
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associated with an increased inflammatory response with elevated solute vascular cell 
adhesion molecules (VCAM-1) and C-reactive protein (CRP) levels in PD patients (Wang 
AY, Lam et al, 2005), possibly as a result of impaired renal elimination of proinflammatory 
cytokines and increased cytokine generation (Witko-Sarsat, Descamps-Latscha et al, 1997). 
Conversely, the presence of inflammation also accelerated the decline of RRF (Shin, Noh et 
al, 1999). 
2.5 RRF and nutritional status 
Malnutrition is a common serious problem in dialysis patients, may be result of multiple 
factors including impairments in protein and energy metabolism, hormonal imbalances and 
poor food intake because of anorexia (Ikizler, Hakim et al, 1996). Dialysis dose may affect 
nutritional status and low dialysis efficacy is associated with higher rates of morbidity and 
mortality (Gotch, Sargent, 1985; Bergstrom, Lindholm, 1993). RRF contributes significantly to 
the appetite and total caloric intake (Wang, Sea et al, 2001; Wang, Sea et al, 2005), and overall 
nutritional status assessed using subjective global assessment, handgrip strength, or lean 
body mass in both HD and PD patients. Nutritional status is closely related to inflammation. 
In our study (Brener, Thijssen et al, 2008) anuric HD patients were older with lower baseline 
serum albumin and showed a trend toward greater length of stay for all causes, and all 
cause mortality including infectious mortality. Analysis of albumin kinetics performed in 
HEMO Study showed that a decrease in serum albumin in adequately dialysed patients was 
mostly due to an increase in the level of inflammation, rather that a decrease in protein 
intake (Kaysen, Dubin et al, 2000). 
3. Preservation of RRF (Table 3) 
 
 PD modality 
 Avoidance of ECF volume depletion                        
 Avoidance of nephrotoxic insults (NSAIDs, radiocontrast agents, aminoglycosides) 
 Antihypertensive medications (ACE-inhibitors and calcium channel blockers) 
Table 3. Preservation of RRF 
3.1 Patient-related factors 
Decline of RRF is an unavoidable phenomenon caused by the degenerative and fibrosis 
process of chronic kidney disease (CKD). However, the rate of RRF loss is different among 
patients and may be affected by other factors such as patient-related factors, treatment 
modalities and practice patterns (Jansen, Hart et al, 2002). Patient-related factors include 
age, causal nephropathy and comorbid conditions. Decline of RRF has been shown to be age 
dependent (Hung, Young, 2003). Intercurrent events such as recurrent blood pressure drop 
during HD, cardiac events and sepsis may precipitate loss of RRF. Diabetics on PD have 
been shown to have a more rapid decline in RRF than nondiabetics (Singhal, Bhaskaran et 
al, 2000). Comorbid conditions, including congestive heart failure, poorly controlled 
hypertension, and coronary artery disease, also are associated with faster rates of RRF 
decrease (Shin, Noh et al, 1999). Patients with CKD secondary to glomerular disease lose 
RRF more rapidly than those with tubulointerstitial disease (Iest, Vanholder et al, 1989). In a 
large multicenter study, the majority of patients with adult polycystic kidney disease were 
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found to maintain a GFR greater than 2 ml/min for more than 4 years (Van Stone, 1995). 
Patients returning to dialysis therapy after kidney transplant failure have a more rapid 
decline in RRF than those initiating dialysis therapy with native kidney disease (Davies, 
2001). 
3.2 Impact of dialysis modality 
Observational studies showed the advantage of PD compared to HD in preserving RRF 
(Moist, Port et al, 2000; Rottembourg, Issad et al, 1983; Misra, Vonesh et al, 2001) but data 
from prospective randomized trials are lacking. PD is associated with better hemodynamic 
stability that may minimize ischemic renal insults and avoidance of the extracorporeal 
circulation of HD that promotes systemic inflammation, oxidative stress, and subsequent 
kidney injury (Rottembourg, Issad et al, 1983). Treatment with ultrapure dialysate and 
biocompatible membranes has been shown to slow the loss of RRF in incident HD patients 
(Schiffl , Lang et al, 2002). It has been suggested use of PD as an initial dialysis modality in 
patients with RRF to maximize RRF conservation and thus survival for patients on dialysis.  
3.3 Avoidance of ECF volume depletion 
Observational data from NECOSAD Study suggest that episodes of volume depletion were 
an independent risk factor for the loss of RRF (Termorshuizen, Korevaar et al, 2003).1 In a 
study by Gunal et al (Gunal AI, Duman et al, 2001) strict volume control in 47 PD patients 
led to 6% decrease in left ventricular hypertrophy and 28% decrease in mean urine volume 
in the 19 patients with RRF. Subclinical hypovolemia, even in presence of normal blood 
pressure, can lead to a decrease in RRF as a result of overzealous ECF volume depletion. 
Diuretics have been shown to increase urine volume and sodium removal, but do not affect 
the solute clearance (Moist, Port et al, 2000; van Olden, Guchelaar et al, 2003), and can be 
used, where appropriate, to provide better control of volume balance. As mentioned above, 
the extended use of loop diuretics may help to prolong diuresis and preserve RRF. 
Correction of fluid volume excess by combining dietary salt restriction and gentle 
ultrafiltration is a simple and effective approach to control hypertension and to reverse LVH 
(Konings, Kooman et al, 2003). 
3.4 Avoidance of nephrotoxic insults 
Avoiding the use of radiocontrast agents or nephrotoxic drugs such as non-steroidal anti-
inflammatory drugs or aminoglycosides is an important approach in protecting RRF. 
Aminoglycoside nephrotoxicity can be decreased by once-daily dosing, avoidance of 
concomitant nephrotoxins, monitoring of drug levels, and choice of the least nephrotoxic 
aminoglycoside used (Baker, Senior et al, 2003). Recent trials that used either adequate 
hydration, low-osmolar radiocontrast agents (Dittrich, Puttinger  et al, 2006) as well as 
prophylactic acetylcysteine (Tepel, van der Giet et al, 2000) did not show long-term decline 
after contrast exposure despite a temporary decline in GFR immediately after contrast 
exposure.  
3.5 Antihypertensive medications 
ACE-inhibitors and calcium channel blockers were associated with preservation of RRF in 
both PD and HD patients (Tepel, van der Giet et al, 2000). In a prospective study by Li PK et 
al (Li PK, Chow et al, 2003), PD patients treated with ramipril had a slower rate of RRF loss 
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associated with an increased inflammatory response with elevated solute vascular cell 
adhesion molecules (VCAM-1) and C-reactive protein (CRP) levels in PD patients (Wang 
AY, Lam et al, 2005), possibly as a result of impaired renal elimination of proinflammatory 
cytokines and increased cytokine generation (Witko-Sarsat, Descamps-Latscha et al, 1997). 
Conversely, the presence of inflammation also accelerated the decline of RRF (Shin, Noh et 
al, 1999). 
2.5 RRF and nutritional status 
Malnutrition is a common serious problem in dialysis patients, may be result of multiple 
factors including impairments in protein and energy metabolism, hormonal imbalances and 
poor food intake because of anorexia (Ikizler, Hakim et al, 1996). Dialysis dose may affect 
nutritional status and low dialysis efficacy is associated with higher rates of morbidity and 
mortality (Gotch, Sargent, 1985; Bergstrom, Lindholm, 1993). RRF contributes significantly to 
the appetite and total caloric intake (Wang, Sea et al, 2001; Wang, Sea et al, 2005), and overall 
nutritional status assessed using subjective global assessment, handgrip strength, or lean 
body mass in both HD and PD patients. Nutritional status is closely related to inflammation. 
In our study (Brener, Thijssen et al, 2008) anuric HD patients were older with lower baseline 
serum albumin and showed a trend toward greater length of stay for all causes, and all 
cause mortality including infectious mortality. Analysis of albumin kinetics performed in 
HEMO Study showed that a decrease in serum albumin in adequately dialysed patients was 
mostly due to an increase in the level of inflammation, rather that a decrease in protein 
intake (Kaysen, Dubin et al, 2000). 
3. Preservation of RRF (Table 3) 
 
 PD modality 
 Avoidance of ECF volume depletion                        
 Avoidance of nephrotoxic insults (NSAIDs, radiocontrast agents, aminoglycosides) 
 Antihypertensive medications (ACE-inhibitors and calcium channel blockers) 
Table 3. Preservation of RRF 
3.1 Patient-related factors 
Decline of RRF is an unavoidable phenomenon caused by the degenerative and fibrosis 
process of chronic kidney disease (CKD). However, the rate of RRF loss is different among 
patients and may be affected by other factors such as patient-related factors, treatment 
modalities and practice patterns (Jansen, Hart et al, 2002). Patient-related factors include 
age, causal nephropathy and comorbid conditions. Decline of RRF has been shown to be age 
dependent (Hung, Young, 2003). Intercurrent events such as recurrent blood pressure drop 
during HD, cardiac events and sepsis may precipitate loss of RRF. Diabetics on PD have 
been shown to have a more rapid decline in RRF than nondiabetics (Singhal, Bhaskaran et 
al, 2000). Comorbid conditions, including congestive heart failure, poorly controlled 
hypertension, and coronary artery disease, also are associated with faster rates of RRF 
decrease (Shin, Noh et al, 1999). Patients with CKD secondary to glomerular disease lose 
RRF more rapidly than those with tubulointerstitial disease (Iest, Vanholder et al, 1989). In a 
large multicenter study, the majority of patients with adult polycystic kidney disease were 
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found to maintain a GFR greater than 2 ml/min for more than 4 years (Van Stone, 1995). 
Patients returning to dialysis therapy after kidney transplant failure have a more rapid 
decline in RRF than those initiating dialysis therapy with native kidney disease (Davies, 
2001). 
3.2 Impact of dialysis modality 
Observational studies showed the advantage of PD compared to HD in preserving RRF 
(Moist, Port et al, 2000; Rottembourg, Issad et al, 1983; Misra, Vonesh et al, 2001) but data 
from prospective randomized trials are lacking. PD is associated with better hemodynamic 
stability that may minimize ischemic renal insults and avoidance of the extracorporeal 
circulation of HD that promotes systemic inflammation, oxidative stress, and subsequent 
kidney injury (Rottembourg, Issad et al, 1983). Treatment with ultrapure dialysate and 
biocompatible membranes has been shown to slow the loss of RRF in incident HD patients 
(Schiffl , Lang et al, 2002). It has been suggested use of PD as an initial dialysis modality in 
patients with RRF to maximize RRF conservation and thus survival for patients on dialysis.  
3.3 Avoidance of ECF volume depletion 
Observational data from NECOSAD Study suggest that episodes of volume depletion were 
an independent risk factor for the loss of RRF (Termorshuizen, Korevaar et al, 2003).1 In a 
study by Gunal et al (Gunal AI, Duman et al, 2001) strict volume control in 47 PD patients 
led to 6% decrease in left ventricular hypertrophy and 28% decrease in mean urine volume 
in the 19 patients with RRF. Subclinical hypovolemia, even in presence of normal blood 
pressure, can lead to a decrease in RRF as a result of overzealous ECF volume depletion. 
Diuretics have been shown to increase urine volume and sodium removal, but do not affect 
the solute clearance (Moist, Port et al, 2000; van Olden, Guchelaar et al, 2003), and can be 
used, where appropriate, to provide better control of volume balance. As mentioned above, 
the extended use of loop diuretics may help to prolong diuresis and preserve RRF. 
Correction of fluid volume excess by combining dietary salt restriction and gentle 
ultrafiltration is a simple and effective approach to control hypertension and to reverse LVH 
(Konings, Kooman et al, 2003). 
3.4 Avoidance of nephrotoxic insults 
Avoiding the use of radiocontrast agents or nephrotoxic drugs such as non-steroidal anti-
inflammatory drugs or aminoglycosides is an important approach in protecting RRF. 
Aminoglycoside nephrotoxicity can be decreased by once-daily dosing, avoidance of 
concomitant nephrotoxins, monitoring of drug levels, and choice of the least nephrotoxic 
aminoglycoside used (Baker, Senior et al, 2003). Recent trials that used either adequate 
hydration, low-osmolar radiocontrast agents (Dittrich, Puttinger  et al, 2006) as well as 
prophylactic acetylcysteine (Tepel, van der Giet et al, 2000) did not show long-term decline 
after contrast exposure despite a temporary decline in GFR immediately after contrast 
exposure.  
3.5 Antihypertensive medications 
ACE-inhibitors and calcium channel blockers were associated with preservation of RRF in 
both PD and HD patients (Tepel, van der Giet et al, 2000). In a prospective study by Li PK et 
al (Li PK, Chow et al, 2003), PD patients treated with ramipril had a slower rate of RRF loss 
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compared to the control group. Investigation of the role of combination therapy with ACE 
inhibitors and ARBs and direct aldosterone blockade on RRF represent promising future 
strategies in slowing the rate of RRF decline in dialysis patients. 
4. Conclusion 
RRF contributes to the clearance of both small and medium-sized solutes. It serves 
important metabolic and hemodynamic functions, and plays a crucial role in maintaining 
the cardiovascular health, nutritional status, and well-being of dialysis patients. RRF has 
also been shown to have a significant impact on the survival of dialysis patients, especially 
in PD dialysis. Health care providers need to realize that RRF is a very valuable asset to 
dialysis patients. Efforts to preserve RRF should continue even after patients are started on 
dialysis treatment, irrespective of the modality used 
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1. Introduction 
Since 1970s several studies have shown a significant prevalence of cardiovascular disease 
(CVD) among patients with end-stage renal disease (Linder et al., 1974). Among patients 
treated by hemodialysis and peritoneal dialysis, the prevalence of CVD is approximately 
40%. Even after stratification by age, sex, race, and diabetes, CVD mortality in chronic 
kidney disease (CKD) patients is 10 to 20 times higher than in the general population (Foley 
et al., 1998). End-stage-renal-disease patients often have a high prevalence of cardiovascular 
risk factors as hypertension, diabetes and dyslipemia. Nevertheless, previous studies have 
shown that the high prevalence of CVD in hemodialysis patients is only partly explained by 
traditional risk factors (Cheung et al., 2000). Non-traditional risk factors have been emerged 
in the last decade. One of this non-traditional risk factor is C-reactive protein (CRP). 
In this chapter, it is tried to explain the results of several studies supporting an association 
between inflammation (measured by high levels of CRP), left-ventricular dysfunction and 
volume overload among patients with CKD and how volume overload, which is present at 
the very early stages of CKD, could be the main underlying factor contributing to the worse 
CV prognosis among these patients. 
2. Inflammation (C-reactive protein) in patients with chronic kidney disease: 
prevalence and prognostic factor 
CRP is considered the prototypical acute-phase reactant in man. Plasma CRP is produced by 
hepatocytes although other sites of local CRP synthesis have been suggested. 
The plasma half-life of CRP is about 19 hours and is constant under all conditions of health 
and disease, so that the sole determinant of circulating CRP concentration is the synthesis 
rate, which thus directly reflects the intensity of the pathological process stimulating CRP 
production. In most disease, the circulating value of CRP reflects ongoing inflammation 
and/or tissue damage much more accurately than other laboratory parameters of the acute-
phase response. The CRP concentration is thus a very useful nonspecific biochemical marker 
of inflammation, measurement of which contributes importantly to screening for organic 
disease, monitoring of the response to treatment of inflammation and infection and 
detection of intercurrent infection (Pepys et al., 2003). 
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Elevated CRP levels have been described in a significant proportion of end-stage-renal-
disease patients on hemodialysis or peritoneal dialysis (Arici et al., 2001). About one-third of 
patients with chronic renal failure have serum CRP concentration > 10 mg/l (Owen et al., 
1998). In healthy men, high CRP level has been identified as a risk factor for cardiovascular 
disease (Ridker et al., 2001). As occurs in the general population, prospective studies point 
to a correlation between CRP plasma levels and overall and cardio-vascular mortality also in 
end-stage-renal disease patients (Arici et al., 2001; Ikizler et al., 1999; Noh et al., 1998; Owen 
et al., 1998; Panichi et al., 2008; Wang et al., 2009; Yeun et al. 2000; Zimmermann et al., 1999). 
3. Inflammation and anemia 
In dialysis patients, inflammation expressed by high levels of CRP is also associated with 
low blood hemoglobin and/or resistance to eritropoyesis-stimulating agents (Barany et al., 
1997; Bradbury et al., 2009; Gunnel et al., 1999; Owen et al., 1998). This has been attributed to 
the inhibition of erythropoietin secretion by pro-inflammatory cytokines. Inflammation also 
contributes to anemia by inducing functional iron deficiency probably blocking the delivery 
of iron from the reticuloendothelial cells to the hemathopoietic cells. Cytokines may  
also induce ferritin synthesis directly or by increasing iron uptake into hepatocytes. The 
increase in ferritin synthesis by hepatocytes and reticuloendothelial cells underlies in the 
iron storage pool during inflammation. Thus, inflammation among patients with CKD can 
contribute to anemia and impaired response to erythropoietin. Erythropoietin resistance by 
itself has been associated with higher short-term mortality in CKD patients (López-Gómez 
et al., 2008). 
4. Inflammation and malnutrition 
High concentration of acute phase protein is correlated with low serum albumin in 
malnourished hemodialysis patients (Kaysen et al., 1997; Qureshi et al., 1998). Low serum 
albumin concentrations are highly associated with increased mortality risk in patients with 
renal replacement therapy (Lowrie et al., 1990). Hypoalbuminemia has been traditionally 
been assumed to result from inadequate protein and calorie intake. However, albumin is a 
negative acute-phase protein. The synthesis of this protein decreases during inflammation 
independently of nutritional state. Albumin concentration in dialysis patients is negatively 
correlated with levels of positive acute-phase protein. Moreover, inflammation and 
malnutrition data has been associated with the presence of atherosclerotic carotid plaques 
(Stenvinkel et al., 1999) describing the so called MIA (malnutrition-inflammation-
atherosclerosis) syndrome in patients with advanced renal failure. 
In summary, inflammation is high prevalent among patients with chronic kidney disease 
and predicts anemia, malnutrition and CV death. An intriguing question is whether CRP is 
just a sensitive marker of systemic inflammation or actively contributes to the development 
and progression of atherosclerotic lesions and, therefore, to the CV damage. Some authors 
have demonstrated CRP content inside the atherosclerotic lesions, suggesting the active 
participation in the inflammatory process (Zhang et al., 1999) what hints that inflammation 
could be the cause rather than the consequence of CV damage. Based on the bad prognosis 
of patients with markers of inflammation, it is important to try to known the possible causes 
of inflammation in this population in order to prevent morbidity and mortality. 
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5. Possible causes of inflammation  
The causes of inflammation in patients with CKD patients remained unclear over time.  
Several studies have attempted to address the question as to whether some factors related to 
the dialysis technique by itself could induce the inflammatory response. Activation of 
monocytes with the subsequent enhanced release of inflammatory cytokines can be caused 
by membrane-induced complement activation, by direct cell-membrane interaction and by 
dialysis fluids containing endotoxins (Carracedo et al., 2006; Honkanen et al., 1991; Kerr et 
al., 2007; Schouten et al. 2000).  
However, a similar prevalence of inflammation has been described in patients with 
advanced renal failure not yet on dialysis (Ortega et al., 2002; Panichi et al., 2002; Stenvinkel 
et al., 1999). An inverse correlation between CRP levels and clearance of creatinine has been 
observed (Panichi et al., 2002); thus, CRP levels increase as renal function declines. This 
finding suggests the possibility of a decreased renal clearance of CRP as a cause of an 
activated acute-phase response in patients with chronic kidney disease. Another possibility 
could be that uremia by itself could be the cause of inflammation among these patients. 
However, in another study performed in pre-dialysis patients with a more homogeneous 
clearance of creatinine   (Ortega et al., 2002), a non-normal distribution of CRP levels were 
detected. That means that only a group of patients with advanced renal failure shows high 
levels of CRP, whereas other patients with the same degree of renal insufficiency have even 
normal CRP values. Hence, it seems that uremia by itself is not the unique cause of 
inflammation. Probably, inflammation could be related to some factors, frequently 
associated with renal failure, which can worsen with the worsening of renal function. In this 
study (Ortega et al., 2002), CRP levels were higher in those patients with a previous history 
of CVD. Comparing with patients with normal CRP levels at baseline, patients with higher 
levels maintained significant higher levels on follow-up. This group of inflamed patients 
showed during the study period persistently lower serum albumin, lower blood 
hemoglobin, needed higher doses of erythropoietin stimulating agents and showed higher 
hospitalization rate (table 1). 
 
 Group I 
(CRP>6 mg/dL) 
n = 23 
Group II 
(CRP<6 mg/dL) 
n = 43 
P value 
CRP (mg/L)* 21.6 (12.9 - 32.6) 2 (2 - 4.6) 0.00001 
Albumin (g/dL) 3.5 ± 0.4 3.8 ± 0.4 0.017 
Hemoglobin (g/dL) 11.6 ± 1.1 12.2 ± 0.8 0.045 
Epo (IU/kg/week) 67 ± 32 43 ± 20 0.025 
Hemoglobin/Epo 0.19 ± 0.08 0.32 ± 0.13 0.004 
Hospitalization (n) 0.52 ± 0.8 0.03 ± 0.19 0.004 
Table 1. Comparison of the evolution of analytical and clinical data between patients with 
high (Group I) or low (Group II) CRP levels at baseline. Mean ± standard deviation. 
*Median (interquartile range). 
In summary, at this point we know  that inflammation is high prevalent among patients 
with CKD, that the prevalence is higher among patients with associated CVD, that 
inflammation tends to increase with the decline of renal function but that only about one 
third of patients with advance renal function shows persistently high levels of inflammatory 
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markers. Thus, we could argue that uremia by itself is not the cause of inflammation. It 
seems that another factor, usually associated with uremia and which usually worsens with 
the decline of renal function could be the responsible of inflammation in patients with CKD. 
In the past decade, it has been observed that circulating inflammatory cytokines are elevated 
in patients with chronic heart failure (Levin et al., 1990) and it has been suggested that 
cytokines can be in part responsible for cardiac disease progression in these patients (Seta et 
al., 1996). Some authors have detected elevated plasma levels of endotoxins and cytokines 
during the acute phase of heart failure and that normalization of endotoxins and cytokines 
concentration can be achieved using intensive diuretic treatment (Niebauer et al. 1999, 
Peschel et al. 2003). The authors hypothesized that during acute cardiac decompensation, 
acute mesenteric venous congestion with subsequently altered gut permeability for 
endotoxins would lead to translocation of these materials into the circulation inducing the 
inflammatory response. Thus, the authors highlight that inflammation could be the 
consequence, rather than the cause of heart failure. 
6. Association between inflammation, overhydratacion and cardiac disease: 
B-type natriuretic peptide 
Cardiac disease is high prevalent among patients with CKD (Foley et al. ,1995; Hayashi et 
al., 2006; Levin et al., 1996; Zocali et al., 2004). The typical feature of uremic cardiomyopathy 
is left ventricular diastolic dysfunction related to left ventricular hypertrophy and left 
ventricular fibrosis (Ahmed et al., 2007; Losi et al., 2010; Mark et al., 2006). Left ventricular 
hypertrophy is particularly highly prevalent in end-stage renal disease patients because of 
hypertension, hyperparathyroidism and increased volume. However, myocardial fibrosis is 
a specific finding among patients with CKD comparing with patients with isolated 
hypertension as revealed autopsy studies (Sharer et al., 1999). Probably, volume overload 
could be a main cause of myocardial fibrosis among these patients as volume overload can 
produce mechanical stress on the ventricular wall and it has been demonstrated that 
mechanical factors can induce the activation of the fibroblasts of the myocardium 
synthesizing the extracellular matrix (MacKenna et al., 2000). Volume overload is present 
very early in the course of CKD and is the consequence of the inability of the insufficient 
kidney to eliminate the excess of water and salt. Usually, the increase in extracellular water 
in the very early course of CKD is modest and may easily be underestimated by clinical 
examination and can only be proved by accurate measurement of body water volume, as 
with bioimpedance. Extracellular water excess increases when glomerular filtration rate 
declines and has emerged as an independent factor in the structural cardiac damage, as  a 
direct relation between extracellular water excess and left ventricular mass has been 
demonstrated as well as with left ventricular data of diastolic dysfunction (Essig et al., 2008). 
The authors also highlighted that cardiac remodeling was present at the very early stages of 
CKD. Over time, structural myocardial alterations progress, leading to diastolic dysfunction. 
The central disturbance in diastolic dysfunction involves abnormalities in myocardial 
relaxation and ventricular compliance (Martos et al., 2007). Thus, in order to complete 
ventricular filling and achieve a sufficient end-diastolic volume, which will provide 
adequate stroke volume, the left ventricle needs filling pressure higher than normal. 
Diastolic dysfunction, in fact, means that the left ventricle fills at higher pressure. 
Echocardiographic data of diastolic dysfunction are the most frequent findings among 
patients with CKD (Hayashy et al., 2006). 
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Based on the association between inflammation and heart failure in the general population 
and as myocardial dysfunction is high prevalent among patients with CKD, several authors 
tried to find an association between inflammation and cardiac disease also in this 
population. Furthermore, this hypothesis could explain why only some patients (those with 
more ventricular damage) show high levels of CRP, whereas other patients with similar 
clearance of creatinine (those with less cardiac disease) could present even normal values of 
CRP.  
Some authors (Ates et al., 2005; Kim et al., 2005) have observed an association between CRP 
and left ventricular hypertrophy or dysfunction among patients with CKD. However, most 
authors have employed in their studies the measurement of a biochemical marker of 
ventricular dysfunction such as B-type natriuretic peptide.  
B-type natriuretic peptide (BNP) is a cardiac neurohormone specifically secreted from 
cardiac ventricles in response to an increased left-ventricular wall tension (Maeda et al., 
1998). When end-diastolic filling pressure is increased (related to ventricular dysfunction, 
hypervolemia or both conditions), the release of BNP is induced. BNP is a potent natriuretic 
peptide by enhancing renal sodium excretion, reducing so the intravascular volume and, 
therefore, the end-diastolic volume and pressure. BNP is a strong predictor of systolic and 
diastolic abnormalities and is a powerful marker for prognosis and risk stratification in the 
setting of heart failure (Tabbibizar et al., 2002). In the general population, a cut point of 
about 100 pg/ml can discriminate patients with heart failure from patients without it.  
BNP is increased among patients with CKD and an inverse correlation between BNP levels 
and glomerular filtration rate has been observed (McCullough et al., 2003). This increased 
BNP level among these patients is in part related to the decreased renal clearance as well as 
the accompanying increased intravascular volume which is usually present in these 
patients. However, values above a cut-point reflect ventricular dysfunction and predict 
heart failure also among patients with CKD. In general, as CKD stage advances, a higher cut 
point of BNP is implied. BNP levels higher than 500 pg/ml usually predict heart failure 
even in patients with renal failure. Diastolic dysfunction is the most frequent cardiac disease 
among patients with CKD. In this setting, a small increment in end-diastolic volume lead to 
an exaggerated increase in diastolic pressure (Mandinov et al., 2000), inducing the release of 
natriuretic peptide. Probably, this pathophysiological mechanism partly explains the high 
levels of BNP detected among patients with CKD. In fact, several studies have observed an 
association between natriuretic peptide levels and echocardiographic data of left ventricular 
hypertrophy and dysfunction among patients with CKD (Guo et al., 2009; Paniagua et al., 
2010; Zocali et al., 2001). Natriuretic peptide levels among patients with CKD predict death, 
as it occurs in patients with heart failure and normal renal function. Otherwise, some 
authors (Jacobs  et al., 2010) have demonstrated a direct correlation between extracellular 
water, measured by bioelectrical impedance, and natriuretic peptide in CKD patients, 
explaining how volume overload can increase end-diastolic volume and, therefore, end-
diastolic pressure favoring the release of BNP. Probably both mechanisms, volume overload 
and myocardial damage, both high prevalent among patients with CKD, could explained 
the high levels of natriuretic peptides detected in this population. 
NT-proBNP is the amino-terminal peptide fragment of the precursor of BNP and shows a 
close correlation to BNP (Masson et al., 2002). A non-normal distribution of NT-proBNP 
levels was observed among patients with advanced renal failure, as previously observed 
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with CRP (Ortega et al., 2004). Newly, it means that only a group of patients with advanced 
renal failure shows high levels of natriuretic peptides, whereas other patients with similar 
creatinine clearance show even normal values. This finding probably reflects the presence of 
a mixed population among patients with advanced CKD with a group of patients with more 
severe cardiac disease whereas other patients can achieve the end-stage disease phase with 
less myocardial damage. But most importantly, a strong correlation between NT-proBNP 
and CRP levels is found (figure 1), suggesting an association between left-ventricular filling 





Fig. 1. Regression graph demonstrating the correlation between NT-proBNP and C-reactive 
protein values at baseline (r: 0.7; p< 0.001) 
This association between left-ventricular filling pressure and inflammation among CKD 
patients has been confirmed in subsequent years (Guo et al., 2009; Jacobs et al., 2010; 
Paniagua et al., 2010). Otherwise, the same studies and other authors (Booth et al., 2010) 
observed a relationship between cardiac and inflammatory biomarkers and volume 
overload. An association between volume overload and inflammation had been previously 
observed among patients on peritoneal dialysis (Woodrow, 2006). Overhydration by itself 
has emerged as an independent predictor on mortality in chronic hemodialysis patients 
(Wizemann et al., 2009). 
Thus, all these findings show the complex relation between overhydration, malnutrition, 
inflammation and cardiac biomarkers in CKD patients. Although CRP can actively 
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participate in the atherosclerotic process inducing CV damage, it has also been suggested 
that inflammation among patients with CKD could be the consequence, rather than the 
cause, of an increased left-ventricular filling pressure, related to ventricular dysfunction, 
hypervolemia or both conditions (Ortega, 2005). 
The complex relation between ventricular dysfunction, overhydration and inflammation 
highlights the importance of strict volume control in patients with CKD. Usually, 
ventricular dysfunction progress over time. In an interesting longitudinal study performed 
in hemodialysis patients, a progressive deterioration of left ventricular filling pressure (an 
index of diastolic dysfunction) was observed in parallel with the progression of left 
ventricular hypertrophy and a progressive increment in levels of NT-proBNP (Kim et al., 
2011). Thus, these results suggest that diastolic dysfunction progress over time among 
patients with chronic kidney disease. In another longitudinal study performed in 
hemodialysis patients (Ortega et al., 2009), the effect of strict volume control on the 
evolution of cardiac biomarker levels over time was analyzed. In this study, the strategy of 
strict volume control permitted the stabilization of cardiac biomarker levels over time, 
suggesting that this strategy may prevent further progression of left ventricular 
hypertrophy, cardiac fibrosis and diastolic dysfunction. Patients with higher biomarker 
levels at baseline, probably those with more severe myocardial damage, were the most 
beneficed as NT-proBNP levels could even be reduced over time (figure 2). In these high 
risk patients, continuous prevention of fluid overload diminished the inflammatory 
parameters on follow-up, confirming the importance of volume control for preventing 





Fig. 2. Evolution over time of NT-proBNP values among patients distributed in high quartile 
at baseline (NT-proBNP high) and those distributed in other basal quartiles (NT-proBNP). 
Data expressed as mean ± standard error. 
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Fig. 3. Evolution over time of CRP values among patients distributed in high quartile at 
baseline (CRP high) and those distributed in other basal quartiles (CRP). * p<0.05 vs baseline 
levels. Data expressed as mean ± standard error. 
7. Other cardiac biomarkers: Troponin T 
Cardiac troponins are regulatory proteins within the myocardium that are released into the 
circulation when damage to the cardiomyocite has occurred. Therefore, serum troponin is 
an exquisitely sensitive marker of myocardial injury during the acute coronary syndrome 
and is necessary for establishing the diagnosis of myocardial infarction (Daubert et al., 
2010). 
Cardiac troponins control the calcium-mediated interaction of actin and myosin, which 
results in contraction and relaxation of striated muscle. The troponin complex is made up to 
three subunits: troponin C, troponin I and troponin T. Troponin C is expressed by cells in 
both cardiac and skeletal muscle. In contrast, troponin I and T are unique to cardiac muscle. 
Among patients with acute coronary syndrome, cardiac troponin has not only diagnostic 
value, but yield prognostic information as well. It has been proven to be a potent 
independent indicator of recurrent ischemic events and an estimate for the risk of death 
among patients presenting with acute coronary syndrome (Heidenreich et al., 2001). 
Persistently elevated cardiac troponin is frequently observed among asymptomatic patients 
with end-stage-renal-disease and is associated with increased mortality (Apple et al., 2002; 
de Fillipi et al., 2003; Ogi et al., 2001). There has been proposed several mechanisms for 
explaining the high levels of troponin among patients with CKD. Although troponin is a 
relative large molecule which is believed to be cleared by the reticuloendothelial system, 
more recent evidence suggest that troponin T is fragmented into molecules small enough  to 
be renally excreted, which may partly explain the high prevalence of troponin T elevation in 
patients with renal failure (Diris et al., 2004). 
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Cardiac microinfarctions and arrhythmia have also been suggested as possible causes of 
elevations of troponin among patients with CKD. 
More recently,  it has been observed that CKD patients with high troponin T concentrations 
had clear evidence of myocardial dysfunction and raised left ventricular filling pressure  
(Sharma et al., 2006), supporting that volume and pressure overload can cause excessive 
ventricular wall tension with resultant myofibrillary damage or cardiomyocites death 
(Horwich TB et al., 2003). In this way, a strong association between troponin T and NT-
proBNP has been observed in hemodialysis patients (figure 4) (Ortega et al., 2009) and both 
troponin T and NT-proBNP levels has been observed to be higher in volume-overloaded 





Fig. 4. Regression graph demonstrating the correlation between NT-proBNP and troponin T 
values at baseline (r: 0.4; p= 0.002) 
Thus, it seems that the increased troponin T in a high proportion of patients with CKD could 
be related to myocardial injury induced by an increased left ventricular volume especially in 
those patients with diastolic dysfunction, in whom a small increase in end-diastolic volume 
produces an exaggerated increment in end-diastolic pressure with the subsequent 
myocardial damage. Furthermore, in hemodialysis patients, a strategy of strict volume 
control over time could significantly reduce the troponin T levels especially in those patients 
with higher biomarker levels at baseline, probably those with more severe myocardial 
dysfunction (figure 5) (Ortega et al., 2009). 
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Fig. 5. Evolution over time of troponin T values among patients distributed in the high 
quartile at baseline (Troponin T high) vs those distributed in the other basal quartiles 
(Troponin T). * p<0.05 vs baseline levels. Data expressed as mean ± standard error. 
8. Summary and future perspectives 
There is a complex association between ventricular dysfunction, cardiac biomarkers, 
malnutrition, inflammation and overhydration among patients with CKD, which could 
partly explain the high CV morbidity and mortality among these patients, comparing with 
the general population. 
Probably, these alterations begin in the very early stages of CKD and volume overload could 
be an important underlying factor. The inability of the insufficient kidney for excreting water 
and salt induces an increase in extracellular volume, which may be underestimated in the 
early phases of CKD. Persistently volume overload can induce an increment in blood pressure, 
myocardial hypertrophy and myocardial fibrosis. Over time, diastolic dysfunction develops. 
In this setting, further small increments in end-diastolic volume produce an exaggerated 
increment in end-diastolic pressure favoring the release of BNP and also, myocardial damage 
and cardiac remodeling. During cardiac remodeling, death of cardiomyocites is produced 
inducing a serum increment in troponins, and normal myocardium is progressively 
substituted by a fibrotic matrix, worsening so diastolic dysfunction. In this situation, systemic 
inflammation is produced by a yet non clear mechanism. 
Thus, in this chapter, it is  tried to highlight the importance of early intervention for 
controlling volume excess in the very early stages of CKD in order to prevent future cardiac 
dysfunction and inflammation, reducing so the bad CV prognosis of these patients. 
It is noteworthy that at this early stage of CKD some patients can show normal plasma 
creatinine, especially older patients or patients with low muscle mass, but they may be 
subclinically overhydrated. A prescription of low sodium diet and the carefully use of 
diuretics at this phase of CKD could be the main tool for preventing volume overload and 
future CV damage. 
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inducing a serum increment in troponins, and normal myocardium is progressively 
substituted by a fibrotic matrix, worsening so diastolic dysfunction. In this situation, systemic 
inflammation is produced by a yet non clear mechanism. 
Thus, in this chapter, it is  tried to highlight the importance of early intervention for 
controlling volume excess in the very early stages of CKD in order to prevent future cardiac 
dysfunction and inflammation, reducing so the bad CV prognosis of these patients. 
It is noteworthy that at this early stage of CKD some patients can show normal plasma 
creatinine, especially older patients or patients with low muscle mass, but they may be 
subclinically overhydrated. A prescription of low sodium diet and the carefully use of 
diuretics at this phase of CKD could be the main tool for preventing volume overload and 
future CV damage. 
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Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with 
end-stage renal disease. Traditional risk factors for CV disease include hypertension, 
smoking, diabetes, dyslipidemia, left ventricular hypertrophy, advanced age and male sex 
in the general population. Although hemodialysis patients have a high prevalence of many 
of these factors, they also have nontraditional, or uremia-related, specific factors such as 
anemia, altered calcium-phosphorus metabolism, inflammation, oxidative stress, nitric 
oxide synthase inhibitors, hypoalbuminemia, carbamylation, abnormal lipoproteins and 
hyperhomocysteinemia (Parfrey, 2000; London&Drüeke 1997). So the risk markers that 
predict CV events in hemodialysis patients may differ from those in the general population. 
This increased CV risk has often been attributed to ‘accelerated atherosclerosis’ in end-stage 
renal disease (Cheung, 2000; Kasiske et al., 2000). However, CV causes of death are most 
prominent in the first years of dialysis and are rare in patients who have been on long term 
dialysis – the reverse of what would be expected if dialysis itself caused ‘accelerated 
atherosclerosis (Mailloux et al., 1991). Because many patients with end-stage renal disease 
already have one or more comorbidities and clinically evident vascular disease, it is difficult 
to determine from clinical or epidemiological studies whether traditional or non-traditional 
risk factors are more responsible for the high risk of CV events.   
The presence of comorbid disease is an increasingly common problem, being much more 
prevelant in new patients started on dialysis today than previously (Godkin et al., 2003; 
Mailloux et al., 1996; Merkus et al., 2000; Miskulin et al., 2009; Wallen et al., 2001). 
Hemodialysis patients who are under 55 years of age and without diabetes, significant 
comorbid diseases and obesity are very rare in the general hemodialysis population. For this 
reason, fewer epidemiological studies which focus on the determinants of CV risk of a 
relatively ‘healthy’ hemodialysis population are available. However, it is increasingly 
appreciated that chronic kidney disease alone is an independent risk factor for the 
development of CV disease. In this topic review of available data, an overview is presented 
of CV risk factors in hemodialysis patients without significant comorbidities. 
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2. Markers of inflammation 
Chronic inflammation is one of the well-known non-traditional cardiovascular risk factors in 
hemodialysis patients. Chronic kidney disease results in a chronic, low-grade inflammatory 
process that becomes evident even in the early stages of the disease. After the start of 
dialysis treatment, various factors associated with the dialysis procedure may also 
contribute to a stronger, more active inflammatory response. All available evidence suggests 
that chronic inflammation in hemodialysis patients may contribute significantly to the 
development and progression of CV disease (Filiopoulos&Vlassopoulos, 2009; Stenvinkel, 
2006; Zimmermann et al., 1999).  
Although few studies are available concerning the relationship between inflammatory status 
and CV risk in hemodialysis patients without co-morbid diseases, the studies that do exist in 
this area also support the role of inflammation.  
2.1 C-reactive protein  (CRP)  
CRP is the best studied inflammation marker associated with CV events. It is the 
prototypical acute phase response protein produced by the liver under the control of 
various proinflammatory cytokines, namely interleukin-6, interleukin-1, and tumor necrosis 
factor-α. Its uniquiness is due to rapid (within 6 hours) and dramatic increases (up to 1000-
fold) in circulating concentrations after a cytokine-mediated response to most forms of 
tissue injury, infection, and inflammation. Moreover, it was shown that plasma half-life (19 
hours) and fractional clearance rates of CRP were nearly constant in normal subjects, as well 
as in patients with infectious, inflammatory, and neoplastic conditions. This marks CRP as a 
‘precise objective index’ of overall inflammatory activity and a surrogate of underlying 
cytokine stimulus (Arici& Walls, 2001; Pepys&Baltz, 1983; Vigushin et al., 1993). 
Several observations have demonstrated that in a significant proportion of hemodialysis 
patients CRP is elevated for no apparent reason. A wide variety of factors in hemodialysis 
patients may be responsible for this elevation. First, the uremic state is associated with an 
altered immune response and uremia per se may cause a proinflammatory status with 
ongoing acute phase response. Also, extracorporeal circulation of blood during each 
hemodialysis session may act as a fresh stimulus for acute phase response. Increased 
cytokine release, the role of dialysis membranes, the dialysate and the patient-specific 
processes, such as the type of vascular access or unrecognized infections, may also play a 
role in inciting an inflammatory response (Arici&Walls, 2001; Stenvinkel, 2002a, 2002b).  
The predictive value of CRP in CV risk and mortality in hemodialysis patients was shown in 
numerous studies, and evidence from experimental and clinical studies showed that CRP 
may contribute directly to the pathogenesis of atherosclerosis and its complications through 
a variety of mechanisms (Arici&Walls, 2001; Yeun&Kaysen, 2000; Zimmermann et al., 1999).  
So it has been suggested that this hepatic–derived protein is not only a marker, but also a 
mediator, of vascular disease (Lagrand et al., 1997; Torzewski et al., 1998). Although a wide 
variety of potential sources may be associated with elevated CRP in this patient population, 
underlying silent CV disease may be one of the possible links for this elevation. So the clear 
association between CRP and CV disease in the hemodialysis population has added CRP as 
a new predictive CV risk factor which may actually be in a midway position between 
traditional and uremia-related CV risk factors (Arici&Walls, 2001). 
One of the studies investigated the associations of different risk factors with carotid artery 
intima-media thickness in non-diabetic hemodialysis patients who had no clinical evidence 
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of atherosclerosis and no comorbidities (Zumrutdal et al., 2005). Seventy-two patients (43 
men, 29 women; mean age 34.5 ± 10.6 years, mean time on hemodialysis 47.9 ± 40.0 months) 
were included in the study. Patients without history or evidence of myocardial, 
cerebrovascular or peripheral vascular disease, those without diabetes mellitus, and those 
who had been stabilized on hemodialysis therapy for more than six months and were less 
than 55 years old were enrolled. Patients were excluded whose chest radiograph showed 
calcified plaques in the aortic arch, or who had ischaemic findings on electrocardiography 
and/or ventricular wall motility disorders or valvular calcifications on echocardiography. 
Additionally, patients with conditions known to be associated with acute-phase responses 
were excluded. The control group consisted of 40 age-and sex-matched healthy subjects, 
who had been recruited from hospital staff. Body mass index, triglycerides, lipoprotein (a), 
fibrinogen, CRP, haematocrit-corrected erythrocyte sedimentation rate, serum cardiac 
troponin I, beta2 microglobulin, and homocysteine levels were found to be significantly 
different in patients on hemodialysis compared with control subjects. The mean value of the 
right and left carotid intima media thickness was 0.59 ± 0.06 mm for patients and 0.53 ± 0.07 
mm for control subjects. The difference was significant (p=0.002). The carotid intima-media 
thickness of patients was correlated with age, body mass index, CRP, haematocrit-corrected 
erythrocyte sedimentation rate, beta2 microglobulin, serum cardiac troponin I, triglyceride, 
and fibrinogen. CRP, haematocrit-corrected erythrocyte sedimentation rate, serum cardiac 
troponin I, and fibrinogen were significantly correlated with each other, but not with beta2 
microglobulin. The only parameter correlated with beta2 microglobulin was time on 
hemodialysis. The mean carotid intima-media thickness was significantly greater in patients 
with both left ventricular hypertrophy and a CRP level > 6.0 mg/L than it was in those with 
a CRP level ≤ 6.0 mg/L. In that study, multivariate regression analysis showed that age, 
CRP, beta2 microglobulin, and left ventricular hypertrophy were independent predictors of 
carotid artery intima-media thickness. The results of that study supported the hypothesis of 
an ‘accelerated atherogenesis’ in the hemodialysis population, even if those patients do not 
have clinical evidence of atherosclerosis. And CRP was found to be one of the independent 
predictors of early-onset atherosclerosis. 
Most investigations of CV risk in patients on hemodialysis have been cross-sectional in 
nature and representative of the general hemodialysis population. In the previous study, the 
same subgroup of hemodialysis patients was followed up over the course of one year and 
the determinants of the progression of carotid artery intima-media thickness were assessed 
again (Zumrutdal et al., 2006). Fifty-four of the 72 patients completed the study and re-
tested under the same standardized conditions after 12 months. The findings at 12 months 
showed that carotid artery intima-media thickness had progressed in 75.9 % patients. Age, 
CRP, beta2 microglobulin and left ventricular hypertrophy were independently related with 
baseline carotid artery intima-media thickness. At 12 months, age and CRP were found to be 
independent variables related with carotid artery intima-media thickness. The independent 
risk factors related with the change in carotid artery intima-media thickness from baseline to 
12-month stage were age and male sex.   
According to those results, age and male sex were related to progression of carotid artery 
intima-media thickness as unavoidable risk factors in this subgroup of the hemodialysis 
population. That agreed with the results of major clinical and epidemiological studies of the 
general population. The independent relation between CRP and carotid artery intima-media 
thickness both at baseline and 12 months supports the additional role of non-specific 
inflammation in hemodialysis patients without comorbidities. 
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2.2 Hematocrit-corrected erythrocyte sedimentation rate (Hct-corrected ESR) 
Although ESR is widely used in the general population as an inflammation marker, it was 
judged to be of no clinical utility in chronic hemodialysis patients in the mid-1980s. So ESR 
has seldom been studied in patients on hemodialysis. However, in 2001, it was proposed 
that after correction of ESR values according to Hct levels in hemodialysis patients, Hct-
corrected ESR could serve to select the inflammation-afflicted hemodialysis patients from 
those without this comorbid state (Borawski& Mysliwic, 2001). Supporting that study, while 
no relationship between ESR and carotid artery intima-media thickness was found, a 
relationship in hemodialysis patients without comorbidities was found between Hct-
corrected ESR and carotid artery intima-media thickness, beyond other inflammatory 
markers, CRP, and fibrinogen.  Although larger additional studies are needed to determine 
the potential value of Hct-corrected ESR as an inflammatory marker for early-onset 
atherosclerosis, this relationship may again reflect the role of non-specific inflammation in 
CV risk of the ‘healthy’ hemodialysis patients ( Zumrutdal et al., 2005).  
2.3 Fibrinogene  
In the normal population, increased activity of procoagulant proteins including factor VII 
and fibrinogen is associated with coronary risk. Factor VII coagulant activity and markers of 
thrombin activation are elevated in patients with chronic renal failure and correlate 
positively with serum triglycerides and the acute phase reactants interleukin 6 and 
fibrinogen and negatively with serum albumin (Tomson, 2000). The presence of generalized 
endothelial dysfunction in uraemic patients is also suggested by higher plasma levels of 
fibrinogen, endothelin and other factors. The relationship between carotid artery intima-
media thickness and fibrinogene in hemodialysis patients without comorbidities may reflect 
the role of fibrinogene in early-onset atherosclerosis as one of the best-studied inflammation 
markers (Zumrutdal et al., 2005). 
3. Cardiac markers 
3.1 Left ventricular hypertrophy 
Left ventricular hypertrophy is a well-known potent predictor of CV mortality in patients on 
renal replacement therapy (Ma et al., 1992). This may result either from pressure overload, 
causing increased tensile stress, or from volume overload, causing increased shear stres 
(Tomson, 2000). Recently published results demonstrated that even with good control of 
hypertension and anaemia, conventional hemodialysis is associated with significant left 
ventricular hypertrophy. And high prevalence of CV disease was positively associated with 
left ventricular hypertrophy in hemodialysis population.  
In the study assessing the predictive markers of CV risk in asymptomatic hemodialysis 
patients, in total, 113 hemodialysis patients were included. Demographic, anthropometric, 
clinical, and laboratory data were collected. Silent myocardial damage was defined by 
elevated cardiac troponin I values above cutoff values. Cardiac troponin I concentrations 
were below cutoff value in 103 (91.2%) patients (group 1), whereas 10 (8.8%) patients (group 
2) had elevated concentrations. Group 1 patients had higher levels of hemoglobin and high-
density lipoprotein cholesterol and lower C-reactive protein and tumor necrosis factor-alpha 
levels, as well as less incidence of left ventricular hypertrophy, when compared to group 2 
patients. Diabetes mellitus, left ventricular hypertrophy, uncontrolled blood pressure, 
normalized protein equivalent of total nitrogen appearence, hemoglobin and tumor necrosis 
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factor-alpha were found to be independently associated with silent myocardial damage 
(Afsar et al., 2009).  
In hemodialysis patients without comorbidities, mean carotid intima-media thickness, 
which reflects generalized atherosclerosis and CV risk, was significantly greater in patients 
with left ventricular hypertrophy, than it was in patients without left ventricular 
hypertrophy. Mean carotid intima-media thickness in subjects in the heathy control group 
was significantly lower than it was in hemodialysis patients both with and without left 
ventricular hypertrophy. The mean serum cardiac troponin I level in the control group was 
significantly lower than it was in patients both with and without left ventricular 
hypertrophy. The mean serum cardiac troponin I level was significantly higher in patients 
with left ventricular hypertrophy than it was in those without left ventricular hypertrophy 
(Zumrutdal et al., 2005). The relationship between carotid artery intima-media thickness, 
serum cardiac troponin I levels and left ventricular hypertrophy may demonstrate that 
subclinical atherosclerotic changes and/or adaptation may occur along with cardiac 
alterations. So it may be reasonable to apply early strategies for prevention and treatment of 
left ventricular hypertrophy in hemodialysis patients before clinically evident CV disease. 
3.2 Cardiac troponins 
Cardiac troponins are the most specific biomarkers for myocardial damage, although they 
may be elevated in situations other than acute coronary syndrome. Hemodialysis patients 
often have raised cardiac troponin I and T levels in the absence of acute ischaemic 
symptoms. The source of this increase has been a point of confusion over the past decade. At 
the beginning, some authors suggested that this might be related to the cardiac expression of 
troponins, while others argued for the skeletal muscle as a possible extracardiac source of 
abnormally elevated cardiac troponins in hemodialysis patients (Bodor et al., 1997; Kals et 
al., 2011; McLaurin et al., 1997).  
In initial experience with two troponin subunits, serum troponin T was elevated more 
frequently than troponin I in patients with renal failure, and that led the clinicians to 
question its specificity for the diagnosis of myocardial infarction. Additionally, the poorer 
specificity of troponin T was attributed to subclinical myocardial injury in the setting of left 
ventricular hypertrophy or to uremia-induced skeletal muscle expression of the cardiac 
isoform of troponin T, while cardiac troponin I has been exclusively of cardiac origin and 
does not express in the skeletal muscle at any developmental stage. Thus, troponin I was 
proposed to be a better marker of myocardial injury in renal failure than T (Yeun&Kaysen, 
2000). However, subsequent studies reported the absence of extracardiac cardiac troponin T 
expression in truncal skeletal muscle biopsy specimens from patients with end-stage renal 
failure at the RNA and protein levels (Haller et al., 1998). Another study, based on the 
electromyographic evaluation of 50 chronic hemodialysis patients, investigated the 
relationship between increased cardiac troponin T levels and uremic myopathy. Proximal-
extremity muscles-deltoid, biceps, vastus laterali-, which were the most common targets of 
uremic myopathy, were studied. Five of 50 patients (10%) had a positive troponin T test, but 
only 1 of those patients had characteristic electromyographic findings. Totally, 4 of 50 
patients (8%) had electromyographic findings characteristic of uremic myopathy. Positive 
troponin test results were not associated with calcium, phosphate, parathormone levels. 
There was no association between serum cardiac troponin T levels and uremic myopathy 
(Zumrutdal AO et al., 2000).  
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2.2 Hematocrit-corrected erythrocyte sedimentation rate (Hct-corrected ESR) 
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no relationship between ESR and carotid artery intima-media thickness was found, a 
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corrected ESR and carotid artery intima-media thickness, beyond other inflammatory 
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factor-alpha were found to be independently associated with silent myocardial damage 
(Afsar et al., 2009).  
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symptoms. The source of this increase has been a point of confusion over the past decade. At 
the beginning, some authors suggested that this might be related to the cardiac expression of 
troponins, while others argued for the skeletal muscle as a possible extracardiac source of 
abnormally elevated cardiac troponins in hemodialysis patients (Bodor et al., 1997; Kals et 
al., 2011; McLaurin et al., 1997).  
In initial experience with two troponin subunits, serum troponin T was elevated more 
frequently than troponin I in patients with renal failure, and that led the clinicians to 
question its specificity for the diagnosis of myocardial infarction. Additionally, the poorer 
specificity of troponin T was attributed to subclinical myocardial injury in the setting of left 
ventricular hypertrophy or to uremia-induced skeletal muscle expression of the cardiac 
isoform of troponin T, while cardiac troponin I has been exclusively of cardiac origin and 
does not express in the skeletal muscle at any developmental stage. Thus, troponin I was 
proposed to be a better marker of myocardial injury in renal failure than T (Yeun&Kaysen, 
2000). However, subsequent studies reported the absence of extracardiac cardiac troponin T 
expression in truncal skeletal muscle biopsy specimens from patients with end-stage renal 
failure at the RNA and protein levels (Haller et al., 1998). Another study, based on the 
electromyographic evaluation of 50 chronic hemodialysis patients, investigated the 
relationship between increased cardiac troponin T levels and uremic myopathy. Proximal-
extremity muscles-deltoid, biceps, vastus laterali-, which were the most common targets of 
uremic myopathy, were studied. Five of 50 patients (10%) had a positive troponin T test, but 
only 1 of those patients had characteristic electromyographic findings. Totally, 4 of 50 
patients (8%) had electromyographic findings characteristic of uremic myopathy. Positive 
troponin test results were not associated with calcium, phosphate, parathormone levels. 
There was no association between serum cardiac troponin T levels and uremic myopathy 
(Zumrutdal AO et al., 2000).  
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Subsequent studies showed that frequently positive T test results in hemodialysis patients 
were likely due to use of the older and less specific troponin T assay with some cross-
reactivity to skeletal muscle (Yeun&Kaysen, 2000). And with the use of the latest generation 
assays, accumulated data from groups of renal failure patients have suggested that elevated 
levels of both troponin T and I in asymptomatic hemodialysis patients could be associated 
with added CV risk, including general mortality.  Most of the recent studies supported the 
troponin tests as predictive markers of asymptomatic atherosclerosis and silent myocardial 
damage in hemodialysis patients (Kanderian& Francis, 2006; Kanwar et al., 2006). 
The carotid artery intima-media thickness measurement has been proposed as a method for 
establishing risk stratification for CV events.  To the best of our knowledge, we were the first 
to examine the relationship between serum cardiac troponin I level and early onset 
atherosclerosis in a selected subgroup of hemodialysis patients without any clinical 
evidence of either atherosclerosis or comorbidities.  Based on those results, the increased 
serum cardiac troponin I level was positively correlated with the carotid intima-media 
thickness and seemed to be a valuable predictive marker for the assessment of CV risk in 
asymptomatic hemodialysis patients (Zumrutdal et al., 2005). Also, a possible association 
was found between elevated serum cardiac troponins and inflammatory markers such as 
CRP, fibrinogen and Hct-corrected ESR. The association between carotid intima-media 
thickness, serum cardiac troponin I levels and inflammatory parameters needs to be clarified 
with further studies. Although the underlying pathophysiology of elevated cardiac 
troponins is still not clearly understood, it may reflect ongoing, often subclinical, myocardial 
damage or microinfarctions that are partially independent of acute ischaemic injury.  So 
serum cardiac troponin elevations might be very effective in elucidating cardiac risks of 
hemodialysis patients without any clinical evidence of atherosclerosis and comorbidities.  
In conclusion, in addition to traditional risk factors such as age and male sex, non-specific 
inflammation may play a key role in the progression of atherosclerosis in patients on 
hemodialysis without comorbidities. Although it is well-established that end-stage renal 
failure is a state of chronic systemic inflammation, both nondialysis-related factors and the 
dialysis procedure per se may be responsible for this high risk. Beta2 microglobulin and 
serum cardiac troponins may be the potential new additions for CV risk in this group of 
patients. Further studies are needed to determine whether there is a causal relationship.  
4. Metabolic markers 
4.1 Beta 2 microglobulin 
Elevated plasma beta2 microglobulin is a well-known characteristic of chronic renal failure, 
and among uremic toxins in the middle molecule range, it is certainly one of the most 
studied compounds. Beta 2 microglobulin is a key component in the genesis of dialysis-
associated amyloidosis. The source of the elevated serum beta2 microglobulin has not been 
explained absolutely in hemodialysis patients. There is controversy as to whether elevated 
levels are caused predominantly by increased synthesis of beta2 microglobulin, the use of 
membranes in hemodialysis with different clearance capacities, or diminished renal 
elimination (Drüeke et al., 2009). Use of middle and high-flux biocompatible membranes 
was shown to be associated with a notable reduction in beta2 microglobulin and, in some 
other studies, the systemic inflammatory response, in the general hemodialysis population. 
However, the role of proinflammatory monocytic cytokines, such as interleukin-1 and 
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interleukin-6, in the pathogenesis of elevated beta2 microglobulin, and its role as a potential 
initiator of the inflammatory response were discussed (Vraetz et al., 1999; Xie & Yi, 2003).  
Recently, a study comparatively evaluated the effect of hemodialysis and peritoneal dialysis 
on oxidative stress and inflammatory biomarkers and the associated factors. It found similar 
degrees of inflammaton and oxidative stress activation in both groups.  In that study, beta2 
microglobulin was one of the parameters which correlated to oxidative stress and 
inflammatory biomarkers.  It was negatively correlated both with total antioxidant capacity 
in hemodialysis patients and with superoxide dismutase in peritoneal dialysis patients 
(Filiopoulos et al., 2009). 
Previously, for what was probably the first time in the available literature, we provided data 
about the association between beta2 microglobulin and early-onset atherosclerosis in 
hemodialysis patients without comorbidities (Zumrutdal et al., 2005). In our study, the only 
parameter correlated with beta2 microglobulin was time on hemodialysis therapy. At that 
time, we speculated that the relationship we found might be casual (inflammatory) or just 
an epiphenomenon, and added that further follow up studies were needed to elucidate the 
importance of beta2 microglobulin as a new nontraditional cardiovascular risk factor in 
hemodialysis patients. Subsequently, few studies have evaluated the association of beta 2 
microglobulin levels with clinical outcome in dialyzed patients. The patients were divided 
into two groups according to their serum beta2 microglobulin levels (lower beta2 
microglobulin group, n=245 and higher beta2 microglobulin group, n=245) and followed-
up. During the follow-up period of 40±15 months, there were 91 all-cause deaths, and out of 
them, 36 were from CV disease. All cause mortality in the higher beta2 microglobulin group 
was significantly higher compared to that in the lower beta2 microglobulin group. And 
serum beta2 microglobulin level was a significant predictor of mortality in hemodialysis 
patients, independent of hemodialysis duration, diabetes, malnutrition and chronic 
inflammation (Okuno et al., 2009).  
A few studies also supported the correlation between serum beta2 microglobulin levels and 
various cardiovascular risk factors, including CRP, in hemodialysis patients (Kuragano et 
al., 2010). And recently, beta2 microglobulin has been suggested to be a novel biomarker of 
peripheral arterial disease and an independent predictor of aortic stiffness in atherosclerosis, 
in the general population (Wilson et al., 2007). Additionally, higher serum beta2 
microglobulin levels were proposed to be a novel marker to distinguish levels of risk in 
acute heart failure patients with creatinine ≤ 3mg/dl (Kawai et al., 2010).  
All of those findings strongly support the role of beta2 microglobulin in CV risk of 
hemodialysis patients, and it seems it will be a potential new CV risk marker in the future. 
Further studies are needed to clarify the importance of beta2 microglobulin as a CV risk 
factor in hemodialysis patients without comorbidities. 
5. Determinants of cardiovascular risk in nondiabetic hemodialysis patients 
Diabetes is not only a traditional risk factor for CV disease, but also one of the most common 
causes of end-stage renal disease. While a decline in CV deaths has occurred in the general 
population, a similar trend has not been observed in dialysis patients.  This discrepancy is in 
part due to the demographics of patients about to be started on dialysis: about 40 percent 
are diabetic. Also, the average age of hemodialysis patients is approximately 60 years and 
about 20 percent are over 75 years, and many patients have underlying cardiac disease 
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Subsequent studies showed that frequently positive T test results in hemodialysis patients 
were likely due to use of the older and less specific troponin T assay with some cross-
reactivity to skeletal muscle (Yeun&Kaysen, 2000). And with the use of the latest generation 
assays, accumulated data from groups of renal failure patients have suggested that elevated 
levels of both troponin T and I in asymptomatic hemodialysis patients could be associated 
with added CV risk, including general mortality.  Most of the recent studies supported the 
troponin tests as predictive markers of asymptomatic atherosclerosis and silent myocardial 
damage in hemodialysis patients (Kanderian& Francis, 2006; Kanwar et al., 2006). 
The carotid artery intima-media thickness measurement has been proposed as a method for 
establishing risk stratification for CV events.  To the best of our knowledge, we were the first 
to examine the relationship between serum cardiac troponin I level and early onset 
atherosclerosis in a selected subgroup of hemodialysis patients without any clinical 
evidence of either atherosclerosis or comorbidities.  Based on those results, the increased 
serum cardiac troponin I level was positively correlated with the carotid intima-media 
thickness and seemed to be a valuable predictive marker for the assessment of CV risk in 
asymptomatic hemodialysis patients (Zumrutdal et al., 2005). Also, a possible association 
was found between elevated serum cardiac troponins and inflammatory markers such as 
CRP, fibrinogen and Hct-corrected ESR. The association between carotid intima-media 
thickness, serum cardiac troponin I levels and inflammatory parameters needs to be clarified 
with further studies. Although the underlying pathophysiology of elevated cardiac 
troponins is still not clearly understood, it may reflect ongoing, often subclinical, myocardial 
damage or microinfarctions that are partially independent of acute ischaemic injury.  So 
serum cardiac troponin elevations might be very effective in elucidating cardiac risks of 
hemodialysis patients without any clinical evidence of atherosclerosis and comorbidities.  
In conclusion, in addition to traditional risk factors such as age and male sex, non-specific 
inflammation may play a key role in the progression of atherosclerosis in patients on 
hemodialysis without comorbidities. Although it is well-established that end-stage renal 
failure is a state of chronic systemic inflammation, both nondialysis-related factors and the 
dialysis procedure per se may be responsible for this high risk. Beta2 microglobulin and 
serum cardiac troponins may be the potential new additions for CV risk in this group of 
patients. Further studies are needed to determine whether there is a causal relationship.  
4. Metabolic markers 
4.1 Beta 2 microglobulin 
Elevated plasma beta2 microglobulin is a well-known characteristic of chronic renal failure, 
and among uremic toxins in the middle molecule range, it is certainly one of the most 
studied compounds. Beta 2 microglobulin is a key component in the genesis of dialysis-
associated amyloidosis. The source of the elevated serum beta2 microglobulin has not been 
explained absolutely in hemodialysis patients. There is controversy as to whether elevated 
levels are caused predominantly by increased synthesis of beta2 microglobulin, the use of 
membranes in hemodialysis with different clearance capacities, or diminished renal 
elimination (Drüeke et al., 2009). Use of middle and high-flux biocompatible membranes 
was shown to be associated with a notable reduction in beta2 microglobulin and, in some 
other studies, the systemic inflammatory response, in the general hemodialysis population. 
However, the role of proinflammatory monocytic cytokines, such as interleukin-1 and 
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interleukin-6, in the pathogenesis of elevated beta2 microglobulin, and its role as a potential 
initiator of the inflammatory response were discussed (Vraetz et al., 1999; Xie & Yi, 2003).  
Recently, a study comparatively evaluated the effect of hemodialysis and peritoneal dialysis 
on oxidative stress and inflammatory biomarkers and the associated factors. It found similar 
degrees of inflammaton and oxidative stress activation in both groups.  In that study, beta2 
microglobulin was one of the parameters which correlated to oxidative stress and 
inflammatory biomarkers.  It was negatively correlated both with total antioxidant capacity 
in hemodialysis patients and with superoxide dismutase in peritoneal dialysis patients 
(Filiopoulos et al., 2009). 
Previously, for what was probably the first time in the available literature, we provided data 
about the association between beta2 microglobulin and early-onset atherosclerosis in 
hemodialysis patients without comorbidities (Zumrutdal et al., 2005). In our study, the only 
parameter correlated with beta2 microglobulin was time on hemodialysis therapy. At that 
time, we speculated that the relationship we found might be casual (inflammatory) or just 
an epiphenomenon, and added that further follow up studies were needed to elucidate the 
importance of beta2 microglobulin as a new nontraditional cardiovascular risk factor in 
hemodialysis patients. Subsequently, few studies have evaluated the association of beta 2 
microglobulin levels with clinical outcome in dialyzed patients. The patients were divided 
into two groups according to their serum beta2 microglobulin levels (lower beta2 
microglobulin group, n=245 and higher beta2 microglobulin group, n=245) and followed-
up. During the follow-up period of 40±15 months, there were 91 all-cause deaths, and out of 
them, 36 were from CV disease. All cause mortality in the higher beta2 microglobulin group 
was significantly higher compared to that in the lower beta2 microglobulin group. And 
serum beta2 microglobulin level was a significant predictor of mortality in hemodialysis 
patients, independent of hemodialysis duration, diabetes, malnutrition and chronic 
inflammation (Okuno et al., 2009).  
A few studies also supported the correlation between serum beta2 microglobulin levels and 
various cardiovascular risk factors, including CRP, in hemodialysis patients (Kuragano et 
al., 2010). And recently, beta2 microglobulin has been suggested to be a novel biomarker of 
peripheral arterial disease and an independent predictor of aortic stiffness in atherosclerosis, 
in the general population (Wilson et al., 2007). Additionally, higher serum beta2 
microglobulin levels were proposed to be a novel marker to distinguish levels of risk in 
acute heart failure patients with creatinine ≤ 3mg/dl (Kawai et al., 2010).  
All of those findings strongly support the role of beta2 microglobulin in CV risk of 
hemodialysis patients, and it seems it will be a potential new CV risk marker in the future. 
Further studies are needed to clarify the importance of beta2 microglobulin as a CV risk 
factor in hemodialysis patients without comorbidities. 
5. Determinants of cardiovascular risk in nondiabetic hemodialysis patients 
Diabetes is not only a traditional risk factor for CV disease, but also one of the most common 
causes of end-stage renal disease. While a decline in CV deaths has occurred in the general 
population, a similar trend has not been observed in dialysis patients.  This discrepancy is in 
part due to the demographics of patients about to be started on dialysis: about 40 percent 
are diabetic. Also, the average age of hemodialysis patients is approximately 60 years and 
about 20 percent are over 75 years, and many patients have underlying cardiac disease 
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(Mailloux, 2010). Thus, epidemiologic studies concerning the predictive factors of CV 
disease in nondiabetic hemodialysis patients are less available. 
5.1 Association with traditional and nontraditional risk factors 
In a study of the CV assessment of 75 nondiabetic hemodialysis patients, the main cause of 
renal failure was hypertension. Compared with normal controls, the patients were found to 
have increased inflammatory cytokines such as interleukin- 6, tumor necrosis factor alpha, 
and intercelluler adhesion molecule, as well as a high frequency of carotid intima media 
thickening, left ventricular hypertrophy, and aortic calcifications (Kunstmann et al., 2009). 
Mortality predictors among 84 diabetic and 161 nondiabetic patients undergoing hemodialysis 
were investigated for two years.  Forty-three diabetic patients and 30 nondiabetic patients 
died. Among diabetic patients, oliguria, elevated CRP, and elevated D-dimer levels predicted 
all-cause mortality. Oliguria was the most important predictor, particularly for infectious 
disease-related death. Among nondiabetic patients elevated cardiac troponin T levels, elevated 
D-dimer levels, and low cholesterol levels predicted all-cause mortality rates. Subdivision of 
the causes of death among nondiabetic patients revealed that cardiac troponin T levels 
predicted CV mortality rates. According to those results, mortality predictors among 
hemodialysis patients differed between diabetic and nondiabetic patients (Hocher et al., 2003). 
In one comparison, two groups of nondiabetic hemodialysis patients (both groups n=30) 
matched for age and sex, were selected according to the absence or presence of symptomatic 
atherothrombotic vascular disease affecting the coronary, cerebral, or peripheral arteries. The 
two groups were identical regarding primary renal disease, duration of hemodialysis, and Epo 
treatment. The presence of hypertension, lipoprotein (a), and fibronectin levels were 
independent predictors for the presence of atherothrombotic CV disease which may contribute 
to the high prevalence of CV risk. Smoking was not a predictor. (Tzanatos et al., 2009). 
Left ventricular hypertrophy: Left ventricular hypertrophy is one of the strongest 
predictors of CV mortality in the general dialysis population. It is an independent predictor 
of survival in patients with chronic renal failure and it is present in a large number of 
patients on hemodialysis. In 30 nondiabetic hemodialysis patients, predictive factors 
associated with left ventricular hypertrophy at baseline and in the follow-up period (at 0, 12, 
and 24 months) were studied. Systolic blood pressure, residual glomerular filtration rate 
and serum albumin levels were the predictive factors for left ventricular mass index at 
initiation of hemodialysis. Systolic blood pressure, human atrial natriuretic peptide, and 
hemoglobin levels were independent risk factors for left ventricular mass index, after 24 
months. Systolic blood pressure, human atrial natriuretic peptide, and hemoglobin levels 
were also predictive factors for left ventricular mass index after initiation of hemodialysis 
(Io et al., 2010). Better management of hypertension and anaemia may be priorities for 
preventing or improving CV risk in these patients.   
Carotid intima-media thickness: Carotid intima-media thickness is a strong predictor of CV 
events in the general population. The predictive value of carotid intima-media thickness in 99 
nondiabetic hemodialysis patients was investigated. During a follow-up of 42.4±19.5 months, 
33 patients died, 19 (57.6%) of them of CV causes. In those 19 patients carotid thickness was 
significantly higher than in those who survived. So carotid intima-media thickness was an 
independent predictor of CV death in nondiabetic hemodialysis patients (Ekart et al., 2005). 
Asymptomatic atherosclerosis and major risk factors in 104 nondiabetic patients with different 
stages of chronic kidney disease (stage 1-5) were also investigated. Carotid intima-media 
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thickness and plaque occurrence were compared with 40 healthy control subjects. Nondiabetic 
patients with chronic kidney disease showed advanced atherosclerosis, intima-media 
thickness, and plaque occurrence, and their numbers increased directly with the level of renal 
dysfunction. Another important risk factor was hypertension (Ekart et al., 2008). 
Vascular calcification: The uremic state is associated with numeous metabolic abnormalities 
and endocrine disturbances primarily involving calcium and phosphorus metabolism. 
Vascular calcification is highly prevelant in dialysis patients and increases CV mortality. The 
presence and progression of vascular calcification in hemodialysis patients have been 
significantly associated with chronic inflammation, malnutrition, and disorders of mineral 
metabolism. Through a review of the literature examining vascular calcification in end stage 
renal failure patients, hyperphosphatemia is significantly associated with vascular 
calcification in nondiabetic patients, while it may not be a significant risk factor for vascular 
calcification in diabetic patients. In diabetic patients vascular calcification occurs long before 
the initiation of dialysis therapy and and the factors associated with vascular calcification in 
non-uremic diabetics appear to be hyperglycemia and related metabolic disorders, such as 
increased glycation and oxidative stress. In diabetic end stage renal failure patients, 
hyperglycemia is also suggested to be a significant factor associated with the progression of 
vascular calcification. Thus, the importance of glycemic control in diabetic and phosphate 
control in nondiabetic end stage renal failure patients is suggested (Ishimura et al., 2008).  
The accumulating data demonstrate the role of abnormalities of calcium, phosphorus, 
vitamin D, and parathyroid hormone in CV disease and the importance of phosphate 
control is suggested for preventing vascular calcification and CV risk (Andress, 2008; 
London et al., 2000).  
Diabetes mellitus and ethnicity are known factors that affect the extent of CV calcifications. 
The extent of CV calcifications was assessed in non-diabetic Caucasian hemodialysis 
patients by a novel composite calcification score. Body mass index, cholesterol, triglycerides, 
intact PTH, and serum levels of fetuin-A and uncarboxylated matrix Gla protein were not 
associated with CV calcifications. Age, male gender, dialysis vintage, smoking, calcium-
phosphate product, CRP, and lower Kt/V were independent risk factors for CV 
calcifications (Schlieper et al., 2009). Increasing dialysis efficiency and lowering calcium-
phosphate product can reduce CV calcifications. Generally, a calcium X phosphate product 
of less than 55 is the therapeutic optimum and it is possible that even lower levels offer 
further survival advantage. However, no prospective randomized studies have 
demonstrated a CV benefit and/or a survival advantage with any of the current therapeutic 
options. But observational studies have shown improved survival in hemodialysis patients 
treated with active vitamin D analogues (Levin&Li, 2005).  
Metabolic abnormalities: Chronic kidney disease is associated with complex metabolic 
changes including insulin resistance, and insulin resistance is associated with increased CV 
risk (O’Sullivian&Kelly, 2007). In contrast to the general population, a higher body mass 
index is associated with better survival among hemodialysis patients. Theoretically, high 
energy supplementation in nondiabetic hemodialysis patients might adversely affect insulin 
resistance, and with this goal in mind, the effects of high energy supplementation on 
nondiabetic hemodialysis patients was investigated. According to the results, body fat mass 
and CRP were the primary determinants of insulin resistance in nondiabetic hemodialysis 
patients. High energy supplementation, increased adiposity, and inflammation exacerbated 
insulin resistance. However, long term metabolic effects of this strategy were unclear (Hung 
& Tang, 2009).  
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(Mailloux, 2010). Thus, epidemiologic studies concerning the predictive factors of CV 
disease in nondiabetic hemodialysis patients are less available. 
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have increased inflammatory cytokines such as interleukin- 6, tumor necrosis factor alpha, 
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all-cause mortality. Oliguria was the most important predictor, particularly for infectious 
disease-related death. Among nondiabetic patients elevated cardiac troponin T levels, elevated 
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matched for age and sex, were selected according to the absence or presence of symptomatic 
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two groups were identical regarding primary renal disease, duration of hemodialysis, and Epo 
treatment. The presence of hypertension, lipoprotein (a), and fibronectin levels were 
independent predictors for the presence of atherothrombotic CV disease which may contribute 
to the high prevalence of CV risk. Smoking was not a predictor. (Tzanatos et al., 2009). 
Left ventricular hypertrophy: Left ventricular hypertrophy is one of the strongest 
predictors of CV mortality in the general dialysis population. It is an independent predictor 
of survival in patients with chronic renal failure and it is present in a large number of 
patients on hemodialysis. In 30 nondiabetic hemodialysis patients, predictive factors 
associated with left ventricular hypertrophy at baseline and in the follow-up period (at 0, 12, 
and 24 months) were studied. Systolic blood pressure, residual glomerular filtration rate 
and serum albumin levels were the predictive factors for left ventricular mass index at 
initiation of hemodialysis. Systolic blood pressure, human atrial natriuretic peptide, and 
hemoglobin levels were independent risk factors for left ventricular mass index, after 24 
months. Systolic blood pressure, human atrial natriuretic peptide, and hemoglobin levels 
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thickness and plaque occurrence were compared with 40 healthy control subjects. Nondiabetic 
patients with chronic kidney disease showed advanced atherosclerosis, intima-media 
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Another study on nondiabetic hemodialysis patients showed that liver fat, visceral 
adiposity, and sleep disturbances contributed to the development of insulin resistance and 
glucose intolerance. However, further studies in the long term are still needed to clarify 
whether interventions that improve insulin sensitivity improve clinical outcomes and CV 
risk in nondiabetic hemodialysis patients (Sakkas et al., 2008). The study comparing fasting 
glucose levels and impaired fasting glucose levels with malnutrition and inflammatory 
parameters in nondiabetic hemodialysis patients demonstrated that fasting glucose levels 
predict one-year all-cause mortality in non-diabetic hemodialysis patients. And they also 
showed that basal fasting glucose levels, or the presence of impaired fasting glucose, plays 
an important role in inflammation, malnutrition and short term mortality (Lin-Tan, 2007).  
Diabetes mellitus and deficiency in n-3 long-chain polyunsaturated fatty acids are known to 
increase the incidence of CV disease. The study investigated the relationship between n-3 
long-chain polyunsaturated fatty acids and the pulse wave velocity from the brachium to 
the ankle, which was measured as a marker of atherosclerosis in 54 diabetic and 93 
nondiabetic hemodialysis patients. The mean pulse wave velocity in diabetic patients was 
significantly higher than that of nondiabetic patients. There was a significant inverse 
association between pulse wave velocity and docasahexaenoic acid levels and 
docasahexaenoic acid/aracidonic acid ratios in nondiabetic patients. It was concluded that 
n-3 long-chain polyunsaturated fatty acids may be a negative risk factor for CV disease in 
nondiabetic hemodialysis patients (Hamazaki et al., 2009). 
Numerous abnormalities of lipid and lipoprotein metabolism are described in renal disease. 
These abnormalities are caused by complex alterations in several pathways of lipoprotein 
metabolism. In addition, nonenzymatic modification of lipoprotein particles enhances their 
atherogenicity without affecting the measured levels of cholesterol, triglycerides, or the 
HDL, LDL and very-low-density lipoprotein fractions (Tomson, 2000). Dyslipidemia may be 
present in more than 90 % of hemodialysis patients and has been reported to correlate with 
CV disease in some, but not all, cross sectional studies of nondiabetic patients on 
hemodialysis. Among other lipid parameters, low HDL cholesterol was one of the 
independent determinants of coronary artery disease in nondiabetic hemodialysis patients 
(Zumrutdal et al., 2007). However there are limited data concerning the effectiveness of lipid 
lowering with statins in decreasing CV outcomes in patients on hemodialysis. 
Coagulation defects: In 68 nondiabetic hemodialysis patients, the probable association of 
circulating levels of plasminogen activator inhibitor type-1 and the expression of plasminogen 
activator inhibitor type-1 in internal iliac artery walls with atherosclerotic disease was 
investigated. Fifty age- and sex-matched healthy normotensive controls participated in the 
study. Atherosclerotic disease in both groups was assessed by measuring carotid intima-media 
thickness. Compared with control subjects, hemodialysis patients had significantly increased 
carotid thickness. Atherosclerotic plaques were detected in 61.7% of hemodialysis patients and 
4% of controls. Carotid intima-media thickness was correlated with age, systolic blood 
pressure, low-density lipoprotein, CRP, and interleukin-6. In hemodialysis patients, a close 
correlation was found between serum plasminogen activator inhibitor type-1 level, CRP, and 
interleukin-6 level. Also, carotid intima-media thickness and plaque score were correlated with 
circulating levels of plasminogen activator inhibitor type-1 and with the expression of it in 
internal iliac artery walls. The circulating levels of plasminogen activator inhibitor type-1 and 
the expression of plasminogen activator inhibitor type-1 in internal iliac rtery walls were 
statistically associated with CRP, interleukin-6, and low density lipoprotein cholesterol. With 
all of those correlations, authors have suggested that increased circulating plasminogen 
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activator inhibitor type-1 and an upregulated expression of plasminogen activator inhibitor 
type- 1 in the vasculature could indicate a chronic endothelium activated state and that may 
identify the risk of atherothrombosis related with inflammation in nondiabetic hemodialysis 
patients (Peng et al., 2008). Among nondiabetic patients, generalized endothelial dysfunction is 
associated with an increase in CV risk.  
Gene polymorphisms: Cytokine gene polymorphisms have been implicated as potential 
genetic risk factors for CV disease. The study assessed the role of cytokine gene 
polymorphisms in carotid intima-media thickness and left ventricular mass index, as surrogate 
markers for CV risk, in nondiabetic hemodialysis patents. Carotid intima-media thickness and 
left ventricular mass index progression for 2 years were detected at higher levels in patients 
with high-producer genotypes than in the patients with the low-producer genotype during the 
study period. The TNF-alpha-308 G/A polymorphism was closely associated with CRP.  So 
polymorphisms in inflammatory genes could be additional factors affecting inflammation and 
CV risk in non diabetic hemodialysis patients (Yilmaz et al., 2010). 
Synthesis of nitric oxide by endothelial nitric oxide synthase plays a key role in the 
atherosclerotic process. Several polymorphisms of the gene encoding endothelial nitric 
oxide synthase are known and have been investigated with respect to their influence on CV 
disease risk in the general population. The association between endothelial nitric oxide 
synthase gene polymorphism and CV events in nondiabetic Japanese hemodialysis patients 
was also investigated. Three endothelial nitric oxide synthase polymorphisms were 
genotyped for the patients and two endothelial nitric oxide synthase polymorphisms were 
found to be associated with major cardiac, cerebrovascular, or peripheral vascular events 
(Asakimori et al., 2004).  
5.2 Coronary artery disease in nondiabetic hemodialysis patients 
It is increasingly appreciated that chronic renal failure alone is an independent risk factor 
for the development of coronary artery disease. For evaluating the determinants of coronary 
artery disease in nondiabetic hemodialysis patients, among 312 consecutive patients on 
regular hemodialysis, 26 nondiabetic patients with angiographically defined coronary artery 
disease were compared with a subject group of nondiabetic hemodialysis patients of the 
same gender, smoking status, and hypertension with similar ages and body mass indexes, 
who had normal electrocardiography and myocardial perfusion scintigraphy. 
Demographics, CRP, ESR, Hct-corrected ESR, beta 2 microglobulin, cardiac troponin I, 
parathyroid hormone, albumin, calcium X phosphorus, and lipid profiles were compared 
between the groups. The nondiabetic patients with coronary artery disease had higher CRP, 
higher cardiac troponin I, and lower HDL-cholesterol levels than the patients without 
coronary artery disease. Backwards stepwise logistic regression analysis revealed that high 
CRP and troponin I levels and low HDL cholesterol levels were independently related with 
coronary artery disease in nondiabetic hemodialysis patients (Zumrutdal et al., 2007).  
The predictive value of CRP in CV risk and mortality in hemodialysis patients was previously 
shown in numerious studies, and underlying coronary artery disease may be one of the 
possible links for this elevation.  Additionally, even small elevations of serum cardiac troponin 
I concentration, at levels lower than those traditionally used for the diagnosis of acute events, 
were independently associated with the presence of coronary artery disease in asymptomatic 
hemodialysis patients.  Thus, small and non-specific increases in cardiac troponin I levels may 
reflect underlying coronary artery disease in nondiabetic hemodialysis patients. 
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All hemodialysis patients, diabetic or nondiabetic, are at markedly increased CV risk, with 
chronic renal disease alone currently considered a coronary heart disease risk equivalent. A 
large number of risk factors for CV disease and decreased survival that are related or 
unrelated to the dialysis procedure have been identified. Since no data are available about 
the outcome comparing hemodialysis patients with comorbidities with those without, it is 
not possible to suggest increased benefits for survival for hemodialysis patients without 
comorbidities.  Cardiovascular risk factor modification should be undertaken for all dialysis 
patients with or without comorbidities, given that they are considered a coronary heart 
disease equivalent.  
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1. Introduction 
Reverse epidemiology, or risk factor paradox, has been used to describe the observed effect 
that traditional risk factors for cardiovascular disease may not necessarily signify the same 
risk for hemodialysis patients (HP) as for healthy populations. In fact, recent published 
findings have suggested counter-intuitive outcomes (Chavalitdhamrong, Danovitch, & 
Bunnapradist, 2007; Tsirpanlis et al., 2009) regarding the role cholesterol may play in disease 
progression in HP with chronic inflammation and malnutrition comorbidities (Dungan, 
Guster, DeWalt, & Buse, 2007). However, contemporary experimental studies regarding 
reverse epidemiology are lacking. The few published findings on this topic suggest chronic 
inflammation, as measured by C-reactive protein (CRP), and malnutrition, as measured by 
albumin, is associated with normal cholesterol levels yet higher levels of mortality 
(Chavalitdhamrong, et al., 2007; Chmielewski, Carrero, Nordfors, Lindholm, & Stenvinkel, 
2008). 
In contrast, traditional risk factors such dyslipidemia, hyperhomocysteinemia, obesity, or 
hypertension may provide protective effects in HP, at least in the short term (Kalantar-
Zadeh, Block, Humphreys, & Kopple, 2003). Important predictors of clinical outcomes in HP 
are protein-energy wasting (malnutrition) (PEM) and inflammation (Fleischmann, Bower, & 
Salahudeen, 2001; Kalantar-Zadeh & Kopple, 2001; Kopple, 1997; Kopple, Zhu, Lew, & 
Lowrie, 1999; Lowrie & Lew, 1990; Nishizawa, Shoji, Ishimura, Inaba, & Morii, 2001). 
Because inflammation and PEM are interconnected and similarly affect markers of 
nutritional status both are considered part of a malnutrition inflammation complex (MIC) 
(Kalantar-Zadeh, et al., 2003; Kalantar-Zadeh & Kopple, 2001; Kalantar-Zadeh, Kopple, 
Block, & Humphreys, 2001). Thus, this chapter will address inflammation, malnutrition, 
cholesterol, and the overall concept of reverse epidemiology in HP relative to MIC as well as 
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1. Introduction 
Reverse epidemiology, or risk factor paradox, has been used to describe the observed effect 
that traditional risk factors for cardiovascular disease may not necessarily signify the same 
risk for hemodialysis patients (HP) as for healthy populations. In fact, recent published 
findings have suggested counter-intuitive outcomes (Chavalitdhamrong, Danovitch, & 
Bunnapradist, 2007; Tsirpanlis et al., 2009) regarding the role cholesterol may play in disease 
progression in HP with chronic inflammation and malnutrition comorbidities (Dungan, 
Guster, DeWalt, & Buse, 2007). However, contemporary experimental studies regarding 
reverse epidemiology are lacking. The few published findings on this topic suggest chronic 
inflammation, as measured by C-reactive protein (CRP), and malnutrition, as measured by 
albumin, is associated with normal cholesterol levels yet higher levels of mortality 
(Chavalitdhamrong, et al., 2007; Chmielewski, Carrero, Nordfors, Lindholm, & Stenvinkel, 
2008). 
In contrast, traditional risk factors such dyslipidemia, hyperhomocysteinemia, obesity, or 
hypertension may provide protective effects in HP, at least in the short term (Kalantar-
Zadeh, Block, Humphreys, & Kopple, 2003). Important predictors of clinical outcomes in HP 
are protein-energy wasting (malnutrition) (PEM) and inflammation (Fleischmann, Bower, & 
Salahudeen, 2001; Kalantar-Zadeh & Kopple, 2001; Kopple, 1997; Kopple, Zhu, Lew, & 
Lowrie, 1999; Lowrie & Lew, 1990; Nishizawa, Shoji, Ishimura, Inaba, & Morii, 2001). 
Because inflammation and PEM are interconnected and similarly affect markers of 
nutritional status both are considered part of a malnutrition inflammation complex (MIC) 
(Kalantar-Zadeh, et al., 2003; Kalantar-Zadeh & Kopple, 2001; Kalantar-Zadeh, Kopple, 
Block, & Humphreys, 2001). Thus, this chapter will address inflammation, malnutrition, 
cholesterol, and the overall concept of reverse epidemiology in HP relative to MIC as well as 
the implications of this information on short- and long-term treatment. 
2. Inflammation in hemodialysis patients 
2.1 Acute vs. chronic inflammation 
Initially, the inflammatory response is a defense mechanism to cellular injury or pathogenic 
invasion. The acute response includes vasodilatation, hyperemia and vascular permeability 
and can be detected within a relatively short amount of time (minutes to days) via an 
increase in neutrophils and the presence of fluid protein exudates (Sprague & Khalil, 2009). 
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Additional responders involved in the inflammatory response are cytokines (Sprague & 
Khalil, 2009) and acute phase proteins, which reach peak circulating levels within two days 
in the acute setting (Ceciliani, Giordano, & Spagnolo, 2002). Typically, the inflammatory 
process ceases when the mechanism responsible for cellular injury is removed, subsequent 
cellular intermediaries are inhibited, and healing takes place (Sprague & Khalil, 2009). 
However, in some instances that inflammatory process is not resolved. Thus, the response 
remains active and proceeds into a chronic process, which can result in necrosis and/or loss 
of functional tissue.  
2.2 Markers of inflammation in hemodialysis patients 
In HP the inflammatory response and markers of inflammation, namely CRP and the 
inflammatory cytokine interleukin-6 (IL-6), are predictive of mortality (Barreto et al., 2009; 
Pecoits-Filho, Barany, Lindholm, Heimburger, & Stenvinkel, 2002; Stenvinkel, Barany, 
Heimburger, Pecoits-Filho, & Lindholm, 2002; Yeun, Levine, Mantadilok, & Kaysen, 2000; 
Zimmermann, Herrlinger, Pruy, Metzger, & Wanner, 1999). In addition to CRP and IL-6, 
albumin and the inflammatory cytokine tumor necrosis factor-alpha (TNF-) are markers of 
inflammation commonly found in the literature. Each marker can provide evidence 
regarding the inflammatory state of HP, but there is debate as to which marker should be 
used and even debate as to the role in the inflammatory process of certain markers, namely 
CRP. For example, IL-6 and TNF- are known pro-inflammatory cytokines and are also 
associated with declining kidney function. Various cells including, macrophages and mast 
cells, produce TNF- and IL-6 (Sprague & Khalil, 2009). Among the numerous effects of 
TNF- are the stimulation of a febrile response, up-regulation of other cytokines, such as IL-
6, and stimulation of acute phase reactants (Sprague & Khalil, 2009). IL-6, in turn, has 
pleiotropic effects that include antibody secretion, the acute phase response and has also 
been shown to be pro-atherogenic, to name a few. However, TNF- and IL-6 are not 
typically used in clinical medicine and are more often found in research; therefore other 
means of assessing inflammation are used as these tests can become costly. Conversely, 
albumin and CRP are measurements of inflammation readily available to physicians. 
Interestingly, albumin levels are also commonly used to assess nutritional status as both 
nutrition and inflammation can affect albumin (more on this topic will be presented later in 
the chapter). 
CRP, however, is frequently used to confirm the presence of inflammation, as it is an acute 
phase protein produced by the liver and greatly regulated by IL-6. Additionally CRP is 
associated with reduction in nitric oxide production, induces monocyte recruitment and 
plays a strong role in foam cell formation. However, the causal role of CRP in cardiovascular 
events is still being debated (Genest, 2010; Lippi, Favaloro, Montagnana, & Franchini, 2010; 
Sattar & Lowe, 2006) and the use of CRP must be justified as it incurs added cost (Kaysen, 
2009). Regardless, it is a marker of inflammation that in the native form consists of five 
noncovalently bonded subunits and is termed pentameric CRP or pCRP. This is typically the 
CRP measured in plasma or serum, and is also known as high sensitivity CRP (hsCRP). 
High sensitivity CRP can dissociate into monomeric CRP (mCRP) after binding with 
activated platelets (Eisenhardt et al., 2009). New evidence suggests that mCRP, through the 
interaction of hsCRP with activated platelets, may play a more dominant role in the 
inflammatory process than hsCRP as mCRP was found to colocalize with macrophages and 
platelets (Eisenhardt, Habersberger, Murphy, et al., 2009).  High sensitivity CRP has also 
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been found in atherosclerotic lesions (Sun et al., 2005), but the antibodies used to detect CRP 
in this study detected both pCRP and mCRP (Eisenhardt, Habersberger, & Peter, 2009). It 
has been reported that once pCRP dissociates into mCRP, mCRP stimulates monocytes to a 
greater extent than pCRP, leads to increased monocyte adhesion, and exerts 
proinflammatory properties (Eisenhardt, Habersberger, Murphy, et al., 2009). Additionally, 
mCRP may be more effective at regulating LDL metabolism than pCRP (Ji, Wu, Potempa, 
Qiu, & Zhao, 2006). 
2.3 Causes of inflammation in hemodialysis patients 
Aside from the primary reason for the patient being placed on hemodialysis, often a disease 
associated with inflammation, dialysis and the integral pieces of hemodialysis can be 
sources of inflammation. Kaysen (2009) indicates that the type of vascular access used in 
dialysis, the insertion of the catheters, biofilm on catheters, bacterial components present in 
dialysate, and water supply can all be sources of inflammation (Kaysen, 2009). Markers of 
inflammation associated with vascular access alone include albumin (Chand, Teo, Fatica, & 
Brier, 2008; Wystrychowski et al., 2009), CRP (Costa et al., 2008; Movilli et al., 2006; 
Sachdeva, Kovalchuk, Bitzer, & Mokrzycki, 2009), and IL-6 (Costa, et al., 2008; Sachdeva, et 
al., 2009). As Kaysen (2009) points out, the type of vascular access in HP is associated with 
mortality (Xue, Dahl, Ebben, & Collins, 2003). Acutely, initial insertion of vascular access, 
especially catheter or arteriovenous graft (AVG), resulted in transient elevations of CRP and 
IL-6 whereas arteriovenous fistulas (AVF) did not demonstrate a transient rise in 
inflammatory markers (Sachdeva, et al., 2009). In regards to chronic inflammation, changing 
vascular access type from a catheter to AVG was shown to cause an increase in albumin, 
where as a change from AVG to catheter caused a decrease in albumin (Wystrychowski, et 
al., 2009). Similarly, catheter and AVG use have been demonstrated to result in elevated 
levels of CRP and IL-6 and lower levels of albumin than AVF (Costa, et al., 2008; Movilli, et 
al., 2006). Thus, the type of vascular access has an impact on inflammation levels. An 
additional impact on inflammation levels is adipose tissue as adipocytes produce IL-6 
(Fasshauer, Klein, Lossner, & Paschke, 2003), which is also a strong predictor of mortality in 
HP (Barreto, et al., 2009; Pecoits-Filho, et al., 2002; Stenvinkel, et al., 2002). 
3. Malnutrition in hemodialysis patients  
3.1 Albumin as a marker of nutritional status 
Albumin is the most abundant plasma protein with a half-life of about twenty-one days. It is 
a negative acute-phase protein that functions to maintain oncotic pressure and act as a 
transport protein (Carlson, 2004). Normal serum albumin concentration is between 3.5 and 
5.2 g/dL, and this reference range is often utilized as a marker of nutritional status in 
healthy older populations (Carlson, 2004; Covinsky, Covinsky, Palmer, & Sehgal, 2002). The 
cutoff point for low serum albumin concentration (hypoalbuminemia) has been proposed to 
be even higher at about 3.9 g/dL in HP (Trivedi, Xiang, & Klein, 2009). However, it must be 
noted that conclusions derived from measures of serum albumin concentration are not 
always in agreement with the conclusions derived from clinical assessments regarding 
nutritional status (Covinsky, et al., 2002). Forty HP with CRP levels below 0.80 mg/dL were 
evaluated for malnutrition by measuring serum albumin and through the use of the 
Subjective Global Assessment (SGA) described by Detsky, McLaughlin, and Baker et al. 
(1987). The SGA was used to determine whether a patient was classified as well-nourished 
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been found in atherosclerotic lesions (Sun et al., 2005), but the antibodies used to detect CRP 
in this study detected both pCRP and mCRP (Eisenhardt, Habersberger, & Peter, 2009). It 
has been reported that once pCRP dissociates into mCRP, mCRP stimulates monocytes to a 
greater extent than pCRP, leads to increased monocyte adhesion, and exerts 
proinflammatory properties (Eisenhardt, Habersberger, Murphy, et al., 2009). Additionally, 
mCRP may be more effective at regulating LDL metabolism than pCRP (Ji, Wu, Potempa, 
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(Fasshauer, Klein, Lossner, & Paschke, 2003), which is also a strong predictor of mortality in 
HP (Barreto, et al., 2009; Pecoits-Filho, et al., 2002; Stenvinkel, et al., 2002). 
3. Malnutrition in hemodialysis patients  
3.1 Albumin as a marker of nutritional status 
Albumin is the most abundant plasma protein with a half-life of about twenty-one days. It is 
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cutoff point for low serum albumin concentration (hypoalbuminemia) has been proposed to 
be even higher at about 3.9 g/dL in HP (Trivedi, Xiang, & Klein, 2009). However, it must be 
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always in agreement with the conclusions derived from clinical assessments regarding 
nutritional status (Covinsky, et al., 2002). Forty HP with CRP levels below 0.80 mg/dL were 
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or malnourished. Using 3.5 g/dL as the cutoff point for hypoalbuminemia resulted in a 
sensitivity of just 14.3% compared to the results of the SGA. Raising the hypoalbuminemia 
cutoff point to 4.1 g/dL increased the sensitivity of the measurement to 64%. Furthermore, 
the mean albumin concentrations for the well-nourished and malnourished groups were 4.3 
g/dL and 4.0 g/dL, respectively, with considerable overlap between the two groups. These 
data suggest that serum albumin alone may not be a sensitive marker of malnutrition in the 
absence of inflammation in HP (Santos et al., 2003). Regardless, serum albumin is a very 
important marker of mortality risk in HP (Iseki, Kawazoe, & Fukiyama, 1993). Despite the 
lack of total agreement with clinical assessments of nutritional status, hypoalbuminemia has 
been demonstrated to be an independent risk factor for all-cause mortality in older persons 
especially when combined with measures of physical disability (Corti, Guralnik, Salive, & 
Sorkin, 1994). Additionally, hypoalbuminemia is associated with mortality in various 
disease populations including cardiovascular, cancer, and HP (Iseki, et al., 1993; Phillips, 
Shaper, & Whincup, 1989). A 1 g/dL reduction in serum albumin has been associated with a 
47% greater risk of mortality in HP, with the serum albumin concentration in these 
particular HP being linked to inflammation more so than the presence of malnutrition (de 
Mutsert et al., 2009).  
3.2 Regulation of serum albumin: malnutrition and inflammation  
Serum albumin concentration is controlled by the rate of its synthesis, fractional catabolic 
rate (FCR), and distribution between intra and extravascular compartments. These three 
variables controlling albumin concentration are heavily influenced by both nutritional status 
and inflammation (Kaysen, 2003). In healthy individuals and HP without inflammation that 
are malnourished, albumin levels usually stay within a normal range until the degree of 
starvation is preterminal (Kaysen, 2009). Renal disease is associated with anorexia and PEM 
due to the build-up of uremic toxins. Additionally, hemodialysis for the removal of these 
toxins is also associated with anorexia and PEM because of the resulting nausea and post-
dialysis fatigue (Bergstrom, 1996). PEM leads to a decreased rate of albumin synthesis. In 
normal individuals, the FCR of albumin and resting energy expenditure are also down-
regulated in order to compensate for its decreased synthesis during periods of PEM. For HP 
that are in an inflammatory state, normal down-regulation of FCR is blunted leading to an 
imbalance between albumin synthesis and catabolism that result in hypoalbuminemia 
(Kaysen, 2009). Even in the absence of malnutrition, positive acute phase proteins that result 
from the production of pro-inflammatory cytokines are associated with decreased albumin 
synthesis. Additionally, inflammation leads to a greater than normal albumin FCR for a 
given serum albumin level (Kaysen, 2003). On top of the challenges presented by 
malnutrition and inflammation in HP, amino acid loss from hemodialysis itself may 
contribute further to nitrogen restriction and hypoalbuminemia (Kaysen, 2009).  
3.3 Nutritional supplementation and hemodialysis patients  
Recently, studies have investigated the effects of protein and amino acid supplements on 
serum albumin levels in HP (Bolasco, Caria, Cupisti, Secci, & Saverio Dioguardi, 2011; 
Moretti, Johnson, & Keeling-Hathaway, 2009; Taylor et al., 2011). When selecting an 
appropriate nutritional supplement for HP, phosphorus levels must be taken into 
consideration as it has been demonstrated that high-protein intake with concurrent low-
phosphorus ingestion and normal serum phosphorus levels is associated with the lowest 
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mortality rate among HP (Kalantar-Zadeh et al., 2010). Supplementation with 15 grams of 
liquid hydrolyzed collagen protein three times per week after each hemodialysis treatment 
in one crossover group increased serum albumin by month 3 of supplementation. However, 
this change was small (+0.03 g/dL) and was not sustained throughout the remaining 3 
months of treatment (Moretti, et al., 2009). Conversely, two pilot studies have shown 
promising effects of nutritional supplementation on serum albumin. In one study, 
maintenance HP consumed eight ounces of egg whites (egg whites are low in phosphorus) 
once per day for six weeks (Taylor, et al., 2011). Mean serum albumin concentrations 
increased by 0.19 g/dL along with a fall in mean serum phosphorus of 0.94 mg/dL. In the 
other pilot study, four grams of oral amino acid supplementation three times daily increased 
mean serum albumin concentration by 0.50 g/dL after 3 months of treatment (Covinsky, et 
al., 2002). Also, inflammation was attenuated in the study group as demonstrated by a 
decrease in CRP levels. Based on these pilot studies, protein and amino acid 
supplementation may benefit HP, but more research including larger sample sizes with 
controlled trials is needed before a definite conclusion or treatment protocol can be 
formulated.  
4. Cardiovascular disease and hemodialysis patients  
The number of HP patients in the United States is approximately 350,000 with an 
expectation of reaching 1.5 million by 2016. Most HP have a significant decline in quality of 
life with two-thirds dying within 5 years of dialysis initiation; a survival rate worse than 
most cancers (Kilpatrick et al., 2007). Cardiovascular disease (CVD) is a leading cause of 
death in HP with rates higher than the general population and risk primarily associated 
with elevated lipids, inflammation, malnutrition, hypertension, hyperhomocysteinemia, 
obesity, and insulin resistance (Third Report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III) Final Report, 2002). Most HP patients’ elevated lipid profiles are 
associated with a higher incidence of CVD morbidity and mortality (Vaziri, 2009) and all-
cause mortality (Tsirpanlis, et al., 2009). Additionally, non-fatal CVD is 10-30 times higher in 
HP suggesting this population is more prone to heart disease (Nanayakkara & Gaillard, 
2010). Though traditional treatment of CVD in HP has demonstrated promise, many large 
randomized trials in HP have not demonstrated a survival benefit from traditional treatment 
strategies (Nanayakkara & Gaillard, 2010). The challenge becomes understanding why 
traditional risk factors are less predictive and whether the progression of disease is so 
advanced in HP that risk factor management should be different in this patient population. It 
should be noted however, that traditional and non-traditional risk factors for CVD in HP do 
have some crossover, complicating our understanding of how risk factor management may 
assist in disease causation and association. Though this chapter focuses on HP, chronic kidney 
disease patients who are predialysis share some of the same counter-intuitive findings. 
Therefore it should be noted that progression of CVD begins well before HP begin dialysis and 
could be detected as early as stage I CKD. Finally, it has been suggested that plaque 
accumulation may occur differently in HP. In the general population arterial plaque is more 
associated with lipid accumulation, but with HP it is more likely to be associated with calcified 
plaques and increased arterial stenosis (Diepeveen, Wetzels, Bilo, van Tits, & Stalenhoef, 2008).  
Various research groups, including the National Cholesterol Education Program (NCEP) 
(Third Report of the National Cholesterol Education Program Expert Panel on Detection, 
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data suggest that serum albumin alone may not be a sensitive marker of malnutrition in the 
absence of inflammation in HP (Santos et al., 2003). Regardless, serum albumin is a very 
important marker of mortality risk in HP (Iseki, Kawazoe, & Fukiyama, 1993). Despite the 
lack of total agreement with clinical assessments of nutritional status, hypoalbuminemia has 
been demonstrated to be an independent risk factor for all-cause mortality in older persons 
especially when combined with measures of physical disability (Corti, Guralnik, Salive, & 
Sorkin, 1994). Additionally, hypoalbuminemia is associated with mortality in various 
disease populations including cardiovascular, cancer, and HP (Iseki, et al., 1993; Phillips, 
Shaper, & Whincup, 1989). A 1 g/dL reduction in serum albumin has been associated with a 
47% greater risk of mortality in HP, with the serum albumin concentration in these 
particular HP being linked to inflammation more so than the presence of malnutrition (de 
Mutsert et al., 2009).  
3.2 Regulation of serum albumin: malnutrition and inflammation  
Serum albumin concentration is controlled by the rate of its synthesis, fractional catabolic 
rate (FCR), and distribution between intra and extravascular compartments. These three 
variables controlling albumin concentration are heavily influenced by both nutritional status 
and inflammation (Kaysen, 2003). In healthy individuals and HP without inflammation that 
are malnourished, albumin levels usually stay within a normal range until the degree of 
starvation is preterminal (Kaysen, 2009). Renal disease is associated with anorexia and PEM 
due to the build-up of uremic toxins. Additionally, hemodialysis for the removal of these 
toxins is also associated with anorexia and PEM because of the resulting nausea and post-
dialysis fatigue (Bergstrom, 1996). PEM leads to a decreased rate of albumin synthesis. In 
normal individuals, the FCR of albumin and resting energy expenditure are also down-
regulated in order to compensate for its decreased synthesis during periods of PEM. For HP 
that are in an inflammatory state, normal down-regulation of FCR is blunted leading to an 
imbalance between albumin synthesis and catabolism that result in hypoalbuminemia 
(Kaysen, 2009). Even in the absence of malnutrition, positive acute phase proteins that result 
from the production of pro-inflammatory cytokines are associated with decreased albumin 
synthesis. Additionally, inflammation leads to a greater than normal albumin FCR for a 
given serum albumin level (Kaysen, 2003). On top of the challenges presented by 
malnutrition and inflammation in HP, amino acid loss from hemodialysis itself may 
contribute further to nitrogen restriction and hypoalbuminemia (Kaysen, 2009).  
3.3 Nutritional supplementation and hemodialysis patients  
Recently, studies have investigated the effects of protein and amino acid supplements on 
serum albumin levels in HP (Bolasco, Caria, Cupisti, Secci, & Saverio Dioguardi, 2011; 
Moretti, Johnson, & Keeling-Hathaway, 2009; Taylor et al., 2011). When selecting an 
appropriate nutritional supplement for HP, phosphorus levels must be taken into 
consideration as it has been demonstrated that high-protein intake with concurrent low-
phosphorus ingestion and normal serum phosphorus levels is associated with the lowest 
 
Malnutrition, Inflammation and Reverse Epidemiology in Hemodialysis Patients 
 
301 
mortality rate among HP (Kalantar-Zadeh et al., 2010). Supplementation with 15 grams of 
liquid hydrolyzed collagen protein three times per week after each hemodialysis treatment 
in one crossover group increased serum albumin by month 3 of supplementation. However, 
this change was small (+0.03 g/dL) and was not sustained throughout the remaining 3 
months of treatment (Moretti, et al., 2009). Conversely, two pilot studies have shown 
promising effects of nutritional supplementation on serum albumin. In one study, 
maintenance HP consumed eight ounces of egg whites (egg whites are low in phosphorus) 
once per day for six weeks (Taylor, et al., 2011). Mean serum albumin concentrations 
increased by 0.19 g/dL along with a fall in mean serum phosphorus of 0.94 mg/dL. In the 
other pilot study, four grams of oral amino acid supplementation three times daily increased 
mean serum albumin concentration by 0.50 g/dL after 3 months of treatment (Covinsky, et 
al., 2002). Also, inflammation was attenuated in the study group as demonstrated by a 
decrease in CRP levels. Based on these pilot studies, protein and amino acid 
supplementation may benefit HP, but more research including larger sample sizes with 
controlled trials is needed before a definite conclusion or treatment protocol can be 
formulated.  
4. Cardiovascular disease and hemodialysis patients  
The number of HP patients in the United States is approximately 350,000 with an 
expectation of reaching 1.5 million by 2016. Most HP have a significant decline in quality of 
life with two-thirds dying within 5 years of dialysis initiation; a survival rate worse than 
most cancers (Kilpatrick et al., 2007). Cardiovascular disease (CVD) is a leading cause of 
death in HP with rates higher than the general population and risk primarily associated 
with elevated lipids, inflammation, malnutrition, hypertension, hyperhomocysteinemia, 
obesity, and insulin resistance (Third Report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III) Final Report, 2002). Most HP patients’ elevated lipid profiles are 
associated with a higher incidence of CVD morbidity and mortality (Vaziri, 2009) and all-
cause mortality (Tsirpanlis, et al., 2009). Additionally, non-fatal CVD is 10-30 times higher in 
HP suggesting this population is more prone to heart disease (Nanayakkara & Gaillard, 
2010). Though traditional treatment of CVD in HP has demonstrated promise, many large 
randomized trials in HP have not demonstrated a survival benefit from traditional treatment 
strategies (Nanayakkara & Gaillard, 2010). The challenge becomes understanding why 
traditional risk factors are less predictive and whether the progression of disease is so 
advanced in HP that risk factor management should be different in this patient population. It 
should be noted however, that traditional and non-traditional risk factors for CVD in HP do 
have some crossover, complicating our understanding of how risk factor management may 
assist in disease causation and association. Though this chapter focuses on HP, chronic kidney 
disease patients who are predialysis share some of the same counter-intuitive findings. 
Therefore it should be noted that progression of CVD begins well before HP begin dialysis and 
could be detected as early as stage I CKD. Finally, it has been suggested that plaque 
accumulation may occur differently in HP. In the general population arterial plaque is more 
associated with lipid accumulation, but with HP it is more likely to be associated with calcified 
plaques and increased arterial stenosis (Diepeveen, Wetzels, Bilo, van Tits, & Stalenhoef, 2008).  
Various research groups, including the National Cholesterol Education Program (NCEP) 
(Third Report of the National Cholesterol Education Program Expert Panel on Detection, 
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Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
Final Report, 2002) have established that lipids play a significant role in the progression of 
CVD and with reductions in cholesterol levels there is a similar and graded reduction in risk 
(Kalantar-Zadeh, et al., 2003). Dyslipidemia characterized in HP is primarily associated with 
hypertriglyceridemia, low HDL concentrations, elevated levels of LDL, elevated LDL 
particle numbers, a higher propensity of smaller and denser LDL particles which contain 
high levels of residual triglycerides, and elevated levels of lipoprotein (a) (Vaziri, 2009). 
Cholesterol metabolism in HP can be significantly altered by dialysis protocol, lipid 
controlling medication, malnutrition, and inflammation (Montazerifar, Hashemi, Karajibani, 
& Dikshit, 2010). HDL can be significantly reduced in HP due to a reduced plasma 
concentration of ApoA-I and ApoA-II (Bowden, Hebert, Wilson, Gentile, & Lanning, 2007; 
Vaziri, 2009), reduced transporter proteins such as ABCA-1 (Vaziri, 2009), and the down-
regulation of enzymatic process associated with HDL maturation (Malgorzewicz et al., 
2010). Down-regulation also occurs with HDL paraoxonase which is associated with 
impaired protection against oxidative stress. Hypertriglyceridemia also occurs in HP, is 
normally associated with impaired VLDL and is the most prominent dyslipidemic 
abmormality reported in 70% of HP (Eisenhardt, Habersberger, & Peter, 2009). Additionally, 
hypertriglyceridemia is associated with increases in IDL, chylomicrons, and chylomicron 
remnants postprandial (Chmielewski, et al., 2008). Primarily a reduction in lipoprotein 
lipase, an enzyme associated with binding to VLDL and the release of the corresponding 
triglycerides, is associated with changes that cause a concomitant increase in plasma 
triglycerides that seems to correspond with a decrease in VLDL receptors. Finally, LDL in 
HP is normally more atherogenic as particles are usually smaller, denser and are more likely 
to be oxidized and engulfed by macrophages leading to more unstable arterial plaques 
(Kaysen, 2009). Oxidation can further cause LDL to no longer be recognizable to LDL 
receptors on the cell causing less deposition of LDL in intracellular pools. Less deposition 
can lead to the same amount of circulating LDL cholesterol being associated with smaller 
and denser LDL particles which can carry more risk for CVD. Excess LDL cholesterol is then 
removed from circulation primarily by being engulfed by macrophages which lead to more 
atherogenic foam cells leading to risk acceleration. Lipoprotein (a) is a LDL-like lipid with 
higher levels associated with increased risk of CVD and is associated with overproduction 
of apolipoproteins, specifically apoB. Apolipoprotein B is bound with LDL and is associated 
with increased numbers of LDL particles.    
4.1 Reverse epidemiology 
Though cholesterol metabolism in HP is associated with dyslipidemia and many CVD 
related deaths are associated with elevated levels of lipoproteins, recent evidence suggests 
that many HP have normal or reduced plasma cholesterol levels that are associated with a 
higher rate of mortality (Bowden & Wilson, 2010). CVD related mortality accounts for 40-
45% of all-cause mortality in HP suggesting factors other than lipids may be associated with 
CVD in this patient population (Dungan, et al., 2007; Tsirpanlis, et al., 2009). Counter-
intuitive outcomes regarding the role cholesterol may play in disease progression in HP 
may be affected by chronic inflammation and malnutrition with much of the published 
literature concerned with MIC (Bowden & Wilson, 2010; Chavalitdhamrong, et al., 2007). 
The term, though controversial, that has been used in the literature associated with this 
counter-intuitive finding is reverse epidemiology (Dungan, et al., 2007). Experimental 
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studies are deficient, but the few published on this topic have suggested that HP with 
chronically elevated levels of inflammation, as measured by C-reactive protein (CRP) or 
interleukin-6 (IL-6), and malnutrition, as measured by albumin, are associated with normal 
cholesterol values but higher levels of mortality (Chavalitdhamrong, et al., 2007; 
Chmielewski, et al., 2008).  
5. Malnutrition-inflammation complex 
Cano et al. (2009) has reported that between 20-60% of HP may have MIC and that patients 
also have lower body weights, lower BMI, lower albumin levels, lower blood pressure and 
elevated CRP (Diepeveen, et al., 2008). Albumin has been specifically mentioned as a marker 
of nutritional status and identified as one of the criteria used to measure PEM which is 
associated with MIC. The association between hypoalbuminemia (< 3.9 mg/dL) and 
mortality has been well-established and albumin has been identified as a strong predictor of 
cardiovascular disease (Kaysen, 2009). Supporting this theory is the fact that most studies 
reporting on reverse epidemiology report no counter-intuitive findings with HDL. The 
cholesterol esters in HDL are primarily received from albumin (Vaziri, 2009) and therefore 
hypoalbuminemia would be associated with low HDL. This is also one possible explanation 
for why other lipoproteins would be low, yet still associated with a significantly higher 
mortality rate in HP. Challenging our understanding of how this might impact mortality 
and cholesterol is that albumin is also used as a measure of inflammation and may not 
necessarily be related a nutritional etiology (Trivedi, et al., 2009). Finally, CRP along with IL-
6 are inflammatory markers that have been associated with higher rates of mortality as well 
(Bowden & Wilson, 2010). 
5.1 Reverse epidemiology and cholesterol 
In a subset of HP a decrease in baseline cholesterol levels, excluding HDL, has been 
associated with decreases in CVD mortality and all-cause mortality when patients have 
chronic levels of inflammation and poor nutritional status (Krane et al., 2009). Recent study 
authors have suggested the need to consider both malnutrition and inflammation 
simultaneously as albumin has been shown to be affected by inflammation levels. 
Inflammatory cytokines and acute phase reactants have been reported to decrease appetite, 
reduced albumin, increase catabolism (Liu et al., 2004) and quite possibly cause lower levels 
of cholesterol suggesting that low albumin levels may simply be a reflection of inflammation 
rather than malnutrition. Specifically most lipoproteins seem to be affected by MIC with the 
exception of HDL. In most studies where HDL was either low or unaffected most patients 
experience hypoalbuminemia and low protein intake in the diet (Kilpatrick, et al., 2007). 
Krane et al. (2009) in a study of 1,229 Type II diabetics who were HP reported that high 
levels of CRP strongly predicted all-cause mortality, sudden death and myocardial 
infarction when cholesterol levels were both low and high. Yet, when CRP levels were high 
and cholesterol levels were low, relative risks for CVD related deaths were even greater. It 
was further reported that CRP level and not LDL level was the variable more likely to 
predict risk for mortality and cardiovascular events. Another study confirmed the existence 
of reverse epidemiology in the presence of high inflammation suggesting the inflammation 
better predicted both morbidity and mortality (Tsirpanlis, et al., 2009). The study authors 
also reported that nutritional cachexia along with low cholesterol were good nutritional 
indices for malnutrition and may be the reason low cholesterol levels are associated with 
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Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
Final Report, 2002) have established that lipids play a significant role in the progression of 
CVD and with reductions in cholesterol levels there is a similar and graded reduction in risk 
(Kalantar-Zadeh, et al., 2003). Dyslipidemia characterized in HP is primarily associated with 
hypertriglyceridemia, low HDL concentrations, elevated levels of LDL, elevated LDL 
particle numbers, a higher propensity of smaller and denser LDL particles which contain 
high levels of residual triglycerides, and elevated levels of lipoprotein (a) (Vaziri, 2009). 
Cholesterol metabolism in HP can be significantly altered by dialysis protocol, lipid 
controlling medication, malnutrition, and inflammation (Montazerifar, Hashemi, Karajibani, 
& Dikshit, 2010). HDL can be significantly reduced in HP due to a reduced plasma 
concentration of ApoA-I and ApoA-II (Bowden, Hebert, Wilson, Gentile, & Lanning, 2007; 
Vaziri, 2009), reduced transporter proteins such as ABCA-1 (Vaziri, 2009), and the down-
regulation of enzymatic process associated with HDL maturation (Malgorzewicz et al., 
2010). Down-regulation also occurs with HDL paraoxonase which is associated with 
impaired protection against oxidative stress. Hypertriglyceridemia also occurs in HP, is 
normally associated with impaired VLDL and is the most prominent dyslipidemic 
abmormality reported in 70% of HP (Eisenhardt, Habersberger, & Peter, 2009). Additionally, 
hypertriglyceridemia is associated with increases in IDL, chylomicrons, and chylomicron 
remnants postprandial (Chmielewski, et al., 2008). Primarily a reduction in lipoprotein 
lipase, an enzyme associated with binding to VLDL and the release of the corresponding 
triglycerides, is associated with changes that cause a concomitant increase in plasma 
triglycerides that seems to correspond with a decrease in VLDL receptors. Finally, LDL in 
HP is normally more atherogenic as particles are usually smaller, denser and are more likely 
to be oxidized and engulfed by macrophages leading to more unstable arterial plaques 
(Kaysen, 2009). Oxidation can further cause LDL to no longer be recognizable to LDL 
receptors on the cell causing less deposition of LDL in intracellular pools. Less deposition 
can lead to the same amount of circulating LDL cholesterol being associated with smaller 
and denser LDL particles which can carry more risk for CVD. Excess LDL cholesterol is then 
removed from circulation primarily by being engulfed by macrophages which lead to more 
atherogenic foam cells leading to risk acceleration. Lipoprotein (a) is a LDL-like lipid with 
higher levels associated with increased risk of CVD and is associated with overproduction 
of apolipoproteins, specifically apoB. Apolipoprotein B is bound with LDL and is associated 
with increased numbers of LDL particles.    
4.1 Reverse epidemiology 
Though cholesterol metabolism in HP is associated with dyslipidemia and many CVD 
related deaths are associated with elevated levels of lipoproteins, recent evidence suggests 
that many HP have normal or reduced plasma cholesterol levels that are associated with a 
higher rate of mortality (Bowden & Wilson, 2010). CVD related mortality accounts for 40-
45% of all-cause mortality in HP suggesting factors other than lipids may be associated with 
CVD in this patient population (Dungan, et al., 2007; Tsirpanlis, et al., 2009). Counter-
intuitive outcomes regarding the role cholesterol may play in disease progression in HP 
may be affected by chronic inflammation and malnutrition with much of the published 
literature concerned with MIC (Bowden & Wilson, 2010; Chavalitdhamrong, et al., 2007). 
The term, though controversial, that has been used in the literature associated with this 
counter-intuitive finding is reverse epidemiology (Dungan, et al., 2007). Experimental 
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studies are deficient, but the few published on this topic have suggested that HP with 
chronically elevated levels of inflammation, as measured by C-reactive protein (CRP) or 
interleukin-6 (IL-6), and malnutrition, as measured by albumin, are associated with normal 
cholesterol values but higher levels of mortality (Chavalitdhamrong, et al., 2007; 
Chmielewski, et al., 2008).  
5. Malnutrition-inflammation complex 
Cano et al. (2009) has reported that between 20-60% of HP may have MIC and that patients 
also have lower body weights, lower BMI, lower albumin levels, lower blood pressure and 
elevated CRP (Diepeveen, et al., 2008). Albumin has been specifically mentioned as a marker 
of nutritional status and identified as one of the criteria used to measure PEM which is 
associated with MIC. The association between hypoalbuminemia (< 3.9 mg/dL) and 
mortality has been well-established and albumin has been identified as a strong predictor of 
cardiovascular disease (Kaysen, 2009). Supporting this theory is the fact that most studies 
reporting on reverse epidemiology report no counter-intuitive findings with HDL. The 
cholesterol esters in HDL are primarily received from albumin (Vaziri, 2009) and therefore 
hypoalbuminemia would be associated with low HDL. This is also one possible explanation 
for why other lipoproteins would be low, yet still associated with a significantly higher 
mortality rate in HP. Challenging our understanding of how this might impact mortality 
and cholesterol is that albumin is also used as a measure of inflammation and may not 
necessarily be related a nutritional etiology (Trivedi, et al., 2009). Finally, CRP along with IL-
6 are inflammatory markers that have been associated with higher rates of mortality as well 
(Bowden & Wilson, 2010). 
5.1 Reverse epidemiology and cholesterol 
In a subset of HP a decrease in baseline cholesterol levels, excluding HDL, has been 
associated with decreases in CVD mortality and all-cause mortality when patients have 
chronic levels of inflammation and poor nutritional status (Krane et al., 2009). Recent study 
authors have suggested the need to consider both malnutrition and inflammation 
simultaneously as albumin has been shown to be affected by inflammation levels. 
Inflammatory cytokines and acute phase reactants have been reported to decrease appetite, 
reduced albumin, increase catabolism (Liu et al., 2004) and quite possibly cause lower levels 
of cholesterol suggesting that low albumin levels may simply be a reflection of inflammation 
rather than malnutrition. Specifically most lipoproteins seem to be affected by MIC with the 
exception of HDL. In most studies where HDL was either low or unaffected most patients 
experience hypoalbuminemia and low protein intake in the diet (Kilpatrick, et al., 2007). 
Krane et al. (2009) in a study of 1,229 Type II diabetics who were HP reported that high 
levels of CRP strongly predicted all-cause mortality, sudden death and myocardial 
infarction when cholesterol levels were both low and high. Yet, when CRP levels were high 
and cholesterol levels were low, relative risks for CVD related deaths were even greater. It 
was further reported that CRP level and not LDL level was the variable more likely to 
predict risk for mortality and cardiovascular events. Another study confirmed the existence 
of reverse epidemiology in the presence of high inflammation suggesting the inflammation 
better predicted both morbidity and mortality (Tsirpanlis, et al., 2009). The study authors 
also reported that nutritional cachexia along with low cholesterol were good nutritional 
indices for malnutrition and may be the reason low cholesterol levels are associated with 
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higher levels of mortality in HP. A more recent study reported on the cross-sectional 
association with MIC and the effects on cholesterol in HP (Bowden & Wilson, 2010). When 
comparing cholesterol levels, those classified as having hypoalbuminemia had a reverse 
epidemiological effect with LDL particle number. In the same study when HP were 
classified as having high inflammation, based on CRP, LDL, VLDL, and LDL particle 
number reported counter-intuitive findings. But, in patients classified as having both 
hypoalbuminemia and high inflammation, all lipid variables, with the exception of HDL, 
reported a reverse epidemiological effect. This suggests that though inflammation may play 
a more prominent role with reverse epidemiology, both inflammation and malnutrition can 
have a pronounced effect on lipids causing low cholesterol levels to be associated with more 
mortality. Additionally, other study authors have reported inverse associations with 
cholesterol and all-cause mortality, but also a U-shaped relationship with cholesterol in the 
presence of malnutrition and inflammation (Liu, et al., 2004). When malnutrition and 
inflammation were controlled for in the analysis, a strong, graded and positive association 
existed between high cholesterol levels and mortality further supporting the thought that 
reverse epidemiological associations with cholesterol in HP is associated with MIC. An 
additional review paper has suggested that previous studies that have controlled 
statistically for factors associated with MIC in HP, risk associated with cholesterol was the 
same as the general population and further speculates that cholesterol may be an additional 
marker of malnutrition (Chmielewski, et al., 2008). It should be noted that not all studies 
agree with these findings. 
Another theory behind why low cholesterol in HP patients can be associated with high 
mortality has been called survival selection. It is well-established that most chronic kidney 
disease patients will not survive to kidney failure and End-Stage Renal Disease. Presently, it 
is suggested that only 10% (Trivedi, et al., 2009) of patients will live long enough to initiate 
dialysis. Therefore, since so few survive it is thought that only those who have a strong 
genetic predisposition for survival may be more likely to live but may also have a poorer 
risk profile. Additionally, simply stated, HP may not live long enough to die of the 
consequences of traditional CVD risk factors. Though this theory is not very new, it has yet 
to be confirmed with well controlled studies that take into consideration the age of the 
patients. Kalantar-Zadeh et al. (2003) also suggests that reverse epidemiology may be 
normal and that over-nutrition is primarily a 20th and 21st century phenomenon and that our 
understanding of traditional Framingham risk factors may in fact be new and the exception. 
Though over-nutrition is a problem in many countries it has been associated with longer 
living populations in Western nations. As one would expect this idea is highly controversial 
among scientist and nephrologists.    
Additional study authors (Nanayakkara & Gaillard, 2010) have reported reverse 
epidemiology in HP concerning lipids could possibly be due oxidative stress. Reactive 
oxygen species (ROS) production that is not balanced by antioxidant control is associated 
with oxidative stress. Furthermore, oxidative injury has been reported to alter lipids in both 
the general population and HP and is involved in CVD acceleration (Diepeveen, et al., 2008). 
Though HP are normally supplemented with B vitamins and folic acid, many still have 
deficiencies in antioxidants with many patients shifting to a more pro-oxidative stress 
profile. High oxidized LDL is a well established comorbidity in both HP and CKD patients 
and is associated with small, dense LDL particles. Moreover, modification of LDL through 
oxidation is thought to be the first step in the development of CVD and specifically 
atherosclerosis. Oxidative stress occurs routinely in HP, especially in patients with a long-
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term dialysis vintage, making LDL smaller and denser and is associated with more 
endothelial dysfunction, inflammation, stenosis and intima media thickness. Therefore, the 
oxidative stress hypothesis may help to further explain reverse epidemiology. Oxidative 
stress in combination with MIC could cause lower levels of LDL and LDL particle numbers, 
but more atherogenic particles that can accelerate mortality and morbidity.  Yet, those 
associations do exist, a causal relationship between oxidative stress, CVD, and reverse 
epidemiology has yet to be established suggesting the need for further study. 
Chmielewski (2008) reports on an endotoxinlipoprotein hypothesis that suggests higher 
levels of cholesterol may be beneficial in HP. The theory suggests that higher levels of 
lipoproteins more readily bind bacterial lipopolysaccharide or endotoxins and modulate 
inflammatory immune responses. The authors continues to state that cholesterol levels and 
their ability to predict CVD fall on a continuum with lower and higher levels associated 
with mortality (Kalantar-Zadeh, 2007). Liu, et al. (2004) may help support this theory as they 
have reported a U-shaped curve regarding cholesterol levels and moratlity in HP. This 
theory is highly speculative and needs further study. 
Finally, as mentioned previously, HP patients have been reported to have smaller, dense 
LDL particles that are more oxidized which may play a stronger role than LDL. Small LDL 
particle size has been identified as an emerging risk factor for CVD (Third Report of the 
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, 2002). A previous 
study (Bowden, Griggs, Wilson, & Gentile, 2009) has demonstrated that LDL particle 
number and LDL size can classify more HP at risk when compared to LDL and triglycerides. 
Since more HP have small, dense LDL particles there may be mortality associated with 
smaller LDL particles even when LDL particle number is lower. Therefore, though HP may 
have less LDL cholesterol and less of the smaller LDL particles, because smaller LDL 
particles are more atherogenic, more patients have increased morality with decrease levels 
of cholesterol.  
6. Treatment 
Reverse epidemiology has been associated with cholesterol but also body mass index (BMI), 
systolic and diastolic blood pressure, homocysteine, and creatinine levels (Balakrishnan & 
Rao, 2007) in HP suggesting the need for novel treatments. Since the counter-intuitive 
findings are prevalent in HP additional approaches are necessary to help identify novel 
treatments and to discover if new therapies are warranted. Though counter-intuitive 
findings are present in HP as well as advanced age, congestive heart failure, malignancies, 
and AIDS little data exists to support changes in non-traditional risk factors as a means to 
control CVD. To help increase albumin levels it has been proposed to increase protein 
content in the diet. But levels of protein augmentation with HP patients on chronic 
hemodialysis has not been sufficiently elucidated simply because dietary protein can be a 
significant source of uremic toxins and increase phosphate levels which can have deleterious 
effects on the health of HP patients (Stolic, 2010). It should be noted that hypercaloric 
consumption may take several years and even decades for serious health effects to occur, yet 
hypocaloric consumption, measured by albumin levels in HP patients, normally causes a 
more rapid deterioration in health. Combined with high inflammation levels, a decreased 
appetite and hypocaloric levels may cause a significant decrease in cholesterol but 
accelerated risk for mortality (Kalantar-Zadeh, et al., 2001). This short-term effect of 
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higher levels of mortality in HP. A more recent study reported on the cross-sectional 
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comparing cholesterol levels, those classified as having hypoalbuminemia had a reverse 
epidemiological effect with LDL particle number. In the same study when HP were 
classified as having high inflammation, based on CRP, LDL, VLDL, and LDL particle 
number reported counter-intuitive findings. But, in patients classified as having both 
hypoalbuminemia and high inflammation, all lipid variables, with the exception of HDL, 
reported a reverse epidemiological effect. This suggests that though inflammation may play 
a more prominent role with reverse epidemiology, both inflammation and malnutrition can 
have a pronounced effect on lipids causing low cholesterol levels to be associated with more 
mortality. Additionally, other study authors have reported inverse associations with 
cholesterol and all-cause mortality, but also a U-shaped relationship with cholesterol in the 
presence of malnutrition and inflammation (Liu, et al., 2004). When malnutrition and 
inflammation were controlled for in the analysis, a strong, graded and positive association 
existed between high cholesterol levels and mortality further supporting the thought that 
reverse epidemiological associations with cholesterol in HP is associated with MIC. An 
additional review paper has suggested that previous studies that have controlled 
statistically for factors associated with MIC in HP, risk associated with cholesterol was the 
same as the general population and further speculates that cholesterol may be an additional 
marker of malnutrition (Chmielewski, et al., 2008). It should be noted that not all studies 
agree with these findings. 
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mortality has been called survival selection. It is well-established that most chronic kidney 
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is suggested that only 10% (Trivedi, et al., 2009) of patients will live long enough to initiate 
dialysis. Therefore, since so few survive it is thought that only those who have a strong 
genetic predisposition for survival may be more likely to live but may also have a poorer 
risk profile. Additionally, simply stated, HP may not live long enough to die of the 
consequences of traditional CVD risk factors. Though this theory is not very new, it has yet 
to be confirmed with well controlled studies that take into consideration the age of the 
patients. Kalantar-Zadeh et al. (2003) also suggests that reverse epidemiology may be 
normal and that over-nutrition is primarily a 20th and 21st century phenomenon and that our 
understanding of traditional Framingham risk factors may in fact be new and the exception. 
Though over-nutrition is a problem in many countries it has been associated with longer 
living populations in Western nations. As one would expect this idea is highly controversial 
among scientist and nephrologists.    
Additional study authors (Nanayakkara & Gaillard, 2010) have reported reverse 
epidemiology in HP concerning lipids could possibly be due oxidative stress. Reactive 
oxygen species (ROS) production that is not balanced by antioxidant control is associated 
with oxidative stress. Furthermore, oxidative injury has been reported to alter lipids in both 
the general population and HP and is involved in CVD acceleration (Diepeveen, et al., 2008). 
Though HP are normally supplemented with B vitamins and folic acid, many still have 
deficiencies in antioxidants with many patients shifting to a more pro-oxidative stress 
profile. High oxidized LDL is a well established comorbidity in both HP and CKD patients 
and is associated with small, dense LDL particles. Moreover, modification of LDL through 
oxidation is thought to be the first step in the development of CVD and specifically 
atherosclerosis. Oxidative stress occurs routinely in HP, especially in patients with a long-
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term dialysis vintage, making LDL smaller and denser and is associated with more 
endothelial dysfunction, inflammation, stenosis and intima media thickness. Therefore, the 
oxidative stress hypothesis may help to further explain reverse epidemiology. Oxidative 
stress in combination with MIC could cause lower levels of LDL and LDL particle numbers, 
but more atherogenic particles that can accelerate mortality and morbidity.  Yet, those 
associations do exist, a causal relationship between oxidative stress, CVD, and reverse 
epidemiology has yet to be established suggesting the need for further study. 
Chmielewski (2008) reports on an endotoxinlipoprotein hypothesis that suggests higher 
levels of cholesterol may be beneficial in HP. The theory suggests that higher levels of 
lipoproteins more readily bind bacterial lipopolysaccharide or endotoxins and modulate 
inflammatory immune responses. The authors continues to state that cholesterol levels and 
their ability to predict CVD fall on a continuum with lower and higher levels associated 
with mortality (Kalantar-Zadeh, 2007). Liu, et al. (2004) may help support this theory as they 
have reported a U-shaped curve regarding cholesterol levels and moratlity in HP. This 
theory is highly speculative and needs further study. 
Finally, as mentioned previously, HP patients have been reported to have smaller, dense 
LDL particles that are more oxidized which may play a stronger role than LDL. Small LDL 
particle size has been identified as an emerging risk factor for CVD (Third Report of the 
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, 2002). A previous 
study (Bowden, Griggs, Wilson, & Gentile, 2009) has demonstrated that LDL particle 
number and LDL size can classify more HP at risk when compared to LDL and triglycerides. 
Since more HP have small, dense LDL particles there may be mortality associated with 
smaller LDL particles even when LDL particle number is lower. Therefore, though HP may 
have less LDL cholesterol and less of the smaller LDL particles, because smaller LDL 
particles are more atherogenic, more patients have increased morality with decrease levels 
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malnutrition enhanced by inflammation may overcome the long-term impact of traditional 
risk factors for CVD and may cause the HP patients to not live long enough to develop 
elevated levels of cholesterol causing them die sooner than is expected. Also, evidence 
suggests that lipid levels become more elevated and more strongly associated with CVD the 
longer the HP receives dialysis and suggests that even though counter-intuitive cholesterol 
findings are evident in early dialysis traditional therapies such as statins, fibrates and niacin 
are necessary even with cholesterol levels are low (Chavalitdhamrong, et al., 2007). 
Therefore, treatment for HP patients with MIC needs to focus short-term on inflammation 
and malnutrition through dietary counseling and medication. Once MIC is controlled, a 
more long-term therapy may need to look at controlling lipids associated with CVD risk.  
7. Conclusions  
Reverse epidemiology in cholesterol levels associated with HP introduces a number of 
questions concerning our understanding of CVD and findings from the Framingham study. 
The questions becomes whether nephrologists should recommend the same cut-points for HP 
as is normally used in general populations. Should nephrologists attempt to control 
malnutrition and inflammation first and focus on lipids once HP have MIC under control?  
Though statins can help control lipids they may also help control inflammation which in turn 
may help to regulate appetite and increase albumin levels suggestions that statin therapy may 
still need to be used in most HP. Finally, more clinical trials are needed to discover if reverse 
epidemiology is “normal” in HP or simply a new understanding of traditional risk factors.    
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1. Introduction 
1.1 High mortality in dialysis patients 
Dialysis patients have extraordinarily high mortality rates. Cardiac disease is the major 
cause of death accounting for 43% of all-cause mortality among patients receiving 
hemodialysis and peritoneal dialysis [Henry et al., 2002; US Renal Data System Annual Data 
Report Bethesta, 2005]. In previous report, patients with end-stage kidney disease (chronic 
kidney disease (CKD) stage 5) on dialysis, in comparison with the general population, also 
have a 3- to 30-fold increase in mortality, depending on the age group examined, and 
cardiovascular disease accounts for more than half of all deaths, with myocardial infarction, 
ischaemic cardiomyopathy, stroke and peripheral vascular disease making up the bulk of 
deaths (Foley et al., 1998). The marked excess in cardiovascular mortality in CKD, compared 
with the general population, is not explained by the presence of traditional Framingham risk 
factors, such as diabetes, smoking, hypertension and elevated cholesterol levels ( Zoccali, 
2000; Longenecker et al., 2002). With vascular calcification and arterial stiffness being 
observed in young and middle-aged dialysis patients without conventional cardiovascular 
risk factors (London et al., 2003), the search for non-traditional risk factors has led to 
increasing evidence of a multitude of factors that contribute to ectopic calcification in CKD.  
1.2 High mortality rate and hyperphosphatemia 
Inorganic phosphate (phosphate) retention, or hyperphosphatemia, has been identified as 
playing a major role in the progression of renal failure and in the generation of secondary 
hyperparathyroidism and uremic bone disease (Slatopolsky et al., 2002). Further 
observational data have also shown a significant association of hyperphosphatemia with 
increased mortality among patients who have end-stage kidney disease and are on 
hemodialysis (Block et al., 1998; Owen & Lowrie, 1998; Ganesh et al., 2001). Moreover, 
elevated serum phosphorus has been associated with an increased risk for cardiovascular 
mortality and hospitalization (all-cause, cardiovascular, and fracture) among dialysis 
patients (Block et al., 2004). Elevated phosphorus and Ca × P are also independent risk 
factors for all-cause and cardiovascular mortality in CKD stage 5, and increased levels of 
parathyroid hormone may be associated with both cardiovascular disease and increased 
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vascular calcification (Braun et al., 1996; Block et al., 1998; Ganesh et al., 2001; Wang et al., 
2003; Young et al., 2005). Thus, phosphorus has the potential to induce vascular calcification 
and may be cardiotoxic (Achinger & Ayus, 2006). Hyperphosphatemia is sometimes 
regarded as a distinct syndrome (Hruska et al., 2008), and its treatment should be 
considered preferentially and even independently of other laboratory values (Fig. 1).  
 
Hyperphosphatemia
Vascular calcification, Arterial stiffness, Endothelial dysfunction
Atherosclerosis, Arteriolosclerosis, Arterial thickening
Left ventricular hypertrophy, Cardiac interstitial fibrosis
Cardiovascular disease
myocardial infarction, ischemic infarction
stroke, peripheral vascular disease
High mortality  Sudden death
Hyperparathyroidism   1,25(OH)2D          FGF23    Klotho
 
Fig. 1. Hyperphosphatemia in hemodialysis 
2. Phosphate metabolism in human 
2.1 Phosphate metabolism in normal physiology 
Phosphorus is essential for multiple and diverse biological functions, including cellular 
signal transduction, mineral metabolism, and energy exchange. Although more than 80% of 
total body phosphorus is stored in bone and teeth, intracellular phosphorus exists in the 
form of organic compounds such as adenosine triphosphate and as free anions like H2PO4-, 
which are commonly referred to as phosphate. Serum phosphorus primarily occurs in the 
form of inorganic phosphate, which is maintained within the physiological range by 
regulation of dietary absorption, bone formation, and renal excretion, as well as 
equilibration with intracellular stores (Takeda et al., 2000; Bringhurst et al., 2004; Fukagawa 
et al., 2004; Blumsohn, 2004).  
Phosphate absorption in the renal proximal tubule and the small intestine is important for 
phosphate homeostasis. This is a major regulator of phosphate homeostasis and has the 
phosphate reabsorptive capacity to accommodate physiologic phosphate requirement. Up to 
70% of filtered phosphate is reabsorbed in the proximal tubule where sodium-dependent 
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phosphate transport systems in the brush-border membrane mediate the rate limiting step 
in the overall phosphate reabsorptive process (Murer et al, 2000; Takeda et al, 2000; 
Miyamoto et al, 2007; Tenenhouse, 2005; Biber et al, 2009). Three different types of sodium-
dependent phosphate transporters have been identified till now, types I, II and III. The 
sodium-dependent phosphate transport system includes the type IIa and type IIc Na-
dependent phosphate cotransporters, which are localized in the apical membrane of the 
renal proximal tubular cells, and the type IIb Na-dependent phosphate cotransporter, which 
is localized in the apical membrane of the intestinal epithelial cells. The type IIa Na-
dependent phosphate transporter is the major determinant of plasma phosphate level and 
urinary phosphate excretion (Murer et al, 2000; Takeda et al, 2000; Miyamoto et al, 2007; 
Tenenhouse, 2005; Biber et al, 2009). This transporter is regulated by physiological stimuli, 
for example, type IIa transporter levels in the apical membrane are increased in response to 
dietary restriction of phosphate and 1,25-dihydroxy-vitamin D3 [1,25(OH)2D3] and 
decreased in response to parathyroid hormone, or a high- phosphate diet. In addition, 
intestinal phosphate transport activity and type IIb Na-dependent phosphate transporter 
levels are upregulated by 1,25(OH)2D3 (Xu et al., 2002; Segawa et al., 2004).  
In addition, fibroblast growth factor 23 (FGF23), a recently identified member of the FGF 
family, is involved in renal phosphate homeostasis (Yu X & White, 2005; Yu & White, 2005). 
FGF23 induces urinary phosphate excretion by suppressing the expression of type IIa and 
IIc Na-dependent phosphate cotransporters in the brush border of renal proximal tubules 
(Shimada et al., 2004; Shimada et al., 2005). It also suppresses 1,25(OH)2D production by 
inhibiting 1a-hydroxylase (CYP27B1), which converts 25-hydroxyvitamin D [25(OH)D] to 
1,25(OH)2D, and by stimulating 24-hydroxylase (CYP24), which converts 1,25(OH)2D to 
inactive metabolites in the proximal tubule of the kidney (Shimada et al., 2004; Shimada et 
al., 2005). Given the fact that FGF23 promotes renal phosphaturia, its secretion should be 
regulated by serum phosphate levels. Experimental and clinical studies showed that several 
days of dietary phosphate loading lead to an increase in serum FGF23 in humans (Ferrari et 
al, 2005; Perwad et al., 2005; Nishida et al., 2006).  
2.2 Phosphate metabolism in hemodialysis patients 
Several studies have measured circulating FGF23 levels in predialysis and dialysis patients 
and reported progressively elevated FGF23 levels as serum creatinine or phosphate levels 
increase (Larsson et al., 2003; Imanishi et al., 2004). Thus, it appears that in patients with 
CKD, FGF23 production increases to counteract chronic phosphate retention by promoting 
urinary phosphate excretion in the face of reduced nephron mass. Notably, in this setting, a 
previous study showed that FGF23 was a strong independent predictor of diminished 
1,25(OH)2D levels, even after adjustment for renal function, serum phosphorus levels and 
25(OH)D levels (Gutierrez et al., 2005). This finding suggests that in patients with CKD, 
increases in FGF23 intended to maintain neutral phosphate balance result in suppression of 
renal 1,25(OH)2D production, thereby triggering the early development of secondary 
hyperparathyroidism (Fig. 1). 
3. Cardiovascular disease in hemodyalysis 
3.1 Hyperphosphatemia and cardiovascular disease 
Cardiomyopathy and ischemic heart disease including acute myocardial infarctions, which 
are both common conditions in dialysis patients, likely play a role in the development of 
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sudden death. After percutaneous and surgical coronary revascularization, dialysis patients 
are still remaining at a high risk for sudden cardiac death (Furgeson, 2008). 
Hyperphosphatemia is a known factor contributing to the increased risk of cardiac death 
both in patients with end-stage renal disease and in those under renal replacement 
treatment with dialysis (Goodman et al., 2000). In patients with renal disease, in fact, the 
well-known relationship between hyperphosphataemia, secondary hyperparathyroidism, 
bone turnover and extra osseous calcifications has recently been followed by the recognition 
of a major role played by elevated serum phosphorus levels in the induction of vascular 
calcification, cardiac interstitial fibrosis and arterial thickening which highly increase the 
risk of cardiac death (Goodman et al., 2000; Block & Port, 2000; Amann et al., 2003; 
Goldsmith et al., 2004; Floege & Ketteler, 2004).  
3.2 Vascular calcification 
Phosphate is probably the predominant inducer of vascular calcification, and elevated 
serum levels are strongly associated with increased vascular calcification and mortality 
(Goodman et al., 2000). Elevated phosphate triggers a concentration-dependent precipitation 
of calcium in vascular smooth muscle cells, and phosphate is also a potent stimulus for the 
differentiation of vascular smooth muscle cells. In vitro studies demonstrate that high 
phosphate levels in incubation media enhance calcification with associated extracellular 
matrix synthesis(Jono et al., 2000). Phosphate and sodium dependent phosphate transporter 
seem to play a very important role in vascular smooth muscle cells mineralization. Type III 
sodium-dependent phosphate transporter presents two discrete subtypes, Pit-1 and Pit-2. In 
human vascular smooth muscle cells, Pit-1 is mainly expressed (London et al., 2000). Apatite 
formation by smooth muscle cells, as a response to increased phosphate levels, is fully 
inhibited by phosphonoformic acid (PFA), a sodium dependent phosphate transporter 
inhibitor, a finding supporting the notion that vascular calcification is an active rather than 
passive cellular process (Giachelli et al., 2001; Ketteler et al., 2003). 
Hyperphosphataemia induces osteocalcin and Cbfa-1 in vascular smooth muscle cells and 
promotes vascular calcification. Animals deficient in Cbfa-1 fail to mineralize bone(Komori 
et al., 1997), and there is also increased expression of Cbfa-1 when vascular smooth muscle 
cells are incubated in uremic serum compared with pooled human serum (Moe et al., 2003). 
There is now considerable evidence that hyperphosphataemia regulates several signalling 
pathways of cell functions. Of great interest is the recent identification of a novel phosphate-
regulating gene, klotho (Kuro-o et al., 1997; Yoshida et al., 2002), which in mice is involved 
in the development of a syndrome resembling human ageing. The klotho mutant mice show 
abnormal calcium phosphate vitamin D metabolism and develop hyperphosphataemia and 
vascular calcification (Kuro-o et al., 1997; Yoshida et al., 2002). Hyperphosphataemia also 
down-regulates klotho gene expression (Fig. 1). 
3.3 Endothelial dysfunction 
Endothelial dysfunction is the principal cause of atherosclerosis resulting in cardio vascular 
disease (Ross, 1999). High phosphate loading on endothelial cells inhibited nitrogen oxide 
(NO) production through increased reactive oxygen species (ROS) production and 
endothelial NO syntase (eNOS) inactivation via conventional protein kinase C, resulting in 
impaired endothelium-dependent vasodilation (Shuto et al., 2009). Furthermore, dietary 
phosphate loading can deteriorate flow-mediated vasodilation in healthy men, suggesting 
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that dietary phosphate loading or elevation of serum phosphorus level may be a risk factor 
for cardiovascular disease in healthy persons as well as CKD patients (Takeda et al., 2006; 
Shuto et al., 2009). Di Marco et al. also reported that high phosphate loading increased ROS 
production via phosphate influx and induced apoptosis in endothelial cells (Di Marco et al., 
2008). Association of serum phosphorus level and vascular dysfunction has been well 
investigated, because fasting serum phosphorus level could not increase in healthy persons, 
even if dietary phosphate was overloaded. However, postprandial phosphorus elevation 
was associated with %FMD in young healthy men (Shuto et al., 2009). Thus, dietary 
phosphate loading can cause endothelial dysfunction within a short time. Oxidative stress 
and decreased NO production in endothelial cells are possible mechanisms for the impaired 
endothelial function mediated by phosphate loading (Fig. 2).  
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Fig. 2. Dual pathways for vascular dysfunction caused by hyperphosphatemia 
3.4 Arterial stiffness 
Arterial disease observed in end-stage kidney disease patients is characterized by extensive 
intimal as well as medial calcification. Histological changes in coronary arteries from 
dialysis patients, compared with age matched controls, reveal a similar magnitude of 
atherosclerotic plaque burden and intimal thickness but markedly increased medial 
calcification (arteriolosclerosis) (Schwarz et al., 2000). Medial calcification has been shown to 
affect vascular elasticity and leads to increased arterial wall stiffness of large capacity, 
elastic-type arteries like the aorta and the common carotid artery, increased pulse pressure 
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and decreased perfusion of coronary arteries during diastole (Blacher et al., 1998; London, 
2003; Speer & Giachelli, 2004). Recent studies also demonstrated that elevated FGF23 levels 
were associated with arterial stiffness, increased left ventricular mass index and increased 
prevalence of left ventricular hypertrophy in patients with CKD (Hsu & Wu, 2009; Mirza et 
al., 2009; Gutierrez et al., 2009).  
4. Management of hyperphosphatemia in hemodialysis patients 
4.1 Target of management 
As elevated serum phosphorus and calcium levels are associated with vascular calcification 
and cardiovascular mortality in CKD, priority should be given to normalization of these 
parameters. It is generally accepted that adequate control of serum phosphorus remains a 
cornerstone in the clinical management of patients with CKD not only to attenuate the 
progression of secondary hyperparathyroidism but also possibly to reduce the risk for 
vascular calcification and cardiovascular mortality. A Ca x P more tan 72 mg2/dl2 is 
associated with a significant increase in the relative risk (RR) of mortality (RR = 1.34) 
compared with Ca x P less than 50 mg2/dl2 (Cozzolino et al., 2001). In a study in patients on 
hemodialysis, those who did not experience valvular calcification had maintained Ca x P at 
an average of 51 mg2/dl2 in the 6 months prior to the study, while those who did experience 
valvular calcification had an average Ca x P of 60 mg2/dl2 (Ribeiro et al., 1998). The target of 
treatment should be to maintain serum phosphorus level less than 5 mg/dl with serum 
calcium level less than 10 mg/dl to prevent cardio vascular consequences. This will allow 
the maintenance of Ca x P less than 50 mg2/dl2, a level which available evidence has so far 
shown not to promote calcification or increase mortality (Ribeiro et al., 1998).  
High FGF23 levels are more strongly associated with kidney disease progression, left 
ventricular hypertrophy, vascular disease, and mortality than serum phosphorus levels, and 
were most predictive of adverse events in patients with normal serum phosphorus 
(Thadhani et al., 2008; Oliveira et al., 2010). Dietary phosphate binders can lower FGF23 in 
CKD (Oliveira et al., 2010). Management of hyperphosphatemia relies on dietary restriction, 
the use of phosphate binders and dialysis.  
4.2 Dietary restriction of phosphate intake 
The average diet in North America and Europe contains approximately 1,000 to 1,500 mg of 
phosphorus per day (Willett & Buzzard, 1998). Dietary approach to phosphate retention in 
advanced renal failure patients, dietary approach to phosphate reduction is an important 
step in the treatment of hyperphosphatemia. The level of expression of klotho mRNA was 
greatly reduced in the kidneys of all chronic renal failure patients. Dietary phosphate 
restriction induced klotho expression, which enhances the beneficial effect of phosphate 
restriction in patients with chronic renal failure and or on hemodialysis. However, dietary 
restriction cannot considerably reduce the level of phosphate retention. As dialysis patients 
tend to need higher levels of protein due to the losses via dialysis, tight restriction on 
phosphate is difficult without compromising a patient's nutritional status. Because most 
dietary phosphate is contained in protein-rich foods, there is some concern about excessive 
protein restriction. In fact, the minimum amount of protein of 1.2 g/kg body weight/day, 
recommended to prevent malnutrition makes planning a diet with less than 1 g of 
phosphorus impossible (Kopple, 2001; Eknoyan et al., 2003). Recommendations that call for 
1.0 to 1.2 g/kg/day protein will usually obligate a phosphorus intake of 800 to 1,400 
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mg/day. Net phosphorus absorption averages 60% to 70% of intake (Delmez & Slatopolsky, 
1992; Sheikh et al., 1989), however, this percentage can rise as high as 86% of ingested 
phosphate with calcitriol use and decrease to 30% to 40% of ingested phosphate with 
optimal binder usage.(Sheikh et al., 1989; Delmez & Slatopolsky, 1992). 
Other foods that are high in phosphate are processed foods such as processed meats which 
have phosphate based additives to improve the consistency and appearance of the food. 
Since 1990, intake of phosphate from additives has doubled and has been 1,000 mg in USA 
(Calvo & Park, 1996). This is the amount that some renal patients are advised for the whole 
day from all food groups (James & Jackson, 2002). As people are becoming more reliant on 
processed and packaged meals due to convenience, phosphate from these sources needs to 
be considered when advising on diet. Fresh meat is considered suitable for someone 
following a phosphate restriction, however processed foods may in fact be providing much 
more phosphate than realised (Sullivan et al., 2007). Beverages such as sodas, juices and 
sport drinks also contain phosphate additives (Murphy-Gutekunst, 2007). It has been 
estimated that for a person on hemodialysis the average phosphate removal per day is 300 
mg (Vaithilingham et al., 2004). This leaves the patient with a positive balance for 
phosphate.  
4.3 Hemodialysis 
The clearance of phosphate varies among the different modalities of dialysis. Ideally, 
adequate dialysis in any form would remove adequate amounts of all uremic toxins, 
including phosphate. Unfortunately, conventional thrice-weekly hemodialysis (4 h duration) 
removes approximately 900 mg of phosphorus each treatment (an average of only 300 
mg/day) (Gotch et al., 2003). Increasing the dosage of dialysis, preferably to lengthy three 
times per week dialysis, hemodiafiltration, or, even better, daily/nightly dialysis may 
prevent phosphorus retention and even require no dietary phosphate restriction or the 
withdrawal of phosphate binders (Maduell et al., 2003; Benaroia et al., 2008). However, 
regular dialysis treatment is not able to remove all the phosphorus ingested with a diet 
containing protein of 1.0 - 1.2 g/kg/day (Mallick & Gokal, 1999).  
4.4 Phosphate binders 
Isakova et al analyzed a prospective cohort study of 10,044 incident hemodialysis patients at 
Fresenius Medical Care facilities in 2004 and 2005 comparing 1-year all-cause mortality 
among patients who were treated with phosphate binders (Isakova et al., 2009). In an 
intention-to-treat analysis, they compared patients who began treatment with any 
phosphate binder during the first 90 days after initiating hemodialysis, with those who 
remained untreated during that period. Treatment with phosphate binders was 
independently associated with decreased mortality compared with no treatment. In the 
unmatched cohort, the phosphate binder-treated group had a relative risk reduction of 42%, 
while in the intention-to-treat and as-treated analyses, the magnitude of the survival benefit 
ranged between 18% and 30% in multivariate models. The association between use of 
phosphorus binders and survival was observed within each quartile of baseline serum 
phosphorus except the lowest. Results from human data suggest that lowering of 
phosphorus levels by intake of phosphate binders will substantially reduce serum FGF-23 
levels (Koiwa et al., 2005; Pande et al., 2006). In this prospective observational study, 
treatment with phosphate binders was associated with a reduced 1-year mortality among 
incident hemodialysis patients (Isakova et al., 2009).  
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Sevelamer hydrochloride and lanthanum carbonate are a phosphate binders containing 
neither calcium nor aluminium, and are useful in those being administered concurrent 
vitamin D to reduce the potential for hypercalcemia. Attenuation in the progression of 
coronary artery calcification, after 6 and 12 months, was shown in hemodialysis patients 
treated with sevelamer, with reduced serum calcium, compared with patients on calcium 
carbonate (Chertow et al., 2002). A more recent randomized study of 114 incident 
hemodialysis patients demonstrated a survival advantage for patients on sevelamer 
compared with calcium carbonate after 18-month follow up (Block et al., 2007). A further 
beneficial effect of sevelamer has been proved on markers of coronary artery and aortic 
calcification compared with calcium based phosphate binders (Chertow et al., 2002). The 
attenuation of vascular and, in particular, coronary calcifications compared with calcium-
based phosphate binders in end-stage kidney disease patients under dialysis has been 
studied by electron beam computed tomography (Raggi, 2002; Raggi, 2004). High doses of 
sevelamer (3.2–8 g/day) are necessary to bring hyperphosphatemia back to target level, and 
the number of pills per day (about 8 x 800 mg tablets) may certainly be a conditioning factor 
for the patient’s compliance (Chertow et al., 2002).  
Patients with end-stage kidney disease treated with lanthanum carbonate up to 2.5–3.8 
g/day for up to 2 years have been reported to obtain effective reduction of serum 
phosphorus level (Finn, 2006). Lanthanum-carbonate-treated patients have, also been shown 
to reach a significantly reduced calcium/phosphate product and parathyroid hormone level 
compared with the placebo (Joy & Finn, 2009). Lanthanum carbonate, therefore, is an 
effective, at least as effective as calcium carbonate, well-tolerated phosphate binder 
(Hutchison, 2004; Hutchison et al., 2006). However, despite the very encouraging results, 
further studies involving larger numbers of patients are needed to definitively establish the 
long-term safety of lanthanum regarding tissue deposition, as well as its efficacy on vascular 
calcifications or outcomes in treated patients, which also need to be confirmed in the long 
term. 
4.5 Combination in treatment 
A multiple-factor approach can be used to reduce serum phosphate including reduced 
phosphorus intake in the diet, using phosphate binders efficiently and avoidance of 
under- dialysis. The patient's diet should be high in nutrition but with the lowest possible 
phosphorus content. Since dietary control of phosphorus intake and dialysis removal are 
usually not sufficient, phosphate binders are usually needed as adjuvants to increase fecal 
excretion (Bover et al; 2005). For an optimal protein diet of 1-1.2 g/kg/day, the 
phosphorus intake was 778-1,444 mg/day and 5,500-10,000 mg/week. Dialysis has limited 
ability for phosphate control, although phosphate removal by hemodialysis is very much 
a time-dependent process. The amount of phosphorus removed by hemodialysis, 
extrapolated to an average week, is 250-300 mg/day. The introduction of non-calcium-
based phosphate binders has enabled a reduction in the total phosphate load and 
provides a useful tool in the prevention of vascular calcification in CKD. The use of 
phosphate binders may decrease the phosphorus absorbed from the diet to 40% (Llach & 
Bover, 2000). In these circumstances, 320 mg of phosphorus and 21g of protein (0.3-0.35g 
of protein/kg/day) intake should be the critical value above which a positive balance of 
phosphate may occur (Fig. 3).  
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Fig. 3. Phosphate balance in hemodialysis patient 
Those in restricted protein and phosphate intake are shown in bold. 
Successful control of phosphate is one of the key aspects in the management of dialysis 
patients (Rodriguez-Benot et al., 2005; Young et al., 2004, Young et al., 2005), However, 
numerous studies have revealed the difficulty in achieving phosphorus targets less than 5.5 
mg/dl (Arenas et al., 2006; Lorenzo et al., 2006: Wei et al., 2006), despite the wide variety of 
drugs available for its treatment (Joy & Finn, 2003; Sprague, 2007; Arenas et al., 2008). Both 
endothelial dysfunction and medial calcification are closely associated with development of 
cardiovascular disease. It is well known that long-term exposure to phosphate, generally 
observed in end-stage renal failure patients, can mediate vascular calcification (Jono et al., 
2000; Giachelli, 2003). Dietary high phosphate loading can be involved in the postprandial 
elevation of serum phosphorus level, and this short-term exposure to phosphate was 
enough to decrease endothelium-dependent vasodilation.  
5. Conclusion 
The goals of therapy have been to reduce phosphorus intake with low protein diet and 
phosphate binders. Since low protein diet is thought to be induce malnutrition, it is thought 
that strict adherence to a low protein diet is not practical. A diet rich in proteins is usually 
also rich in phosphorus. However, proteins with very different phosphorus contents can 
provide equivalent nutritional value, as can be seen from the difference in phosphorus 
content between meat, cheese, and eggs. Egg white is an excellent example of food with a 
high level of protein but low phosphorus content. Moe et al. demonstrates the importance of 
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phosphate may occur (Fig. 3).  
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Fig. 3. Phosphate balance in hemodialysis patient 
Those in restricted protein and phosphate intake are shown in bold. 
Successful control of phosphate is one of the key aspects in the management of dialysis 
patients (Rodriguez-Benot et al., 2005; Young et al., 2004, Young et al., 2005), However, 
numerous studies have revealed the difficulty in achieving phosphorus targets less than 5.5 
mg/dl (Arenas et al., 2006; Lorenzo et al., 2006: Wei et al., 2006), despite the wide variety of 
drugs available for its treatment (Joy & Finn, 2003; Sprague, 2007; Arenas et al., 2008). Both 
endothelial dysfunction and medial calcification are closely associated with development of 
cardiovascular disease. It is well known that long-term exposure to phosphate, generally 
observed in end-stage renal failure patients, can mediate vascular calcification (Jono et al., 
2000; Giachelli, 2003). Dietary high phosphate loading can be involved in the postprandial 
elevation of serum phosphorus level, and this short-term exposure to phosphate was 
enough to decrease endothelium-dependent vasodilation.  
5. Conclusion 
The goals of therapy have been to reduce phosphorus intake with low protein diet and 
phosphate binders. Since low protein diet is thought to be induce malnutrition, it is thought 
that strict adherence to a low protein diet is not practical. A diet rich in proteins is usually 
also rich in phosphorus. However, proteins with very different phosphorus contents can 
provide equivalent nutritional value, as can be seen from the difference in phosphorus 
content between meat, cheese, and eggs. Egg white is an excellent example of food with a 
high level of protein but low phosphorus content. Moe et al. demonstrates the importance of 
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the protein source of phosphate in overall mineral metabolism after only 7 days of 
controlled diets. Despite equivalent protein and phosphorus concentrations in the diets, 
subjects had lower serum phosphorus levels, a trend toward decreased urine 24-hour 
phosphorus excretion, and significantly decreased FGF23 levels in the vegetarian diet 
compared with the meat-based diet (Moe et al., 2011).  
Lafage et al. (Lafage et al., 1992) used a very low protein diet (0.3 g/kg/d) supplemented 
with amino acids and ketoanalogues and with only 1 g of calcium carbonate and 1,000 IU of 
vitamin D2 in 17 patients with advanced renal failure. They have shown not only a beneficial 
effect related to the control of hyperphosphatemia on the biologic and histologic parameters 
of hyperparathyroidism but also a correction of acidosis, which resulted in the 
disappearance of the osteomalacic component. Thus, dietary control often considered to be 
of minor importance, is actually one of the major keys to success in the management of 
hyperphosphataemia. 
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1. Introduction 
Secondary hyperparathyroidism (sHPT) represents the adaptive and very often finally 
maladaptive response of the organism to control the disturbed homeostasis of calcium, 
phosphorus and vitamin D metabolism caused by declining renal function. Dysregulation of 
calcium and phosphorus homeostasis leads to elevated levels of the phosphatonin fibroblast 
growth factor 23 (FGF23), decreased renal phosphorus excretion, increased serum 
phosphorus, and diminished synthesis of calcitriol (1,25(OH)2D3), the active form of vitamin 
D. These alterations result in increased secretion and synthesis of parathyroid hormone 
(PTH) and parathyroid cell hyperplasia (Cunningham et al., 2011).  
Evidence is available that these disturbances in mineral metabolism lead to vascular 
(Goodman et al., 2000; Raggi et al., 2002) and valvular (Ribeiro et al., 1998) calcifications and 
are directly linked to an increased risk of cardiovascular morbidity and mortality as well as 
excess all-cause mortality (Covic et al., 2009). In accordance to a recent systematic review, 
the risk of cardiovascular and all-cause mortality is greatest with elevated serum 
phosphorus followed by increased serum calcium and PTH (Covic et al., 2009). Apart from 
extra-skeletal side effects, sHPT also leads to profound alterations in bone metabolism 
which become obvious in the different forms of renal osteodystrophy (Malluche & Faugere, 
1990; Moe et al., 2006). This clinical syndrome encompassing mineral, bone and 
cardiovascular abnormalities has been termed CKD-related Mineral and Bone Disorder 
(CKD-MBD) (Moe et al., 2006). Furthermore, sHPT is thought to play a role in various other 
complications of end-stage renal disease as bone pain, bone fractures, muscle dysfunction, 
sexual dysfunction, disturbed hematopoiesis, immune dysfunction, pruritus and calcific 
uremic arteriolopathy (calciphylaxis) (Rodriguez & Lorenzo, 2009). An overview of the 
current understanding of the pathogenesis of sHPT is given in Figure 1. 
In an attempt to improve clinical care, the National Kidney Foundation’s Kidney Disease 
Outcomes Quality Initiative (NKF-K/DOQITM [KDOQI]) has recommended target ranges 
for serum intact PTH, serum phosphorus and total corrected serum calcium (KDOQI, 2003). 
More recently, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for 
diagnosis, evaluation, prevention and treatment of CKD-MBD have been published 
(KDIGO, 2009) and endorsed by the US KDOQI (Uhlig et al., 2010) and European Renal Best 
Practice (Goldsmith et al., 2010) groups. These latter guidelines have tried to provide 
evidence-based recommendations, but due to the very limited availability of high quality 
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Fig. 1. Pathogenesis of secondary hyperparathyroidism. Declining kidney function causes 
reduced renal conversion of 25(OH)D to 1,25(OH)2D by CYP27B1 (25(OH)D-1-hydroxylase) 
and elevated serum phosphorus levels due to diminished phosphorus excretion. Increased 
phosphorus concentration, decreased calcium concentration and markedly reduced serum 
calcitriol levels lead to increased PTH synthesis and secretion in the parathyroid glands. 
Elevated FGF23 expression, to counteract the reduced phosphorus excretion, downregulates 
residual renal 25(OH)D-1-hydroxylase, additionally promoting the development of sHPT. 
These metabolic changes are accompanied by a variable downregulation and underexpression 
of the calcium-sensing receptor and vitamin D receptor on parathyroidal cells, rendering the 
parathyroid gland unable to respond appropriately to calcium and calcitriol. Dashed lines 
indicate counter-regulatory pathways. Abbreviations: FGF23, fibroblast growth factor 23; P, 
phosphorus; Ca2+, calcium; CaSR, calcium-sensing receptor; VDR, vitamin D receptor; FGFR1, 
fibroblast growth factor receptor 1, PTG, parathyroid gland. 
clinical interventional trials with skeletal, cardiovascular or mortality end-points in this 
field, fewer and less mandatory recommendations are given compared to the older KDOQI 
guidelines. 
The achievement of these target ranges set by the KDOQI or KDIGO guidelines is quite 
challenging (Young et al., 2004) and failure to reach these targets has been shown to be 
associated with increased risk for death compared to simultaneously achieving the targets 
for all three biochemical parameters PTH, calcium and phosphorus (Danese et al., 2008). 
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The 84-amino-acid peptide hormone PTH has a very short half-life of two to four minutes 
after parathyroid secretion. It is metabolized to shorter fragments in the liver which are then 
excreted by the kidneys. With increasing renal failure and progressive CKD the proportion 
of these fragments with a 5 to 10 times longer half-life raises due to decreased renal 
clearance. Although the exact composition and possible function of the various PTH 
fragments are not yet fully elucidated, experimental data clearly found a clinically relevant 
biological activity of some of these fragments. Routinely used second-generation PTH 
assays, globally called “intact” PTH assays because they were thought to measure the full-
length PTH 1-84 molecule only, recognize with various cross-reactivities (from 
approximately 50 to 100%) a PTH fragment, which co-elutes in high-performance liquid 
chromatography with a synthetic PTH 7–84 fragment. With progressive renal failure the 
amount of this and related PTH fragments gradually increases from about 20% in healthy 
individuals to about 50% in hemodialysis patients (Brossard et al., 2000). Therefore, at least 
in part, the progressive increase in measured PTH with decreasing renal function is also 
linked to the decreased renal metabolism and clearance of PTH 1-84 and its fragments. The 
different commercially available second-generation PTH assays have variable cross-
reactivity with the PTH 7-84 fragment, therefore PTH measurements with different assays 
are not fully comparable and due to lacking standardization of PTH measurement sHPT 
patients might be classified differently according to KDOQI or KDIGO guidelines, resulting 
in different and due to misclassification potentially disadvantageous therapeutic 
interventions (Koller et al., 2004). Newer third-generation PTH assays, which show no cross-
reactivity with the PTH 7-84 and related fragments, have been developed. Unfortunately, in 
all bone biopsy studies, which were later used to establish the KDOQI and KDIGO PTH 
target ranges, the first available second-generation PTH assay was used, but this assay is no 
longer commercially available. In an attempt to provide some kind of comparability of PTH 
measurements and consistent classification, correcting factors for the different second-
generation PTH assays were proposed (Souberbielle et al., 2010). 
Current therapeutic strategies include the modification of calcium and phosphorus balance 
through restricted dietary calcium and phosphorus intake and removal during 
hemodialysis, administration of phosphate binders, vitamin D receptor activators (calcitriol 
and newer vitamin D analogues) and the calcimimetic cinacalcet, and ultimately 
parathyroidectomy in very severe sHPT. These interventions have been shown to improve 
the biochemical parameters (PTH, calcium, phosphorus), bone histology or 
histomorphometry and cardiovascular calcification, but still there is lacking evidence that 
improvements in these surrogate parameters translate into better patient outcomes. 
Traditionally interventions to treat sHPT primarily aimed at bone health, but over the years 
new experimental insights into cardiovascular calcification and epidemiological data about 
associated cardiovascular morbidity and mortality risk switched the emphasis from bone to 
cardiovascular health. 
2. Treatment of hyperphosphatemia 
Declining renal function inevitably causes phosphorus retention due to decreased renal 
phosphorus clearance. This mechanism starts early in chronic kidney disease. However, 
hyperphosphatemia is prevented until the late stages of chronic kidney disease by an 
increase in FGF23 and PTH which control phosphorus homeostasis for a definite time. 
Initially, phosphorus retention stimulates FGF23 and PTH secretion, which in turn suppress 
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clearance. Although the exact composition and possible function of the various PTH 
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parathyroidectomy in very severe sHPT. These interventions have been shown to improve 
the biochemical parameters (PTH, calcium, phosphorus), bone histology or 
histomorphometry and cardiovascular calcification, but still there is lacking evidence that 
improvements in these surrogate parameters translate into better patient outcomes. 
Traditionally interventions to treat sHPT primarily aimed at bone health, but over the years 
new experimental insights into cardiovascular calcification and epidemiological data about 
associated cardiovascular morbidity and mortality risk switched the emphasis from bone to 
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2. Treatment of hyperphosphatemia 
Declining renal function inevitably causes phosphorus retention due to decreased renal 
phosphorus clearance. This mechanism starts early in chronic kidney disease. However, 
hyperphosphatemia is prevented until the late stages of chronic kidney disease by an 
increase in FGF23 and PTH which control phosphorus homeostasis for a definite time. 
Initially, phosphorus retention stimulates FGF23 and PTH secretion, which in turn suppress 
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renal phosphorus reabsorption and increase renal phosphorus excretion. FGF23 also 
suppresses calcitriol (1,25(OH)2D3) production, which diminishes intestinal phosphorus 
absorption but allows increases in PTH levels. Whereas FGF23 suppresses PTH secretion in 
normal parathyroid glands, resistance to its effect occurs with further loss of kidney 
function because of decreased Klotho and FGF receptor 1 expression in the parathyroid 
glands and the kidney. Thus, as chronic kidney disease progresses to late stages, these 
homeostatic mechanisms are inevitably overwhelmed, hyperphosphatemia ensues, and the 
levels of PTH and FGF23 increase progressively (Cunningham et al., 2011). 
Robust observational data show a clear association of higher serum phosphorus levels with 
cardiovascular events and mortality (Block et al., 1998, 2004). The exact threshold above 
which risk significantly increases is not definitely known and varies across the studies from 
5.0 to 7.0 mg/dL (1.6 to 2.3 mmol/L) (Covic et al., 2009). However, it has never been 
determined in randomized placebo-controlled trials whether treating hyperphosphatemia to 
specific target ranges improves clinical patient outcomes. The KDIGO guidelines therefore 
suggest to decrease serum phosphorus levels toward the reference range in patients with 
chronic kidney disease 5D (KDIGO, 2009). 
Therapeutic interventions to treat hyperphosphatemia include restriction of dietary 
phosphorus intake, administration of phosphate binders and increasing the frequency or 
length of dialysis sessions. 
2.1 Dietary phosphorus restriction 
Dietary phosphorus assessment and restriction is the cornerstone of the treatment of 
hyperphosphatemia. Educational support and dietary guidelines should be offered to the 
patients by a skilled dietician. Restriction of dietary phosphorus intake, however, requires a 
reduction in oral protein intake, as protein-rich foods are the main source of dietary 
phosphorus (Shinaberger et al., 2008). Lowering protein intake can lead to malnutrition and 
protein-energy wasting and thereby increasing mortality in dialysis patients (Lacson et al., 
2007). It is very important to avoid concomitant malnutrition by forced dietary protein 
restriction, as protein restriction as means to lower dietary phosphorus intake may 
outweigh the benefit of controlled phosphorus and may lead to greater mortality 
(Shinaberger et al., 2008). One possibility for overcoming the problem of concordant overall 
protein restriction and the risk of malnutrition with reduced dietary phosphorus intake 
would be to avoid phosphorus-rich ingredients that are added to processed foods and 
beverages (Sherman & Mehta, 2009a, 2009b). Contrary to natural sources of organic 
phosphorus, such as meat or dairy products, such phosphorus sources are dissociated from 
protein intake. Reducing the consumption of such phosphorus additives might help to 
decrease phosphorus intake without the risk of protein-energy wasting (Sullivan et al., 
2009). Additionally, the intake of protein sources with low phosphorus to protein ratios 
might further help to limit phosphorus intake (Noori et al., 2010).  Nutritional guidelines 
recommend a maximum of 800 to 1000 mg (25 to 35 mmol) daily dietary phosphorus intake 
(Fouque et al., 2007). Nevertheless, dietary modifications alone are generally not sufficient to 
reduce phosphorus intake sufficiently in most patients, but help to save phosphate binders 
and probably reduce the high pill burden. 
2.2 Phosphate binders 
The use of oral phosphate binders to block intestinal phosphorus absorption has been 
shown to effectively reduce serum phosphorus levels irrespective of the phosphate binder 
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class. Although no placebo-controlled randomized trial has been done so far to prove that 
reduction in serum phosphorus by the use of phosphate binders improves patient outcomes, 
a recent prospective observational study in a large number of incident dialysis patients has 
shown that the use of any phosphate binder (versus none) offers a clear survival benefit 
independent of absolute serum phosphorus concentration and co-medication (Isakova et al., 
2009).  
Available phosphate binders include the calcium salts calcium acetate and calcium 
carbonate, aluminium hydroxide, the polymeric anion-exchange resins sevelamer 
hydrochloride and sevelamer carbonate, lanthanum carbonate and the newer so far not well 
studied compounds ferric citrate, SBR759 (iron-based), magnesium/calcium carbonate and 
magnesium carbonate/calcium acetate. They differ in composition, phosphate-binding 
capacity, form and have specific potential advantages and disadvantages, which are 
summarized in Table 1. 
Considering the different agents there are no data at present to favour one phosphate 
binder, because there is no proven superiority of any phosphate binder or binder class for 
relevant clinical outcomes. According to a recent systematic review and meta-analysis of 
available randomized controlled trials all phosphate binders decrease serum phosphorus 
levels compared with placebo. The newer drugs sevelamer hydrochloride and lanthanum 
carbonate do not result in superior control of biochemical parameters compared with 
calcium salts. In contrast, in head-to-head studies calcium salts enable a greater reduction of 
serum phosphorus than sevelamer hydrochloride. Whereas both calcium salts (calcium 
acetate and carbonate) do not differ with regard to serum calcium levels, sevelamer 
hydrochloride and lanthanum carbonate are associated with significantly lower rates of 
treatment-related hypercalcemia, which may result in decreased cardiovascular calcification. 
However, the finding of slower or less progression of cardiovascular calcification in 
sevelamer-treated patients is inconsistent across the studies. Studies revealed no difference 
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renal phosphorus reabsorption and increase renal phosphorus excretion. FGF23 also 
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class. Although no placebo-controlled randomized trial has been done so far to prove that 
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shown that the use of any phosphate binder (versus none) offers a clear survival benefit 
independent of absolute serum phosphorus concentration and co-medication (Isakova et al., 
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Table 1. Overview of available phosphate binders (adapted from KDOQI, 2003; KDIGO, 
2009; Tonelli et al., 2010; Uhlig et al., 2010). Abbrevations: Ca2+, calcium; HCl, hydrochloride; 
Mg, magnesium; CO3, carbonate; NA, not available. 
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carbonate with calcium carbonate, but found a significantly lower PTH reduction with 
sevelamer hydrochloride in comparison to calcium salts. When all studies were pooled, 
gastrointestinal side effects occurred more often with sevelamer hydrochloride than with 
calcium salts. With the use of sevelamer hydrochloride significantly lower serum 
bicarbonate is found, aggravating already existing metabolic acidosis. The new formula of 
sevelamer carbonate does not negatively influence acid-base status. A possible advantage of 
sevelamer is its significant reduction of LDL-cholesterol. However, no difference in all-cause 
mortality could be found comparing calcium acetate and carbonate, or sevelamer with 
calcium salts. All-cause mortality as endpoint has not been studied with all other phosphate 
binders (Navaneethan et al., 2009).  
Hypercalcemia is a known side effect of calcium salts, especially when combined with 
vitamin D receptor activators. Persistent hypercalcemia necessitates a dose reduction or 
cessation of calcium salts as phosphate binders. The KDOQI guidelines suggest limiting the 
daily calcium intake from calcium-containing phosphate binders to 1500 mg per day for 
elemental calcium and 2000 mg per day for total intake of elemental calcium including the 
dietary calcium content (KDOQI, 2003). Nevertheless, there is no data available to 
recommend a specific upper limit of a safe amount of calcium intake.  Restrictive use of 
calcium-based phosphate binders may be considered in the following situations (Cozzolino 
et al., 2011; Goldsmith et al., 2010): 
 presence of cardiovascular disease 
 presence of vascular or valvular calcification 
 older age (>65 years) 
 diabetes mellitus 
 evidence of adynamic bone disease 
 hypercalcemia 
Although very effective, a prolonged (>3 months continuously, or >6 months cumulative) 
use of aluminium hydroxide should be avoided because of the potential toxicity of 
accumulated aluminium leading to encephalopathy, osteomalacia and anemia (Goldsmith et 
al., 2010). 
Irrespective of the phosphate binder class the successful practical management of 
hyperphosphatemia with phosphate binders includes: 
 concomitant dietary phosphorus restriction (especially phosphorus-rich additives) 
 administration of phosphate binders with the meal 
 individual dosing with respect to eating habits and serum phosphorus level 
A new and promising concept for the management of hyperphosphatemia was recently 
developed to enable patients to self-adjust the phosphate binder dose in relation to the 
phosphorus content of each individual meal: “Phosphate Education Program” (PEP) 
(Ahlenstiel et al., 2010). Patients are taught to eye-estimate the meal phosphorus content 
based on “phosphate units” (PU; 1 PU is defined per 100 mg of phosphorus per serving size 
of the meal) and then phosphate binders are prescribed dependent on an individual 
phosphate binder/PU ratio. This concept is similar to the individualized adjustments of 
insulin dose to carbohydrate intake in the treatment of diabetes mellitus. 
Novel agents under development for the treatment of hyperphosphatemia are MCI-196 
(colestilan) (Locatelli et al., 2010), a non-metallic anion-exchange resin, and niacin and 
nicotinamid, which probably directly inhibit the sodium-dependent phosphate 
cotransporter Na-Pi-2b in the gastrointestinal tract (Muller et al., 2007). 
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2.3 Dialytic methods for phosphorus removal 
Dialytic methods to improve phosphorus removal include prolonged (nocturnal) 
hemodialysis (Culleton et al. 2007; Walsh et al., 2010) and convective strategies (Tonelli et 
al., 2009). 
3. Vitamin D therapy 
3.1 Correction of vitamin D deficiency and insufficiency 
Neither the normal nor the desirable target ranges for 25-hydroxyvitamin D (25(OH)D) 
levels are known in patients on hemodialysis. In accordance with patients without chronic 
kidney disease, 25(OH)D levels <12.5 ng/mL (<30 nmol/L) are defined as vitamin D 
deficiency, values <30 ng/mL (<75 nmol/L) as vitamin D insufficiency. Observational 
studies have shown an association between low 25(OH)D levels and adverse clinical 
outcomes (Holick,  2005; Wolf et al., 2007; Giovannucci, 2008). Although data from clinical 
trials are missing to show a survival benefit after increasing 25(OH)D levels in insufficient or 
deficient hemodialysis patients, current guidelines suggest to replete 25(OH)D stores in 
these patients on grounds of low costs, relative safety of repletion and potential therapeutic 
impact (KDIGO, 2009). After initial measurement and diagnosis of vitamin D deficiency, a 
supplementation using cholecalciferol or ergocalciferol may be initiated with 
remeasurement after 3 months of supplementation. There are no data regarding the choice 
of vitamin D product or the administration route. Altogether, oral repletion seems to be 
more favourable compared to intramuscular route in hemodialysis patients. In accordance 
with the general population a daily dose of 1000 to 2000 IU of cholecalciferol or a 
corresponding weekly dose are given (KDOQI, 2003; KDIGO, 2009; Uhlig et al., 2010). In a 
recent study in 107 hemodialysis patients, 91% of the patients had a serum 25(OH)D level 
higher than the target level of 75 nmol/L (30 ng/mL) after 3 months of monthly oral 
substitution of 100,000 IU (at first dialysis session of the month) (Jean et al., 2009). This 
approach seems to be safe and guarantee patient compliance. If hypercalcemia or 
hyperphosphatemia occurs, vitamin D repletion should be temporarily discontinued or 
abandoned. Table 2 gives an overview of the key differences between 25(OH)D and its 
“active” form 1,25(OH)2D. 
 
 25(OH)D 1,25(OH)2D 
Total plasma concentration  
(recommended  normal values) 
30 to 50 ng/mL 
(75 to 125 nmol/L) 
30 to 50 pg/mL 
(75 to 125 pmol/L) 
Total plasma concentration (relative 
values) 1000 1 
Binding affinity to vitamin D-binding 
protein (relative values) 1000 1 
Free concentration (relative values) 1 1 
Half-life 25 to 30 days 4 to 8 hours 
VDR affinity  (relative values) 1 500 to 1000 
 
Table 2. Characteristics and differences of 25(OH)D and 1,25(OH)2D. Abbrevations: VDR, 
vitamin D receptor. 
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3.2 Vitamin D receptor activators 
Treatment of sHPT with active vitamin D receptor activators (VDRA) is a well established 
therapeutic modality, and current practice guidelines recommend to treat patients with 
elevated and/or increasing PTH levels with a VDRA (KDIGO, 2009).  Observational studies 
are indicating a survival benefit of VDRA in hemodialysis patients in comparison with 
patients without VDRA treatment (Teng et al., 2003, 2005; Tentori et al., 2006; Naves-Diaz et 
al., 2008). Again, prospective controlled randomised clinical trials indicating a benefit on 
patient-level clinical outcomes with VDRA therapy are missing but strongly awaited. 
Calcitriol, the physiological VDRA, is the natural regulator of parathyroid gland function and 
growth and exerts its effect on PTH secretion by inhibiting mRNA synthesis through its action 
on the vitamin D receptor (VDR), a highly specific receptor that acts as a transcription factor. 
In addition, calcitriol is able to inhibit PTH secretion by increasing calcium absorption in the 
intestine, while also increasing bone resorption and, consequently, calcium release from bone. 
Moreover, calcitriol regulates the expression of its own receptor, stimulating its synthesis. The 
deficit of calcitriol observed in hemodialysis patients as well as a transformation into nodular 
hyperplasia with progressive sHPT is associated with a decrease in VDR levels in the 
parathyroid gland. Decreased VDR expression may than cause resistance to VDRA. VDRA 
generally control sHPT well in patients with moderately increased hypertrophic glands and 
less well in patients with enlarged hyperplastic glands and should therefore be started early in 
the development of sHPT (Cunningham et al., 2011). Beyond the classical endocrine effects on 
parathyroid gland, bone and intestine, the pleiotropic paracrine and autocrine effects of 
vitamin D have been associated with improvement of cardiovascular risk factors, including 
increased renin activity, hypertension, inflammation, insulin resistance, diabetes, albuminuria 
and an improved immune response.  
Besides the native active hormone calcitriol (1,25(OH)2D3), the two prodrugs alfacalcidol 
(1(OH)D3) and doxercalciferol (1(OH)D2) and the two vitamin D analogues paricalcitol (19-
nor-1,25(OH)2D2) and maxacalcitol (22-oxa-1,25(OH)2D3) can be used. Paricalcitol and 
maxacalcitol (oxacalcitriol) bind directly to the VDR, whereas doxercalciferol and 
alfacalcidol need an enzymatic 25-hydroxylation activation step in the liver. So far no 
prospective, placebo-controlled and blinded clinical trial involving 22-oxacalcitriol, 
paricalcitol, or doxercalciferol has yet demonstrated additional clinical benefits when 
compared with calcitriol, nor have any studies been published showing that either calcitriol 
or alfacalcidol has an advantage over the other with respect to biochemical or clinical end 
points (Cunningham & Zehnder, 2011). Therefore, low dose therapy with calcitriol (e.g. 0.25 
µg/d orally or 0.25 µg thrice weekly orally or intravenously as a starting dose) is 
recommended with elevated or increasing PTH levels (KDIGO, 2009). Characteristics and 
oral calcitriol equivalent doses of various available VDRA are presented in Table 3. 
According to current practice guidelines, the target range for PTH is now 2-9 times the 
upper limit of the normal range (KDIGO, 2009; Uhlig et al., 2010; Goldsmith et al., 2010). 
This wide range takes into account a significant interassay variability of values obtained 
with different commercial PTH assays (Koller et al., 2004; Souberbielle et al., 2010), inability 
to uniformly predict bone histologic and histomorphometric states by means of PTH within 
this range and the epidemiological observation of increased all-cause mortality starting from 
PTH values >400 to 600 pg/mL (Uhlig et al., 2010). If there is no successful response with 
PTH reduction into the suggested target range, or dose-limiting side effects occur, especially 
hypercalcemia and hyperphosphatemia, a calcimimetic can be initiated instead or combined 
with a low dose of VDRA.  
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2.3 Dialytic methods for phosphorus removal 
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Treatment of sHPT with active vitamin D receptor activators (VDRA) is a well established 
therapeutic modality, and current practice guidelines recommend to treat patients with 
elevated and/or increasing PTH levels with a VDRA (KDIGO, 2009).  Observational studies 
are indicating a survival benefit of VDRA in hemodialysis patients in comparison with 
patients without VDRA treatment (Teng et al., 2003, 2005; Tentori et al., 2006; Naves-Diaz et 
al., 2008). Again, prospective controlled randomised clinical trials indicating a benefit on 
patient-level clinical outcomes with VDRA therapy are missing but strongly awaited. 
Calcitriol, the physiological VDRA, is the natural regulator of parathyroid gland function and 
growth and exerts its effect on PTH secretion by inhibiting mRNA synthesis through its action 
on the vitamin D receptor (VDR), a highly specific receptor that acts as a transcription factor. 
In addition, calcitriol is able to inhibit PTH secretion by increasing calcium absorption in the 
intestine, while also increasing bone resorption and, consequently, calcium release from bone. 
Moreover, calcitriol regulates the expression of its own receptor, stimulating its synthesis. The 
deficit of calcitriol observed in hemodialysis patients as well as a transformation into nodular 
hyperplasia with progressive sHPT is associated with a decrease in VDR levels in the 
parathyroid gland. Decreased VDR expression may than cause resistance to VDRA. VDRA 
generally control sHPT well in patients with moderately increased hypertrophic glands and 
less well in patients with enlarged hyperplastic glands and should therefore be started early in 
the development of sHPT (Cunningham et al., 2011). Beyond the classical endocrine effects on 
parathyroid gland, bone and intestine, the pleiotropic paracrine and autocrine effects of 
vitamin D have been associated with improvement of cardiovascular risk factors, including 
increased renin activity, hypertension, inflammation, insulin resistance, diabetes, albuminuria 
and an improved immune response.  
Besides the native active hormone calcitriol (1,25(OH)2D3), the two prodrugs alfacalcidol 
(1(OH)D3) and doxercalciferol (1(OH)D2) and the two vitamin D analogues paricalcitol (19-
nor-1,25(OH)2D2) and maxacalcitol (22-oxa-1,25(OH)2D3) can be used. Paricalcitol and 
maxacalcitol (oxacalcitriol) bind directly to the VDR, whereas doxercalciferol and 
alfacalcidol need an enzymatic 25-hydroxylation activation step in the liver. So far no 
prospective, placebo-controlled and blinded clinical trial involving 22-oxacalcitriol, 
paricalcitol, or doxercalciferol has yet demonstrated additional clinical benefits when 
compared with calcitriol, nor have any studies been published showing that either calcitriol 
or alfacalcidol has an advantage over the other with respect to biochemical or clinical end 
points (Cunningham & Zehnder, 2011). Therefore, low dose therapy with calcitriol (e.g. 0.25 
µg/d orally or 0.25 µg thrice weekly orally or intravenously as a starting dose) is 
recommended with elevated or increasing PTH levels (KDIGO, 2009). Characteristics and 
oral calcitriol equivalent doses of various available VDRA are presented in Table 3. 
According to current practice guidelines, the target range for PTH is now 2-9 times the 
upper limit of the normal range (KDIGO, 2009; Uhlig et al., 2010; Goldsmith et al., 2010). 
This wide range takes into account a significant interassay variability of values obtained 
with different commercial PTH assays (Koller et al., 2004; Souberbielle et al., 2010), inability 
to uniformly predict bone histologic and histomorphometric states by means of PTH within 
this range and the epidemiological observation of increased all-cause mortality starting from 
PTH values >400 to 600 pg/mL (Uhlig et al., 2010). If there is no successful response with 
PTH reduction into the suggested target range, or dose-limiting side effects occur, especially 
hypercalcemia and hyperphosphatemia, a calcimimetic can be initiated instead or combined 
with a low dose of VDRA.  
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Calcitriol 1,25(OH)2D3; natural hormone 
oral 0.25 µg 
intravenous 0.5 µg 
Alfacalcidol 1(OH)D3; synthetic prohormone 
oral 0.5 µg 
intravenous 1 µg 
Doxercalciferol 1(OH)D2, synthetic prohormone 
oral 2.5 µg 
intravenous 5 µg 
Paricalcitol 19nor-1,25(OH)2D2; synthetic analogue 
oral 1 µg 
intravenous 2 µg 
Maxacalcitol 
(Oxacalcitriol) 22oxa-1,25(OH)2D;3; synthetic analogue NA 
Table 3. Characteristics and oral calcitriol equivalent doses of vitamin D receptor activators 
(VDRA). Abbreviation: NA, not available. 
4. Calcimimetics 
Calcimimetics are allosteric modulators of the calcium sensing receptor that sensitize the 
receptor to extracellular calcium. This results in reduced PTH secretion and inhibited 
parathyroid cell proliferation (Nemeth et al., 1998; Chin et al., 2000). This decrease in serum 
PTH is accompanied by control of serum calcium and phosphorus levels in patients with 
sHPT as well as a halt or regression of parathyroid gland hyperplasia (Meola et al., 2009). 
Initial phase III trials and various observational studies have shown that cinacalcet enables 
more patients to reach the recommended biochemical targets (Block et al., 2004; Lindberg et 
al., 2005; Urena et al., 2009) and allows sustained biochemical control for long term up to 3 
years (Sprague et al., 2009). At present cinacalcet hydrochloride is the only calcimimetic 
available for clinical use. In contrast to VDRA, cinacalcet decreases all three important 
biochemical parameters of CKD-MBD (PTH, phosphorus, calcium) (Urena et al., 2009). In 
addition to excellent results on laboratory parameters, cinacalcet has also shown favourable 
effects on cardiovascular hospitalization, bone fracture rate, parathyroidectomy rate and 
quality of life (Cunningham et al., 2005). In a prospectively designed observational study 
use of cinacalcet on top of standard sHPT therapy with VDRA and phosphate binders 
resulted in a 26% lower all-cause mortality and a 24% lower cardiovascular mortality than in 
patients without cinacalcet, with the largest survival benefit for patients with most severe 
sHPT (PTH >600 pg/mL) (Block et al., 2010). The ongoing double-blind, randomised 
placebo-controlled EVOLVE trial (Evaluation of cinacalcet HCl therapy to lower 
cardiovascular events) currently determines whether cinacalcet reduces all-cause mortality 
or non-fatal cardiovascular events (Chertow et al., 2007). 
Generally, initial therapy starts with a daily dose of 30 mg followed by dose-titration every 2 
to 4 weeks if necessary. Serum calcium levels must be monitored regularly because of its 
known hypocalcemic effect.  
Whereas VDRA reduce PTH gene transcription and hormone synthesis over a period of 
several hours or even days, cinacalcet inhibits PTH secretion within minutes, with a 
maximal decrease occurring within 2 to 4 hours after administration. Besides 
gastrointestinal side effects, hypocalcemia is one of the most common adverse events seen 
with cinacalcet. It is thought to occur after decreased mobilization of calcium from bone 
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caused by lowered PTH levels. In most patients, this hypocalcemia can be successfully 
managed with dose adjustments or a combination with low doses of VDRA in patients with 
moderate to severe sHPT. Clinical trials have demonstrated the superior suppression of 
PTH production and control of calcium and phosphorus in hemodialysis patients who use 
cinacalcet, both as adjunctive therapy to VDRA and as primary therapy with reduced doses 
of VDRA , compared with sHPT therapy  with VDRA and phosphate binders only (Chertow 
et al., 2006; Block et al., 2008; Fishbane et al., 2008; Messa et al., 2008). 
5. Parathyroidectomy 
Persistently increased serum PTH levels >800 pg/mL (88.0 pmol/L) in presence of 
hypercalcemia or hyperphosphatemia refractory to medical therapy and calcific uremic 
arteriolopathy (calciphylaxis) with concomitantly elevated PTH levels are an indication for 
surgery (KDOQI, 2003; KDIGO, 2009). Subtotal and total parathyroidectomy (PTX) with or 
without forearm autograft arose as a treatment option in the 1990s (Tominaga et al., 1997) 
and PTX continues to be a primary therapeutic option for refractory sHPT in both Europe 
and the US. Rates of PTX increased for US patients on hemodialysis from 1998 to 2002 
despite an increase in therapeutic options (Foley et al., 2005). The frequency of PTX across 
Europe has remained relatively stable since the mid-1980s (Malberti et al., 2001) and is lower 
in older patients (Pelletier et al., 2010).   
PTX effectively decreases PTH, calcium and phosphorus and offers the highest percentage 
cure for sHPT, compared to all other medical and surgical treatments. However, recurrent 
hyperparathyroidism can be observed in 10 - 70% of patients dependent on follow-up time 
(Johnson et al., 1988; Gagne et al., 1992; Gasparri et al., 2001).  For total parathyroidectomy 
with autotransplantation an intra-operative selection of parathyroid tissue with diffuse 
hyperplasia but low proliferative potential (and exclusion of nodular tissue) is feasible and 
minimizes the risk of graft-dependent recurrent hyperparathyroidism (Neyer et al., 2002). 
Alternatively to surgery, ultrasound-guided percutaneous fine-needle ethanol injection into 
nodular hyperplastic parathyroid glands is very common in Japan (Giangrande et al., 1992; 
Kitaoka et al., 1994; Fukagawa et al., 1999). Apart from ethanol, also calcitriol or novel 
VDRA can be directly placed into enlarged parathyroid glands using the same technique 
(Shiizaki et al., 2003).  
To date no specific guidelines considering sHPT treatment in hemodialysis patients on 
kidney transplant waiting list have been established. After successful kidney transplantation 
persistent HPT can be observed in up to 25% of patients one year after transplantation 
despite adequate renal graft function. Severity of sHPT at time of transplantation was found 
to be a significant indicator of persistent HPT (Evenepoel et al., 2004).  If indicated, therapy 
for persistent HPT should be initiated about three months after renal transplantation 
because further spontaneous improvement thereafter is rare. Because this special situation 
of persistent HPT after transplantation is usually accompanied by hypercalcemia and 
hypophosphatemia, conventional therapy with phosphate binders, VDRA or calcium 
supplements is not indicated in most patients. Therefore, PTX is the preferred treatment 
option in this situation and has been shown to be effective, safe, though associated with a 
mild deterioration of graft function in the early postoperative phase but similar graft 
survival in the long-term compared to kidney transplant patients without PTX and linked to 
a blood pressure and lipid lowering effect (Triponez et al., 2008). Recently, also cinacalcet 
has been proposed to offer an alternative therapeutic option to PTX, although not approved 
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VDRA can be directly placed into enlarged parathyroid glands using the same technique 
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persistent HPT can be observed in up to 25% of patients one year after transplantation 
despite adequate renal graft function. Severity of sHPT at time of transplantation was found 
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because further spontaneous improvement thereafter is rare. Because this special situation 
of persistent HPT after transplantation is usually accompanied by hypercalcemia and 
hypophosphatemia, conventional therapy with phosphate binders, VDRA or calcium 
supplements is not indicated in most patients. Therefore, PTX is the preferred treatment 
option in this situation and has been shown to be effective, safe, though associated with a 
mild deterioration of graft function in the early postoperative phase but similar graft 
survival in the long-term compared to kidney transplant patients without PTX and linked to 
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for the use in this situation and cost-intensive if used for many years (Kruse et al., 2005; 
Serra et al., 2005; Srinivas et al., 2006; Zitt et al., 2007).  
Therefore, we believe that a good and early control of sHPT prior to kidney transplantation 
is mandatory. This should be initially done using all medical options including cinacalcet, 
but if unsuccessful in control of severe sHPT proceeding straight to PTX for an optimal and 
cost-effective treatment. Randomized clinical trials directly comparing medical with surgical 
therapy of sHPT are lacking.   
To avoid severe postoperative hypocalcemia (“hungry bone syndrome), pre-/peri- and 
postoperative calcium and calcitriol supplementation (e.g. 1 to 2 g elemental calcium thrice a 
day, 1 to 4 µg calcitriol per day; parenteral calcium substitution if symptomatic 
hypocalcemia is present with 1 to 2 mg elemental calcium/kg/h) must be guaranteed along 
with frequent controls of serum calcium levels. In case of recurrent or persistent 
hyperparathyroidism after parathyroidectomy, cinacalcet has been shown to be a viable and 
safe treatment option (Zitt et al., 2010).  
6. Dialysate calcium concentration 
A near-neutral calcium flux could be expected in patients with a dialysate calcium 
concentration of 1.25 mmol/L (2.5 mEq/L), although there is considerable interindividual 
variability among patients (Hou et al., 1991; Argiles et al., 1993). Based on calcium kinetic 
modelling even lower dialysate calcium concentrations of 1.0 mmol/L (2.0 mEq/L) might be 
needed to avoid net positive calcium balance (Gotch et al., 2010). The risks of hemodynamic 
instability and cardiac rhythm disturbances with a very low dialysate calcium concentration 
must be kept in mind (Drueke & Touam, 2009). Overall calcium balance is influenced by 
dietary calcium intake, vitamin D level, calcium-containing phosphate binders, use of 
VDRA and calcimimetics and dialysate calcium concentration. Therefore, selecting an 
individual dialysate calcium concentration is based on various parameters and must always 
be a compromise between the need to guarantee cardiovascular stability during the 
hemodialysis session and the goal to maintain normal bone turnover and mineralization in 
order to avoid bone pain and fractures but avoid extraskeletal calcification. 
7. Summary 
Whereas there are insufficient high-quality randomized controlled trials in the field, this 
shortcoming should not lead to a nihilistic approach to the relevant clinical problems of 
hemodialysis patients with sHPT. Nevertheless, because of insufficient clinical data, a single 
treatment modality, be it phosphorus binders, vitamin D substitution with inactive forms or 
vitamin D receptor activators, calcimimetics or parathyroidectomy may not claim to be 
uniformly superior to the others, and a wider therapeutic window often prompts the use of 
a combination of these options and individualization of sHPT management. The ultimate 
goal is to improve the very poor survival of hemodialysis patients, so any suggested 
approach for the management of sHPT should be tested. 
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VDRA and calcimimetics and dialysate calcium concentration. Therefore, selecting an 
individual dialysate calcium concentration is based on various parameters and must always 
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vitamin D receptor activators, calcimimetics or parathyroidectomy may not claim to be 
uniformly superior to the others, and a wider therapeutic window often prompts the use of 
a combination of these options and individualization of sHPT management. The ultimate 
goal is to improve the very poor survival of hemodialysis patients, so any suggested 
approach for the management of sHPT should be tested. 
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1.1 Kidney disease and cardiovascular mortality 
Cardiovascular disease is a leading case of mortality not only in the whole population but 
also in groups with different, noncardiovascular chronic conditions. Kidney disease is one of 
these and many patients with kidney disease paradoxically do not die from end stage 
kidney failure but from cardiovascular causes. Already mild or moderate renal impairment 
represents a considerable excess risk of cardiovascular mortality. The probability of 
premature death is even more striking in some subgroups of kidney patients – e.g. the 
cardiovascular mortality rate of young end stage renal disease (ESRD) patients is 500 times 
higher as compared with an age-matched control group. The situation is moreover 
complicated by the fact that traditional risk factors (the “Framingham factors”) are of lesser 
predictive value in kidney disease than in general population (Foley et al, 1998,  Magnus 
and Beaglehole, 2001,   Go et al, 2004). 
To explain this dismal picture it is not sufficient to disclose that chronic kidney disease 
(CKD) and chronic renal insufficiency (CRI) is associated with accelerated atherosclerosis 
and abnormal lipid/lipoprotein metabolism (Felström et al., 2003, Lacquaniti, 2010). One 
should keep in mind that “CKD”, “CRI” and “ESRD” are collective terms and the actual 
diseases and conditions behind them are manifold (Table 1). Some of them (e.g. diabetes 
mellitus and hypertension) have a profound effect on lipid metabolism and atherosclerosis 
independently from kidney function already before the manifestation of renal impairment. 
From the data in Table 1 is evident that diabetes and hypertension is behind ESRD in one 
quarter (Great Britain) or even two thirds (USA) of cases.     
The natural history of each underlying disease is dependent on a wide range of factors and 
although the K/DOQI classification based on glomerulal filtration rate is a very useful one 
from practical point of view it does not reveal anything about the pathogenesis of the 
particular condition. 
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cardiovascular mortality rate of young end stage renal disease (ESRD) patients is 500 times 
higher as compared with an age-matched control group. The situation is moreover 
complicated by the fact that traditional risk factors (the “Framingham factors”) are of lesser 
predictive value in kidney disease than in general population (Foley et al, 1998,  Magnus 
and Beaglehole, 2001,   Go et al, 2004). 
To explain this dismal picture it is not sufficient to disclose that chronic kidney disease 
(CKD) and chronic renal insufficiency (CRI) is associated with accelerated atherosclerosis 
and abnormal lipid/lipoprotein metabolism (Felström et al., 2003, Lacquaniti, 2010). One 
should keep in mind that “CKD”, “CRI” and “ESRD” are collective terms and the actual 
diseases and conditions behind them are manifold (Table 1). Some of them (e.g. diabetes 
mellitus and hypertension) have a profound effect on lipid metabolism and atherosclerosis 
independently from kidney function already before the manifestation of renal impairment. 
From the data in Table 1 is evident that diabetes and hypertension is behind ESRD in one 
quarter (Great Britain) or even two thirds (USA) of cases.     
The natural history of each underlying disease is dependent on a wide range of factors and 
although the K/DOQI classification based on glomerulal filtration rate is a very useful one 
from practical point of view it does not reveal anything about the pathogenesis of the 
particular condition. 
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Etiology of ESRD Great Britain Australia USA Japan 
Chronic glomerulonephritis 30% 30% 9% 47% 
Diabetic nephropathy 16% 22% 43% 31% 
Hypertension 12% 14% 26% 10% 
Chronic interstitial nephritis 8% 10% 2% 2% 
Polycystic degeneration 6% 6% 2% 2% 
Other/unkown 28% 18% 13% 8% 
Table 1. Etiology of end stage renal disease in different regions of word. (According to 
Viklický, 2006) 
1.2 Accelerated atherosclerosis in CKD 
Despite all above mentioned uncertanities concerning the causal association between renal 
disease and accelerated atherosclerosis there is a considerable amount of knowledge in the 
field of pathophysiology and pathobiochemistry of this topic (Felström et al, 2003, Vaziri, 
2006, Kwan et al, 2007, Saland &t Ginsberg, 2007, Tsimihodimos et al. 2008 and 2011, 
Basnakian at al, 2010; Karumanchi & Thadhani, 2010). An overview of different factors 
influencing the rate of atherosclerosis in CKD, CRI and ESRD is summarized in Table 2. 
These factors however do not act independently but in the frame of a complicated and not 
yet fully understood network (Fig 1.). They are present already in the early phases of kidney 
diseases and in many cases other pathological conditions associated with accelerated 
atherosclerosis (obesity, diabetes, hypertension, etc.) are present, too.  
 
Dyslipidemia (increased triglycerides and LDL-cholesterol, decreased HDL-cholesterol) 
Atherogenic lipid fractions (oxidized and carbamylated LDL, small dense LDL, 
triglyceride rich particles) 
Abnormal values and forms of apolipoproteins (apoB, apoAI, Lp(a)) 
Uremic toxins 
Alterations of calcium and phosphorus metabolism 
Oxidative stress (increased formation of reactive oxygen species and advanced glycation 
endproducts, decreased acitivty of antioxidants) 
Immunodeficiency 
Inflammation 
Malnutrition, hypalbuminemia and proteinuria 
Anaemia 
Physical inactivity 
Ethnicity and genetic polymorphism 
Drug treatment  
Hemodialysis modalities 
Peritoneal dialysis 
Table 2. Factors influencing atherosclerosis development in CKD, CRI and ESRD 
1.3 The aim of this chapter 
In this chapter the authors try to answer some question conserning accelerated 
atherosclerosis and its assessment in CRI patients. In the subsequent parts they: 
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1. Describe and analyze the lipid and lipoprotein abnormalities in CRI, ESRD and HD. 
2. Show the results of a metaanalysis dealing with methodological problems measuring 
LDL-cholesterol in CRI, ESRD and HD patients and results from a study on analytical 
quality of LDL-cholesterol assessment in real word laboratories. 
3. Give simple advice how to assess cardiovascular risk in CRI, ESRD and HD patients in 
everyday clinical practice. 
Therapeutic attempts and possibilities to normalize the lipid abnormalities and decrease the 
high risk of cardiovascular events in CRI, ESRD and HD patients are not the topics of this 
chapter. 
 































Fig. 1. Factors responsible for abnormal lipid metabolism and accelerated atherosclerosis in 
kidney disease form a complicated and intertwined network 
2. Lipid and lipoprotein abnormalities in kidney disease 
2.1 Changes of routinely measured lipid parameters in CRI and HD 
The changes of two basic lipid parameters – the concentration of triglycerides (TG) and total 
cholesterol (TC) in different forms of renal disease are in Table 3. Increased triglyceride 
concentration is a general feature of  kidney disease whereas increased cholesterol is not. 
Assesment the risk of atherosclerosis related morbidity from these two parameters is of course 
not possible because they do not reflect the real metabolic situation sufficiently. Lipids are 
insoluble in blood plasma and therefore they can circulate only in the form of lipoproteins. On 
the other side increased TG alone is an important warning sign of the presence of highly 
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atherogenic triglyceride rich lipoprotein particles (TRL). The concentration of total cholesterol 
on the other side does not provide a valuable information because its carriers can be less and 
more atherogenic or even antiatherogenic. In table 4 data on changes of HDL-cholesterol, non-
HDL-cholesterol and the highly atherogenhic Lp(a) in CRI are shown. LDL-cholesterol is not 
involved in this table for reasons of its analytical uncertainity which is further analyzed in part 
3 of this chapter. From data in Table 3 and 4 the shift towards accelerated atherosclerosis is 
evident – high amount of triglycerides in the lipoproteins and a low level of antiatherogenic 
HDL particles regardless on the form and stage of kidney disease (Vazari, 2006, Saland et 
Ginsberg, 2007, Tsimihodimos et al., 2008, Attman et al., 2010). 
 
Condition Triglycerides Total cholesterol 
Minimal proteinuria Increased No change or decrease 
Heavy proteinuria Increased Highly increased in nephrotic syndrome 
Chronic renal insufficiency Increased No change 
Hemodialysis Increased Controversial data – mostly no change 
Peritoneal dialysis Increased Increased 
Table 3. Triglycerides and total cholesterol in different conditions associated with kidney 
disease 
 
Condition Non-HDL cholesterol HDL-cholesterol Lp(a) 
Chronic renal 
insufficiency Increased Decreased Increased 
Hemodialysis Increased Decreased Increased 
Peritoneal dialysis Increased Decreased Increased 
Table 4. Non-HDL cholesterol, HDL cholesterol and lipoprotein(a)  in chronic renal 
insufficiency, hemodialysis and peritoneal dialysis  
2.2 Lipoprotein metabolism in health and kidney disease   
Lipoproteins are complex particles consisting from lipids transferred from and to the tissues 
and a phospholipid envelope containing different proteins.  They are not passive containers 
of TG and cholesterol but dynamic particles with variable composition. Both lipoprotein 
turnover and composition is altered in kidney diseases and therefore basic knowledge about 
it is essential for the proper assessment of cardiovascular risk in this special case. 
Lipoprotens are divided int three families: Chylomicrons and their remnants, the VLDL-
IDL-LDL family and the HDL family. Their composition and apoprotein content is in Tables 
5 and 6. 
Chylomicrons produced in enterocytes are carriers of lipids from guts to liver.  There are 
much bigger than the other lipoproteins and during ultracentrifugation they do not 
sediment at all. Chylomicrons contain one molecule of apoprotein is B48 and some 
apoprotein molecules A I, A II and A IV. During their life span they acquire apo E and 
apo C from HDL particles. In contact with muscle and fat tissue capillary endothelial cells 
they release fatty acids through triglyceride lipolysis catalyzed by endothelium-bound 
lipoprotein lipase.  Remnants of chylomicrons are removed by the liver.  
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Table 5. Basic characteristics of lipoproteins (According to Žák, 2002, modified; PL = 
phospholipids) 
 
Apoprotein, function Gene Finding 
A I – activator of LCAT 11q23-qter HDL, CHY 
A II – activator of liver lipase, 
Inhibitor of LCAT 11q21-q23 HDL, CHY 
A IV – activator of LCAT 11q23-qter HDL, CHY 
B 100 - key protein for assembly and receptor 
binding 2p23-24 LDL, IDL, VLDL 
B 48 - short form of B 100 The same as B100 CHY 
C I –Cofactor of LCAT 19q12-q13.2 CHY, VLDL 
C II – activator of lipoprotein lipase 19q12-q13.2 CHY, VLDL, HDL 
C III – inhibitor of VLDL transfer into liver 11q23-qter CHY, VLDL, IDL 
D – regulator of cholesterol ester transfer 3q14.2-qter HDL 
E – Transfer of CHY remnants into liver 19q12-q13.2 CHY, VLDL, IDL 
Table 6. Apoprotein function and their occurence in lipoproteins 
After a meal rich in fat the peak value of chylomicrons occurs approximately in 3 hours and 
they disappear in 8 – 9 hours. Visible plasma turbidity is a clear sign of chylomicron 
presence (mostly caused when blood sampling is not realized in fasting state).  
Chylomicrons are not involved singificantly in atherogenesis but in the case of their 
decreased catabolism (which is a case in kidney disease) the accumulated remnants can be 
atherogenic (Chan et al, 2009). 
Endogenous lipid carrier particles are formed in the liver as VLDL. They contain a bigger 
variant of apoB (apoB100) but the function of this protein is the same as in chylomicrons. 
Apoproteins B are of key importance during the assembly of lipoprotein particles and also 
serve as a docking structure when the lipoprotein binds to the LDL-receptor. The interaction 
of VLDL with HDL and with the tissues is similar to that of chylomicrons and during their 
circulation they became smaller – known as IDL and LDL. LDL particles during their 
relatively long life span (t1/2 = 2 – 4 hours and in CRI probably even more) can undergo 
oxidation, glycation and carbamylation. These random postsynthetic events alter the quality 
of liporoteins with a profound effect on their cellular metabolism – e.g. the uptake of 
damaged LDL particles through the scavenger receptor and not through the LDL-receptor. 
Another important topic important for the rate of atherosclerosis (not only) in CRI patients 
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is the presence of small dense LDL particles and (Table 7) and increased levels of abnormal 
particles as Lp(a) – Tables 4 and 8. All these features render the interpretation of basic 
laboratory parameters of lipid/lipoprotein metabolism in regard to the assessment of 
atherosclerosis difficult (Table 9). 
Despite the complicated and sometimes contradictory data on LDL metabolism in CRI, 
ESDR and HD it is possible to summarize the underlying picture in a relatively simple way. 
According to Ikerwaka et al (2005) and  Chan et al (2009) all lipid and lipoprotein alterations 
associated with LDL particles have a common soil – their decreased catabolism.  Increased 
synthesis can play an additonal role in the case of massive proteinuria. 
 
Class Density, g/ml Size, nm % of LDL 
I 1.026 27.5 – 26.0 3 
II 1.028 26.0 – 25.5 16 
III 1.034 25.5 – 24.2 50 
IV 1.048 24.2 – 21.8 22 
V > 1.048 < 21.8 9 
Table 7. Normal density distribution of LDL particles 
 
Lipoprotein Lp(a)  has a similar  structure and composition as LDL particles 
Density:  1,050 – 1,100 
Size:   25 – 35 nm 
Proteins: ApoB 100 and an abnormal protein, Apo(a) attached to the B 100 
                                Apo(a) has a variable molecular weight between 300 – 800 kDa, 
                                its  structure is similar  to the plasminogen (involved in fibrinolysis). 
Subtypes: 6 different forms – F, B and S1 – S4 
Concentration: 0 – 1200 mg/l with abnormal distribution of values. As atherogenic are 
                            considered concentrations above 200 – 300 mg/l 
Lp(a) in CRI: Increased but the cause of increase is not clear. The basic level of Apo(a) 
                                              is probably associated with gene polymorphisms and the kidney 
                            disease is a provocative factor for further increase  (Danesh et al, 2000) 
Table 8. Structure of Lp(a) 
The basic function of HDL is the reverse transport of surplus cholesterol from the tissues to 
liver. HDL particles are synthetized as discoid particles poor in lipids. Nascent HDL (or 
HDL3) particles contain a lot of different apoproteins (70 % of total protein is Apo A-I and 20 
% Apo A-II) crucial in TG and cholesterol metabolism which they exchange with 
chylomicrons and VLDL. Cholesterol bound to the surface of HDL is esterified by the 
enzyme LCAT and the esters are internalized. The cholesterol-ester loaded HDL2 particles 
unload their content through a specific receptor into the liver.  The low number and 
decreased function of LDL particles (manifest as “low HDL-C”) is probably a consequence 
of the enzyme LCAT and the apoprotein A-I. Recently Rosenson et al (2011) highlighted the 
topic of HDL heterogeneity and its possible role in the pathophysiology of accelerated 
atherosclerosis in kidney disease. According to this concept not the low level of “good 
cholesterol” but rather the altered constellation of HDL structure and function is of 
importance in atherogenesis. 
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Tiacylglycerols and cholesterol are insoluble in water. They circulate in the blood 
exclusively as lipoproteins. 
Lipoproteins are complex particles; their cholesterol content (measured or calculated as 
HDL-C and LDL-C) does not reflect their real composition and structure. 
Lipoproteins are dynamic, changing their lipid and protein composition during their life 
span in the circulation. 
Lipoproteins are heterogeneous and their different density is not a simple biological 
variation but it has profound effect on their metabolism. Small dense lipoproteins are 
more atherogenic than those with low density. 
In some people and in some pathological conditions there are also abnormal lipoproteins 
in the blood. One of them is lipoprotein(a)  which is highly aterogenic and its 
concentration is increased in renal disease. 
Some of the assay methods for lipids and lipoproteins are not bulletproof from analytical 
point of view – see part 3 of this chapter 
Table 9. Pitfalls in interpretation of basic lipid parameters from clinical point of view 
3. Methods for measurement and lipids, lipoproteins with special attention to 
LDL-cholesterol measurement  
3.1 Basic lipid assays and the short history of lipid and lipoprotein measurement 
The first cumbersome but at that time reliable colorimetric methods for cholesterol and 
triglyceride assays were developed in the first half of the last century. From  today’s point of 
view obsolete methods were crucial for understanding the association between lipid 
metabolism and cardiovascular disease. Later  there were replaced with enzymatic assays 
and adjusted for the use in automatic analyzers. Isolation of lipoproteins by 
ultracentrifugation giving basis for the today lipoprotein terminology was introduced in the 
40’s of the last century. Analytical and preparative ultracentrifugation is also today the gold 
standard method for quantification, separation and research on lipoproteins. About the 
same time paper electrophoresis (later replaced by agarose and polyacrylamide gel) gave 
the rise not only to an alternative nomenclature  (alpha, pre-beta and beta lipoproteins) but 
also to the epoch-making phenotypic classification of dyslipoproteinemias by Fredrickson & 
Lees in 1965 and a better understanding of the pathobiochemistry of atherosclerosis. This 
methodology is currently reserved only for specialized applications. (For an excellent review 
on this topic see Mcnamara et al., 2006).  
Triglyceride and total cholesterol assays are the starting points of lipid status assessment 
also today but their information value is different. Strictly speaking both are “artefacts” but 
whereas total triglycerides provide an important information about the presence of TRLs, 
total cholesterol itself has a limited diagnostic value.  
3.2 Estimation of LDL-cholesterol 
Lipoproteins are prone to differential precipitation in arteficial conditions (e.g. heparin-
manganese or dextran-magnesium solutions) and this allowed to develop methods to 
separate them without ultracentrifugation or electrophoresis. Based on this procedure in 
70’s first the direct measurement of HDL-C was developed and introduced into clinical 
chemistry. On the other side direct measurement of LDL-C was not possible until the end of 
the century. In the 25 year long interim period there was only one possibility to estimate the 
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concentration of LDL-C in everyday practice. It was the calculation according to Friedewald 
formula (Friedewald et al, 1972). The formula was based on the analysis of a large LDL 
database created in research laboratories using ultracentrifugation. It was however clear that 
a calculation from three (TC, TG, HDL-C) measured values with their own analytical 
uncertainity is only a recourse from necessity. 
The uncertainity of the currently employed 3rd generation methods is much lower than that 
of the Friedewald formula or the older methods but from strictly analytical point of view 
they are also not sufficient to obtain accurate results (Bairaktari et al., 2005). Another 
unsolved problem is that the assay methods from different providers are not yet 
harmonized at all (Fuentes-Arderiu et al, 2009, Miller et al, 2010). 
3.3 Apoprotein measurements  
The discovery of immunochemical methodology in 70’s made apoprotein assays possible. In 
the same time their function and their role in lipid metabolism was identified. According to 
recent view some of them belong to parameters providing important information when 
assessing cardiovascular disease risk (Ritz & Wanner, 2004, Batista et al, 2005) There are 
three apoproteins which should be measured in each patiens with elevated risk of 
cardiovascular disease: Apoprotein B100, apoprotein A-I and lipoprotein(a). 
Only one molecule of ApoB100 is present in each LDL-type particle (Fig 2). ApoB100 is a big  
molecule (m.w. 550 kDa) crucial already in the synthesis of VLDL and playing an essential 
role in the removal of LDL from the circulation. Measurement of ApoB100 in routine clinical 
practice is possible and in contrast to dynamic and heterogenous entities as “HDL-
cholesterol” and “LDL-cholesterol” is an unambiguously defined analyte. The concentration 
of ApoB100 therefore provides the best information about the presence of LDL-type 
particles circulating in the blood (Olofsson et al, 2007). Elevated concentration apoB100 and 
normal or slightly elevated LDL-C or nonHDL-C is an indirect but valuable marker of small 
dense LDL particles  
Apoprotein A-I is a small molecule (28 kDa) and HDL particles contain several of them. 
They are activators of LCAT, that means the concentration of Apo A-I is a marker of HDL 
particle function and the metabolic activity of the particles and not their size or number.  
 
 
Fig. 2. Apoprotein B100 is a big ringlike flexible molecule holding the whole particle 
together in its different stages of metabolism and making its binding to LDL-receptor 
 
Lipid and Lipoprotein Abnormalities in Chronic Renal Insufficiency: Review 
 
357 
4. Analytical accuracy of LDL-C in kidney disease and hemodialysis  
4.1 Metaanalysis of results achieved with Friedewald equation compared to reference 
ultracentrifugation method 
Our metaanalysis contains data from all available published papers dealing (entirely or as 
a part of broader study) with analytical accuracy of LDL-C assessment according to the 
Friedewald equation as compared with the reference UC method in CRI patients. The 
methodology of the metanalysis is described in our previous paper (Gaško et Sánchez-Meca, 
2009). It includes studies from 1990 until the end of year 2010. Four studies were found but 
two of them were further divided according to the details of the study. The basic data of the 
studies are summarized in Table 10 and the results of metaanalysis in Fig 3.  
 
Study, Year Probands Location % Weight Inclusion criteria 
Nauck & al 1, 1996 887 Germany 0.0% healthy (not included) 
Nauck & al 2, 1996 136 Germany 23.2% HD, TG < 4.56 mmol/l 
Nauck & al 3, 1996 171 Germany 29.2% CAPD, TG < 4.56 mmol/l 
Pedro-Botet & al, 1996 101 Spain 17.2% HD, age 20 - 80 years 
Bairaktari & al 1, 2001 54 Greece 9.2% HDs, TG < 2.26 mmol/l 
Bairaktari & al 2, 2001 38 Greece 6.5% HD, TG 2,26 – 4.52 mmol/l 
Bairaktari & al, 2004 86 Greece 14.7% HDs TG < 4.5 mmol/l 
 586  100.0%  
Table 10. Studies included in metaanalysis, divided into subgroups according to inclusion 
criteria. 
Model Study name Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit
Nauck et al 2, 1996                               0,020 -0,045 0,085
Nauck et al 3, 1996                               -0,070 -0,117 -0,023
Pedro-Botet et al 1, 1996                         -0,310 -0,398 -0,222
Bairaktari et al 1, 2001                          -0,110 -0,164 -0,056
Bairaktari et al 2, 2001                          -0,390 -0,521 -0,259
Bairaktari et al, 2004                            -0,180 -0,250 -0,110
Fixed -0,115 -0,142 -0,089
Random -0,163 -0,259 -0,068
-1,00 -0,50 0,00 0,50 1,00
Favours FF Favours BQ
 
Fig. 3. Difference in means LDL-C with 95% CI in 4 studies included with 6 subgroups of 
patients with severe nephropathy on different forms of dialysis, with fixed and random 
effects model summary difference. Forest plot. Units: mmol/l. Patients included 586. 
For patients in different dialysis regimes the summary differences of means of LDL-C is 
0.234 mmol/l, what presents a bias of -4.9%. The information value of this result is much 
higher when compared with results on healthy probands od with results of patients with 
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other diseases. We identified 23 publications including 17 213 patients analyzing accuracy of 
LDL-C assessment on healthy probands or in patients with hyperlipidemia from 1990 until 
2009. The summary differences of means in this setting is 0.108 mmol/l and the bias is 
+2.3%. Furhter 3 papers followed analytical accuracy LDL-C in 350 patients with I and II 
diabetes mellitus or with hepatopathy. Total difference in means in this group was 0.234 
mmol/l,  (bias +6.8%;  Fig 4). 
From these findings it is possible to conclude that calculated concentrations of LDL-C 
according to the Friedewald equation can differ from the true values by almost 12 % 
systemic error. For clinical practice this analytical error can have a unwelcome situation 
because in approximately 7% of patients proper and necessary treatment according to 
guidelines is not prescribed and in another 5 % superfluous treatment is prescribed. This 
second group however is not in a danger of non-treated dyslipidemia because but there is 
problem of pharmacoeconomy.  
Model Study name Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit
Matas et al 2, 1994                               0,370 0,214 0,526
Matas et al 3, 1994                               0,310 0,215 0,405
Hirany et al 1, 1997                              0,180 0,099 0,261
Hirany et al 2, 1997                              0,280 0,234 0,326
Wägner et al, 2000                                0,240 0,197 0,283
Wägner et al, 2003                                0,090 0,038 0,142
Fixed 0,220 0,196 0,245
Random 0,234 0,160 0,309
-1,00 -0,50 0,00 0,50 1,00
Favours FF Favours BQ
 
Fig. 4. Difference in means LDL-C with 95% CI in 3 studies included with 6 subgroups of 
patients with diabetes mellitus or hepatopathy, with fixed and random effects model 
summary difference. Forest plot. Units: mmol/l. Patients included 350. Figure from Gaško & 
Sánchez-Meca, 2009, with permision. 
4.2 Unreliability of LDL-C assessment in everyday laboratory practice 
There is only one method providing a true picture about the composition of the particles 
ultracentrifugation with subsequent chemical analysis of their composition. This method is 
the golden standard and the anchor of all methods used in routine clinical practice.   
For a couple of years there was only one indirect way to estimate the cholesterol content of 
LDL particles. Despite modern methods estimating total cholesterol, HDL-cholesterol and 
triglycerides with a high level of precision and accuracy they have a certain degree of 
uncertainity and the overall uncertainity is too high to give a reliable picture on LDL-
cholesterol even in probands without any confounding factors. In CRI patients the situation 
is even worse. 
Recently clinical chemistry laboratories can use one commercial kits based on 7 different 
method for direct LDL-C assays. Some laboratories however calculate LDL-C according to 
the Friedewald formula or use both procedures (e.g. direct assay only in the case of elevated 
total cholesterol or in patients with otherwise elevated cardiovascular risk). According to 
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Agrawal et al (2010) in USA in 2009 approximately 2200 laboratories used direct assays but 
3300 calculated LDL-C according to Friedewald. In Czech and Slovak republics the ratio was 
different (159 laboratories on direct assays and only 83 on formula (Gaško et al, 2011).  
There is no official recommendation on international level about the methodology of LDL-C 
estimation. The choice depends solely on the decision of the laboratory and/or the health 
care provider. Another confounding factor is that the same laboratory can change the actual 
type of the direct method or use alternatively a direct method or the calculation mostly 
without any warning towards the clinician.   
We realized a multicentric prospective study to compare the results achieved by different 
direct method compared with the results of Friedewald calculation (Gaško et al, 2011) in 13 
laboratories. All of them were controlled also in the frame of an external quality assesment 
system. All of them diclosed results of the control sera in the appropriate range. Results of 
the direct assay and the calculation were compared on a set of randomly selected 200 patient 
samples with a broad range of diseases including CRI. In Fig 5. the average difference 
between the results of direct (considred in this study as reference) method and the 
calculated results are shown. The differences are in the range from -8 % ap to + 30 %.  Of 
course the evident limitation of this study is the lack of comparison with the reference 
ultacentrifugation method. Despite this limitation the results of this simple study combined 
with the results of metanalysis (4.1.) show an unacceptable degree of uncertainity  of LDL-C 





























1 2 3 4 5 6 7 8 9 10 11 12 13
 
Fig. 5. Average differences (n = 200) in calculated LDL-C compared with results of the direct 
assay in 13 different laboratories. Value measured by the direct method in each laboratory is 
considered 100%. Data are shown as median and 2.5 to 97.5 percentiles. 
A very interesting question is the situation after kidney transplatation. These patients at the 
first sight are „cured“ but as a matter of fact they are far from being „healthy“ beacause of 
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A very interesting question is the situation after kidney transplatation. These patients at the 
first sight are „cured“ but as a matter of fact they are far from being „healthy“ beacause of 
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the long-life immunosuppression therapy and of the slightly decreased kidney function in 
most of them. Balal et al (2010) compared results from 103 renal transplant recipients and 
the sum of differences between the calculation according to Friedewaldovho and the direct 
method was – 6,5 % ± 6,6 % (mean ± SD). According to Tsimihodimos et al (2008) after 
transplantation one very important atherogenic factor disappears – the increased level of 
Lp(a).  
5. Conclusions 
5.1 Where we stand today? 
From our metaanalysis and the study on the unreliability of LDL-C estimation we conclude 
that the Friedewald formula seems to be no longer a viable test for appropriate targeted 
therapy in chronic renal failure and hemodialysis. Direct assays of LDL-C are not absolutely 
without error but they provide considerably more reliable results as a calculation from three 
measurements. 
Clinicians should be aware that despite our gradually better understanding of the 
pathobiochemistry, pathobiochemistry and genetic background of atherosclerosis and 
kidney disease laboratories are not able to provide full explanation about the situation in 
individual patients. According to McNamara et al (2006) “we are still only scratching the 
surface, and mich more research and discovery remains to fully understand these critically 
important particles”. As is depicted in Fig. 6   the scientist are looking on the different visible 
parts of the problem. The situation in clinical chemistry is even more problematic because 
the currently available methods are showing only the footprints of the real situation, not its 
essence.   
 
Fig. 6. Scientist looking at miscellaneous aspects of the problem and a clinical chemist trying 
to gain some information from the footseps. 
5.2 Conclusion 
In patients with CRI and/or ESRD, HD the pace of atherosclerosis development should be 
estimated as follows: 
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Proper clinical and biochemical evaluation of the underlying kidney disease and continuous 
monitoring of its progression. Special attenttion should be devoted to proteinuria and 
hypalbuminemia because they directly influence the metabolism of LDL-type particles and 
their concentration in the blood. 
Evaluation of the risk factors not directly associated with the kidney disease (smoking, 
obesity, diabetes, hypertension, etc.) 
Evaluation of lipid parameters – total cholesterol, LDL-cholesterol measured directly, HDL-
cholesterol, triglycerides, apoprotein B100, apoporotein AI and Lp(a). The evaluation should 
not be a mechanistical process but should be based on pathophysiology of atherosclerosis in 
renal disease and should consider the strengths and weaknesses of the employed methods.  
Measurement of other parameters not fully validated yet from analytical point of view and 
from their clinical usefulness (small dense LDLs, parameters of the oxidative stress and 
antioxidant systems) is possible for research purposes. 
6. List of abbreviations 
C   Cholesterol (as LDL-C, HDL-C, nonHDL-C) 
CHY   Chylomicron 
CKD   Chronic kidney disease 
CRI   Chronic renal insufficiency 
ESRD   End stage renal disease 
HD   Hemodialysis 
HDL   High-density lipoprotein 
IDL   Intermediate-density lipoprotein 
LCAT   Lecithin-cholesterol acyltransferase 
LDL   Low-density lipoprotein 
TC   Total cholesterol 
TG   Triglyceride 
TRL   Triglyceride rich particle 
VLDL   Very low-density lipoprotein 
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1. Introduction 
A successful functioning vascular access is the “lifeline” for a hemodialysis patient.  
Hemodialysis vascular access dysfunction is a major cause of morbidity and mortality in 
hemodialysis patients1-3. Improving vascular access outcomes remains an ongoing challenge 
for nephrologists, vascular access surgeons, and interventionists.  In arteriovenous fistulas 
(AVF) and grafts (AVG), the most common cause of this vascular access dysfunction is 
venous stenosis as a result of neointimal hyperplasia within the peri-anastomotic region 
(AVF) or at the graft-vein anastomosis (AVG) 4,5. There have been few effective treatments 
to-date for venous neointimal hyperplasia in part because of the poor understanding of the 
pathogenesis of venous neointimal hyperplasia.  Central venous catheters (CVC) are prone 
to frequent thrombosis and infection and the treatment of catheter-related bacteremia (CRB) 
remains on ongoing debate 6-8. Therefore, this review will: (1) describe the pathology and 
pathophysiology of hemodialysis access stenosis in AVFs and AVGs, (2) discuss the 
pathogenesis of CRB and catheter thrombosis (3) discuss current and future novel therapies 
for treating venous neointimal hyperplasia, (4) discuss current strategies to treat CRB and 
catheter thrombosis, and (5) suggest future research areas in the field of hemodialysis 
vascular access dysfunction. 
1.1 Types of hemodialysis access 
Successful hemodialysis treatment requires access to the bloodstream to deliver a high 
enough blood flow to achieve an adequate dialysis dose.  There are three primary types of 
hemodialysis vascular access to achieve this goal:  (1) arteriovenous fistula, (2) arteriovenous 
graft, and (3) tunneled central venous catheter.  Each type of access has unique advantages 
and individual problems. 
1.1.1 Arteriovenous fistula 
AVFs are the preferred vascular access for hemodialysis patients, because once mature and 
functional, they require fewer interventions to maintain patency and develop fewer 
infections compared to AVGs 9-13. However, AVFs have higher rates of nonmaturation and 
longer maturation times compared to AVGs, which may lead to prolonged periods of CVC 
dialysis 9,14,15. Recent reports from the United States have shown that up to 60% of AVFs 
never mature adequately to be successfully cannulated for dialysis 16 compared to 20-25 
years ago where the nonmaturation rates in AVFs was approximately 10% 12. 
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1.1.2 Arteriovenous graft 
Arteriovenous grafts (made from polytetrafluoroethylene, a synthetic fluoropolymer of 
tetrafluoroethylene) are advantageous because of short maturation time and relative ease to 
cannulation compared to AVFs 12,17-19.  Until recently, AVGs were the most common access 
used in hemodialysis patients in the Unites States 20.  However, the main disadvantages of 
AVGs are development of recurrent venous stenosis, requiring frequent interventions to 
maintain patency, and graft infection 19,21-24. 
1.1.3 Tunneled central venous catheter 
Tunneled central venous catheters have the advantage of immediate use, multiple sites for 
insertion, and the ability to provide access for hemodialysis for a period of months, permitting 
time for AVF or AVG maturation, in patients who require immediate hemodialysis 19,25-28. 
However, the main disadvantages are the high risks of morbidity and mortality caused by 
infection 7,29-33, catheter thrombosis 19,34-37, and central venous stenosis 37-39.   
2. Epidemiology and clinical significance of hemodialysis vascular access 
dysfunction 
2.1 Epidemiology of hemodialysis vascular access 
Due to reduced AVF use and increased AVG (70% in 1993 40) and catheter use in the United 
States from the mid-1980’s-1990’s, the National Kidney Foundation in 1997, in an effort to 
improve vascular access outcomes, published the first Kidney Disease Outcome Quality 
Initiative (K/DOQI) clinical practice guidelines for vascular access to optimize the care of 
vascular access in hemodialysis patients using evidenced and opinion-based guidelines 41.  
Since these initial clinical practice guidelines have been published, we have seen the creation 
of the Fistula First Breakthrough Initiative (FFBI) 42-45 and two more revised K/DOQI 
clinical practice guidelines and performance measures for vascular access 19,46, which have 
clearly impacted and improved hemodialysis vascular access management.  The most recent 
report from the 2009 United States Renal Data System (USRDS) has showed an AVF 
prevalence of 50% 47, a marked improvement since 2004 (39% AVF prevalence), 2000 (30% 
AVF prevalence), and 1998 (26% AVF prevalence)48 in the United States.  In contrast, AVF 
prevalence in Europe and Japan, reported from the Dialysis Outcomes and Practice Patterns 
Study (DOPPS) has been historically much higher, ranging from 57-91% 20. 
While the K/DOQI guidelines and FFBI have clearly played an instrumental role in meeting 
the initial target goal of 50% AVF prevalence (new goal 66% 19,42), the prevalence of CVC use 
continues to remain between 20-30% in the United States 42. Furthermore, this trend of 
increased catheter use has also been observed in other countries, such as Spain, France, 
Belgium, Germany, and Italy 20. This is likely due to an increase in the number of AVFs that 
have failed to mature for dialysis use in recent years 14,16.   
2.2 Clinical significance and economic implications of hemodialysis vascular access 
dysfunction 
When patients develop vascular access dysfunction, due to an immature AVF or 
thrombosed AVF or AVG, they are often consigned to CVC use for prolonged periods.  
Because dialysis with a catheter is associated with increased morbidity and mortality 49-55, 
CVC use has significant clinical implications such as increased risk of bacteremia which has 
been reported to occur at a frequency ranging from 2.5 to 5.5 episodes per 1000-catheter 
 
Hemodialysis Vascular Access Dysfunction 
 
367 
days 6,56, increased risk of 1-year mortality 49, and 60-70% higher risk of subsequent AVF 
failure 32,57. The cost of treating one CVC-related bacteremia in the United States has been 
estimated to be as high as $45,000 per episode with an average of $22,000 per bacteremic 
episode 58. 
3. Pathology and pathophysiologic mechanisms of hemodialysis vascular 
access dysfunction 
3.1 Pathology of Hemodialysis Vascular Access Stenosis in AVF and AVG 
Venous stenosis that occurs in both AVFs and AVGs is primarily due to neointimal 
hyperplasia.  Venous stenosis in AVGs most frequently arises from the development of 
aggressive neointimal hyperplasia, characterized by (a) the presence of alpha smooth muscle 
actin positive cells myofibroblasts, and microvessels within the neointima, (b) an abundance 
of extracellular matrix components, (c) angiogenesis (neovascularization) within the 
neointima and adventitia, (d) a macrophage layer lining the perigraft region, and (e) an 
increased expression of mediators and inflammatory cytokines such as TGF-β, PDGF, and 
endothelin within the media, neointima and adventitia 59-64.   
While the neointimal hyperplasia in AVFs is similar to AVGs in regards to pathogenesis, the 
venous stenosis that develops in AVFs is highly influenced by the capacity of the vein to 
vasodilitate and vascular injury from surgical technique 65.  In AVFs the two main etiologies 
of failure are an initial failure to mature (nonmaturation) and a subsequent (late) venous 
stenosis 4.  Similar to AVGs, venous neointimal hyperplasia in late AVF stenosis has been 
shown to be composed primarily of alpha smooth muscle actin positive cells, together with 
expression of mediators and cytokines such as TGF-β, PDGF, and endothelin within the 
media and intima of the vein 60,65.  However, recently, the lesion of AVF nonmaturation at 6 
weeks after AVF creation has also been described to have significant neointimal hyperplasia 66.  
3.2 Pathophysiologic mechanisms of neointimal hyperplasia formation in 
hemodialysis access dysfunction 
The pathogenesis of venous neointimal hyperplasia in AVG stenosis and late AVF stenosis 
has been well described and is commonly divided into upstream and downstream events4. 
Upstream events are characterized as the initial events and insults that are responsible for 
endothelial and smooth muscle cell injury, which leads to a cascade of mediators 
(downstream events) that regulate oxidative stress, endothelial dysfunction, and 
inflammation (eventually resulting in venous neointimal hyperplasia).  Upstream events 
that are believed to contribute to the pathogenesis of neointimal hyperplasia include 4,62,67-70: 
(1) surgical trauma at the time of AV surgery, (2) hemodynamic shear stress at the vein-
artery or vein-graft anastomosis, (3) bioincompatability of the AVG, (4) vessel injury due to 
dialysis needle punctures, (5) uremia resulting in endothelial dysfunction, and (6) repeated 
angioplasties causing further endothelial injury.  Downstream events represent the response 
to endothelial (vascular) injury from the upstream events, resulting in the migration of 
smooth muscle cells from the media to the intima and eventually the development of 
neointimal hyperplasia 65.   
The pathogenesis in AVFs that fail to mature (early failure) for dialysis, in contrast to AVG 
and late AVF failure, remains poorly understood.  At a histological level early AVF failure is 
also characterized by aggressive neointimal hyperplasia in both animal and human models, 
seen as early as 1 month in animals 63,71 and 3 months in humans 64,66. The underlying factors 
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1.1.2 Arteriovenous graft 
Arteriovenous grafts (made from polytetrafluoroethylene, a synthetic fluoropolymer of 
tetrafluoroethylene) are advantageous because of short maturation time and relative ease to 
cannulation compared to AVFs 12,17-19.  Until recently, AVGs were the most common access 
used in hemodialysis patients in the Unites States 20.  However, the main disadvantages of 
AVGs are development of recurrent venous stenosis, requiring frequent interventions to 
maintain patency, and graft infection 19,21-24. 
1.1.3 Tunneled central venous catheter 
Tunneled central venous catheters have the advantage of immediate use, multiple sites for 
insertion, and the ability to provide access for hemodialysis for a period of months, permitting 
time for AVF or AVG maturation, in patients who require immediate hemodialysis 19,25-28. 
However, the main disadvantages are the high risks of morbidity and mortality caused by 
infection 7,29-33, catheter thrombosis 19,34-37, and central venous stenosis 37-39.   
2. Epidemiology and clinical significance of hemodialysis vascular access 
dysfunction 
2.1 Epidemiology of hemodialysis vascular access 
Due to reduced AVF use and increased AVG (70% in 1993 40) and catheter use in the United 
States from the mid-1980’s-1990’s, the National Kidney Foundation in 1997, in an effort to 
improve vascular access outcomes, published the first Kidney Disease Outcome Quality 
Initiative (K/DOQI) clinical practice guidelines for vascular access to optimize the care of 
vascular access in hemodialysis patients using evidenced and opinion-based guidelines 41.  
Since these initial clinical practice guidelines have been published, we have seen the creation 
of the Fistula First Breakthrough Initiative (FFBI) 42-45 and two more revised K/DOQI 
clinical practice guidelines and performance measures for vascular access 19,46, which have 
clearly impacted and improved hemodialysis vascular access management.  The most recent 
report from the 2009 United States Renal Data System (USRDS) has showed an AVF 
prevalence of 50% 47, a marked improvement since 2004 (39% AVF prevalence), 2000 (30% 
AVF prevalence), and 1998 (26% AVF prevalence)48 in the United States.  In contrast, AVF 
prevalence in Europe and Japan, reported from the Dialysis Outcomes and Practice Patterns 
Study (DOPPS) has been historically much higher, ranging from 57-91% 20. 
While the K/DOQI guidelines and FFBI have clearly played an instrumental role in meeting 
the initial target goal of 50% AVF prevalence (new goal 66% 19,42), the prevalence of CVC use 
continues to remain between 20-30% in the United States 42. Furthermore, this trend of 
increased catheter use has also been observed in other countries, such as Spain, France, 
Belgium, Germany, and Italy 20. This is likely due to an increase in the number of AVFs that 
have failed to mature for dialysis use in recent years 14,16.   
2.2 Clinical significance and economic implications of hemodialysis vascular access 
dysfunction 
When patients develop vascular access dysfunction, due to an immature AVF or 
thrombosed AVF or AVG, they are often consigned to CVC use for prolonged periods.  
Because dialysis with a catheter is associated with increased morbidity and mortality 49-55, 
CVC use has significant clinical implications such as increased risk of bacteremia which has 
been reported to occur at a frequency ranging from 2.5 to 5.5 episodes per 1000-catheter 
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days 6,56, increased risk of 1-year mortality 49, and 60-70% higher risk of subsequent AVF 
failure 32,57. The cost of treating one CVC-related bacteremia in the United States has been 
estimated to be as high as $45,000 per episode with an average of $22,000 per bacteremic 
episode 58. 
3. Pathology and pathophysiologic mechanisms of hemodialysis vascular 
access dysfunction 
3.1 Pathology of Hemodialysis Vascular Access Stenosis in AVF and AVG 
Venous stenosis that occurs in both AVFs and AVGs is primarily due to neointimal 
hyperplasia.  Venous stenosis in AVGs most frequently arises from the development of 
aggressive neointimal hyperplasia, characterized by (a) the presence of alpha smooth muscle 
actin positive cells myofibroblasts, and microvessels within the neointima, (b) an abundance 
of extracellular matrix components, (c) angiogenesis (neovascularization) within the 
neointima and adventitia, (d) a macrophage layer lining the perigraft region, and (e) an 
increased expression of mediators and inflammatory cytokines such as TGF-β, PDGF, and 
endothelin within the media, neointima and adventitia 59-64.   
While the neointimal hyperplasia in AVFs is similar to AVGs in regards to pathogenesis, the 
venous stenosis that develops in AVFs is highly influenced by the capacity of the vein to 
vasodilitate and vascular injury from surgical technique 65.  In AVFs the two main etiologies 
of failure are an initial failure to mature (nonmaturation) and a subsequent (late) venous 
stenosis 4.  Similar to AVGs, venous neointimal hyperplasia in late AVF stenosis has been 
shown to be composed primarily of alpha smooth muscle actin positive cells, together with 
expression of mediators and cytokines such as TGF-β, PDGF, and endothelin within the 
media and intima of the vein 60,65.  However, recently, the lesion of AVF nonmaturation at 6 
weeks after AVF creation has also been described to have significant neointimal hyperplasia 66.  
3.2 Pathophysiologic mechanisms of neointimal hyperplasia formation in 
hemodialysis access dysfunction 
The pathogenesis of venous neointimal hyperplasia in AVG stenosis and late AVF stenosis 
has been well described and is commonly divided into upstream and downstream events4. 
Upstream events are characterized as the initial events and insults that are responsible for 
endothelial and smooth muscle cell injury, which leads to a cascade of mediators 
(downstream events) that regulate oxidative stress, endothelial dysfunction, and 
inflammation (eventually resulting in venous neointimal hyperplasia).  Upstream events 
that are believed to contribute to the pathogenesis of neointimal hyperplasia include 4,62,67-70: 
(1) surgical trauma at the time of AV surgery, (2) hemodynamic shear stress at the vein-
artery or vein-graft anastomosis, (3) bioincompatability of the AVG, (4) vessel injury due to 
dialysis needle punctures, (5) uremia resulting in endothelial dysfunction, and (6) repeated 
angioplasties causing further endothelial injury.  Downstream events represent the response 
to endothelial (vascular) injury from the upstream events, resulting in the migration of 
smooth muscle cells from the media to the intima and eventually the development of 
neointimal hyperplasia 65.   
The pathogenesis in AVFs that fail to mature (early failure) for dialysis, in contrast to AVG 
and late AVF failure, remains poorly understood.  At a histological level early AVF failure is 
also characterized by aggressive neointimal hyperplasia in both animal and human models, 
seen as early as 1 month in animals 63,71 and 3 months in humans 64,66. The underlying factors 
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(upstream events) which may contribute to early AVF failure, include 4,72-81: (1) small 
diameter sizes in the vein and artery, (2) surgical injury at the time AV fistula placement, (3) 
previous venipunctures, (4) development of accessory veins after surgery, (5) hemodynamic 
shear stress at the AV anastomosis, (6) a genetic predisposition to vascular constriction and 
neointimal hyperplasia, and (7) pre-existing venous neointimal hyperplasia. 
The subsequent sections will focus on the downstream events and three main mechanisms 
responsible for neointimal hyperplasia such as oxidative stress, inflammation, endothelial 
dysfunction, and alternative origins of neointimal-derived cells.   
3.2.1 Oxidative stress 
Many of the upstream mechanisms above (particularly hemodynamic shear stress and 
angioplasty injury) have been documented to result in an increase in the production of free 
radicals and its downstream products nitrotyrosine and latter (peroxynitrate). The latter is a 
potent upregulator of the matrix metalloproteinases (MMPs) 82,83. MMPs are key enzymes 
that cause breakdown of extracellular matrix proteins such as collagen and elastin which 
facilitate the migration of vascular smooth muscle cells (VSMCs) in neointimal hyperplasia 
formation 84.  MMPs, paradoxically, have also been shown to facilitate a beneficial dilatation 
of the feeding artery (through degradation of the internal elastic laminae) in both rabbit and 
mouse AVF models 82,85. Experimental studies of AVGs have demonstrated a differential 
upregulation of MMP-2 at the graft-vein anastomosis, with early expression (9 days) in the 
adventitia and a later expression (19 days) within the intima, supporting the concept of 
cellular migration from the adventitia to the intima 86. Furthermore, linkages between 
hemodynamic shear stress and the expression of oxidative stress markers and cytokines 
have also been described in a porcine model of AVG stenosis 87. Clinical studies of stenotic 
and thrombotic AVGs and AVFs have also demonstrated an upregulation of MMPs 88, and 
have documented the co-localization of oxidative stress markers with inflammatory 
cytokines such as transforming growth factor-beta (TGF-), and platelet-derived growth 
factor (PDGF), within the neointima of both stenotic AVGs and AVFs 60.   
Heme-oxygenase-1 (HO-1) is an important enzyme pathway which has been shown to 
confer protective effects in the vascular endothelium and other organ systems through its 
anti-inflammatory, antioxidant, or antiproliferative actions and properties 89. Experimental 
studies in AVFs have described an increase in both the magnitude of arteriovenous stenosis 
and the frequency of thrombosis following the creation of AVFs in HO-1 knock out mice 
(increased baseline oxidative stress) as compared to wild type animals 90. Furthermore, in 
the HO-1 knockout mice, there was significant induction of MMP-9 expression in the vein at 
1 week compared to wild type mice, suggesting that MMP expression in vascular tissue and 
its deleterious effects with regard to promoting cellular migration may in part be inhibited 
by HO-1.  Clinical studies have demonstrated a higher frequency of AVF failure in patients 
with heme-oxygenase-1 (HO-1) gene polymorphisms with long GT repeats (resulting in 
increased oxidative stress) 73.  
3.2.2 Inflammation 
ESRD is associated with a chronic inflammatory state, characterized by the elevation of 
circulating cytokines and chemokines 91. This inflammation has been proposed to play an 
important role in the initiation and progression of atherosclerosis in ESRD, but may also 
play a significant role in vascular access stenosis.  Support for this paradigm comes from 
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recent work in which uremic mice developed a 2-3 fold greater magnitude of neointimal 
hyperplasia at the arteriovenous anastomosis as compared to non-uremic animals in a 
mouse model of AVF stenosis 92, and a recent study which showed marked upregulation of 
monocyte chemoattractant protein-1 (MCP-1) in the venous segment of AVF compared to 
rats deficient in the MCP-1 gene 93.   
In clinical studies, possible linkages have described the presence of inflammatory cells 
(macrophages and lymphocytes), cytokines such as TGF-ß and insulin-like growth factor-1 
(IGF-1) and the magnitude of neointimal hyperplasia and venous stenosis within stenotic 
AVFs 94.  
Local bioincompatability to synthetic polytetrafluoroethylene (PTFE) material in AVGs 
could also result in local inflammation 95. In vitro studies have demonstrated that 
conditioned media obtained after the interaction of peripheral blood mononuclear cells 
(PBMCs) with PTFE graft material resulted in a significant upregulation of smooth muscle 
cell proliferation as compared to control media 96.  This proliferative response has been 
shown to be attenuated by tumor necrosis-alpha (TNF-) inhibitors 96. Furthermore, the 
presence of macrophages that line PTFE graft material has been described in both 
experimental and clinical AVG stenosis with co-expression of inflammatory cytokines such 
as basic fibroblast growth factor (bFGF) 61,97.  
3.2.3 Endothelial dysfunction 
An intact and functional endothelium is essential for the vein to properly respond to acute 
changes in blood flow that occurs after creation of AVFs and AVGs 98. Nitric oxide (NO) is 
an important mediator responsible for these transformations 99,100. The presence of uremia in 
hemodialysis patients has been shown to exacerbate endothelial dysfunction, possibly 
through the pathways of inflammation and oxidative stress described above 101,102. In the 
specific context of vascular access stenosis, endothelial dysfunction is likely to be 
responsible for the development of pre-existing venous neointimal hyperplasia 77-81, medial 
hypertrophy 77,81 and radial artery intima-media thickening 103-105 that is present even before 
the creation of AVFs in uremic patients. Pre-existing arterial intima-media thickness has 
been correlated with future AVF dysfunction 103. Recently, pre-existing venous neointimal 
hyperplasia has been linked to poor AVF maturation in a small clinical study 77.  
Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase and 
has been implicated as an important contributor to endothelial dysfunction in ESRD patients 
106. ADMA is not excreted in ESRD patients and its levels have been reported to be two to six 
times higher in this patient population as compared to non-uremic individuals 107. In a 
recent clinical study in AVFs, patients with elevated ADMA levels at the time of 
percutaneous transluminal angioplasty of an initial AVF stenosis had a significantly 
increased risk of a recurrent AVF stenosis 108.  
3.2.4 Alternative origins of neointimal cells 
Although the traditional paradigm for the pathogenesis of neointimal hyperplasia has 
emphasized the migration of smooth muscle cells from the media to the intima, where they 
proliferate and contribute to the final volume of neointimal hyperplasia, a number of studies 
have reported that following coronary angioplasty or saphenous vein bypass grafting there 
is also a migration of cells (fibroblasts) from the adventitia, through the media, and into the 
intima, where these cells transform into  “myofibroblasts” 109-111. In dialysis access, a number 
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(upstream events) which may contribute to early AVF failure, include 4,72-81: (1) small 
diameter sizes in the vein and artery, (2) surgical injury at the time AV fistula placement, (3) 
previous venipunctures, (4) development of accessory veins after surgery, (5) hemodynamic 
shear stress at the AV anastomosis, (6) a genetic predisposition to vascular constriction and 
neointimal hyperplasia, and (7) pre-existing venous neointimal hyperplasia. 
The subsequent sections will focus on the downstream events and three main mechanisms 
responsible for neointimal hyperplasia such as oxidative stress, inflammation, endothelial 
dysfunction, and alternative origins of neointimal-derived cells.   
3.2.1 Oxidative stress 
Many of the upstream mechanisms above (particularly hemodynamic shear stress and 
angioplasty injury) have been documented to result in an increase in the production of free 
radicals and its downstream products nitrotyrosine and latter (peroxynitrate). The latter is a 
potent upregulator of the matrix metalloproteinases (MMPs) 82,83. MMPs are key enzymes 
that cause breakdown of extracellular matrix proteins such as collagen and elastin which 
facilitate the migration of vascular smooth muscle cells (VSMCs) in neointimal hyperplasia 
formation 84.  MMPs, paradoxically, have also been shown to facilitate a beneficial dilatation 
of the feeding artery (through degradation of the internal elastic laminae) in both rabbit and 
mouse AVF models 82,85. Experimental studies of AVGs have demonstrated a differential 
upregulation of MMP-2 at the graft-vein anastomosis, with early expression (9 days) in the 
adventitia and a later expression (19 days) within the intima, supporting the concept of 
cellular migration from the adventitia to the intima 86. Furthermore, linkages between 
hemodynamic shear stress and the expression of oxidative stress markers and cytokines 
have also been described in a porcine model of AVG stenosis 87. Clinical studies of stenotic 
and thrombotic AVGs and AVFs have also demonstrated an upregulation of MMPs 88, and 
have documented the co-localization of oxidative stress markers with inflammatory 
cytokines such as transforming growth factor-beta (TGF-), and platelet-derived growth 
factor (PDGF), within the neointima of both stenotic AVGs and AVFs 60.   
Heme-oxygenase-1 (HO-1) is an important enzyme pathway which has been shown to 
confer protective effects in the vascular endothelium and other organ systems through its 
anti-inflammatory, antioxidant, or antiproliferative actions and properties 89. Experimental 
studies in AVFs have described an increase in both the magnitude of arteriovenous stenosis 
and the frequency of thrombosis following the creation of AVFs in HO-1 knock out mice 
(increased baseline oxidative stress) as compared to wild type animals 90. Furthermore, in 
the HO-1 knockout mice, there was significant induction of MMP-9 expression in the vein at 
1 week compared to wild type mice, suggesting that MMP expression in vascular tissue and 
its deleterious effects with regard to promoting cellular migration may in part be inhibited 
by HO-1.  Clinical studies have demonstrated a higher frequency of AVF failure in patients 
with heme-oxygenase-1 (HO-1) gene polymorphisms with long GT repeats (resulting in 
increased oxidative stress) 73.  
3.2.2 Inflammation 
ESRD is associated with a chronic inflammatory state, characterized by the elevation of 
circulating cytokines and chemokines 91. This inflammation has been proposed to play an 
important role in the initiation and progression of atherosclerosis in ESRD, but may also 
play a significant role in vascular access stenosis.  Support for this paradigm comes from 
 
Hemodialysis Vascular Access Dysfunction 
 
369 
recent work in which uremic mice developed a 2-3 fold greater magnitude of neointimal 
hyperplasia at the arteriovenous anastomosis as compared to non-uremic animals in a 
mouse model of AVF stenosis 92, and a recent study which showed marked upregulation of 
monocyte chemoattractant protein-1 (MCP-1) in the venous segment of AVF compared to 
rats deficient in the MCP-1 gene 93.   
In clinical studies, possible linkages have described the presence of inflammatory cells 
(macrophages and lymphocytes), cytokines such as TGF-ß and insulin-like growth factor-1 
(IGF-1) and the magnitude of neointimal hyperplasia and venous stenosis within stenotic 
AVFs 94.  
Local bioincompatability to synthetic polytetrafluoroethylene (PTFE) material in AVGs 
could also result in local inflammation 95. In vitro studies have demonstrated that 
conditioned media obtained after the interaction of peripheral blood mononuclear cells 
(PBMCs) with PTFE graft material resulted in a significant upregulation of smooth muscle 
cell proliferation as compared to control media 96.  This proliferative response has been 
shown to be attenuated by tumor necrosis-alpha (TNF-) inhibitors 96. Furthermore, the 
presence of macrophages that line PTFE graft material has been described in both 
experimental and clinical AVG stenosis with co-expression of inflammatory cytokines such 
as basic fibroblast growth factor (bFGF) 61,97.  
3.2.3 Endothelial dysfunction 
An intact and functional endothelium is essential for the vein to properly respond to acute 
changes in blood flow that occurs after creation of AVFs and AVGs 98. Nitric oxide (NO) is 
an important mediator responsible for these transformations 99,100. The presence of uremia in 
hemodialysis patients has been shown to exacerbate endothelial dysfunction, possibly 
through the pathways of inflammation and oxidative stress described above 101,102. In the 
specific context of vascular access stenosis, endothelial dysfunction is likely to be 
responsible for the development of pre-existing venous neointimal hyperplasia 77-81, medial 
hypertrophy 77,81 and radial artery intima-media thickening 103-105 that is present even before 
the creation of AVFs in uremic patients. Pre-existing arterial intima-media thickness has 
been correlated with future AVF dysfunction 103. Recently, pre-existing venous neointimal 
hyperplasia has been linked to poor AVF maturation in a small clinical study 77.  
Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase and 
has been implicated as an important contributor to endothelial dysfunction in ESRD patients 
106. ADMA is not excreted in ESRD patients and its levels have been reported to be two to six 
times higher in this patient population as compared to non-uremic individuals 107. In a 
recent clinical study in AVFs, patients with elevated ADMA levels at the time of 
percutaneous transluminal angioplasty of an initial AVF stenosis had a significantly 
increased risk of a recurrent AVF stenosis 108.  
3.2.4 Alternative origins of neointimal cells 
Although the traditional paradigm for the pathogenesis of neointimal hyperplasia has 
emphasized the migration of smooth muscle cells from the media to the intima, where they 
proliferate and contribute to the final volume of neointimal hyperplasia, a number of studies 
have reported that following coronary angioplasty or saphenous vein bypass grafting there 
is also a migration of cells (fibroblasts) from the adventitia, through the media, and into the 
intima, where these cells transform into  “myofibroblasts” 109-111. In dialysis access, a number 
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of recent studies in AVGs have supported the concept of a migration of adventitial cells into 
the intima where they contribute to final neointimal volume 59,112.  In addition, recent data 
from several experimental AVF stenosis models have shown that smooth muscle cells in the 
neointima, may in part, originate from bone-marrow-derived cells that bind to the site of 
vascular injury and later differentiate into a smooth muscle cell phenotype in the neointima 
82,113,114. From a therapeutic standpoint, it is likely that better information about the true 
source of neointimal cells will allow for the development of novel therapeutic interventions 
targeting specific cell types. 
3.3 Hemodynamic and vascular remodeling in hemodialysis access dysfunction 
A number of experimental studies have shown that turbulent, low flow, low fluid sheer 
stress are involved in neointimal hyperplasia development 115-119.  High sheer stress has been 
associated with vascular dilatation through inhibition of smooth muscle cell proliferation 
and high levels of nitric oxide release, whereas low sheer stress has been associated with 
smooth muscle cell proliferation and lack of vasodilatation 120-123. Poor hemodynamic 
profiles could be a risk factor for neointimal hyperplasia development and poor venous 
dilatation, and the degree of luminal stenosis is dependent upon both the magnitude of 
neointimal hyperplasia and the capacity for vasodilatation or vasocontriction.  Therefore, a 
significant amount of neointimal hyperplasia and medial hypertrophy may not result in 
luminal stenosis in the presence of adequate vasodilatation, while a small amount of 
neointimal hyperplasia, but with poor vasodilatation, may result in severe venous stenosis 
4,124.  Unfortunately, the factors that are responsible for vascular remodeling are unknown, 
but adventitial angiogenesis and scar formation are hypothesized to play a significant 
role125,126.  Thus, the ideal therapy for vascular stenosis would be an intervention that would 
prevent vascular constriction (adverse remodeling) and neointimal hyperplasia4 
4. Central venous dialysis catheters 
CVC dysfunction and related-infection remains a common cause of morbidity, mortality, 
and high economic costs in treating chronic hemodialysis patients.  This section will provide 
a brief overview of catheter dysfunction and catheter-related infections. 
4.1 Catheter dysfunction 
Catheter dysfunction can occur immediately after placement or in a catheter which has been 
previously functioning without difficulties, and most commonly manifests with low catheter 
blood flows during dialysis or negative arterial pressures on the dialysis machine 6. In more 
severe cases catheter thrombosis is characterized by the inability to aspirate blood from the 
dialysis port 6. Catheter dysfunction which occurs immediately after placement is most 
likely due to placement problems 6.   
Installation of a thrombolytic agent for 30 to 60 minutes is a treatment for catheter 
dysfunction, followed by a second installation if necessary 6. Recently published studies 
have reported varied success rate when treating catheter dysfunction with thrombolytics, 
ranging anywhere between 60-95% 26,28,35,127,128.  When thrombolytic therapy is unsuccessful 
in providing adequate blood flow and adequate dialysis, despite repeated installations, then 
catheter exchange needs to be performed. The current K/DOQI guidelines recommends 
treatment with thrombolytic agents in all catheters with a persistently low blood flow rate 
(<300 ml/min) 19. 
 
Hemodialysis Vascular Access Dysfunction 
 
371 
The current standard of care to prevent catheter thrombosis is installation of an 
anticoagulant in both dialysis ports at the completion of each dialysis session.  In the United 
States, heparin is most commonly used, while in Europe citrate is the more common 
anticoagulant 6.  The studies to-date have shown similar efficacy when comparing citrate to 
heparin for prophylaxis of catheter thrombosis, but with fewer complications of systemic 
bleeding with citrate 129-132. A recent multicenter, randomized-controlled trial has reported 
that use of a thrombolytic, tissue plasminogen activator as a locking solution compared to 
heparin had reduced incidence of catheter dysfunction 34.  
4.2 Catheter-related bacteremia 
Currently, a precise definition for diagnosis catheter-related bacteremia is lacking.  More 
rigorous definitions require a positive blood culture obtained from the catheter and a 
peripheral vein with the quantitative colony count being at minimum four-fold higher from 
the catheter sample 133.  However, recently, the Infectious Disease Society of America has 
recognized the challenges in obtaining peripheral blood cultures from hemodialysis patients 
(e.g. priority for preserving veins and difficult cannulations) and has considered a definition 
of “possible” catheter-related bacteremia as positive blood culture obtained from the 
catheter in a symptomatic patient 134.  
The two main pathways where organisms can gain entry into the blood stream to initiate 
catheter-related bacteremia are intraluminal and extraluminal 135.  Organisms gain entrance 
through the bloodstream extraluminally through contact between the skin surface 
organisms and the external surface of the catheter at the time of catheter placement or 
following catheter placement before healing of the exit site or endothelialization of the 
subcutaneous tunnel 7. Subsequently, the organisms colonize or migrate through the 
intracutaneous exterior tract of the catheter to the tip, allowing for hematagenous dispersion 
of the organisms and leading to catheter-related bacteremia 7. Intraluminal-derived 
infections results from the transfer of organisms from hand contact with the catheter, 
leading to contamination of the internal catheter surfaces 7.  Infection from the extraluminal 
pathway most commonly occurs immediately after catheter insertion, while infections from 
the intraluminal pathway occurs throughout the life of the catheter 7. Irrespective of the 
route of bacterial entry, the bacteria will either adhere to the CVC or become incorporated 
into a fibrin sheath.  Adherence of the bacterial organisms to the CVC initiates a common 
pathway of biofilm production. A mature biofilm is a self-sustaining colony of 
microorganism, guarded by an exopolysaccharide matrix, that is stimulated and secreted by 
the organism and very difficult to eradicate 7,136-140.  
Catheter-related bacteremia can result in devastating complications such as endocarditis, 
osteomyelitis, thrombophlebitis, septic arthritis, spinal epidural abscess, and large atrial 
thrombi 30,31,141-149.  The majority of isolated organisms from catheter-related bacteremia are 
gram-positive organisms (52-84%) with Staph Aureus responsible for the majority of these 
organisms 7,30,31,143,150,151. Gram-negative are isolated in 27-36% of episodes and fungal 
isolated are relatively uncommon (<10%) 141-143,149,152. Therefore, it is important to identify 
catheter-related bacteremia early so treatment can be initiated immediately. 
4.2.1 Treatment of catheter-related bacteremia 
Initial empiric antibiotic treatment should include broad-spectrum coverage for gram-
positive and gram-negative organisms using knowledge of the common organisms and 
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of recent studies in AVGs have supported the concept of a migration of adventitial cells into 
the intima where they contribute to final neointimal volume 59,112.  In addition, recent data 
from several experimental AVF stenosis models have shown that smooth muscle cells in the 
neointima, may in part, originate from bone-marrow-derived cells that bind to the site of 
vascular injury and later differentiate into a smooth muscle cell phenotype in the neointima 
82,113,114. From a therapeutic standpoint, it is likely that better information about the true 
source of neointimal cells will allow for the development of novel therapeutic interventions 
targeting specific cell types. 
3.3 Hemodynamic and vascular remodeling in hemodialysis access dysfunction 
A number of experimental studies have shown that turbulent, low flow, low fluid sheer 
stress are involved in neointimal hyperplasia development 115-119.  High sheer stress has been 
associated with vascular dilatation through inhibition of smooth muscle cell proliferation 
and high levels of nitric oxide release, whereas low sheer stress has been associated with 
smooth muscle cell proliferation and lack of vasodilatation 120-123. Poor hemodynamic 
profiles could be a risk factor for neointimal hyperplasia development and poor venous 
dilatation, and the degree of luminal stenosis is dependent upon both the magnitude of 
neointimal hyperplasia and the capacity for vasodilatation or vasocontriction.  Therefore, a 
significant amount of neointimal hyperplasia and medial hypertrophy may not result in 
luminal stenosis in the presence of adequate vasodilatation, while a small amount of 
neointimal hyperplasia, but with poor vasodilatation, may result in severe venous stenosis 
4,124.  Unfortunately, the factors that are responsible for vascular remodeling are unknown, 
but adventitial angiogenesis and scar formation are hypothesized to play a significant 
role125,126.  Thus, the ideal therapy for vascular stenosis would be an intervention that would 
prevent vascular constriction (adverse remodeling) and neointimal hyperplasia4 
4. Central venous dialysis catheters 
CVC dysfunction and related-infection remains a common cause of morbidity, mortality, 
and high economic costs in treating chronic hemodialysis patients.  This section will provide 
a brief overview of catheter dysfunction and catheter-related infections. 
4.1 Catheter dysfunction 
Catheter dysfunction can occur immediately after placement or in a catheter which has been 
previously functioning without difficulties, and most commonly manifests with low catheter 
blood flows during dialysis or negative arterial pressures on the dialysis machine 6. In more 
severe cases catheter thrombosis is characterized by the inability to aspirate blood from the 
dialysis port 6. Catheter dysfunction which occurs immediately after placement is most 
likely due to placement problems 6.   
Installation of a thrombolytic agent for 30 to 60 minutes is a treatment for catheter 
dysfunction, followed by a second installation if necessary 6. Recently published studies 
have reported varied success rate when treating catheter dysfunction with thrombolytics, 
ranging anywhere between 60-95% 26,28,35,127,128.  When thrombolytic therapy is unsuccessful 
in providing adequate blood flow and adequate dialysis, despite repeated installations, then 
catheter exchange needs to be performed. The current K/DOQI guidelines recommends 
treatment with thrombolytic agents in all catheters with a persistently low blood flow rate 
(<300 ml/min) 19. 
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The current standard of care to prevent catheter thrombosis is installation of an 
anticoagulant in both dialysis ports at the completion of each dialysis session.  In the United 
States, heparin is most commonly used, while in Europe citrate is the more common 
anticoagulant 6.  The studies to-date have shown similar efficacy when comparing citrate to 
heparin for prophylaxis of catheter thrombosis, but with fewer complications of systemic 
bleeding with citrate 129-132. A recent multicenter, randomized-controlled trial has reported 
that use of a thrombolytic, tissue plasminogen activator as a locking solution compared to 
heparin had reduced incidence of catheter dysfunction 34.  
4.2 Catheter-related bacteremia 
Currently, a precise definition for diagnosis catheter-related bacteremia is lacking.  More 
rigorous definitions require a positive blood culture obtained from the catheter and a 
peripheral vein with the quantitative colony count being at minimum four-fold higher from 
the catheter sample 133.  However, recently, the Infectious Disease Society of America has 
recognized the challenges in obtaining peripheral blood cultures from hemodialysis patients 
(e.g. priority for preserving veins and difficult cannulations) and has considered a definition 
of “possible” catheter-related bacteremia as positive blood culture obtained from the 
catheter in a symptomatic patient 134.  
The two main pathways where organisms can gain entry into the blood stream to initiate 
catheter-related bacteremia are intraluminal and extraluminal 135.  Organisms gain entrance 
through the bloodstream extraluminally through contact between the skin surface 
organisms and the external surface of the catheter at the time of catheter placement or 
following catheter placement before healing of the exit site or endothelialization of the 
subcutaneous tunnel 7. Subsequently, the organisms colonize or migrate through the 
intracutaneous exterior tract of the catheter to the tip, allowing for hematagenous dispersion 
of the organisms and leading to catheter-related bacteremia 7. Intraluminal-derived 
infections results from the transfer of organisms from hand contact with the catheter, 
leading to contamination of the internal catheter surfaces 7.  Infection from the extraluminal 
pathway most commonly occurs immediately after catheter insertion, while infections from 
the intraluminal pathway occurs throughout the life of the catheter 7. Irrespective of the 
route of bacterial entry, the bacteria will either adhere to the CVC or become incorporated 
into a fibrin sheath.  Adherence of the bacterial organisms to the CVC initiates a common 
pathway of biofilm production. A mature biofilm is a self-sustaining colony of 
microorganism, guarded by an exopolysaccharide matrix, that is stimulated and secreted by 
the organism and very difficult to eradicate 7,136-140.  
Catheter-related bacteremia can result in devastating complications such as endocarditis, 
osteomyelitis, thrombophlebitis, septic arthritis, spinal epidural abscess, and large atrial 
thrombi 30,31,141-149.  The majority of isolated organisms from catheter-related bacteremia are 
gram-positive organisms (52-84%) with Staph Aureus responsible for the majority of these 
organisms 7,30,31,143,150,151. Gram-negative are isolated in 27-36% of episodes and fungal 
isolated are relatively uncommon (<10%) 141-143,149,152. Therefore, it is important to identify 
catheter-related bacteremia early so treatment can be initiated immediately. 
4.2.1 Treatment of catheter-related bacteremia 
Initial empiric antibiotic treatment should include broad-spectrum coverage for gram-
positive and gram-negative organisms using knowledge of the common organisms and 
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sensitivity patterns that are grown at the dialysis center.  Due to the high prevalence of 
methicillin-resistant Staph Aureus (MRSA), empiric therapy should include coverage for 
MRSA. When the specific organism and antibiotic sensitivities are identified, it is important 
to narrow the antibiotic therapy to prevent the development of drug resistant organisms.  
While the exact duration of antibiotic treatment for catheter-related bacteremia is uncertain, 
the Infectious Disease society of America recommends a 2 week course of antibiotics 153, 
while the K/DOQI guidelines recommends a 3 week course of antibiotics 19. Other 
therapies, which have been used in conjunction with systemic antibiotics, to treat catheter-
related bacteremia are antibiotic catheter locks.  A number of studies have shown that 
antibiotic locks (which may treat the biofilm layer) used in conjunction with systemic 
antibiotics, in tunneled dialysis catheters, have documented a 70% cure rate 30,145,154-156.   
Recent studies have evaluated pharmacologic therapies to prevent catheter-related 
bacteremia. Routine application of topical antibiotic ointments at the CVC exit such as 
mupirocin, povidine-iodine, and polysporin triple ointment has been associated with a 73-
93% reduction in the risk of catheter-related bacteremia 7,151,157-159.  Prophylactic antibiotic 
catheter locks have also recently been evaluated.  A marked reduction in catheter-related 
bacteremia has been reported, ranging from 51-99%, with use of a prophylactic antibiotic 
catheter locking solution 7,160-164.  However, of concern, a recent study has shown emergence 
of gentamicin-resistant organisms after 6 months when using a gentamicin-heparin 
prophylactic catheter lock 165. 
The above strategies for treatment of catheter-related bacteremia apply to patients who are 
clinically stable.  However, catheter removal, in addition to antibiotic therapy, should be the 
treatment of choice when patients: (1) are clinically unstable, (2) have persistent fever for 48 
hours, (3) have evidence of tunnel infection, or (4) develop metastatic infectious 
complications 7. 
5. Translating science to therapies in hemodialysis vascular access 
dysfunction:  from the bench to bedside 
There are currently few if any effective therapies to treat hemodialysis vascular access 
stenosis and neointimal hyperplasia. However, the knowledge obtained in recent years 
regarding the pathology and pathogenesis of vascular access access dysfunction has 
provided a framework for development of therapies that target neointimal hyperplasia and 
vascular stenosis. The purpose of the next section is to (1) describe current therapies for AVF 
and AVG stenosis and (2) novel therapies using localized delivery systems for AVF and 
AVG.  
5.1 Systemic therapies 
Systemic therapies, such as dipyridamole, angiotensin-converting enzyme inhibitors, 
aspirin, and fish oil, from small clinical trials and observational studies have been shown to 
have the potential to block smooth muscle cell proliferation and migration and to prevent 
thrombosis in AVFs and AVGs 166-170.  Most recently, two large randomized controlled trials, 
sponsored by the National Institutes of Health, evaluating anti-platelet agents in AVG and 
AVF to prevent neointimal hyperplasia were published 16,171. In the AVG study, 
dipyridamole and aspirin, modestly reduced the risk of stenosis and improved primary 
unassisted patency 171.  In the AVF study clopidogrel reduced frequency of early thrombosis 
but did not improve AVF suitability defined as cannulation with two needles, minimum 
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dialysis blood flow of 300ml/min, successful use 8/12 dialysis sessions, and use after 120 
days from creation 16.  While these two studies have shown some promising results, the 
clinical significance of these drugs used as standard treatment for hemodialysis access 
stenosis remains questionable. 
Fish oil has been shown to prevent AVG stenosis and thrombosis in one randomized, 
controlled trial 172. Currently, another study evaluating fish oil and AVG stenosis and 
thrombosis is ongoing 173. Other systemic agents, though not tested in randomized clinical 
trials, which have shown potential anti-proliferative effects targeting neointimal hyperplasia 
in CVD or PVD models, include peroxisome proliferation-activated receptor  agonist 174-176, 
sirolimus 177, and imatinib mesylate 176,178,179. 
5.2 Radiation therapy 
Radiation therapy has been hypothesized to be a potential therapy to treat vascular stenosis 
due to its antiproliferative effects and potential beneficial effects of vascular remodeling180-
183. In experimental models, both external beam and endovascular radiation therapy has 
proven effective to reduce neointimal hyperplasia in AVF and AVG 184,185. However, in 
clinical studies, a recent randomized-controlled trial of in AVGs 25 patients showed that 
42% of the radiated AVGs achieved the target lesion primary patency end point at 6 months 
as compared to 0% of the control group (p = 0.015), but this did not translate into an 
improvement in secondary patency at either 6 or 12 months 186.  
5.3 Far infrared therapy 
Infrared radiation is an invisible electromagnetic wave with a longer wavelength than that 
of visible light.  In experimental models, far infrared therapy has been shown to improve 
skin blood flow and endothelial function in cardiovascular disease 187-189.  The rationale for 
far infrared therapy to treat dialysis vascular access stenosis is that the dialysis vascular 
access in patients are located at a superficial site and improving access flow may improve 
vascular access performance.  In the lone clinical study of far infrared in dialysis access in 
AVFs, patients who received far infrared therapy had improved access flows and longer 
unassisted patencies 190. 
5.4 Local drug delivery systems for hemodialysis access 
The rationale behind local delivery of drugs treat hemodialysis vascular access stenosis is 
that (1) AVFs and AVGs could be the ideal clinical model for the use of perivascular 
therapies since these can be easily applied at the time of surgery, (2) perivascular therapies 
preferentially target the “active” adventitia, (3) studies have demonstrated that lipophilic 
molecules when placed over the adventitia rapidly diffuse through all the layers of the 
vessel wall, and (4) small amounts of otherwise toxic drugs can be safely delivered to the 
site of stenosis using the perivascular approach resulting in high local concentrations with 
minimal systemic toxicity 4. The subsequent section will discuss local therapies to treat 
hemodialysis vascular access stenosis from experimental models and clinical studies. 
5.4.1 Drug eluting paclitaxel perivascular wraps 
Experimental studies have previously demonstrated the efficacy of paclitaxel eluting wraps 
in AVG stenosis likely due to anti-proliferative effects 191-193.  In 2007, a large multi-center 
randomized-controlled study, evaluating the use of paclitaxel-eluting mesh wraps, Vascular 
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sensitivity patterns that are grown at the dialysis center.  Due to the high prevalence of 
methicillin-resistant Staph Aureus (MRSA), empiric therapy should include coverage for 
MRSA. When the specific organism and antibiotic sensitivities are identified, it is important 
to narrow the antibiotic therapy to prevent the development of drug resistant organisms.  
While the exact duration of antibiotic treatment for catheter-related bacteremia is uncertain, 
the Infectious Disease society of America recommends a 2 week course of antibiotics 153, 
while the K/DOQI guidelines recommends a 3 week course of antibiotics 19. Other 
therapies, which have been used in conjunction with systemic antibiotics, to treat catheter-
related bacteremia are antibiotic catheter locks.  A number of studies have shown that 
antibiotic locks (which may treat the biofilm layer) used in conjunction with systemic 
antibiotics, in tunneled dialysis catheters, have documented a 70% cure rate 30,145,154-156.   
Recent studies have evaluated pharmacologic therapies to prevent catheter-related 
bacteremia. Routine application of topical antibiotic ointments at the CVC exit such as 
mupirocin, povidine-iodine, and polysporin triple ointment has been associated with a 73-
93% reduction in the risk of catheter-related bacteremia 7,151,157-159.  Prophylactic antibiotic 
catheter locks have also recently been evaluated.  A marked reduction in catheter-related 
bacteremia has been reported, ranging from 51-99%, with use of a prophylactic antibiotic 
catheter locking solution 7,160-164.  However, of concern, a recent study has shown emergence 
of gentamicin-resistant organisms after 6 months when using a gentamicin-heparin 
prophylactic catheter lock 165. 
The above strategies for treatment of catheter-related bacteremia apply to patients who are 
clinically stable.  However, catheter removal, in addition to antibiotic therapy, should be the 
treatment of choice when patients: (1) are clinically unstable, (2) have persistent fever for 48 
hours, (3) have evidence of tunnel infection, or (4) develop metastatic infectious 
complications 7. 
5. Translating science to therapies in hemodialysis vascular access 
dysfunction:  from the bench to bedside 
There are currently few if any effective therapies to treat hemodialysis vascular access 
stenosis and neointimal hyperplasia. However, the knowledge obtained in recent years 
regarding the pathology and pathogenesis of vascular access access dysfunction has 
provided a framework for development of therapies that target neointimal hyperplasia and 
vascular stenosis. The purpose of the next section is to (1) describe current therapies for AVF 
and AVG stenosis and (2) novel therapies using localized delivery systems for AVF and 
AVG.  
5.1 Systemic therapies 
Systemic therapies, such as dipyridamole, angiotensin-converting enzyme inhibitors, 
aspirin, and fish oil, from small clinical trials and observational studies have been shown to 
have the potential to block smooth muscle cell proliferation and migration and to prevent 
thrombosis in AVFs and AVGs 166-170.  Most recently, two large randomized controlled trials, 
sponsored by the National Institutes of Health, evaluating anti-platelet agents in AVG and 
AVF to prevent neointimal hyperplasia were published 16,171. In the AVG study, 
dipyridamole and aspirin, modestly reduced the risk of stenosis and improved primary 
unassisted patency 171.  In the AVF study clopidogrel reduced frequency of early thrombosis 
but did not improve AVF suitability defined as cannulation with two needles, minimum 
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dialysis blood flow of 300ml/min, successful use 8/12 dialysis sessions, and use after 120 
days from creation 16.  While these two studies have shown some promising results, the 
clinical significance of these drugs used as standard treatment for hemodialysis access 
stenosis remains questionable. 
Fish oil has been shown to prevent AVG stenosis and thrombosis in one randomized, 
controlled trial 172. Currently, another study evaluating fish oil and AVG stenosis and 
thrombosis is ongoing 173. Other systemic agents, though not tested in randomized clinical 
trials, which have shown potential anti-proliferative effects targeting neointimal hyperplasia 
in CVD or PVD models, include peroxisome proliferation-activated receptor  agonist 174-176, 
sirolimus 177, and imatinib mesylate 176,178,179. 
5.2 Radiation therapy 
Radiation therapy has been hypothesized to be a potential therapy to treat vascular stenosis 
due to its antiproliferative effects and potential beneficial effects of vascular remodeling180-
183. In experimental models, both external beam and endovascular radiation therapy has 
proven effective to reduce neointimal hyperplasia in AVF and AVG 184,185. However, in 
clinical studies, a recent randomized-controlled trial of in AVGs 25 patients showed that 
42% of the radiated AVGs achieved the target lesion primary patency end point at 6 months 
as compared to 0% of the control group (p = 0.015), but this did not translate into an 
improvement in secondary patency at either 6 or 12 months 186.  
5.3 Far infrared therapy 
Infrared radiation is an invisible electromagnetic wave with a longer wavelength than that 
of visible light.  In experimental models, far infrared therapy has been shown to improve 
skin blood flow and endothelial function in cardiovascular disease 187-189.  The rationale for 
far infrared therapy to treat dialysis vascular access stenosis is that the dialysis vascular 
access in patients are located at a superficial site and improving access flow may improve 
vascular access performance.  In the lone clinical study of far infrared in dialysis access in 
AVFs, patients who received far infrared therapy had improved access flows and longer 
unassisted patencies 190. 
5.4 Local drug delivery systems for hemodialysis access 
The rationale behind local delivery of drugs treat hemodialysis vascular access stenosis is 
that (1) AVFs and AVGs could be the ideal clinical model for the use of perivascular 
therapies since these can be easily applied at the time of surgery, (2) perivascular therapies 
preferentially target the “active” adventitia, (3) studies have demonstrated that lipophilic 
molecules when placed over the adventitia rapidly diffuse through all the layers of the 
vessel wall, and (4) small amounts of otherwise toxic drugs can be safely delivered to the 
site of stenosis using the perivascular approach resulting in high local concentrations with 
minimal systemic toxicity 4. The subsequent section will discuss local therapies to treat 
hemodialysis vascular access stenosis from experimental models and clinical studies. 
5.4.1 Drug eluting paclitaxel perivascular wraps 
Experimental studies have previously demonstrated the efficacy of paclitaxel eluting wraps 
in AVG stenosis likely due to anti-proliferative effects 191-193.  In 2007, a large multi-center 
randomized-controlled study, evaluating the use of paclitaxel-eluting mesh wraps, Vascular 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
374 
WrapTM, (Angiotech Pharmaceuticals, Inc.; Vancouver, British Columbia, Canada), was 
initiated to study the effectiveness and safety of this therapy on primary AVG patency 
compared to a standard AVG. However, this study was recently suspended in 2009 
following a data safety monitoring review, due to an imbalance in the incidence of infections 
in one of the arms (either control or treatment). An alternative approach is the use of 
sirolimus eluting COLL-R® wraps (Covalon Technologies Ltd: Mississauga, Ontario, 
Canada). An initial Phase II study demonstrated primary unassisted AVG patency of 75% 
and 38% at 1 and 2 years respectively with these wraps 194. 
5.4.2 Endothelial cell loaded gel foam wraps 
The rationale behind the use of these wraps is that the endothelial cell (in addition to lining 
blood vessels) is also a “bioreactor” which produces a large number of beneficial mediators 
that reduces thrombosis, inflammation, stenosis, and increases lumen diameter.  Initial 
experimental studies have documented a beneficial effect of endothelial cell loaded gel-foam 
wraps in porcine models of AV fistula and graft stenosis 195-198. A recent Phase II study (“V-
HEALTH”) was able to demonstrate technical feasibility and safety in hemodialysis patients 
who received a “Vascugel®” wrap loaded with treated human aortic endothelial cells at the 
time of AVF or AVG placement 97. A phase III multi-center randomized-controlled study 
using the Vascugel® (Pervasis Therapeutics, Inc., Cambridge, MA) wraps in human AVGs is 
currently being designed.   
5.4.3 Vascular Endothelial Growth Factor D (VEGF-D) gene therapy  
In animal models of angioplasty induced restenosis, the delivery of adenoviral particles 
encoding for vascular-endothelial growth factor C to the site of vascular injury has been 
shown to trigger the release of nitric oxide and prostacyclin and reduce neointimal 
hyperplasia 199. Preliminary studies on the use of VEGF-D gene therapy (using a packaged 
adenoviral vector and a biodegradable local delivery device (collar) made of collagen 
wrapped at the venous anastomosis at the time of surgery), “Trinam®” (Ark Therapeutics; 
London, UK), in patients receiving AVGs, have been able to document technical feasibility 
and safety.  A phase III study using this technology was initiated in 2009 but terminated in 
2010 due to poor enrollment. 
5.4.4 Recombinant elastase PRT-201  
PRT-201 (Proteon Therapeutics; Waltham, MA) is a recombinant pancreatic elastase 
topically applied at the outflow vein at the time of surgery access creation which has been 
shown to result in both arterial and venous dilation and an increase in AVF blood flow in 
experimental models 200.  The clinical benefit of this approach is the potential ability to 
enhance AVF maturation (through rapid vascular dilation) and prevent venous stenosis in 
AVGs.  A phase II study using this novel technology is ongoing in the United States 
evaluating this therapy and whether or not it improves primary patency and cumulative 
survival in AVG and AVF, as well as safety.  
5.5 Endovascular stent therapy 
Endovascular vascular therapies (angioplasty or angioplasty with stent placement) remains 
the only true intervention available to treat vascular stenosis.  The main advantage of stent 
therapy after angioplasty is a reduction in adverse remodeling.  In dialysis access, placement 
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of bare metal stents after angioplasty compared to angioplasty 201 alone has been shown to 
improve primary patency 202,203.  However, bare-metal stents have yielded poor results due 
to aggressive development of in-stent restenosis.  In experimental models of dialysis access 
in AVGs, drug-eluting stents have shown to reduce neointimal hyperplasia and improve 
luminal stenosis compared to bare-metal stents 204. However, there are no clinical studies 
evaluating drug-eluting stents in dialysis access to date. 
Stent grafts (covered stents constructed from the same material of AVGs) have received 
recent attention as a therapy for prevention of restenosis due to its ability to prevent elastic 
recoil and inability of the neointimal cells to penetrate the covered barrier. A recently 
published multicenter, randomized controlled, clinical trial showed stent grafts (Bard 
Peripheral Vascular, Tempe, AZ), placed after angioplasty, to treat venous stenosis had 
better primary unassisted patency compared to angioplasty alone 205. This is the only 
treatment to date that has shown to be effective to treat vascular access stenosis in a large, 
randomized, clinical trial. 
5.6 Improving hemodynamics  
Hemodynamic sheer stresses play a significant role in development of neointimal 
hyperplasia 87,112,206,207. Therefore, altering the sheer stress pattern to prevent turbulent, low-
flow, and low-sheer stresses could reduce the development of neointimal hyperplasia.  
Previous clinical data to date to support such an intervention comes from several studies 
evaluating cuffed AVG grafts (“Venaflo”; Bard Vascular, Tempe Arizona) 208-210. In a recent 
randomized control trial evaluating cuffed vs non-cuffed AVG, cuffed AVGs showed better 
primary patency and cumulative survival 211. Finally, results from a newly developed 
anastomotic implant device, “OptiflowTM” (Bioconnect Systems; Ambler, PA), to connect 
the artery and vein in AVFs and improve hemodynamics by providing a symmetric flow 
pattern, have shown a primary patency of 83% at 90 days 212. This primary patency rate was 
higher compared to other similarly published studies 213. 
6. Future perspectives: new frontiers in research 
In the last decade our knowledge of vascular access dysfunction has significantly evolved.  We 
now understand that the most common pathologic lesion seen in AVF and AVG dysfunction is 
aggressive venous neointimal hyperplasia, and biofilms and fibrin sheaths play a major role in 
CVC infection and dysfunction.  In order to advance the field further, we need to further our 
current understanding of both the clinical and experimental pathways that result in venous 
neointimal hyperplasia and mechanisms that lead to biofilm and fibrin sheath production in 
CVCs by using the advanced technologies and tools in cellular and molecular biology, 
bioengineering, genomics, proteomics, and vascular imaging (ultrasound, computed 
tomography, and magnetic resonance imaging) 65,124,214. Finally, small and large animal models 
of AVF and AVG, which a number of investigators in this field have already developed 
61,93,207,215-217, will play an essential role in “translating” our knowledge of pathophysiologic 
mechanisms in vascular access dysfunction to novel therapies for patients. 
7. Conclusion 
The magnitude and costs of dialysis access dysfunction is clearly evident, and will only 
become magnified in the coming years as the prevalent dialysis population continues to 
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WrapTM, (Angiotech Pharmaceuticals, Inc.; Vancouver, British Columbia, Canada), was 
initiated to study the effectiveness and safety of this therapy on primary AVG patency 
compared to a standard AVG. However, this study was recently suspended in 2009 
following a data safety monitoring review, due to an imbalance in the incidence of infections 
in one of the arms (either control or treatment). An alternative approach is the use of 
sirolimus eluting COLL-R® wraps (Covalon Technologies Ltd: Mississauga, Ontario, 
Canada). An initial Phase II study demonstrated primary unassisted AVG patency of 75% 
and 38% at 1 and 2 years respectively with these wraps 194. 
5.4.2 Endothelial cell loaded gel foam wraps 
The rationale behind the use of these wraps is that the endothelial cell (in addition to lining 
blood vessels) is also a “bioreactor” which produces a large number of beneficial mediators 
that reduces thrombosis, inflammation, stenosis, and increases lumen diameter.  Initial 
experimental studies have documented a beneficial effect of endothelial cell loaded gel-foam 
wraps in porcine models of AV fistula and graft stenosis 195-198. A recent Phase II study (“V-
HEALTH”) was able to demonstrate technical feasibility and safety in hemodialysis patients 
who received a “Vascugel®” wrap loaded with treated human aortic endothelial cells at the 
time of AVF or AVG placement 97. A phase III multi-center randomized-controlled study 
using the Vascugel® (Pervasis Therapeutics, Inc., Cambridge, MA) wraps in human AVGs is 
currently being designed.   
5.4.3 Vascular Endothelial Growth Factor D (VEGF-D) gene therapy  
In animal models of angioplasty induced restenosis, the delivery of adenoviral particles 
encoding for vascular-endothelial growth factor C to the site of vascular injury has been 
shown to trigger the release of nitric oxide and prostacyclin and reduce neointimal 
hyperplasia 199. Preliminary studies on the use of VEGF-D gene therapy (using a packaged 
adenoviral vector and a biodegradable local delivery device (collar) made of collagen 
wrapped at the venous anastomosis at the time of surgery), “Trinam®” (Ark Therapeutics; 
London, UK), in patients receiving AVGs, have been able to document technical feasibility 
and safety.  A phase III study using this technology was initiated in 2009 but terminated in 
2010 due to poor enrollment. 
5.4.4 Recombinant elastase PRT-201  
PRT-201 (Proteon Therapeutics; Waltham, MA) is a recombinant pancreatic elastase 
topically applied at the outflow vein at the time of surgery access creation which has been 
shown to result in both arterial and venous dilation and an increase in AVF blood flow in 
experimental models 200.  The clinical benefit of this approach is the potential ability to 
enhance AVF maturation (through rapid vascular dilation) and prevent venous stenosis in 
AVGs.  A phase II study using this novel technology is ongoing in the United States 
evaluating this therapy and whether or not it improves primary patency and cumulative 
survival in AVG and AVF, as well as safety.  
5.5 Endovascular stent therapy 
Endovascular vascular therapies (angioplasty or angioplasty with stent placement) remains 
the only true intervention available to treat vascular stenosis.  The main advantage of stent 
therapy after angioplasty is a reduction in adverse remodeling.  In dialysis access, placement 
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of bare metal stents after angioplasty compared to angioplasty 201 alone has been shown to 
improve primary patency 202,203.  However, bare-metal stents have yielded poor results due 
to aggressive development of in-stent restenosis.  In experimental models of dialysis access 
in AVGs, drug-eluting stents have shown to reduce neointimal hyperplasia and improve 
luminal stenosis compared to bare-metal stents 204. However, there are no clinical studies 
evaluating drug-eluting stents in dialysis access to date. 
Stent grafts (covered stents constructed from the same material of AVGs) have received 
recent attention as a therapy for prevention of restenosis due to its ability to prevent elastic 
recoil and inability of the neointimal cells to penetrate the covered barrier. A recently 
published multicenter, randomized controlled, clinical trial showed stent grafts (Bard 
Peripheral Vascular, Tempe, AZ), placed after angioplasty, to treat venous stenosis had 
better primary unassisted patency compared to angioplasty alone 205. This is the only 
treatment to date that has shown to be effective to treat vascular access stenosis in a large, 
randomized, clinical trial. 
5.6 Improving hemodynamics  
Hemodynamic sheer stresses play a significant role in development of neointimal 
hyperplasia 87,112,206,207. Therefore, altering the sheer stress pattern to prevent turbulent, low-
flow, and low-sheer stresses could reduce the development of neointimal hyperplasia.  
Previous clinical data to date to support such an intervention comes from several studies 
evaluating cuffed AVG grafts (“Venaflo”; Bard Vascular, Tempe Arizona) 208-210. In a recent 
randomized control trial evaluating cuffed vs non-cuffed AVG, cuffed AVGs showed better 
primary patency and cumulative survival 211. Finally, results from a newly developed 
anastomotic implant device, “OptiflowTM” (Bioconnect Systems; Ambler, PA), to connect 
the artery and vein in AVFs and improve hemodynamics by providing a symmetric flow 
pattern, have shown a primary patency of 83% at 90 days 212. This primary patency rate was 
higher compared to other similarly published studies 213. 
6. Future perspectives: new frontiers in research 
In the last decade our knowledge of vascular access dysfunction has significantly evolved.  We 
now understand that the most common pathologic lesion seen in AVF and AVG dysfunction is 
aggressive venous neointimal hyperplasia, and biofilms and fibrin sheaths play a major role in 
CVC infection and dysfunction.  In order to advance the field further, we need to further our 
current understanding of both the clinical and experimental pathways that result in venous 
neointimal hyperplasia and mechanisms that lead to biofilm and fibrin sheath production in 
CVCs by using the advanced technologies and tools in cellular and molecular biology, 
bioengineering, genomics, proteomics, and vascular imaging (ultrasound, computed 
tomography, and magnetic resonance imaging) 65,124,214. Finally, small and large animal models 
of AVF and AVG, which a number of investigators in this field have already developed 
61,93,207,215-217, will play an essential role in “translating” our knowledge of pathophysiologic 
mechanisms in vascular access dysfunction to novel therapies for patients. 
7. Conclusion 
The magnitude and costs of dialysis access dysfunction is clearly evident, and will only 
become magnified in the coming years as the prevalent dialysis population continues to 
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increase.  Only by launching a “translational” research initiative (“from animal to human”) 
can recent advances in the understanding of the mechanisms of neointimal hyperplasia 
formation and vascular stenosis and catheter dysfunction be translated to the development 
of novel effective therapies for patients.  
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increase.  Only by launching a “translational” research initiative (“from animal to human”) 
can recent advances in the understanding of the mechanisms of neointimal hyperplasia 
formation and vascular stenosis and catheter dysfunction be translated to the development 
of novel effective therapies for patients.  
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1. Introduction 
The distinction between antibiotic and non antibiotic medications is in fact quite arbitrary as 
drugs against bacteria can have unpredictable side effects in man and drugs developed for 
use in humans can affect microbes. It would be extremely surprising if it was otherwise, as 
eukaryotes and prokaryotes are related by evolution and share conserved molecular 
mechanisms. Many antibiotic and non antibiotic medications have closely related 
chemistries and share the same historic roots.  
For example, both antimicrobial activity and an affinity for brain tissue of the phenothiazine 
compound methylene blue were described by Paul Ehrlich in the 19th century. Early uses of 
phenothiazines included treatment of urinary tract infection and postoperative analgesia. As 
a positive effect on psychotic patients was discovered, phenothiazines became with the 
development of chlorpromazine an important tool in psychiatry (Williams, 1995). With the 
discovery of penicillin the antimicrobial activities of phenothiazines and other earlier 
compounds fell into the background, but with the emergent problem of antibiotic resistance 
in more recent years there was new interest. Phenothiazines have activity against multidrug 
resistant Staphylococcus aureus and Enterococcus faecalis, presumably through the inhibition of 
bacterial efflux pumps (Kristiansen J.E. et al., 2007).   
As a routine, antibiotic medications are tested for their effects on the eukaryotic host as these 
constitute potential side effects. While the ideal antibiotic would have no side effects at all, 
the discovery of unexpected side effects has lead to important drug developments. For 
instance, the clinical observation of a hypoglycemic effect of sulfonamide antibiotics led to 
the development of sulfonylureas for the treatment of diabetes. Likewise the observation 
that Sulfanilamide causes hens to lay eggs without shells because of alkaline diuresis led to 
the development of acetazolamide and ultimately the thiazide diuretics. The initial 
observation derived from the similarity between the sulfonamide ion and the bicarbonate 
ion. The antiviral amantadine was found to be useful in the treatment of Parkinson’s disease 
and motility agents to treat gastroparesis are derived from the observation of the 
bothersome gastrointestinal side effects of erythromycin. As described below, even Lipitor, 
the “best selling drug in the world” with $11 Billion of annual sales according to Forbes 
magazine, was developed from a compound initially discovered as an antibiotic originating 
from a fungal broth. 
On the other hand side, the efforts to look into the unintended effects on microbes of non 
antibiotic medications have been less systematic.  Non antibiotic medications can affect 
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microbes in various ways: Compounds may have direct anti microbial effects in vitro, 
similar to traditional antibiotics. However, to be clinically useful the drug level to achieve 
minimum inhibitory concentration has to be within a range that is achievable and tolerable 
in humans.  Compounds can exert an antimicrobial effect by inhibition of bacterial pumps. 
A well known example is the potentiation of antibiotic treatment against Helicobacter pylori 
through omeprazole. Many psychotropic medications including the phenothiazines fall into 
this category. Aspirin appears to modulate the expression of genes that are important for 
Staphylococcal virulence and the statins appear to have immune modulatory effects. Both 
medications are discussed in more detail below. 
This chapter deals with the anti microbial effects of medications that are not traditionally 
regarded as antibiotics with regards to dialysis. 
2. A combination of unfortunate events: infection in dialysis 
The current epidemic of obesity and, as a complication, diabetic nephropathy associated to 
type 2 diabetes mellitus has fueled the spectacular growth of hemodialysis into an industry 
that is dominated by a handful of large companies. Infection is a leading cause of morbidity 
and mortality in dialysis patients and the annual mortality rate caused by sepsis is several 
hundred folds higher in patients with end stage renal disease than in the general population 
(Laupland et al., 2004). The incidence of bacteremia has increased in hemodialysis patients 
over the years, mainly because of increased rates of serious Staphylococcus aureus infection in 
this population (Foley at al., 2004). S. aureus has its name from a gold coloured caroten 
virulence factor called staphyloxanthin which allows the bacteria to survive oxidative bursts 
of neutrophils (Liu G.Y. & Nizet V., 2009).  S.aureus produces a battery of surface proteins, 
enzymes and toxins which enable the bacteria to both persist in intracellular locations and in 
biofilms for long periods of time, and to rapidly disseminate in the host in an opportunistic 
fashion which makes it one of the most dangerous and pathogenic bacteria in humans. 
The use of dialysis catheters is a major risk factor for developing S.aureus infection because 
of disruption of the normal skin barrier, thus forming a gateway for bacterial entry into the 
blood stream (Vandecasteele S.J. et al., 2009). Despite Kidney Disease Outcomes Quality 
Initiative clinical practice guidelines recommending the use of auto logos arterio-venous 
fistulae as dialysis access and other efforts, the overall prevalence of hemodialysis catheter 
use has been increasing, approaching 30% in the United States (Rayner et al., 2004). Humans 
are the main natural reservoir for S.aureus which can colonize skin, gastrointestinal and 
urogenital tracts. The most frequent site of colonization is the anterior nose and longitudinal 
studies have shown that there are three types of S.aureus nasal carriage in healthy adults: 
fifty percent are persistent non carriers, thirty percent are intermittent carriers and twenty 
percent are persistent carriers (VandenBergh et al., 1999). Hands are the main vector of 
transmission and in the majority of cases the same strain that is found in the bloodstream is 
also found on the hands and in the nose (von Eiff C. et al., 2001). It follows that rigorous 
hand washing is extremely important to prevent infection in the dialysis units as it is 
elsewhere in the medical setting. The majority of S.aureus infections has its source in the 
endogenous reservoir in the nose of the same person and can thus be considered an 
“autoinfection” (Boelart et al., 1995 as quoted in Vandecasteele et al., 2009). Consistent with 
this view is that in prospective studies the interval between catheter placement and 
staphylococcemia can be very short, with 23% of episodes occurring less than one week after 
catheter insertion (Little M.A. et al., 2001). S.aureus bacteremia is associated frequently with 
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metastatic infection such as endocarditis, osteoarticular infection, septic pulmonary 
embolism and epidural abscess and carries a mortality that is higher than with other 
pathogens. While the original observation by Fleming that led to the discovery of penicillin 
involved the accidental overgrowth of an S.aureus culture with fungus, staphylococcal 
resistance to penicillin has since become very frequent both in community and hospital 
acquired infections. A recent study in the US found that methicillin resistant S.aureus 
accounted for 65% of isolates from the nose in hospitalized dialysis patients (Johnson L.B. et 
al., 2009). As with methicillin sensive S.aureus, colonization seems to precede clinical 
infection. A scheme of three times a week nasal mupirocin ointment can decrease nasal 
carriage but is cumbersome, the rate of recurrence is high and rapid development of 
resistance has been observed (Vandecasteele et al., 2009). 
3. Salicylic acid 
Salicylic acid, the active ingredient of willow bark, is one of the oldest medicines still in use, 
in the buffered form of aspirin. The beneficial effect on fever, pain and inflammation were 
already described by Hippocrates. Fallen out of favour because of other non steroidal anti 
inflammatory drugs with more favorable side effects profiles aspirin has made a spectacular 
come back fifty years ago as the antiplatelet effects of aspirin were discovered. Since then 
aspirin has found widespread therapeutic use in the treatment of cardiovascular disease. 
Chronic treatment with Aspirin may prevent colorectal cancer, presumably by inhibition of 
cyclooxygenase 2 (COX-2) which is expressed in large amounts in adenocarcinoma (Ruder 
E.H. et al., 2011). Salicylic acid is ubiquitous in plants as a phytohormone. It is part of the 
innate immune system of plants, involved in local resistance to pathogens and in systemic 
acquired resistance (SAR), where a pathogenic attack one part of a plant induces resistance 
in other parts. Depending on the amount of fruit and vegetables in the diet humans have 
detectable serum levels of salicylic acid. It has been hypothesized that diet derived salicylic 
acid could in part account for the observed link between diet and colorectal cancer (Paterson 
J.R.& Lawrence J.R., 2001) and this might possibly apply to the relation between diet and 
cardiovascular disease as well. Salicylic acid is used as a food preservative and an antiseptic 
in toothpaste. Aspirin is thus not only one of the oldest but also one of the most versatile 
and successful drugs known.  
3.1 Laboratory evidence for an anti staphylococcal effect of salicylic acid 
Early studies in the rabbit endocarditis model showed that platelets provide a nidus for 
bacteria and that aspirin can decrease vegetation size (Pujadas et al., 1988). The observation 
was made that aspirin can reduce not only the weight of vegetations in a rabbit model of 
S.aureus endocarditis but also bacterial density although neither aspirin nor salicylic acid 
have known antibacterial effects at the low concentrations employed (Nicolau D.P. et al., 
1993). This benefit was seen if aspirin was given together with antibiotics but also if aspirin 
was provided prior to the infectious challenge with which endocarditis was induced 
(Nicolau D.P. et al., 1995). Even more puzzling in this study was that vegetation weight and 
bacterial density were higher if higher doses of aspirin were administered while the 
optimum beneficial effect was seen at a lower dose, suggesting that serum levels may be 
very important. Subsequently this observation has been called the “Goldilocks effect” in 
which too little and too much aspirin may cause paradoxically diminished effects on 
outcome parameters in the infectious endocarditis model (Eisen et al., 2008). The beneficial 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
390 
microbes in various ways: Compounds may have direct anti microbial effects in vitro, 
similar to traditional antibiotics. However, to be clinically useful the drug level to achieve 
minimum inhibitory concentration has to be within a range that is achievable and tolerable 
in humans.  Compounds can exert an antimicrobial effect by inhibition of bacterial pumps. 
A well known example is the potentiation of antibiotic treatment against Helicobacter pylori 
through omeprazole. Many psychotropic medications including the phenothiazines fall into 
this category. Aspirin appears to modulate the expression of genes that are important for 
Staphylococcal virulence and the statins appear to have immune modulatory effects. Both 
medications are discussed in more detail below. 
This chapter deals with the anti microbial effects of medications that are not traditionally 
regarded as antibiotics with regards to dialysis. 
2. A combination of unfortunate events: infection in dialysis 
The current epidemic of obesity and, as a complication, diabetic nephropathy associated to 
type 2 diabetes mellitus has fueled the spectacular growth of hemodialysis into an industry 
that is dominated by a handful of large companies. Infection is a leading cause of morbidity 
and mortality in dialysis patients and the annual mortality rate caused by sepsis is several 
hundred folds higher in patients with end stage renal disease than in the general population 
(Laupland et al., 2004). The incidence of bacteremia has increased in hemodialysis patients 
over the years, mainly because of increased rates of serious Staphylococcus aureus infection in 
this population (Foley at al., 2004). S. aureus has its name from a gold coloured caroten 
virulence factor called staphyloxanthin which allows the bacteria to survive oxidative bursts 
of neutrophils (Liu G.Y. & Nizet V., 2009).  S.aureus produces a battery of surface proteins, 
enzymes and toxins which enable the bacteria to both persist in intracellular locations and in 
biofilms for long periods of time, and to rapidly disseminate in the host in an opportunistic 
fashion which makes it one of the most dangerous and pathogenic bacteria in humans. 
The use of dialysis catheters is a major risk factor for developing S.aureus infection because 
of disruption of the normal skin barrier, thus forming a gateway for bacterial entry into the 
blood stream (Vandecasteele S.J. et al., 2009). Despite Kidney Disease Outcomes Quality 
Initiative clinical practice guidelines recommending the use of auto logos arterio-venous 
fistulae as dialysis access and other efforts, the overall prevalence of hemodialysis catheter 
use has been increasing, approaching 30% in the United States (Rayner et al., 2004). Humans 
are the main natural reservoir for S.aureus which can colonize skin, gastrointestinal and 
urogenital tracts. The most frequent site of colonization is the anterior nose and longitudinal 
studies have shown that there are three types of S.aureus nasal carriage in healthy adults: 
fifty percent are persistent non carriers, thirty percent are intermittent carriers and twenty 
percent are persistent carriers (VandenBergh et al., 1999). Hands are the main vector of 
transmission and in the majority of cases the same strain that is found in the bloodstream is 
also found on the hands and in the nose (von Eiff C. et al., 2001). It follows that rigorous 
hand washing is extremely important to prevent infection in the dialysis units as it is 
elsewhere in the medical setting. The majority of S.aureus infections has its source in the 
endogenous reservoir in the nose of the same person and can thus be considered an 
“autoinfection” (Boelart et al., 1995 as quoted in Vandecasteele et al., 2009). Consistent with 
this view is that in prospective studies the interval between catheter placement and 
staphylococcemia can be very short, with 23% of episodes occurring less than one week after 
catheter insertion (Little M.A. et al., 2001). S.aureus bacteremia is associated frequently with 
 
Nontraditional Anti - Infectious Agents in Hemodialysis 
 
391 
metastatic infection such as endocarditis, osteoarticular infection, septic pulmonary 
embolism and epidural abscess and carries a mortality that is higher than with other 
pathogens. While the original observation by Fleming that led to the discovery of penicillin 
involved the accidental overgrowth of an S.aureus culture with fungus, staphylococcal 
resistance to penicillin has since become very frequent both in community and hospital 
acquired infections. A recent study in the US found that methicillin resistant S.aureus 
accounted for 65% of isolates from the nose in hospitalized dialysis patients (Johnson L.B. et 
al., 2009). As with methicillin sensive S.aureus, colonization seems to precede clinical 
infection. A scheme of three times a week nasal mupirocin ointment can decrease nasal 
carriage but is cumbersome, the rate of recurrence is high and rapid development of 
resistance has been observed (Vandecasteele et al., 2009). 
3. Salicylic acid 
Salicylic acid, the active ingredient of willow bark, is one of the oldest medicines still in use, 
in the buffered form of aspirin. The beneficial effect on fever, pain and inflammation were 
already described by Hippocrates. Fallen out of favour because of other non steroidal anti 
inflammatory drugs with more favorable side effects profiles aspirin has made a spectacular 
come back fifty years ago as the antiplatelet effects of aspirin were discovered. Since then 
aspirin has found widespread therapeutic use in the treatment of cardiovascular disease. 
Chronic treatment with Aspirin may prevent colorectal cancer, presumably by inhibition of 
cyclooxygenase 2 (COX-2) which is expressed in large amounts in adenocarcinoma (Ruder 
E.H. et al., 2011). Salicylic acid is ubiquitous in plants as a phytohormone. It is part of the 
innate immune system of plants, involved in local resistance to pathogens and in systemic 
acquired resistance (SAR), where a pathogenic attack one part of a plant induces resistance 
in other parts. Depending on the amount of fruit and vegetables in the diet humans have 
detectable serum levels of salicylic acid. It has been hypothesized that diet derived salicylic 
acid could in part account for the observed link between diet and colorectal cancer (Paterson 
J.R.& Lawrence J.R., 2001) and this might possibly apply to the relation between diet and 
cardiovascular disease as well. Salicylic acid is used as a food preservative and an antiseptic 
in toothpaste. Aspirin is thus not only one of the oldest but also one of the most versatile 
and successful drugs known.  
3.1 Laboratory evidence for an anti staphylococcal effect of salicylic acid 
Early studies in the rabbit endocarditis model showed that platelets provide a nidus for 
bacteria and that aspirin can decrease vegetation size (Pujadas et al., 1988). The observation 
was made that aspirin can reduce not only the weight of vegetations in a rabbit model of 
S.aureus endocarditis but also bacterial density although neither aspirin nor salicylic acid 
have known antibacterial effects at the low concentrations employed (Nicolau D.P. et al., 
1993). This benefit was seen if aspirin was given together with antibiotics but also if aspirin 
was provided prior to the infectious challenge with which endocarditis was induced 
(Nicolau D.P. et al., 1995). Even more puzzling in this study was that vegetation weight and 
bacterial density were higher if higher doses of aspirin were administered while the 
optimum beneficial effect was seen at a lower dose, suggesting that serum levels may be 
very important. Subsequently this observation has been called the “Goldilocks effect” in 
which too little and too much aspirin may cause paradoxically diminished effects on 
outcome parameters in the infectious endocarditis model (Eisen et al., 2008). The beneficial 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
392 
effects of aspirin in the rabbit model of endocarditis have been recapitulated with salicylic 
acid, its major biometabolite (Kupferwasser et al., 1999). As salicylic acid has no anti-platelet 
properties, this indicates that platelet independent mechanisms are likely to have a more 
significant role in the action of aspirin on S.aureus endocarditis that the platelet dependant 
effects. Further experimental work in vivo in animal models of infectious S.aureus 
endocarditis showed that aspirin reduced a multitude of measurable parameters of the 
severity of the infection and metastasis such as vegetation weight and the bacterial density 
in vegetations and the number of renal emboli and these effects were dose dependant, more 
pronounced at lower rather than higher doses (Kupferwasser et al., 1999). In vitro studies 
showed that salicylic acid inhibits the expression of two key virulence genes in S. aureus that 
are involved in endovascular pathogenesis: alpha-toxin [hla] and fibronectin-binding 
adhesion [fnbA], through activation of genetic pathways involving the major stress response 
operon, sigma factor B (Kupferwasser et al., 2003). These aspirin mediated effects on sigma 
factor B were observed at serum concentrations that are achieved by usual clinical dosages 
of aspirin in humans (Kupferwasser et al., 2003). On the other hand side, it has been shown 
that the presence of salicylic acid decreases expression of capsular polysaccharides. It has 
been hypothesized that the loss of these capsular virulence factors could lead to an increased 
capacity of S.aureus to invade epithelial cells and that chronic treatment with aspirin could 
potentially lead to more persistent or recurrent infection (Alvarez C.P. et al., 2010). 
In conclusion a significant body of in vitro and in vivo evidence indicates that aspirin may 
have the potential to be useful in the treatment of S.aureus infection by down modulating 
key regulator and structural genes resulting in the abrogation of virulent phenotypes but it 
has to be noted that important questions remain. 
3.2 Clinical evidence for a beneficial effect of aspirin in S.aureus endocarditis 
The earliest clinical observations of a potential salutatory role of aspirin come from the 
study of bacterial endocarditis. In a small retrospective study a decreased rate of embolic 
events was found in patients with native valve endocarditis who were on long term aspirin 
treatment (11% versus 47%), although the number of patients treated with aspirin was too 
small to be conclusive (Schunemann S. et al., 1997). A small preliminary prospective 
observational study conducted in 9 patients found adjunctive treatment of established 
endocarditis with aspirin beneficial (Taha et al., 1992). 
Subsequently, a Canadian prospective multicenter study in 115 patients with endocarditis 
showed no benefit of the adjunctive treatment with a 325mg dose of aspirin (Chan et al., 
2003). Despite its prospective design this study was criticized as patients on chronic aspirin 
treatment were excluded from this study although the greatest benefit might be expected in 
this population. Moreover, Aspirin was added only after an average of 35 days after onset of 
symptoms. Only 14 patients (25%) in the Aspirin treatment group had Staphylococcus aureus 
endocarditis while the majority had streptococcal endocarditis. As the putative mechanism 
of action of aspirin involves the inhibition of S.aureus virulence factors, the benefit of aspirin 
is likely greatest if it is used before infection occurs. The benefit of aspirin is also very likely 
to be limited to S.aureus as the mechanism seems to be specific to this pathogen. The same 
authors presented a post hoc analysis of their data in 2008, comparing 84 patients who had 
been excluded from their previous study because of long term aspirin treatment with 54 
patients in the placebo arm and again found no significant clinical differences in the 
outcome between both groups (Chan et al., 2008). Only 29% of patients, 16 and 24 patients 
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respectively, in both arms had S.aureus endocarditis and thus the same concern that the 
study was underpowered to detect a difference was voiced for this study as well (Eisen D.P. 
& Bayer A.S., 2008).  
A retrospective single center cohort study of 600 patients with infectious endocarditis, who 
were treated over a 18 year period at the Mayo Clinic, found that the odds of suffering 
symptomatic embolic events was decreased by 64% in patients who were treated with 
antiplatelet agents for at least 6 months prior to the diagnosis: Aspirin was the antiplatelet 
agent in 98% of cases and an 81mg daily dose was used in the majority of patients 
(Anavekar et al., 2007). 
Eisen et al. used the International Collaboration on Endocarditis –Prospective Cohort Study 
(ICE-PCS) database to assess the influence of aspirin usage at the time of diagnosis on the 
outcome of definitive S.aureus endocarditis. A cohort of 670 patients had both information 
on prior aspirin use and S.aureus endocarditis. Aspirin use at the time of diagnosis in 132 
patients was a predictor for a decreased risk of acute valve surgery, independent of 
methicillin resistance status. A statistically significant decrease in embolic events in aspirin 
users was found in a univariate analysis that became a trend in multivariate analysis. A 
comparison of groups with and without aspirin use among patients with Streptococcal 
endocarditis was made and no association of aspirin with improved outcomes was found 
(Eisen et al., 2009).  
Thus the data on aspirin use in S.aureus endocarditis suggests that aspirin likely does alter 
the course of illness. The non dependence of the effect on methicillin resistance status and 
the absence of an observed effect of aspirin on other pathogens are consistent with the 
proposed specific mechanism of aspirin on staphylococcal virulence factors. It is also 
noteworthy that Staphylococcal endocarditis is rather difficult to study in adequate numbers 
as the population incidence is fortunately low.  
3.3 Aspirin and S.aureus nasal carriage 
Karabay et al. investigated the prevalence of S.aureus nasal carriage in an outpatient cardiology 
clinic. Of a total of 346 patients 199 were chronic aspirin user while 147 patients were not. The 
prevalence of S.aureus nasal carriage was 5% on patient treated chronically with aspirin versus 
16% in those that did not take aspirin. Only aspirin was found to be associated with a 
decreased rate of nasal carriage in a multivariate analysis (Karabay et al., 2006). These findings 
are of obvious significance to hemodialysis patients as nasal colonization is considered the 
initiating event that leads to catheter associated staphylococcal bacteremia. If confirmed, 
aspirin could decrease nasal carriage at a fraction of the cost and effort of mupirocin ointment. 
Given the fact that aspirin is a very old drug the findings of Karabay et al. have another 
potential significance: If a clinical effect of aspirin on S.aureus can still be detected after decades 
of over-the-counter use it would be unlikely that S.aureus would develop resistance to this 
effect in the future. It is clear that the important findings of Karabay et al. merit further 
investigation both in hemodialysis and in the general population. 
3.4 A potential beneficial effect of aspirin in hemodialysis patients 
Patient undergoing hemodialysis treatments suffer staphylococcal infections with increased 
frequency because of a high prevalence of tunneled or non tunneled dialysis catheters. The 
hemodialysis setting is thus well suited to study the potential beneficial clinical anti 
staphylococcal effects of aspirin.  
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been excluded from their previous study because of long term aspirin treatment with 54 
patients in the placebo arm and again found no significant clinical differences in the 
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We conducted a single center retrospective study in 872 patients with tunneled catheters who 
dialyzed over a ten year time period from 1995 to 2005.  During this time period our patients 
had 1853 tunneled dialysis catheters placed and accumulated more than 476 patient-catheter-
years and had 4722 blood cultures performed. Temporary dialysis catheters were excluded 
because of the high variability in the circumstances of placement of temporay catheters and 
also greater difficulty in tracking them retrospectively. The overall incidence of bacteremia 
was 7.2 episodes per 100 patient-catheter-months and the incidence of S.aureus bacteremia was 
2.1 episodes per 100 patient-catheter-months. The incidence of S.aureus endocarditis was 0.16 
episodes per 100 patient-catheter-months. These numbers are within the range reported in the 
literature. Blood cultures were obtained at the discretion of the treating physician if infection 
was suspected. Tunneled catheters that were a suspected source of infection were usually 
removed and negative cultures were required before insertion of a new tunneled catheter. All 
tunneled catheters were placed and removed by the same interventional radiology service. 
Suspected infection was the principal reason for tunneled catheter removal (19%), followed by 
poor catheter blood flow (14%) and presence of a mature permanent vascular access (14%). 
Infection rates were compared by Poisson regression analysis. In this study catheter associated 
bacteremia was defined as one or more positive blood cultures in a patient with a tunneled 
catheter. In retrospect it was impossible to exclude other sources of infection and 
contamination and for this reason all positive blood culture results that were obtained in the 
presence of a tunneled catheter were included without discrimination. Blood cultures that 
were obtained after a tunneled catheter was removed were excluded per definition. Our 
institution is a tertiary care medical center that offered hemodialysis in two outpatient units, 
serving a population of about 400,000 people. Because of location in a rural area, limited 
availability of hemodialysis and other geographical factors limiting access to other institutions 
the long term follow up of patients was excellent. A proprietary medical record system 
integrated electronic inpatient and outpatient records with procedure notes and laboratory, 
radiological and microbiological test result and was ideally suited for a large retrospective 
study. As a result the fate of only 8 catheters (<0.5%) was unaccounted for.  
The number of episodes and rates of catheter associated bacteria is shown in Table 1 which 
includes repeated episodes and polymicrobial infections with more than one bacterial 
isolate. As expected, Gram positive bacteria accounted for the majority of bacteremic 
episodes. When all bacteremic episodes were considered together, there was no difference 
between patients treated with aspirin or not. In fact, the only pathogen with a lower rate of 
catheter-associated bacteremia in patients treated with aspirin was S.aureus which caused 
only half as many episodes in the aspirin group compared to patients not treated with 
aspirin (0.17 versus 0.34 events/patient-catheter-years, p=0.003). In addition to blood 
cultures 369 catheter tip cultures were performed in the same time interval, albeit in a less 
systematic fashion. Of these 53 catheter tip cultures grew S.aureus. In such a case treatment 
is usually recommended because S.aureus bacteremia is considered more likely than 
contamination (Peacock et al., 1998). If these tip cultures were added to bona fide blood 
cultures in the analysis, the difference was statistically more significant: 83 instances (0.36 
events per patient-catheter-year) of S.aureus in the non aspirin treated group versus 45 (0.18 
event per patient-catheter-year) in the aspirin treated group (p=0.001).  
Moreover, if we excluded repeated events in the same patient from our data and considered 
only first episodes of S.aureus bacteremia, the difference looked between the two groups 
looked even more impressive: 28 first episodes of S.aureus bacteremia in patients treated 
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with aspirin (0.23 events per patient-catheter year) versus more than double, 64 first 
episodes of S.aureus bacteremia (0.57 events per patient catheter year) in patient not treated 
with aspirin (p<0.001). 
We explored the association between aspirin dose and rates of catheter associated S.aureus 
and MRSA bacteremia in table 2. There was a dose effect as only a 325mg dose of Aspirin, 
but not an 81mg dose (common formulations in the United States), was associated with a 
decreased rate of Staphylococcus aureus infection compared to patients not treated with 
aspirin. Importantly there was a significantly lower rates of Methicillin resistant 
Staphylococcus aureus bacteremia (MRSA) in patients treated with 325mg of aspirin a day.  
  
 















All positive 232 1.02 207 0.83 0.30 
Gram-positive 
Coagulase-negative Staphylococcus 96 0.42 93 0.37 0.85 
S aureus 77 0.34 43 0.17 0.003* 
MRSA 19 0.08 11 0.04 0.16 
Enterococcus species 21 0.09 30 0.12 0.18 
Corynebacterium species 7 0.03 6 0.02 0.82 
Streptococcus species 4 0.02 7 0.03 0.34 
Bacillus species 4 0.02 4 0.02 0.97 
Gram-negative 
Enterobacter species 20 0.09 21 0.09 0.81 
Pseudomonas species 11 0.05 13 0.05 0.64 
Serratia species 12 0.05 9 0.04 0.55 
Klebsiella species 9 0.04 10 0.04 0.77 
Escherichia coli 7 0.03 4 0.02 0.39 
Acinetobacter species 4 0.02 4 0.02 0.97 
Bacteroides species 3 0.01 3 0.01 0.78 
Note: Multiple bacterial isolates and repeated episodes were included in this table. Fungal isolates and 
bacterial species found fewer than 5 times during the 10-year study period were omitted. 
*Significant difference by Poisson regression. 
Table 1. Number of Episodes and Rates of Catheter-Associated Bacteremia in a 10-Year 
Period from 1995 to 2005 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
394 
We conducted a single center retrospective study in 872 patients with tunneled catheters who 
dialyzed over a ten year time period from 1995 to 2005.  During this time period our patients 
had 1853 tunneled dialysis catheters placed and accumulated more than 476 patient-catheter-
years and had 4722 blood cultures performed. Temporary dialysis catheters were excluded 
because of the high variability in the circumstances of placement of temporay catheters and 
also greater difficulty in tracking them retrospectively. The overall incidence of bacteremia 
was 7.2 episodes per 100 patient-catheter-months and the incidence of S.aureus bacteremia was 
2.1 episodes per 100 patient-catheter-months. The incidence of S.aureus endocarditis was 0.16 
episodes per 100 patient-catheter-months. These numbers are within the range reported in the 
literature. Blood cultures were obtained at the discretion of the treating physician if infection 
was suspected. Tunneled catheters that were a suspected source of infection were usually 
removed and negative cultures were required before insertion of a new tunneled catheter. All 
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with aspirin (0.23 events per patient-catheter year) versus more than double, 64 first 
episodes of S.aureus bacteremia (0.57 events per patient catheter year) in patient not treated 
with aspirin (p<0.001). 
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and MRSA bacteremia in table 2. There was a dose effect as only a 325mg dose of Aspirin, 
but not an 81mg dose (common formulations in the United States), was associated with a 
decreased rate of Staphylococcus aureus infection compared to patients not treated with 
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Table 2. Association between Aspirin Dose and Rates of Catether-Associated S aureus and 
MRSA Bacteremia 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
We used Cox proportional hazard analysis to study risk factors for developing a first episode 
of S.aureus bacteremia. Table 3 shows the patient characteristics and distribution of covariates 
that were used for this analysis. Patient treated with aspirin were on average 10 years older 
and had a higher prevalence of coronary artery disease, peripheral vascular disease, history of 
stroke, hypertension and diabetes mellitus than patients not treated with aspirin.  
Table 4 shows the result of the Cox proportional hazard analysis. Aspirin decreased the 
odds of developing a first episode of S.aureus bacteremia by 54% (with a confidence interval 
of 72% to 24%, p=0.002). No other cardiovascular medication and neither clopidogrel nor 
Warfarin had a similar effect.  Also, no beneficial effect of statins on the odds of S.aureus 
bacteremia was observed in this study. On the opposite side, the presence of diabetes 
mellitus increased the risk of developing a first episode of catheter associated S.aureus 
bacteremia, as was previous recognized (Breen et al. 1995). COPD decreased the odds of a 
first episode S.aureus bacteremia in this study. A potential explanation for this observation 
could be more frequent antibiotic use in this condition which might reduce nasal carriage. A 
greater incidence of S.aureus bacteremia was reported in patients with cardiovascular 
disease (K/DOQI, 2005) but the opposite, lower numbers of S.aureus bacteremia was 
observed in this sicker patient population which may be taken as a sign of the potential 
clinical importance of the anti staphylococcal effects of aspirin. Similar results were obtained 
when multiple logistic regression analysis was used instead of Cox analysis. 
Data on metastatic infection (endocarditis, osteomyelitis, septic arthritis) was analyzed as 
well. There were significantly less events in patients treated with aspirin compared with 
events in patients not treated with aspirin (3 versus 11 events, p=0.04). 
A Kaplan-Meier plot of cumulative catheter failure associated with S.aureus bacteremia is 
shown in Figure 1. Grouping by aspirin treatment resulted in two divergent graphs with 
catheter failure caused by S.aureus infection significantly more frequent in the non aspirin 
group (p<0.001). The two graphs diverge very early which is consistent with the clinical 
observation that almost a quarter of S.aureus infection occur very early within a week after 
catheter insertion (Little M.A. et al., 2001). Figure 1 also illustrates another measure of the 
beneficial anti staphylococcal effect of aspirin: delayed onset of infection. 
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  No Aspirin (454 patients) Aspirin (418 patients) P 
Age (y) 59 ± 19* 68 ± 13* <0.0001 
Time on dialysis (d) 362 ± 810 346 ± 542 0.73 
Catheter no. 1.8 ± 1.8 1.9 ± 1.7 0.70 
Female sex 194 (42) 186 (44) 0.54 
Tobacco use 205 (45)* 225 (54)* 0.01 
Diabetes mellitus 170 (38)* 236 (56)* <0.0001 
Hypertension 333 (74)* 364 (87)* <0.0001 
COPD 92 (20)* 117 (28)* 0.009 
Coronary artery disease 159 (35)* 309 (79)* <0.0001 
Peripheral vascular disease 113 (25)* 200 (48)* <0.0001 
Stroke 66 (15)* 99 (24)* 0.007 
Arthritis 141 (31)* 164 (39)* 0.01 
Cancer 102 (23) 80 (19) 0.24 
Previous transplant 50 (11)* 14 (3)* <0.0001 
Clopidogrel 12 (3)* 40 (10)* <0.0001 
Warfarin 61 (14) 60 (14) 0.77 
Statin 69 (15)* 172 (41)* <0.0001 
B-Blocker 248 (55)* 315 (75)* <0.0001 
ACE inhibitor/ARB 136 (30)* 187 (45)* <0.0001 
Calcium channel blocker 216 (48) 216 (52) 0.28 
Aspirin 0 418 <0.0001 
Note: Values expressed as mean ± SD or number (percent). 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. 
*Statistically significant difference between aspirin-treated and non–aspirin-treated groups by means of 
Fisher exact test or unpaired Student t-test, as appropriate.  
Table 3. Patient Characteristic and Distribution of Covariates for the Cox Proportional 
Hazard Analysis 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With Tunneled 
Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
A second study that addressed the anti staphylococcal effects of aspirin in hemodialysis 
patients was published in abstract form (Sedlacek et al., 2008). We performed a historical 
cohort study of the United States Renal Data System (USRDS) Dialysis Morbidity and 
Mortality Study (DMMS) Wave II data, linking medication data to mortality data from the 
core files. The updated USRDS Wave II data comprise 4024 patients, 16% of which were 
treated with Aspirin at study start date and 2776 of whom died. 54 of 2262 deaths (2.39%) in 
patients not treated with aspirin were attributed to septicemia due to vascular access either 
as primary or secondary cause, while there were only 4 of 510 deaths (0.78%) in patients 
treated with aspirin that were attributed to this cause (p<0.02, 2-tailed Fisher’s Exact Test). 
Although anti platelet agents and other cardiovascular medications are underused in 
dialysis patients, we still find a strong negative association between aspirin treatment and 
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catheter insertion (Little M.A. et al., 2001). Figure 1 also illustrates another measure of the 
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  No Aspirin (454 patients) Aspirin (418 patients) P 
Age (y) 59 ± 19* 68 ± 13* <0.0001 
Time on dialysis (d) 362 ± 810 346 ± 542 0.73 
Catheter no. 1.8 ± 1.8 1.9 ± 1.7 0.70 
Female sex 194 (42) 186 (44) 0.54 
Tobacco use 205 (45)* 225 (54)* 0.01 
Diabetes mellitus 170 (38)* 236 (56)* <0.0001 
Hypertension 333 (74)* 364 (87)* <0.0001 
COPD 92 (20)* 117 (28)* 0.009 
Coronary artery disease 159 (35)* 309 (79)* <0.0001 
Peripheral vascular disease 113 (25)* 200 (48)* <0.0001 
Stroke 66 (15)* 99 (24)* 0.007 
Arthritis 141 (31)* 164 (39)* 0.01 
Cancer 102 (23) 80 (19) 0.24 
Previous transplant 50 (11)* 14 (3)* <0.0001 
Clopidogrel 12 (3)* 40 (10)* <0.0001 
Warfarin 61 (14) 60 (14) 0.77 
Statin 69 (15)* 172 (41)* <0.0001 
B-Blocker 248 (55)* 315 (75)* <0.0001 
ACE inhibitor/ARB 136 (30)* 187 (45)* <0.0001 
Calcium channel blocker 216 (48) 216 (52) 0.28 
Aspirin 0 418 <0.0001 
Note: Values expressed as mean ± SD or number (percent). 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. 
*Statistically significant difference between aspirin-treated and non–aspirin-treated groups by means of 
Fisher exact test or unpaired Student t-test, as appropriate.  
Table 3. Patient Characteristic and Distribution of Covariates for the Cox Proportional 
Hazard Analysis 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With Tunneled 
Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
A second study that addressed the anti staphylococcal effects of aspirin in hemodialysis 
patients was published in abstract form (Sedlacek et al., 2008). We performed a historical 
cohort study of the United States Renal Data System (USRDS) Dialysis Morbidity and 
Mortality Study (DMMS) Wave II data, linking medication data to mortality data from the 
core files. The updated USRDS Wave II data comprise 4024 patients, 16% of which were 
treated with Aspirin at study start date and 2776 of whom died. 54 of 2262 deaths (2.39%) in 
patients not treated with aspirin were attributed to septicemia due to vascular access either 
as primary or secondary cause, while there were only 4 of 510 deaths (0.78%) in patients 
treated with aspirin that were attributed to this cause (p<0.02, 2-tailed Fisher’s Exact Test). 
Although anti platelet agents and other cardiovascular medications are underused in 
dialysis patients, we still find a strong negative association between aspirin treatment and 
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death from septicemia due to vascular access in USRDS data. These results provide a 
confirmation of a clinical anti-staphylococcal effect of aspirin in hemodialysis patient that is 
independent from the data pool used in our first study. 
 
Relative Risk (95% CI) P 
Age (y) 1.0 (1.0-1.0) 0.99 
Time on dialysis (d) 1.0 (1.0-1.001) 0.88 
Catheter no. 0.95 (0.83-1.09) 0.45 
Female sex 1.19 (0.76-1.86) 0.45 
Tobacco use 0.78 (0.49-1.24) 0.30 
Diabetes mellitus 1.65 (1.02-2.67) 0.04*
Hypertension 1.36 (0.74-2.51) 0.33 
COPD 0.49 (0.24-0.97) 0.04*
Coronary artery disease 0.80 (0.48-1.34) 0.40 
Peripheral vascular disease 1.01 (0.62-1.65) 0.97 
Stroke 1.11 (0.63-1.96) 0.72 
Arthritis 1.22 (0.78-1.92) 0.39 
Cancer 1.04 (0.59-1.83) 0.89 
Previous transplant 1.19 (0.55-2.55) 0.66 
Clopidogrel 1.06 (0.40-2.83) 0.91 
Warfarin 1.79 (1.03-3.10) 0.04*
Statin 1.08 (0.63-1.85) 0.79 
B-Blocker 1.13 (0.70-1.83) 0.62 
ACE inhibitor/ARB 0.79 (0.50-1.25) 0.31 
Calcium channel blocker 0.73 (0.46-1.15) 0.17 
Aspirin 0.46 (0.28-0.76) 0.002*
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. 
*Statistical significance in Cox proportional hazard model.  
Table 4. Risk of First S aureus Bacteremia Episode in 872 Dialysis Patients with a Tunneled 
Catheter by using Cox Proportional Hazard Analysis 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
3.5 Concerns about aspirin use in hemodialysis patients 
The abuse of non steroidal inflammatory drugs is a well described risk factor for upper 
gastrointestinal bleeding. The concern has been raised that the use of aspirin in dialysis 
patients could be harmful by causing bleeding (Chan et al., 2003 and 2008). As noted in a 
recent metanalysis the available data is conflicting for a variety of reasons such as selection 
bias, insufficient length of follow up and concomitant treatment with proton pump 
inhibitors (Hiremath et al., 2009). In the study of Chan et al a trend towards a higher 
incidence of bleeding was observed which did not reach statistical significance as both the 
initial study as well as the subsequent post hoc analysis was underpowered to either   
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Fig. 1. Cumulative plot of tunneled catheter failure associated with S aureus bacteremia. The 
failure plot was obtained using the Kaplan-Meier method. Tics represent censoring of 
catheter removal unrelated to S aureus bacteremia. Log-rank test was used to calculate P. 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
support or refute this hypothesis. In our own study no increased risk of bleeding was 
observed (unpublished data, Sedlacek et al., 2008). A study on aspirin use in 28320 patients 
from the Dialysis Outcomes and Practice Patterns Study I and II found neither a decreased 
cardiovascular risk nor an increase in the gastrointestinal bleeding with the use of aspirin 
(Ethier J et al., 2007). (Of note, no data on infectious complications was included in this 
manuscript which why it was not discussed in the above sections.) 
While there is no unequivocal proof that aspirin increases the risk of upper gastrointestinal 
bleeding in dialysis patients, it must not be forgotten that upper gastrointestinal bleeding is 
a well documented part of the uremic syndrome and that anticoagulation is routinely used 
during the hemodialysis procedure. It would thus seem reasonable to adopt a similar 
approach to high risk dialysis patients as has been recommended in high risk cardiac 
patients who would benefit from aspirin. Patients can be screened and treated for H.pylorii 
and proton pump inhibitors may be considered. Lastly it has to be noted that upper 
gastrointestinal bleeding is more amenable to treatment and represents a lesser risk to a 
high risk dialysis patient than for example cardiac stent occlusion. 
4. Statins 
Statins are cholesterol reducing medications that similarly to aspirin have become a 
cornerstone in the prevention and treatment of cardiovascular disease. The antimicrobial 
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support or refute this hypothesis. In our own study no increased risk of bleeding was 
observed (unpublished data, Sedlacek et al., 2008). A study on aspirin use in 28320 patients 
from the Dialysis Outcomes and Practice Patterns Study I and II found neither a decreased 
cardiovascular risk nor an increase in the gastrointestinal bleeding with the use of aspirin 
(Ethier J et al., 2007). (Of note, no data on infectious complications was included in this 
manuscript which why it was not discussed in the above sections.) 
While there is no unequivocal proof that aspirin increases the risk of upper gastrointestinal 
bleeding in dialysis patients, it must not be forgotten that upper gastrointestinal bleeding is 
a well documented part of the uremic syndrome and that anticoagulation is routinely used 
during the hemodialysis procedure. It would thus seem reasonable to adopt a similar 
approach to high risk dialysis patients as has been recommended in high risk cardiac 
patients who would benefit from aspirin. Patients can be screened and treated for H.pylorii 
and proton pump inhibitors may be considered. Lastly it has to be noted that upper 
gastrointestinal bleeding is more amenable to treatment and represents a lesser risk to a 
high risk dialysis patient than for example cardiac stent occlusion. 
4. Statins 
Statins are cholesterol reducing medications that similarly to aspirin have become a 
cornerstone in the prevention and treatment of cardiovascular disease. The antimicrobial 
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effects of statins have been known for a long time. In fact, statins were discovered by 
searching for compounds that would inhibit HMG-CoA reductase in microbes that require 
sterols or other isoprenoids, which are part of bacterial cytoskeleton, for growth. The first 
statins were described as antibiotics secreted by Penicillium species. The first statin 
compound, mevastatin, is derived from a culture of Pythium ultimum and Penicillium 
citrinum and under the name compactin the same compound was isolated from a culture of 
Penicillium brevicompactum (Endo et al., 1976). A mevastatin analog currently in use, 
lovastatin, was isolated from a culture of Aspergillus terreus. (Endo A., 1992). The 
antimicrobial effects of statins were rediscovered at a later time and it was noted that the 
minimum inhibitory concentration of simvastatin for S.aureus was much higher than the 
serum levels that can be achieved during routine treatment at recommended doses (Jerwood 
S. & Cohen J., 2008). Direct antimicrobial effects with potential clinical relevance have been 
postulated for HIV, CMV, HCV, Salmonella and yeast (Gupta et al., 2007) but are perhaps 
less relevant for dialysis catheter associated infection. Newer laboratory evidence shows that 
the interferon response to viral infection of the innate immune immune system is coupled to 
the mevalonate-isoprenoid arm of the sterol pathway. These findings may explain the 
observation that the CMV and HCV viruses are sensitive to statin administration and that 
treatment with interferon decreases plasma cholesterol levels similar to treatment with 
statins (Blanc M et al., 2011). 
Several observational studies in patients with severe bacterial infections have reported 
improved survival in patients treated with statins (Bjoerkheim-Bergman et al., 2010). These 
beneficial effects appear to be greater than what might be expected with lipid lowering 
alone and are attributed to pleiotropic effects of statins. Such effects involve improving 
endothelial function, decreasing oxidative stress and inflammation and inhibiting the 
thrombogenic response (Liao J.K. & Laufs U., 2005).  
The hypothesis that treatment with statins could have an influence on the rate of septic 
events in dialysis patients was investigated by Gupta et al in 2007. The authors used data 
from a prospective study to investigate choices and outcomes of dialysis care, which 
enrolled 1041 patients from 1995 to 1998, the majority of which dialyzed in units associated 
with Dialysis Clinic Inc in Nashville TN. These patient data were linked to United States 
Renal Data System administrative data which included hospitalizations and data from other 
treatment settings, including outpatient and skilled nursing facilities. Primary outcome were 
sepsis events but “only episodes in which the primary event was sepsis were included (…) 
to avoid including cases in which infection was acquired as a secondary phenomenon” 
(Correction by the same authors in JAMA Vol 299 P 765). The correction to their method 
section published later by the authors raises the possibility that their data analysis could 
come to a different conclusion if all episodes of sepsis were considered, not only the events 
that were considered”primary”. The authors found that 143 patients (14%) received statin 
treatment compared with 898 patients (86%) who were not. Among all 1041 patients there 
were a total of 303 events of primary sepsis during a mean follow up of 3.4 years. The crude 
incidence rate of sepsis events was 63% lower in patients treated with statins compared with 
the control group (41 events per 1000 patient-years compared with 110 events per 1000 
patient years) The authors found that the odds ratio for a primary septic event in statin users 
was 0.38 (95% CI 0.21-0.67) with adjustments for demographics, dialysis modality, 
comorbidities and laboratory values. In a propensity-matched subcohort analysis statin use 
was even more protective with an odds ratio of 0.24 (CI 0.11-0.49) (Gupta et al., 2007). In 
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contrast to the results of this study no difference in the rate of death from fatal infection with 
the use of atorvastatin was found in the 4D study (Wanner et al., 2005).  
An interesting question that is raised by the study by Gupta et al. is whether the observed 
benefit could be due to concomitant treatment with aspirin (Gupta et al., 2007). Both statins 
and aspirin are used for the treatment of coronary artery disease and a head to head 
comparison would be instructive. Our aspirin study did not find a beneficial effect of statins 
on the risk of septic events (Sedlacek et al., 2007) and the study by Gupta et al. did not 
control for aspirin use.  
It has to be noted that the relation between lipid parameters and mortality in dialysis 
patients is complex, confounded by the fact that elevated serum cholesterol levels are 
paradoxically protective in this population, probably because they are a marker for the 
absence of malnutrition and inflammation. In practical terms it is advised to use low doses 
of statins to reduce side effects and to avoid the concomittant administration of other drugs 
metabolized by the cytochrome P-450 system such as cyclosporine, azole antifungals and 
fibrates (Olyaei et al., 2011). 
5. Effects of other drugs used on dialysis 
Several other drugs that are frequently used on dialysis have known interactions with 
microbes. Heparin is used frequently to block dialysis catheters when not in use to preserve 
their patency. Unfortunately, heparin has been found to promote growth of bacterial biofilm 
in dialysis catheters (Shanks et al., 2005). Citrate has been used as an alternative to heparin 
to block catheters and was found to have inhibitory effects on biofilms at elevated 
concentration. Reminiscent of the “Goldilocks effect” observed with aspirin, citrate 
stimulates biofilm formation at sub inhibitory concentrations, an effect which might have 
clinical relevance at catheter tips (Shanks et al., 2006). EDTA also has an inhibitory effect on 
biofilm. The mechanism for both EDTA and citrate is thought to be through chelation  
of divalent ions essential to the extracellular matrix structure of biofilm (Percival et al., 
2005).  
Diltiazem, Amlodipine and the angiotension converting enzyme inhibitor Zofenopril have 
modest in vitro antimicrobial activity against S.aureus. Most of these effects are 
bacteriostatic and occur at higher drug concentrations in vitro than the therapeutic 
concentrations that are usually achieved during therapy in vivo. It has to be noted however, 
that drug concentration can vary considerably throughout different organs and body 
compartments. In the case of Amiloride it has been determined that urine concentrations 
achieved in patients are not sufficient to replicate the antibacterial effects that are observed 
in vivo (Cederlund et al., 1993). The relevance of these observations probably concerns more 
microbial purity testing of drugs during the fabrication process rather than clinical effects.  
Emla cream, a mixture of lidocaine, prilocaine and preservatives, which is used for topical 
anesthesia at the site of dialysis fistula puncture, has no effect on microbial growth 
(Kruszewska et al., 2010). Other drugs relevant to ESRD that have been tested and were 
found to be devoid of antimicrobial effects are the loop diuretics furosemide and 
bumetanide. 
The antihistaminic drug diphenhydramine has been reported to be synergistic with the 
penicillins (Kristiansen, 1992) and amiloride reportedly enhances uptake of tobramycin in 
pseudomonas aeruginosa (Cederlund et al., 1993). 
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6. Last but not least: Honey 
Honey has been used for the treatment of wounds since ancient times and its medicinal use 
is sanctioned by the Bible, Torah and Koran (Namias N., 2003). Johnson et al. conducted a 
prospective trial of topical honey versus topical Mupirocin ointment for the prevention of 
dialysis catheter associated infection. In a two year study period the authors enrolled 101 
patients with tunneled dialysis catheters in their hospital based dialysis unit. Honey was 
applied three times a week to the dialysis catheter exit site in 51 patients while mupirocin 
ointment was used in 50 patients. No exit site infections were observed in either group and 
no difference in the rate of catheter associated bacteremia could be demonstrated. The cost 
of the Australian grown medicinal honey that the authors used was equivalent to 
mupirocin. As the authors noted, it is interesting that at the time of the study about 2% of 
staphylococcal isolates in their hospital were resistant to mupirocin while no bacterial 
resistance to honey has yet been reported despite millennia of being around (Johnson D.W. 
et al., 2005). 
7. Conclusion 
In summary, a couple of observational studies have shown that both aspirin and statins 
might have significant salutatory effects on infectious complications in hemodialysis 
patients. Of note, aspirin does not have growth inhibitory or bactericidal activity at 
pharmacologically relevant concentrations and thus may be less likely to promote bacterial 
resistance as traditional antimicrobials do (Eisen et al., 2009). The same might apply for 
statins as well (Jerwood & Cohen, 2008). However, retrospective and observational studies 
are prone to multiple sources of bias that are unquantifiable and of indeterminate direction. 
Thus, randomized prospective trials are needed to further investigate this exciting new 
approach to the prevention of infectious complications in dialysis patients.  
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6. Last but not least: Honey 
Honey has been used for the treatment of wounds since ancient times and its medicinal use 
is sanctioned by the Bible, Torah and Koran (Namias N., 2003). Johnson et al. conducted a 
prospective trial of topical honey versus topical Mupirocin ointment for the prevention of 
dialysis catheter associated infection. In a two year study period the authors enrolled 101 
patients with tunneled dialysis catheters in their hospital based dialysis unit. Honey was 
applied three times a week to the dialysis catheter exit site in 51 patients while mupirocin 
ointment was used in 50 patients. No exit site infections were observed in either group and 
no difference in the rate of catheter associated bacteremia could be demonstrated. The cost 
of the Australian grown medicinal honey that the authors used was equivalent to 
mupirocin. As the authors noted, it is interesting that at the time of the study about 2% of 
staphylococcal isolates in their hospital were resistant to mupirocin while no bacterial 
resistance to honey has yet been reported despite millennia of being around (Johnson D.W. 
et al., 2005). 
7. Conclusion 
In summary, a couple of observational studies have shown that both aspirin and statins 
might have significant salutatory effects on infectious complications in hemodialysis 
patients. Of note, aspirin does not have growth inhibitory or bactericidal activity at 
pharmacologically relevant concentrations and thus may be less likely to promote bacterial 
resistance as traditional antimicrobials do (Eisen et al., 2009). The same might apply for 
statins as well (Jerwood & Cohen, 2008). However, retrospective and observational studies 
are prone to multiple sources of bias that are unquantifiable and of indeterminate direction. 
Thus, randomized prospective trials are needed to further investigate this exciting new 
approach to the prevention of infectious complications in dialysis patients.  
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Sleep has been identified as an essential human need; this is partly because of the metabolic 
activities that occur while the individual is sleeping. Normal sleep is divided into non–rapid 
eye movement (NREM) and rapid eye movement (REM) sleep. NREM sleep comprises 75% 
to 80% of total sleep time (TST), and is characterized by relatively quiescent brain activity 
and decreased metabolic rate (Carskadon & Dement, 2000). NREM sleep consists of four 
stages (S1-S4), with each stage leading to a progressively deeper sleep. REM sleep follows 
slow wave sleep (SWS), or deep sleep, and increases over the night, comprising 20% to 25% 
of TST. REM sleep is characterized by an activated EEG pattern, muscle atonia, and episodic 
bursts of rapid eye movements. Normal sleep provides a period of physiologic and mental 
rest. During sleep, sympathetic tone decreases and parasympathetic tone increases, leading 
to a reduction in heart rate, arterial blood pressure, and cardiac output (Rosenthal, 1998). 
Deep sleep is theorized to be necessary for physiologic restoration. REM sleep is associated 
with dreaming, and is essential for maintaining emotional and cognitive well-being (Redline 
et al., 2004).   
Waking and consciousness depend on the activity, of neurons in the ascending reticular 
activating system of the brainstem. These neurons project into the thalamus, hypothalamus 
and basal forebrain and eventually send projections to the cortex. There are particular 
neurotransmitters, such as the catecholamines, acetylcholine, histamine, glutamate and 
aspartate, that are localized within the reticular formation and have important roles in 
cortical activation and arousal (Jones, 1989). Sleep-promoting neurotransmitters include 
gamma aminobutyric acid (GABA), adenosine, and melatonin. Specific stages of sleep are 
regulated by the turning “on” and “off” of various neurons. REM “on” cells use GABA, 
acetylcholine, and glutamine, whereas REM “off” cells use norepinephrine and serotonin." 
REM On cells" are cholinergic cells in the lateral pontine and medial medullary reticular 
areas that innervate the thalamus, hippocampus and hypothalamus. These cells discharge at 
high rates during REM and show little or no activity during NREM."REM Off cells" are 
noradrenergic and serotonergic cells found in the locus coeruleus and raphe. These are cells 
which are slow or silent during REM sleep. Affecting levels of norepinephirne or serotonin 
can have an effect on REM sleep (Hoyt, 2005).  
Sleep regulation is a balance between a homeostatic sleep need and an intrinsic body clock, 
or circadian pacemaker. Located in the suprachiasmic nucleus, the circadian pacemaker 
determines the onset and termination of sleep, and is partially regulated by environmental 
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cues such as light and ambient temperature (Rosenthal, 1998). Melatonin, a physiologic 
sleep promoter, is inhibited by ambient light, and its circulation is decreased during 
daylight hours. The adrenal secretion of cortisol, which is associated with wakefulness, 
follows a circadian pattern. Regulated by the hypothalamic-pituitary axis, cortisol levels 
peak in the early morning hours in preparation for the increased metabolic demands during 
wakefulness (Mahowald, & Schenk, 1989). 
Some medical illnesses, such as congestive heart failure (CHF), diabetes mellitus, chronic 
obstructive pulmonary disease and renal disease, can directly impair sleep physiology, 
leading to a cyclical interaction (Ballard, 2005).  End-stage renal disease (ESRD) is one of 
these diseases. Approximately 50% of patients with chronic end-stage renal disease 
undergoing hemodialysis (HD) have insomnia and other sleep disorders (Hanly, 2007). 
Patients often complain of restless leg syndrome (RLS), periodic limb movement disorder 
(PLMD), bone pain, nausea, and pruritus (Merlino et al., 2006). The etiology of sleep 
disorders appears to be related to metabolic derangements associated with ESRD or from 
coexisting diabetes mellitus (Ballard, 2005). 
2. Sleep problems in hemodialysis patients 
Sleep complaints and sleep disorders are common in patients with end-stage renal disease. 
Although variable, their prevalence has been reported to be higher when compared to the 
general population (Merlino et al., 2006). The experiences of sleep alteration in ESRD 
patients have been studied. Interestingly, 80% of hemodialysis patients suffer from sleep 
abnormalities and the prevalence is higher than that in the general population (Gul et al., 
2006). Holley et al. (1992) surveyed 70 dialysis patients, and reported sleep disturbance 
experienced mainly included trouble falling asleep (67%), nighttime waking (80%), early 
morning waking (72%), restless legs (83%), and jerking legs (28%). However, Walker et al. 
(1995) found daytime sleepiness was the most commonly reported problem (66.7%) 
followed by restless legs syndrome (57.4%).  Generally, the most prominent sleep disorders 
among hemodialysis patients are sleep apnea syndrome, restless leg syndrome, periodic 
limb movement disorders, and insomnia (De Santo et al., 2005; Holley et al., 1992; Sabry et 
al., 2010). 
2.1 Sleep apnea syndrome 
The prevalence of sleep apnea syndrome in hemodialysis patients is at least 10 times higher 
(Kraus & Hamburger, 1997) than those values reported in the general population (Young et 
al., 1993). In another recent investigation, an apnea/hypopnea index higher than 5 was 
found in 31% of the (young) non-diabetic HD patients studied (Rodriquez et al, 2005). 
Sleep apnea syndrome (SAS) is a major clinical disturbance defined as an intermittent 
interruption of air flow at the level of nose and mouth during sleep. These abnormalities 
cause frequent decreases in O2 saturation and awakenings. Episodes of apnea are considered 
clinically significant if they persist for more than 10 s; however, apnea episodes may last up 
to 2 min. SAS is the clinical consequence of frequent (at least 10 events per hour) episodes of 
apnea during sleep (Tatomir et al., 2007). There are three major types of sleep apnea: 
obstructive sleep apnea (OSA), the central type (CSA), and the mixed type, which includes 
features of both obstructive and central apnea. OSA is characterized by obstruction of the air 
flow determined by the occlusion of the oropharyngeal tract (Zoccali et al., 2001).  
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OSA occurs when the patient no longer has airflow but there is respiratory effort. CSA is 
determined by the transient abolition of nerve conduction to the respiratory muscles. 
Central apnea is defined when the patient has both cessation of airflow and the lack of 
respiratory effort followed by spontaneous resumption of breathing. Mixed apnea is the 
combination of central and obstructive apneas. All of these conditions can cause arterial 
oxygen desaturation and they may even be present in the same person (Tatomir et al., 2007; 
Zoccali et al., 2001). Researchers have speculated that the chronic metabolic acidosis suffered 
by patients with hemodialysis causes these sleep disorders; as the body attempts to correct 
the acidosis, the patient exhales more carbon dioxide and the hypocapnia that results may 
be inadequate to fuel respiration (Kimmel, 1989). Another theory is that these patients 
frequently have peripheral neuropathy, either from the ESRD or diabetes mellitus, and if the 
neuropathy affects the nerves innervating the upper airway, then SAS will occur (Fletcher, 
1993). There is also evidence that SAS is associated with increased morbidity, and mortality, 
as the patient with ESRD who suffers with SAS is looking at a future with probable 
pulmonary hypertension and right heart failure, as well as a shortened lifespan (Fletcher, 
1993; Parker, 1997). While, there are no ready answers for the causes of these sleep disorders 
seen in patients with ESRD undergoing HD, it is crucial that the health care provider be 
aware of the syndrome. 
The awareness of SAS as a potent cardiovascular risk factor in ESRD undergoing HD has 
generated new enthusiasm in examining novel therapeutic strategies to modify sleep apnea 
in the patient population. To date, conservative non-pharmacological treatments (e.g. 
weight loss and avoidance of potentiating medications) have yielded limited success. Nasal 
continuous positive airway pressure therapy remains a mainstay of treatment of SAS in the 
non-ESRD population. Continuous positive airway pressure involves a mask fitting over the 
nose or mouth in which positive pressure is administered to the airway keeping the upper 
airway patent during sleep. In the general population, the treatment of sleep apnea with 
continuous positive airway pressure improves quality of life ( D'Ambrosio et al.,1999), 
vigilance, cognition, sexual performance, and normalizes nocturnal blood pressure profile 
(Faccenda et al., 2001).  In the HD population, continuous positive airway pressure was used 
in a small study of eight patients with some improvement in nocturnal oxygenation, and 
five of six patients reporting improved daytime alertness (Pressman, 1993). Finally, given 
the contribution of uremia in the pathogenesis of SAS in ESRD, attempts in optimizing 
uremia control in the forms of nocturnal hemodialysis (NHD) and renal transplantation 
have shown early clinical success (Auckley et al, 1999;Hanly & Pierratos, 2001). It is 
tempting to speculate that similar to those with refractory hypertension, the treatment of 
sleep apnea in the HD population would improve their quality of life, augment 
rehabilitation, and perhaps impact on the poor survival of patients. 
2.2 Restless Legs Syndrome  
Restless Legs Syndrome (RLS) is a neurological movement disorder that is common, under-
diagnosed, under-treated, and has a poorly understood etiology (Patrick,2007). Restless legs 
syndrome (RLS) is a sensorimotor movement disorder characterized by the irresistible need 
to move associated with feelings of discomfort and parasthesias (International Restless Legs 
Syndrome Study Group, 2003). The incidence of idiopathic RLS (iRLS) varies between 5–
15% in the general population (Nicholas et al., 2003). In the HD population, the prevalence 
of secondary RLS may be greater, reported to be between 6–62% (Takaki et al., 2003;Unruh 
et al.,2004) with some geographic variability (Kavanagh et al., 2004). With employment of 
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standardized criteria by IRLSSG, this decreased to 12–48% (Siddiqui  et al.,2005; Takaki et al, 
2003;Unruh et al., 2004).  RLS is observed more commonly in women than men, more 
commonly with increasing age and with co-morbid diabetes. Other potential correlates of 
RLS include lower socio-economic status, worse somatic and mental health and diabetes 
(Berger et al., 2004; Siddiqui  et al.,2005). A high correlation between RLS and PLMS has also 
been noted (Allen et al. 2003, Liao et al.,2008). 
The pathophysiology of RLS in uremia remains unknown however, several theories have 
been proposed. Potential risk factors include anemia, iron deficiency, dialysis vintage, 
calcium/phosphate imbalance, and peripheral and central nervous system 
abnormalities(Berger et al., 2004;Unruh et al.,2004).  
Evidence for a possible relationship of iron deficiency to RLS in this patient population has 
been explained by the universal occurrence of anemia, which is commonly acquired in 
patients with end-stage renal disease due to inadequate production of erythropoietin (Gigli 
et al.,2004). Anemia in ESRD is associated with several co-morbid conditions, including 
congestive heart failure, stroke, cognitive dysfunction, left ventricular hypertrophy,and 
worsening iron deficiency due to loss from hemodialysis (Allen,2004; Gigli et al.,2004) 
Ferritin levels under 100 ng/mL reflect depletion of iron stores and complicate the treatment 
of anemia in patients on dialysis (Easom, 2006; Patrick ,2007) 
Multiple causes of secondary RLS including iron deficiency anemia, diabetes mellitus, 
Parkinsons disease, pregnancy, rheumatic disease, venous insufficiency and less commonly in 
association with peripheral neuropathies, vitamin deficiencies, lumbosacral radiculopathy, 
spinal stenosis, excess caffeine intake, administration of some tricyclic antidepressants, 
hypoglycemia and hypothyroidism (Nichols et al.,2003;  Siddiqui  et al.,2005;Unruh et al.,2004). 
The revised IRLSSG criteria (Allen et al. 2003) for RLS included four essential diagnostic 
criteria additional supportive features. The criteria include unpleasant and uncomfortable 
sensations associated with an urge to move the limbs with symptoms worsened by rest, 
relieved by activity and typically worse toward the evening. Positive family history, initial 
therapeutic response to L-dopa or a dopamine-receptor agonist are supportive evidence. At 
least 85% of patients with RLS may also have concomitant periodic limb movements (PLMS) 
though this may be the result of other disorders such as obstructive sleep apnea. 
Treatment of ESRD-associated anemia with erythropoietin has been shown to decrease 
arousal due to PLMS and produce trends toward higher sleep quality (Benz et al 2000). As 
will be reviewed later, intravenous (I.V.) iron in ESRD patients has been shown to be highly 
effective in causing remission of RLS symptoms (Sloand et al., 2004). 
Given that alterations of the dopaminergic pathways may contribute to the development of 
RLS in ESRD, pharmacological treatment of RLS with Levodopa (L-DOPA) has been studied 
and was shown to improve sleep and reduce nocturnal limb movements in three 
prospective trials (Sandyk et al.1987; Trenkwalder et al., 1995; Walker, 1996). Recently, 
treatment with pergolide, a dopamine agonist was also examined in a double-blind placebo-
controlled crossover study in ESRD patients (Pieta et al., 1998).  In contrast to the use of L-
DOPA, pergolide resulted in decreased symptoms without objective improvements in 
nocturnal limb movement or sleep architecture. Limited beneficial data regarding the use of 
other dopamine agonists have also been reported (Miranda et AL., 2004; Pellecchia et al., 
2004). Folate is also involved in the production of dopamine in the CNS. Folate, as 5-
methyltetrahydrofolate, increases production of CNS tetrahydrobiopterin, a cofactor in 
tyrosine hydroxylase production  significant reduction in RLS symptoms and decreased leg 
movements during sleep (p=0.018). With the exception of this one trial, there is only limited 
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information from case reports of significant symptom reduction in pediatric RLS using 
dopaminergic agents (Konofal et al.,2005) 
2.3 Periodic Limb Movement Disorder  
Periodic limb movement disorder (PLMD) is a condition characterized by periodic episodes 
of repetitive and highly stereotyped limb movements that occur either during sleep (PLMS) 
or in wakefulness (PLMW) (Walker et al., 1995). This syndrome is more often seen in the 
patient with ESRD than in the general population (Pressman et al., 1995). The presence of 
PLMS is responsible for sleep problems in up to 72% of patients with ESRD (Benz et al., 
2000) and the presence of PLMS is a more accurate predictor of mortality than coexisting 
diseases, serum albumin, or urea reduction ratio (Winkelman et al., 1996). A high correlation 
between RLS and PLMS has also been noted (Allen et al. 2003). 
Treatments with high-dose iron dextran and normalization of hematocrit with recombinant 
human erythropoietin have been demonstrated to improve RLPLMD in ESRD patients 
(Benz et al, 1999; Sloand et al., 2004). Alterations in dopamine and opioid synthesis may also 
play a role in the high prevalence of RLS and PLMD in uremia; however, data are limited. 
Indirect evidence stems from the notion that treatment with dopamine agonists, dopamine 
precursors in ESRD patients may improve RLS and PLMD symptoms (Sandyk et al.1987; 
Trenkwalder et al., 1995; Walker, 1996).  
2.4 Insomnia 
Insomnia is defined as a disorder of difficulty initiating sleep (DIS), difficulty maintaining 
sleep (DMS), and/or early morning awakening (EMA). Insomnia is commonly defined as 
the subjective sensation of short, unsatisfying sleep, despite the ability to sleep (Sabbatini et 
al., 2002). It may be secondary either to trouble falling asleep and/or to night‐time waking, 
which must be persistently present (i.e. three to four times a week for several weeks) ( Leger 
et al.,2002). The prevalence estimates of insomnia vary because of differences in definition, 
diagnosis, population characteristics, and research methodologies. Insomnia is a common 
sleep problem, however, and its prevalence in the general population ranges from 4% to 
64% (Terzano et al., 2004; Chesson et al., 2000).  The prevalence of insomnia is substantially 
greater in dialysis patients and has been reported to range from 45% to 59% (İliescu et al., 
2003; İliescu et al., 2004; Sabbatini et al., 2002).  
Insomnia is characterized by one or more of the following symptoms: difficulty falling asleep 
("sleep onset insomnia"), difficulty staying asleep ("sleep maintenance insomnia"), early 
awakening or poor sleep quality ("non-restorative sleep") (Ohayon et al., 2002; Meyer, 1998). 
Insomnia is primarily a clinical diagnosis and it is most frequently diagnosed from data 
obtained from the history and from sleep diaries. PSG is not indicated in the initial evaluation 
of insomnia but may be necessary in chronic treatment-resistant cases and in patients in whom 
specific sleep disorders (SASRLSPLMS) are suspected (Bonner et al., 2008).  
Insomnia may be caused by a variety of reasons, with the most frequent causes listed by 
researchers as: restless legs syndrome (RLS), periodic leg movements during sleep (PLMS), 
sleep apnea syndrome (SAS) and depression (Kimmel, 1989; Parker, 1997; Welch & Austin, 
2001). The prevalence of insomnia due to RLS in dialysis patients ranges from 57% to 83% ( 
Holley et al., 1992; Sabbatini et al., 2002; Walker et al., 1995). Elderly patients, those with longer 
dialysis durations, dialysis shift, and those with high levels of parathyroid hormone (PTH) or 
diabetes mellitus are at higher risk of insomnia; however, the dialysis type and biochemical 
parameters are not important determinants of insomnia (Han et al., 2002; Sabbatini et al., 2002).  
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of anemia in patients on dialysis (Easom, 2006; Patrick ,2007) 
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other dopamine agonists have also been reported (Miranda et AL., 2004; Pellecchia et al., 
2004). Folate is also involved in the production of dopamine in the CNS. Folate, as 5-
methyltetrahydrofolate, increases production of CNS tetrahydrobiopterin, a cofactor in 
tyrosine hydroxylase production  significant reduction in RLS symptoms and decreased leg 
movements during sleep (p=0.018). With the exception of this one trial, there is only limited 
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information from case reports of significant symptom reduction in pediatric RLS using 
dopaminergic agents (Konofal et al.,2005) 
2.3 Periodic Limb Movement Disorder  
Periodic limb movement disorder (PLMD) is a condition characterized by periodic episodes 
of repetitive and highly stereotyped limb movements that occur either during sleep (PLMS) 
or in wakefulness (PLMW) (Walker et al., 1995). This syndrome is more often seen in the 
patient with ESRD than in the general population (Pressman et al., 1995). The presence of 
PLMS is responsible for sleep problems in up to 72% of patients with ESRD (Benz et al., 
2000) and the presence of PLMS is a more accurate predictor of mortality than coexisting 
diseases, serum albumin, or urea reduction ratio (Winkelman et al., 1996). A high correlation 
between RLS and PLMS has also been noted (Allen et al. 2003). 
Treatments with high-dose iron dextran and normalization of hematocrit with recombinant 
human erythropoietin have been demonstrated to improve RLPLMD in ESRD patients 
(Benz et al, 1999; Sloand et al., 2004). Alterations in dopamine and opioid synthesis may also 
play a role in the high prevalence of RLS and PLMD in uremia; however, data are limited. 
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precursors in ESRD patients may improve RLS and PLMD symptoms (Sandyk et al.1987; 
Trenkwalder et al., 1995; Walker, 1996).  
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Insomnia is defined as a disorder of difficulty initiating sleep (DIS), difficulty maintaining 
sleep (DMS), and/or early morning awakening (EMA). Insomnia is commonly defined as 
the subjective sensation of short, unsatisfying sleep, despite the ability to sleep (Sabbatini et 
al., 2002). It may be secondary either to trouble falling asleep and/or to night‐time waking, 
which must be persistently present (i.e. three to four times a week for several weeks) ( Leger 
et al.,2002). The prevalence estimates of insomnia vary because of differences in definition, 
diagnosis, population characteristics, and research methodologies. Insomnia is a common 
sleep problem, however, and its prevalence in the general population ranges from 4% to 
64% (Terzano et al., 2004; Chesson et al., 2000).  The prevalence of insomnia is substantially 
greater in dialysis patients and has been reported to range from 45% to 59% (İliescu et al., 
2003; İliescu et al., 2004; Sabbatini et al., 2002).  
Insomnia is characterized by one or more of the following symptoms: difficulty falling asleep 
("sleep onset insomnia"), difficulty staying asleep ("sleep maintenance insomnia"), early 
awakening or poor sleep quality ("non-restorative sleep") (Ohayon et al., 2002; Meyer, 1998). 
Insomnia is primarily a clinical diagnosis and it is most frequently diagnosed from data 
obtained from the history and from sleep diaries. PSG is not indicated in the initial evaluation 
of insomnia but may be necessary in chronic treatment-resistant cases and in patients in whom 
specific sleep disorders (SASRLSPLMS) are suspected (Bonner et al., 2008).  
Insomnia may be caused by a variety of reasons, with the most frequent causes listed by 
researchers as: restless legs syndrome (RLS), periodic leg movements during sleep (PLMS), 
sleep apnea syndrome (SAS) and depression (Kimmel, 1989; Parker, 1997; Welch & Austin, 
2001). The prevalence of insomnia due to RLS in dialysis patients ranges from 57% to 83% ( 
Holley et al., 1992; Sabbatini et al., 2002; Walker et al., 1995). Elderly patients, those with longer 
dialysis durations, dialysis shift, and those with high levels of parathyroid hormone (PTH) or 
diabetes mellitus are at higher risk of insomnia; however, the dialysis type and biochemical 
parameters are not important determinants of insomnia (Han et al., 2002; Sabbatini et al., 2002).  
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Most studies assessing the effectiveness of different treatment modalities in insomniacs 
address short-term treatment of insomnia (Montgomery &Dennis., 2004; Morgan et al., 2003; 
Smith et al., 2002). Extra care and caution has to be exercised when treating insomnia in 
patients with renal impairment. Most hypnotics should be administered in appropriately 
reduced doses and interactions with the numerous medications used in the different HD 
populations should be considered carefully when prescribing a hypnotic to patients with 
renal failure (Novak et al., 2006). Surprisingly there is an almost complete lack of 
pharmacologic studies in renal patients suffering from insomnia. In a small randomized 
study using the PSQI Sabbatini et al. (2003). suggested that zaleplon improved sleep efficacy 
in maintenance hemodialysis patients. 
Nonpharmacologic interventions include sleep hygiene measures relaxation therapy and 
biofeedback stimulus control therapy sleep restriction and cognitive behavioral therapy 
(Montgomery &Dennis., 2004; Morgan et al., 2003). These interventions have been shown to 
be beneficial in the long-term management of patients with chronic hypnotic use. Cognitive 
behavioral therapy for insomnia in the routine general practice setting improved sleep 
quality reduced hypnotic drug use and improved health-related quality of life at a favorable 
cost in chronic insomniacs. 
3.  Related factors with sleep problems in hemodialysis patients 
A multitude of causes including anemia, blood urea levels, plasma creatinine levels, 
parathyroid hormone (PTH) concentrations, increased blood pressure, quality of life, and 
illness intrusiveness may contribute to sleep disturbances in patients on maintenance 
hemodialysis (Hanly et al., 2003; Iliescu et al., 2004; Sabbatini et al.,2003). Furthermore, there 
is a positive correlation between sleep disturbances and increased morbidity and mortality 
related to cardiovascular disease and infectious  complications, the 2 major causes of death 
in hemodialysis patients (De Santo et al., 2005). Sleep disorders in hemodialysis patients is a 
multifactorial complaint, stemming from Uremic toxins and dialysis procedure, other 
medical problems, psychiatric or psychosocial background. 
3.1 Uremic toxins 
Several studies in the past 30 years have shown that uremic patients are at great risk for 
disordered sleep. A study by Millman et al. (1985) noticed a slight but significant 
relationship between sleep apnea syndrome and azotemia. In a recent prospective study of 
incident HD patients followed-up for 1 year, higher dialysis efficiency was associated with 
fewer sleep disturbances (Unruh et al., 2006). These latter data are further supported by the 
results of Hanly et al. (2001), who studied patients on conventional hemodialysis (4 h three 
times a week) who then switched to nocturnal (intensive) dialysis (8 h for 6 or 
7 days/week). A spectacular correction of sleep apnea was recorded in this small-scale 
study (Hanly et al., 2001). Finally, the impact of uremic toxins is highlighted by the fact that 
sleep disorders are more frequent and more severe in dialyzed patients compared with 
subjects with pre-dialysis CKD (Merlino et al., 2006).  
3.2 Interdialytic weight gain and hypertension 
Excessive interdialytic weight gain has been associated with poor compliance and high 
blood pressure (Rahman et al., 2000). While the mechanism of the association between 
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interdialytic weight gain and sleep problems is unclear, we speculate that large interdialytic 
weight gains result in expanded intravascular volume, which has been associated with 
upper airway obstruction (Chiu et al., 2006).  
The length of sleep during the night before a hemodialysis session after a long interdialytic 
interval (3 days, the “weekend interval”) is significantly shorter compared to the usual sleep 
length following a short interdialytic interval. This led to some speculation regarding the 
possible effect of interdialytic weight gain (IWG) on sleep (Bertini et al., 1999). Furthermore, 
patients with uncontrolled pre-dialysis systolic pressure (usually a sign of hypervolemia in 
these patients) experience clinically overt insomnia more frequently (De Santo et al., 2001); 
in patients with chronic diseases, systolic hypertension appears to be a cause of sleep 
disturbances (Katz & McHorney 1998; Sabbatini et al., 2002; Thase, 2005). 
3.3 Dialysis shift 
The dialysis shift has several effects on patients with ESRD.  Morning-shift HD patients 
experience more insomnia (Sabbatini et al., 2002), but also have longer survival times 
(Bliwise., 2001)  than patients on other dialysis shifts. In according to another study (Merlino 
et al., 2006), for patients undergoing HD in the morning shift, the risk of subclinical 
insomnia is up to 18 times higher than for those who have their dialysis session in the 
afternoon.  However, morning-shift HD patients have higher intradialytic sleepiness, which 
is associated with more decreased body temperature during HD, than patients on other 
dialysis shifts (Parker et al., 2003). 
3.4 Dialysis vintage 
The longer the dialysis vintage, the more significant is the prevalence of sleep quality 
disorders (Veiga et al., 1997).   In a study by De Santo et al., (2005), patients with subclinical 
or clinical sleep disorders had double the dialysis vintage of those without sleep complaints; 
in patients with a medium dialytic age of 75 months, the prevalence of sleep disorders is 
close to 80%. These data are not surprising, taking into account the accumulation of 
comorbidites, including peripheral neuropathy and CVD, whilst on dialysis on long-term. In 
a polysomnographic study by Tatomir et al.,(2007)  in patients hemodialyzed for more than 
10 years, all patients has disturbed sleep with frequent awakening and reduced sleep 
efficiency. One-half of these patients had sleep-related breathing disorders, i.e. sleep apnea 
syndrome. 
3.5 Restless legs syndrome 
Restless legs syndrome (RLS) usually becomes apparent during resting and may 
significantly interfere with sleep.  An association between RLS and insomnia in patients on 
maintenance hemodialysis has been suggested already by a few papers (Musci et al., 2005; 
Sabbatini et al., 2002; Walker et al., 1995). Moreover, RLS is associated with a low quality of 
sleep and lower quality of life.  
3.6 Other medical factors  
Other medical factors include the pain and discomfort caused by illnesses such as arthritis, 
cardiovascular disease, chronic obstructive pulmonary disease (COPD), cerebrovascular 
disease, neurological disorders, asthma, headaches, and more.  The prognosis of patients 
with chronic uremia is influenced by the presence of comorbidities, mainly by 
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Most studies assessing the effectiveness of different treatment modalities in insomniacs 
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behavioral therapy for insomnia in the routine general practice setting improved sleep 
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illness intrusiveness may contribute to sleep disturbances in patients on maintenance 
hemodialysis (Hanly et al., 2003; Iliescu et al., 2004; Sabbatini et al.,2003). Furthermore, there 
is a positive correlation between sleep disturbances and increased morbidity and mortality 
related to cardiovascular disease and infectious  complications, the 2 major causes of death 
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Several studies in the past 30 years have shown that uremic patients are at great risk for 
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relationship between sleep apnea syndrome and azotemia. In a recent prospective study of 
incident HD patients followed-up for 1 year, higher dialysis efficiency was associated with 
fewer sleep disturbances (Unruh et al., 2006). These latter data are further supported by the 
results of Hanly et al. (2001), who studied patients on conventional hemodialysis (4 h three 
times a week) who then switched to nocturnal (intensive) dialysis (8 h for 6 or 
7 days/week). A spectacular correction of sleep apnea was recorded in this small-scale 
study (Hanly et al., 2001). Finally, the impact of uremic toxins is highlighted by the fact that 
sleep disorders are more frequent and more severe in dialyzed patients compared with 
subjects with pre-dialysis CKD (Merlino et al., 2006).  
3.2 Interdialytic weight gain and hypertension 
Excessive interdialytic weight gain has been associated with poor compliance and high 
blood pressure (Rahman et al., 2000). While the mechanism of the association between 
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interdialytic weight gain and sleep problems is unclear, we speculate that large interdialytic 
weight gains result in expanded intravascular volume, which has been associated with 
upper airway obstruction (Chiu et al., 2006).  
The length of sleep during the night before a hemodialysis session after a long interdialytic 
interval (3 days, the “weekend interval”) is significantly shorter compared to the usual sleep 
length following a short interdialytic interval. This led to some speculation regarding the 
possible effect of interdialytic weight gain (IWG) on sleep (Bertini et al., 1999). Furthermore, 
patients with uncontrolled pre-dialysis systolic pressure (usually a sign of hypervolemia in 
these patients) experience clinically overt insomnia more frequently (De Santo et al., 2001); 
in patients with chronic diseases, systolic hypertension appears to be a cause of sleep 
disturbances (Katz & McHorney 1998; Sabbatini et al., 2002; Thase, 2005). 
3.3 Dialysis shift 
The dialysis shift has several effects on patients with ESRD.  Morning-shift HD patients 
experience more insomnia (Sabbatini et al., 2002), but also have longer survival times 
(Bliwise., 2001)  than patients on other dialysis shifts. In according to another study (Merlino 
et al., 2006), for patients undergoing HD in the morning shift, the risk of subclinical 
insomnia is up to 18 times higher than for those who have their dialysis session in the 
afternoon.  However, morning-shift HD patients have higher intradialytic sleepiness, which 
is associated with more decreased body temperature during HD, than patients on other 
dialysis shifts (Parker et al., 2003). 
3.4 Dialysis vintage 
The longer the dialysis vintage, the more significant is the prevalence of sleep quality 
disorders (Veiga et al., 1997).   In a study by De Santo et al., (2005), patients with subclinical 
or clinical sleep disorders had double the dialysis vintage of those without sleep complaints; 
in patients with a medium dialytic age of 75 months, the prevalence of sleep disorders is 
close to 80%. These data are not surprising, taking into account the accumulation of 
comorbidites, including peripheral neuropathy and CVD, whilst on dialysis on long-term. In 
a polysomnographic study by Tatomir et al.,(2007)  in patients hemodialyzed for more than 
10 years, all patients has disturbed sleep with frequent awakening and reduced sleep 
efficiency. One-half of these patients had sleep-related breathing disorders, i.e. sleep apnea 
syndrome. 
3.5 Restless legs syndrome 
Restless legs syndrome (RLS) usually becomes apparent during resting and may 
significantly interfere with sleep.  An association between RLS and insomnia in patients on 
maintenance hemodialysis has been suggested already by a few papers (Musci et al., 2005; 
Sabbatini et al., 2002; Walker et al., 1995). Moreover, RLS is associated with a low quality of 
sleep and lower quality of life.  
3.6 Other medical factors  
Other medical factors include the pain and discomfort caused by illnesses such as arthritis, 
cardiovascular disease, chronic obstructive pulmonary disease (COPD), cerebrovascular 
disease, neurological disorders, asthma, headaches, and more.  The prognosis of patients 
with chronic uremia is influenced by the presence of comorbidities, mainly by 
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cardiovascular disease (CVD), which causes roughly 50% of deaths (Covic et al., 2006).  A 
study by Mucsi et al. (2004), demonstrated that comorbidities are independent predictors of 
sleep disturbances in patients on maintenance dialysis. According to another study, the 
average Charlson Comorbidity Index (CCI) in patients without sleep disorders was 4.10, 
while scores in patients with subclinical and clinically overt sleep disorders were 6.10 and 
6.81, respectively (De Santo et al.,2005). This highly significant association in the Italian HD 
population was maintained regardless of age. To conclude so far, any in-depth research on 
the quality of sleep in renal patients must consider the magnitude of comorbidities.  
3.7 Age 
Sleep difficulties are closely correlated with older age in patients with chronic uremia 
(Iliescu et al., 2003). Yoshioka et al.(1993) found that advanced age and long-term dialysis 
therapy directly affected patients experiencing sleep problems. The disorders are similar to 
those described in the general population, where the prevalence and severity of sleep 
disorders are also associated with old age. Each decade of age increases the risk of insomnia 
by 239%, and the risk of overt clinical insomnia by 51% (De Santo et al., 2005). Mollaoğlu 
(2004) reported a negative correlation between age and sleep quality, with sleep quality 
decreasing with advanced age in their study of 105 HD patients. In addition, community-
based studies have shown that sleep quality could be deteriorated in elderly patients due to 
increased frequency of physical diseases, multiple drug use, primary sleep disturbances, or 
lifestyle modifications (Brandenberger et al., 2003; Kamel & Gammack 2006).  
3.8 Depression 
The psychiatric condition most commonly causing sleep disorders is depression that may 
affect up to 50% of this patient population (Covic et al., 2006). The relationship between 
depression and sleep disorders is well known both in the general population and in patients 
undergoing hemodialysis (İliescu et al.,2003). Depression can be a cause, as well as a result, of 
insomnia. Dialysis patients with a Pittsburg Quality Index Sleep score of >5 (patients with a 
“difficult sleep”) have a prevalence of overt depression of 20%, while among ESRD patients 
reporting a normal sleep, the prevalence of depression is almost nil (İliescu et al.,2003).  
3.9 Medications and other substances 
Medications and other substances which may cause insomnia include beta-blockers, 
bronchodilators, corticosteroids, CNS stimulants, Tagamet, cardiovascular drugs, 
neurological drugs, alcohol, caffeine and nicotine (Merlino et al., 2006; Rosenthal, 1998; 
Unruh et al., 2006). Most prescribed as well as over-the-counter medications produce side 
effects which are either sedating or stimulating.  Drugs which cause daytime sleepiness 
include analgesics, benzodiazepines and antihistamines (Rosenthal, 1998; Unruh et al., 
2006). According to recent investigations, the use of hypnotic medication in dialysis patients 
is rather modest: 8–10% (De Santo et al., 2005; De Santo et al., 2001). In a large study, the 
reported use of sleep-inducing medication was even lower—3.6% (Merlino et al., 2006). 
However, dialysis patients with severe sleep disorders use specific medication more 
frequently (24%) (De Santo et al., 2005). Improved hemodialysis techniques, socio-
economical disparities in the studied populations, and reluctance by nephrologists to 
prescribe psychotropic medication may explain these disparities. However, we must be 
aware that chronic auto-administration of hypnotic medication may be more frequent in 
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ESRD patients compared to the general population. Moreover, according to recent data from 
the CHOICE incident dialysis population, use of benziodiazepines is associated with altered 
sleep quality during the first year of dialysis. Although this study was unable to distinguish 
between cause and effect, more effective dialysis and cognitive behavioral therapy have 
been suggested in patients with sleep disorders in need of sleep-inducing medication 
(Unruh et al., 2006). Moreover, many antidepressants actually cause paradoxical 
restlessness, therefore systematic administration of these drugs should be subjected to close 
clinical follow-up, which should be easy to accomplish in hemodialysis patients. 
Alcohol is widely used as a sleep aid. Although it does shorten sleep latency, it also causes 
sleep fragmentation, decreased REM, REM rebound and early morning awakenings. The use 
of alcohol combined with hypnotics may exacerbate sleep difficulties even more (Rosenthal, 
1998). Alcohol and (particularly) tobacco abuse is highly associated with increased 
prevalence of sleep disorders in ESRD (Merlino et al., 2006). Caffeine and other stimulants 
such as nicotine have been shown to increase sleep latency and sleep fragmentation, and to 
decrease total sleep time (Rosenthal, 1998).  Current smoking is also related with decreases 
in sleep quality during the first year of dialysis therapy in incident patients (Unruh et al., 
2006). Caffeine intake appears to have no significant impact on insomnia in ESRD (Sabbatini 
et al., 2002).  
4. Sleep quality and evaluation of sleep in hemodialysis patients 
Sleep quality is an important clinical construct for two major reasons. First, complaints 
about sleep quality are common; epidemiological surveys indicate that 15-35 % of the adult 
population complain of frequent sleep quality disturbance, such as difficulty falling asleep 
or difficulty maintaining sleep. Second, poor sleep quality can be an important symptom of 
many sleep and medical disorders (Buysse et al., 1989). 
Sleep quality” is sometimes used to refer to a collection of sleep measures including total 
sleep time (TST), sleep onset latency (SOL), degree of fragmentation, total wake time, sleep 
efficiency, and sometimes sleep disruptive events such as spontaneous arousals or apnea. 
The widely employed Pittsburgh Sleep Quality Index (PSQI), for example, provides a 
measure of global sleep quality based on a respondent’s retrospective appraisal (past 
month) of an array of sleep measures, including sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction (Krystal 
& Edinger, 2008). Sleep quality is also sometimes inferred from a collection of objective 
indices taken from polysomnography (PSG).  PSG is the most valid and accurate way to 
assess sleep.  Measures derived from PSG include: (a) total sleep time, (b) sleep efficiency 
(ratio of time spent asleep/time in bed), (c) sleep latency (time to fall asleep after lights out), 
(d) amount of wake time during sleep periods (waking after sleep onset, WASO), (e) 
number of awakenings, and (f) amount of each sleep stage ( Landis al., 2002). 
Among these objective indices are measures such as sleep onset latency, total sleep time, 
wake time after sleep onset, sleep efficiency, and number of awakenings that correspond to 
like measures taken from various available self-report instruments (e.g., sleep diaries, PSQI, 
etc.) (Buysse et al., 2006). However, PSG also provides a number of measures that reflect the 
architecture of sleep such as the percentage or temporal amounts of stage 1 sleep, stage 2 
sleep, slow wave sleep or rapid eye movement (REM) sleep. Despite having no self-report 
analogues, these latter measures also have been employed by some as indices of sleep 
quality (Krystal & Edinger, 2008). 
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Most of the recent studies on quality of sleep use different questionnaires assessing various 
aspects of sleep. The Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, and the 
Berlin Questionnaire are most frequently applied. Results derived from these questionnaires 
are limited by the subjective perception/sincerity of the patients, and thus are an imperfect 
substitute for more objective research methods on sleep in patients with chronic uremia 
(Chen et al, 2006; Iliescu et al., 2003; Mollaoglu & Mollaoglu, 2009; Sabbatini et al., 2003). 
Researchers have documented that ESRD patients reported significantly poorer subjective 
quality of sleep in comparison to the general population (Holley et al., 1992; Parker, 2005). 
The reported prevalence of ‘poor sleep’, including sleep-wake complaints, sleep-disordered 
breathing and excessive sleepiness, in dialysis patients is in the range of 45–80% (Afshar et 
al., 2011; Parker, 1996; Walker et al., 1995; Wei et al., 2011 ). In a another study It was 
examined the quality of sleep in 89 subjects with ESRD on haemodialysis using the PSQI 
and found a prevalence of ‘poor sleep’ (global PSQI>5) of 71% (Iliescu et al., 2003). Also, 
decreased quality of sleep is common in dialysis patients and is associated with decreased 
health-related quality of life (Iliescu et al., 2003; Williams et al., 2002). 
 The complex evaluation of sleep in patients with renal disease may be accomplished only 
by means of polysomnography. Polysomnography includes the comprehensive evaluation 
of the patient during sleep by electroencephalography, electrooculography, myography, 
quantification of respiratory efforts (by plethysmography), pulseoxymetry and noninvasive 
evaluation of CO2 blood level, and heart rate measuring (Tatomir et al., 2007).  Parker et al. 
(2003) examined by polysomnography 16 patients with HD and 8 patients with pre-dialysis 
CKD. Dialysis patients, in comparison with non-dialyzed CKD subjects, have a shorter sleep 
time. The REM phase is also shortened, time until falling asleep is longer, and respiratory 
events are more frequent. The sleep latency period was double in renal patients without 
dialysis compared to those with dialysis. Moreover, the prevalence and severity of 
periodical limb movement is higher in dialysis patients, as well as the number of short-term 
awakening periods (Parker et al., 2003). The authors suggest that sleep disturbances may 
have a different etiology in dialyzed patients compared to pre-dialysis CKD subjects. 
Functional and psychological factors may play a more prominent role in the pre-dialysis 
group, whereas intrinsic sleep disruption (arousals, apneas and limb movements) secondary 
to intermittent daytime HD sessions may play a more prominent role in patients with 
chronic uremia. Taken as a whole, renal patients experience a significant reduction in sleep 
length and efficiency compared to the general population (Parker et al., 2005). 
The studies have shown poor the quality of sleep in HD patients to be associated with 
female sex, older age, caffeine intake, recombinant erythropoietin therapy, pain, 
cardiovascular disease, physical functioning, larger body mass index (BMI), exercise, 
dialysis adequacy, parathyroid hormone, serum creatinine and quality of life (QOL) (Benz et 
al., 1999; Sabatini et al., 2002; Walker et al., 1995). Hanly et al. (2003) examined daytime 
sleepiness with multiple sleep latency tests in 24 haemodialysis patients and found strong 
correlation between sleep latency and BUN. In addition, psychological problems do 
represent crucial factors in influencing the quality of sleep in hemodialysis patients, as 
emphasized by all the previous studies in prevalent patients with renal disease, with 
depression playing a prominent role, followed by anxiety, sexual problems, financial strains, 
and isolation (İliescu et al., 2003; İliescu et al., 2004; Markou et al.,2006; Novak et al.,2006).  
Considering the strict linkage between some of these factors affecting sleep and 
hemodialysis, it is tempting to speculate that treating sleep problems, while improving the 
overall quality of life, might positively affect hemodialysis. In addition, with this point of 
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view, psychological, behavioural and pharmacologic interventions that promote sleep will 
represent a more than promising area for future research in hemodialysis patients. 
The above  studies results show that the sleep characteristics of hemodialysis patients need 
to be routinely evaluated. In addition to medical treatment to eliminate the sleep problems 
of hemodialysis patients and increase their sleep quality, the implementation of sleep 
hygiene interventions that can play a part in the regularity of patients’ sleep could also be 
beneficial. These interventions would include an environment with a comfortable room 
temperature and ventilation, minimal noise, a comfortable bed, and proper lighting. These 
interventions should apply to each patient’s personal routines (Mollaoglu & Mollaoglu, 
2009). 
5. Management of sleep problems in hemodialysis patients 
Proper management of sleep problems in ESRD patients requires in the first instance a 
proper identification of sleep abnormalities (extensively discussed above). Although 
significant research has been done to characterize sleep abnormalities in hemodialysis 
patients (Holey et al., 1992; De Santo et al., 2005; Merlino et al., 2006), little has been 
published regarding proper treatment. In the absence of guidelines, nephrologists rely 
largely on some published data and on opinion-based medicine. Sleep problems lower 
quality of life and contribute to physical and mental health problems. Sleep disorders and 
lack of sleep are an under treated threat to the public health. Sleep professionals have 
recognized the behavioral components of sleep disorders for decades, yet most patients 
never get a proper diagnosis and treatment (Mollaoglu & Mollaoğlu, 2009). 
Periodic clinical assessment of sleep complaints should become routine for dialysis staff. 
Early identification of sleep problems and interventions to improve sleep quality is essential, 
because sleep disturbance that persists for a long period of time could decrease general 
health and functioning (Sabbatini et al., 2003; Tatomir et al., 2007). Increasing evidence 
supports the effectiveness of both pharmacologic and nonpharmacologic therapies for sleep 
problems (Edinger et al., 2001; Montgomery & Dennis, 2004; Smith et al., 2002).  
Pharmacologic therapy are discussed in the sleep disorders section. 
The most effective nonpharmacologic interventions tested to date include all or most of the 
following components: sleep hygiene instruction, sleep restriction, stimulus control, relaxation 
training, and cognitive modification (Edinger et al., 2001; Montgomery & Dennis, 2004).  
5.1 Sleep hygiene 
Sleep hygiene involves basic education on how the sleep environment, caffeine, alcohol, 
nicotine, food and exercise affect sleep (Smith et al., 2002). Sleep Hygiene is an educational 
approach designed to teach insomnia patients as well as the population at large how to 
maintain healthy behavioral habits which promote better sleep. It is important to 
understand that successful treatment is only possible if the patient complies with 
suggestions to improve sleep hygiene (Edinger et al., 2001). Below are summarized tips for 
sleep hygiene 
Sleep hygiene tips 
 Sleep only when sleepy. If you can't fall asleep within 20 min get up and do something 
boring until you feel sleepy, 
 Don't take nap sunless your doctor advises so. 
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 Regular sleep-wake schedule is important. Get up and go to bed the same time every 
day even on weekends. 
 Regular exercise improves sleep but most people should refrain from exercise at least 4 
hr before bedtime. 
 Develop sleep rituals (listening to musicetc.). It is important to give your body cues that 
it is time to slow down and sleep. 
 Only use your bed for sleeping and intimacy. Refrain from using your bed to watch TV 
or work. 
 Stay away from caffeine-containing beverages foods and medications nicotine and 
alcohol at least 4–6 hr before bedtime. 
 Have a light snack before bed with a glass of milk which contains sleep-promoting 
tryptophan. 
 Take a hot bath 90 min before bedtime. A hot bath will raise your body temperature but 
it is the drop in body temperature that may leave you feeling sleepy. 
 Make sure your bed and bedroom are quiet and comfortable. Use appropriate curtains 
ear plugs or a white noise machine if necessary. A cooler room is recommended. Use a 
humidifier if the air is too dry. 
These suggestions often combine several methods and may sound trivial. Compliance with 
such advice is still relatively poor however as it frequently requires changes in persistent 
“bad” habits which are ingrained (Morin et al., 1999). Building a regular sleep schedule and 
creating an appropriate sleeping environment as well as regular physical activity are very 
important in combating insomnia or insomnia-like presentations in RLS/PLMD 
(Montgomery & Dennis, 2004).  
In terms of sleep hygiene for RLS/PLMD, there are a two main points that bear 
highlighting. First, the avoidance of alcohol, caffeine and nicotine may be underscored 
because of their potential contribution to RLS symptoms and/or PLMs. Second, other sleep 
hygiene practices may or may not have any utility for patients with RLS. Particularly when 
sleep hygiene is provided to patients as a handout or pamphlet, there is no indication that 
this helps promote sleep in any patient group. (Martin, 2000; Pigeon &Yurcheshen, 2009). 
5.2 Relaxation and biofeedback techniques 
Relaxation and biofeedback techniques for treating insomnia are based on the assumption 
that insomnia patients are overly aroused and anxious, and this interferes with their ability 
to initiate and/or maintain sleep (Lacks, 1993). Relaxation techniques are designed simply to 
teach patients to relax, and thus improve their ability to sleep. Of several relaxation 
methods, none has been shown to be more efficacious than the others. Progressive muscle 
relaxation, autogenic training and electromyographic biofeedback seek to reduce somatic 
arousal (e.g., muscle tension), whereas attention-focusing procedures such as imagery 
training and meditation are intended to lower presleep cognitive arousal (e.g., intrusive 
thoughts, racing mind) (Spielman et al., 1987). 
 In general, biofeedback training is an effective treatment for some insomnia patients, and is 
as effective as other non-pharmacologic interventions (Morin et al., 1999). If patients can 
train themselves to relax before sleep or at night after an awakening, they are more capable 
or falling asleep and staying asleep. It is believed that the beneficial effects of these methods 
extend beyond the sleep problems in that they facilitate better coping skills in general 
(Martin, 2000). 
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Structured exercise programs may also improve symptoms of insomnia (Montgomery & 
Dennis., 2004). Despite the promise of CBT the relative efficacy of these various 
nonpharmacologic approaches has not been well established. Data also suggest that CBTin 
contrast to medications may have a lasting effect beyond the termination of treatment. The 
extent to which the concomitant use of nonpharmacologic therapy augments the performance 
of pharmacologic treatments needs to be established in further studies (Novak et al., 2006). 
5.3 Stimulus-control therapy 
Stimulus-control therapy is a behavioral approach based on the premise that some sleep 
disturbances are behaviorally conditioned, so that the patient associates the bedroom 
environment with arousal. The main objective of stimulus control therapy is to reassociate 
the bed and bedroom with the rapid onset of sleep. 
Below are summarized instructions for stimulus-control therapy (Martin, 2000).  
Instructions for Stimulus-Control Therapy 
 Patient goes to bed only when sleepy. 
 If not asleep within about 10 minutes, patient gets out of bed, and does not return to 
bed until sleepy. 
 When patient returns to bed, if not asleep within 15 minutes, gets out of bed. 
 Pattern is repeated until patient can fall asleep within a few minutes. 
 Must get up at the same time each morning (even if only slept 2 hours). 
 Bed is used only for sleeping (not for watching television, reading exciting books, etc). 
 All naps during the day must be avoided. 
This method focuses primarily on shortening sleep onset, however, in the case of sleep 
maintenance insomnia, the instructions may be followed when the patient awakens and 
cannot fall back to sleep during the night. The patient should avoid lying awake in bed as 
much as possible and only go to bed when sleepy. No stimulating or distracting activities 
(e.g. reading exciting books or articles, watching television, looking at a clock) should be 
available. Although the patient cannot control sleep onset, wake up time should be fixed, so 
that a regular sleep/wake schedule will develop. Pro hibiting daytime naps is important to 
take advantage of the sleep deficit accumulated since the sleep period on the previous night, 
which in itself can shorten sleep onset. As with all psychological therapies, compliance is 
enhanced when the instructions and their rationales are explained to the patient. 
Stimulus control therapy has been shown to be effective in shortening sleep latency 
compared with placebo intervention in insomnia patients (Lacks, Bertelson, Gans & Kunkel, 
1996). Clinical trials have documented the efficacy of stimulus control therapy for both sleep 
onset and sleep-maintenance insomnia (Espie et al., 1989; Lacks et al., 1993) 
5.4 Sleep restriction therapy 
Sleep restriction therapy, is based on the observation that many insomnia patients spend an 
excessive amount of time in bed in futile attempts to achieve more sleep (Spielman, Saskin, 
& Thorpy, 1987).. Sleep restriction therapy consists of curtailing the amount of time spent in 
bed to increase the percentage of time spent asleep. This improves the patient's sleep 
efficiency (time asleep/time in bed). For example, a person who reports staying in bed for 
eight hours but sleeping an average of five hours per night would initially be told to 
decrease the time spent in bed to five hours. The allowable time in bed per night is increased 
15 to 30 minutes as sleep efficiency improves. Adjustments are made over a period of weeks 
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until an optimal sleep duration is achieved. Typically, it is best to alter the bedtime and to 
keep the rising time constant in order to maintain a regular sleep-wake rhythm. By creating 
a mild state of sleep deprivation, this therapy promotes more rapid sleep onset and more 
efficient sleep (Hauri, 2000). To minimize daytime sleepiness, time in bed should not be 
reduced to less than five hours per night. Sleep restriction therapy is modified in older 
adults by allowing a short afternoon nap. 
Lichstein and Reidel (1994) concluded that sleep restriction therapy is actually the preferred 
technique for insomnia in older patients. In a later study they combined sleep restriction 
with sleep education for older insomnia patients, comparing a self-help technique (a guiding 
video) with therapist guidance (Riedel et al., 1995). While the self-help technique alone 
showed improvement on some sleep variables, therapist guidance was superior in that it 
improved sleep latency, wake time after sleep onset and sleep satisfaction. 
Implementation of this technique requires a high level of motivation and compliance on the 
patient’s part, and close follow up by the clinician. Below are listed the rules for sleep 
restriction therapy. 
Instructions for Sleep Restriction Therapy 
 Patient is only allowed to stay in bed for the amount of time they think they sleep each 
night, plus 15 minutes. For example, if patient reports sleeping only 5.75 hours, they are 
allowed to stayin bed for 6 hours. 
 Patient must get up at the same time each day. If normal waking time is 6:30, patient is 
allowed to go to bed at 12:30. 
 Napping is not allowed. 
 When sleep efficiency has reached 85%, the patient can go to bed 15 minutes earlier. 
 This procedure is repeated until the patient can sleep for the desired amount of time. 
5.5 Weight loss 
Upper-body obesity is a risk factor for OSA, and it is well documented that weight loss has a 
notable ameliorative impact on the occurrence of OSA (Ancoli-Israel et al., 1996; Smith et al., 
1985). Since OSA results from closure of the airway, excess fatty tissue in theneck area may 
be a contributing factor. This supports the notion that weight plays a significant role in the 
presence and severity of sleep disordered breathing although no conclusive treatment trials 
have been published at this time. 
5.6 Light therapy 
The most influential treatment for circadian rhythm disturbances is increased exposure to 
bright light. This form of therapy, which directly targets the circadian system, is much 
preferred over hypnotics and other sedative medications. Since light is the most important 
synchronizer in our circadian system, increasing bright light exposure during certain times 
of the day can shift circadian rhythm phase and increase its amplitude. Specifically, bright 
light exposure in the evening causes a phase delay, while morning bright light exposure 
causes a phase advance in circadian rhythms, including rhythms of melatonin, core body 
temperature and sleepiness (Martin et al., 2000). 
5.7 Cognitive-behavioral therapies 
Many behavioral sleep medicine interventions are based on cognitive-behavioral therapies 
(CBT). The focus is on systematically introducing behavioral changes that have been proven 
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to improve sleep. This could include changes in sleep schedule and changes in the 
contingencies and reinforcers that promote sleep. The cognitive approach focuses on looking 
internally to examine, manage, or modify sleep interfering thoughts and beliefs that can 
interfere with sleep. Cognitive behavioral therapy for insomnia in the routine general 
practice setting improved sleep quality reduced hypnotic drug use and improved health-
related quality of life at a favorable cost in chronic insomniacs. Randomized controlled trials 
(RCTs) report somewhat conflicting results on the effectiveness of CBT in patients with 
insomnia but one systematic review including six RCTs (282 people) found that group or 
individual cognitive behavioral therapy (including sleep hygiene stimulus control sleep 
restriction muscle relaxation and sleep education) significantly improved PSQI scores 
compared with no treatment immediately after treatment and at 3 months (Montgomery 
&Dennis, 2004). Furthermore another meta-analysis involving 2102 patients in 59 trials 
found that sleep restriction and stimulus control therapies were more effective than 
relaxation techniques when used alone (Edinger & Sampson., 2003).   
6. Conclusion 
Considering that the most frequent sleep complaints, such as insomnia, OSAS and RLS, are 
related to a significant negative impact on functional health status in uraemic patients, the 
nephrologists should improve their recognition and treatment of these conditions to restore 
the quality of life of their patients. A good sleep history and, when indicated, a sleep 
recording, will help the clinician to make an accurate diagnosis and thus identify the best 
treatment. Nonpharmacologic methods such as behavioral techniques and cognitive 
therapyas well as pharmacologic approaches and combinations of these methods should be 
used for the treatment of sleep problems in hemodialysis patients. 
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1. Introduction 
The lifestyle today is new. We sit with our computers, televisions etc. Usually, we do not 
carry heavy things.  We gain weight and loose muscle strength. Through history the life has 
included moments with physical efforts. The body has not changed. It still needs physical 
training and efforts. The person who is untrained gets quickly tired. Therefore it is 
important to make the efforts regularly. The capacity of the heart to transport oxygen 
increases and the energy increases with physical training. The muscle condition is 
important. The mitochondria in the muscles cells may increase with 30-40 % after one month 
of exercise. With more mitochondria more fat is consumed and less carbohydrate is needed. 
Consequently, less lactic acid is formed and the blood does not change the pH towards 
acidosis as easily.  
Thus, modern people need exercise. You need not to go to a gym or run every day. It is 
more about having an active life. Take the cycle or walk to the job or to the shop, take the 
stairs instead of escalator or elevator. The exercise is a part of the natural common life and 
the body is a tool which needs to be used. It could be enough with 30 minutes of activity to 
reach physical efforts the heart rate has to increase, maybe to 120 beats/minute. This could 
be a dilemma for many patients since they have decreased maximal capacity and interacting 
medication. The training program has to be individualized but the goal is to improve the 
capacity.  If success the daily normal activities feel easier and the patients get more 
improved trust and comfort. Physical activities mean also better control and less fear of 
having fall accidents. With a feeling of control there are fewer obstacles.  
Thus exercise and effort are important to all of us which are true for many people with 
different diseases. For patients with cardiac diseases, hypertension, diabetes mellitus there 
are often exercise programs but for patients with different stages of chronic kidney disease, 
CKD, there is no obvious exercise treatment program. However, more and more evidence 
exists that exercises are important for these patients. The dialysis treatment hours have 
increased more and more to increase KT/V, the dialysis dose, but this also means less time 
for activities like exercise, work, family life and spear time. How could we help these 
patients? 
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Hence, this chapter is chosen with the intention to provide the reader with information 
concerning exercise capacity and level of physical activity in adults with chronic kidney 
disease. It also has the aim to make health-care providers within renal medicine aware of 
exercise training as an evidence-based intervention to improve health and well-being in 
adults with CKD. Despite the fact that exercise training is easy, cost effective and 
preventive, exercise training has not been implemented into clinical practice. We hope that 
this chapter will stimulate to action and provide some knowledge about these patients and 
their problems in order to understand why exercise training should be included in the 
standard care for adults with CKD. The chapter also contains general information about 
exercise and expected effects in healthy individuals. 
2. What is a training program for grown-up people? 
It is important to consider the training models, methodology, and expected changes that 
happen at regular physical activity in general. We consider different measures to describe 
the activities.  
 Frequency - That means how often we do the training. A daily dosage of effort like 
taking walks, taking stair-cases is basic. 
 Intensity - This is how the levels of efforts are. A common used definition is RM that is 
repetition maximum. One RM is the weight or load you are able to lift once but not 
twice. It has been shown that 60-70% of 1 RM could be enough for the starter to give an 
increase of muscle strength. For the well-trained it is necessary with almost 70-84% for 
the increase of muscle mass and strength (Kramer et al 1997). 
  Duration - It is the length of the exercise period at a time.  A 30 minute period of 
physical exercise is nowadays a common, recommended duration.  A simple and 
common instrument is the pedometer, which could quantify the number of steps and 
calculate the calories, the walking distance one could obtain during a period.  
Concerning intensity this could be varied by adding different muscle groups. The level of 
effort and the muscle groups involved are important for the results. If you add walking with 
sticks, the shoulder and arm muscles become involved and increase the results. In these 
moments also the important coordination becomes involved.  
The general effects of training are many. Below are some aspects and findings. 
Muscles 
Skeletal muscle is not a simple homogenous group of fibers. Type I fibers are characterized by 
slow speed of contraction, low activity of myosin ATPase and are well suited for prolonged 
aerobic exercise. Type II fibers have the ability to generate energy for quick and forceful 
contractions. At training there is an increase in both muscle fibre size and muscle number, the 
largest effect being increase of muscle size. The number of mitochondria and the small vessels 
in the muscles increase. Interestingly, even very old people could increase the strength. In an 
interesting study it was shown that 90-year old persons living at a nursing home could double 
the muscle strength, increase the quadriceps muscular volume with 10 % as well as increase 
the daily function after 8 weeks of bodybuilding (Fiatarone et al 1990). 
Cardiosvascular system 
The cardiac output will increase. The normal pulse will be reduced. The small arteries will 
dilate which contribute to decreasing blood pressure. The blood circulation to the heart and 
muscles will increase and both the blood volume and the haemoglobin level will increase. 
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Many patients with CKD have hypertension. In dialysis the hypertension is most linked to 
salt and water over load. After kidney transplantation the immunosuppressive drugs CNI 
(calcineurin inhibitors such as tacrolimus and ciclosporin) and corticosteroids contribute to 
hypertension. In transplants patients with CAN (chronic allograft nephropathy) ischemia in 
the kidneys aggravate the situation and give severe hypertension with often therapy 
resistant blood pressure.  
The basis of treatment in hypertension is life style changes, exercise, stop smoking habits 
and decrease of the sodium chloride in the diet. These are basic advice applicable also to the 
CKD patients. Many patients have treatment with diuretics to decrease salt and water.  Beta-
blockers protect the heart from stress and lower the pulse rate, sometimes hamper maximal 
training efforts. Calcium blockers are frequently used, cause relaxation of the muscles and 
vasodilatation.  
ACE-inhibitors block the angiotensin system and are often well tolerated. It could however 
be important to be aware of the fact that severe dehydration could be dangerous due to risk 
of high serum potassium and loss of blood pressure which is a severe condition. This 
information is important to give to the patient in case of any situation with loss of water like 
gastrointestinal acute diseases. 
Regular physical activity lowers the blood pressure but the blood pressure increases during 
exercise, mostly the systolic blood pressure. With a stress ECG the individual patient could 
get information about the level of blood pressure and ECG changes during efforts. There are 
recommended levels not to exceed. 
Nerve system 
Regular physical activity affects the nerves. The coordination, the balance and the ability to 
react becomes better. Most of the persons who do regular exercise have better sleep, less 
depressions and more self-esteem. 
Hormone system 
The exercise increases the insulin sensitivity in the skeletal muscle and decreases the insulin 
in the blood. This means less adiposities and a more healthy profile of the lipids with 
increased HDL-cholesterol and decreased triglycerides. For body builders the growth 
hormone may increase. Also testosterone levels have been found to increase and androgen 
receptors which increase the effect of testosterone (Kraemer et al 2005). Added testosterone 
has a much stronger effect, both increasing the muscle mass and adding new cells. 
However, this substance is classified as doping preparation. Cortisol is a catabolic substance 
and could be increased at stress caused by some exercises and exercisers. However, cortisol 
is a life-necessary substance. Catecholamine (noradrenalin and adrenalin) are also produced 
in the moments of stress, fight and flight response. There is probably an anabolic effect on 
the skeletal muscles which has been shown in certain animal studies. That is why these 
preparations are on the doping list. Insulin-like growth factor (IGF-1) could also be 
produced locally in the muscle but the systemic effect is unclear. 
3. Physical fitness and physical functioning and self-evaluation in patients 
with CKD  
The physical fitness and physical functioning (= the ability and capacity to perform activities 
of daily living) is severely reduced in adults with CKD (Kettner-Melsheimer et al 1987; 
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Kouidi et al 1998; Heiwe et al 2003; Johansen et al 2003; Heiwe et al 2005). It is declining 
from 70% of the expected norm in a pre-uremic phase to 50% of the expected norm when 
starting dialysis therapy (Painter et al 1986; Kettner-Melsheimer et al 1987; Brodin et al 
2001). However, also ageing decreases muscle mass. The median age at dialysis start in 
Sweden is 66 years. The muscle mass in 70-year old person is 25% lower compared with 25-
year old persons (Klitgaard et al 1990).  
Patients with a renal transplant have a lower physical fitness of approximately 70-80% of the 
age-matched controls (Painter et al 1986). Here, the corticosteroids, still a basic 
immunosuppressive treatment, contribute to muscular atrophy. Thus, the physical fitness in 
adults with CKD is reduced and affects the capacity of the patients to perform activities in 
everyday life and occupational tasks. 
Physical functioning in patients with CKD is affected by several factors like consequences of 
CKD in it-self, the original disease process that brought about the patient’s kidney disease 
and the treatment of CKD which may have further detrimental effects (Marlowe et al 2001). 
The main factors causing reduced physical fitness are anaemia (Clyne et al 1987; McMahon 
et al 1999) and muscular weakness (Bohannon et al 1994; Johansen et al 2003). This results in 
fatigue and increasing inactivity, which in turn reduces physical fitness even further and 
increases impairments in physical functioning (Bohannon et al 1994; Nielens et al 2001; 
Johansen et al 2003).  
Today, anaemia is successfully corrected by erythropoietin treatment and results in an 
improved, but not normalised, physical fitness (McMahon et al 1999). When analysing 
muscle biopsies it has been shown that adults with CKD have muscular histopathological 
abnormalities already in the pre-uremic phase (Heiwe et al 2005). The causes of muscular 
weakness in patients with CKD have, however, not been fully elucidated. Muscle atrophy, a 
neuropathic process and myopathy are potential causes of the muscular weakness. It is 
suggested that myopathy is due to abnormal energy metabolism (Thompson et al 1993), 
secondary hyperparathyreoidism (Ritz et al 1980), malnutrition (Guarnieri et al 1983), 
prolonged physical inactivity (Jones et al 1990) and to uraemia itself (Sakkas et al 2003). 
It is important that the consultant renal physiotherapist, renal nurse, renal dietician and 
renal physician have an understanding of limitations in physical fitness and physical 
functioning that adults with CKD are expected to face and how various unique issues may 
alter the treatment approach. All training methods have to start with cautions and feed-back 
to the patients. 
It has been shown that adults with CKD experience limitations in their daily life due to 
insufficient physical fitness. In a previous study (Heiwe et al 2003) it was shown that adult 
with CKD experience fatigue both mental and physical fatigue. This results in a reduced 
physical fitness and reduced physical functioning in terms of impact on performance and 
endurance. The experienced fatigue appeared frequently and varied in strength.  
The informants described having a more or less always-present mental fatigue, which was 
experienced as something that they really had to fight to overcome. Feeling listless and 
paralysed by fatigue was a common trait of this group of descriptions. The feeling of 
physical fatigue appeared as soon as they started performing a physical activity and could 
vary in extent from day to day. They experienced muscular weakness and rapid onset of 
tiredness. Pagels et al (2006) have shown that when asked to rate the level of physical 
activity 40% of the adults being in a pre-uremic phase had a low activity and 11% were 
mostly sitting or lying down. Thus, the daily basic walks became an effort. 
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Many adults with CKD experience difficulties in walking if the ground is not level, as in the 
case of stairs or steps, uphill slopes, etc. In such conditions, they experience physical 
resistance very quickly. Many elderly with CKD also have difficulties in performing 
everyday chores, such as managing their personal hygiene, making their bed, hanging up 
laundry, vacuum-cleaning, lifting things, rising from a squatting position, cleaning, etc. 
They also experience difficulty in performing a physical activity over a prolonged period of 
time, for instance, hanging up laundry, without having to pause several times, which they 
have not had to do prior to the disease. Most of the patients also have difficulties in 
performing physical activities at the same pace as they did prior to the CKD. 
Adults with CKD may also experience temporal stress since they cannot do as much as they 
would have liked to. They need more time to perform various activities, partly due to 
“internal demands”, like the need for physical rest and partly due to their experiences of 
external demands as a result of all the medical appointments and other appointments. All 
these factors may have a negative impact on the patients’ level of activity and participation 
as well as their social life (Heiwe et al 2003). It seems urgent to do something for these 
patients. 
Rehabilitation has a positive effect on physical fatigue and improves both ‘endurance’ and 
physical ‘performance’, which, in turn, could reduce the need for more time to be able to 
perform everyday chores or other physical activities. It would then be possible for the 
patients to find more time for their own activities, increasing their physical activity level. It 
is important to make clear to patients that just by putting time and effort into physical 
exercise or activity they can improve several aspects of their experience of fatigue, reduced 
physical fitness and temporal stress. It is, though, important that appointments for physical 
exercise training are co-ordinated, as far as possible, with the patients’ other medical 
appointments. This would give the patients more time to perform their own physical 
activities. 
It is also important that physiotherapists consider patients’ views when reflecting upon and 
interpreting how they can support and strengthen patients in their effort to be able to 
perform physical activities as well as social activities that are of importance to them.  
Adults with CKD are subjected to multiple physiological and psychological stressors. Welch 
et al (1999) have for instance showed that the most common treatment-related stressors in 
patients with haemodialysis are fluid limitations, the length of dialysis and vacation 
limitations. When adults with CKD rank the stressors that they are subjected to, it is 
limitation of physical activity which is the number one stressor (Lok et al 1996). Therefore, it 
is important to include questions concerning physical activity when meeting these patients. 
Coping has been proposed as an important mediating factor with regard to adaptation to 
illness. Coping refers to ‘an individual’s efforts to master demands that are appraised (or 
perceived) as exceeding or taxing his or her resources. It is a process that may consist of 
behaviours and intra-psychic responses designed to overcome, reduce or tolerate these 
demands (Lazarus et al 1984). There are many ways in which coping responses can be 
grouped, but the two general categories of coping strategies are problem-solving efforts and 
strategies aimed at the regulation of emotions (Lazarus et al 1984). Problem-focused coping 
refers to efforts to improve the troubled person-environment relationship by changing 
things, for instance by seeking information about what to do. Emotional-focused (or 
palliative) coping refers to thoughts or actions whose goal is to relieve the emotional impact 
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Kouidi et al 1998; Heiwe et al 2003; Johansen et al 2003; Heiwe et al 2005). It is declining 
from 70% of the expected norm in a pre-uremic phase to 50% of the expected norm when 
starting dialysis therapy (Painter et al 1986; Kettner-Melsheimer et al 1987; Brodin et al 
2001). However, also ageing decreases muscle mass. The median age at dialysis start in 
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physical fitness and reduced physical functioning in terms of impact on performance and 
endurance. The experienced fatigue appeared frequently and varied in strength.  
The informants described having a more or less always-present mental fatigue, which was 
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paralysed by fatigue was a common trait of this group of descriptions. The feeling of 
physical fatigue appeared as soon as they started performing a physical activity and could 
vary in extent from day to day. They experienced muscular weakness and rapid onset of 
tiredness. Pagels et al (2006) have shown that when asked to rate the level of physical 
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mostly sitting or lying down. Thus, the daily basic walks became an effort. 
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Many adults with CKD experience difficulties in walking if the ground is not level, as in the 
case of stairs or steps, uphill slopes, etc. In such conditions, they experience physical 
resistance very quickly. Many elderly with CKD also have difficulties in performing 
everyday chores, such as managing their personal hygiene, making their bed, hanging up 
laundry, vacuum-cleaning, lifting things, rising from a squatting position, cleaning, etc. 
They also experience difficulty in performing a physical activity over a prolonged period of 
time, for instance, hanging up laundry, without having to pause several times, which they 
have not had to do prior to the disease. Most of the patients also have difficulties in 
performing physical activities at the same pace as they did prior to the CKD. 
Adults with CKD may also experience temporal stress since they cannot do as much as they 
would have liked to. They need more time to perform various activities, partly due to 
“internal demands”, like the need for physical rest and partly due to their experiences of 
external demands as a result of all the medical appointments and other appointments. All 
these factors may have a negative impact on the patients’ level of activity and participation 
as well as their social life (Heiwe et al 2003). It seems urgent to do something for these 
patients. 
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physical ‘performance’, which, in turn, could reduce the need for more time to be able to 
perform everyday chores or other physical activities. It would then be possible for the 
patients to find more time for their own activities, increasing their physical activity level. It 
is important to make clear to patients that just by putting time and effort into physical 
exercise or activity they can improve several aspects of their experience of fatigue, reduced 
physical fitness and temporal stress. It is, though, important that appointments for physical 
exercise training are co-ordinated, as far as possible, with the patients’ other medical 
appointments. This would give the patients more time to perform their own physical 
activities. 
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is important to include questions concerning physical activity when meeting these patients. 
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illness. Coping refers to ‘an individual’s efforts to master demands that are appraised (or 
perceived) as exceeding or taxing his or her resources. It is a process that may consist of 
behaviours and intra-psychic responses designed to overcome, reduce or tolerate these 
demands (Lazarus et al 1984). There are many ways in which coping responses can be 
grouped, but the two general categories of coping strategies are problem-solving efforts and 
strategies aimed at the regulation of emotions (Lazarus et al 1984). Problem-focused coping 
refers to efforts to improve the troubled person-environment relationship by changing 
things, for instance by seeking information about what to do. Emotional-focused (or 
palliative) coping refers to thoughts or actions whose goal is to relieve the emotional impact 
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of stress (for example, bodily or psychological disturbances). Although both sets of 
strategies are brought to bear on most stressful events, problem-solving efforts are especially 
useful for managing controllable stressors, and emotional-regulation efforts are well suited 
to managing the impact of uncontrollable stressors.  
It has been shown that in order to cope with the limited physical fitness three coping 
activities are used: 1) avoiding physical activities, 2) adjusting pace and 3) scheduling.  The 
strategies were problem-focused, and patients used active-, avoidant- and social-support 
coping strategies. When coping with limited physical fitness, adults with CKD tend to use 
coping strategies that have a positive short-term outcome. These strategies are, however, 
also associated with negative long-term outcomes. The individual is placed in an evil circle 
where the physical functioning decreases as the experience of mental and physical fatigue 
increases (Heiwe et al 2004). It is therefore important that renal physicians and renal nurses 
identify these patients and refer them to a renal physiotherapist at an early stage, so that 
they can get information and help with physical exercise training. This could contribute to 
the patients’ own resources which can then be used to improve the level of participation and 
also to improve some parts of the patient’s social life. 
All people employ different combinations of problem-focused and emotion-focused 
methods to cope with stress. The conditions determining our coping methods in specific 
situations are complex and at present largely unknown, but they are likely to depend on the 
conditions being faced, the options available to us and our personality. An issue often 
emerging in discussions about coping is whether some coping processes are more effective 
than others. For instance, whether avoidant responses to stressful events are more adaptive 
or whether more confrontational coping methods are superior. However, coping processes 
have both positive and negative consequences for an individual. A behaviour that might be 
effective from, say, the physiological perspective might have devastating consequences for 
the psychological or sociological domains. Moreover, what is an optimal response in one 
situation at a particular point in time may be damaging in some other situation or at a 
different point in time. Most people appear to use a variety of coping strategies to deal with 
a stressor. Successful coping may depend more on a match of different coping strategies to 
the features of the stressful event than on the relative efficacy of one coping strategy over 
another. Therefore, when meeting a patient with CKD and evaluating his or her coping and 
adaptation, the health-care provider must take into account diverse levels of analysis 
(physiological, psychological, sociological), short versus long-term consequences and the 
specific nature of the situation in question.  
4. Evidence based effects of exercise training in patients with CKD 
There is scientific evidence showing that if adults with CKD do not exercise only having a 
certain level of physical activity in their daily living: 
 The muscle mass and physical fitness will continue to decrease (Painter et al 1986; 
Kettner-Melsheimer et al 1987; Bohannon et al 1994; Brodin et al 2001; Heiwe et al 2001; 
Sakkas et al 2003; Heiwe et al 2005; McIntyre et al 2006; Zamojska et al 2006) 
 The patient’s possibility to maintain, for him or her, a satisfyingly active and social life 
will be reduced = reduced health-related quality of life (Brodin et al 2001; Fukuhara et 
al 2003; Heiwe et al 2003; Heiwe et al 2004) 
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 An already high cardiovascular risk factor and co-morbidity burden (Yao et al 2004; 
Venkataraman et al 2005) will increase even more due to the severely reduced level of 
physical activity 
Published articles concerning effects of physical exercise on patients with CKD started to 
appear in the 1980s. Since then, interest in effects of physical exercise has increased in renal 
medicine, and today there are numerous published articles showing positive effects of 
exercise training. Data from previously and recently published studies have shown that 
exercise training in adults with CKD can affect the following factors: 
 Muscular hypotrophy, -strength, -endurance & physical functioning (Kouidi et al 1998; 
Mercer et al 2002; Painter et al 2002; DePaul et al 2002; Sakkas et al 2003; Heiwe et al 
2005; McIntyre et al 2006; Heiwe & Jacobson 2011) 
 The structure and number of capillaries and mitochondria (Kouidi et al 1998; Sakkas et 
al 2003, Cheema et al 2010) 
 Glucose metabolism (Goldberg et al 1983) 
 Aerobic capacity (Painter et al 1986; Painter et al 2002; DePaul et al 2002) 
 Blood pressure (Goldberg et al 1983; Pechter et al 2003) 
 Cardiac performance (i.e. augmentation of cardiac vagal activity, decrease of 
vulnerability to arrhythmias) and improvement of coronary risk profiles 
(Venkataraman et al 2005) 
 Depression, performance of pleasant activities in daily living and health-related quality 
of life (Suh et al 2002; Molsted et al 2004; van Vilsteren et al 2005) 
 Circulating cytokines (Cheema BS et al 2010) 
 Nutritional parameters and energy expenditure using SWA, SenseWearTM Armband 
(Cupusti A el al 2011) 
A review article, based on 29 trials on this issue, shows that exercise training in dialysis 
patients improves arterial compliance, cardiac autonomic control and left ventricular 
systolic function. Moreover, exercise diminishes oxidative stress, blood pressure and 
inflammation. As shown in Table 1, significant effects of exercise and training were found.  
It is interesting to notice that haemoglobin levels, s-albumin, PCR (protein catabolic rate) 
and KT/V increase. This tells us that less erythropoietin is needed, which means that 
training is cost-effective. The patients have better protein intake. They probably eat more to 
get energy. The recommended protein intake at training in general is 1.6-1.7 g/kg. The 
recommendations for uremic patients in dialysis are a protein intake above 1.3 g/kg body 
weight.  
Also, the decrease in CRP is an interesting finding. CRP is connected to residual renal 
function (Pecoits-Filho et al 2003). The low inflammatory process in the dialysis patients 
becomes thus better after 6 months of repeated cycle training and this might be an adequate 
prescription! Actually, today the physiotherapists give prescriptions on physical activities 
like the doctors do on medication. The difficulties could be the compliance or adherence of 
the patient to the physical program suggested but the same problem exists with the 
prescribed drugs. 
Here is a prescription or suggestions to patients with CKD. To obtain improvements it is, 
however, important that the exercise program has an adequate intensity, frequency and 
duration. Examples and type of exercises are given (Table 2). 
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All people employ different combinations of problem-focused and emotion-focused 
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than others. For instance, whether avoidant responses to stressful events are more adaptive 
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the psychological or sociological domains. Moreover, what is an optimal response in one 
situation at a particular point in time may be damaging in some other situation or at a 
different point in time. Most people appear to use a variety of coping strategies to deal with 
a stressor. Successful coping may depend more on a match of different coping strategies to 
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adaptation, the health-care provider must take into account diverse levels of analysis 
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medicine, and today there are numerous published articles showing positive effects of 
exercise training. Data from previously and recently published studies have shown that 
exercise training in adults with CKD can affect the following factors: 
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 Circulating cytokines (Cheema BS et al 2010) 
 Nutritional parameters and energy expenditure using SWA, SenseWearTM Armband 
(Cupusti A el al 2011) 
A review article, based on 29 trials on this issue, shows that exercise training in dialysis 
patients improves arterial compliance, cardiac autonomic control and left ventricular 
systolic function. Moreover, exercise diminishes oxidative stress, blood pressure and 
inflammation. As shown in Table 1, significant effects of exercise and training were found.  
It is interesting to notice that haemoglobin levels, s-albumin, PCR (protein catabolic rate) 
and KT/V increase. This tells us that less erythropoietin is needed, which means that 
training is cost-effective. The patients have better protein intake. They probably eat more to 
get energy. The recommended protein intake at training in general is 1.6-1.7 g/kg. The 
recommendations for uremic patients in dialysis are a protein intake above 1.3 g/kg body 
weight.  
Also, the decrease in CRP is an interesting finding. CRP is connected to residual renal 
function (Pecoits-Filho et al 2003). The low inflammatory process in the dialysis patients 
becomes thus better after 6 months of repeated cycle training and this might be an adequate 
prescription! Actually, today the physiotherapists give prescriptions on physical activities 
like the doctors do on medication. The difficulties could be the compliance or adherence of 
the patient to the physical program suggested but the same problem exists with the 
prescribed drugs. 
Here is a prescription or suggestions to patients with CKD. To obtain improvements it is, 
however, important that the exercise program has an adequate intensity, frequency and 
duration. Examples and type of exercises are given (Table 2). 
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prescription duration variable % change significance 
Cycle ergometer, 
walking, jogging 
8-9 months HDL cholesterol
Hemoglobin 
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6 months VO2 peak
Peak blood lactate 
Isometric strength 
Type muscle fibre area I  
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walking or cycle 
ergometer 









Table 1. 29 studies and effects of physical activity in dialysis patients on metabolic and 
nutritional parameters. (Cheema BS, Sing MA 2005). 
 





Individual program with 
weight cuffs as resistance 
50 % 1RM Maximal number of 
correctly performed 
repetitions. Corresponding 
to self-rated total exertion 
13-15 according to Borg’s 
RPE-scale 








Walking, eg on treadmill 
or balance carpet. 
Standing on balance plate
Knee bow 
Stairs 
Standing up from knee 
bow
Maximal walking and 
number of correctly 
performed repetitions. 
Corresponding to self-rated 
total exertion 13-15 






Individual training with 
weight cuffs or other 
things as resistance
80% 1RM 1 set á 8-10 reps 3 times/w  
Borg´s RPE scale = Borg rating of perceived exertion. It was constructed in the 60-ties by Gunnar Borg, 
professor in perception and psychophysics in Stockholm. The scale indicates different degrees of effort 
from 6 to 20. The rated RPE  shows a linear relation to workload and heart pulse frequency. It is used 
within rehabilitation and training (Borg 1970). 
VO2 peak: This is the oxygen uptake which reflects the maximal performance of the individual. This has to 
be measured before start of programme and this helps to adjust the programme for each individual. 
Reps = repetitions, RM repetition maximum see page 2 
Table 2. Prescription on physical activities in patients with CKD and explanations  
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5. Details and aim of physical training 
 Get the patient informed about the importance of physical training in CKD both in 
dialysis and after kidney transplantation. 
 To make the patient independent in the daily life and to keep/increase the quality of 
life.  
 Diminish the risk of cardiovascular disease, osteoporosis and loss of muscle mass. 
Increase/maintain muscular strength and endurance, balance as well as the sub 
maximal oxygen uptake.  
 Minimize the risk of fall accident.  




 Maximal number of muscle contractions with a strain 
corresponding to 50 % of 1RM and at fixed frequency. 




 Maximal number of seconds the patient is able to maintain an 
isometric muscle contraction, for example knee extension, 
with loading corresponding to 50% of 1RM. 
 Unilateral isotonic shoulder flexion, bilateral isometric 
shoulder abduction  
Functional capacity  6-minutes walking test with patient’s experienced leg fatigue, 
breathlessness and possible cardiac pain is rated by the 
patient according to Borg’s CR-10 scale and the total effort 
according to Borg’s RPE-scale before and after the test 
performed 
 Walking 30 meters in self-selected normal rate and maximal 
rate  
 Timed ”Up & Go” 
 Stand on one leg Functional reach  
 Stairs 
Muscular strength  One repetition maximum (1RM) 
 GRIPPIT(grip strength), Jamar hand dynamometer: 
correlating to muscular mass  
 Isometric leg strength.  
Self-rated physical 
level of activity  
 Disability Rating Index (DRI). Activity rating according to 
Grimby Frändin  
Physical capacity  Standardized, symptom limited ergometer cycling with 
patient’s experienced leg fatigue, breathlessness and possible 
cardiac pain is rated by the patient according to Borgs CR-10 
scale and the total effort according to Borg’s RPE-scale. 
Quality of life  SF-36  
Notes: General about CKD 4-5 
 For patients with secondary kidney diseases it is important to consider the original 
disease at assessment of physical capacity, general advice and follow-up. For patients 
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performed 
 Walking 30 meters in self-selected normal rate and maximal 
rate  
 Timed ”Up & Go” 
 Stand on one leg Functional reach  
 Stairs 
Muscular strength  One repetition maximum (1RM) 
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Physical capacity  Standardized, symptom limited ergometer cycling with 
patient’s experienced leg fatigue, breathlessness and possible 
cardiac pain is rated by the patient according to Borgs CR-10 
scale and the total effort according to Borg’s RPE-scale. 
Quality of life  SF-36  
Notes: General about CKD 4-5 
 For patients with secondary kidney diseases it is important to consider the original 
disease at assessment of physical capacity, general advice and follow-up. For patients 
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
438 
with diabetes mellitus for instance it is important to consider the present foot status and 
the insulin regimen.  
 Patients with polycystic kidney disease should avoid contact sports like karate since hard 
hits against the kidneys may cause bleeding and pain. There is also a higher risk of hernia 
of the abdominal wall in this disease. Patients with kidney transplants should also avoid 
contact sports like ice-hockey and land-hockey due to risk of tackling moments. 
 Patients with CKD 4 and 5 suffer more easily from tendinitis. Treatment with 
chinolones means increased risk of tendinitis. Because of this it is important with 
heating and cool-down to be prolonged. Also the training of mobility and agility should 




Fig. 1. The amount of training and training effects in CKD patients in a schematic form 
Concerning haemodialysis patients: 
 When is the physical training to be performed? It is the medical condition of the patient 
and the desire of the patient which decide the optimal timing for the training. The most 
optimal training effect is obtained with the physical activity on dialysis free days. If this 
Health results
More advanced exercise 
3 times/w
30 min of daily exercise
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is a problem for the patient, for instance far distance to travel, confinement to the 
hospital etc, the training may be performed before the dialysis treatment or during the 
first two hours in dialysis. It is not recommended to do the exercise after dialysis 
treatment since the patients are dehydrated and there is great risk of hypotensive 
episodes.  Since the patients often have lack of time, it is important to coordinate the 
different treatments within the team. 
 The amount of fluid, sodium, potassium and blood pressure is constantly variable in a 
dialysis patient. As a physical therapist it is important to consider these factors in 
planning the training schedule and in every training opportunity. Consider the 
restriction of water in individual patients! However, in jogging and running all need 
water. The simplest method is to instruct the patient to weigh himself/herself before 
and after the running episodes. 
 The signs of exercise-induced hyponatremia should be recognized by everyone 
handling dialysis patients. These are symptoms of cerebral over hydration: nausea, 
malaise when sodium is below 125-130 mmol/L. If plasma sodium falls below 115 to 
120 mmol/L there are adding symptoms with headache, lethargy, seizures, and coma. 
This is a risk identified in marathon runners (Ayes et al 2000). 
 Avoid circular pressure in the arm with arteriovenous (AV)-fistula/graft. The blood 
pressure should not be measured in that arm because of risk to strangle and destroy the 
important blood flow to the access. 
 Before surgery of AV-fistula/graft it is important to perform endurance training of the 
muscles in the forearm and the hand. This may increase the size of the vena cephalica 
which is valuable. During a short period after the surgery the patient should not use 
watches, bracelets or carry heavy bags which may hamper the blood flow in the 
important AV access. Training the arm with squeezing a soft ball could be important to 
increase the blood flow in the vein. This makes the AV-fistula more strong and useful.  
Shoulder and elbow move ability should be alerted and the arm/hand could be used 
for easier house and family work. Depending on the surgeon’s prescription and the 
status of the patient it may be valuable to start strength training after 3-4 weeks to 
maintain muscular fitness.  
 Patients with central dialysis catheters (CDK) on the neck or frontal thorax may start 
training of muscle and motility. If the sutures cause pain or prevent movements in the 
neck/shoulder, the physician is consulted for possible adjustment. Considering the risk 
of infection the patient with CDK is not allowed to exercise in a pool.  
6. Nutrition and exercise 
Nutrition is a most important issue in CKD patients. Before start of dialysis many patients 
have protein restricted diet. This has to be changed as soon as dialysis treatment is initiated. 
The protein intake has instead to be increased. Both the dialysis process and the physical 
activities need proteins and amino acids. We usually calculate the PCR = protein catabolic 
rate every month in the dialysis patients based on urea determinations before and after 
dialysis session and urea before the next dialysis. The patients could get feedback on their 
protein intake and add protein supplements if needed.  
Carbohydrates are important to refill the glycogen stores in the liver and the muscles. The 
more glycogen, the more energy is available for the exercise. It is considered that 5-7 
g/kg/day on training days are needed. If we eat too much more fat is stored instead. 
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Fats are needed, in the first hand, the essential fatty acids. But any fat to get the important 
energy balance is important. 
Fruit and vegetables are recommended to sportsmen and sportswomen. However, due to 
risk of hyperpotassemia and high water content in fruits, caution is needed for patients in 
dialysis. The patients should have lists from dieticians to find the most proper fruits. 
Vitamins are needed. Especially C-vitamins since they are removed at hemodialysis or 
hemofiltration (Fehrman-Ekholm et al 2008). D-vitamins are needed for the skeleton and in 
treatment of secondary hyperparathyroidism. Iron is necessary in anemia treatment and 
today most patients have intravenous iron supply at dialysis sessions. 
General recommendation is to eat often and to eat after the exercise to fill up the glycogen 
stores again. 
In co work with other team members the physical therapist works to motivate the patient to 
continue exercises for the rest of life. Regular check-ups by physiotherapist with knowledge 
of renal medicine and transplant medicine are of greatest importance to maintain maximal 
physical performance whatever CKD treatment the patient has. We also know that there are 
several national guidelines that include exercise training and physical activity as part of the 
treatment for problems that are common in patients with CKD, i.e. high blood pressure, 
hyperlipidemia and cardiovascular diseases. Within renal care and -medicine we spend a lot 
of time trying to find ways to optimise the outcome of the care that is given to our patients. 
But there is already an easy, low-tech intervention that has multiple advantages for these 
patients’ health and well-being, but which hasn’t been implemented as a part of the 
standard care for patients with CKD: Exercise training and physical activity in daily living! 
Another question is if aerobic exercise and strength training starting early in renal disease 
could play an important role in prevention or progression of CKD (Moinuddin et al 2008).  
7. Conclusion 
 The physical fitness is severely reduced among adults with haemodialysis treatment 
 Physical exercise programs should be initiated with gentle start and preferably non-
dialysis days or before dialysis treatment 
 Exercise training including various programs improves aerobic capacity, muscular 
strength and endurance, physical functioning, physical- and psychological well-being if 
the program is regular and monitored 
 Exercise training has positive effects on the cardiovascular risk profile, oxidative stress 
and inflammation 
 Exercise training improves protein intake (PCR), dialysis effects (KT/V), haemoglobin 
and the endothelial function which are important treatment parameters in hemodialysis 
patients. 
We need to encourage our patients with CKD to get more physically active and to start 
exercising. We need to refer them to physiotherapists with special knowledge in renal 
medicine that can give them adequate, individually adapted exercise recommendations.  
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Hemodialysis (HD) represents the first successful long-term substitutive therapy 
with an artificial organ for severe failure of a vital organ. Because HD was started 
many decades ago, a book on HD may not appear to be up-to-date. Indeed, HD covers 
many basic and clinical aspects and this book reflects the rapid expansion of new and 
controversial aspects either in the biotechnological or in the clinical field. This book 
revises new technologies and therapeutic options to improve dialysis treatment of 
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